<SEC-DOCUMENT>0001564590-22-012877.txt : 20220331
<SEC-HEADER>0001564590-22-012877.hdr.sgml : 20220331
<ACCEPTANCE-DATETIME>20220331130159
ACCESSION NUMBER:		0001564590-22-012877
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		87
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220331
DATE AS OF CHANGE:		20220331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATALYST BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0001124105
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562020050
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51173
		FILM NUMBER:		22790831

	BUSINESS ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-871-0761

	MAIL ADDRESS:	
		STREET 1:		611 GATEWAY BLVD., SUITE 710
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TARGACEPT INC
		DATE OF NAME CHANGE:	20000919
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>cbio-10k_20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-31T02:21:01.8292552+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : ef934a25c5c94284985388408cc8aae1 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:cbio="http://www.catalystbiosciences.com/20211231" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
cbio-10k_20211231.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001124105_20210101_20211231">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0001124105_20210101_20211231">FY</ix:nonNumeric>
			<ix:nonNumeric id="F_000007" name="dei:EntityCentralIndexKey" contextRef="C_0001124105_20210101_20211231">0001124105</ix:nonNumeric>
			<ix:nonNumeric id="F_000008" name="dei:CurrentFiscalYearEndDate" contextRef="C_0001124105_20210101_20211231">--12-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000280" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001124105_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20211231">P3Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000282" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001124105_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210101_20211231">P3Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000482" name="us-gaap:TaxCreditCarryforwardExpirationDate" contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">2040-12-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000509" name="cbio:ResearchServicesAgreementOptionToExtend" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_us-gaapTransactionTypeAxis_cbioLicenseAndCollaborationAgreementMember_20191218_20191218">P12M</ix:nonNumeric>
			<ix:nonNumeric id="F_000537" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20211231">2022-08-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000557" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001124105_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_cbioBiogenAgreementMember_20220301_20220331">2022-05-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000556" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001124105_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_cbioSubleaseArrangementMember_20220301_20220331">2023-04-30</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001124105_20211231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000073" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001124105_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000074" name="us-gaap:PreferredStockValue" contextRef="C_0001124105_20211231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000075" name="us-gaap:PreferredStockValue" contextRef="C_0001124105_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonNumeric id="F_000407" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001124105_20190101_20191231">P8Y1M24D</ix:nonNumeric>
			<ix:nonNumeric id="F_000408" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001124105_20200101_20201231">P7Y11M15D</ix:nonNumeric>
			<ix:nonNumeric id="F_000409" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001124105_20210101_20211231">P7Y5M15D</ix:nonNumeric>
			<ix:nonNumeric id="F_000410" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_0001124105_20210101_20211231">P6Y4M6D</ix:nonNumeric>
			<ix:nonNumeric id="F_000419" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">P6Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000420" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">P5Y9M21D</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="cbio-20211231.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001124105_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001124105_20220325">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-25</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001124105_20210630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001124105_srtProductOrServiceAxis_cbioLicenseRevenueMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:LicenseRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CollaborationRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CollaborationRevenueMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtProductOrServiceAxis_cbioCostOfLicenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CostOfLicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtProductOrServiceAxis_cbioCostOfCollaborationMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CostOfCollaborationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtProductOrServiceAxis_cbioCostOfCollaborationMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CostOfCollaborationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_cbioSegment">
				<xbrli:measure>cbio:Segment</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001124105_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapComputerSoftwareIntangibleAssetMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_cbioLongTermInvestmentsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">cbio:LongTermInvestmentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapFinancialInstrumentAxis_cbioFederalAgencySecuritiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cbio:FederalAgencySecuritiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapOtherLongTermInvestmentsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtRangeAxis_srtMaximumMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioAGCBiologicsIncMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:AGCBiologicsIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioMarzeptacogAlfaActivatedMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapServiceAgreementsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:MarzeptacogAlfaActivatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioMarzeptacogAlfaActivatedMember_srtProductOrServiceAxis_cbioDalcinonacogAlfaMember_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapServiceAgreementsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:MarzeptacogAlfaActivatedMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:DalcinonacogAlfaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioIntegrityBioMember_srtProductOrServiceAxis_cbioGMPMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:IntegrityBioMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:GMPMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioAGCBiologicsIncMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapServiceAgreementsMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:AGCBiologicsIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_20211101_20211130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-11-01</xbrli:startDate>
					<xbrli:endDate>2021-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtProductOrServiceAxis_cbioIntravitrealAntiComplementFactor3Member_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_us-gaapTypeOfArrangementAxis_cbioBiogenCollaborationMember_20200110">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbio:MosaicBiosciencesIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cbio:BiogenCollaborationMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:IntravitrealAntiComplementFactor3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-01-10</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtProductOrServiceAxis_cbioIntravitrealAntiComplementFactor3Member_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbio:MosaicBiosciencesIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:IntravitrealAntiComplementFactor3Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200508_20200508">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbio:MosaicBiosciencesIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-05-08</xbrli:startDate>
					<xbrli:endDate>2020-05-08</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200508_20200508">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbio:MosaicBiosciencesIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-05-08</xbrli:startDate>
					<xbrli:endDate>2020-05-08</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_20211001_20211031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-10-01</xbrli:startDate>
					<xbrli:endDate>2021-10-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioLeaseLabAndOfficeSpaceMember_us-gaapTypeOfArrangementAxis_cbioSubleaseArrangementMember_20210430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbio:LeaseLabAndOfficeSpaceMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cbio:SubleaseArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioLeaseLabAndOfficeSpaceMember_us-gaapTypeOfArrangementAxis_cbioSubleaseArrangementMember_20210401_20210430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbio:LeaseLabAndOfficeSpaceMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cbio:SubleaseArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-04-01</xbrli:startDate>
					<xbrli:endDate>2021-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_20200716_20200717">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-07-16</xbrli:startDate>
					<xbrli:endDate>2020-07-17</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_20200717">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-07-17</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenOmnibusIncentivePlanMember_20210609_20210609">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenOmnibusIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-06-09</xbrli:startDate>
					<xbrli:endDate>2021-06-09</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenOmnibusIncentivePlanMember_20210609">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenOmnibusIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-06-09</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapAwardTypeAxis_cbioPerformanceBasedStockOptionGrantsMember_us-gaapPlanNameAxis_cbioTwoThousandEighteenOmnibusIncentivePlanMember_20210228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenOmnibusIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cbio:PerformanceBasedStockOptionGrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-02-28</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20180613_20180613">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-06-13</xbrli:startDate>
					<xbrli:endDate>2018-06-13</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20180613">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-06-13</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20071231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2007-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_stprCA_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_stprCA_20200629_20200629">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-06-29</xbrli:startDate>
					<xbrli:endDate>2020-06-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_stprCA_20200629">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:IsuAbxisMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:IsuAbxisMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-12-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:IsuAbxisMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:IsuAbxisMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-12-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_us-gaapTransactionTypeAxis_cbioLicenseAndCollaborationAgreementMember_20191218_20191218">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:BiogenMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-12-18</xbrli:startDate>
					<xbrli:endDate>2019-12-18</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_us-gaapTransactionTypeAxis_cbioExclusiveLicenseMember_20200101_20200131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:BiogenMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:ExclusiveLicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioExclusiveLicenseMember_20200101_20200131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:BiogenMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:ExclusiveLicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:BiogenMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtProductOrServiceAxis_cbioLicenseRevenueMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cbioTransferOfExclusiveLicenseAndRelatedKnowHowMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:LicenseRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cbio:TransferOfExclusiveLicenseAndRelatedKnowHowMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtProductOrServiceAxis_cbioExclusiveLicenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:ExclusiveLicenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cbioReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CollaborationRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cbio:ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cbioReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CollaborationRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cbio:ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_cbioUnderwritersOverallotmentOptionMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cbio:UnderwritersOverallotmentOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapSubsidiarySaleOfStockAxis_cbioTwoThousandTwentyOneATMProgramMember_20211015">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cbio:TwoThousandTwentyOneATMProgramMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-10-15</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapSubsidiarySaleOfStockAxis_cbioTwoThousandTwentyOneATMProgramMember_20211015_20211015">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cbio:TwoThousandTwentyOneATMProgramMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-10-15</xbrli:startDate>
					<xbrli:endDate>2021-10-15</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioOptionsToPurchaseCommonStockMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cbio:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioOptionsToPurchaseCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cbio:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioCommonStockWarrantsMember_20210101_20211231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cbio:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioCommonStockWarrantsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cbio:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_20211130_20211130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-11-30</xbrli:startDate>
					<xbrli:endDate>2021-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_cbioSubleaseArrangementMember_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cbio:SubleaseArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2022-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_cbioSubleaseArrangementMember_20220301_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cbio:SubleaseArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-03-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_cbioBiogenAgreementMember_20220301_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cbio:BiogenAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-03-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapRelatedPartyTransactionAxis_cbioRaymondJamesAndAssociatesMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_cbioAdvisorAgreementMember_20220301_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cbio:AdvisorAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cbio:RaymondJamesAndAssociatesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-03-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionAxis_cbioRaymondJamesAndAssociatesMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_cbioAdvisorAgreementMember_20220301_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cbio:AdvisorAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cbio:RaymondJamesAndAssociatesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-03-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001124105_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220301_20220331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001124105</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2022-03-01</xbrli:startDate>
					<xbrli:endDate>2022-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_000000" fromRefs="F_000289 F_000290 F_000295 F_000296"></ix:relationship>
			<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_000001" fromRefs="F_000291 F_000292 F_000297 F_000298 F_000299 F_000300"></ix:relationship>
			<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_000002" fromRefs="F_000429 F_000430"></ix:relationship>
		</ix:resources>
	</ix:header>
</div>

<p style="border-bottom:none 0pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">002018 $480,800&#160;&#160; </p>
<p style="border-bottom:none 0pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="text-align:center;border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40.6%;margin-right:40.6%;text-indent:0%;font-weight:bold;;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form&#160;<ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001124105_20210101_20211231">10-K</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40.6%;margin-right:40.6%;text-indent:0%;font-weight:bold;;font-size:2pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark One)</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000032" name="dei:DocumentAnnualReport" contextRef="C_0001124105_20210101_20211231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr></table></div>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the year ended <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001124105_20210101_20211231" format="ixt:datemonthdayyearen">December&#160;31, <ix:nonNumeric id="F_000003" name="dei:DocumentFiscalYearFocus" contextRef="C_0001124105_20210101_20211231">2021</ix:nonNumeric></ix:nonNumeric></p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OR</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Segoe UI Symbol;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000033" name="dei:DocumentTransitionReport" contextRef="C_0001124105_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr></table></div>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from <span style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span> to <span style="text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission file number: <ix:nonNumeric id="F_000022" name="dei:EntityFileNumber" contextRef="C_0001124105_20210101_20211231">000-51173</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40.6%;margin-right:40.6%;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:22pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityRegistrantName" contextRef="C_0001124105_20210101_20211231">Catalyst Biosciences, Inc.</ix:nonNumeric></p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact Name of Registrant as Specified in its Charter)</p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40.6%;margin-right:40.6%;text-indent:0%;font-weight:bold;;font-size:3pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000023" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001124105_20210101_20211231" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="top" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000024" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001124105_20210101_20211231">56-2020050</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or Other Jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporation or Organization)</p></td>
<td valign="top" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000025" name="dei:EntityAddressAddressLine1" contextRef="C_0001124105_20210101_20211231">611 Gateway Blvd</ix:nonNumeric>. <ix:nonNumeric id="F_000026" name="dei:EntityAddressAddressLine2" contextRef="C_0001124105_20210101_20211231">Suite 710</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000027" name="dei:EntityAddressCityOrTown" contextRef="C_0001124105_20210101_20211231">South San Francisco</ix:nonNumeric>, <ix:nonNumeric id="F_000028" name="dei:EntityAddressStateOrProvince" contextRef="C_0001124105_20210101_20211231" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></p></td>
<td valign="bottom" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000029" name="dei:EntityAddressPostalZipCode" contextRef="C_0001124105_20210101_20211231">94080</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of Chief Executive Offices)</p></td>
<td valign="top" style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonNumeric id="F_000030" name="dei:CityAreaCode" contextRef="C_0001124105_20210101_20211231">650</ix:nonNumeric>) <ix:nonNumeric id="F_000031" name="dei:LocalPhoneNumber" contextRef="C_0001124105_20210101_20211231">871-0761</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s Telephone Number, Including Area Code)</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act:</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:33.24%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Title of each class</span></p></td>
<td valign="top" style="width:33.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Trading Symbol(s)</span></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33.38%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Name of each exchange on which registered</span></p></td>
</tr>
<tr>
<td valign="top" style="width:33.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000020" name="dei:Security12bTitle" contextRef="C_0001124105_20210101_20211231">Common stock</ix:nonNumeric></p></td>
<td valign="top" style="width:33.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:TradingSymbol" contextRef="C_0001124105_20210101_20211231">CBIO</ix:nonNumeric></p></td>
<td valign="top" style="width:33.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:SecurityExchangeName" contextRef="C_0001124105_20210101_20211231">NASDAQ</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act:&#160;None</p>
<p style="text-align:center;margin-bottom:2pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40.6%;margin-right:40.6%;text-indent:0%;font-weight:bold;;font-size:2pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span>&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000009" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_0001124105_20210101_20211231">No</ix:nonNumeric>&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Securities Exchange Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span>&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000011" name="dei:EntityVoluntaryFilers" contextRef="C_0001124105_20210101_20211231">No</ix:nonNumeric>&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000010" name="dei:EntityCurrentReportingStatus" contextRef="C_0001124105_20210101_20211231">Yes</ix:nonNumeric>&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;&#8201;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000019" name="dei:EntityInteractiveDataCurrent" contextRef="C_0001124105_20210101_20211231">Yes</ix:nonNumeric>&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:25.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="bottom" style="width:44.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="bottom" style="width:25.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="bottom" style="width:5.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr>
<td valign="middle" style="width:25.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="middle" style="width:44.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="middle" style="width:25.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="middle" style="width:5.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:25.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000012" name="dei:EntityFilerCategory" contextRef="C_0001124105_20210101_20211231" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></p></td>
<td valign="bottom" style="width:44.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;&#160;</p></td>
<td valign="bottom" style="width:25.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="bottom" style="width:5.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000014" name="dei:EntitySmallBusiness" contextRef="C_0001124105_20210101_20211231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:25.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="bottom" style="width:44.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="bottom" style="width:25.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="bottom" style="width:5.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:25.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:44.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:25.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="bottom" style="width:5.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000015" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001124105_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000018" name="dei:IcfrAuditorAttestationFlag" contextRef="C_0001124105_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000013" name="dei:EntityShellCompany" contextRef="C_0001124105_20210101_20211231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 25, 2022, the number of outstanding shares of the registrant&#8217;s common stock, par value $0.001 per share, was <ix:nonFraction unitRef="U_xbrlishares" id="F_000016" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0001124105_20220325" decimals="INF" format="ixt:numdotdecimal">31,477,053</ix:nonFraction>. The aggregate market value of the voting stock held by non-affiliates of the registrant as of June 30, 2021, was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000017" name="dei:EntityPublicFloat" contextRef="C_0001124105_20210630" decimals="0" format="ixt:numdotdecimal">135,045,079</ix:nonFraction>.</p><ix:nonNumeric id="F_000222" name="dei:DocumentsIncorporatedByReferenceTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true">
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the Registrant's proxy statement for its 2022 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8221;), to be filed with the U.S. Securities and Exchange Commission, no later than 120 days after the Registrant&#8217;s fiscal year ended December 31, 2021, are incorporated by reference to Part III of this Annual Report on Form 10-K.</p></ix:nonNumeric>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CATALYST BIOSCIENCES, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Annual Report on Form 10-K</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Page</span><span style="text-decoration:underline;font-weight:normal;"> </span></p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I"><span style="text-decoration:none;">PART I</span></a><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><span style="text-decoration:none;">Business</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_Risk_Factors"><span style="text-decoration:none;">Risk Factors</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><span style="text-decoration:none;">Unresolved Staff Comments</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES_NEED_TO_UPDATE_WITH_SU"><span style="text-decoration:none;">Properties</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><span style="text-decoration:none;">Legal Proceedings</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="text-decoration:none;">Mine Safety Disclosures</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
</tr>
<tr style="height:6pt;">
<td colspan="3" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II"><span style="text-decoration:none;">PART II</span></a><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><span style="text-decoration:none;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<a href="#ITEM_6_SELECTED_FINANCIAL_DATA"><span style="text-decoration:none;font-size:10pt;">Reserved</span></a><span style="text-decoration:none;">]</span><span style="font-size:10pt;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><span style="text-decoration:none;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><span style="text-decoration:none;">Quantitative and Qualitative Disclosures About Market Risk</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><span style="text-decoration:none;">Financial Statements and Supplementary Data</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><span style="text-decoration:none;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><span style="text-decoration:none;">Controls and Procedures</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OTHER_INFORMATION"><span style="text-decoration:none;">Other Information</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 9C.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9C_DISCLOSURE_FOREIGN_JURISDICTION"><span style="text-decoration:none;">D</span><span style="text-decoration:none;">isclosure</span><span style="text-decoration:none;"> Regarding Foreign Jurisdictions that Prevent Inspections</span><span style="text-decoration:none;"></span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
</tr>
<tr style="height:6pt;">
<td colspan="3" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_III"><span style="text-decoration:none;">PART III</span></a><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><span style="text-decoration:none;">Directors, Executive Officers and Corporate Governance</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><span style="text-decoration:none;">Executive Compensation</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><span style="text-decoration:none;">Security Ownership of Certain Beneficial Owners and Management</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and Related Stockholder Matters </span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><span style="text-decoration:none;">Certain Relationships and Related Transactions and Director Independence</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><span style="text-decoration:none;">Principal Accountant Fees and Services</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
<tr style="height:6pt;">
<td colspan="3" valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IV"><span style="text-decoration:none;">PART IV</span></a><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><span style="text-decoration:none;">Exhibit and Financial Statement Schedules</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 16.</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><span style="text-decoration:none;">Form 10-K Summary</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:10.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:83.56%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:93.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#LIST_EXHIBITS"><span style="text-decoration:none;">LIST OF EXHIBITS</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:93.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:93.58%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><span style="text-decoration:none;">SIGNATURES</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_I">PART I</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements and Market Data</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K and the documents incorporated by reference herein contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). All statements, other than statements of historical facts, included or incorporated by reference in this Annual Report on Form 10-K regarding our strategy, future results of operations, future financial condition, future revenues, projected costs, prospects, plans, intentions and objectives of management, as well as the assumptions that underlie these statements, are forward-looking statements. These forward-looking statements should not be relied upon as predictions of future events as we cannot assure you that the events or circumstances reflected in these statements will be achieved or will occur. Forward-looking statements are identified by words such as &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;seeks,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;pro forma,&#8221; &#8220;estimates,&#8221; or &#8220;anticipates&#8221; or the negative of these words and phrases or other variations of these words and phrases or comparable terminology, although not all forward-looking statements contain these identifying words. Such forward-looking statements are based on our management&#8217;s assumptions and assessments in light of information currently available to our management, its experience and its perception of historical trends, current conditions, expected future developments and other factors our management believes to be appropriate. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You should read these statements carefully because they discuss future expectations, contain projections of future results of operations or financial condition, or state other &#8220;forward-looking&#8221; information. These statements relate to our plans, objectives, expectations, intentions and financial performance and the assumptions that underlie these statements. For example, forward-looking statements include any statements regarding:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the strategies, prospects, plans, expectations or objectives of management for future operations&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our focus on specific product candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the scope, duration, progress or outcomes of the development of product candidates or programs&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the timelines, progress and potential results of our current and future clinical studies and trials&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the competitiveness of our products candidates against other competing products&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the benefits that may be derived from product candidates or the commercial or market opportunity in any target indication&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our ability to protect intellectual property rights&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our anticipated operations, financial position, revenues, costs or expenses, statements regarding future economic conditions or performance, statements of belief and any statement of assumptions underlying any of the foregoing&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">potential regulatory filings for or approval of any of our product candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the progress of our third-party collaborations, including estimated milestones&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our intention to seek, and the ability to enter into, strategic alliances, partnerships and collaborations&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the responsibilities of our collaborators, including the responsibility to make cost reimbursement, milestone, royalty and other payments to us, and our expectations regarding our collaborators&#8217; plans with respect to our products&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the results and timing of clinical trials and the possible commencement of future clinical trials&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">conditions for obtaining regulatory approval of our product candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">submission and timing of applications for regulatory approval&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the impact of the United States (U.S.) Food and Drug Administration (&#8220;FDA&#8221;) and other government regulations on our business&#59;</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-family:'Times New Roman';"></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uncertainties associated with obtaining and protecting patents and other intellectual property rights, as well as avoiding the intellectual property rights of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">others&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">products and companies that will compete with the products we license to third-party collaborators&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the possibility we may commercialize our own products and build up our commercial, sales and marketing capabilities and other required infrastructure&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our employees, including the number of employees and the continued service of key management, technical and scientific personnel&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our future performance and obligations under agreements we have entered into, such as our collaboration agreement with Biogen&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">our future performance and our expectations regarding our ability to achieve profitability&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">requirements for us to purchase supplies and raw materials from third parties, and the ability of third parties to provide us with required supplies and raw materials&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">sufficiency of our cash resources, anticipated capital requirements and capital expenditures and our need for additional financing, as well as our plans for obtaining and ability to obtain such additional financing&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the composition of future revenues&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">accounting policies and estimates, including revenue recognition policies&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">statements of belief and any statement of assumptions underlying any of the foregoing.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any such forward-looking statements are not guarantees of future performance and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in or contemplated by such forward-looking statements. Factors that might cause such a difference include, but are not limited to, the risks and uncertainties described in this Annual Report on Form 10-K, including those risks described in Part I, Item 1A, &#8220;Risk Factors,&#8221; as well as others that we may consider immaterial or do not anticipate at this time. The risks and uncertainties described in this report, including in Part I, Item 1A, &#8220;Risk Factors,&#8221; are not exclusive and further information concerning our company and our businesses, including factors that potentially could materially affect our operating results or financial condition, may emerge from time to time. All forward-looking statements are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. These statements, like all statements in this report, speak only as of their date, and we undertake no obligation to update or revise these statements considering future developments. We caution investors that our business and financial performance are subject to substantial risks and uncertainties and they should carefully consider the factors set forth in other reports or documents that we file from time to time with the Securities and Exchange Commission (the &#8220;SEC&#8221;).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K also contains estimates, projections and other information concerning our industry, our business, and the markets for certain drugs, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless the context requires otherwise, in this Annual Report on Form 10-K the terms &#8220;Catalyst,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Catalyst Biosciences, Inc., together with our subsidiary, Catalyst Bio, Inc., which we refer to as &#8220;Catalyst Bio.&#8221; See &#8220;Item 1&#8212; Business&#8212; Business Organization.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">I</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">tem</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;1.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_1_BUSINESS">BUSINESS. </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a research and clinical development biopharmaceutical company focused on developing protease therapeutics to address unmet medical needs in disorders of the complement system or where complement components are associated with progression of the disease state. Proteases are an important class of enzymes, which are key natural regulators of many biological processes, including the complement system. We use our protease engineering platform to create improved or novel molecules for treatment of diseases that result from dysregulation of the complement system. Our complement pipeline consists of a preclinical complement component 3 (&#8220;C3&#8221;) degrader program for geographic atrophy (&#8220;GA&#8221;) in dry age-related macular degeneration (&#8220;dAMD&#8221;), an improved Complement Factor I (&#8220;CFI&#8221;) protease, CB 4332, for subcutaneous (&#8220;SQ&#8221;) or intravitreal (&#8220;IVT&#8221;) therapy to restore complement homeostasis in diseases of overactive complement or CFI deficiencies, and proteases from our ProTUNE&#8482; C3b/C4b degrader and ImmunoTUNE&#8482; C3a/C5a degrader platforms designed to target specific disorders of the complement or inflammatory pathways. Historically, we also used our protein engineering platform to develop potential therapies for coagulation disorders, including marzeptacog alfa (activated) (&#8220;MarzAA&#8221;), a SQ administered next-generation engineered coagulation Factor VIIa (&#8220;FVIIa&#8221;) for the treatment of episodic bleeding and prophylaxis in subjects with rare bleeding disorders, and dalcinonacog alfa (&#8220;DalcA&#8221;), a next-generation SQ FIX, both of which has shown sustained efficacy and safety in mid-stage clinical trials.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The product candidates generated by our protease engineering platform are designed to have improved functional properties such as longer half-life, improved specificity and targeting, higher potency, and increased bioavailability. These characteristics potentially allow for improved safety and efficacy for SQ administration of recombinant complement regulators, or less frequently dosed intravitreal products than current therapeutics in development.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current complement portfolio consists of the development candidates CB 4332 and CB 2782-PEG. CB 4332 is a wholly owned, first-in-class improved albumin-fused CFI molecule intended for prophylactic SQ or IVT administration in individuals with an imbalance in complement homeostasis or a CFI deficiency. CB 2782-PEG is a potential best-in-class C3 degrader product candidate in preclinical development for the treatment of dry AMD that we had licensed to Biogen. In March 2022, we re-acquired the full rights to CB 2782-PEG adding to our promising portfolio, which includes CB 4332 our enhanced CFI development candidate. We have several engineered protease programs in discovery or early non-clinical development. These programs all target diseases caused by deficient regulation of the complement system and inflammation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2021 we commenced patient enrollment in the screening (&#8220;CFI-001&#8221;) and natural history of disease (&#8220;CFI-002&#8221;) studies to assess CFI blood levels in patients who have diseases related to CFI deficiency and identify those who would benefit from CB 4332 treatment (&#8220;ConFIrm&#8221; and &#8220;ConFIdence&#8221;, respectively). As of February 2022 we have completed enrollment of these studies.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our current development programs.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="guycyz0ib1ig000001.jpg" title="" alt="" style="width:624px;height:294px;" /></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to experience operational and other challenges as a result of the COVID-19 global pandemic, which could delay or impact our development programs. See Note 7, <span style="font-style:italic;">Commitments and Contingencies </span>and Other Recent Developments and Item 1A &#8211; Risk Factors for further discussion of the current and expected impact on our business and development programs.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Complement</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our protease programs are designed to take advantage of nature&#8217;s natural complement regulators that restore complement homeostasis and potentially treat a variety of complement-mediated disorders. We have several protease programs currently in preclinical discovery or early non-clinical development. These programs target diseases caused by aberrant regulation of the complement system including both ocular programs, specifically for dry AMD, and systemic complement disorders, all of which are wholly owned by Catalyst.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The complement system is an enzyme-based innate immune defense system with the primary role of protecting the body from pathogens. The system is naturally regulated by proteases which is the basis for our approach to addressing complement-driven diseases. Similar to the coagulation system, the complement system employs several triggering pathways, known as the classical pathway (&#8220;CP&#8221;), lectin pathway (&#8220;LP&#8221;) and alternative<span style="font-size:12pt;"> </span>pathway (&#8220;AP&#8221;), which are followed by a cascading system of enzymatic reactions driven by proteases and their cofactors that, when functioning properly, ultimately leads to the destruction and removal of the pathogen or unwanted cells and proteins.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:13.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="guycyz0ib1ig000002.jpg" title="" alt="" style="width:530px;height:530px;" /><span style="color:#000000;font-size:13.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;color:#000000;">*</span><span style="font-size:8pt;color:#000000;">Figure adapted from </span><span style="font-size:8pt;color:#000000;">Mastellos</span><span style="font-size:8pt;color:#000000;"> </span><span style="font-style:italic;font-size:8pt;color:#000000;">et</span><span style="font-size:8pt;color:#000000;"> </span><span style="font-style:italic;font-size:8pt;color:#000000;">al</span><span style="font-size:8pt;color:#000000;">., Clinical promise of </span><span style="font-size:8pt;color:#000000;">next-generation</span><span style="font-size:8pt;color:#000000;"> complement therapeutics. Nature Reviews. 2019</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deficient or excessive activation of the complement system leads to severe disorders, including <span style="color:#000000;">micro-thrombotic, </span>autoimmune and/or immune-complex diseases<span style="color:#000000;">, severe infectious diseases, and degenerative ophthalmic or neurologic diseases affecting a variety of tissues and organ systems</span>. Disorders of the complement system are typically manifested by the <span style="color:#000000;">absence or imbalance of </span>complement regulator activity, or an overactivation<span style="color:#000000;"> of one or more pathways. The absence of regulation can cause the complement system to become self-destructive or not provide the necessary protection when needed. The protease therapeutic candidates generated by our platforms are designed to correct or restore the missing balance in the complement system that drives several diseases.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proteases are uniquely poised to regulate key biological functions such as the complement system, either by promoting or limiting the cascade of events that leads to eventual clearing of foreign and damaged proteins, inflammation and formation of the membrane attack complex, which is deposited on the surface of cells and drives their destruction. Compared with antibodies and small molecule inhibitors that generally require a sustained excess of therapeutic compound over that of the target, Catalyst&#8217;s protease therapeutic candidates are based on natural regulatory proteins that are capable of rapidly engaging and modulating large quantities of target molecules, as each protease molecule can degrade many target molecules over their effective lifetime. This means that our proteases are ideal for regulating high abundancy targets such as complement proteins in a way antibodies and small molecule </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inhibitors canno</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t. </span><span style="color:#000000;">A</span><span style="color:#000000;"> protease therapeutic </span><span style="color:#000000;">is </span><span style="color:#000000;">not consumed in the process of </span><span style="color:#000000;">cleaving or degrading</span><span style="color:#000000;"> its target</span><span style="color:#000000;">, t</span><span style="color:#000000;">herefore, smaller amounts of protease-based drug molecules can have</span><span style="color:#000000;"> a</span><span style="color:#000000;"> profound impact on biological pathways</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CB 2782-PEG: C3 Degrading Protease</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CB 2782-PEG is an engineered pegylated C3 degrader previously licensed to Biogen that we designed with a best-in-class anti-C3 profile for geographic atrophy (&#8220;GA&#8221;) in dry AMD.<span style="color:#000000;"> </span>Dry AMD is an ocular disease that leads to vision loss and blindness for which there is currently no approved therapy. CB 2782-PEG degrades C3 in the eye reducing the steady state level of C3 activity. It is expected that maintaining low C3 levels in the eye can significantly slow disease progression and vision loss in patients with dry AMD. We have demonstrated in preclinical non-human primate models that we have the potential to reduce C3 levels in humans based on modeling studies for up to 3 months with a single intravitreal injection. In September 2021, Apellis released the results of the DERBY and OAKS phase 3 trials for GA secondary to dry AMD, showing that once-monthly pegcetacoplan, a pegylated C3 targeted inhibitor, was safe and efficacious, meeting its primary endpoint in one trial and narrowly missing the primary endpoint in a second trial for reducing GA lesion growth over a 12-month period. Further subpopulation analyses demonstrated a greater effect of reducing GA lesion growth in those subjects with extrafoveal lesions at baseline. CB 2782-PEG provides a differentiated mechanism of action by degrading both C3 and one of its byproducts, C3a potentially offering not only less frequent dosing but a more efficacious mechanism than pegcetacoplan or other complement inhibitors in development for GA.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The global market potential in dry AMD has been estimated to be $8.6 billion which could grow to over $18.0 billion by 2028. In December 2019, we entered into a License and Collaboration Agreement with Biogen for the development and commercialization of CB2782-PEG.<span style="color:#000000;"> In March 2022, Biogen terminated the license agreement and returned full rights to CB 2782-PEG</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">CB 4332: Engineered Complement Factor I</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CB 4332 is an engineered albumin-fused version of the CFI protease with an extended half-life that can be dosed subcutaneously or intravitreally in individuals who would benefit from enhanced regulation of complement. CFI is the central regulator of the complement system and CB 4332 has the potential to address several mechanistically related diseases driven by complement imbalance such as: Lupus Nephritis (&#8220;LN&#8221;), Systemic Lupus Erythematosus (&#8220;SLE&#8221;), warm Autoimmune Hemolytic Anemia (&#8220;wAIHA&#8221;), atypical Hemolytic Uremic Syndrome (&#8220;aHUS&#8221;), C3 Glomerulonephritis (&#8220;C3G&#8221;), and Immune Complex Membranoproliferative Glomerulonephritis (&#8220;IC-MPGN&#8221;), dry AMD and complete CFI deficiency (&#8220;CFID&#8221;), a rare immunodeficiency primarily affecting children. These are severe, chronic, life-threatening diseases that result in a significantly decreased quality of life for the afflicted individual.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CB 4332 can be dosed subcutaneously for systemic diseases or by IVT injection for ophthalmic indications. As a key complement regulator, CFI has the potential to be used in several complement dysregulated diseases (<span style="font-style:italic;">e.g</span>., those associated with hyperactive complement) in which additional upstream regulation may prove more effective than inhibiting specific downstream targets such as C3 or C5, where many of current molecules in development are targeted.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Individuals with complete or significant absence of endogenous CFI may present with a variety of disease manifestations, such as recurrent invasive infections with encapsulated bacteria, but are also at risk of developing autoimmune and/or immune-complex diseases such as chronic inflammation of the blood vessels of the brain, spinal cord, heart, or kidneys. No CFI replacement therapy, including for prophylactic use, has been approved, and patients often receive supportive care with lifelong antibiotic treatment, which may cause a range of additional problems. <span style="color:#000000;">We have received pre-IND guidance from the FDA as well as Rare Pediatric Disease Designation of CB 4332 for treatment of CFI deficiency in January 2022.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Low circulating serum CFI levels have been shown to be associated with rare CFI genetic variants and all forms of AMD ranging from early to late-stage manifestations. Studies have estimated the prevalence rates of CFI deficiency in GA to be approximately 20%, suggesting that CFI is a prognostic biomarker for progression of GA. Approximately 1 million individuals globally are predicted to have low serum CFI levels and may potentially benefit from targeted CFI therapy. Gyroscope released interim results from its FOCUS phase 1/2a trial for patients with GA and having rare CFI variants, showing that gene therapy with GT005, an AAV-delivered CFI rebalanced </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the overactivation of complement observed in the vitreous with sustained expression of CFI.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The FOCUS data also showed that AAV-delivered CFI reduced complement biomarkers in the broader GA population who do not have a rare CFI genetic variant.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have additional early-stage complement discovery programs that target different proteins of the complement system including proteases from our ProTUNE&#8482; C3b/C4b degrader and ImmunoTUNE&#8482; C3a/C5a degrader platforms. These proteases are designed to target specific disorders of the complement or inflammatory pathways. The ProTUNE&#8482; platform generates optimized, next-generation engineered CFI molecules that are selectively enhanced for potency and target engagement. We expect to nominate a development candidate and target indication from this platform in 2022. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Complement intellectual property</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The United States Patent and Trademark Offices issued a patent covering Catalyst&#8217;s portfolio of engineered proteases that selectively cleave and degrade complement Factor 3 (C3), including the lead candidate CB 2782-PEG, a potential best-in-class treatment for dry AMD. These modified proteases inhibit complement activation and have the potential to treat multiple diseases in which complement activation plays a role. The patent provides protection until at least 2038. Our portfolio further encompasses additional issued patents on complement protein degrading proteases and pending applications in the complement space across a range of targets and protease scaffolds, including multiple pending applications covering CB 4332 and next generation engineered CFI molecules.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Coagulation Programs for Licensing </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hemophilia is a rare and serious bleeding disorder that results from a genetic or an acquired deficiency of a factor required for normal blood coagulation. There are two major types of hemophilia: Hemophilia A and Hemophilia B, caused by abnormalities in coagulation Factor VIII or Factor IX, respectively. Deficiencies in these factors reduce the ability of the affected individuals to form clots and stop bleeding. Hemophilia A occurs in approximately 1 in 5,000 male births, and Hemophilia B in approximately 1 in 20,000 male births. Patients with hemophilia suffer from spontaneous and traumatic bleeding episodes that can become limb- or life-threatening. In cases of severe hemophilia, spontaneous bleeding into muscles or joints is frequent and often results in disabling irreversible joint damage. Currently there is no cure for hemophilia.<span style="font-style:italic;"> </span><span style="color:#000000;">Hemophilia treatments involve on-demand management of acute bleeding episodes or prophylactic treatment using factor replacement or bypassing therapy. Replacement therapy involves frequent IV administration of the missing factors to prevent or stop bleeding. IV infusion is invasive, painful, time consuming and particularly challenging to administer to children. Often times, patients must seek assistance of a health professional for the IV infusion.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that SQ dosing will be an important improvement for the treatment of hemophilia and other rare benign hematology indications. Our nonclinical and clinical studies have shown that MarzAA is nine-fold more potent than NovoSeven RT and that DalcA is 22-fold more potent than BeneFIX. The enhanced potency of MarzAA and DalcA allows for SQ dosing using a small volume injection, which we believe will provide for more effective, durable and convenient treatments of spontaneous bleeds with MarzAA and prophylactic protection with MarzAA and DalcA, especially for children and adults with difficult IV access. In late 2018 Hemlibra&#174;, a bispecific antibody mimicking FVIIIa, was approved for SQ prophylaxis in Hemophilia A with or without inhibitors but Hemlibra cannot treat breakthrough spontaneous bleeding.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">MarzAA and DalcA Clinical Development </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MarzAA is a potent, subcutaneously administered, next-generation Factor VIIa variant. The development program began with a Phase 1 clinical trial evaluating the pharmacokinetics and pharmacodynamics of MarzAA administered IV in patients with severe Hemophilia A and B with and without inhibitors. In 2019, we successfully completed a Phase 2 open-label SQ prophylaxis trial that met all primary and secondary end points. The Phase 2 trial was designed to evaluate the efficacy of MarzAA in preventing bleeding episodes. We completed a Phase 1/2 PK/PD study in 2020, to evaluate the pharmacokinetics and pharmacodynamics of ascending single dose levels of MarzAA and twice and thrice dosing at 3-hourly intervals in individuals with Hemophilia A or B with or without inhibitors. The purpose of the trial was to determine if the timing and peak levels achieved were sufficient to treat spontaneous, episodic or breakthrough bleeding with SQ dosing and determine if increasing dose levels resulted in dose proportional pharmacokinetics. W<span style="color:#000000;">e commenced enrollment of a Phase 3 registrational trial of MarzAA for episodic </span></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;">treatment of spontaneous or traumatic bleeding episodes in adolescents and adults with congenital </span><span style="color:#000000;">hemophilia </span><span style="color:#000000;">A or </span><span style="color:#000000;">hemophilia </span><span style="color:#000000;">B with inhibitors</span><span style="color:#000000;"> in May 2021.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">On November 12, 2021, we announced the discontinuation of</span> the Phase 3 trial based on a number of factors, including challenges in enrollment resulting from the limited number of potential patients eligible to enroll in this trial, competition from competing approved therapies, delays in enrollment resulting from COVID-19, the capital requirements to complete the trial, and other factors. Patients enrolled in the study returned to their standard of care and completed all required safety assessments. In the patients enrolled to date, we have successfully treated bleeds with SQ MarzAA and have not observed any adverse events. We plan to report these data at an appropriate medical conference in the future. We had also begun enrollment of <span style="color:#000000;">a Phase 1/2 trial of MarzAA for treatment of bleeding in individuals with Factor VII Deficiency, Glanzmann Thrombasthenia, and hemophilia A with inhibitors on emicizumab prophylaxis. We have discontinued this trial as well, in light of the difficulties in identifying and enrolling eligible patients, the capital requirements to complete the trial, and other factors. We believe that a SQ recombinant Factor VIIa therapy, like MarzAA, has the potential to be an important treatment option for patients with various bleeding disorders and are exploring opportunities to license or sell MarzAA to another party for further development.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DalcA is a next-generation SQ Factor IX product candidate for the prophylactic treatment of individuals with Hemophilia B. We completed a Phase 1/2 SQ dosing trial that evaluated the safety and efficacy of DalcA in patients with severe Hemophilia B in a collaboration with ISU Abxis. In 2020, we completed an open-label Phase 2b study to evaluate the ability of DalcA to maintain steady state protective Factor IX levels above 12% in six individuals with severe hemophilia B. Each subject received a single intravenous dose, followed by daily SQ doses of DalcA for 28 days during which FIX activity levels, clotting parameters, half-life, safety, tolerability and anti-drug antibody formation were monitored. <span style="Background-color:#FFFFFF;">We are actively seeking a partner for this program. </span>We have received guidance from the FDA on the design of the registrational Phase 3 clinical trial, have the necessary data to support its initiation, and are exploring opportunities to license or sell DalcA to another party for further development.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Preclinical Factor IX Gene Therapy</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Factor IX gene therapy construct CB 2679d-GT has demonstrated a 2-fold to 3-fold higher activity resulting in improved clotting time and blood loss in a preclinical Hemophilia B mouse model compared with the Padua variant of Factor IX. By its increased activity, CB 2679d-GT has the potential to reach higher Factor IX activity levels at lower vector doses which could improve tolerability of the vector as well as efficacy of the transgene, and ultimately lower manufacturing costs. We have licensed AAV technology from The Board of Trustees of The Leland Stanford Junior University (&#8220;Stanford&#8221;) and have evaluated optimized vector constructs in a non-human primate study under a sponsored research agreement with Stanford.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Strategy</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are leveraging a unique protease engineering platform that builds on nature&#8217;s way of regulating key processes to generate a portfolio of novel and differentiated biopharmaceutical drug candidates. Our portfolio of engineered protease therapies is designed for individuals with disorders of the complement system across a range of potential indications where new or better treatment options are in need. The scientific basis of our strategy is based on the use of proteases, nature&#8217;s key regulatory proteins that can be engineered to circumvent the limitations of small molecule and antibody-based therapies. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In late 2021 we announced a strategic change in corporate strategy, pivoting from hemophilia to a highly promising complement therapeutics and protease medicines platform. In February of 2022 we announced that we would explore strategic alternatives for the company. In March of 2022, we re-acquired the full rights to CB 2782-PEG, adding to our promising portfolio, including CB 4332 our enhanced CFI development candidate. Having the full rights to these two potentially best-in-class candidates in dry AMD provides another opportunity in our exploration of strategic alternatives. We also implemented additional expense reduction measures, including headcount reductions, while we continue this exploration.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Collaborations</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">MarzAA. <span style="font-style:normal;color:#000000;">In 2009, we licensed MarzAA to Wyeth Pharmaceuticals, Inc. (&#8220;Wyeth&#8221;). Wyeth was subsequently acquired by Pfizer, Inc. (&#8220;Pfizer&#8221;) who terminated the license and collaboration agreement after completing a Phase 1 IV trial. Pursuant to the collaboration termination agreement, in exchange for the rights to certain Pfizer technology, we agreed to make payments to Pfizer in an aggregate amount equal to up to $17.5 million, payable upon the achievement of clinical, regulatory and commercial milestones. Following commercialization of any covered product, Pfizer would also receive a single-digit royalty on net product sales on a country-by-country basis for a predefined royalty term. In February 2018, we paid Pfizer a $1.0 million milestone payment based on the dosing of the first patient in a Phase 2 study.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">DalcA<span style="color:#000000;">. </span><span style="font-style:normal;">We collaborated with ISU Abxis (&#8220;ISU&#8221;), in the early development of DalcA. Under the collaboration agreement, ISU conducted the Phase I clinical trial of DalcA and was responsible for all manufacturing activities for the Phase 1 clinical trial. Pursuant to the agreement, as amended in December 2018, ISU is entitled to a low single-digit royalty payment, on a country-by-country basis, for net product sales of DalcA by the Company or its affiliates in each country other than South Korea. ISU is also entitled up to $19.5 million in milestone payments, of which $2.5 million are regulatory and development milestone payments and up to $17.0 million in commercial milestone payments.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">CB2782-PEG. <span style="font-style:normal;">In 2019, we agreed to collaborate with Biogen to develop and commercialize CB 2782-PEG and our other anti-C3 proteases for the potential treatment of dry AMD and other disorders. In March 2022, Biogen terminated the license and collaboration agreement. As a result of the termination, Biogen will no longer have the rights to develop and commercialize CB 2782-PEG. We were responsible for certain preclinical and manufacturing activities, and Biogen was solely responsible for funding the preclinical and manufacturing activities and performing investigational new drug (&#8220;IND&#8221;) enabling activities, worldwide clinical development, and commercialization. We received a $15.0 million upfront payment from Biogen in January 2020 and were eligible to receive up to $340.0 million in milestone payments, along with tiered royalties for worldwide net sales of this product candidate up to low double-digits. </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also collaborated with Mosaic Biosciences (&#8220;Mosaic&#8221;) in the development of our complement product candidates including CB 2782-PEG and CB 4332. Under the collaboration agreement, as amended in December 2019, Mosaic will perform all future services for an FTE-based fee. Pursuant to a subsequent amendment in May 2020, Mosaic received a one-time cash payment of $0.8 million and is eligible to receive up to $4.0 million in potential future milestone payments for regulatory and clinical development milestones resulting from the development of CB 2782-PEG and CB 4332 payable in cash or common stock at the Company&#8217;s election. As a result, we now own one hundred percent of all future payment streams related to these product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Competition</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates will face competition from approved therapeutics. Competition for our product candidate pipeline comes primarily from large, well-established pharmaceutical companies, who have greater financial resources and expertise in research and development, manufacturing, conducting clinical trials, and marketing approved products. Mergers and acquisitions within the pharmaceutical and biotechnology industries may further concentrate competitors&#8217; resources. We are not only competing with these companies in terms of technology, but also in recruiting and retaining qualified scientists and management personnel, in establishing partnerships with clinical trial sites, and in enrolling individuals into clinical trials.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to current Standard of Care for individuals, clinical trials are being pursued by several parties in the field of biologics and in our lead indications. These products in development may provide efficacy, safety, convenience, and other benefits that are not provided by currently marketed therapies. As a result, they may provide significant competition for any of our product candidates for which we obtain marketing approval. Based on publicly available information, the following are some of the products currently on market or being developed by competitors in indications overlapping with those of our programs.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Ocular Complement Competition</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">While there are no currently approved treatments for dry AMD, several companies are developing cyclic peptide, aptamer, antibody or gene therapy based anti-complement product candidates for the treatment of dry AMD that are currently in clinical studies:</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Apellis has completed two Phase 3 studies (DERBY/OAKS) in 2021 to compare the efficacy and safety of intravitreal pegacetacoplan therapy, a PEGylated cyclic peptide, in patients aged 60 years and older with GA secondary to AMD.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Iveric Bio (formerly Ophthotech) is developing two therapies to treat GA secondary to dry AMD. Iveric Bio completed its Phase 2b clinical of Zimura&#174; (avacincaptad pegol) with positive data in patients with dry AMD and has an ongoing Phase 3 trial (GATHER2).</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Gemini Therapeutics is developing &#8220;GEM103&#8221; a recombinant human complement factor H (&#8220;FH&#8221;) for patients with genetically well-defined dry AMD and for other genetically defined subpopulations of patients with dry AMD.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Gyroscope Therapeutics is developing &#8220;GT005&#8221; a gene therapeutic approach to expressing additional CFI in the patient&#8217;s eye after subretinal delivery. GT005 is being developed for a genetically well-defined subpopulation of patients with dry AMD in a Phase 1/2b trial (FOCUS). In February 2022, Gyroscope announced that Novartis has completed its acquisition of Gyroscope.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">NGM Biopharmaceuticals is expecting topline data from the Phase 2a study (CATALINA) to evaluate the safety and efficacy of intravitreal NGM621 in the fourth quarter of 2022. NGM621 is a C3-targeting monoclonal antibody being developed to treat geographic atropy secondary to AMD.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Systemic Complement Competition</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Alexion Pharmaceuticals (a division of AstraZeneca) markets eculizumab and ravulizumab for use in aHUS.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Apellis is conducting clinical development for APL-2 (pegcetacoplan), a pegylated peptide based C3 inhibitor, in IgA Nephropathy (&#8220;IgAN&#8221;), LN, Membranous Nephropathy (&#8220;MN&#8221;), C3G, and Dense Deposit Disease.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">ChemoCentryx markets avacopan (&#8220;TAVNEOS&#8221;), a twice daily oral small molecule inhibitor of the complement 5a receptor (&#8220;C5aR&#8221;) for use in combination with other standard of care such as glucocorticoids to treat adults with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Avacopan is further being developed for in C3G and Hidradenitis Suppurativa (&#8220;HS&#8221;) in ongoing phase 2 studies.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Novartis is conducting clinical development for iptacopan (&#8220;LNP023&#8221;), a small peptide complement factor B inhibitor. Iptacopan is in development for PNH, as well as C3G and several other rare renal diseases including IgAN, aHUS, and membranous nephropathy. Novartis expect first FDA filings in 2023. Iptacopan has received Rare Pediatric Disease Designation in C3G.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Omeros is developing OMS721 (&#8220;narsoplimab&#8221;). Narsoplimab is a human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (&#8220;MASP-2&#8221;), the effector enzyme of the lectin pathway of the complement system. Clinical activities have been initiated in IgAN, LN, MN, &#38; C3G and a phase 3 clinical program is underway in aHUS.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Argenx is developing ARGX-117, a humanized antibody targeting complement compenent 2 (&#8220;C2&#8221;) intended to inhibit the function of C2 and downstream complement activation. ARGX-117 is currently in a Phase 1 study for Multifocal Motor Neuropathy (&#8220;MMN&#8221;).</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:7.69%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Factor VIIa Competition</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Novo Nordisk&#8217;s NovoSeven RT is an intravenous recombinant Factor VIIa indicated for treatment of bleeding episodes in individuals with Hemophilia A or B with an inhibitor to Factor VIII or Factor IX. NovoSeven was approved in 1999 and was approved as a room temperature formulation &#8220;NovoSeven RT&#8221; in 2008. The treatment has since been approved for on demand use in individuals with Factor VII deficiency and Glanzmann thrombasthenia, but not for prophylaxis. It is also approved for treatment of bleeding episodes and peri-operative management in adults with Acquired Hemophilia.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Takeda&#8217;s FEIBA is a plasma-based composition of coagulation factors indicated for intravenous on-demand and prophylactic use in the treatment of individuals with Hemophilia A or B with inhibitors. FEIBA has been on the market for more than 30 years.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Roche&#8217;s Hemlibra (emicizumab-kxwh), a bispecific Factor IXa-Factor X monoclonal antibody is indicated for routine SQ prophylaxis in adults and children with Hemophilia A with a Factor VIII inhibitor. Emicizumab received approval from the FDA in 2017. Emicizumab cannot treat episodic bleeding.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:11.54%;text-indent:-3.85%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">HEMA Biologics&#8217; SEVENFACT is an intravenous recombinant Factor VIIa indicated for treatment of bleeding episodes in individuals with Hemophilia A or B with or without an inhibitor to Factor VIII or Factor IX approved in 2020.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">In addition to currently approved products, several other companies including Novo Nordisk, Pfizer, Genzyme, Hemab and others are developing SQ agents for the treatment of rare bleeding disorders using a variety of technologies.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:11.54%;text-indent:-3.85%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Factor IX Competition</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">BeneFIX, a recombinant Factor IX indicated for treatment of individuals with Hemophilia B, was approved in 1997 and is marketed by Pfizer.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Alprolix, a Factor IX-Fc fusion product was approved in 2014 and is marketed by Sanofi Aventis and Swedish Orphan Biovitrum (&#8220;SOBI&#8221;) in Europe, Russia, North Africa and the Middle East. Idelvion, a Factor IX-albumin fusion product marketed by CSL Behring was approved by the FDA in 2016. Idelvion is approved for weekly dosing for adolescents and adults and bi-weekly at a higher dose for those same patients if well controlled on the original regimen. It is approved for weekly in patients &#60;12 years of age.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Novo Nordisk&#8217;s glycopegylated-Factor IX product Rebinyn&#174; was approved by the FDA in 2017 but is not indicated for routine prophylaxis in the U.S. Rebinyn is approved for on-demand treatment and control of bleeding episodes as well as Perioperative management of bleeding.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:11.54%;text-indent:-3.85%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Factor IX Gene Therapy Competition</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Courier New;text-transform:none;font-variant: normal;letter-spacing:0pt;">o</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">While there are no currently approved Factor IX gene therapy treatments for Hemophilia B, several companies, are developing Factor IX gene therapy treatments in clinical studies with the Padua FIX variant including UniQure/CSL, Spark/Pfizer and Freeline.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial opportunity in different indications could be reduced or eliminated if our competitors develop and market products that are safer, more effective, more convenient to use, or less expensive to use than our products. Furthermore, if competitors gain FDA approval faster than we do, we may be unable to establish a strong market presence or to gain market share. The key competitive factors affecting the success of all our product candidates, if approved, are likely to be their efficacy, safety, convenience, price, the level of generic competition, and the availability of reimbursement from government and other third-party payors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have established a broad intellectual property portfolio including patents and patent applications covering the identification, selection, optimization, and manufacture of human proteases, the composition of matter and methods of use of our product candidates and related technology, and other inventions that are important to our business.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also rely on trade secrets relating to our proprietary technology platform and know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen, and maintain our proprietary position in the field of human protease engineering</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our patent portfolio as of December 31, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> is more fully described below.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success will depend significantly on our ability to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Defend and enforce our patents&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Maintain our licenses to use intellectual property owned by third parties&#894; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Preserve the confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and other proprietary rights of third parties.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, a third-party may hold intellectual property, including patent rights that are important or necessary to the development of our products. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There may be third party patents or patent applications with claims to compositions of matter, materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe.There is a patent family pending in the U.S. in which claims that may read on MarzAA have been filed. We, however, do not believe such claims are patentable. If they were to issue, we would take appropriate action to challenge their enforceability and/or validity. We are also aware of additional patents that have issued in the United States and Europe that have claims related to Factor VII. We do not believe that MarzAA does or will infringe any valid claims in such patents.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent positions of biopharmaceutical companies like us are generally uncertain and involve complex legal, scientific, and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Consequently, we do not know whether any of our product candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented, or invalidated by third parties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because patent applications in the United States and certain other jurisdictions are maintained in secrecy for 18 months, and since publication of discoveries in the scientific or patent literature often lags actual discoveries, we cannot be certain of the priority of inventions covered by pending patent applications. Moreover, we may have to participate in interference proceedings declared by the United States Patent and Trademark Office, or USPTO, or a foreign patent office to determine priority of invention or in post-grant challenge proceedings, such as oppositions, that challenge priority of invention or other features of patentability. Such proceedings could result in substantial cost, even if the eventual outcome is favorable to us.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All our patents and applications were internally developed and assigned to us, except for two granted South Korean patents that are co-owned. Members of the family directed to screening methods (4 patents, including 2 of the issued U.S. patents) are jointly owned with the Torrey Pines Institute for Molecular Studies, which licensed its interest to us. As of December 31, 2021, our current patents and patent applications include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">73 issued patents, including 4 issued U.S. patents, and 10 patent applications, including 3 pending U.S. patent applications, covering modified Factor VII polypeptides, including our lead product candidate, </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="color:#000000;">MarzAA, and methods of production</span><span style="color:#000000;"> and use</span><span style="color:#000000;"> of modified Factor VII polypeptides. The U.S. patents, with patent term adjustment, expire in 2029 and 2031.</span><span style="color:#000000;"> The pending applications, if granted, are expected to expire in 2029 and 2040.</span><span style="color:#000000;"> The foreign patents expire in 2029.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">34 patents, including 4 issued U.S. patents, and 7 patent applications, including 2 U.S. patent applications, covering modified Factor IX polypeptides, such as our clinical candidate DalcA, nucleic acid molecules encoding modified Factor IX polypeptides, therapeutic uses, and a provisional application directed to formulations. The U.S. patents and patent applications, including patent term adjustment, expire, or are expected to expire, respectively, in 2030-2031 and 2038, and the foreign patents and patent applications, if granted, expire, or are expected to expire, respectively, in 2031. The provisional application directed to formulations, if when filed as a utility patent, and if issued, would expire in 2041, or later if there are patent term adjustments.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">1 PCT patent application filed and 1 U.S. patent application in progress, covering adeno-associated viral vectors that have increased tropism for hepatocytes and encode modified factor IX polypeptides. The applications, if granted, are expected to expire in 2040.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">65 patents, including 7 issued U.S. patents, and 59 patent applications, including 3 U.S. patent applications, covering novel proteases, nucleic acid molecules encoding novel proteases, or therapeutic uses. The U.S. patents and patent applications, including patent term adjustment, expire, or are expected to expire, respectively in 2025-2029 and 2038-2041, and the foreign patents and foreign patent applications, if granted, expire, or are expected to expire, respectively, in 2025-2027 and 2038-2039.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">7 patent applications, including 1 non-provisional U.S. patent application, 3 provisional U.S. patent applications, and 3 foreign patent applications covering CB 4332 and next-generation engineered CFI molecules.&#160;&#160;The U.S. patent applications and foreign patent applications , if pursued and granted, are expected to expire in 2041-2042. The foreign patent applications, if granted, are expected to expire in 2041.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">2 provisional U.S. patent applications covering modified Factor B proteases, if pursued and granted, are expected to expire in 2042. 2 provisional U.S. patent applications covering other complement targeting proteases, if pursued and granted, are expected to expire in 2042.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term for individual patents depends upon the legal term for patents in the countries in which they are granted. In most countries, including the United States, the patent term is 20 years from the earliest claimed filing date of a non-provisional patent application in that country or the international filing date. In the United States, a patent&#8217;s term may, in certain cases, be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and granting a patent, or may be shortened if a patent is terminally disclaimed over a commonly owned patent or a patent naming a common inventor and having an earlier expiration date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration date of a U.S. patent as partial compensation for the length of time the drug is under regulatory review while the patent is in force. The regulatory review period that occurs after the patent to be extended was issued is eligible to be counted for extension. The extension is calculated as one-half of the time of the testing phase added to time in the approval phase. The testing phase is the period between the effective date of an investigational product exemption (Investigational New Drug Application) and the initial submission of the marketing application (New Drug Application or Biologic License Application). The approval phase is the period between the submission and approval of the marketing application. Extensions can be reduced by any time that the applicant did act not with due diligence as determined by the FDA. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent applicable to each regulatory review period may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. Similar provisions are available in the European Union and certain other foreign jurisdictions to extend the term of a patent that covers an approved drug.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the future, to the extent our product candidates including MarzAA, DalcA, Anti-C3 and systemic complement proteases receive approval by the FDA or foreign regulatory authorities, we expect to apply for patent term </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">extensions on issued patents covering those products, depending upon the length of the clinical trials for each drug and other factors.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="Manufacturing">Manufacturing</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our team has in-depth knowledge on biologics development, manufacturing and CMC regulatory requirements. We do not have any manufacturing facilities and we currently rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for clinical or commercial uses. We own or have rights to all intellectual property developed in such manufacturing development activities that are specifically related to our product candidates and have a royalty-free and perpetual license to use the intellectual property to the extent reasonably necessary to make our product candidates, including commercial manufacturing. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Drug Substance manufacturing</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have a long-term development and manufacturing services agreement with AGC Biologics, Inc. (&#8220;AGC&#8221;). AGC has global manufacturing sites and we use their facilities in the U.S. and Europe for drug substance manufacturing of MarzAA, DalcA, and CB 2782-PEG. <span style="letter-spacing:-0.1pt;">In November 2021, we provided notice of intent to terminate our agreements with AGC related to the manufacturing of MarzAA and incurred charges of $3.8 million to write-off prepaid manufacturing costs that will no longer be used for the development of MarzAA.</span>  Additionally we have development and manufacturing services agreements with Abzena (&#8220;Abzena&#8221;) at their San Diego facility for drug substance manufacturing of CB 4332.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Drug Product manufacturing</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have a long-term clinical supply services agreement with Catalent Indiana, LLC (&#8220;Catalent&#8221;). Catalent has facilities in the U.S. and Europe and conducts drug product development and manufacturing for MarzAA and DalcA. We also work with Symbiosis Pharmaceutical Services Limited on drug product manufacturing for MarzAA on a fee-for-services basis. Symbiosis has a facility in the United Kingdom. For drug product finish and fill services supporting the CB 4332 program, we are working with Integrity Bio (now part of Curia).&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commercialization</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have yet to establish a sales, marketing, or product distribution infrastructure for our product candidates, which are still in pre-clinical or clinical development. We may retain commercial rights for our product candidates in the United States. We have also granted ISU rights to commercialize DalcA in South Korea. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Government Regulation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a clinical-stage biopharmaceutical company that operates in the United States, we are subject to extensive regulation. Our engineered human protease products will be regulated as biological products. Biological products, including engineered human proteases, are subject to regulation under the Federal Food, Drug, and Cosmetic Act, or FD&#38;C Act, and the Public Health Service Act, or PHS Act, and other federal, state, local, and foreign statutes and regulations. The FD&#38;C Act and the PHS Act and their implementing regulations govern, among other things, the research, development, testing, manufacturing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of biological products. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA approval must be obtained before clinical testing of a biological product begins and before the marketing of biological products. The process of obtaining regulatory approvals and the subsequent compliance with federal, state, local, and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development, the approval process, or after product approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could include, among other actions, refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning or untitled letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">US Biological Products Development Process</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process required by the FDA before a biological product may be marketed in the United States generally involves the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">completion of nonclinical laboratory tests and animal studies according to good laboratory practices, or GLPs, and applicable requirements for the humane use of laboratory animals or other applicable regulations&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">submission to the FDA of an investigational new drug application or IND, which must become effective before human clinical trials may begin&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">performance of adequate and well-controlled human clinical trials according to the FDA&#8217;s regulations, commonly referred to as good clinical practices, or GCPs, and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biological product for its intended use&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">submission to the FDA of a biologics license application or BLA for marketing approval that includes substantial evidence of safety, purity and potency from results of nonclinical testing and clinical trials&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced to assess compliance with good manufacturing practices or GMP, to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s identity, strength, quality and purity and, if applicable, the FDA&#8217;s current good tissue practices, or GTPs, for the use of human cellular and tissue products&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-family:Times New Roman;">potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA&#894; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:2.88%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.88%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">FDA review and approval, or licensure, of the BLA.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before testing any biological product candidate, including an engineered human protease, in humans, the product candidate enters the preclinical testing stage. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the product candidate. The conduct of the preclinical tests must comply with federal regulations and requirements, including GLPs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical trial sponsor must submit the results of the preclinical tests, together with the manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some preclinical testing may continue even after an IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA places the clinical study on a clinical hold within that 30-day period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a biological product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such trials.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of the biological product candidate to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted and monitored in accordance with the FDA&#8217;s regulations comprising the GCP requirements, including the requirement that all research patients provide informed consent. Further, each clinical trial must be reviewed and approved by an independent institutional review board, or IRB, at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Clinical trials also may be reviewed by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees basic and clinical research conducted at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Phase 1:</span><span style="font-family:Times New Roman;"> The product candidate is initially introduced into healthy human subjects and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.03%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Phase 2:</span><span style="font-family:Times New Roman;"> The product candidate is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.37%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.08%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;">Phase 3:</span><span style="font-family:Times New Roman;"> Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the product candidate and provide an adequate basis for product labeling.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In most cases, the FDA requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the drug. A single Phase 3 trial with other confirmatory evidence may be sufficient in instances where the study is a large multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible such as in rare or orphan diseases like hemophilia. In the case of hemophilia, almost all clinical trials are conducted as open-label single arm trials, in which both the researchers and participants know which treatment is being administered and there is no placebo or blinded portion of the trial because there are too few subjects available in these orphan populations to perform statistically powered placebo or active comparator trials. Endpoints for on-demand therapies are the number of treatments required to control bleeding episodes and for prophylaxis therapies are the calculated annualized bleeding rates. Bleeding rates during the trial are compared to historic bleeding rates for participating individuals. Patients are often studied for at least 50 treatment days to see if neutralizing anti-drug antibodies (inhibitors) develop.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the 21st Century Cures Act, which was enacted on December 13, 2016, the manufacturer of an investigational drug for a serious or life-threatening disease is required to make available, such as by posting on its website, its policy on evaluating and responding to requests for expanded access to such investigational drug. This requirement applies on the later of 60 calendar days after the date of enactment of the law or the initiation of a Phase 2 or Phase 3 trial of the investigational drug.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrently with clinical trials, companies usually complete additional animal studies and must also develop additional information about the physical characteristics of the biological product as well as finalize a process for manufacturing the product in commercial quantities in accordance with GMP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHS Act emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">US Review and Approval Processes</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the completion of clinical trials of a biological product, FDA approval of a BLA must be obtained before commercial marketing of the biological product. The BLA must include results of product development, laboratory and animal studies, human trials, information on the manufacture and composition of the product, proposed labeling and other relevant information. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will accept the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. PDUFA also imposes an annual product fee for biological products and an annual establishment fee on facilities used to manufacture prescription biological products. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. No user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. MarzAA has been granted orphan drug designation for routine prophylaxis to prevent bleeding episodes in individuals with Hemophilia A and B with inhibitors and DalcA has received orphan designation for routine prophylaxis to prevent bleeding episodes for Hemophilia B patients.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe and potent, or effective, for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with GMP to assure and preserve the product&#8217;s identity, safety, strength, quality, potency and purity. The FDA may refer applications for novel biological products or biological products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the biological product approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy, or REMS, is necessary to assure the safe use of the biological product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve a BLA without a REMS, if required.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving a BLA, the FDA will generally inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with GMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements. To assure GMP and GCP compliance, an applicant must incur significant expenditure of time, money and effort in the areas of training, record keeping, production, and quality control.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than how we interpret the same data. If the agency decides not to approve the BLA in its present form, the FDA will issue a complete response letter that describes all the specific deficiencies in the BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">condition for approval. If a complete response letter is issued, the applicant may either resubmit the BLA, addressing all the deficiencies identified in the letter, or withdraw the application.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a REMS, or otherwise limit the scope of any approval. In addition, the FDA may require post marketing clinical trials, sometimes referred to as Phase 4 clinical trials, designed to further assess a biological product&#8217;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has agreed to certain review goals under PDUFA and aims to complete its review of 90% of standard BLAs within ten months from filing and 90% of priority BLAs within six months from filing. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs and its review goals are subject to change from time to time. The review process and the PDUFA goal date may be extended by three months if the FDA requests, or the BLA sponsor otherwise provides, additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Fast Track Designation, Accelerated Approval, Priority Review, Orphan Drug Designation, and Breakthrough Therapy Programs</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fast Track</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are several FDA programs intended to help facilitate the development of new drugs and biologics that meet certain criteria. Specifically, new drugs and biological products are eligible for Fast Track designation if they are intended to treat a serious or life- threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a new drug or biological product may request the FDA to designate the drug or biological product as a Fast Track product at any time during the clinical development of the product. Under a Fast Track designation, the FDA may consider for review sections of the marketing application on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the application. FDA has granted Fast Track Designation for MarzAA for the treatment of episodic bleeding in subjects with Hemophilia A or B with inhibitors and for the treatment of subjects with Factor FVII deficiency (&#8220;FVIID&#8221;).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Priority Review</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug or biological product designated for priority review to facilitate the review. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Accelerated Approval</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A product that is being studied for safety and effectiveness in treating serious or life-threatening illnesses and provides meaningful therapeutic benefit over existing treatments may receive accelerated approval, which means that it may be approved on the basis of adequate and well-controlled clinical trials establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. As a condition of approval, the FDA may require that a sponsor of a drug or biological product receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. In addition, the FDA currently requires pre-approval of promotional materials as a condition for accelerated approval, which could adversely impact the timing of the commercial launch of the product.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Orphan Drug Designation</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. If a product that has orphan drug designation subsequently receives FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same disease, except in limited circumstances, for seven years. These circumstances are an inability to supply the drug in sufficient quantities or a situation in which a new formulation of the drug has shown superior safety or efficacy or a major contribution to patient care. This exclusivity, however, could also block the approval of our product for seven years if a competitor obtains earlier approval of the same drug for the same indication.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MarzAA has been granted orphan drug designation in the U.S. for routine prophylaxis to prevent bleeding episodes in individuals with Hemophilia A and B with inhibitors and for routine prophylaxis to prevent bleeding episodes in individuals with Hemophilia B with inhibitors in the E.U. DalcA has been granted orphan drug designation in the U.S. and the E.U. for routine prophylaxis to prevent bleeding episodes for Hemophilia B patients. MarzAA has also been granted orphan drug designation for the treatment of subjects with Factor FVII deficiency (&#8220;FVIID&#8221;).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Rare Pediatric Drug Designation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are FDA programs intended to help facilitate the development of new drugs and biologics that meet certain criteria. Specifically, new drugs and biological products are eligible for rare pediatric disease designation if they treat a serious or life-threatening condition that affects less than 200,000 individuals in the U.S. per year and who are primarily less than 18 years of age. Under the FDA's rare pediatric disease designation program, the FDA may grant a priority review voucher to a sponsor who receives a product approval for a rare pediatric disease. In January 2022, CB 4332 was granted rare pediatric disease designation for Complement Factor I (&#8220;CFI&#8221;) deficiency (&#8220;CFID&#8221;).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Break Through Designation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A product may also be eligible for receipt of a Breakthrough Therapy designation. The Breakthrough Therapy designation is intended to expedite the FDA&#8217;s review of a potential new drug for serious or life-threatening diseases where &#8220;preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.&#8221; The designation of a drug as a Breakthrough Therapy provides the same benefits as are available under the Fast Track program, as well as intensive FDA guidance on the product&#8217;s development program. Fast Track designation, priority review, accelerated approval and Breakthrough Therapy designation do not change the standards for approval, but they may expedite the development or approval process.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Post-approval Requirements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maintaining substantial compliance with applicable federal, state and local statutes and regulations requires the expenditure of substantial time and financial resources. Rigorous and extensive FDA regulation of biological products continues after approval, particularly with respect to GMP. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of any products that we may commercialize. Manufacturers of our products are required to comply with applicable requirements in the GMP regulations, including quality control and quality assurance and maintenance of records and documentation. Other post-approval requirements applicable to biological products include reporting of GMP deviations that may affect the identity, potency, purity and overall safety of a distributed product, record-keeping requirements, reporting of adverse effects, reporting updated safety and efficacy information, and complying with electronic record and signature requirements. After a BLA is approved, the product also may be subject to official lot release. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the results of all the manufacturer&#8217;s tests performed on the lot. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">potency</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and effectiveness of biological products.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also must comply with the FDA&#8217;s advertising and promotion requirements, such as those related to direct-to-consumer advertising, the prohibition on promoting products for uses or in-patient populations that are not described in the product&#8217;s approved labeling (known as &#8220;off-label use&#8221;), industry-sponsored scientific and educational activities, and promotional activities involving the internet. Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical hold, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biological product manufacturers and other entities involved in the manufacturing and distribution of approved biological products are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with GMPs and other laws. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain GMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer or holder of an approved BLA, including withdrawal of the product from the market. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Marketing Exclusivity and U.S. Patent Term Restoration</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Biologics Price Competition and Innovation Act, or BPCIA, amended the PHS Act to authorize the FDA to approve similar versions of innovative biologics, commonly known as biosimilars. A competitor seeking approval of a biosimilar must file an application to establish its molecule as highly similar to an approved innovator biologic, among other requirements. The BPCIA, however, bars the FDA from accepting biosimilar applications for four years after an innovator biological product receives initial marketing approval and from approving biosimilar applications for 12 years after an innovator biological product receives initial marketing approval. As innovative biological products, we believe that our products would receive this data protection if the FDA approves them for marketing.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pediatric exclusivity is another type of regulatory market exclusivity that may apply to biological products approved in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods, include the 4- and 12-year periods discussed. This six-month exclusivity, which runs from the end of other exclusivity protection, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#8220;Written Request&#8221; for such a trial.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and specifics of the FDA approval of the use of our product candidates, some of our U.S. patents, if granted, may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years, as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may intend to apply for restoration of patent term for one of </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Disclosure of clinical trial information</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sponsors of clinical trials of FDA-regulated products, including biological products, are required to register and disclose certain clinical trial information. Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed in certain circumstances for up to two years after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;" id="Commercialization">Other U.S. Healthcare Laws and Compliance Requirements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including but not limited to, the Centers for Medicare and Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services (e.g., the Office of Inspector General), the U.S. Department of Justice, or DOJ, and individual U.S. Attorney offices within the DOJ, and state and local governments. For example, sales, marketing and scientific/educational grant programs must comply with the anti-fraud and abuse provisions of the Social Security Act, the false claims laws, the privacy provisions of the Health Insurance Portability and Accountability Act, or HIPAA, and similar state laws, each as amended.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. There are statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances. Our practices may not in all cases meet all the criteria for protection under a statutory exception or regulatory safe harbor.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the intent standard under the Anti-Kickback Statute was amended by the Affordable Care Act (&#8220;ACA&#8221; to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it to have committed a violation. In addition, the ACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act (discussed below).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The civil monetary penalties statute imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to, or approval by, the federal government or knowingly making, using, or causing to be made or used, a false record or statement material to a false or fraudulent claim to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. Recently, several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of the product for unapproved, and thus non-reimbursable, uses.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HIPAA created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of, or payment for healthcare benefits, items or services.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may be subject to data privacy and security regulations by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, imposes requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to business associates, independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the federal Physician Payments Sunshine Act within the ACA, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report information related to certain payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain ownership and investment interests held by physicians and their immediate family members.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. All our activities are potentially subject to federal and state consumer protection and unfair competition laws.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our operations are found to be in violation of any of the federal and state healthcare laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including without limitation, civil, criminal and/or administrative penalties, damages, fines, disgorgement, exclusion from participation in government programs, such as Medicare and Medicaid, injunctions, private &#8220;qui tam&#8221; actions brought by individual whistleblowers in the name of the government, or refusal to allow us to enter into government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Coverage, Pricing and Reimbursement</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage and establish adequate reimbursement levels for such products. In the United States, third-party payors include federal and state healthcare programs, privately managed care providers, health insurers and other organizations. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list,&#160;&#160;also known as a formulary, which might not include all the FDA-approved products for a particular indication. Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. We may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain the FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. A payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product.&#160;&#160;This is also true of Medicare reimbursement, where different vendors process payments, so that coverage by one vendor does not assure that all other vendors will provide coverage. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.&#160;&#160;In addition, the United States federal government position on matters related to drug pricing is evolving and uncertain, and any changes could have a material impact on drug pricing generally in the United States, including for our product candidates if approved.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Different pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines but monitor and control company profits. The National Institute for Health and Care Excellence (NICE) in the United Kingdom also requires consideration of cost-benefit analysis. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if the government and third- party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on healthcare pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The Foreign Corrupt Practices Act</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Additional Regulation</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern the use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on its business. We cannot predict, however, how changes in these laws may affect its future operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Government Regulation Outside of the United States</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products. Whether or not we obtain FDA approval of a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. In the EU, for example, a clinical trial application must be submitted to each country&#8217;s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the clinical trial application is approved in accordance with a country&#8217;s requirements, clinical trial development may proceed. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To obtain regulatory approval of an investigational drug or biological product under EU regulatory systems, we must submit a marketing authorization application. The application used to file the BLA in the United States is similar to that required in the EU, with the exception of, among other things, country-specific document requirements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials are conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or our potential collaborators fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Employees</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consider our ability to recruit, retain and motivate our employees to be critical to our success. We are an equal opportunity employer and we are fundamentally committed to creating and maintaining a work environment in which employees are treated with respect and dignity. All&#160;&#160;human resources policies, practices and actions related to hiring, promotion, compensation, benefits and termination are administered in accordance with the principal of equal employment opportunity, meaning that they are made on the basis of individual skills, knowledge, abilities, job performance and other legitimate criteria and without regard to race, color, religion, sex, sexual orientation, gender expression or identity, ethnicity, national origin, ancestry, age, mental or physical disability, genetic information, any veteran status, any military status or application for military service, or membership in any other category protected under applicable law.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, we had 45 full-time employees. Of the full-time employees, as of such date, 25 employees were engaged in manufacturing and clinical development activities and 20 employees were engaged in finance, business development, facilities and general management. Of our employees as of December 31, 2021, 49% </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> male and </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> female.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have no collective bargaining agreements with our employees, and we have not experienced any work stoppages. We consider our relations with our employees to be good.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the quarter ended March 31, 2022, we had voluntary employee resignations and implemented a reduction-in-force of 19 full-time employees, which we expect to be completed by April 30, 2022. Following these reductions, we expect to have 8 full-time employees.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We aim to provide our employees with competitive salary and benefits that enable them to achieve a good quality of life and plan for the future. Our benefits are based on local norms and market preferences, but include all salary and social benefits required by local law (including paid time off for vacation and sick leave) and many additional benefits that go beyond legal requirements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To maintain and enhance the safety of our employees, we promote a culture of continuous improvement and individual accountability to provide safe workplaces. The safety of our employees has been a priority throughout our response to the COVID-19 pandemic. Our management team guided our operations in the processes and procedures to comply with applicable government-imposed health and safety-related operating restrictions, and to enhance the safety of our facilities to protect the health of our employees. The management team continues to operate, updating guidance as the pandemic has continued and the medical science and government guidance and orders have evolved. We continue to enforce COVID-19 health and safety protocols and have implemented protocols to address actual and suspected cases of COVID-19 and resulting contact tracing and quarantine requirements. Throughout the pandemic, we have been communicating regularly with our employees and monitoring their views on issues related to COVID-19 and the workplace as well as general levels of engagement. In addition, management has regularly updated our Board of Directors on our COVID-19 status and response, including with respect to employee safety.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Business Organization</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We commenced operations in 2002 and are a Delaware corporation. On August 20, 2015, we merged with Targacept, Inc. Our corporate headquarters are in South San Francisco, California. We conduct our research and development activities and general and administrative functions primarily from our South San Francisco, California location. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Available Information</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports, are available for free at www.catalystbiosciences.com as soon as reasonably practicable after they are electronically filed with or furnished to the SEC. They are also available for free on the SEC&#8217;s website at www.sec.gov. The information in or accessible through the SEC and our website are not incorporated into, and are not considered part of, this filing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1A_Risk_Factors"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;">Item&#160;1A.</span><span style="font-weight:bold;margin-left:36pt;"></span><span style="font-weight:bold;">RISK </span><span style="font-weight:bold;">FACTORS</span><span style="font-weight:bold;font-style:italic;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The following section includes the most significant factors that may adversely affect our business and operations. You should carefully consider the risks and uncertainties described below and all information contained in this Annual Report on Form 10-K before deciding to invest in our common stock. If any of the following risks actually occur, our business, financial condition, results of operations and growth prospects may be materially and adversely affected. In that event, the trading price of our common stock could decline, and you could lose all or part of your investment. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Summary of Risk Factors</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Investing in our securities involves a high degree of risk. Below please find a summary of the principal risks we face. These risks are discussed more fully below. </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We have incurred significant losses since our inception and are expected to continue to incur significant losses for the foreseeable future.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We may not be able to identify or execute on any strategic alternatives.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We will need additional capital to continue product development and may not be able to do so. If we are unable to raise sufficient capital, we will be forced to delay, reduce or eliminate product development programs.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Raising additional funds by issuing securities or through licensing arrangements may cause dilution to stockholders, restrict our operations or require us to relinquish proprietary rights.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We have no history of obtaining regulatory approval or commercialization of pharmaceutical products, which may make it difficult to evaluate the Company&#8217;s prospects.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">The outbreak of the novel coronavirus disease, COVID-19, could adversely impact our business, including our preclinical studies.&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">CB 2782-PEG and CB 4332, are in the early stages of development and their commercial viability remains subject to current and future preclinical studies, clinical trials, regulatory approvals and the risks generally inherent in the development of a pharmaceutical product candidate. If we are unable to successfully advance or develop our complement product candidates, our business may be materially harmed.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">CB 2782-PEG, CB 4332 and all of our other product candidates will require additional clinical testing before they can be sold.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">If we experience delays or difficulties in the commencement of clinical trials or patient enrollment in clinical trials, our regulatory approvals could be delayed or prevented.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">The operations of our third-party manufacturers may be requisitioned, diverted or allocated by U.S. or foreign government orders such as under emergency, disaster and civil defense declarations in connection with the COVID-19 pandemic or otherwise.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">The coronavirus disease, COVID-19, and the conflict between Russia and Ukraine, may impact our third-party supply of the raw materials and components needed for our product candidates, which increases the risk that we will not have sufficient quantities of such product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development efforts.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Our complement product candidates may cause the generation of neutralizing antibodies, which could prevent their further development.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We may not be successful in our efforts to build a pipeline of additional product candidates.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Results from preclinical or early stage clinical trials may not be confirmed in later trials, and if serious adverse or unacceptable side effects are identified during the development of our product candidates, we may need to abandon or limit our development of some of our product candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Fast Track designation by the FDA may not actually lead to a faster development or regulatory review or approval process.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Breakthrough therapy designation by the FDA for any product candidate may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that the product candidate will receive marketing approval. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We expect to seek to establish additional collaborations, and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We contract with third parties for the manufacture of our product candidates for preclinical testing and expect to continue to do so for clinical testing and commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities or quality of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We are subject to many manufacturing risks, any of which could substantially increase our costs and limit supply of our product candidates and any future products.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We and our contract manufacturers will be subject to significant regulation with respect to manufacturing our products. The manufacturing facilities on which we will rely may not continue to meet regulatory requirements and have limited capacity.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We rely on third parties to conduct certain aspects of our preclinical studies and any clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such tasks or trials.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We will continue to incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">If we are unable to obtain, protect or enforce intellectual property rights related to our product candidates, we may not be able to compete effectively in our markets.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Third-party claims of intellectual property infringement or challenging the inventorship or ownership of our patents may prevent or delay our development and commercialization efforts.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We may be involved in lawsuits to protect or enforce our patents.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our product candidates, and our ability to generate revenue will be materially impaired.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">The FDA may disagree with our regulatory </span><span style="font-style:italic;color:#000000;">plan</span><span style="font-style:italic;color:#000000;"> and we may fail to obtain regulatory approval of our product candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Our results of operations may be adversely affected by current and potential future healthcare legislative and regulatory actions.&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We are subject to evolving privacy and data protection laws, including HIPAA and the EU General Data Protection Regulation (&#8220;GDPR&#8221;). If we fail to protect personal information or comply with existing or future data protection regulations, our business, financial condition, results of operations and prospects may be materially adversely affected.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs. If the use of our product candidates harms patients or is perceived to harm patients even when such harm is unrelated to our product candidates, regulatory approvals could be revoked or otherwise negatively impacted, and we could be subject to costly and damaging product liability claims.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We identified a material weakness in our internal control over financial reporting in our consolidated financial statements for the year ended December 31, 2021. If we are unable to remediate this material weakness, or if we identify additional material weaknesses in the future or otherwise fail to maintain effective internal control over financial reporting, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect our business and share price.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Even if any of our product candidates receives marketing approval, we may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Our product candidates are years away from regulatory approval.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">If we are unable to establish sales, marketing and distribution capabilities, we may not be successful in commercializing our product candidates if they are approved.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We face substantial competition that may result in others discovering, developing or commercializing products before or more successfully than we do.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Even if we commercialize any product candidates, the products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives that would harm our business.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">If the market opportunities for our product candidates are smaller than expected, our revenues may be adversely affected and our business may suffer.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">The market price of our common stock has historically been highly volatile.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Fluctuations in operating results could adversely affect the price of our common stock.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Sales of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur, could depress the market price of our common stock.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Anti-takeover provisions in our charter documents and provisions of Delaware law may make an acquisition more difficult and could result in the entrenchment of management.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">Our business could be negatively affected </span><span style="font-style:italic;color:#000000;">as a result of</span><span style="font-style:italic;color:#000000;"> actions of activist stockholders, and such activism could impact the trading value of our securities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-style:italic;color:#000000;">We are a smaller reporting company, and we cannot be certain if the reduced disclosure requirements applicable to smaller reporting companies will make our common stock less attractive to investors.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks related to our financial condition and capital requirements</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We have incurred significant losses since our inception and are expected to continue to incur significant losses for the foreseeable future.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a preclinical-stage biotechnology company, and we have not yet generated significant revenues. We have incurred net losses in each year since our inception in August 2002, including net losses of $87.9 million and $56.2 million for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of $402.7 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are still in the early stages of development of our product candidates, and have no products approved for commercial sale. To date, we have financed our operations primarily through issuances of shares of common stock, from private placements of convertible preferred stock, and from payments under collaboration agreements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have devoted most of our financial resources to research and development, including our preclinical and clinical development activities. We expect to continue to incur significant expenses and operating losses over the next several years as we continue the development of our complement product candidates. Our operating losses may fluctuate significantly from quarter to quarter and year to year. We are expected to continue to incur significant expenses and operating losses for at least the next several years as we:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">continue preclinical development and begin clinical development of CB 2782-PEG, CB 4332 and our other complement product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">continue having CB 4332 and our other complement product candidates manufactured for preclinical and clinical development&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">further develop the manufacturing process for our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">attract, hire and retain skilled personnel&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">seek regulatory and marketing approvals for any of our product candidates that successfully complete clinical studies&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">acquire or in-license other product candidates and technologies&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">maintain, protect and expand our intellectual property portfolio&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">create additional infrastructure to support operations as a public company and our product development and planned future commercialization efforts&#894; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">experience any delays or other issues with any of the above.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling any products for which regulatory approval is obtained. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, we may never generate revenues that are significant enough to achieve profitability.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Failure to become and remain profitable would depress the value of our common stock and could impair our ability to raise capital, expand our business, maintain research and development efforts, diversify product offerings or even continue operations. A decline in the value of our common stock could also cause you to lose all or part of your investment.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to identify or </span><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">execute</span><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> any strategic alternatives.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2022 we announced that we were exploring strategic alternatives. There can be no assurance that this strategic review process will result in us pursuing any transaction or that any transaction, if pursued, will be completed on attractive terms or at all. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We will need additional capital to continue product development and may not be able to do so. If we are unable to raise sufficient capital, we will be forced to delay, reduce or eliminate product development programs.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. If we continue with preclinical and clinical development activities, we will continue to incur expenses related to the preclinical and clinical development of our complement product candidates. We believe that our available cash, cash equivalents and investments will be sufficient to fund our operations for at least the next 12 months. However, we expect to need to raise substantial additional capital to begin the clinical development of CB 2782-PEG, CB 4332 or any of our other complement product candidates, and depending on the availability of capital, may need to delay or cease development of some or all of our product candidates. Even if we raise additional capital, we may elect to focus our efforts on one or more development programs and delay or cease other development programs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until we can generate sufficient revenue from our product candidates, if ever, we expect to finance future cash needs through public or private equity offerings, debt financings, corporate collaborations and/or licensing arrangements. Additional funds may not be available when we need them on terms that are acceptable, or at all. If adequate funds are not available, we may be required to delay, reduce the scope of or eliminate some or all of our research or development programs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because successful development of our product candidates is uncertain, we are unable to estimate the actual funds required to complete research and development and commercialize our products under development. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs and results of preclinical studies or clinical trials of CB 2782-PEG, CB 4332 or our other complement product candidates, and expenses related to potential clinical development of such candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the number and characteristics of product candidates that we pursue&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs we incur related to our cessation of development of MarzAA and DalcA&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs we incur to purchase CB 2782-PEG inventory from Biogen&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the terms and timing of any future collaboration, licensing or other arrangements that we may establish&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our headcount and costs associated with hiring or retaining personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the outcome, timing and cost of regulatory approvals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost of obtaining, maintaining, defending and enforcing intellectual property rights, including patent rights&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the effect of competing technological and market developments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost and timing of completing outsourced manufacturing activities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">market acceptance of any product candidates for which we may receive regulatory approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs of continuing to operate our business, including costs associated with being a public company&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the extent to which we acquire, license or invest in businesses, products or technologies.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will require additional capital to achieve our business objectives. Additional funds may not be available on a timely basis, on favorable terms or at all, and such funds, if raised, may not be sufficient to enable us to continue to implement our long-term business strategy. Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. Further, our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic or the conflict between Russia and Ukraine. If we are unable to raise sufficient additional capital, we could be forced to curtail our planned operations and the pursuit of our strategy.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Raising additional funds by issuing securities or through licensing arrangements may cause dilution to stockholders, restrict our operations or require us to relinquish proprietary rights.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of common stockholders. We currently have in place an Equity Distribution Agreement with Piper Sandler &#38; Co. that permits us, subject to applicable SEC regulations, up to $50.0 million worth of shares of our common stock in &#8220;at the market&#8221; transactions at prevailing market prices.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt financing, if available at all, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, product candidates or future revenue streams or grant licenses on terms that are not favorable to us. We may also seek to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time. There can be no assurance that we will be able to obtain additional funding if, and when necessary. If we are unable to obtain adequate financing on a timely basis, we could be required to delay, curtail or eliminate one or more, or all, of our development programs or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="OLE_LINK1">We currently have an effective registration statement on Form S-3 that allows us to offer up to $150.0 million of securities in one or more offerings, subject to limitations under applicable SEC rules, including up to $50.0 million of common stock issuable under our Equity Distribution Agreement with Piper Sandler &#38; Co. Any additional sales in the public market of our common stock or other securities under these shelf registration statements could adversely affect prevailing market prices for our common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We have no history of obtaining regulatory approval or commercialization of pharmaceutical products, which may make it difficult to evaluate the Company&#8217;s prospects.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We began operations in August 2002. Our operations to date have been limited to financing and staffing the Company, developing our technology and product candidates, establishing collaborations and conducting Phase 2 clinical trials on small numbers of patients. We have not yet demonstrated an ability to successfully conduct a Phase 3 clinical trial, obtain marketing approvals, manufacture a product at commercial scale repeatedly, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, predictions about the Company&#8217;s future product development timelines, clinical trial plans, expenses, success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing pharmaceutical products.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks related to our business operations and product candidates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The outbreak of the novel coronavirus disease, COVID-19, could adversely impact our business, including our preclinical studies.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The global coronavirus pandemic has resulted in widespread requirements for individuals to work from their homes, strained medical facilities worldwide and is causing disruptions to certain pharmaceutical manufacturing and product supply chains. We are experiencing operational and other challenges as a result of the COVID-19 global </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pandemic across our programs. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The i</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mpact</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of COVID-19</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> on the enrollment of the MAA-304 and MAA-202 studies </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">contributed</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to their being halted in </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 2021, and</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may delay or halt our development in other programs. In particular, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as a result of</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the COVID-19 pandemic, we may experience disruptions that could severely impact our business, preclinical studies, drug manufacturing and clinical trials including: </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays in manufacturing of our product candidates as third-party manufacturing capacity is shifted towards the production of COVID-19 vaccines&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">interruption or delays in the operations of the FDA, European Medicines Agency (the &#8220;EMA&#8221;) or other regulatory authorities, which may impact review and approval timelines&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">interruption of, or delays in receiving, supplies of our product candidates from our contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">interruptions in preclinical studies due to restricted or limited operations at laboratory facilities&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">limitations on employee resources that would otherwise be focused on the conduct of our preclinical studies, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">material delays and complications with respect to our research and development programs.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the trading prices for our common stock and other biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic. Furthermore, a recession or market correction resulting from the spread of COVID-19 could materially affect our operations and the value of our common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CB 2782-PEG and CB 4332 are in the early stages of development and their commercial viability remains subject to current and future preclinical studies, clinical trials, regulatory approvals and the risks generally inherent in the development of a pharmaceutical product candidate. If we are unable to successfully advance or develop our complement product candidates, our business may be materially harmed.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have no products approved for commercial sale, and all of our product candidates are currently in clinical and preclinical development. <span style="color:#000000;">To date, we have not successfully commercially marketed, distributed or sold any product candidate. The success of our business depends primarily upon our ability to successfully advance the development of our product candidates through preclinical studies and clinical trials, have the product candidates approved for sale by the FDA or regulatory authorities in other countries, and ultimately have the product candidates successfully commercialized by us or a strategic partner. We cannot assure you that the results of our ongoing preclinical studies or future clinical trials will support or justify the continued development of CB 2782-PEG or CB 4332, or that we will receive approval from the FDA, or similar regulatory authorities in other countries, to advance the development of CB 2782-PEG or CB 4332.</span></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to generate revenue from our product candidates, which may not occur for several years, if ever, will depend heavily on the successful development, regulatory approval, obtaining of manufacturing supply, capacity and expertise, and eventual commercialization of our product candidates. The success of CB 2782-PEG, CB 4332 or any other product candidates that we develop or otherwise may acquire will depend on several factors, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing and progress of preclinical and clinical development activities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the number and scope of preclinical and clinical programs we decide to pursue&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">filing acceptable investigational new drug applications, or INDs, with the U.S. Food and Drug Administration, or the FDA, or comparable foreign applications that allow commencement of our planned clinical trials or future clinical trials for our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials, manufacture the product candidates and complete associated regulatory activities&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">our ability to establish and maintain agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing and successfully develop, obtain regulatory approval for, and then successfully commercialize our product </span><span style="color:#000000;">candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">successful enrollment and timely completion of clinical trials, including our ability to generate positive data from any such clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs associated with the development of any additional development programs and product candidates we identify in-house or acquire through collaborations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">receipt of timely marketing approvals from applicable regulatory authorities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">developing and expanding sales, marketing and distribution capabilities and launching commercial sales of products, if approved, whether alone or in collaboration with others&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">acceptance of the benefits and use of our products, including method of administration, if approved, by patients, the medical community and third-party payors, for their approved indications&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the prevalence and severity of adverse events experienced with CB 2782-PEG, CB 4332 or any other product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the availability, perceived advantages, cost, safety and efficacy of alternative therapies for any product candidate that we develop&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the terms and timing of any collaboration, license or other arrangement, including the terms and timing of any milestone payments thereunder&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to obtain and maintain patent, trademark and trade secret protection and regulatory exclusivity for our product candidates, if and when approved, and otherwise protecting our rights in our intellectual property portfolio&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to maintain compliance with regulatory requirements, including Good Clinical Practices, or GCPs, current Good Laboratory Practices, or cGLPs, and cGMPs, and to comply effectively with other rules, regulations and procedures applicable to the development and sale of pharmaceutical products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">potential significant and changing government regulation, regulatory guidance and requirements and evolving treatment guidelines&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">obtaining and maintaining third-party coverage and adequate reimbursement and patients&#8217; willingness to pay out-of-pocket in the absence of such coverage and adequate reimbursement&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to maintain a continued acceptable safety, tolerability and efficacy profile of the products following approval&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the impact of any business interruptions to our operations or those of third parties with which we work, particularly in light of the current COVID-19 pandemic.</span></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<span style="font-size:10pt;">If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize the product candidates we develop, which would materially harm our business. </span><span style="color:#000000;font-size:10pt;">Failure to successfully advance the development of our complement product candidates, including CB 2782-PEG and CB 4332, may have a material adverse effect on us. </span></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CB 2782-PEG, </span><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CB 4332 and </span><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">a</span><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ll of</span><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> our </span><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">other </span><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">product candidates will require additional clinical testing before they can be sold.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates must satisfy rigorous regulatory standards of safety and efficacy before we can advance or complete their clinical development or they can be approved for sale. To satisfy these standards, we must engage in expensive and lengthy preclinical studies and clinical trials, develop acceptable manufacturing processes, and obtain regulatory approval of our complement product candidates. Despite these efforts, our complement product candidates may not:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">offer therapeutic or other medical benefits over existing drugs or other product candidates in development to treat the same patient population&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">be proven to be safe and effective in current and future preclinical studies or clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">have the desired effects&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">be free from undesirable or unexpected effects&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">meet applicable regulatory standards&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">be capable of being formulated and manufactured in commercially suitable quantities and at an acceptable cost&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">be successfully commercialized by us or by collaborators.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we demonstrate favorable results in preclinical studies and early-stage clinical trials, we cannot assure you that the results of late-stage clinical trials will be favorable enough to support the continued development of our product candidates. A number of companies in the pharmaceutical and biopharmaceutical industries have experienced significant delays, setbacks and failures in all stages of development, including late-stage clinical trials, even after achieving promising results in preclinical testing or early-stage clinical trials. Accordingly, results from completed preclinical studies of our complement product candidates may not be predictive of the results we may obtain in human clinical trials. Furthermore, even if the data collected from preclinical studies and clinical trials involving our complement product candidates demonstrate a favorable safety and efficacy profile, such results may not be sufficient to support the submission of a biologics license application to obtain regulatory approval from the FDA in the United States or other similar regulatory agencies in other jurisdictions, which is required to market and sell the products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates will require significant additional research and development efforts, the commitment of substantial financial resources, and regulatory approvals prior to advancing into clinical development or being commercialized by us or collaborators. We cannot assure you that CB 4332 or CB 2782-PEG will successfully progress into clinical development or through the drug development process or will result in commercially viable products. We do not expect any of our other complement product candidates to be commercialized by us or collaborators for at least several years.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">If we experience delays or difficulties in the commencement of clinical trials or patient enrollment in clinical trials, our regulatory approvals could be delayed or prevented.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We or our collaborators may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate, enroll and maintain enrollment of a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. In particular, there is a relatively small number of individuals with CFI deficiency or dry AMD for whom CB 2782-PEG or CB 4332 can be used in clinical trials. The availability of other approved products and other products in clinical trials have and may limit the number of patients willing to participate in our clinical trials.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patient enrollment is affected by other factors including:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the severity of the disease under investigation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the eligibility criteria for the study in question&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the perceived risks and benefits of the product candidate under study&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the efforts to facilitate timely enrollment in clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">clinical trials of other product candidates in the same indication&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">laboratory testing and turnaround time for samples needed for eligibility assessments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the patient referral practices of physicians&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the ability to monitor patients adequately during and after treatment&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the proximity and availability of clinical trial sites for prospective patients.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our inability to enroll a sufficient number of patients for our clinical trials will result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in clinical trials conducted by us may also result in increased development costs for our product candidates, which would cause the value of the Company to decline and limit our ability to obtain additional financing.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The operations of our third-party manufacturers may be requisitioned, diverted or allocated by U.S. or foreign government orders such as under emergency, disaster and civil defense declarations in connection with the COVID-19 pandemic or otherwise.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The third-party manufacturers of our complement product candidates have advised us that they could be required under orders of the U.S. government to allocate manufacturing capacity to the manufacture or distribution of COVID-19 vaccines. If any of our third-party manufacturers become subject to acts or orders of U.S. or foreign government entities to allocate manufacturing capacity to the manufacture or distribution of COVID-19 vaccines or medical supplies needed to treat COVID-19 patients, this could delay or interrupt, perhaps substantially, our supply of clinical trial material for MarzAA which could materially and adversely affect our business. Refer to the risk factor entitled &#8220;The outbreak of the novel coronavirus disease, COVID-19, could adversely impact our business, including our preclinical studies and clinical trials.&#8221;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The coronavirus disease, COVID-19, and the conflict between Russia and Ukraine, may impact our third-party supply of the raw materials and components needed for our product candidates, which increases the risk that we will not have sufficient quantities of such product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development efforts.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If supplies of the raw materials for our product candidates are significantly delayed, or if the third parties that we engage to supply any materials or to manufacture any products for our preclinical tests and clinical trials should cease to continue to do so for any reason, including due to the effects of the COVID-19 pandemic or the conflict between Russia and Ukraine, we likely would experience delays in advancing these tests and trials while we identify and qualify replacement suppliers or manufacturers and we may be unable to obtain replacement supplies on terms that are favorable to us. In addition, if we are not able to obtain adequate supplies of our product candidates or the substances used to manufacture them, it will be more difficult for us to develop our product candidates and compete effectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current and anticipated dependence upon third-party suppliers may adversely affect our ability to develop product candidates and could delay our clinical trials and development programs, and otherwise harm our operations and financial condition and increase our costs and expenses.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks related to the discovery, </span><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">development</span><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> and commercialization of our product candidates</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our complement product candidates may cause the generation of neutralizing antibodies, which could prevent their further development.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CB 2782-PEG, CB 4332 and our other complement product candidates are protein molecules which may cause the generation of antibodies in individuals who receive them. If clinical trials demonstrate a treatment-related neutralizing immunological response in individuals that causes safety concerns or would limit the efficacy of either product candidate, development of the product candidate could be halted.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we have limited financial and management resources, we must focus on development programs and product candidates that we identify for specific indications. As such, we are currently primarily focused on the development of CB 2782-PEG, CB 4332 and our other complement product candidates. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications for these product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We may not be successful in our efforts to build a pipeline of additional product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to continue to identify and develop new product candidates in addition to our current pipeline. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for clinical development. For example, product candidates may be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be successfully developed, much less receive marketing approval and achieve market acceptance. If we do not successfully develop and commercialize product candidates based upon our approach, we will not be able to obtain product revenue in future periods, which likely would result in significant harm to our financial position and adversely affect our stock price. Clinical drug development involves a lengthy and expensive process with an uncertain outcome. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results from preclinical or early stage clinical trials may not be confirmed in later trials, and if serious adverse or unacceptable side effects are identified during the development of our product candidates, we may need to abandon or limit our development of some of our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical testing is expensive, time consuming and uncertain as to outcome. We cannot guarantee that any preclinical studies and clinical trials will be conducted as planned or completed on schedule, if at all. The clinical development of our product candidates is susceptible to the risk of failure at any stage of drug development, including failure to demonstrate efficacy in a clinical trial or across a suitable population of patients, the occurrence of severe or medically or commercially unacceptable adverse events, failure to comply with protocols or applicable regulatory requirements and determination by the FDA or any comparable foreign regulatory authority that a drug product is not approvable. It is possible that even if one or more of our product candidates has a beneficial effect, that effect will not be detected during clinical evaluation as a result of one or more of a variety of factors, including the size, duration, design, measurements, conduct or analysis of our clinical trials. Conversely, as a result of the same factors, our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any. Similarly, in our clinical trials we may fail to detect toxicity of or intolerability caused by our product candidates, or mistakenly believe that our product candidates are toxic or not well tolerated when that is not in fact the case.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the outcome of preclinical studies and early clinical trials may not be predictive of the success of late-stage clinical trials. Trials of our product candidates in larger numbers of patients may not have similar efficacy results and could result in adverse effects that were not observed in the earlier trials with smaller numbers of patients.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in earlier development, and we may face similar setbacks. The design of a clinical trial can determine whether our results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. In addition, preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval for the product candidates. Even if we believe that the results of clinical trials for our product candidates warrant marketing approval, the FDA or comparable foreign regulatory authorities may disagree and may not grant marketing approval of our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. Any Phase 2, Phase 3 or other clinical trials that we may conduct may not demonstrate the efficacy and safety necessary to obtain regulatory approval to market our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our product candidates are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we may need to abandon development or limit development of the product candidate to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Any such limitations could adversely affect the value of our product candidates or common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fast Track designation by the FDA may not actually lead to a faster development or regulatory review or approval process.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA grants Fast Track designation to therapies that are considered capable of addressing unmet medical needs and possess the potential to treat serious or life-threatening disease conditions in order to facilitate its development and expedite the review procedure. The FDA has broad discretion in granting Fast Track designation, so even if we believe that a particular product candidate is eligible for such designation, the FDA could decide not to grant it. Even though Marzeptacog alfa (activated)&#8212;or MarzAA&#8212;has received Fast Track designation in certain indications, we may not experience a faster development process, review or approval, or receive FDA approval at all, in any of those indications compared to conventional FDA procedures. A Fast Track designation does not change the standards for approval. The FDA may also withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Breakthrough therapy designation by the FDA for any product candidate may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that the product candidate will receive marketing approval.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may, in the future, apply for breakthrough therapy designation, or the equivalent thereof in foreign jurisdictions (where available), for our product candidates. A breakthrough therapy is defined as a product candidate that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Product candidates designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the submission of the BLA.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to product candidates considered for approval under conventional FDA procedures and it would not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidate no longer meets the conditions for </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">qualification</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or it may decide that the time period for FDA review or approval will not be shortened.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks related to our reliance on third parties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We expect to seek to establish additional collaborations, and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our drug development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. We have previously relied on collaborators, such as Biogen, Pfizer and ISU, to contribute to the development of our product candidates. We may seek one or more additional collaborators for the development and commercialization of one or more of our product candidates. For example, we are seeking a new collaborator to develop MarzAA  or DalcA, and we are also seeking collaborators for our complement programs. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face significant competition in seeking appropriate collaborators. Whether we can reach a definitive agreement with a collaborator will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of preclinical trials, the likelihood of approval by the FDA or comparable foreign regulatory authorities and the regulatory pathway for any such approval, the potential market for the product candidate, the costs and complexities of manufacturing and delivering the product to patients and the potential of competing products. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available for collaboration and whether such a collaboration could be more attractive than the one with us. There can also be no assurance that we will enter into any collaboration agreements, or that any such agreements will be on favorable terms.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaborations are complex and time consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay our development program or one or more of our other development programs, delay our potential commercialization or reduce the scope of any sales or marketing activities, and increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We contract with third parties for the manufacture of our product candidates for preclinical testing and expect to continue to do so for clinical testing and commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities or quality of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have no internal capabilities to manufacture our product candidates for clinical use or for preclinical trials following good manufacturing practices (&#8220;GMP&#8221;), or good laboratory practices (&#8220;GLP&#8221;). We expect to rely on one or more third-party contractors to manufacture, package, label and distribute clinical supplies and commercial quantities of any product candidate that we commercialize following approval for marketing by applicable regulatory authorities. We also expect to rely on one or more third-party contractors to manufacture our product candidates for use in our clinical trials. Reliance on such third-party contractors entails risks, including:</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">our inability to identify and negotiate manufacturing and supply agreements with suitable </span><span style="color:#000000;">manufacturers&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">manufacturing delays if our third-party contractors give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the possible termination or nonrenewal of agreements by our third-party contractors at a time that is costly or inconvenient for us&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the possible breach by the third-party contractors of our agreements with them&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the failure of third-party contractors to comply with applicable regulatory requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the possible mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or placebo not being properly identified&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the possibility of clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the possible misappropriation of our proprietary information, including our trade secrets and know-how.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we do not currently rely on third parties with operations in Russia or Ukraine, some of our vendors may do so, and disruptions in supply of materials or components to our vendors as a result of the conflict between Russia and Ukraine could adversely affect us.&#160;&#160;We may incur delays in product development resulting from the need to identify or qualify manufacturers for our product candidates. Our current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We are subject to many manufacturing risks, any of which could substantially increase our costs and limit supply of our product candidates and any future products.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, our product candidates have been manufactured by third-party manufacturers solely for preclinical studies and relatively small clinical trials. The process of manufacturing our complement associated therapeutic product candidates is complex, highly regulated and subject to several risks, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the process of manufacturing biologics is susceptible to product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error and improper storage conditions. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or in the manufacturing facilities in which our products are made, the manufacturing facilities may need to be closed for an extended period of time to investigate and eliminate the contamination&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the manufacturing facilities in which our products are made could be adversely affected by equipment failures, labor and raw material shortages, financial difficulties of our contract manufacturers, including as a result of the evolving effects of the COVID-19 pandemic, natural disasters, power failures, local political unrest and numerous other factors&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">any adverse developments affecting manufacturing operations or the scale up of manufacturing operations for our products may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the supply of our product candidates. We may also have to record inventory write-offs and incur other charges and expenses for product candidates or drug substances that fail to meet specifications, undertake costly remediation efforts or seek costlier manufacturing alternatives.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Specifically, we have entered into various development, manufacturing and clinical supply services agreements with third-party manufacturers for drug substance and drug product manufacturing of our product candidates CB 2782-PEG, CB 4332, MarzAA, and DalcA. If our third-party manufacturers are not able to provide us with sufficient quantities or quality of our of product candidates on a timely basis, or at all, whether due to production shortages or other supply delays or interruptions resulting from the ongoing COVID-19 pandemic or otherwise, our preclinical </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">trials, clinical trials or regulatory approval</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, as applicable, may be delayed. Significant portions of our research and development resources are focused on manufacturing. If any of our third-party manufacturers experiences difficulties in scaling production or experiences product loss due to contamination, equipment failure, improper installation or operation of equipment, vendor or operator error or improper storage conditions, the potential trials of the affected product candidate would be delayed, perhaps substantially, which could materially and adversely affect our business.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have minimal process development capabilities and have access only to external manufacturing capabilities. We do not have, and we do not currently plan to acquire or develop, the facilities or capabilities to manufacture bulk drug substance or filled drug product for use in clinical trials or commercialization. Any delay or interruption in the supply of clinical trial material or preclinical trial material could delay the completion of clinical trials or preclinical trials, increase the costs associated with maintaining such trial programs and, depending upon the period of delay, require us to commence new clinical trials or preclinical trials at additional expense or terminate the trials completely.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We and our contract manufacturers will be subject to significant regulation with respect to manufacturing our products. The manufacturing facilities on which we will rely may not continue to meet regulatory requirements and have limited capacity.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All entities involved in the preparation of therapeutics for clinical studies or commercial sale, including any contract manufacturers for our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical studies must be manufactured in accordance with GMP. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of a BLA on a timely basis and must adhere to the FDA&#8217;s GLP and GMP regulations enforced by the FDA through its facilities inspection program. Our facilities and quality systems and the facilities and quality systems of some or all our third-party contractors must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of our product candidates or the associated quality systems for compliance with the regulations applicable to the activities being conducted. If these facilities do not pass a pre-approval plant inspection or do not have a GMP compliance status acceptable for the FDA, FDA approval of the products will not be granted.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulatory authorities also may, at any time following approval of a product for sale, audit our manufacturing facilities or those of our third-party contractors. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time-consuming for us or a third-party to implement and that may include the temporary or permanent suspension of a clinical study or commercial sales or the temporary or permanent closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new drug product or biologic product, or revocation of a pre-existing approval. As a result, our business, financial condition and results of operations may be materially harmed.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, if supply from one approved manufacturer is interrupted, there could be a significant disruption in commercial supply. An alternative manufacturer would need to be qualified through a BLA supplement which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These factors could cause the delay of clinical studies, regulatory submissions, required approvals or commercialization of our product candidates, cause us to incur higher costs and prevent us from commercializing our products successfully. Furthermore, if our suppliers fail to meet contractual requirements, and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical studies may be delayed, or we could lose potential revenue.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We rely on third parties to conduct certain aspects of our preclinical studies and any clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such tasks or trials.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on third parties such as contract research organizations (&#8220;CROs&#8221;), medical institutions and clinical investigators to conduct certain aspects of preclinical development, including assay development and testing, and to enroll qualified patients and conduct, supervise and monitor clinical trials. Our reliance on these third parties for preclinical and clinical development activities reduces our control over these activities. Our reliance on these third parties, however, will not relieve us of our regulatory responsibilities, including ensuring that our clinical studies are conducted in accordance with good clinical practices, and the investigational plan and protocols contained in the relevant regulatory application, such as an investigational new drug application, or IND. In addition, the CROs with whom we contract may not complete activities on schedule or may not conduct our preclinical studies or clinical studies in accordance with regulatory requirements or our clinical study design. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, our efforts to complete development and obtain regulatory approvals for, and to commercialize, our product candidates may be delayed or prevented.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks related to employee matters, managing growth and our business operations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our executive management and scientific personnel. We do not maintain &#8220;key man&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees. In addition, we will need to add personnel to achieve our business objectives. The loss of the services of any of our executive officers, other key employees, and our inability to find suitable replacements, or our inability to hire new clinical development and manufacturing personnel, could result in delays in product development and harm our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conduct operations at our facility in the San Francisco Bay Area. This region is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To induce valuable employees to remain at Catalyst, in addition to salary and cash incentives, we have provided stock options that vest over time. The value to employees of stock options that vest over time may be significantly affected by movements in the Company&#8217;s stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of management and scientific and development teams may terminate their employment with the Company on short notice. Our employees are under at-will employment arrangements, which means that any of our employees can leave employment with Catalyst at any time, with or without notice. Failure to retain, replace or recruit personnel could harm our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and collaborators. Misconduct by these parties could include intentional failures to comply with the regulations of the FDA and non-US regulators, to provide accurate information to the FDA and non-US regulators, to comply with healthcare fraud and abuse laws and regulations in the United States and abroad, to report financial information or </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">data accurately or to disclose unauthorized activities to us. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In particular, sales</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained during clinical studies that could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We will continue to incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company, we have and will continue to incur significant legal, accounting and other expenses that we did not incur as a private company, including costs associated with public company reporting and corporate governance requirements, in order to comply with the rules and regulations imposed by the Sarbanes-Oxley Act and the Dodd-Frank Wall Street Reform and Consumer Protection (the &#8220;Dodd-Frank Act&#8221;), as well as rules implemented by the SEC and Nasdaq. Stockholder activism, the political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways that are not currently anticipated. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. In addition, these rules and regulations make it difficult and expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain our current levels of such coverage. We expect that we will annually incur significant expenses to comply with the requirements imposed on us as a public company.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our offices are located in the San Francisco Bay Area, which is prone to earthquakes. Earthquakes or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans that, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks related to our intellectual property</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to obtain, protect or enforce intellectual property rights related to our product candidates, we may not be able to compete effectively in our markets.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our product candidates. The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. Third parties may challenge the validity, enforceability or scope of our patents, which may result in those patents being narrowed or invalidated. The patent applications that we own may fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries. The current conflict between Russia and Ukraine may make it difficult or impossible to continue to prosecute patent applications or maintain patents in those countries or other affected territories. Furthermore, even if they are unchallenged, our patents and patent </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">applications may not adequately protect our intellectual property, provide exclusivity for our product </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">candidates</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or prevent others from designing around our claims. Certain of our patents also cover processes, for which enforcement can be difficult. Any of these outcomes could impair our ability to prevent competition from third parties that may have an adverse impact on our business.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the patents or patent applications we hold or have in-licensed for our programs or product candidates are invalidated or fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our product candidates, it could threaten our ability to commercialize future products. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. In addition, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available&#59; however the life of a patent, and the protection it affords, is limited. Once the patent life has expired for a product, we may be open to competition from generic medications.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent and other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we expect all of our employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, others may independently discover our trade secrets and proprietary information.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent material disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Third-party claims of intellectual property infringement or challenging the inventorship or ownership of our patents may prevent or delay our development and commercialization efforts.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and inter partes reexamination proceedings before the USPTO, and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may assert that the manufacture, use or sale of our product candidates infringes patents held by such third parties, or that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to compositions of matter, materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. <span style="color:#000000;">There is a patent family pending in the U.S. in which claims that may read on MarzAA have been filed.</span><span style="color:#FF0000;"> </span><span style="color:#000000;">We, however, do not believe such claims are patentable. If they were to issue, we would take appropriate action to challenge their enforceability and/or validity. We are also aware of additional patents that have issued in the United States and Europe that have claims related to Factor VII. We do not believe that MarzAA does or will infringe any valid claims in such patents.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we have received confidential and proprietary information from third parties, and we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers. Litigation may be necessary to defend against these claims.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Parties making claims against us may obtain injunctive or other equitable relief that could effectively block our ability to further develop and commercialize one or more of our product candidates unless we redesigned infringing products (which may be impossible) or obtained a license under the applicable patents (which may not be available on commercially reasonable terms or at all), or until such patents expire.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We may be involved in lawsuits to protect or enforce our patents.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors may infringe our patents. To counter infringement or unauthorized use, we or our collaborators may be required to file infringement claims that can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one of our patents is not valid, is unenforceable and/or is not infringed, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interference proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims, regardless of their merit, would cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, in addition </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to paying royalties, redesign infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">marketing</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A third-party may hold intellectual property, including patent rights, that is important or necessary to the development of our products. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks related to regulatory approval of our product candidates and other compliance matters</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our product candidates, and our ability to generate revenue will be materially impaired.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we have multiple drug candidates in clinical and advanced preclinical development for a range of diseases, we have not yet submitted BLAs for our engineered human proteases to the FDA, or similar approval filings to comparable foreign authorities. Submission of a BLA requires extensive preclinical and clinical data and supporting information that demonstrates the product candidate&#8217;s safety, purity, and potency, also known as safety and effectiveness, for each desired indication. A BLA must also include significant information regarding the chemistry, manufacturing and controls for the product. However, failure of one or more clinical trials can occur at any stage in the clinical trial process. Accordingly, the regulatory pathway for our product candidates is still uncertain, complex, and lengthy, and ultimately, approval may not be obtained.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may experience delays in completing planned clinical trials for a variety of reasons, including delays related to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>the availability of financial resources to commence and complete the planned trials&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>inability to reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">obtaining approval at each clinical trial site by an independent institutional review board (&#8220;IRB&#8221;)&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">recruiting suitable patients to participate in trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">having patients complete a trial or return for post-treatment follow-up&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">clinical trial sites deviating from trial protocol or dropping out of a trial&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">adding new clinical trial sites&#894; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">manufacturing sufficient quantities of qualified materials under Current Good Manufacturing Practice (&#8220;cGMPs&#8221;) regulations and applying them on a subject-by-subject basis for use in clinical trials.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We could also experience delays in obtaining approval if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles given the serious nature of the diseases for the core indications for our product candidates. Additionally, a clinical trial may be suspended or terminated by us, the IRBs for the institutions </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in which the trials are being conducted, the Data Monitoring Committee for the trial, or by the FDA or other regulatory authorities for a number of reasons, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues, or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, the FDA review and approval process could be delayed by any future shutdown of the U.S. government, and our development activities could be harmed or delayed as a result. If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, our ability to commercialize our product candidates will be harmed and our ability to generate revenue will be materially impaired. Additionally, delays in completing trials will increase costs, slow down our product development and approval process, and impair our ability to commence product sales and generate revenue. Many of the factors that could create or lead to a delay in the commencement or completion of clinical trials may lead to the denial of regulatory approval for our product candidates.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The FDA may disagree with our regulatory plan and we may fail to obtain regulatory approval of our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results of clinical trials we conduct may not support regulatory approval of our product candidates. Our product candidates could fail to receive regulatory approval for many reasons, including the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We may be unable to demonstrate to the satisfaction of the FDA or comparable foreign authorities that our product candidates are safe and effective for any of their proposed indications&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We may be unable to demonstrate that our product candidates&#8217; clinical and other benefits outweigh their safety risks&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we would market, sell and distribute our products. As a pharmaceutical company, even though we do not and may not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights are and will be applicable to our business. These regulations include:</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">the Federal Healthcare Anti-Kickback Statute that prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid, and which will constrain our marketing practices and the marketing practices of our licensees, educational programs, pricing policies, and relationships with healthcare providers or other entities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the federal physician self-referral prohibition, commonly known as the Stark Law, which prohibits physicians from referring Medicare or Medicaid patients to providers of &#8220;designated health services&#8221; with whom the physician or a member of the physician&#8217;s immediate family has an ownership interest or compensation arrangement, unless a statutory or regulatory exception applies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">federal false claims laws that prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other government reimbursement programs that are false or fraudulent, and which may expose entities that provide coding and billing advice to customers to potential criminal and civil penalties, including through civil whistleblower or qui tam actions, and including as a result of claims presented in violation of the Federal Healthcare Anti-Kickback Statute, the Stark Law or other healthcare-related laws, including laws enforced by the FDA&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program and also created federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services that, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;), also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">federal physician sunshine requirements under the ACA, which requires manufacturers of approved drugs, devices, biologics and medical supplies to report annually to the U.S. Department of Health and Human Services or HHS, information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group purchasing organizations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the Federal Food, Drug, and Cosmetic Act, which, among other things, strictly regulates drug product marketing, prohibits manufacturers from marketing drug products for off-label use and regulates the distribution of drug samples&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, state laws requiring pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and which may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, and state and foreign laws governing the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and often are not preempted by federal laws such as HIPAA, thus complicating compliance efforts.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from government funded healthcare programs, </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any physicians or other healthcare providers or entities with whom we expect to do business are found to not </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be in compliance with</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our results of operations may be adversely affected by current and potential future healthcare legislative and regulatory actions.&#160;&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legislative and regulatory actions affecting government prescription drug procurement and reimbursement programs occur relatively frequently. In the United States, the ACA was enacted in 2010 to expand healthcare coverage. Since then, numerous efforts have been made to repeal, amend or administratively limit the ACA in whole or in part. For example, the Tax Cuts and Jobs Act, signed into law by President Trump in 2017, repealed the individual health insurance mandate, which is considered a key component of the ACA. In December 2018, a Texas federal district court struck down the ACA on the grounds that the individual health insurance mandate is unconstitutional, although this ruling has been stayed pending appeal. The ongoing challenges to the ACA and new legislative proposals have resulted in uncertainty regarding the ACA&#8217;s future viability and destabilization of the health insurance market. The resulting impact on our business is uncertain and could be material.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Efforts to control prescription drug prices could also have a material adverse effect on our business. For example, in 2018, President Trump and the Secretary of the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) released the &#8220;American Patients First Blueprint&#8221; and have begun implementing certain portions. The initiative includes proposals to increase generic drug and biosimilar competition, enable the Medicare program to negotiate drug prices more directly and improve transparency regarding drug prices and ways to lower consumers&#8217; out-of-pocket costs. The Trump administration also proposed to establish an &#8220;international pricing index&#8221; that would be used as a benchmark to determine the costs and potentially limit the reimbursement of drugs under Medicare Part B. Among other pharmaceutical manufacturer industry-related proposals, Congress has proposed bills to change the Medicare Part D benefit to impose an inflation-based rebate in Medicare Part D and to alter the benefit structure to increase manufacturer contributions in the catastrophic phase. The volume of drug pricing-related bills has dramatically increased under the current Congress, and the resulting impact on our business is uncertain and could be material.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, many states have proposed or enacted legislation that seeks to indirectly or directly regulate pharmaceutical drug pricing, such as by requiring biopharmaceutical manufacturers to publicly report proprietary pricing information or to place a maximum price ceiling on pharmaceutical products purchased by state agencies. For example, in 2017, California&#8217;s governor signed a prescription drug price transparency state bill into law, requiring prescription drug manufacturers to provide advance notice and explanation for price increases of certain drugs that exceed a specified threshold. Both Congress and state legislatures are considering various bills that would reform drug purchasing and price negotiations, allow greater use of utilization management tools to limit Medicare Part D coverage, facilitate the import of lower-priced drugs from outside the United States and encourage the use of generic drugs. Such initiatives and legislation may cause added pricing pressures on our products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes to the Medicaid program at the federal or state level could also have a material adverse effect on our business. Proposals that could impact coverage and reimbursement of our products, including giving states more flexibility to manage drugs covered under the Medicaid program and permitting the re-importation of prescription medications from Canada or other countries, could have a material adverse effect by limiting our products&#8217; use and coverage. Furthermore, state Medicaid programs could request additional supplemental rebates on our products as a result of an increase in the federal base Medicaid rebate. To the extent that private insurers or managed care programs follow Medicaid coverage and payment developments, they could use the enactment of these increased rebates to exert pricing pressure on our products, and the adverse effects may be magnified by their adoption of lower payment schedules.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other proposed regulatory actions affecting manufacturers could have a material adverse effect on our business. It is difficult to predict the impact, if any, of any such proposed legislative and regulatory actions or resulting state actions on the use and reimbursement of our products in the United States, but our results of operations may be adversely affected.&#160;&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We are subject to evolving privacy and data protection laws, including HIPAA and the EU General Data Protection Regulation (&#8220;GDPR&#8221;). If we fail to protect personal information or comply with existing or future data protection regulations, our business, financial condition, results of operations and prospects may be materially adversely affected.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerous state and federal laws and regulations govern the collection, dissemination, use, privacy, confidentiality, security, availability, integrity, and other processing of personal information. HIPAA establishes a set of national privacy and security standards for the protection of protected health information (as defined in HIPAA) (&#8220;PHI&#8221;) by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, and the business associates with whom such covered entities contract for services. HIPAA requires covered entities and business associates, such as us, to develop and maintain policies with respect to the protection of, use and disclosure of electronic PHI, including the adoption of administrative, physical and technical safeguards to protect such information, and certain notification requirements in the event of a data breach.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By virtue of our clinical trial activities in Europe, we are also subject to European data protection laws, including the GDPR (as implemented in the European Economic Area (the &#8220;EEA&#8221;) and the United Kingdom). The GDPR which came into effect on May 25, 2018, establishes stringent requirements applicable to the processing of personal data (<span style="font-style:italic;">i.e</span>., data which identifies an individual or from which an individual is identifiable), affords various data protection rights to individuals (<span style="font-style:italic;">e.g</span>., the right to erasure of personal data) and imposes potential penalties for serious breaches of up to 4.0% annual worldwide turnover or &#8364;20 million, whichever is greater. Individuals (e.g., study subjects) also have a right to compensation for financial or non-financial losses (<span style="font-style:italic;">e.g</span>., distress). There may be circumstances under which a failure to comply with the GDPR, or the exercise of individual rights under the GDPR, would limit our ability to utilize clinical trial data collected on study subjects. The GDPR imposes additional responsibility and liability in relation to our processing of personal data. This may be onerous and materially adversely affect our business, financial condition, results of operations and prospects. The GDPR also prohibits the international transfer of personal data from the EEA/UK to countries outside of the EEA/United Kingdom unless made to a country deemed to have adequate data privacy laws by the European Commission or a data transfer mechanism has been put in place.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the interpretation and application of consumer, health-related and data protection laws in the United States, Europe and elsewhere are often uncertain, contradictory and in flux. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. If so, this could result in government-imposed fines or orders requiring that we change our practices, which could adversely affect our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we are subject to various U.S. state laws which may require us to modify our data processing practices and policies and to incur substantial costs and expenses in an effort to comply.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could harm our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, but this insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we may incur substantial costs to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts that could adversely affect our business, financial condition, results of operations or prospects. In addition, failure to comply with these laws and regulations may result in substantial fines, </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">penalties</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or other sanctions.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs. If the use of our product candidates harms patients or is perceived to harm patients even when such harm is unrelated to our product candidates, regulatory approvals could be revoked or otherwise negatively impacted, and we could be subject to costly and damaging product liability claims.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. There is a risk that our product candidates may induce adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">impairment of our business reputation&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">withdrawal of clinical trial participants&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">costs due to related litigation&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">distraction of management&#8217;s attention from our primary business&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">substantial monetary awards to patients or other claimants&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the inability to commercialize our product candidates&#894; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">decreased demand for our product candidates, if approved for commercial sale.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We carry product liability insurance of $10,000,000 per occurrence and $10,000,000 aggregate limit. We believe our product liability insurance coverage is sufficient for our current clinical programs&#59; however, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If we obtain marketing approval for product candidates, we intend to expand our insurance coverage to include the sale of commercial products&#59; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits based on drugs or medical treatments that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed insurance coverage, could adversely affect our results of operations and business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patients with the diseases targeted by our product candidates are often already in severe and advanced stages of disease and have both known and unknown significant pre-existing and potentially life-threatening health risks. During treatment, patients may suffer adverse events, including death, for reasons that may be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory approval to market our products, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to our products, the investigation into the circumstance may be time-consuming or inconclusive. These investigations may interrupt our sales efforts, delay our regulatory approval process in other countries, or impact and limit the type of regulatory approvals our product candidates receive or maintain. As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition, results of operations, or cash flows.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We identified a material weakness in our internal control over financial reporting in our consolidated financial statements for the year ended December 31, 2021. If we are unable to remediate th</span><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">is</span><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> material weakness, or if we identify additional material weaknesses in the future or otherwise fail to maintain effective internal control over financial reporting, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect our business and share price.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the preparation and audit of our consolidated financial statements for the year ended December 31, 2021, a material weakness was identified in our internal control over financial reporting. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our consolidated financial statements will not be prevented or detected on a timely basis. Our material weakness related to the following control deficiency: we did not design and maintain effective controls related to the review of certain contracts, including the proper application of U.S. GAAP. Specifically, we did not design and maintain controls to properly review the retention bonuses granted to our employees in November 2021 after our reduction in workforce to assess the appropriate accounting treatment under U.S. GAAP.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To address our material weakness, we are evaluating our accounting policy over monitoring and reviewing contracts so that contracts with a significant impact are reviewed and U.S. GAAP is properly applied. We are also formalizing our internal control documentation and strengthening supervisory reviews by our management. While these actions and planned actions are subject to ongoing management evaluation and will require validation and testing of the design and operating effectiveness of internal controls over a sustained period, we are committed to continuous improvement and will continue to diligently review our internal control over financial reporting.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we believe these efforts will remediate the material weakness, we may not be able to complete our evaluation, testing or any required remediation in a timely fashion, or at all. We cannot assure you that the measures we have taken to date and may take in the future, will be sufficient to remediate the control deficiency that led to our material weakness in internal control over financial reporting or that we will prevent or avoid potential future material weaknesses. The effectiveness of our internal control over financial reporting is subject to various inherent limitations, including cost limitations, judgments used in decision making, assumptions about the likelihood of future events, the possibility of human error and the risk of fraud. If we are unable to remediate the material weakness or identify additional material weaknesses in the future, our ability to record, process and report financial information accurately, and to prepare financial statements within the time periods specified by the forms of the SEC, could be adversely affected which, in turn, may adversely affect our reputation and business and the market price of our common stock. In addition, any such failures could result in litigation or regulatory actions by the SEC or other regulatory authorities, loss of investor confidence, delisting of our securities and harm to our reputation and financial condition, or diversion of financial and management resources from the operation of our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks related to commercialization of our product candidates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Even if any of our product candidates receives marketing approval, we may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our product candidates receives marketing approval, we may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. For example, current hemophilia treatments like intravenous NovoSeven RT are well established in the medical community, and doctors may continue to rely on these treatments. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on several factors, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the subcutaneous efficacy and potential advantages compared with alternative treatments&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to offer our products for sale at competitive prices&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the convenience and ease of subcutaneous administration compared with alternative treatments&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies&#894;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">the strength of marketing and distribution support&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the availability of third-party coverage and adequate reimbursement&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the prevalence and severity of any side effects&#894; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">any restrictions on the use of our products together with other medications.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates are years away from regulatory approval.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our development candidates are not expected to be commercially available for several years, if at all. Further, the commercial success of either product candidate will depend upon its acceptance by physicians, individuals, third-party payors and other key decision-makers as a therapeutic and cost-effective alternative to products available at the time, which may include competing products currently under development by others. See &#8220;We face substantial competition that may result in others discovering, developing or commercializing products before or more successfully than we do.&#8221; If we are unable to successfully develop, obtain regulatory approval in a timely manner (including due to reasons that are beyond our control, such as changes in regulations or a shutdown of the federal government, including the FDA) and commercialize our development candidates, our ability to generate revenue from product sales will be significantly delayed and our business will be materially and adversely affected, and we may not be able to earn sufficient revenues to continue as a going concern.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if the FDA or other regulatory agency approves our product candidates, the approval may impose significant restrictions on the indicated uses, conditions for use, labeling, advertising, promotion, marketing and/or production of such product and may impose ongoing commitments or requirements for post-approval studies, including additional research and development and clinical trials. The FDA and other agencies also may impose various civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval. Regulatory approval from authorities in foreign countries will be needed to market our product candidates in those countries. Approval by one regulatory authority does not ensure approval by regulatory authorities in other jurisdictions. If we fail to obtain approvals from foreign jurisdictions, the geographic market for our product candidates would be limited.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to establish sales, marketing and distribution capabilities, we may not be successful in commercializing our product candidates if they are approved.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not yet established a sales, marketing or product distribution infrastructure for our product candidates, which are still in preclinical or early clinical development. We have not yet developed a commercial strategy for our product candidates. To achieve commercial success for any product for which we obtain marketing approval, we will need to establish a sales and marketing organization within the United States and develop a strategy for sales outside of the United States.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are risks involved with establishing internal sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. If we are unable to establish sales, marketing and distribution capabilities and enter into additional arrangements with third parties to perform these services, then our product revenues and profitability, if any, are likely to be lower than if we were to market, sell and distribute any products that we develop ourselves.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We face substantial competition that may result in others discovering, developing or commercializing products before or more successfully than we do.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary products. We face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and governmental agencies, and public and private research institutions. Any product candidates that we </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although there are no currently approved treatments for dry AMD, several companies are developing cyclic peptide, aptamer, antibody or gene therapy based anti-complement product candidates in clinical studies. Apellis is conducting two Phase 3 studies to compare the efficacy and safety of intravitreal APL-2 therapy with sham injections in patients aged 60 years and older with GA secondary to AMD&#59; Iveric Bio (formerly Ophthotech) is developing two therapies to treat GA secondary to dry AMD, iveric Bio completed its Phase 2b clinical of Zimura&#174; (avacincaptad pegol) with positive data in patients with dry AMD&#59; Gemini Therapeutics is developing &#8220;GEM103&#8221; a recombinant human complement factor H (&#8220;FH&#8221;) for patients with genetically well-defined dry AMD and &#8220;GEM104,&#8221; a recombinant human complement factor I as well as additional molecules in preclinical development for other genetically defined subpopulations of patients with dry AMD, Gyroscope Therapeutics is developing &#8220;GT005&#8221; a gene therapeutic approach to expressing additional CFI in the patient&#8217;s eye after subretinal delivery, and <span style="color:#000000;">NGM Biopharmaceuticals is expecting topline data from the Phase 2a study (CATALINA) to evaluate the safety and efficacy of intravitreal NGM621 in the fourth quarter of 2022. NGM621 is a C3-targeting monoclonal antibody being developed to treat geographic atropy secondary to AMD</span>. In addition, there are currently no approved agents specifically targeting systemic factor I deficiency patients irrespective of the resultant disease phenotype being aHUS, C3G, IC-MPGN, invasive infections or any other or any approved therapies for C3G and IC-MPGN. However, there are less specific treatment options on the market or in clinical development which may be applicable to some disease manifestations of systemic CFI deficiency, for instance aHUS and C3G. These treatment options include: eculizumab and ravulizumab marketed by Alexion Pharmaceuticals (a division of AstraZeneca) for use in aHUS irrespective of the patients&#8217; CFI status&#59; APL-2 (pegcetacoplan), a pegylated peptide based C3 inhibitor, in IgA Nephropathy (&#8220;IgAN&#8221;), LN, Membranous Nephropathy (&#8220;MN&#8221;), C3G, and Dense Deposit Disease which is in clinical development by Apellis&#59; TAVENOS (avacopan), a twice daily oral small molecule inhibitor of the complement 5a receptor (&#8220;C5aR&#8221;) in C3G currently marketed by ChemoCentryx <span style="color:#000000;">for use in combination with other standard of care such as glucocorticoids to treat adults with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, and being is further being developed for in C3G and Hidradenitis Suppurativa (&#8220;HS&#8221;) in ongoing phase 2 studies</span>&#59; iptacopan (&#8220;LNP023&#8221;), a small peptide complement factor B inhibitor which is currently in development by Novartis for PNH, C3G and several other rare renal diseases including IgAN, aHUS, and membranous nephropathy&#59; Omeros has initiated clinical activities in igAN, LN, MN, &#38; C3G and a phase 3 clinical program in aHUS with OMS721 (&#8220;narsoplimab&#8221;), a human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (&#8220;MASP-2&#8221;), the effector enzyme of the lectin pathway of the complement system&#59; and <span style="color:#000000;">Argenx is developing ARGX-117, a humanized antibody targeting complement compenent 2 (&#8220;C2&#8221;) intended to inhibit the function of C2 and downstream complement activation. ARGX-117 is currently in a Phase 1 study for Multifocal Motor Neuropathy (&#8220;MMN&#8221;)</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial opportunity in different indications could be reduced or eliminated if competitors develop and market products or therapies that are more convenient to use, more effective, less expensive, and safer to use than our products. Furthermore, if competitors gain FDA approval earlier than we do, we may be unable to establish a strong market presence or to gain market share. The key competitive factors affecting the success of all our product candidates, if approved, are likely to be their efficacy, safety, convenience, price, the level of generic competition, and the availability of reimbursement from government and other third-party payors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and individual registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Even if we commercialize any product candidates, the products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives that would harm our business.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we may obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for certain medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that we or our collaborators commercialize and, even if these are available, the level of reimbursement may not be satisfactory. Reimbursement may affect the demand for, or the price of, any product candidate that receives marketing approval. Obtaining and maintaining adequate reimbursement for our products may be difficult. We may be required to conduct expensive pharmaco-economic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There may be significant delays in obtaining reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or similar regulatory authorities outside the United States. Moreover, eligibility for reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, ability to raise capital needed to commercialize products and overall financial condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for new or current products could limit our ability to market those products and decrease our ability to generate revenue.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The availability and extent of reimbursement by governmental and private payors is essential for most patients to be able to afford expensive treatments. Sales of our product candidates will depend substantially, both domestically and abroad, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. Moreover, increasing efforts by governmental and third-party payors, in the United States and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">If the market opportunities for our product candidates are smaller than expected, our revenues may be adversely affected and our business may suffer.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We focus our research and product development on hemostasis and inflammation treatment. Our projections of both the number of people who suffer from related conditions, as well as the subset of people with these conditions who have the potential to benefit from treatment with our product candidates, are based on estimates. These estimates may prove to be incorrect and new studies may change the estimated incidence or prevalence of these diseases. The number of patients in the United States, Europe and elsewhere may turn out to be lower than expected or may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks related to our common stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">The market price of our common stock has historically been highly volatile.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading price of our common stock has historically been highly volatile and there have been significant periods of time in which the trading volume of our common stock has been low, which can contribute to volatility in price. Additionally, the stock market in general has experienced extreme price and volume fluctuations. The market prices of securities of pharmaceutical, biopharmaceutical and biotechnology companies in particular have been extremely volatile and have experienced fluctuations that have often been unrelated or disproportionate to operating performance. Factors giving rise to this volatility may include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disclosure of clinical trial results&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory or political developments in both the United States and abroad&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">developments concerning proprietary rights, including patents and litigation matters&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disclosure of new collaborations or other strategic transactions&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">public concern about the safety or efficacy of product candidates or technology, their components, or related technology or new technologies generally&#894;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">public announcements by competitors or others regarding new products or new product candidates&#894; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">general market conditions and comments by securities analysts and investors.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fluctuations in operating results could adversely affect the price of our common stock.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operating results are likely to fluctuate significantly from quarter to quarter and year to year. These fluctuations could cause our stock price to decline. Some of the factors that may cause operating results to fluctuate on a period-to-period basis include the scope, progress, duration results and costs of preclinical and clinical development programs, as well as non-clinical studies and assessments of product candidates and programs, restructuring costs, implementation or termination of collaboration, licensing, manufacturing or other material agreements with third parties, non-recurring </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">revenue or expenses under any such agreement, the cost, timing and outcomes of regulatory compliance, approvals or other regulatory actions and general and industry-specific economic conditions, particularly as affects the pharmaceutical, biopharmaceutical or biotechnology industries in the United States. Period-to-period comparisons of our historical and future financial results may not be meaningful, and investors should not rely on them as an indication of future performance. Fluctuating losses may fail to meet the expectations of securities analysts or investors. Failure to meet these expectations may cause the price of our common stock to decline.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sales of a significant number of shares of our common stock in the public markets, or the perception that such sales could occur, could depress the market price of our common stock.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current trading volumes are modest, and sales of a substantial number of shares of our common stock in the public market, or the perception that these sales could occur, could cause the market price to decline. We have effective registration statements on Form S-3 that enables us to sell up to $150.0 million of securities in one or more offerings, subject to limitations under applicable SEC rules, including up to $50.0 million of common stock issuable under our Equity Distribution Agreement with Piper Sandler &#38; Co. Any additional sales in the public market of our common stock or other securities under these shelf registration statements could adversely affect prevailing market prices for our common stock. In addition, we have outstanding options to purchase 2,603,630 shares of common stock at a weighted average exercise price of $7.70 as of December 31, 2021. If such options are exercised and the shares are sold into the open market, such sales also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. Conversion or exercise of these securities into shares of our common stock will cause dilution to the other holders of our common stock, and all such stock may be sold in the public market after conversion or exercise, subject to restrictions under the securities laws, which may lead to a decline in the market price of our common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Anti-takeover provisions in our charter documents and provisions of Delaware law may make an acquisition more difficult and could result in the entrenchment of management.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are incorporated in Delaware. Anti-takeover provisions of Delaware law and our charter documents may make a change in control or efforts to remove management more difficult. Also, under Delaware law, our board of directors may adopt additional anti-takeover measures. The existence of the following provisions of Delaware law and our restated certificate of incorporation and amended and restated bylaws could limit the price that investors might be willing to pay in the future for shares of our common stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our restated certificate of incorporation authorizes our board of directors to issue up to 5,000,000 shares of preferred stock and to determine the terms of those shares of stock without any further action by our stockholders. If the board of directors exercises this power to issue preferred stock, it could be more difficult for a third-party to acquire a majority of our outstanding voting stock and vote the stock they acquire to remove management or directors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our restated certificate also provides staggered terms for the members of our board of directors, and that directors may be removed by stockholders only by vote of the holders of 66 2/3% of voting shares then outstanding. In addition, our amended and restated bylaws do not permit stockholders to call special or annual meetings of stockholders, or to act by written consent without a meeting. These provisions may prevent stockholders from replacing the entire board in a single proxy contest, making it more difficult for a third party to acquire control without the consent of our board of directors. These provisions could also delay the removal of management by the board of directors with or without cause.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a Delaware corporation, we are also subject to certain Delaware anti-takeover provisions. Under Delaware law, a publicly-held corporation may not engage in a business combination with any holder of 15% or more of our voting stock unless the holder has held the stock for three years or, among other things, the board of directors has approved the transaction. Our board of directors could rely on Delaware law to prevent or delay an acquisition.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our business could be negatively affected </span><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">as a result of</span><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> actions of activist stockholders, and such activism could impact the trading value of our securities.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One of our stockholders, on behalf of himself and certain other stockholders, has requested that we add three individuals to our board of directors to replace existing directors and take steps to declassify our board of directors.&#160;&#160;Although we have engaged in negotions with this stockholder to reach an agreement regarding his requests, we may not be able to do so, and this stockholder may engage in proxy solicitations and submit proposals for consideration at our upcoming annual meeting. Such an activist campaign could conflict with our strategic direction or seek changes in the composition of our board of directors and could have an adverse effect on our operating results and financial condition. A proxy contest would require us to incur significant legal and advisory fees, proxy solicitation expenses and administrative and associated costs, and require significant time and attention by our board of directors and management, diverting their attention from the pursuit of our business strategy. Any perceived uncertainties as to our future direction and control, our ability to execute on our strategy, or changes to the composition of our board of directors or senior management team arising from a proxy contest could lead to the perception of a change in the direction of our business or instability which may result in the loss of potential business opportunities, make it more difficult to pursue our strategy, or limit our ability to attract and retain qualified personnel, any of which could adversely affect our business and operating results. If individuals are ultimately elected to our board of directors with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create additional value for our stockholders. We may choose to initiate, or may become subject to, litigation as a result of the proxy contest or matters arising from the proxy contest, which would serve as a further distraction to our board of directors and management and would require us to incur significant additional costs. In addition, actions such as those described above could cause significant fluctuations in our stock price based upon temporary or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">We are a smaller reporting company, and we cannot be certain if the reduced disclosure requirements applicable to smaller reporting companies will make our common stock less attractive to investors.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have been a &#8220;smaller reporting company&#8221; as defined in the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and thus have been allowed to provide simplified executive compensation disclosures in our filings. We have also had certain other decreased disclosure obligations in our SEC filings. We cannot predict whether investors find our common stock less attractive because of our reliance on any of these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.<span style="font-weight:bold;color:#000000;"><br /></span></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_1B_UNRESOLVED_STAFF_COMMENTS">UNRESOLVED STAFF COMMENTS</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_2_PROPERTIES_NEED_TO_UPDATE_WITH_SU">PROPERTIES</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our corporate headquarters are in South San Francisco, California, where we lease approximately 16,208 rentable square feet of office space. We also lease lab space in South San Francisco, California, for our research and development work, where we lease approximately 2,630 square feet of space. The leases will expire on April 30, 2023. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the restructuring announced on November 12, 2021, we decided to downsize our office space and are actively looking for a tenant to sublease a portion of the rented space.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_3_LEGAL_PROCEEDINGS">LEGAL PROCEEDINGS</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not presently a party to any legal proceedings that in the opinion of our management, if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, financial condition or cash flows.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 4</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_4_MINE_SAFETY_DISCLOSURES">MINE SAFETY DISCLOSURES</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_II">PART II</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">I</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">tem</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160; 5</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.</p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Market Information for Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc. is listed on the Nasdaq Capital Market under the symbol &#8220;CBIO.&#8221; </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Holders of Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 25, 2022, there were approximately 80 holders of record of our common stock. In addition, a substantially greater number of stockholders may be &#8220;street name&#8221; or beneficial holders, whose shares are held of record by banks, brokers and other financial institutions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Securities Authorized for Issuance Under Equity Compensation Plans</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item regarding equity compensation plans is incorporated by reference to the information set forth in Item 12 of this Annual Report on Form 10-K.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dividend Policy</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid cash dividends on our capital stock. We intend to retain all available funds and any future earnings, if any, to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unregistered Sales of Securities&#59; Use of Proceeds from Registered Securities&#59; Issuer Purchases of Equity Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the first quarter of 2021, we issued and sold 9,185,000 shares of our common stock, which included the partial exercise by the underwriters of their option to purchase additional shares, at the public offering price of $5.75 per share and received net proceeds of approximately $49.3 million, after deducting underwriting discounts and commissions of approximately $3.2 million and offering-related transaction costs of approximately $0.4 million. None of the expenses associated with the offering were paid to directors, officers, persons owning ten percent or more of any class of equity securities, or to their associates, or to our affiliates. Piper, Sandler &#38; Co., acted as sole lead active bookrunner and Raymond James &#38; Associates, Inc. acted as a bookrunner for the offering.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There has been no material change in the planned use of proceeds from our public offering from that described in the prospectus filed by us with the SEC on May 3, 2021.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October&#160;15, 2021, we entered into an Equity Distribution Agreement (the &#8220;Equity Distribution Agreement&#8221;) with Piper Sandler&#160;&#38; Co. (&#8220;Piper Sandler&#8221;) under which we may offer and sell, from time to time in our sole discretion, shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), with aggregate gross sales proceeds of up to $50.0 million through an &#8220;at the market&#8221; equity offering program under which Piper Sandler will act as sales agent.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Equity Distribution Agreement, we will set the parameters for the sale of shares, including the number of shares to be issued, the time period during which sales are requested to be made, limitations on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. Subject to the terms and conditions of the Equity Distribution Agreement, Piper Sandler may sell the shares by methods deemed to be an &#8220;at the market&#8221; offering as defined in Rule&#160;415 promulgated under the Securities Act of 1933, as amended, including sales made through The Nasdaq Capital Market or any other trading market for the Common Stock.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Equity Distribution Agreement provides that Piper Sandler will be entitled to compensation for its services equal to 3.0% of the gross proceeds of any shares of Common Stock sold through Piper Sandler under the Equity </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Distribution Agreement&#160;and the Company will reimburse Piper Sandler for certain expenses incurred in connection with its services under the Equity Distribution Agreement, including up to $50,000 for legal expenses in connection with the establishment of the&#160;at-the-market&#160;offering. We have no obligation to sell any shares under the Equity Distribution </span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreement, and</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may at any time suspend solicitation and offers under the Equity Distribution Agreement. The offering of shares pursuant to the Equity Distribution Agreement will terminate upon the earlier of (</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)&#160;the sale of all shares subject to the Equity Distribution Agreement or (ii)&#160;termination of the Equity Distribution Agreement in accordance with its terms.</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The shares will be issued pursuant to the Company&#8217;s shelf registration statement on&#160;Form&#160;S-3&#160;(File&#160;No.&#160;333-253874),&#160;which was declared effective by the SEC on May&#160;3, 2021. The Company filed a prospectus supplement, dated October&#160;15, 2021 with the SEC in connection with the offer and sale of the shares pursuant to the Equity Distribution Agreement.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">I</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">tem</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160; 6</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">. </span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_6_SELECTED_FINANCIAL_DATA">[RESERVED].</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">I</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">tem</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;7.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The following discussion and analysis should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion may contain forward-looking statements based upon current expectations that involve risks and uncertainties, including those set forth under the heading &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K. Our actual results and the timing of selected events discussed below could differ materially from those expressed in, or implied by, these forward-looking statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a research and clinical development biopharmaceutical company focused on developing protease therapeutics to address unmet medical needs in disorders of the complement system or where complement components are associated with progression of the disease state. Proteases are an important class of enzymes, which are key natural regulators of many biological processes, including the complement system. We use our protease engineering platform to create improved or novel molecules for the treatment of diseases that result from dysregulation of the complement system. Our complement pipeline consists of a preclinical complement component 3 (&#8220;C3&#8221;) degrader program for geographic atrophy (&#8220;GA&#8221;) in dry age-related macular degeneration (&#8220;dAMD&#8221;), an improved Complement Factor I (&#8220;CFI&#8221;) protease, CB 4332, for subcutaneous (&#8220;SQ&#8221;) or intravitreal (&#8220;IVT&#8221;) therapy to restore complement homeostasis in disease of overactive complement of CFI deficiencies, and proteases from our ProTUNE&#8482; C3b/C4b degrader and ImmunoTUNE&#8482; C3a/C5a degrader platforms designed to target specific disorders of the complement or inflammatory pathways. Historically, we also used our protein engineering platform to develop potential therapies for coagulation disorders, including marzeptacog alfa (activated) (&#8220;MarzAA&#8221;), a SQ administered next-generation engineered coagulation Factor VIIa (&#8220;FVIIa&#8221;) for the treatment of episodic bleeding and prophylaxis in subjects with rare bleeding disorders, and dalcinonacog alfa (&#8220;DalcA&#8221;), a next-generation SQ FIX, both of which has shown sustained efficacy and safety in mid-stage clinical trials.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The product candidates generated by our protease engineering platform are designed to have improved functional properties such as longer half-life, improved specificity and targeting, higher potency, and increased bioavailability. These characteristics potentially allow for improved safety and efficacy for SQ administration of recombinant complement regulators, or less frequently dosed intravitreal products than current therapeutics in development.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current complement portfolio consists of the development candidates CB 4332 and CB 2782-PEG. CB 4332 is a wholly owned, first-in-class improved albumin-fused CFI molecule intended for prophylactic SQ or IVT administration in individuals with an imbalance in complement homeostasis or a CFI deficiency. CB 2782-PEG is a potential best-in-class C3 degrader product candidate in preclinical development for the treatment of dry AMD that we had licensed to Biogen. In March 2022, we re-acquired the full rights to CB 2782-PEG adding to our promising portfolio, which includes CB 4332 our enhanced CFI development candidate. We have several engineered protease programs in discovery or early non-clinical development. These programs all target diseases caused by deficient regulation of the complement system and inflammation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2021 we commenced patient enrollment in the screening (&#8220;CFI-001&#8221;) and natural history of disease (&#8220;CFI-002&#8221;) studies to assess CFI blood levels in patients who have diseases related to CFI deficiency and identify those who might benefit from CB 4332 treatment (&#8220;ConFIrm&#8221; and &#8220;ConFIdence&#8221; studies, respectively). As of February 2022, we have completed enrollment of these studies.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our current development programs.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="guycyz0ib1ig000003.jpg" title="" alt="" style="width:624px;height:294px;" /></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to experience operational and other challenges as a result of the COVID-19 global pandemic, which could delay or impact our development programs. See Note 7, <span style="font-style:italic;">Commitments and Contingencies,</span> Other Recent Developments and Item 1A - Risk Factors for further discussion of the current and expected impact on our business and development programs.<span style="font-size:8pt;"> </span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Development Program Updates</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Complement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our protease programs are designed to take advantage of nature&#8217;s natural complement regulators that restore complement homeostasis and potentially treat a variety of complement-mediated disorders. We have several protease programs currently in preclinical discovery or early non-clinical development. These programs target diseases caused by aberrant regulation of the complement system including both ocular programs, specifically for dry AMD, and systemic complement disorders, all of which are wholly owned by Catalyst.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The complement system is an enzyme-based <span style="color:#000000;">innate immune </span>defense system with the primary role of protecting the body from pathogens. The system is naturally regulated by proteases which is the basis for our approach to addressing complement-driven diseases. Deficient or excessive activation of the complement system may lead to severe disorders, including microthrombotic, <span style="color:#000000;">autoimmune and/or immune-complex diseases</span>, severe infectious diseases, and degenerative ophthalmic or neurologic diseases affecting a variety of tissues and organ systems. The absence of regulation can cause the complement system to become self-destructive or not provide the necessary protection when needed. The protease therapeutic candidates generated by our platforms are designed to correct or restore the missing balance in the complement system that drives several diseases.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proteases are uniquely poised to regulate key biological functions such as the complement system, either by promoting or limiting the cascade of events that leads to eventual clearing of foreign and damaged proteins, inflammation, and formation of the membrane attack complex, which is deposited on the surface of cells and drives their destruction. Compared with antibodies and small molecule inhibitors that generally require a sustained excess of therapeutic compound over that of the target, Catalyst&#8217;s protease therapeutic candidates are based on natural regulatory proteins that are capable of rapidly engaging and modulating large quantities of target molecules, as each protease molecule can degrade many target molecules over their effective lifetime. This means that our proteases are ideal for regulating high abundancy targets such as complement proteins in a way antibodies and small molecule inhibitors cannot.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CB 2782-PEG is an engineered pegylated C3 degrader previously licensed to Biogen that we designed with a best-in-class anti-C3 profile for geographic atrophy (&#8220;GA&#8221;) in dry AMD. Dry AMD is an ocular disease that leads to vision loss and blindness for which there is currently no approved therapy. CB 2782-PEG degrades C3 in the eye reducing the steady state level of C3 activity. It is expected that maintaining low C3 levels in the eye can significantly slow disease progression and vision loss in patients with dry AMD. We have demonstrated in preclinical non-human primate models that we have the potential to reduce C3 levels in humans based on modeling studies for up to 3 months with a single intravitreal injection. In September 2021, Apellis released the results of the DERBY and OAKS phase 3 trials for GA secondary to dry AMD, showing that once-monthly </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pegcetacoplan</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, a pegylated C3 targeted inhibitor, was safe and efficacious, meeting its primary endpoint in one trial and narrowly missing the primary endpoint in a second trial for reducing GA lesion growth over a 12-month period. Further subpopulation analyses demonstrated a greater effect of reducing GA lesion growth in those subjects with extrafoveal lesions at baseline. CB 2782-PEG provides a differentiated mechanism of action by degrading both C3 and one of its byproducts, C3a potentially offering not only less frequent dosing but a more efficacious mechanism than </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pegcetacoplan</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> or other complement inhibitors in development for GA</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> In March 2022, Biogen terminated the license agreement and returned full rights to CB 2782-PEG.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CB 4332 is an engineered albumin-fused version of the CFI protease with an extended half-life that can be dosed subcutaneously or intravitreally in individuals who would benefit from enhanced regulation of complement. CFI is the central regulator of the complement system and CB 4332 has the potential to address several mechanistically related diseases driven by complement imbalance such as: Lupus Nephritis (&#8220;LN&#8221;), Systemic Lupus Erythematosus (&#8220;SLE&#8221;), warm Autoimmune Hemolytic Anemia (&#8220;wAIHA&#8221;), atypical Hemolytic Uremic Syndrome (&#8220;aHUS&#8221;), C3 Glomerulonephritis (&#8220;C3G&#8221;), and Immune Complex Membranoproliferative Glomerulonephritis (&#8220;IC-MPGN&#8221;), dry AMD and complete CFI deficiency (&#8220;CFID&#8221;), a rare immunodeficiency primarily affecting children. These are severe, chronic, life-threatening diseases that result in a significantly decreased quality of life for the afflicted individual.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CB 4332 can be dosed subcutaneously for systemic diseases and has the potential for infrequent IVT injections for ophthalmic indications. As a key complement regulator, CFI has the potential to be used in several complement dysregulated diseases (<span style="font-style:italic;">e.g.</span>, those associated with hyperactive complement) in which additional upstream regulation may prove more effective than inhibiting specific downstream targets such as C3 or C5, where many of current molecules in development are targeted<span style="color:#000000;">.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Individuals with complete or significant absence of endogenous CFI may present with a variety of disease manifestations, such as recurrent invasive infections with encapsulated bacteria, but these patients are also at risk of developing autoimmune and/or immune-complex diseases such as chronic inflammation of the blood vessels of the brain, spinal cord, heart, or kidneys. No CFI replacement therapy, including for prophylactic use, has been approved, and patients often receive supportive care with lifelong antibiotic treatment, which may cause a range of additional problems. We have received pre-IND guidance from the FDA as well as Rare Pediatric Disease Designation of CB 4332 for treatment of CFI deficiency in January 2022.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Low circulating serum CFI levels have been shown to be associated with rare CFI genetic variants and all forms of AMD ranging from early to late-stage manifestations. Studies have estimated the prevalence rates of CFI deficiency in GA to be approximately 20%, suggesting that CFI is a prognostic biomarker for progression of GA. Approximately 1 million individuals globally are predicted to have low serum CFI levels and may potentially benefit from targeted CFI therapy. Gyroscope released interim results from its FOCUS phase 1/2a trial for patients with GA and having rare CFI variants, showing that gene therapy with GT005, an AAV-delivered CFI rebalanced the overactivation of complement observed in the vitreous with sustained expression of CFI. The FOCUS data also showed that AAV-delivered CFI reduced complement biomarkers in the broader GA population who do not have a rare CFI genetic variant.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have additional early-stage complement discovery programs that target different proteins of the complement system including proteases from our ProTUNE<span style="color:#000000;">&#8482; C3b/C4b degrader and ImmunoTUNE&#8482; C3a/C5a degrader platforms. These proteases are designed to target specific disorders of the complement or inflammatory pathways. The ProTUNE&#8482; platform generates optimized, next-generation engineered CFI molecules that are selectively enhanced for potency and target engagement. We expect to nominate a development candidate and target indication from this platform in 2022.</span></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Coagulation Programs</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">MarzAA<span style="font-style:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MarzAA is a potent, subcutaneously administered, next-generation Factor VIIa variant. We commenced enrollment of a Phase 3 registrational trial of MarzAA for episodic treatment of spontaneous or traumatic bleeding episodes in adolescents and adults with congenital hemophilia A or hemophilia B with inhibitors in May 2021. We have discontinued this trial based on a number of factors, including challenges in enrollment resulting from the limited number of potential patients eligible to enroll in this trial, competition from competing approved therapies, delays in enrollment resulting from COVID-19, the capital requirements to complete the trial, and other factors. Patients enrolled in the study returned to their standard of care and completed all required safety assessments. In the patients enrolled to date, we have successfully treated bleeds with SQ MarzAA and have not observed any adverse events. We plan to report these data at an appropriate medical conference in the future. We had also begun enrollment of <span style="color:#000000;">a Phase 1/2 trial of MarzAA for treatment of bleeding in individuals with Factor VII Deficiency, Glanzmann Thrombasthenia, and hemophilia A with inhibitors on emicizumab prophylaxis. We have discontinued this trial as well, in light of the difficulties in identifying and enrolling eligible patients, the capital requirements to complete the trial and other factors. We believe that a SQ recombinant Factor VIIa therapy, like MarzAA, has the potential to be an important treatment option for patients with various bleeding disorders and are exploring opportunities to license or sell MarzAA to another party for further development.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">DalcA</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DalcA is a next-generation SQ Factor IX product candidate for the prophylactic treatment of individuals with hemophilia B. An open-label, Phase 2b study was completed in 2020, demonstrating that FIX plasma activity levels were raised from severe to mild hemophilia B levels and maintained throughout the course of the study. We have received guidance from the FDA on the design of the registrational Phase 3 clinical trial, have the necessary data to support its initiation, and are exploring opportunities to license or sell DalcA to another party for further development.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Recent Manufacturing Updates</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">CB 4332</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CB 4332 is an engineered albumin-fused version of the CFI protease with an extended half-life that is designed to be a subcutaneously or intravitreally dosed therapy for individuals who would benefit form enhanced regulation of complement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other Recent Developments</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">COVID-19 Business Impact</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The global coronavirus pandemic has resulted in widespread requirements for individuals to work from their homes, strained medical facilities worldwide, and disruptions to certain pharmaceutical manufacturing and product supply chains. While our offices in California have reopened for all employees, we may experience future disruptions in applicable guidelines for workplace safety, necessitating a return to a remote working environment. We are also still experiencing operational and other challenges as a result of the COVID-19 global pandemic, which delayed our enrollment in MAA-304 and MAA-202, contributing to the decision to discontinue these trials, and which may delay or halt our other development programs.<span style="color:#000000;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent Financing</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the first quarter of 2021, we issued and sold an aggregate of 9,185,000 shares of our common stock (including 485,000 shares sold pursuant to the exercise of the underwriters&#8217; overallotment option) at a price of $5.75 per share. The net proceeds to us, after deducting $3.6 million in underwriting discounts and commissions and offering expenses, were approximately $49.3 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have no drug products approved for commercial sale and have not generated any revenue from drug product sales. From inception to December 31, 2021, we have raised net proceeds of approximately $509.3 million, </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">primarily from private placements of convertible preferred stock</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> since converted to common stock,</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> proceeds from our merger with Targacept</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> issuances of shares of common stock and warrants</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, including $</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83.5</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million in total cash receipts from our license and collaboration agreements</span><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="color:#000000;"> </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never been profitable and have incurred significant operating losses in each year since inception. Our net losses were $87.9 million and $56.2 million for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of $402.7 million. As of December 31, 2021, our cash, cash equivalents and short-term investments balance were $46.9 million. Substantially all our operating losses were incurred in our research and development programs and in our general and administrative operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to incur significant expenses and increasing operating losses for at least the next several years as we continue preclinical, manufacturing and clinical development, and seek regulatory approval for our drug candidates. Our operating losses may fluctuate significantly from quarter to quarter and year to year due to timing of preclinical, manufacturing, clinical development programs and regulatory guidance spending.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Leadership Changes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 14, 2021, we promoted Grant Blouse, Ph.D., to chief scientific officer and Tom Knudsen, DVM, Ph.D., to senior vice president, corporate development. Howard Levy, M.B.B.Ch, Ph.D., M.M.M., chief medical officer, announced his plan to retire and transition to a senior clinical advisor role to Catalyst.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 9, 2021 (the &#8220;Effective Date&#8221;), we appointed Ms. Jeanne Y. Jew as a Class III director of Catalyst with a term to expire at the 2024 Annual Meeting of Stockholders. In connection with the appointment, the Board approved an increase in the size of the Board, from seven to eight members, effective as of the Effective Date.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 13, 2021, Clinton Musil, the chief financial officer, resigned for personal reasons effective October 29, 2021. We promoted Seline Miller, the Company&#8217;s controller, to senior vice president, finance. She will serve as the interim chief financial and principal accounting officer while the Company initiates a search for a successor. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Operations Overview </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">License and Collaboration Revenue </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and collaboration revenue consist of revenue earned for performance obligations satisfied pursuant to our license and collaboration agreement with Biogen which was entered into in December 2019. In consideration for the grant of an exclusive license and related know-how, we received an up-front license payment of $15.0 million in January 2020, which was recorded in license revenue during the year ended December 31, 2020. We recognized collaboration revenue for reimbursable third-party vendor, out-of-pocket and personnel costs pertaining to the Biogen Agreement of $7.3 million and $5.8 million during the years ended December 31, 2021 and 2020, respectively. In March 2022, we received notice that Biogen is terminating the license and collaboration agreement. Under the terms of the Biogen Agreement, termination will be effective in May 2022.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not generated any revenue from the sale of any drug products and we do not expect to generate any revenue from the sale of drug products until we obtain regulatory approval of and commercialize our product candidates.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cost of License and Collaboration</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of license and collaboration revenue consists of fees for research and development services payable to third-party vendors, and personnel costs, corresponding to the recognition of license and collaboration revenue from Biogen. Cost of license and collaboration revenue does not include any allocated overhead costs. In connection with the license revenue recognized from Biogen as discussed above in 2020, we paid<span style="color:#000000;"> Mosaic a $3.0 million sublicense fee and recorded such payment as cost of license. We </span>recognized third-party vendor, out-of-pocket and personnel costs, most of which were reimbursable, pertaining to the Biogen Agreement of $7.4 million and $6.1 million during the years ended December 31, 2021 and 2020, respectively, and recorded such costs as cost of collaboration revenue.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses represent costs incurred to conduct research, such as the discovery and development of our product candidates. We recognize all research and development costs as they are incurred. Nonrefundable advance payments for goods or services used in research and development are deferred and capitalized. The capitalized amounts are then expensed as the related goods are delivered or services are performed, or until it is no longer expected that the goods or services will be delivered. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist primarily of the following: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">employee-related expenses, which include salaries, benefits and stock-based compensation&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">laboratory and vendor expenses, including payments to consultants and third parties, related to the execution of preclinical, non-clinical, and clinical studies&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">the cost of acquiring and manufacturing preclinical and clinical materials and developing manufacturing processes&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">clinical trial expenses, including costs of third-party clinical research organizations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">performing toxicity and other preclinical studies&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:3.71%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:10pt;color:#000000;">facilities and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation and amortization expense and other supplies.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below details our internal and external costs for research and development for the period presented (<span style="font-style:italic;">in thousands)</span>. See Overview and Recent Development Program Updates for further discussion of the current research and development programs.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hemophilia</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,791</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Complement</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,698</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Personnel and other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,198</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,202</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,889</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The largest component of our total operating expenses has historically been our investment in research and development activities, including the clinical and manufacturing development of our product candidates. We are focusing substantially all our resources and development efforts on our complement programs. Costs listed for our hemophilia and complement programs above consist of clinical trial, manufacturing and research costs. Our internal resources, employees and infrastructure, identified above as personnel and other, are generally not directly tied to individual product candidates or development programs. As such, we do not maintain information regarding these costs incurred for these research and development programs on a project-specific basis.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our aggregate research and development expenses will fluctuate during the next year as we continue to explore strategic opportunities for the clinical and manufacturing development of our programs. The global coronavirus pandemic may also delay and increase costs of our current development plans.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 20, 2016, we signed a development and manufacturing services agreement with AGC, formerly known as CMC ICOS Biologics, Inc., pursuant to which AGC will conduct manufacturing development of agreed upon product candidates. We will own all intellectual property developed in such manufacturing development activities that are specifically related to our product candidates and will have a royalty-free and perpetual license to use AGC&#8217;s intellectual property to the extent reasonably necessary to make these product candidates, including commercial manufacturing. As of December 31, 2021, six GMP batches have been manufactured at AGC in addition to an engineering batch.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initial term of the agreement is ten years or, if later, until all stages under outstanding statements of work have been completed. Either party may terminate the agreement in its entirety upon written notice of a material uncured breach or upon the other party&#8217;s bankruptcy, and we may terminate the agreement upon prior notice for any reason. In addition, each party may terminate the agreement in the event that the manufacturing development activities </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cannot be completed for technical or scientific </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reasons. We </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">had</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">firm work orders with AGC </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to manufacture MarzAA and DalcA to support clinical trials totaling </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.8</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. T</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he payment obligations </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were fully paid off as of</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 202</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> We also have firm work orders with AGC to perform certain manufacturing services related to our collaboration agreement with Biogen totaling $0.7 million and the payment obligations remaining as of December 31, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> were $0.3 million.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2021, we entered into two separate agreements, one for additional clinical trial services for MarzAA, and another for our screening and natural history of disease clinical studies related to CFI deficiency, with total payments of up to $3.2 million and $6.5 million, respectively. <span style="letter-spacing:-0.1pt;">In November 2021, we provided notice of intent to terminate our MarzAA manufacturing agreements and incurred charges of $3.8 million to write-off prepaid manufacturing costs that will no longer be used for the clinical development of MarzAA. </span>We can terminate the CFI agreement at our discretion and upon termination will be responsible to pay for those services incurred prior to termination plus reasonable wind-down expenses. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 16, 2021, we signed a Manufacturing and Research and Development Studies Agreement to support the lyophilized drug product, CB 4332. The agreement will cover analytical method qualification to support GMP manufacturing. We have firm work orders related to this agreement totaling $0.2 million and the payment obligations were fully paid off as of December 31, 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also have a long-term clinical supply services agreement with Catalent Indiana, LLC (&#8220;Catalent&#8221;). Catalent has facilities in the U.S. and Europe and conducts drug product development and manufacturing for MarzAA and DalcA. We successfully completed development work for a variety of vial sizes which supports flexible dosing.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process of conducting clinical trials necessary to obtain regulatory approval is costly and time consuming. We may never succeed in achieving marketing approval for our product candidates. The probability of success of each product candidate may be affected by numerous factors, including clinical data, competition, manufacturing capability and commercial viability. As a result, we are unable to determine the duration of and costs to complete our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Successful development of current and future product candidates is highly uncertain. Completion dates and costs for our research programs can vary significantly for each current and future product candidate and are difficult to predict. Thus, we cannot estimate with any degree of certainty the costs we will incur in the development of our product candidates. We anticipate we will determine which programs and product candidates to pursue and how much funding to direct to each program and product candidate on an ongoing basis in response to the scientific success of early research programs, results of ongoing and future clinical trials, our ability to enter into collaborative agreements with respect to programs or potential product candidates, as well as ongoing assessments as to each current or future product candidate&#8217;s commercial potential.  </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist of personnel costs, allocated expenses and other expenses for outside professional services, including legal, human resources, audit and accounting services. Personnel costs consist of salaries, bonus, benefits and stock-based compensation. We incur expenses associated with operating as a public company, including expenses related to compliance with the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) and Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;), insurance expenses, audit expenses, investor relations activities, Sarbanes-Oxley compliance expenses and other administrative expenses and professional services. We expect such expenses to fluctuate as we continue to explore strategic opportunities for our programs.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables set forth our results of operations data for the periods presented <span style="font-style:italic;">(in thousands, except percentages)</span>: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change ($)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change&#160;(%)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,100</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,100</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,338</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,848</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,490</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and collaboration revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,338</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,948</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,610</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of license</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,102</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,102</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of collaboration</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,380</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,061</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,319</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,889</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52,975</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,914</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,963</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,180</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,783</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95,232</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,318</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,914</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(87,894</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(57,370</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(30,524</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income (expense), net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,129</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,168</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(87,933</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(56,241</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31,692</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;text-indent:7.69%;"><span style="font-weight:normal;font-style:normal;">*<sup style="font-size:85%;line-height:120%;vertical-align:top">Not meaningful</sup></span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">License and Collaboration Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and collaboration revenues were $7.3 million and $20.9 million for the years ended December 31, 2021 and 2020, respectively. In the year ended December 31, 2021, revenue consisted primarily of reimbursable collaboration expenses from our Biogen Agreement. In the year ended December 31, 2020, revenue consisted primarily of a license payment of $15.0 million and reimbursable collaboration expenses of $5.8 million from our Biogen Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cost of License and Collaboration</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of license and collaboration revenues were $7.4 million and $9.2 million during the years ended December 31, 2021 and 2020, respectively. Cost of collaboration for the year ended December 31, 2021 was primarily related to reimbursable third-party vendor and personnel costs we incurred pertaining to the Biogen Agreement. Cost of license for the year ended December 31, 2020 was primarily the $3.0 million sublicense fee we paid to Mosaic in connection with the recognition of the license revenue from Biogen. Cost of collaboration revenue for the year ended December 31, 2020 was primarily reimbursable third-party vendor, out-of-pocket and personnel related costs we incurred pertaining to the Biogen Agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses were $68.9 million and $53.0 million during the years ended December 31, 2021 and 2020, respectively, an increase of approximately $15.9 million, or 30%. The increase was due primarily to an increase of $9.3 million in clinical manufacturing costs of which $3.8 million related to the write-off of prepaid manufacturing costs as part of our restructuring, an increase of $3.9 million in preclinical research, an increase of $2.1 million in personnel-related costs which includes approximately $0.3 million related to one-time severance costs associated with our restructuring, and an increase of $0.6 million in facilities costs. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses were $19.0 million and $16.2 million during the years ended December 31, 2021 and 2020, respectively, an increase of approximately $2.8 million, or 17%. The increase was due primarily to an increase of $1.4 million in personnel-related costs and an increase of $1.4 million in professional services.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interest and Other Income</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> (Expense)</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">, Net</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The $1.2 million decrease in interest and other income (expense), net for the year ended December 31, 2021 compared to the year ended December 31, 2020 was primarily due to a decrease in interest income and due to the payment received in the first quarter of 2020 under an agreement associated with neuronal nicotinic receptor asset sold in 2016.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Refer to Note 3,<span style="font-style:italic;"> Summary of Significant Accounting Policies,</span> to our consolidated financial statements included within Item 8 of this Annual Report on Form 10-K for a description of recent accounting pronouncements adopted and not yet adopted for the year ended December 31, 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, we had $46.9 million of cash, cash equivalents and short-term investments. During the year ended December 31, 2021, we had a $87.9 million net loss and $83.8 million cash used in operating activities. We have an accumulated deficit of $402.7 million as of December 31, 2021. Our primary uses of cash are to fund operating expenses, including research and development expenditures and general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our existing capital resources, including cash, cash equivalents and investments will be sufficient to meet our projected operating requirements for at least the next 12 months from the date of this filing. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We plan to continue to fund losses from operations and capital funding needs through future equity and/or debt financings, as well as potential additional asset sales, licensing transactions, collaborations or strategic partnerships with other companies. At the year ended December 31, 2021, we had effective registration statements on Form S-3 that enable us to sell up to $150.0 million in securities subject to limitations under SEC rules. The sale of additional equity or convertible debt could result in additional dilution to our stockholders. The incurrence of indebtedness would result in debt service obligations and could result in operating and financing covenants that would restrict our operations. Licensing transactions, collaborations or strategic partnerships may result in us relinquishing valuable rights. We can provide no assurance that financing will be available in the amounts we need or on terms acceptable to us, if at all. If we are not able to secure adequate additional funding we may be forced to delay, make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. Any of these actions could materially harm our business.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2021, we entered into the ATM Agreement with Piper Sandler, which provides that, upon the terms and subject to the conditions and limitations set forth in the ATM Agreement, we may elect to issue and sell, from time to time, shares of our common stock having an aggregate offering price of up to $50.0 million through Piper Sandler acting as our sales agent. Under the ATM Agreement, Piper Sandler may sell the shares of common stock by methods deemed to be an &#8220;at the market&#8221; offering as defined in Rule 415 under the Securities Act of 1933, as amended, including sales made directly on the Nasdaq Capital Market or any other trading market for the common stock. Piper Sandler will use commercially reasonable efforts to sell the shares of common stock subject to the ATM Agreement from time to time, based upon our instructions (including any price, time or size limits or other customary parameters or conditions that we may impose). We will pay Piper Sandler a commission of 3.0% of the gross proceeds of any shares sold through Piper Sandler under the ATM Agreement&#59; however, we are not obligated to make any sales of common stock. For the year ended December 31, 2021, no shares of common stock were sold under the ATM Agreement.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our cash flows for the periods presented </span><span style="font-style:italic;">(in thousands</span><span style="font-style:italic;">)</span><span style="font-style:italic;">:</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(83,755</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(55,048</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,189</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,663</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,553</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,376</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,987</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,991</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash Flows from Operating Activities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used in operating activities for the year ended December 31, 2021 was $83.8 million. The most significant component of our cash used was a net loss of $87.9 million. This included non-cash expense related to stock-based compensation of $3.4 million and depreciation and amortization of $0.3 million. In addition, cash inflow of $0.5 million was attributable to the change in our net operating assets and liabilities primarily as a result of a $3.9 million decrease in prepaid and other assets, a $1.5 million decrease in accounts receivable, and a $0.5 million increase in accounts payable, offset by a $3.7 million decrease in accrued compensation and other accrued liabilities and a $1.8 million decrease in deferred revenue related to the Biogen Agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash used in operating activities for the year ended December 31, 2020 was $55.0 million, due primarily to a net loss of $56.2 million and a net change in our operating assets and liabilities of $2.6 million, due primarily to a $11.7 million decrease in accounts receivable and a $1.7 million increase in accounts payable, partially offset by a $13.0 million decrease in deferred revenue related to the Biogen Agreement and a $3.0 million increase in prepaid and other assets. This is partially offset by non-cash charges of $3.8 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash Flows from Investing Activities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by investing activities for the year ended December 31, 2021 was $48.2 million, due to $49.0 million in proceeds from maturities of investments, offset by $0.8 million in purchases of property and equipment. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by investing activities for the year ended December 31, 2020 was $9.7 million, due to $107.6 million in proceeds from maturities of investments, offset by $97.6 million in purchases of short-term and long-term investments and $0.3 million in purchases of property and equipment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash flows from Financing Activities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by financing activities for the year ended December 31, 2021 was $49.6 million, due to $49.3 million in net proceeds from the issuance of common stock related to our public offering in the first quarter of 2021 and $0.3 million in proceeds from ESPP purchases of common stock and stock option exercises.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash provided by financing activities for the year ended December 31, 2020 was $60.4 million, due to $32.0 million in net proceeds from the <span style="color:#000000;">issuance of common stock related to our public offering in February 2020, $28.0 million in net proceeds from the issuance of common stock related to our public offering in June 2020, and $0.4 million in proceeds from ESPP purchases of common stock and stock option exercises</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Polices and Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and the Company&#8217;s discussion and analysis of its financial condition and operating results require the Company&#8217;s management to make judgments, assumptions and estimates that affect the amounts reported in its consolidated financial statements and accompanying notes. Our significant accounting policies and methods used in preparation of the Company&#8217;s consolidated financial statements are described in Note 3, &#8220;<span style="font-style:italic;">Summary of Significant Accounting Policies</span>,&#8221; of the Notes to the Consolidated Financial Statements of this Annual Report on Form 10-K. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates, and such differences may be material.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management believes the Company&#8217;s critical accounting policies and estimates discussed below are critical to understanding its historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">License and Collaboration Arrangements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may enter into collaboration arrangements that fall under the scope Collaborative Arrangements (Topic 808) (&#8220;ASC 808&#8221;). We analyze collaboration arrangements to assess whether they are within the scope of ASC 808 to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. The accounting for some of the activities under collaboration arrangements may be analogized to ASC 606 for distinct units of accounting that are reflective of a vendor-customer relationship.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, in determining the appropriate amount of revenue to be recognized as we fulfill our obligations under its agreements, we perform the following steps: (i) identification of the promised goods or services in the contract&#59; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract&#59; (iii) measurement of the transaction price, including the constraint on variable consideration&#59; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices&#59; and (v) recognition of revenue when we satisfy each performance obligation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we recognize revenues attributed to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, we use our judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of each arrangement that contains development milestones, we evaluate whether the development milestones included are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee, such as regulatory approvals, are not generally considered probable of being achieved until those approvals are received. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the end of each reporting period, we re-evaluate the probability of achievement of any development milestones, and if necessary, adjust its estimate of the transaction price. Any such adjustments would be recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For research and development services, the Company elected the practical expedient to recognize revenue as the research and development services are invoiced.&#160;&#160;As the Company has a right to consideration from the collaboration agreement with Biogen, in an amount that corresponds directly with the value of the Company&#8217;s performance completed to date for the research services, the Company recognized revenue related to the research services as invoiced, in line with the practical expedient in ASC 606-10-55-18.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price is allocated to each performance obligation on a relative stand-alone selling price (&#8220;SSP&#8221;) basis. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">recognize revenue as or when the performance obligations under the contract are satisfied. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the accounting for these arrangements, </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">must develop assumptions that require judgment to determine the timing of recognition and the SSP for each performance obligation identified in the contract.&#160;</span></p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SSP for licenses are calculated using the residual approach if we have not yet established a price for such license and the license has not previously been sold on a standalone basis.&#160;Otherwise, selling prices for licenses are determined using an income approach model and include key assumptions such as: development timeline, revenue forecast, commercialization expenses, discount rate and probabilities of technical and regulatory success. To estimate the SSP for research and development services, we use a cost-plus margin approach. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We record accrued expenses for estimated costs of our research and development activities conducted by external service providers, which include the conduct of preclinical studies and clinical trials and contract manufacturing activities. We record the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced and includes these costs in other accrued liabilities in the consolidated balance sheet and within research and development expense in the consolidated statement of operations. These costs are a significant component of our research and development expenses. We record accrued expenses for these costs based on the estimated amount of work completed and in accordance with agreements established with these external service providers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We estimate the amount of work completed through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fee to be paid for such services. We make significant judgments and estimates in determining the accrued balance in each reporting period. As actual costs become known, we adjust its accrued estimates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We measure the cost of employee and director services received in exchange for an award of equity instruments based on the fair value-based measurement of the award on the date of grant and recognize the related expense over the period during which an employee or director is required to provide service in exchange for the award on a straight-line basis. The estimated fair value of equity awards that contain performance conditions is expensed over the term of the award once we have determined that it is probable that performance conditions will be satisfied.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Determining the fair value of stock-based awards at the grant date requires judgment. We use the Black-Scholes option-pricing model to determine the fair value of stock options. The determination of the grant date fair value of options using an option-pricing model is affected by our assumptions regarding a number of variables including the fair value of our common stock, our expected common stock price volatility over the expected life of the options, expected term of the stock option, risk-free interest rates and expected dividends. We record stock-based compensation as a compensation expense, net of the forfeited awards. We elected to account for forfeitures when they occur. As such, we recognize stock-based compensation expense only for those stock-based awards that are expected to vest, over their requisite service period, based on the vesting provisions of the individual grants.&#160;See Note 10, <span style="font-style:italic;">Stock Based Compensation, </span>to our consolidated financial statements included in this Annual Report on Form 10-K for more information.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS">Item&#160;7A.<span style="margin-left:36pt;">QUANTITATIVE AND QUALITAT</span>IVE DISCLOSURES ABOUT MARKET RISK</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.47%;text-indent:-10.47%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CATALYST BIOSCIENCES, INC.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Index to Consolidated Financial Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:93.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><span style="text-decoration:none;">Report of Independent Registered Public Accounting Firm</span></a><span style="text-decoration:none;"> </span><span style="text-decoration:none;">(P</span><span style="text-decoration:none;">CAOB ID #<ix:nonNumeric id="F_000034" name="dei:AuditorFirmId" contextRef="C_0001124105_20210101_20211231">274</ix:nonNumeric>)</span></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p></td>
</tr>
<tr>
<td valign="top" style="width:93.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Financial Statements</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.2%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:93.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36.75pt;;text-indent:-12.25pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><span style="text-decoration:none;">Consolidated Balance Sheets</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p></td>
</tr>
<tr>
<td valign="top" style="width:93.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36.75pt;;text-indent:-12.25pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS"><span style="text-decoration:none;">Consolidated Statements of Operations</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p></td>
</tr>
<tr>
<td valign="top" style="width:93.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36.75pt;;text-indent:-12.25pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_COMPREHENSIVE_LO"><span style="text-decoration:none;">Consolidated Statements of Comprehensive Loss</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p></td>
</tr>
<tr>
<td valign="top" style="width:93.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36.75pt;;text-indent:-12.25pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQU"><span style="text-decoration:none;">Consolidated Statements of Stockholders&#8217; Equity</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p></td>
</tr>
<tr>
<td valign="top" style="width:93.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36.75pt;;text-indent:-12.25pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><span style="text-decoration:none;">Consolidated Statements of Cash Flows</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p></td>
</tr>
<tr>
<td valign="top" style="width:93.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36.75pt;;text-indent:-12.25pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><span style="text-decoration:none;">Notes to the Consolidated Financial Statements</span></a><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span></p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Board of Directors and Stockholders of</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Opinion on the Financial Statements </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying balance sheets of Catalyst Biosciences, Inc. (the &#8220;Company&#8221;) as of December 31, 2021 and 2020 and the related statements of operations, comprehensive loss, stockholders&#8217; equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the &#8220;financial statements&#8221;).&#160;&#160;In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the years then ended in conformity with accounting principles generally accepted in the United States of America.&#160;&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis for Opinion </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company&#8217;s management.&#160;&#160;Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits.&#160;&#160;We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB.&#160;&#160;Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.&#160;&#160;The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.&#160;&#160;As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.&#160;&#160;Accordingly, we express no such opinion.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks.&#160;&#160;Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.&#160;&#160;Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.&#160;&#160;We believe that our audits provide a reasonable basis for our opinion.&#160;&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Critical Audit Matter</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or disclosures that are material to the financial statements and (ii) involved especially challenging, subjective, or complex judgments.&#160;&#160;The communication of critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As described in Note 3 to the financial statements, the Company is required to estimate their expenses resulting from their research and development activities conducted by external service providers, which include the performance of preclinical studies and clinical trials and contract manufacturing activities. The Company recorded accrued expenses related to research and development activities of $3.6 million, which are included in other accrued liabilities on the December 31, 2021 balance sheet and also recorded prepaid research and development expenses of $0.9 million, which are included in prepaid and other current assets on the December 31, 2021 balance sheet. The amounts recorded for research and development accruals and for prepaid research and development expenses, within the aforementioned balance sheet captions represent the Company&#8217;s estimate of the unpaid and prepaid research and development expenses based on the progress of the research and development activities for clinical trials compared to the amounts paid for clinical trials through December 31, 2021.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management&#8217;s estimate of research and development expenses is based on the estimated </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">amount</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of services provided but not yet invoiced, the estimated amount of work completed and estimates to completion and in accordance with agreements established with these external service providers.</span></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We identified management&#8217;s estimate of the research and development expenses as a critical audit matter. There was significant judgment required by management with respect to the estimate of the amount of work completed, as the calculation includes estimates of the progress or stage of completion of the services.&#160;&#160;This in turn led to a high degree of auditor judgment, subjectivity and effort in applying the procedures related to those estimates. </p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the financial statements.&#160;&#160;We obtained an understanding and evaluated the design of the controls over the Company&#8217;s process of estimation and assumptions used in the estimation of the research and development expenses.&#160;&#160;We performed procedures to test the research and development accruals and prepaid balances that included, among others, reading agreements with external service providers and evaluating the significant assumptions described above and methods used in developing the research and development estimates and calculating the amounts that were unpaid and prepaid at the balance sheet date. We made direct inquiries of financial and clinical personnel on the status of the research and development activities, progress towards completion, and status of any change orders. We compared the current estimate of expenses incurred to estimates previously made by management. We also assessed the historical accuracy of management&#8217;s estimates and examined invoices issued and payments made to services providers after the balance sheet date.&#160;&#160;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ EisnerAmper LLP</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2014.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000035" name="dei:AuditorName" contextRef="C_0001124105_20210101_20211231">EISNERAMPER LLP</ix:nonNumeric></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000036" name="dei:AuditorLocation" contextRef="C_0001124105_20210101_20211231">Philadelphia, Pennsylvania</ix:nonNumeric></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_BALANCE_SHEETS">Consolidated Balance Sheets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except shares and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">44,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,360</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:ShortTermInvestments" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,504</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:ShortTermInvestments" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">48,994</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,818</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,313</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid and other current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,807</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,843</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:AssetsCurrent" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,476</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:AssetsCurrent" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">89,510</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:LongTermInvestments" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,543</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets, noncurrent</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001124105_20211231" decimals="-3" scale="3">472</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001124105_20201231" decimals="-3" scale="3">528</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,744</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,832</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001124105_20211231" decimals="-3" scale="3">970</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001124105_20201231" decimals="-3" scale="3">433</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:Assets" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,662</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:Assets" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">94,846</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,419</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,931</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,467</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,476</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:DeferredRevenueCurrent" contextRef="C_0001124105_20211231" decimals="-3" scale="3">230</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:DeferredRevenueCurrent" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,983</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,072</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,743</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,977</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001124105_20201231" decimals="-3" scale="3">663</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,165</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">17,796</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability, noncurrent</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001124105_20211231" decimals="-3" scale="3">408</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001124105_20201231" decimals="-3" scale="3">981</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:Liabilities" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,573</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:Liabilities" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,777</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and Contingencies (Note 7)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000072">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000073">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000087" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001124105_20211231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000088" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001124105_20201231" decimals="INF">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="U_xbrlishares" id="F_000089" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001124105_20211231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000090" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001124105_20201231" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000091" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001124105_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000092" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001124105_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000093" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001124105_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000094" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001124105_20201231" decimals="INF" format="ixt-sec:numwordsen">zero</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; shares issued and outstanding</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000074">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000075">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000095" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001124105_20211231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000096" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001124105_20201231" decimals="INF">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="U_xbrlishares" id="F_000097" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001124105_20211231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000098" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001124105_20201231" decimals="INF" format="ixt:numdotdecimal">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized&#59;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; <ix:nonFraction unitRef="U_xbrlishares" id="F_000099" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001124105_20211231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000101" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001124105_20211231" decimals="INF" format="ixt:numdotdecimal">31,409,707</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000100" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001124105_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000102" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001124105_20201231" decimals="INF" format="ixt:numdotdecimal">22,097,820</ix:nonFraction></ix:nonFraction> shares issued and outstanding at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; December 31, 2021 and 2020, respectively</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000076" name="us-gaap:CommonStockValue" contextRef="C_0001124105_20211231" decimals="-3" scale="3">31</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000077" name="us-gaap:CommonStockValue" contextRef="C_0001124105_20201231" decimals="-3" scale="3">22</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000078" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">443,752</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000079" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">390,803</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000080" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001124105_20201231" decimals="-3" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000081" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001124105_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">402,694</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000082" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001124105_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">314,761</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000083" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">41,089</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000084" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">76,069</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000085" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">55,662</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000086" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">94,846</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_OPERATIONS">Consolidated Statements of Operations</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000103" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001124105_srtProductOrServiceAxis_cbioLicenseRevenueMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,100</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000104" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,338</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000105" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,848</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License and collaboration revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000106" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001124105_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,338</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000107" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,948</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of license</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000108" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="C_0001124105_srtProductOrServiceAxis_cbioCostOfLicenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,102</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of collaboration</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000109" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="C_0001124105_srtProductOrServiceAxis_cbioCostOfCollaborationMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,380</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000110" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="C_0001124105_srtProductOrServiceAxis_cbioCostOfCollaborationMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,061</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000111" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001124105_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">68,889</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000112" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">52,975</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000113" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001124105_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,963</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000114" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,180</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000115" name="us-gaap:OperatingExpenses" contextRef="C_0001124105_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">95,232</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000116" name="us-gaap:OperatingExpenses" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">78,318</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000117" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001124105_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">87,894</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001124105_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">57,370</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income (expense), net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000119" name="cbio:InterestAndOtherIncomeExpenseNet" contextRef="C_0001124105_20210101_20211231" decimals="-3" sign="-" scale="3">39</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000120" name="cbio:InterestAndOtherIncomeExpenseNet" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,129</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000121" name="us-gaap:NetIncomeLoss" contextRef="C_0001124105_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">87,933</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000122" name="us-gaap:NetIncomeLoss" contextRef="C_0001124105_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">56,241</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders, basic and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000123" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001124105_20210101_20211231" decimals="2" sign="-">2.87</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000124" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001124105_20200101_20201231" decimals="2" sign="-">2.93</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares used to compute net loss per share attributable to common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; stockholders, basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000125" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001124105_20210101_20211231" decimals="0" format="ixt:numdotdecimal">30,640,977</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000126" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001124105_20200101_20201231" decimals="0" format="ixt:numdotdecimal">19,179,299</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_COMPREHENSIVE_LO">Consolidated Statements of Comprehensive Loss</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="us-gaap:NetIncomeLoss" contextRef="C_0001124105_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">87,933</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000128" name="us-gaap:NetIncomeLoss" contextRef="C_0001124105_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">56,241</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive loss:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss on available-for-sale debt securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001124105_20210101_20211231" decimals="-3" sign="-" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000130" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001124105_20200101_20201231" decimals="-3" sign="-" scale="3">29</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total comprehensive loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000131" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001124105_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">87,938</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000132" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001124105_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">56,270</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_STOCKHOLDERS_EQU">Consolidated Statements of Stockholders&#8217; Equity</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income (Loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000133" name="us-gaap:SharesOutstanding" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">12,040,835</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000134" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" scale="3">12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000135" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">326,810</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000136" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231" decimals="-3" scale="3">34</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000137" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">258,520</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000138" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">68,336</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000139" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">51,056</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000140" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,627</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000141" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,627</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock from ESPP purchases and stock option exercises</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000142" name="cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">82,853</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000143" name="cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" scale="3">435</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000144" name="cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" contextRef="C_0001124105_20200101_20201231" decimals="-3" scale="3">435</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock for public offering, net of issuance costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,559</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000145" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">9,923,076</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000146" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" scale="3">10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000147" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">59,931</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000148" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">59,941</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss on available-for-sale debt securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000149" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" sign="-" scale="3">29</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000150" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001124105_20200101_20201231" decimals="-3" sign="-" scale="3">29</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000151" name="us-gaap:NetIncomeLoss" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">56,241</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="us-gaap:NetIncomeLoss" contextRef="C_0001124105_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">56,241</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000153" name="us-gaap:SharesOutstanding" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">22,097,820</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000154" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" scale="3">22</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000155" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">390,803</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000156" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231" decimals="-3" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">314,761</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">76,069</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000159" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">56,912</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000160" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,405</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001124105_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,405</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock from ESPP purchases and stock option exercises</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000162" name="cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">69,975</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000163" name="cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" scale="3">303</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000164" name="cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" contextRef="C_0001124105_20210101_20211231" decimals="-3" scale="3">303</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock for public offering, net of issuance costs of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000178" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" contextRef="C_0001124105_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,563</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000165" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">9,185,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="-3" scale="3">9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">49,241</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001124105_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">49,250</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss on available-for-sale debt securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20211231" decimals="-3" sign="-" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="C_0001124105_20210101_20211231" decimals="-3" sign="-" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000171" name="us-gaap:NetIncomeLoss" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">87,933</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="us-gaap:NetIncomeLoss" contextRef="C_0001124105_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">87,933</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000173" name="us-gaap:SharesOutstanding" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="INF" format="ixt:numdotdecimal">31,409,707</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000174" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231" decimals="-3" scale="3">31</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000175" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">443,752</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">402,694</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000177" name="us-gaap:StockholdersEquity" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">41,089</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:21.15%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONSOLIDATED_STATEMENTS_CASH_FLOWS">Consolidated Statements of Cash Flows</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating Activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="us-gaap:ProfitLoss" contextRef="C_0001124105_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">87,933</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="us-gaap:ProfitLoss" contextRef="C_0001124105_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">56,241</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000182" name="us-gaap:ShareBasedCompensation" contextRef="C_0001124105_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,405</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000183" name="us-gaap:ShareBasedCompensation" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,627</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000184" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001124105_20210101_20211231" decimals="-3" scale="3">290</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000185" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="C_0001124105_20200101_20201231" decimals="-3" scale="3">138</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000186" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001124105_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,495</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001124105_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">11,687</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid and other assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001124105_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3,880</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000189" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,043</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001124105_20210101_20211231" decimals="-3" scale="3">500</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000191" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,652</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation and other accrued liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000192" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0001124105_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">3,680</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0001124105_20200101_20201231" decimals="-3" scale="3">82</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liability and right-of-use asset</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000194" name="cbio:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" contextRef="C_0001124105_20210101_20211231" decimals="-3" scale="3">41</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000195" name="cbio:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" contextRef="C_0001124105_20200101_20201231" decimals="-3" scale="3">67</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000196" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0001124105_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,753</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000197" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0001124105_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">13,017</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash flows used in operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000198" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001124105_20210101_20211231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">83,755</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000199" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001124105_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">55,048</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Investing Activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from maturities of short-term investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000200" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" contextRef="C_0001124105_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">49,028</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000201" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">107,565</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of short-term and long-term investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000202" name="cbio:PaymentsToAcquireShortTermAndLongInvestments" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">97,635</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000203" name="us-gaap:PaymentsToAcquireInvestments" contextRef="C_0001124105_20210101_20211231" decimals="-3" scale="3">839</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000204" name="us-gaap:PaymentsToAcquireInvestments" contextRef="C_0001124105_20200101_20201231" decimals="-3" scale="3">267</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash flows provided by investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000205" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001124105_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">48,189</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000206" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,663</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financing Activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock for public offering, net of issuance costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000207" name="cbio:ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" contextRef="C_0001124105_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">49,250</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000208" name="cbio:ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">59,941</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock from ESPP purchase and stock option exercises</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000209" name="cbio:ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises" contextRef="C_0001124105_20210101_20211231" decimals="-3" scale="3">303</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000210" name="cbio:ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises" contextRef="C_0001124105_20200101_20201231" decimals="-3" scale="3">435</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash flows provided by financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000211" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001124105_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">49,553</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000212" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">60,376</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000213" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001124105_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,987</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000214" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,991</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at beginning of the period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000215" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,360</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000216" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,369</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:68.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at end of the period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000217" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">44,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.54%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000218" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,360</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental Disclosure of Non-Cash Investing and Financing Activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets obtained in exchange for operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000219" name="cbio:NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities" contextRef="C_0001124105_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,850</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000220" name="cbio:NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities" contextRef="C_0001124105_20200101_20201231" decimals="-3" scale="3">476</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Remeasurement of right-of-use asset due to operating lease modification</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000221" name="cbio:NonCashOrPartNonCashRemeasurementOfRightOfUseAssetDueToOperatingLeaseModification" contextRef="C_0001124105_20210101_20211231" decimals="-3" scale="3">624</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.2%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:5.56%;text-indent:5.56%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN">Notes to the Consolidated Financial Statements</p><ix:nonNumeric id="F_000223" name="us-gaap:NatureOfOperations" contextRef="C_0001124105_20210101_20211231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="NOTES_TO_CONSOLIDATED">Nature of Operations</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc. and its subsidiary (the &#8220;Company&#8221; or &#8220;Catalyst&#8221;) is a <span style="color:#000000;">fully integrated research and clinical development biopharmaceutical company with expertise in protease engineering, discovery, translational research, clinical development, and manufacturing. The Company is focused on advancing its protease product candidates in the fields of hemostasis and complement regulation.</span> <span style="color:#000000;">The Company is located in South San Francisco, California and operates in</span> <ix:nonFraction unitRef="U_cbioSegment" id="F_000274" name="us-gaap:NumberOfOperatingSegments" contextRef="C_0001124105_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> segment. </p></ix:nonNumeric><ix:nonNumeric id="F_000224" name="us-gaap:LiquidationBasisOfAccountingTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"></span>Liquidity<span style="font-weight:normal;"> </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had a net loss of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000277" name="us-gaap:NetIncomeLoss" contextRef="C_0001124105_20210101_20211231" decimals="-5" sign="-" format="ixt:numdotdecimal" scale="6">87.9</ix:nonFraction> million for the year ended December 31, 2021 and an accumulated deficit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000275" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001124105_20211231" decimals="-5" sign="-" format="ixt:numdotdecimal" scale="6">402.7</ix:nonFraction> million as of December 31, 2021. The Company expects to continue to incur losses for the next several years. As of December 31, 2021, the Company had $<ix:nonFraction unitRef="U_iso4217USD" id="F_000276" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="C_0001124105_20211231" decimals="-5" scale="6">46.9</ix:nonFraction> million of cash, cash equivalents and short-term  investments. Its primary uses of cash are to fund operating expenses, including research and development expenditures and general and administrative expenditures. Based on the current status of its research and development plans, the Company believes that its existing cash, cash equivalents and investments as of December 31, 2021 will be sufficient to fund its cash requirements for at least the next 12 months from the date of the filing of this report. If, at any time, the Company&#8217;s prospects for financing its research and development programs decline, the Company may decide to reduce research and development expenses by delaying, discontinuing or reducing its funding of one or more of its research or development programs. Alternatively, the Company might raise funds through strategic collaborations, public or private financings or other arrangements. Such funding, if needed, may not be available on favorable terms, or at all. The Company will continue to evaluate the impact of the novel coronavirus disease (&#8220;COVID-19&#8221;) pandemic on our business, operations, and cash requirements. For recent financing, see Note 14,<span style="color:#000000;"> </span><span style="font-style:italic;color:#000000;">Stockholders&#8217; Equity</span>.</p></ix:nonNumeric><ix:nonNumeric id="F_000225" name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true" continuedAt="F_000225_dcnt_239db0d3-d2f9-4656-bf8c-4cfde007b08e">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Summary of Significant Accounting Policies</p></td></tr></table></div><ix:nonNumeric id="F_000240" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements include the accounts of the Company and its subsidiary. Intercompany accounts and transactions, if applicable, have been eliminated in consolidation. The Company&#8217;s consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;GAAP&#8221;). &#160;&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000241" name="us-gaap:UseOfEstimates" contextRef="C_0001124105_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowance of doubtful accounts, operating lease right-of-use assets and liabilities, accrued expenses, income taxes and stock-based compensation. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p></ix:nonNumeric><ix:nonNumeric id="F_000242" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true" continuedAt="F_000242_dcnt_d6feab47-2170-4cb7-b5c5-d578dd77a8ed">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounting Pronouncements Recently Adopted</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update&#160;(&#8220;ASU&#8221;) 2019-12, <span style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. </span>The amendments in ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes.&#160;ASU 2019-12&#160;removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The Company adopted ASU 2019-12 as of January 1, 2021, on a prospective transition basis. <span style="color:#000000;">The adoption of ASU 2019-12 did not have a material impact on the Company&#8217;s consolidated financial statements.</span></p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000225_dcnt_239db0d3-d2f9-4656-bf8c-4cfde007b08e" continuedAt="F_000225_dcnt_e57aa802-c713-465f-a259-65649fb7b7b1"><ix:continuation id="F_000242_dcnt_d6feab47-2170-4cb7-b5c5-d578dd77a8ed">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">New Accounting Pronouncements &#8211; Issued But Not Yet Adopted</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13,<span style="font-style:italic;">&#160;Measurement of Credit Losses on Financial Instruments</span>. The main objective of ASU 2016-13 is to provide financial statement users with more decision-useful information about an entity's expected credit losses on financial instruments and other commitments to extend credit at each reporting date. To achieve this objective, the amendments in this update replace the incurred loss impairment methodology currently used today with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates. ASU 2016-13 will be effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, using a modified retrospective approach. Early adoption is permitted.&#160;The Company plans to adopt ASU 2016-13&#160;and related updates&#160;as of January 1, 2023.&#160;The Company will assess the impact of adoption of this standard on its consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2021, the FASB issued ASU 2021-04, <span style="font-style:italic;">Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</span>. The amendments in ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The Company plans to adopt ASU 2021-04 and related updates on January 1, 2022, and does not expect the adoption to have a material impact on its consolidated financial statements.</p></ix:continuation><ix:nonNumeric id="F_000243" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company invests its excess cash in bank deposits, consisting primarily of money market mutual funds. The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents.</p></ix:nonNumeric><ix:nonNumeric id="F_000244" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="C_0001124105_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value hierarchy requires that an entity maximize the use of observable inputs when estimating fair value. The fair value hierarchy includes the following three-level classification which is based on the market observability of the inputs used for estimating the fair value of the assets or liabilities being measured:</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 1<span style="font-style:normal;"> &#8211; Quoted prices in active markets for identical assets or liabilities.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 2<span style="font-style:normal;"> &#8211; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 3<span style="font-style:normal;"> &#8211; Inputs that are generally unobservable and typically reflect management&#8217;s estimate of assumptions that market participants would use in pricing the asset or liability.</span></p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000225_dcnt_e57aa802-c713-465f-a259-65649fb7b7b1" continuedAt="F_000225_dcnt_be862237-0f33-4e0c-9e0a-a044dcaed9e7"><ix:nonNumeric id="F_000245" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, which are <ix:nonNumeric id="F_000278" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001124105_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20210101_20211231" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_000279" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001124105_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapComputerSoftwareIntangibleAssetMember_20210101_20211231" format="ixt-sec:durwordsen">three years</ix:nonNumeric></ix:nonNumeric> for computer equipment and software, and three to <ix:nonNumeric id="F_000281" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20211231" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_000283" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210101_20211231" format="ixt-sec:durwordsen">seven years</ix:nonNumeric></ix:nonNumeric> for furniture and leasehold improvements.</p></ix:nonNumeric><ix:nonNumeric id="F_000246" name="us-gaap:MarketableSecuritiesPolicy" contextRef="C_0001124105_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investments</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company invests its excess cash in investment grade, short to intermediate-term, fixed income securities and recognizes purchased securities on the settlement date. All investments have been classified as &#8220;available-for-sale&#8221; and are carried at estimated fair value based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments at the time of purchase and reevaluates such designation as of each consolidated balance sheet date. Unrealized gains and losses on available-for-sale debt securities are excluded from earnings and are reported as a component of comprehensive loss. Realized gains and losses and declines in fair value determined to be other-than-temporary, if any, on available-for-sale debt securities are included in interest and other income (expense), net. The cost of securities sold is based on the specific-identification method. Interest on short-term investments is included in interest and other income (expense), net.</p></ix:nonNumeric><ix:nonNumeric id="F_000247" name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true" continuedAt="F_000247_dcnt_bdf72335-651f-4466-ad35-9b8eb05c9cf4">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">License and Collaboration Arrangements </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.21%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may enter into collaboration arrangements that fall under the scope Collaborative Arrangements (Topic 808). The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808 to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. The accounting for some of the activities under collaboration arrangements may be analogized to ASC 606 for distinct units of account that are reflective of a vendor-customer relationship.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, in determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract&#59; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract&#59; (iii) measurement of the transaction price, including the constraint on variable consideration&#59; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices&#59; and (v) recognition of revenue when the Company satisfies each performance obligation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues attributed to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of each arrangement that contain development milestones, the Company evaluates whether the development milestones included are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not generally considered probable of being achieved until those approvals are received.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the end of each reporting period, the Company re-evaluates the probability of achievement of any development milestones, and if necessary, adjusts its estimate of the transaction price. Any such adjustments </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000225_dcnt_be862237-0f33-4e0c-9e0a-a044dcaed9e7" continuedAt="F_000225_dcnt_4d5c9541-cee4-4137-927c-6c41b71e22a9"><ix:continuation id="F_000247_dcnt_bdf72335-651f-4466-ad35-9b8eb05c9cf4">
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would be recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For research and development services, the Company elected the practical expedient to recognize revenue as the research and development services are invoiced.&#160;&#160;As the Company has a right to consideration from the collaboration agreement with Biogen International GmbH (&#8220;Biogen&#8221;), in an amount that corresponds directly with the value of the Company&#8217;s performance completed to date for the research services, the Company recognized revenue related to the research services as invoiced, in line with the practical expedient in ASC 606-10-55-18.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price is allocated to each performance obligation on a relative stand-alone selling price (&#8220;SSP&#8221;) basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the timing of recognition and the SSP for each performance obligation identified in the contract.&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SSP for licenses are calculated using the residual approach if the Company has not yet established a price for such license and the license has not previously been sold on a standalone basis.&#160;Otherwise, selling prices for licenses are determined using an income approach model and include key assumptions such as: development timeline, revenue forecast, commercialization expenses, discount rate and probabilities of technical and regulatory success. To estimate the SSP for research and development services, the Company uses a cost-plus margin approach. </p></ix:continuation><ix:nonNumeric id="F_000248" name="cbio:CostOfLicenseAndCollaborationRevenuePolicyTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cost of License and Collaboration</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of license revenue includes sublicense fees paid or payable to Mosaic Biosciences, Inc. (&#8220;Mosaic&#8221;), incurred in the period, under the terms of the Mosaic collaboration agreement, and fees for patent development and protection paid or payable to other third-party vendors corresponding to the recognition of license revenue from the Company&#8217;s collaboration agreement with Biogen. See<span style="color:#000000;"> Notes 8 and 12, </span><span style="font-style:italic;color:#000000;">Related Parties </span><span style="color:#000000;">and</span><span style="font-style:italic;color:#000000;"> Collaborations, </span><span style="color:#000000;">respectively. Cost of license revenue does not include any allocated overhead costs.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of collaboration revenue includes fees for research and development services paid or payable to Mosaic and other third-party vendors and personnel cost, incurred in the period pertaining to the Company&#8217;s agreement with Biogen. See<span style="color:#000000;"> Notes 8 and 12, </span><span style="font-style:italic;color:#000000;">Related Parties </span><span style="color:#000000;">and</span><span style="font-style:italic;color:#000000;"> Collaborations, </span><span style="color:#000000;">respectively. Cost of collaboration revenue does not include any allocated overhead costs.</span></p></ix:nonNumeric><ix:nonNumeric id="F_000249" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_0001124105_20210101_20211231" escape="true">
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services used in research and development are initially deferred and capitalized in prepaid and other current assets. The capitalized amounts are then expensed as the related goods are delivered or services are performed, or until it is no longer expected that the goods or services will be delivered. Research and development costs consist of payroll and other personnel-related expenses, laboratory supplies and reagents, contract research and development services, materials, and consulting costs, as well as allocations of facilities and other overhead costs. Under the Company&#8217;s collaboration agreement with Biogen, certain specific expenditures are reimbursed by third parties. During the years ended December 31, 2021 and 2020, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000284" name="cbio:CostOfCollaborationRevenue" contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231" decimals="-5" scale="6">6.5</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000285" name="cbio:CostOfCollaborationRevenue" contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-5" scale="6">5.4</ix:nonFraction> million, respectively, of research and development expense was recorded as cost of collaboration revenue related to the collaboration agreement with Biogen signed in December 2019.</p></ix:nonNumeric><ix:nonNumeric id="F_000250" name="cbio:AccruedResearchAndDevelopmentExpensesPolicyTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true" continuedAt="F_000250_dcnt_73b34cc8-6c3f-474c-a023-70c47d99a4a8">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.81%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses include estimated costs of research and development activities conducted by external service providers, which include the conduct of preclinical studies and clinical trials and contract manufacturing activities. The Company records the estimated costs of research and development activities </p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000225_dcnt_4d5c9541-cee4-4137-927c-6c41b71e22a9" continuedAt="F_000225_dcnt_ce1c0ffa-c7a3-48e9-9400-35a056368928"><ix:continuation id="F_000250_dcnt_73b34cc8-6c3f-474c-a023-70c47d99a4a8">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">based upon the estimated </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">amount</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of services provided but not yet invoiced and includes these costs in</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> other</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> accrued liabilities in the consolidated balance sheet and within research and development expense in the consolidated statement of operations. These costs are a significant component of the research and development expenses. The Company records accrued expenses for these costs based on the estimated amount of work completed and in accordance with agreements established with these external service providers.</span></p></ix:continuation><ix:nonNumeric id="F_000251" name="cbio:ConcentrationRiskCreditRiskPolicyTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, investments and accounts receivable. The Company&#8217;s investment policy restricts cash investments to high credit quality, investment grade investments. The Company believes that it has established guidelines for investment of its excess cash that maintain safety and liquidity through its policies on high quality of investment and investment duration. The Company is exposed to credit risk in the event of default by the institutions holding the cash and cash equivalents to the extent beyond the amount insured by the federal depository insurance corporation. The Company&#8217;s accounts receivable as of December 31, 2021 of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000286" name="us-gaap:AccountsReceivableGrossCurrent" contextRef="C_0001124105_20211231" decimals="-5" scale="6">1.8</ix:nonFraction> million as well as its total license and collaboration revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000287" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001124105_20210101_20211231" decimals="-5" scale="6">7.3</ix:nonFraction> million and $20.9 million for the years ended December 31, 2021 and 2020, respectively, are from one party, see Note 12, <span style="font-style:italic;">Collaborations</span>.&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000252" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" contextRef="C_0001124105_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounts Receivable and Allowance for Doubtful Accounts</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. Customer payments are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under the arrangements. The Company continuously monitors collections and payments from its customers and maintains a provision for estimated credit losses. The Company determines its allowance for doubtful accounts by considering a number of factors, including the length of time balances are past due, the Company&#8217;s previous loss history, the customer&#8217;s current ability to pay its obligations to the Company and the condition of the general economy and the industry as a whole. The Company writes off accounts receivable when they are determined to be uncollectible. For the years ended December 31, 2021 and 2020, there were no allowance for doubtful accounts deemed necessary.</p></ix:nonNumeric><ix:nonNumeric id="F_000253" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes are computed using the liability method. Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company follows the authoritative guidance on accounting for uncertainty in income taxes. This guidance prescribes a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken in the Company&#8217;s income tax returns. This interpretation also provides guidance on accounting for interest and penalties and associated with tax positions, accounting for income taxes in interim periods and income tax disclosures.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s policy is to include penalties and interest expense related to income taxes as a component of other expense and interest expense, respectively, as necessary.</p></ix:nonNumeric><ix:nonNumeric id="F_000254" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_0001124105_20210101_20211231" escape="true" continuedAt="F_000254_dcnt_f18c1698-eeb8-46e6-9eb0-dc7ae89cb321">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures the cost of employee, non-employee and director services received in exchange for an award of equity instruments based on the fair value of the award on the date of grant and recognizes the related expense over the period during which the employee, non-employee or director is required to provide service in exchange for the award on a straight-line basis. The estimated fair value of equity awards that contain performance conditions is expensed over the term of the award once the Company has determined that it is probable that performance conditions will be satisfied.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000225_dcnt_ce1c0ffa-c7a3-48e9-9400-35a056368928"><ix:continuation id="F_000254_dcnt_f18c1698-eeb8-46e6-9eb0-dc7ae89cb321">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the Black-Scholes option-pricing valuation model to estimate the grant-date fair value of stock-based awards. The determination of fair value for stock-based awards on the date of grant using an option-pricing model requires management to make certain assumptions regarding </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a number of</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> variables. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he Company </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">elected to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">account for forfeitures when they occur. As such, the Company recognizes stock-based compensation expense, over their requisite service period, based on the vesting provisions of the individual grants.</span></p></ix:continuation><ix:nonNumeric id="F_000255" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" contextRef="C_0001124105_20210101_20211231" escape="true" continuedAt="F_000255_cnt_1">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restructuring Charges</p></ix:nonNumeric><ix:continuation id="F_000255_cnt_1">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs and liabilities associated with restructuring are recorded in the period management commits to a restructuring or cost reduction plan, or executes specific actions contemplated by the plan and all criteria for liability recognition have been met. One-time employee termination costs are recognized at the time of communication to employees, unless future service is required, in which case the costs are recognized ratably over the future service period. Restructuring charges are recognized as an operating expense within the consolidated statements of operations and related liabilities are recorded within accrued compensation on the consolidated balance sheets. The Company periodically evaluates and, if necessary, adjusts its estimates based on currently available information.</p></ix:continuation><ix:nonNumeric id="F_000257" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.</p></ix:nonNumeric>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has elected to combine lease and non-lease components as a single component. The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the consolidated balance sheet as right-of-use assets, operating lease liabilities, current and operating lease liabilities, non-current. </p><ix:nonNumeric id="F_000258" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss per Share Attributable to Common Stockholders</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss of the Company for all periods presented.</p></ix:nonNumeric></ix:continuation><ix:nonNumeric id="F_000226" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true" continuedAt="F_000226_dcnt_35acbcce-cb97-44b6-bef9-c8094c19abc6">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fair Value Measurements</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For a description of the fair value hierarchy and fair value methodology, see Note 3,<span style="font-style:italic;"> Summary of Significant Accounting Policies</span>. As of December 31, 2021 and 2020, the Company&#8217;s highly liquid money market funds included within cash equivalents and U.S. government agency securities are valued using Level&#160;1 inputs. The Company classifies its federal agency securities as Level 2. There were no transfers in or out of Level 1 and Level 2 during the periods presented. U.S. government agency securities are bonds issued by the U.S. government and are fully backed by the U.S. government. Given the frequency at which U.S. government agency securities trade and the accessibility of observable, quoted prices for such assets in active markets, they are recognized as Level 1 assets. Federal agency securities are bonds and notes issued by government-sponsored enterprises, including Fannie Mae, Freddie Mac and the Federal Home Loan Bank. Since Federal agency securities typically do not trade as U.S. government agency securities and no exchange exists to price such investments, they are recognized as Level 2 assets. </p><ix:nonNumeric id="F_000259" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true" continuedAt="F_000259_dcnt_5d275247-68d0-4410-a7bd-936d93fab9a6"></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000226_dcnt_35acbcce-cb97-44b6-bef9-c8094c19abc6"><ix:continuation id="F_000259_dcnt_5d275247-68d0-4410-a7bd-936d93fab9a6">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present the fair value hierarchy for assets measured at fair value on a recurring basis as of December 31, 2021 and 2020 <span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000289" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">44,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000290" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">44,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">2)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000291" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,504</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000292" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,504</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000293" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">46,851</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000294" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">46,851</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000295" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,360</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000296" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,360</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">2)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000297" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">37,837</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000298" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">37,837</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal agency securities<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">2)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000299" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,700</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000300" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,700</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000301" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">68,197</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000302" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,700</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000303" name="us-gaap:AssetsFairValueDisclosure" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">81,897</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"><ix:footnote id="FNT_000000" xml:lang="en-US">Included in cash and cash equivalents on accompanying consolidated balance sheet.</ix:footnote></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"><ix:footnote id="FNT_000001" xml:lang="en-US">Included in short-term investments on accompanying consolidated balance sheet and are classified as available-for-sale debt securities. $<ix:nonFraction unitRef="U_iso4217USD" id="F_000288" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_cbioLongTermInvestmentsMember_20211231" decimals="-5" scale="6">2.5</ix:nonFraction> million of U.S. government agency securities as of December 31, 2020 are included in long-term investments on the accompanying consolidated balance sheets due to the maturity being more than 12 months.</ix:footnote> &#160;</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-0.43%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of cash, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to the short-term maturity of these instruments.</p></ix:continuation></ix:continuation><ix:nonNumeric id="F_000227" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true" continuedAt="F_000227_dcnt_c3747e9d-e854-4cfe-b1e0-6560ef451a71">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Instruments</p></td></tr></table></div><ix:nonNumeric id="F_000260" name="cbio:SaleSecuritiesAvailableTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents and investments (debt securities) which are classified as available-for-sale securities, consisted of the following <span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds (cash equivalents)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000304" name="cbio:AmortizedCostAvailableForSaleSecurities" contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">44,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000307" name="cbio:SaleSecuritiesAvailable" contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">44,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000305" name="cbio:AmortizedCostAvailableForSaleSecurities" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,504</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000308" name="cbio:SaleSecuritiesAvailable" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,504</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000306" name="cbio:AmortizedCostAvailableForSaleSecurities" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">46,851</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000309" name="cbio:SaleSecuritiesAvailable" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">46,851</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Classified as:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000310" name="cbio:SaleSecuritiesAvailable" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">44,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000311" name="cbio:SaleSecuritiesAvailable" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,504</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000312" name="cbio:SaleSecuritiesAvailable" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">46,851</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds (cash equivalents)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000313" name="cbio:AmortizedCostAvailableForSaleSecurities" contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,360</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000320" name="cbio:SaleSecuritiesAvailable" contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,360</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000314" name="cbio:AmortizedCostAvailableForSaleSecurities" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">37,835</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000317" name="cbio:AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231" decimals="-3" scale="3">2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000321" name="cbio:SaleSecuritiesAvailable" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">37,837</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal agency securities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000315" name="cbio:AmortizedCostAvailableForSaleSecurities" contextRef="C_0001124105_us-gaapFinancialInstrumentAxis_cbioFederalAgencySecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,697</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000318" name="cbio:AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" contextRef="C_0001124105_us-gaapFinancialInstrumentAxis_cbioFederalAgencySecuritiesMember_20201231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000322" name="cbio:SaleSecuritiesAvailable" contextRef="C_0001124105_us-gaapFinancialInstrumentAxis_cbioFederalAgencySecuritiesMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,700</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000316" name="cbio:AmortizedCostAvailableForSaleSecurities" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">81,892</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000319" name="cbio:AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" contextRef="C_0001124105_20201231" decimals="-3" scale="3">5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000323" name="cbio:SaleSecuritiesAvailable" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">81,897</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Classified as:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000324" name="cbio:SaleSecuritiesAvailable" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,360</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000325" name="cbio:SaleSecuritiesAvailable" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">48,994</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000326" name="cbio:SaleSecuritiesAvailable" contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapOtherLongTermInvestmentsMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,543</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000327" name="cbio:SaleSecuritiesAvailable" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">81,897</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000227_dcnt_c3747e9d-e854-4cfe-b1e0-6560ef451a71">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been <ix:nonFraction unitRef="U_iso4217USD" id="F_000328" name="cbio:GrossRealizedGainLossNetAvailableForSalesSecurities" contextRef="C_0001124105_20210101_20211231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction> material realized gains or losses on available-for-sale debt securities for the periods presented. As of December 31, 2021, the remaining contractual maturities of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000329" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001124105_20211231" decimals="-5" scale="6">2.5</ix:nonFraction> million of available-for-sale debt securities were less than <ix:nonNumeric id="F_000330" name="cbio:AvailableForSaleDebtSecuritiesContractualMaturity" contextRef="C_0001124105_srtRangeAxis_srtMaximumMember_20210101_20211231" format="ixt-sec:durwordsen">one year</ix:nonNumeric>. </p></ix:continuation><ix:nonNumeric id="F_000228" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Other Accrued Liabilities </p></td></tr></table></div><ix:nonNumeric id="F_000261" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued liabilities consisted of the following <span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000331" name="cbio:AccruedManufacturingExpensesCurrent" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,381</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000332" name="cbio:AccruedManufacturingExpensesCurrent" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,238</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biogen</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000333" name="cbio:AccruedCollaborationExpensesCurrent" contextRef="C_0001124105_20211231" decimals="-3" scale="3">868</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-clinical</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000334" name="cbio:AccruedPreClinicalExpensesCurrent" contextRef="C_0001124105_20211231" decimals="-3" scale="3">773</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional and consulting services</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000335" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001124105_20211231" decimals="-3" scale="3">509</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000336" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,979</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000337" name="cbio:AccruedClinicalExpensesCurrent" contextRef="C_0001124105_20211231" decimals="-3" scale="3">361</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000338" name="cbio:AccruedClinicalExpensesCurrent" contextRef="C_0001124105_20201231" decimals="-3" scale="3">291</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000339" name="cbio:AccruedAndOtherCurrentLiabilities" contextRef="C_0001124105_20211231" decimals="-3" scale="3">180</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000340" name="cbio:AccruedAndOtherCurrentLiabilities" contextRef="C_0001124105_20201231" decimals="-3" scale="3">235</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other accrued liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000341" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,072</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000342" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,743</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000229" name="us-gaap:CommitmentsDisclosureTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true" continuedAt="F_000229_dcnt_70ead27e-69fd-4ad6-9bb7-c9b6410f0913">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Commitments and Contingencies </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Manufacturing Agreements</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 20, 2016, the Company signed a development and manufacturing services agreement with AGC Biologics, Inc. (&#8220;AGC&#8221;), pursuant to which AGC will conduct manufacturing development of agreed upon product candidates. The Company had firm work orders with AGC to manufacture MarzAA and DalcA to support its clinical trials totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000343" name="cbio:FirmWorkOrderSupportingClinicalTrials" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioAGCBiologicsIncMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_20211231" decimals="-5" scale="6">15.8</ix:nonFraction> million and the payment obligations were fully paid off as of December 31, 2021. The Company also signed an agreement with AGC to perform certain manufacturing services related to the Company&#8217;s collaboration agreement with Biogen, which includes firm work orders totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000347" name="cbio:CostOfManufacturingServices" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioAGCBiologicsIncMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapServiceAgreementsMember_20211231" decimals="-5" scale="6">0.7</ix:nonFraction> million and the payment obligations remaining as of December 31, 2021 were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000348" name="us-gaap:ContractualObligation" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioAGCBiologicsIncMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapServiceAgreementsMember_20211231" decimals="-5" scale="6">0.3</ix:nonFraction> million.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2021, the Company entered into two separate agreements, one for additional clinical trial services for MarzAA, and another for the Company&#8217;s screening and natural history of disease clinical studies related to CFI deficiency, with total payments of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000344" name="cbio:CostOfServicesAsPerAgreement" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioMarzeptacogAlfaActivatedMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapServiceAgreementsMember_20211231" decimals="-5" scale="6">3.2</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000345" name="cbio:CostOfServicesAsPerAgreement" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioMarzeptacogAlfaActivatedMember_srtProductOrServiceAxis_cbioDalcinonacogAlfaMember_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapServiceAgreementsMember_20211231" decimals="-5" scale="6">6.5</ix:nonFraction> million, respectively. In November 2021, the Company provided notice of intent to terminate its MarzAA manufacturing agreements and incurred charges of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000349" name="cbio:ChargesRelatedToWriteOffOfPrepaidManufacturingCost" contextRef="C_0001124105_20211101_20211130" decimals="-5" scale="6">3.8</ix:nonFraction> million to write-off prepaid manufacturing costs that will no longer be used for the clinical development of MarzAA, see Note 16, <span style="font-style:italic;">Restructuring</span>. The Company can terminate the CFI agreement at its discretion and upon termination will be responsible to pay for those services incurred prior to termination plus reasonable wind-down expenses.</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 16, 2021, the Company signed a Manufacturing and Research and Development Studies Agreement to support the lyophilized drug product, CB4332. The agreement will cover analytical method qualification to support good manufacturing practices (&#8220;GMP&#8221;) manufacturing. The Company currently has firm work orders related to this agreement totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000346" name="cbio:FirmWorkOrderSupportingClinicalTrials" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIntegrityBioMember_srtProductOrServiceAxis_cbioGMPMember_20211231" decimals="-5" scale="6">0.2</ix:nonFraction> million and the payment obligations were fully paid off as of December 31, 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COVID-19</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current COVID-19 pandemic has presented a substantial public health and economic challenge around the world and is affecting the Company&#8217;s employees, potential trial participants and business operations. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact and the economic impact on local, regional, national, and international markets. The COVID-19 pandemic may disrupt the operations of the Company&#8217;s manufacturers or disrupt supply logistics, which could impact the timing of deliveries and potentially increase expenses under our agreements. </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000229_dcnt_70ead27e-69fd-4ad6-9bb7-c9b6410f0913">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is actively monitoring the impact of COVID-19 and the possible effects on its financial condition, liquidity, operations, clinical trials, suppliers, </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">industry</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and workforce.</span></p></ix:continuation><ix:nonNumeric id="F_000230" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Related Parties</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 24, 2017, the Company announced a strategic research collaboration with Mosaic to develop intravitreal anti-complement factor C3 products for the treatment of dry AMD and other retinal diseases. <span style="color:#000000;">Dr. Usman, the Company&#8217;s Chief Executive Officer and a member of the Company&#8217;s board of directors, and Mr. Lawlor, a member of the Company&#8217;s board of directors, were also members of the board of directors of Mosaic. On December 21, 2018, the Company amended its collaboration agreement with Mosaic to, among other things, include certain additional products. According to the Mosaic collaboration agreement, as amended, the Company and Mosaic co-funded certain research.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 18, 2019, the Company entered into the second amendment to the Mosaic collaboration agreement following completion of the co-funded research. Pursuant to the second amendment, any future services provided by Mosaic will be performed on a fee-for-service basis. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Company&#8217;s collaboration agreement with Biogen, the Company received a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000350" name="cbio:UpfrontFeeReveivedFromLicenseAndCollaborationAgreement" contextRef="C_0001124105_srtProductOrServiceAxis_cbioIntravitrealAntiComplementFactor3Member_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_us-gaapTypeOfArrangementAxis_cbioBiogenCollaborationMember_20200110" decimals="-5" scale="6">15.0</ix:nonFraction> million upfront license fee on January 10, 2020, see Note 12, <span style="font-style:italic;">Collaborations</span>. As a result, the Company paid Mosaic a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000351" name="cbio:SublicenseFee" contextRef="C_0001124105_srtProductOrServiceAxis_cbioIntravitrealAntiComplementFactor3Member_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200101_20201231" decimals="-5" scale="6">3.0</ix:nonFraction> million sublicense fee and recorded such payment as cost of license revenue for the year ended December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 8, 2020, the Company entered into a subsequent amendment to the Mosaic collaboration agreement. As part of this amendment, the Company paid a one-time $<ix:nonFraction unitRef="U_iso4217USD" id="F_000352" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" contextRef="C_0001124105_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200508_20200508" decimals="-5" scale="6">0.8</ix:nonFraction> million cash payment to Mosaic, and Mosaic is eligible to receive up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000353" name="cbio:MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" contextRef="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200508_20200508" decimals="-5" scale="6">4.0</ix:nonFraction> million in potential future milestone payments related to regulatory and clinical development events for CB 2782-PEG and an additional anti-complement product candidate in lieu of the Company&#8217;s obligations to pay Mosaic a double-digit percentage of funds the Company receives from Biogen or any other amounts the Company receives related to sublicense fees, research and development payments, or any other research, regulatory, clinical or commercial milestones and royalties on any other development candidates. The Company now owns one hundred percent of all future payment streams related to these product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2020, Mosaic was no longer a related party.</p></ix:nonNumeric><ix:nonNumeric id="F_000231" name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true" continuedAt="F_000231_dcnt_47bbd778-ff38-48e2-9928-dcfd7bb35922">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Leases</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. In calculating the present value of the lease payments, the Company has elected to utilize its incremental borrowing rate based on the original lease term and not the remaining lease term. The lease includes non-lease components (<span style="font-style:italic;">e.g.</span>, common area maintenance) that are paid separately from rent based on actual costs incurred and, therefore, were not included in the right-of-use asset and lease liability but are reflected as an expense in the period incurred.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office space for its corporate headquarters, located in South San Francisco, CA. The lease term is through <ix:nonNumeric id="F_000354" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001124105_20210101_20211231" format="ixt:datemonthdayyearen">April 30, 2023</ix:nonNumeric> and there are <ix:nonNumeric id="F_000355" name="cbio:LesseeOperatingLeaseRenewalTermDescription" contextRef="C_0001124105_20210101_20211231">no stated renewal options</ix:nonNumeric>. On July 17, 2020, the Company entered into an amendment to its existing lease agreement to lease additional office space for an aggregated undiscounted future monthly payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000362" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0001124105_20200717" decimals="-5" scale="6">0.5</ix:nonFraction> million. The amendment was treated as a separate lease with a lease term of <ix:nonNumeric id="F_000361" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0001124105_20200717" format="ixt-sec:duryear">2.6</ix:nonNumeric> years and <ix:nonNumeric id="F_000360" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedDescription" contextRef="C_0001124105_20200716_20200717">commenced during the fourth quarter of 2020.</ix:nonNumeric></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2021, the Company entered into a license agreement (the &#8220;License Agreement&#8221;) for the use of laboratory facilities in South San Francisco, CA, for an aggregated undiscounted future payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000357" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0001124105_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioLeaseLabAndOfficeSpaceMember_us-gaapTypeOfArrangementAxis_cbioSubleaseArrangementMember_20210430" decimals="-5" scale="6">1.9</ix:nonFraction> million. <ix:nonNumeric id="F_000358" name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="C_0001124105_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioLeaseLabAndOfficeSpaceMember_us-gaapTypeOfArrangementAxis_cbioSubleaseArrangementMember_20210401_20210430">This License Agreement has an original lease term of one year and a renewal period of six months</ix:nonNumeric>. This License Agreement <ix:nonNumeric id="F_000359" name="us-gaap:LesseeOperatingLeaseDescription" contextRef="C_0001124105_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioLeaseLabAndOfficeSpaceMember_us-gaapTypeOfArrangementAxis_cbioSubleaseArrangementMember_20210401_20210430">commenced during the second quarter of 2021</ix:nonNumeric>.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000231_dcnt_47bbd778-ff38-48e2-9928-dcfd7bb35922">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2021, the Company amended the License Agreement to extend the lease term for a period of one year. The amendment was not accounted for as a separate </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lease, and</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> resulted in an adjustment to the right-of-use asset</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and lease liability of $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000356" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_0001124105_20211001_20211031" decimals="-5" scale="6">0.6</ix:nonFraction></span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The amended lease will expire at the end of April 2023.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2021 and 2020, the Company&#8217;s operating lease expense was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000363" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001124105_20210101_20211231" decimals="-5" scale="6">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000364" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001124105_20200101_20201231" decimals="-5" scale="6">0.7</ix:nonFraction> million, respectively. <ix:nonNumeric id="F_000262" name="cbio:SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true" continuedAt="F_000262_cnt_1">The present value assumptions used in calculating the present value of the lease payments were as follows:</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&#160;</p><ix:continuation id="F_000262_cnt_1">
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000365" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001124105_20211231" format="ixt-sec:duryear">1.3</ix:nonNumeric> years</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000366" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001124105_20201231" format="ixt-sec:duryear">2.3</ix:nonNumeric> years</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000367" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001124105_20211231" decimals="3" scale="-2">4.8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000368" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001124105_20201231" decimals="3" scale="-2">5.7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000263" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:2pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maturity of the Company&#8217;s operating lease liabilities as of&#160;December&#160;31, 2021 were as follows&#160;<span style="font-style:italic;">(in thousands):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000369" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,044</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000370" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_0001124105_20211231" decimals="-3" scale="3">410</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted lease payments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000371" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,454</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000372" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0001124105_20211231" decimals="-3" scale="3">69</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000373" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,385</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000264" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:2pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. The Company did not incur significant variable lease costs for the years ended December 31, 2021 and 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information related to operating leases was as follows&#160;<span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000374" name="cbio:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" contextRef="C_0001124105_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,641</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000375" name="cbio:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" contextRef="C_0001124105_20200101_20201231" decimals="-3" scale="3">602</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid cash payment for lease</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000376" name="cbio:PrepaidCashPaymentForLeaseLiabilities" contextRef="C_0001124105_20210101_20211231" decimals="-3" scale="3">208</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for operating leases that were included in operating cash outflows</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000377" name="us-gaap:OperatingLeasePayments" contextRef="C_0001124105_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,849</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000378" name="us-gaap:OperatingLeasePayments" contextRef="C_0001124105_20200101_20201231" decimals="-3" scale="3">602</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000232" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true" continuedAt="F_000232_dcnt_b002555d-6204-43da-9e98-38a87d787d4f">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stock Based Compensation</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2018 Omnibus Incentive Plan </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, stockholders of the Company approved the Company&#8217;s 2018 Omnibus Incentive Plan (the &#8220;2018 Plan&#8221;). The 2018 Plan had previously been approved by the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) and the Compensation Committee (the &#8220;Committee&#8221;) of the Board, subject to stockholder approval. The 2018 Plan became effective on June 13, 2018. On June 9, 2021, the stockholders of the Company approved an amendment previously approved by the Board to increase the number of shares of common stock reserved for issuance under the 2018 Plan by <ix:nonFraction unitRef="U_xbrlishares" id="F_000379" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenOmnibusIncentivePlanMember_20210609_20210609" decimals="INF" format="ixt:numdotdecimal">2,500,000</ix:nonFraction> to a total of <ix:nonFraction unitRef="U_xbrlishares" id="F_000380" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenOmnibusIncentivePlanMember_20210609" decimals="INF" format="ixt:numdotdecimal">5,300,000</ix:nonFraction> shares. The amendment became effective immediately upon stockholder approval.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Performance-Based Stock Option Grants</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021, the Committee approved the issuance of option grants to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000381" name="cbio:IssuanceOfOptionGrantsToPurchaseCommonStockShares" contextRef="C_0001124105_us-gaapAwardTypeAxis_cbioPerformanceBasedStockOptionGrantsMember_us-gaapPlanNameAxis_cbioTwoThousandEighteenOmnibusIncentivePlanMember_20210228" decimals="INF" format="ixt:numdotdecimal">647,000</ix:nonFraction> shares of common stock for executive officers pursuant to the 2018 Plan, which will vest upon (a) the achievement of specified performance goals and (b) the grantees&#8217; continued employment during the service period specified in each grant. For the year ended December 31, 2021, no expense has been recognized related to these awards. In </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000232_dcnt_b002555d-6204-43da-9e98-38a87d787d4f" continuedAt="F_000232_dcnt_a1d57ad6-05bf-4b99-852c-908468429a13">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">addition, the options </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">never vested and expired </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">since the performance conditions were not satisfied as of December 31, 2021.</span></p><ix:nonNumeric id="F_000265" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity under the Company&#8217;s 2018 Plan and related information:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000382" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001124105_20191231" decimals="INF" format="ixt:numdotdecimal">1,577,541</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000395" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001124105_20191231" decimals="2">10.85</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000407">8.15</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000411" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,350</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000383" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001124105_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">1,091,250</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000396" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001124105_20200101_20201231" decimals="2">6.26</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000384" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001124105_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">44,605</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000397" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001124105_20200101_20201231" decimals="2">5.04</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options forfeited</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000385" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001124105_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">250,641</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000398" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_0001124105_20200101_20201231" decimals="2">10.32</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options expired</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000386" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="C_0001124105_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">17,930</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000399" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_0001124105_20200101_20201231" decimals="2">51.12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000387" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001124105_20201231" decimals="INF" format="ixt:numdotdecimal">2,355,615</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000400" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001124105_20201231" decimals="2">8.59</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000408">7.96</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000412" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,337</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000388" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001124105_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">1,493,238</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000401" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001124105_20210101_20211231" decimals="2">5.31</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000389" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001124105_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">5,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000402" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001124105_20210101_20211231" decimals="2">4.63</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options forfeited</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000390" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001124105_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">1,239,630</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000403" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_0001124105_20210101_20211231" decimals="2">6.26</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options expired</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000391" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="C_0001124105_20210101_20211231" decimals="INF">593</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000404" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="C_0001124105_20210101_20211231" decimals="2">566.33</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000392" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001124105_20211231" decimals="INF" format="ixt:numdotdecimal">2,603,630</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000405" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001124105_20211231" decimals="2">7.70</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000409">7.46</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable &#8212; December 31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000393" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_0001124105_20211231" decimals="INF" format="ixt:numdotdecimal">1,513,039</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000406" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_0001124105_20211231" decimals="2">9.37</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000410">6.35</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available to be granted &#8212; December 31,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000394" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001124105_20211231" decimals="INF" format="ixt:numdotdecimal">3,333,791</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.07%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair value of options granted during the years ended December 31, 2021 and 2020 was $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000413" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001124105_20210101_20211231" decimals="2">4.00</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000414" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001124105_20200101_20201231" decimals="2">5.20</ix:nonFraction>, respectively.</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.07%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value of options exercised during the years ended December 31, 2021 and 2020 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000415" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001124105_20210101_20211231" decimals="0" format="ixt:numdotdecimal">3,000</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000416" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001124105_20200101_20201231" decimals="-5" scale="6">0.1</ix:nonFraction> million, respectively.</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.07%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of options vested during the years ended December 31, 2021 and 2020 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000417" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="C_0001124105_20210101_20211231" decimals="-5" scale="6">2.6</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000418" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="C_0001124105_20200101_20201231" decimals="-5" scale="6">3.0</ix:nonFraction> million, respectively.</p>
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Valuation Assumptions</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimated the fair value of stock options granted using the Black-Scholes option-pricing formula and a single option award approach. Due to its limited history as a public company and limited number of sales of its common stock, the Company estimated its volatility considering a number of factors including the use of the volatility of comparable public companies. The expected term of options granted under the Plan, all of which qualify as &#8220;plain vanilla&#8221; per SEC Staff Accounting Bulletin 107, is determined based on the simplified method due to the Company&#8217;s limited operating history. The risk-free rate is based on the yield of a U.S. Treasury security with a term consistent with the option. This fair value is being amortized ratably over the requisite service periods of the awards, which is generally the vesting period.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000266" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true" continuedAt="F_000266_cnt_1">The fair value of employee stock options was estimated using the following&#160;weighted-average assumptions:</ix:nonNumeric><span style="color:#000000;"> </span></p><ix:continuation id="F_000266_cnt_1" continuedAt="F_000266_dcnt_35f47c87-3138-4d35-a85f-5330eb9eba63">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee Stock Options:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000419">6.00</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000420">5.81</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000421" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231" decimals="4" scale="-2">0.84</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000422" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="4" scale="-2">0.91</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000423" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000424" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="2" format="ixt:zerodash">&#8212;</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000425" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231" decimals="4" scale="-2">93.25</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000426" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="4" scale="-2">113.36</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p></ix:continuation></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000232_dcnt_a1d57ad6-05bf-4b99-852c-908468429a13"><ix:continuation id="F_000266_dcnt_35f47c87-3138-4d35-a85f-5330eb9eba63">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000267" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true" continuedAt="F_000267_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation recognized was as follows <span style="font-style:italic;">(in thousands):</span></p></ix:nonNumeric><ix:continuation id="F_000267_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000427" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,202</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000428" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,487</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative<sup style="font-size:85%;line-height:120%;vertical-align:top"> (1)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000429" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,203</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000430" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,140</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000431" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001124105_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,405</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000432" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,627</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top"><ix:footnote id="FNT_000002" xml:lang="en-US">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-size:8pt;color:#000000;">Included in general and administrative stock-based compensation for the years ended December 31, 2021 and 2020 is $<ix:nonFraction unitRef="U_iso4217USD" id="F_000435" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231" decimals="-5" scale="6">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000436" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-5" scale="6">0.3</ix:nonFraction> million in expense related to <ix:nonFraction unitRef="U_xbrlishares" id="F_000433" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="C_0001124105_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">56,912</ix:nonFraction> shares and <ix:nonFraction unitRef="U_xbrlishares" id="F_000434" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="C_0001124105_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">51,056</ix:nonFraction> shares of common stock, respectively, issued to certain board members in lieu of their cash compensation.</span></p></ix:footnote></td></tr></table></div></ix:continuation>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.19%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the Company had unrecognized employee stock-based compensation expense of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000437" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20211231" decimals="-5" scale="6">3.9</ix:nonFraction> million, related to unvested stock option awards, which is expected to be recognized over an estimated weighted-average period of <ix:nonNumeric id="F_000438" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231" format="ixt-sec:duryear">2.49</ix:nonNumeric> years.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, the Company&#8217;s stockholders approved the 2018 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP had previously been approved by the Board and the Compensation Committee of the Board, subject to stockholder approval which became effective as of June 13, 2018. Under the ESPP, employees meeting certain specific employment qualifications are eligible to participate and can purchase shares of common stock semi-annually on February 9<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> and August 9<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> of each year, through payroll deductions. The purchase price is <ix:nonFraction unitRef="U_xbrlipure" id="F_000439" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20180613_20180613" decimals="INF" scale="-2">85</ix:nonFraction>% of the lower of the fair market value of the stock at the commencement or end of the offering period. The ESPP permits eligible employees to purchase shares of common stock through payroll deductions for up to <ix:nonFraction unitRef="U_xbrlipure" id="F_000440" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20180613" decimals="INF" scale="-2">15</ix:nonFraction>% of qualified compensation.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s ESPP is subject to an Evergreen provision which shares may be added to the pool as needed. As of December 31, 2021, a total of <ix:nonFraction unitRef="U_xbrlishares" id="F_000442" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">359,545</ix:nonFraction> shares of common stock may be granted in accordance with the terms of the ESPP.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2021, a total of <ix:nonFraction unitRef="U_xbrlishares" id="F_000443" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">64,975</ix:nonFraction> shares of common stock for $<ix:nonFraction unitRef="U_iso4217USD" id="F_000444" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20210101_20211231" decimals="-5" scale="6">0.3</ix:nonFraction> million have been issued to employees participating in the two ESPP purchases during 2021 and <ix:nonFraction unitRef="U_xbrlishares" id="F_000441" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20211231" decimals="INF" format="ixt:numdotdecimal">235,469</ix:nonFraction> shares are available for issuance under the ESPP as of December 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense for the ESPP was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000445" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20210101_20211231" decimals="-5" scale="6">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000446" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20200101_20201231" decimals="-5" scale="6">0.1</ix:nonFraction> million for the years ended December 31, 2021 and 2020, respectively, and is included in total stock-based compensation recognized.</p></ix:continuation><ix:nonNumeric id="F_000233" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true" continuedAt="F_000233_dcnt_53ac626f-9be8-4f5f-8375-dae8da0f406b">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Income Taxes </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred cumulative net operating losses since inception and, consequently, has not recorded any income tax expense for the years ended December 31, 2021 and 2020 due to its net operating loss position. </p><ix:nonNumeric id="F_000268" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true" continuedAt="F_000268_dcnt_0382867f-47dd-4ff3-b5bd-373c886f30bb"></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000233_dcnt_53ac626f-9be8-4f5f-8375-dae8da0f406b" continuedAt="F_000233_dcnt_b5161420-5df3-4203-b3a2-0b12f38fe308"><ix:continuation id="F_000268_dcnt_0382867f-47dd-4ff3-b5bd-373c886f30bb">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reconciliation of the federal statutory income tax rate to the Company&#8217;s effective tax rate for the years ended December 31, 2021 and 2020 are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax at statutory federal rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<ix:nonFraction unitRef="U_xbrlipure" id="F_000447" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001124105_20210101_20211231" decimals="INF" scale="-2">21.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<ix:nonFraction unitRef="U_xbrlipure" id="F_000448" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001124105_20200101_20201231" decimals="INF" scale="-2">21.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State Tax (benefit)&#8212;net of federal benefit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000449" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001124105_20210101_20211231" decimals="4" scale="-2">0.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000450" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001124105_20200101_20201231" decimals="4" scale="-2">0.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000451" name="cbio:EffectiveIncomeTaxRateReconciliationPermanentDifferences" contextRef="C_0001124105_20210101_20211231" decimals="4" sign="-" format="ixt:numdotdecimal" scale="-2">0.35</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000452" name="cbio:EffectiveIncomeTaxRateReconciliationPermanentDifferences" contextRef="C_0001124105_20200101_20201231" decimals="4" sign="-" format="ixt:numdotdecimal" scale="-2">0.58</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<ix:nonFraction unitRef="U_xbrlipure" id="F_000453" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="C_0001124105_20210101_20211231" decimals="4" scale="-2">5.86</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<ix:nonFraction unitRef="U_xbrlipure" id="F_000454" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="C_0001124105_20200101_20201231" decimals="4" scale="-2">12.26</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition due to Sec. 382 and 383 limitations</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000455" name="cbio:EffectiveIncomeTaxRateReconciliationDerecognition" contextRef="C_0001124105_20210101_20211231" decimals="4" scale="-2">0.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000456" name="cbio:EffectiveIncomeTaxRateReconciliationDerecognition" contextRef="C_0001124105_20200101_20201231" decimals="4" sign="-" format="ixt:numdotdecimal" scale="-2">44.55</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000457" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001124105_20210101_20211231" decimals="4" sign="-" format="ixt:numdotdecimal" scale="-2">26.26</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-<ix:nonFraction unitRef="U_xbrlipure" id="F_000458" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001124105_20200101_20201231" decimals="4" scale="-2">12.25</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000459" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="C_0001124105_20210101_20211231" decimals="4" sign="-" format="ixt:numdotdecimal" scale="-2">0.25</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000460" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" contextRef="C_0001124105_20200101_20201231" decimals="4" sign="-" format="ixt:numdotdecimal" scale="-2">0.38</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective tax rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000461" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001124105_20210101_20211231" decimals="4" scale="-2">0.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000462" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001124105_20200101_20201231" decimals="4" scale="-2">0.00</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div></ix:continuation><ix:nonNumeric id="F_000269" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s deferred tax assets as of December 31, 2021 and 2020 consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals and reserves</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000463" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000464" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,095</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carry forwards</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000465" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">47,541</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000466" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">29,505</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credit carry forwards</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000467" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,939</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000468" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,789</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed and intangible assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000469" name="cbio:DeferredTaxAssetsFixedAssetsAndIntangibles" contextRef="C_0001124105_20211231" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000470" name="cbio:DeferredTaxAssetsFixedAssetsAndIntangibles" contextRef="C_0001124105_20201231" decimals="-3" scale="3">7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000471" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">61,483</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000472" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">38,396</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the available objective evidence at December 31, 2021, the Company does not believe it is more likely than not that the net deferred tax assets will be realizable. Accordingly, the Company has provided a full valuation allowance against its net deferred tax assets at December 31, 2021 and 2020. The net valuation allowance increased by approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000473" name="us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease" contextRef="C_0001124105_20210101_20211231" decimals="-5" sign="-" scale="6">23.1</ix:nonFraction> million and decreased approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000474" name="us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease" contextRef="C_0001124105_20200101_20201231" decimals="-5" scale="6">6.9</ix:nonFraction> million during the years ended December 31, 2021 and 2020, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, after consideration of certain limitations (see below), the Company had approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000475" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231" decimals="-5" scale="6">226.4</ix:nonFraction> million federal and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000476" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231" decimals="-5" scale="6">8.0</ix:nonFraction> million state net operating loss carryforwards (&#8220;NOL&#8221;) available to reduce future taxable income which, if unused, will begin to expire in <ix:nonNumeric id="F_000477" name="cbio:OperatingLossCarryforwardsExpirationYear" contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231">2037</ix:nonNumeric> for federal and <ix:nonNumeric id="F_000478" name="cbio:OperatingLossCarryforwardsExpirationYear" contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231">2032</ix:nonNumeric> for state tax purposes. The federal net operating loss carryforward includes $<ix:nonFraction unitRef="U_iso4217USD" id="F_000479" name="cbio:OperatingLossCarryforwardsWithIndefiniteLife" contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231" decimals="-5" scale="6">218.9</ix:nonFraction> million that have an indefinite life.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the Company also had tax credit carry forwards available to offset future tax liabilities of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000480" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231" decimals="-5" scale="6">11.4</ix:nonFraction> million for federal and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000481" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231" decimals="-5" scale="6">7.5</ix:nonFraction> million for state. If unused, the federal credit will begin to expire in 2040 and the state tax credit does not expire. &#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Company experiences a greater than 50 percentage point aggregate change in ownership over a three-year period (a Section 382 ownership change), utilization of its pre-change NOL carry forwards are subject to annual limitation under Section 382 of the Internal Revenue Code (California has similar provisions). The annual limitation is determined by multiplying the value of the Company's stock at the time of such ownership change by the applicable long-term tax-exempt rate. Such limitations may result in expiration of a portion of the NOL carryforwards before utilization. The Company determined that ownership changes occurred December 21, 2007, August 20, 2015, April 13, 2017, February 15, 2018, and February 18, 2020. Approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000483" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20071231" decimals="-5" scale="6">156.3</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000484" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_stprCA_20211231" decimals="-5" scale="6">70.8</ix:nonFraction> million of the NOLs will expire unutilized for federal and California purposes, respectively. The Company has derecognized NOL related deferred tax assets in the tax affected amounts of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000485" name="cbio:DeferredTaxAssetsStateNetOperatingLossCarryForwards" contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231" decimals="-5" scale="6">32.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000486" name="cbio:DeferredTaxAssetsStateNetOperatingLossCarryForwards" contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_stprCA_20211231" decimals="-6" scale="6">0</ix:nonFraction> for federal and California purposes, respectively.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000233_dcnt_b5161420-5df3-4203-b3a2-0b12f38fe308" continuedAt="F_000233_dcnt_3165308f-a085-4610-88b9-c5b1957a3643">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of the federal tax credits could expire unutilized as well, whereas none of the California tax credits are subject to expiration. Approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000487" name="cbio:ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" contextRef="C_0001124105_20210101_20211231" decimals="-5" scale="6">15.2</ix:nonFraction> million of gross federal tax credit-related deferred tax assets were derecognized due to the Section 383 limitation. The ability of the Company to use its remaining NOL and tax credit carry forwards may be further limited if the Company experiences a Section 382 ownership change as a result of future changes in its stock ownership. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 27, 2020, the &#8220;Coronavirus Aid, Relief and Economic Security (CARES) Act&#8221; (the &#8220;Act&#8221;) was signed into law. The Act includes provisions relating to refundable payroll tax credits, deferment of the employer portion of certain payroll taxes, net operating loss carryback periods, alternative minimum tax credit refunds, and modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The Company analyzed the provisions of the Act and determined there was no significant impact to its 2020 tax provision.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 29, 2020, the California Governor signed Assembly Bill 85 (&#8220;A.B. 85&#8221;), which now becomes California law. A.B. 85, which includes several tax measures, provides for a three-year suspension of the use of net operating losses for medium and large businesses and a three-year cap on the use of business incentive tax credits to offset no more than $<ix:nonFraction unitRef="U_iso4217USD" id="F_000488" name="cbio:MaximumAmountOfTaxOffsetPerYear" contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_stprCA_20200629_20200629" decimals="-5" scale="6">5.0</ix:nonFraction> million of tax per year. Generally, A.B. 85 suspends the use of net operating losses for taxable years 2020, 2021, and 2022 for taxpayers with taxable income of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000489" name="cbio:RequiredMinimumTaxableIncome" contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_stprCA_20200629" decimals="-5" scale="6">1.0</ix:nonFraction> million or more. Since the Company is not expected to generate California source taxable income of more than $1.0 million, no material impact is anticipated at this time.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 27, 2020, the &#8220;Consolidated Appropriations Act, 2021&#8221; (the &#8220;CAA&#8221;) was signed into law. The CAA includes provisions meant to clarify and modify certain items put forth in CARES Act, while providing aid to businesses affected by the pandemic.&#160;&#160;The CAA allows deductions for expenses paid for by Paycheck Protection Program (&#8220;PPP&#8221;) and Economic Injury Disaster Loan (&#8220;EIDL&#8221;) Program, clarifies forgiveness of EIDL advances, and other business provisions.&#160;&#160;The Company analyzed the provisions of the CAA and determined there was no significant impact to its 2021 tax provision.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounting for Uncertainty in Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company only recognizes tax benefits if it is more likely than not that they will be sustained upon audit by the relevant tax authority based upon their technical merits. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000490" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001124105_20211231" decimals="-5" scale="6">4.7</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000491" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001124105_20201231" decimals="-5" scale="6">3.0</ix:nonFraction> million of unrecognized tax benefits as of December 31, 2021 and 2020, respectively. As the Company has a full valuation allowance on its deferred tax assets, the unrecognized tax benefits have reduced the deferred tax assets and the valuation allowance in the same amount. The Company does not expect the amount of unrecognized tax benefits to materially change in the next twelve months.</p><ix:nonNumeric id="F_000270" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true" continuedAt="F_000270_dcnt_57a26047-20aa-40fb-936a-d81e68479c47">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the beginning and ending balance of the unrecognized tax benefits is as follows <span style="font-style:italic;">(in thousands)</span>: </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Beginning Balance at January 1, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000492" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001124105_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,871</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase/(Decrease) of unrecognized tax benefits taken</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; in prior years</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000493" name="cbio:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" contextRef="C_0001124105_20200101_20201231" decimals="-3" sign="-" scale="3">295</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase/(Decrease) of unrecognized tax benefits</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related to current year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000494" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,379</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ending Balance at December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000495" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001124105_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,955</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase/(Decrease) of unrecognized tax benefits taken</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; in prior years</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase/(Decrease) of unrecognized tax benefits</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related to current year</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000496" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="C_0001124105_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,749</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ending Balance at December&#160;31, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000497" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001124105_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,704</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000233_dcnt_3165308f-a085-4610-88b9-c5b1957a3643"><ix:continuation id="F_000270_dcnt_57a26047-20aa-40fb-936a-d81e68479c47">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and penalties related to unrecognized tax benefits would be included as income tax expense in the Company&#8217;s consolidated statements of operations. As of December 31, 2021 and 2020, the Company had <ix:nonFraction unitRef="U_iso4217USD" id="F_000498" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" contextRef="C_0001124105_20211231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000499" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" contextRef="C_0001124105_20201231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t recognized any tax-related penalties or interest in its consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files income tax returns in the United States federal, California, Kansas, Missouri and New Jersey state jurisdictions. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. As of December 31, 2021 and 2020, the Company had <ix:nonFraction unitRef="U_iso4217USD" id="F_000500" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" contextRef="C_0001124105_20211231" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_000501" name="us-gaap:LiabilityForUncertainTaxPositionsCurrent" contextRef="C_0001124105_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction></ix:nonFraction> uncertain tax positions which affected its financial position and its results of operations or its cash flow, and will continue to evaluate for uncertain positions in the future. The Company is subject to United States federal and state income tax examinations by authorities for all tax years due to accumulated net operating losses that are being carried forward for tax purposes.</p></ix:continuation><ix:nonNumeric id="F_000234" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true" continuedAt="F_000234_dcnt_ad29afd1-5bd7-4820-929b-f95864311c4b">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Collaborations</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Mosaic</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2017, the Company entered into a strategic research collaboration with Mosaic to develop intravitreal anti-complement factor 3 (C3) products for the treatment of dry Age-related Macular Degeneration (AMD) and other retinal diseases. The Company entered into two amendments to the Mosaic research collaboration agreements in December 2019 and May 2020. See Note 8, <span style="font-style:italic;">Related Parties</span>.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ISU Abxis</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2018, the Company entered into an amended and restated license agreement with ISU Abxis (the &#8220;A&#38;R ISU Abxis Agreement&#8221;), which amended and restated its previous license and collaboration agreement with ISU Abxis previously entered into in September 2013, as subsequently amended in October 2014 and December 2016 <span style="color:#000000;">(the &#8220;Original ISU Abxis Agreement&#8221;)</span>. Under the A&#38;R ISU Abxis Agreement, <span style="color:#000000;">ISU Abxis will receive commercialization rights in South Korea to the Company&#8217;s engineered Factor IX dalcinonacog alfa - DalcA and the Company will receive clinical development and commercialization rights in the rest of world (excluding South Korea) and manufacturing development and manufacturing rights worldwide (including South Korea)</span>. <span style="color:#000000;">The </span>A&#38;R ISU Abxis Agreement <span style="color:#000000;">eliminates the profit-sharing arrangement in the Original ISU Abxis Agreement and</span> p<span style="color:#000000;">rovides for a low single-digit royalty payment to ISU Abxis, on a country-by-country basis, for net product sales of DalcA by the Company or its affiliates in each country other than South Korea. Pursuant to the A&#38;R </span>ISU Abxis Agreement<span style="color:#000000;">, the Company will also pay up to an aggregate of</span> <span style="color:#000000;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000503" name="cbio:MilestonePayments" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231" decimals="-5" scale="6">19.5</ix:nonFraction> million in milestone payments to ISU Abxis, including $<ix:nonFraction unitRef="U_iso4217USD" id="F_000505" name="cbio:RegulatoryAndDevelopmentMilestonePayment" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231" decimals="-5" scale="6">2.5</ix:nonFraction>&#160;million in regulatory and development milestone payments and up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000507" name="cbio:CommercialMilestonePayments" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231" decimals="-5" scale="6">17.0</ix:nonFraction>&#160;million in commercial milestone payments, if the applicable milestones are met. As of December 31, 2021, <ix:nonFraction unitRef="U_iso4217USD" id="F_000502" name="cbio:MilestonePayments" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20210101_20211231" decimals="-6" format="ixt-sec:numwordsen" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000504" name="cbio:RegulatoryAndDevelopmentMilestonePayment" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20210101_20211231" decimals="-6" format="ixt-sec:numwordsen" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000506" name="cbio:CommercialMilestonePayments" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20210101_20211231" decimals="-6" format="ixt-sec:numwordsen" scale="6">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> milestones have been met.</span><span style="letter-spacing:-0.2pt;"> </span>&#160;&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Biogen</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 18, 2019, the Company and Biogen entered into a License and Collaboration Agreement (the &#8220;Biogen Agreement&#8221;), under which the Company granted Biogen a worldwide, royalty-bearing, exclusive, with the right to sublicense, license (&#8220;Exclusive License&#8221;) to develop and commercialize CB 2782-PEG and other anti-C3 proteases for potential treatment of dry AMD and other disorders. Pursuant to the Biogen Agreement, the Company will perform certain pre-clinical and manufacturing activities (&#8220;Research Services&#8221;), and Biogen will be solely responsible for funding the pre-clinical and manufacturing activities and performing IND-enabling activities, worldwide clinical development, and commercialization. The Company will provide the Research Services over a term of <span style="color:#000000;"><ix:nonNumeric id="F_000508" name="cbio:ResearchServicesAgreementTerm" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_us-gaapTransactionTypeAxis_cbioLicenseAndCollaborationAgreementMember_20191218_20191218" format="ixt-sec:durwordsen">thirty months</ix:nonNumeric></span> with Biogen having the option to extend the term for two additional <span style="color:#000000;"><span style="-sec-ix-hidden:F_000509">twelve-month</span></span> periods.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000234_dcnt_ad29afd1-5bd7-4820-929b-f95864311c4b">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Biogen Agreement, the Company received an up-front payment for the transfer of the Exclusive License (inclusive of certain know-how) of <span style="color:#000000;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000510" name="us-gaap:ProceedsFromLicenseFeesReceived" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_us-gaapTransactionTypeAxis_cbioExclusiveLicenseMember_20200101_20200131" decimals="-5" scale="6">15.0</ix:nonFraction></span> million in January 2020. The Company is eligible to receive development milestones and sales milestones of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000511" name="cbio:DevelopmentMilestonesPaymentReceivable" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioExclusiveLicenseMember_20200101_20200131" decimals="-5" scale="6">340.0</ix:nonFraction> million. In addition, the Company is eligible to receive royalties in the range of single-digit to low double-digit percentage rates of annual net sales on a product-by-product and country-by-country basis. The Company will also receive reimbursements for costs associated with the performance of the Research Services.<span style="color:#000000;">   </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the performance obligations under the Biogen Agreement were the Exclusive License and the Research Services. For the Exclusive License, the Company used the residual approach in determining the standalone selling price, or SSP, which includes the upfront payments, milestones and royalties. For the Research Services, the Company used the historical pricing approach for determining the SSP, which includes the reimbursement of personnel and out-of-pocket costs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Biogen Agreement will continue on a product-by-product and country-by-country basis until the tenth anniversary of the first commercial sale of the first product in a country, unless terminated earlier by either party as specified under the agreement. In March 2022, the Company received written notice from Biogn to terminate the Biogen Agreement effective in May 2022. See Note 17, <span style="font-style:italic;">Subsequent Event</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2021, the Company recognized <ix:nonFraction unitRef="U_iso4217USD" id="F_000512" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_20210101_20211231" decimals="-3" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction> license revenue from the Biogen Agreement. For the year ended December 31, 2020, the Company recognized the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000513" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001124105_srtProductOrServiceAxis_cbioLicenseRevenueMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cbioTransferOfExclusiveLicenseAndRelatedKnowHowMember_20200101_20201231" decimals="-5" scale="6">15.0</ix:nonFraction> million in license revenue upon the transfer of the Exclusive License and the related know-how, and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000514" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001124105_srtProductOrServiceAxis_cbioExclusiveLicenseMember_20200101_20201231" decimals="-5" scale="6">0.1</ix:nonFraction> million in license revenue for reimbursable out-of-pocket costs incurred.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2021 and 2020, the Company recognized $<ix:nonFraction unitRef="U_iso4217USD" id="F_000515" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cbioReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_20210101_20211231" decimals="-5" scale="6">7.3</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000516" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cbioReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_20200101_20201231" decimals="-5" scale="6">5.8</ix:nonFraction> million in collaboration revenue for reimbursable out-of-pocket and personnel costs incurred related to Research Services.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2021, the Company recognized $<ix:nonFraction unitRef="U_iso4217USD" id="F_000517" name="us-gaap:DeferredRevenueRevenueRecognized1" contextRef="C_0001124105_20210101_20211231" decimals="-5" scale="6">2.0</ix:nonFraction> million in collaboration revenue from the beginning of period deferred revenue balance.</p></ix:continuation><ix:nonNumeric id="F_000235" name="us-gaap:InterestAndOtherIncomeTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">13.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Interest and Other Income (Expense), Net </p></td></tr></table></div><ix:nonNumeric id="F_000271" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table shows the detail of interest and other income (expense), net as follows <span style="font-style:italic;">(in thousands):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000518" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="C_0001124105_20210101_20211231" decimals="-3" scale="3">39</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000519" name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="C_0001124105_20200101_20201231" decimals="-3" scale="3">561</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Miscellaneous income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000520" name="cbio:MiscellaneousIncomeExpense" contextRef="C_0001124105_20210101_20211231" decimals="-3" scale="3">9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000521" name="cbio:MiscellaneousIncomeExpense" contextRef="C_0001124105_20200101_20201231" decimals="-3" scale="3">659</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000522" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001124105_20210101_20211231" decimals="-3" sign="-" scale="3">87</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000523" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001124105_20200101_20201231" decimals="-3" sign="-" scale="3">91</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total interest and other income (expense), net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000524" name="cbio:InterestAndOtherIncomeExpenseNet" contextRef="C_0001124105_20210101_20211231" decimals="-3" sign="-" scale="3">39</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000525" name="cbio:InterestAndOtherIncomeExpenseNet" contextRef="C_0001124105_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,129</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric id="F_000236" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true" continuedAt="F_000236_dcnt_f88e6dce-52ef-4fb8-9017-787f0e25b3cb">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:15pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">14.</span></p></td>
<td valign="top">
<p style="margin-top:15pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stockholders&#8217; Equity</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the first quarter of 2021, the Company issued and sold an aggregate of <ix:nonFraction unitRef="U_xbrlishares" id="F_000526" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">9,185,000</ix:nonFraction> registered shares of its common stock (including <ix:nonFraction unitRef="U_xbrlishares" id="F_000527" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_cbioUnderwritersOverallotmentOptionMember_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">485,000</ix:nonFraction> shares sold pursuant to the exercise of the underwriters&#8217; overallotment option) at a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000528" name="us-gaap:SharePrice" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331" decimals="2">5.75</ix:nonFraction> per share. The net proceeds to the Company, after deducting $<ix:nonFraction unitRef="U_iso4217USD" id="F_000529" name="cbio:UnderwritingCommissionsAndOfferingExpensesPayable" contextRef="C_0001124105_20210101_20210331" decimals="-5" scale="6">3.6</ix:nonFraction> million in underwriting discounts and commissions, and offering expenses, were approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000530" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001124105_20210101_20210331" decimals="-5" scale="6">49.3</ix:nonFraction> million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had <ix:nonFraction unitRef="U_xbrlishares" id="F_000531" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20211231" decimals="INF"><ix:nonFraction unitRef="U_xbrlishares" id="F_000532" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20201231" decimals="INF"><ix:nonFraction unitRef="U_xbrlishares" id="F_000533" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20211231" decimals="INF"><ix:nonFraction unitRef="U_xbrlishares" id="F_000534" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20201231" decimals="INF">85</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding common stock warrants as of December 31, 2021 and 2020, respectively, with a weighted-average exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000535" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20211231" decimals="2"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000536" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20201231" decimals="2">392.70</ix:nonFraction></ix:nonFraction>. The warrants expire in <span style="-sec-ix-hidden:F_000537">August 2022</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2021 ATM Program </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 15, 2021, the Company entered into an Equity Distribution Agreement (the &#8220;ATM Agreement&#8221;) with Piper Sandler &#38; Co. (&#8220;Piper Sandler&#8221;), as sales agent, pursuant to which the Company may offer and sell, from time to time, through Piper Sandler, shares of the Company&#8217;s common stock, par value of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000538" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001124105_us-gaapSubsidiarySaleOfStockAxis_cbioTwoThousandTwentyOneATMProgramMember_20211015" decimals="3">0.001</ix:nonFraction> per </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000236_dcnt_f88e6dce-52ef-4fb8-9017-787f0e25b3cb">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">share, with aggregate gross sales proceeds of up to $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000539" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="C_0001124105_us-gaapSubsidiarySaleOfStockAxis_cbioTwoThousandTwentyOneATMProgramMember_20211015_20211015" decimals="-5" scale="6">50.0</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million through an &#8220;at the market&#8221; equity offering program (the &#8220;ATM Program&#8221;). The Company will pay Piper Sandler a commission of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000540" name="cbio:PercentageOfCommissionForSharesSold" contextRef="C_0001124105_us-gaapSubsidiarySaleOfStockAxis_cbioTwoThousandTwentyOneATMProgramMember_20211015" decimals="3" scale="-2">3.0</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of the gross proceeds of any shares sold. The Company also agreed to reimburse Piper Sandler for certain expenses incurred in connection with its services under the ATM Agreement, including up to $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000541" name="cbio:LegalExpensesIncurred" contextRef="C_0001124105_us-gaapSubsidiarySaleOfStockAxis_cbioTwoThousandTwentyOneATMProgramMember_20211015_20211015" decimals="0" format="ixt:numdotdecimal">50,000</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for legal expenses in connection with the establishment of the ATM Program.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of shares of common stock under the ATM Program will be made pursuant to the registration statement on Form S-3 (File No. 333-253874), which was declared effective by the SEC on May 3, 2021, and a related prospectus supplement file with the SEC on October 15, 2021. For the year ended December 31, 2021, no shares of common stock were sold under the ATM Program. </p></ix:continuation><ix:nonNumeric id="F_000237" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Net Loss per Share Attributable to Common Stockholders</p></td></tr></table></div><ix:nonNumeric id="F_000272" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000542" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioOptionsToPurchaseCommonStockMember_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">2,603,630</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000543" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioOptionsToPurchaseCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">2,355,615</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000544" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioCommonStockWarrantsMember_20210101_20211231" decimals="INF">85</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000545" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioCommonStockWarrantsMember_20200101_20201231" decimals="INF">85</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000546" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001124105_20210101_20211231" decimals="INF" format="ixt:numdotdecimal">2,603,715</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000547" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001124105_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">2,355,700</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric id="F_000238" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:15pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16.</span></p></td>
<td valign="top">
<p style="margin-top:15pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Restructuring</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2021, the Board approved a restructuring of its business based on its decision to stop the clinical development of MarzAA and focus solely on its complement programs and protease medicines platform. The restructuring included a reduction-in-force whereby approximately <ix:nonFraction unitRef="U_xbrlipure" id="F_000548" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" contextRef="C_0001124105_20211130_20211130" decimals="2" scale="-2">35</ix:nonFraction>% of employees were terminated. During the year ended December 31, 2021, the Company recorded charges of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000549" name="us-gaap:SeveranceCosts1" contextRef="C_0001124105_20210101_20211231" decimals="-5" scale="6">0.4</ix:nonFraction> million related to one-time severance costs and related expenses in connection with the workforce reduction, and charges of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000550" name="cbio:ChargesRelatedToWriteOffOfPrepaidManufacturingCost" contextRef="C_0001124105_20210101_20211231" decimals="-5" scale="6">3.8</ix:nonFraction> million related to the write-off of prepaid manufacturing costs that will no longer be used for the clinical development of MarzAA. <span style="color:#000000;">As of December 31, 2021, the remaining restructuring liability was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000551" name="cbio:RestructuringLiability" contextRef="C_0001124105_20210101_20211231" decimals="-5" scale="6">0.2</ix:nonFraction> million, which the Company expects to pay in the first quarter of 2022.</span></p><ix:nonNumeric id="F_000273" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true">
<p style="margin-bottom:6pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes restructuring charges recorded in each component of operating expenses in the Company&#8217;s consolidated statements of operations (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000552" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,025</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000553" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231" decimals="-3" scale="3">143</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total restructuring charges</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000554" name="us-gaap:RestructuringCharges" contextRef="C_0001124105_20210101_20211231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,168</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric id="F_000239" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_0001124105_20210101_20211231" escape="true" continuedAt="F_000239_dcnt_c1ef585e-fbee-44b7-ba96-2d72f3aedc1a">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Subsequent Event</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.81%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Biogen Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.76%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2022, the Company received written notice that Biogn is terminating the Biogen Agreement. Pursuant to the terms of the Biogen Agreement, termination will be effective in <span style="-sec-ix-hidden:F_000557">May 2022</span>. As a result of the termination, Biogen will no longer have an exclusive license to develop, manufacture and commercialize CB 2782-PEG and other anti-C3 proteases for potential treatment of dry AMD and other disorders.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000239_dcnt_c1ef585e-fbee-44b7-ba96-2d72f3aedc1a">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sublease</span><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> Agreement</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.76%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2022, the Company entered into a sublease agreement for one of its leased facilities that commences in April 2022. Under the terms of the sublease agreement, the Company will receive $<ix:nonFraction unitRef="U_iso4217USD" id="F_000555" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" contextRef="C_0001124105_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_cbioSubleaseArrangementMember_20220331" decimals="-5" scale="6">0.2</ix:nonFraction> million in base lease payments over the term of the sublease, which ends in <span style="-sec-ix-hidden:F_000556">April 2023</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Advisor Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.76%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2022, the Company entered into a financial advisor agreement with Raymond James &#38; Associates, Inc. (&#8220;Raymond James&#8221;) to help the Company evaluate the possible sale or merger of the Company with various third-parties. Raymond James will be paid an advisory fee of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000558" name="cbio:AdvisoryFeesPayable" contextRef="C_0001124105_us-gaapRelatedPartyTransactionAxis_cbioRaymondJamesAndAssociatesMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_cbioAdvisorAgreementMember_20220301_20220331" decimals="-5" scale="6">1.0</ix:nonFraction> million upon the effective sale or merger of the Company and will be reimbursed up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000559" name="cbio:ReimbursementOfAdvisoryFee" contextRef="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionAxis_cbioRaymondJamesAndAssociatesMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_cbioAdvisorAgreementMember_20220301_20220331" decimals="0" format="ixt:numdotdecimal">20,000</ix:nonFraction> for reasonable legal, travel and out-of-pocket expenses. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Event</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.76%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2022, the Company announced that it intends to further reduce its workforce as part of its restructuring plan. Under the restructuring plan, the Company will provide employees one-time severance payments upon termination, continued benefits for a specific period, and outplacement services. The Company expects to incur total expenses of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000560" name="us-gaap:RestructuringCharges" contextRef="C_0001124105_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220301_20220331" decimals="-5" scale="6">0.8</ix:nonFraction> million, which is expected to be paid out during the second quarter of 2022.</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman Bold;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.46%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_9A_CONTROLS_PROCEDURES">CONTROLS AND PROCEDURES</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Evaluation of disclosure controls and procedures</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management maintains disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) that are designed to provide reasonable assurance that information required to be disclosed in our reports filed or submitted under the Exchange Act is processed, recorded, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to management, including our Chief Executive Officer and our Interim Chief Financial Officer (our principal executive officer and principal financial officer, respectively), as appropriate, to allow for timely decisions regarding required disclosure.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, including the Chief Executive Officer and Interim Chief Financial Officer, carried out an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on this evaluation, our Chief Executive Officer and Interim Chief Financial Officer concluded that due to the material weakness in our internal control over financial reporting described below, our disclosure controls and procedures were not effective. In light of this material weakness, our management, including our Chief Executive Officer and Interim Chief Financial Officer, has performed additional analysis and other post-closing procedures and has concluded that, notwithstanding the material weakness in our internal control over financial reporting, the consolidated financial statements for the periods covered by and included in this Annual Report on Form 10-K fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented in conformity with U.S. GAAP.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). Because of its inherent limitations, internal control over financial reporting may not prevent or detect all misstatements. Our internal control system was designed to provide reasonable assurance to our management and board of directors regarding the preparation and fair presentation of published financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Material Weaknesses in Internal Control Over Financial Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our consolidated financial statements will not be prevented or detected on a timely basis.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2021. Our assessment was based on the framework in the updated <span style="font-style:italic;">Internal Control &#8211; Integrated Framework (2013)</span> issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, our management concluded that, as of December 31, 2021, a material weakness existed in our internal control over financial reporting. Because of the material weakness, management concluded that the Company did not maintain effective internal control over financial reporting as of December 31, 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our material weakness related to the following control deficiency:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not design and maintain effective controls related to the review of certain contracts, including the proper application of U.S. GAAP. Specifically, we did not design and maintain controls to properly review the retention bonuses granted to our employees in November 2021 after our reduction in workforce to assess the appropriate accounting treatment under U.S. GAAP.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The deficiency described above, if not remediated, could result in a misstatement of one or more account balances or disclosures in our consolidated </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">financial statements that would not be prevented or detected, and, accordingly, we determined that this control deficiency constitutes a material weakness based on the criteria set forth in the 2013 </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ramework.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K does not include a report of our independent registered public accounting firm on the effectiveness of internal control over financial reporting due to an exemption for smaller reporting companies established by the rules of the SEC.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Remediation Plans</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To address our material weakness, we are evaluating our accounting policy over monitoring and reviewing contracts so that contracts with a significant impact are reviewed and U.S. GAAP is properly applied. We are also formalizing our internal control documentation and strengthening supervisory reviews by our management. While these actions and planned actions are subject to ongoing management evaluation and will require validation and testing of the design and operating effectiveness of internal controls over a sustained period, we are committed to continuous improvement and will continue to diligently review our internal control over financial reporting.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Changes in internal control over financial reporting</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are taking actions to remediate the material weaknesses relating to our internal control over financial reporting as described above. Except as described above, there were no changes in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) during the fiscal quarter ended December 31, 2021 that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_9B_OTHER_INFORMATION">OTHER INFORMATION</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">C</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_9C_DISCLOSURE_FOREIGN_JURISDICTION">DISCLOSURES REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_III">PART III</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE&#160;&#160;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information required by this Item is incorporated by reference to the information set forth in the sections titled &#8220;Information About Our Board of Directors&#8221; and &#8220;Information About Our Executive Officers Who Are Not Directors,&#8221; &#8220;Corporate Governance,&#8221; &#8220;Corporate Governance &#8211; Code of Business Conduct and Ethics,&#8221; &#8220;Delinquent Section 16(a) Reports,&#8221; &#8220;Corporate Governance &#8211; Committees of the Board of Directors &#8211; Nominating and Corporate Governance Committee,&#8221; &#8220;Corporate Governance &#8211; Committees of the Board of Directors &#8211; Audit Committee&#8221; and &#8220;Corporate Governance &#8211; Committees of the Board of Directors &#8211; Compensation Committee&#8221; in our definitive proxy statement to be filed with the SEC on Schedule 14A in connection with our 2021 Annual Meeting of Shareholders, or the Proxy Statement, which is expected to be filed not later than 120 days after December 31, 2021.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_11_EXECUTIVE_COMPENSATION">EXECUTIVE COMPENSATION</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information required by this Item is incorporated by reference to the information set forth in the sections titled &#8220;Executive Compensation,&#8221; &#8220;Director Compensation&#8221; and &#8220;Committees of the Board of Directors &#8212; Compensation Committee Interlocks and Insider Participation&#8221; in the Proxy Statement and is incorporated herein by reference.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information required by this Item is included in the sections titled &#8220;Securities Authorized For Issuance Under Equity Compensation Plans&#8221; and &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; in the Proxy Statement and is incorporated herein by reference.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR">CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information required by this Item is included in the sections titled &#8220;Corporate Governance &#8211; Board of Directors Independence&#8221; and &#8220;Transactions With Related Persons&#8221; in the Proxy Statement and is incorporated herein by reference.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC">PRINCIPAL ACCOUNTING FEES AND SERVICES</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information required by this Item is included in the sections titled &#8220;Independent Registered Public Accounting Firm Fees and Services&#8221; in the Proxy Statement and is incorporated herein by reference.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_IV">PART IV</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH">EXHIBIT AND FINANCIAL STATEMENT SCHEDULES&#160;&#160;</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) The following documents are filed as part of this Annual Report on Form 10-K:</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. Consolidated Financial Statements</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:10.47%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See Index to Consolidated Financial Statements at Part II, Item&#160;8 Financial Statements and Supplementary Data, herein.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Consolidated Financial Statement Schedules</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:10.47%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All schedules are omitted because they are not applicable or the required information is shown under Item 8. &#8220;Financial Statements and Supplementary Data&#8221; of this Annual Report on Form 10-K.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. See LIST OF EXHIBITS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) See LIST OF EXHIBITS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item 16.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_16_FORM_10K_SUMMARY">FORM 10-K SUMMARY</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="LIST_EXHIBITS"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">LIST OF </span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EXHIBITS</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100.04%;">
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="7" valign="bottom" style="width:41.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by reference</p></td>
<td colspan="2" valign="bottom" style="width:9.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="bottom" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit title</p></td>
<td valign="bottom" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">File No.</p></td>
<td valign="bottom" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="bottom" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Filing Date</p></td>
<td valign="bottom" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Filed or</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Furnished</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">herewith</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1(a)</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312515079787/d887299dex21.htm"><span style="text-decoration:none;">Agreement and Plan of Merger dated as of March 5, 2015, by and among Targacept, Catalyst Biosciences, Inc. and Talos Merger Sub, Inc.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mar. 6, 2015</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1(b)</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312515183156/d924437dex101.htm"><span style="text-decoration:none;">Amendment No. 1 to Agreement and Plan of Merger by and among Targacept, Talos Merger Sub, Inc., and Catalyst dated May 6, 2015.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 12, 2015</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1(c)</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312515186989/d925981dex101.htm"><span style="text-decoration:none;">Amendment No. 2 to Agreement and Plan of Merger by and among Targacept, Talos Merger Sub, Inc., and Catalyst dated May 13, 2015.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 14, 2015</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312506103288/dex41.htm"><span style="text-decoration:none;">Fourth Amended and Restated Certificate of Incorporation of the Company.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-8</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-133881</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 8, 2006</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312515297752/d24322dex31.htm"><span style="text-decoration:none;">Certificate of Amendment to Fourth the Amended and Restated Certificate of Incorporation of the Company.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aug. 20, 2015</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312517037156/d326649dex31.htm"><span style="text-decoration:none;">Second Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation of the Company.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Feb. 10, 2017</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312515079787/d887299dex31.htm"><span style="text-decoration:none;">Bylaws of the Company, as amended.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Jun. 6, 2020</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312517121994/d375894dex31.htm"><span style="text-decoration:none;">Certificate of Designation of Preferences, Rights and Limitations, filed with the Delaware Secretary of State on April 10, 2017, with respect to the Series A Preferred Stock.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Apr. 13, 2017</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000156459020005546/cbio-ex41_709.htm"><span style="text-decoration:none;">Description of Securities.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Feb. 20, 2020</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001124105/000119312516498295/d117011dex43.htm"><span style="text-decoration:none;">Warrant to Purchase Stock of Catalyst Biosciences, Inc., issued to Silicon Valley Bank on March 3, 2005.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mar. 9, 2016</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001124105/000119312516498295/d117011dex45.htm"><span style="text-decoration:none;">Form of Warrant to Purchase Stock of Catalyst Biosciences, Inc., issued to purchasers of convertible promissory notes.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mar. 9, 2016</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1**</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312516554394/d165946ddef14a.htm"><span style="text-decoration:none;">Catalyst Biosciences, Inc. (formerly Targacept, Inc.) 2015 Stock Incentive Plan (as Amended and Restated Effective June 9, 2016).</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DEF 14A</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Apr. 25, 2016</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2**</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312516548415/d149784dex101.htm"><span style="text-decoration:none;">Catalyst Biosciences, Inc. 2016 Inducement Stock Incentive Plan.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Apr. 20, 2016</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3**</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312515198706/d899628dex1031a.htm"><span style="text-decoration:none;">Catalyst's 2004 Stock Plan.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-204423</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.31(a)</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 22, 2015</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100.04%;">
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="7" valign="bottom" style="width:41.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by reference</p></td>
<td colspan="2" valign="bottom" style="width:9.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="bottom" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit title</p></td>
<td valign="bottom" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">File No.</p></td>
<td valign="bottom" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="bottom" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Filing Date</p></td>
<td valign="bottom" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Filed or</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Furnished</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">herewith</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4**</span></p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000156459017013442/cbio-ex101_24.htm"><span style="text-decoration:none;">Form of Incentive Stock Option Award Notice.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 14, 2017</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5**</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000156459017013442/cbio-ex102_25.htm"><span style="text-decoration:none;">Form of Non-qualified Stock Option Award Notice.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 14, 2017</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6**</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000156459020020531/cbio-def14a_20200611.htm"><span style="text-decoration:none;">Catalyst Biosciences, Inc. 2018 Omnibus Incentive Plan.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DEF 14A</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix A</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 1, 2020</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7**</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312518160813/d581034ddef14a.htm#toc581034_35"><span style="text-decoration:none;">Catalyst Biosciences, Inc. 2018 Employee Stock Purchase Plan.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DEF 14A</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Appendix B</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 11, 2018</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8**</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cbio-ex108_9.htm"><span style="text-decoration:none;">Form of Stock Option Award Agreement.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.25</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001124105/000156459021041373/cbio-ex101_133.htm"><span style="text-decoration:none;">L</span><span style="text-decoration:none;">icense</span><span style="text-decoration:none;"> </span><span style="text-decoration:none;">Agreement, dated as of April 15, 2021, by and between SL 2T, LLC and Catalyst Biosciences, Inc.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 5, 2021</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9**</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312518265035/d612321dex101.htm"><span style="text-decoration:none;">Amended and Restated Employment Agreement, dated as of August 28, 2018, by and between Catalyst Biosciences, Inc. and Dr. Nassim Usman, Ph.D.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aug. 31, 2018</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10**</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312518265035/d612321dex102.htm"><span style="text-decoration:none;">Amended and Restated Employment Agreement, dated as of August 29, 2018, by and between Catalyst Biosciences, Inc. and Dr. Howard Levy, M.B.B.Ch., Ph.D., M.M.M.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aug. 31, 2018</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12++</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000156459019013422/cbio-ex1016b_9.htm"><span style="text-decoration:none;">Amended and Restated License Agreement, dated December 17, 2018, by and between Catalyst Biosciences, Inc. and ISU Abxis.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K/A</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 29, 2019</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13+</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000156459016022517/cbio-ex101_419.htm"><span style="text-decoration:none;">Development and Manufacturing Services Agreement, by and between CMC ICOS Biologics, Inc. and Biosciences, Inc., dated as of May 20, 2016.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aug. 4, 2016</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14+</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000156459017003722/cbio-ex1016_464.htm"><span style="text-decoration:none;">Termination Agreement, dated December 8, 2016, between Catalyst Biosciences, Inc. and Wyeth LLC, a wholly-owned subsidiary of Pfizer Inc.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mar. 8, 2017</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15(a)</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312517347025/d465134dex101.htm"><span style="text-decoration:none;">Lease Agreement, dated November 8, 2017 by and between BXP 611 Gateway Center, LP and Catalyst Biosciences, Inc..</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nov. 17, 2017</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15(b)</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312518249889/d610054dex101.htm"><span style="text-decoration:none;">First Amendment to Office Lease, dated as of August 9, 2018, by and between BXP 611 Gateway Center, LP and Catalyst Biosciences, Inc.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aug. 15, 2018</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16++</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312519267593/d820794dex101.htm"><span style="text-decoration:none;">Clinical Supply Agreement, effective as of October 4, 2019, by and between Catalyst Biosciences, Inc. and Catalent Indiana, LLC.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">October&#160;15,&#160;2019</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100.04%;">
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="7" valign="bottom" style="width:41.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by reference</p></td>
<td colspan="2" valign="bottom" style="width:9.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="bottom" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit title</p></td>
<td valign="bottom" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">File No.</p></td>
<td valign="bottom" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="bottom" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Filing Date</p></td>
<td valign="bottom" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Filed or</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Furnished</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">herewith</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17++</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000156459020005546/cbio-ex1017_708.htm"><span style="text-decoration:none;">License and Collaboration Agreement, dated December 18, 2019, by and between Biogen International GMBH and Catalyst Biosciences, Inc.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 20, 2020</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.18++</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000156459020005546/cbio-ex1018_773.htm"><span style="text-decoration:none;">Amended and Restated Collaboration Agreement, dated December 18, 2019, by and between Mosaic Biosciences, Inc. and Catalyst Biosciences, Inc.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.18</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 20, 2020</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.19</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312520009556/d847025dex101.htm"><span style="text-decoration:none;">Cooperation Agreement, dated January 13, 2020, by and between CCUR Holdings, Inc. and certain of its affiliates and Catalyst Biosciences, Inc</span><span style="text-decoration:none;">.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January 10, 2020</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.20</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000156459020005546/cbio-ex1020_631.htm"><span style="text-decoration:none;">Description of Annual Cash Incentive Program</span><span style="text-decoration:none;">.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.20</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 20, 2020</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.21**</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001124105/000119312518265035/d612321dex103.htm"><span style="text-decoration:none;">Form of Indemnification Agreement between the Company and each of its directors and members of executive management.</span></a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August&#160;31,&#160;2018</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.22++</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000156459020037483/cbio-ex101_66.htm"><span style="text-decoration:none;">Amended and Restated Collaboration Agreement, dated May 8, 2020, by and between Mosaic Biosciences, Inc. and Catalyst Biosciences, Inc.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 6, 2020</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.23</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000156459020051083/cbio-ex101_33.htm"><span style="text-decoration:none;">Second Amendment to Office Lease, dated July 17, 2020, by and between 611 Gateway Center, L.P. and Catalyst Biosciences, Inc.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November&#160;5,&#160;2020</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.24</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000156459020051083/cbio-ex102_126.htm"><span style="text-decoration:none;">Offer Letter by and between Clinton Musil and Catalyst Biosciences, Inc. dated June 9, 2020.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 5, 2020</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1124105/000119312516498295/d117011dex211.htm"><span style="text-decoration:none;">List of subsidiaries of Catalyst Biosciences, Inc.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-51173</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 9, 2016</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cbio-ex231_8.htm"><span style="text-decoration:none;">Consent of EisnerAmper LLP, Independent Registered Public Accounting Fir</span><span style="text-decoration:none;">m</span><span style="text-decoration:none;">.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.1</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#POWER_ATTORNEY"><span style="text-decoration:none;">Power of Attorney </span><span style="text-decoration:none;">(included as part of the signature page hereto)</span><span style="text-decoration:none;">.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cbio-ex311_11.htm"><span style="text-decoration:none;">Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cbio-ex312_6.htm"><span style="text-decoration:none;">Certification of the Interim Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934,</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="text-decoration:none;">as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100.04%;">
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="7" valign="bottom" style="width:41.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by reference</p></td>
<td colspan="2" valign="bottom" style="width:9.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="bottom" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit title</p></td>
<td valign="bottom" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">File No.</p></td>
<td valign="bottom" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">No.</p></td>
<td valign="bottom" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Filing Date</p></td>
<td valign="bottom" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Filed or</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Furnished</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">herewith</p></td>
</tr>
<tr>
<td valign="bottom" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="bottom" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cbio-ex321_7.htm"><span style="text-decoration:none;">Certification of the Chief Executive Officer pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr style="height:3.85pt;">
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.2</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="cbio-ex322_10.htm"><span style="text-decoration:none;">Certification of the Interim Chief Financial Officer pursuant to Rule 13a-14(b) of the Exchange Act and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following materials from the Company's Annual Report on Form 10-K for the year ended December 31, 2021, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets as of December 31, 2021 and December 31, 2020&#59; (ii) the Consolidated Statement of Operations for the years ended December 31, 2021 and 2020&#59; (iii) the Consolidated Statements of Comprehensive Loss for the years ended December 31, 2021 and 2020&#59; (iv) the Consolidated Statements of Stockholders' Equity as of December 31, 2021&#59; (v) the Consolidated Statements of Cash Flows for the twelve months ended December 31, 2021 and 2020&#59; and (vi) the Notes to the Consolidated Financial Statements.</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="width:7.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="top" style="width:0.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:39.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td>
<td valign="top" style="width:0.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:5.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:10.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:8.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:16.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top" style="width:9.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Denotes management contract, compensatory plan or arrangement.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Confidential treatment has been granted with respect to certain portions of this Exhibit, which portions have been omitted and filed separately with the SEC as part of an application for confidential treatment.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">++</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit were omitted by means of marking such portions with an asterisk because the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="SIGNATURES">SIGNATURES</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr style="height:12.4pt;">
<td colspan="2" valign="top" style="width:46.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CATALYST BIOSCIENCES, INC</p></td>
<td colspan="2" valign="top" style="width:53.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CATALYST BIOSCIENCES, INC.</p></td>
</tr>
<tr style="height:12.4pt;">
<td colspan="2" valign="top" style="width:46.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top" style="width:53.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:12.4pt;">
<td valign="top" style="width:4.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top" style="width:42.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Nassim Usman, Ph.D.</p></td>
<td valign="top" style="width:4.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top" style="width:48.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ <span style="color:#000000;">Seline Miller</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:13.2pt;">
<td valign="top" style="width:4.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:42.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Nassim Usman, Ph.D.</p></td>
<td valign="top" style="width:4.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Seline Miller</p></td>
</tr>
<tr style="height:24.75pt;">
<td valign="top" style="width:4.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:42.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
<td valign="top" style="width:4.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:48.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Interim Chief Financial Officer</p></td>
</tr>
<tr style="height:9pt;">
<td valign="top" style="width:4.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="top" style="width:42.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td>
<td valign="top" style="width:4.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="top" style="width:48.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="POWER_ATTORNEY">POWER OF ATTORNEY</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each person whose individual signature appears below hereby authorizes and appoints Nassim Usman and Seline Miller, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this annual report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:39.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Signature</p></td>
<td valign="top" style="width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:38.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="top" style="width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:19.24%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="middle" style="width:39.1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:38.8%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:19.24%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Nassim Usman, Ph.D.</p></td>
<td valign="top" style="width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td rowspan="2" valign="middle" style="width:38.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer<br />(<span style="font-style:italic;">Principal Executive Officer</span>)</p></td>
<td valign="top" style="width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Nassim Usman, Ph.D.</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:19.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="middle" style="width:39.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:38.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:19.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Seline Miller</p></td>
<td valign="top" style="width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td rowspan="2" valign="middle" style="width:38.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interim Chief Financial Officer (Interim Financial and Principal Accounting Officer)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Seline Miller</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:19.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="middle" style="width:39.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:38.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Augustine Lawlor</p></td>
<td valign="top" style="width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:38.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chairman of the Board of Directors</p></td>
<td valign="top" style="width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Augustine Lawlor</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:38.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:19.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="middle" style="width:39.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:38.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:19.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Errol B. De Souza, Ph.D.</p></td>
<td valign="top" style="width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:38.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Errol B. De Souza, Ph.D.</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:38.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:19.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="middle" style="width:39.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:38.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom" style="width:39.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Andrea Hunt</p></td>
<td valign="top" style="width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:38.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom" style="width:39.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Andrea Hunt</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:38.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="middle" style="width:39.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:38.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Jeanne Jew</p></td>
<td valign="top" style="width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:38.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Jeanne Jew</p></td>
<td valign="top" style="width:1.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:38.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom" style="width:39.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:38.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Geoffrey Ling, M.D., Ph.D.</p></td>
<td valign="top" style="width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:38.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Geoffrey Ling, M.D., Ph.D.</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:38.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:19.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="bottom" style="width:39.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:1pt;">&#160;</p></td>
<td valign="top" style="width:1.16%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="bottom" style="width:38.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&#160;</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Sharon Tetlow</p></td>
<td valign="top" style="width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:38.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sharon Tetlow</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:38.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:19.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="middle" style="width:39.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="middle" style="width:38.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Eddie Williams</p></td>
<td valign="top" style="width:1.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:38.8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:19.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022</p></td>
</tr>
<tr style="height:12.25pt;">
<td valign="bottom" style="width:39.1%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Eddie Williams</p></td>
<td valign="top" style="width:1.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:38.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:1.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:19.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>2
<FILENAME>cbio-ex108_9.htm
<DESCRIPTION>EX-10.8
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cbio-ex108_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;text-transform:none;font-weight:bold;font-size:10pt;font-style:normal;font-variant: normal;">Exhibit 10.8</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;text-transform:uppercase;font-size:10pt;font-style:normal;font-variant: normal;">CATALYST BIOSCIENCES INC. 2018 OMNIBUS INCENTIVE PLAN</p>
<p style="margin-bottom:24pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;text-transform:uppercase;font-size:10pt;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">NOTICE OF STOCK OPTION AWARD</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:33.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grantee&#8217;s Name and Address:</p></td>
<td valign="top"  style="width:17.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:48.54%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">You (the &#8220;Grantee&#8221;) have been granted an option to purchase shares of Common Stock (the &#8220;Option&#8221;), subject to the terms and conditions of this Notice of Stock Option Award (the &#8220;Notice&#8221;), the Catalyst Biosciences, Inc. 2018 Omnibus Incentive Plan, as amended from time to time (the &#8220;Plan&#8221;) and the Stock Option Award Agreement (the &#8220;Option Agreement&#8221;) attached hereto, as follows.&nbsp;&nbsp;Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Notice.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant Date</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting Commencement Date</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price per Share</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  style="width:48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Number of Shares Subject <br />to the Option (the &#8220;Shares&#8221;)</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="bottom"  style="width:48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total Exercise Price</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  style="width:48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Type of Option:</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Incentive Stock Option</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:17.4pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:17.4pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-Qualified Stock Option</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:17.4pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:17.4pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expiration Date:</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Ten (10)&#160;Year Anniversary of Grant Date]</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:17.4pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:17.4pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Post-Termination Exercise Period:</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Ninety (90)&#160;Days]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Vesting Schedule:</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the Grantee&#8217;s Continuous Service and other limitations set forth in this Notice, the Plan and the Option Agreement, the Option may be exercised, in whole or in part, in accordance with the following schedule (the &#8220;Vesting Schedule&#8221;):</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Vesting Schedule]</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During any authorized leave of absence, the vesting of the Option as provided in this schedule shall be suspended after the leave of absence exceeds a period of [three (3)&#160;months].&nbsp;&nbsp;Vesting of the Option shall resume upon the Grantee&#8217;s termination of the leave of absence and return to service to the Company or a Related Entity.&nbsp;&nbsp;The Vesting Schedule of the Option shall be extended by the length of the suspension.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;">
<p style="margin-top:12pt;margin-bottom:0pt;line-height:10pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the Company and the Grantee have executed this Notice and agree that the Option is to be governed by the terms and conditions of this Notice, the Plan, and the Option Agreement.</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc.,</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a Delaware corporation</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:50%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:45%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THE GRANTEE ACKNOWLEDGES AND AGREES THAT THE SHARES SUBJECT TO THE OPTION SHALL VEST, IF AT ALL, ONLY DURING THE PERIOD OF THE GRANTEE&#8217;S CONTINUOUS SERVICE (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THE OPTION OR ACQUIRING SHARES HEREUNDER).&nbsp;&nbsp;THE GRANTEE FURTHER ACKNOWLEDGES AND AGREES THAT NOTHING IN THIS NOTICE, THE OPTION AGREEMENT, OR THE PLAN SHALL CONFER UPON THE GRANTEE ANY RIGHT WITH RESPECT TO FUTURE AWARDS OR CONTINUATION OF THE GRANTEE&#8217;S CONTINUOUS SERVICE, NOR SHALL IT INTERFERE IN ANY WAY WITH THE GRANTEE&#8217;S RIGHT OR THE RIGHT OF THE COMPANY OR RELATED ENTITY TO WHICH THE GRANTEE PROVIDES SERVICES TO TERMINATE THE GRANTEE&#8217;S CONTINUOUS SERVICE, WITH OR WITHOUT CAUSE, AND WITH OR WITHOUT NOTICE.&nbsp;&nbsp;THE GRANTEE ACKNOWLEDGES THAT UNLESS THE GRANTEE HAS A WRITTEN EMPLOYMENT AGREEMENT WITH THE COMPANY TO THE CONTRARY, THE GRANTEE&#8217;S STATUS IS AT WILL.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By clicking &#8220;Accept&#8221; on the button below, the Grantee acknowledges receipt of a copy of the Plan and the Option Agreement, and represents that he or she is familiar with the terms and provisions thereof, and hereby accepts the Option subject to all of the terms and provisions hereof and thereof.&nbsp;&nbsp;The Grantee has reviewed this Notice, the Plan, and the Option Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Notice, and fully understands all provisions of this Notice, the Plan and the Option Agreement.&nbsp;&nbsp;The Grantee hereby agrees that all questions of interpretation and administration relating to this Notice, the Plan and the Option Agreement shall be resolved by the Administrator in accordance with Section&#160;13 of the Option Agreement.&nbsp;&nbsp;The Grantee further agrees to the venue selection in accordance with Section&#160;12 of the Option Agreement.&nbsp;&nbsp;The Grantee further agrees to notify the Company upon any change in the residence address indicated in this Notice.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;">
<p style="margin-top:12pt;margin-bottom:0pt;line-height:10pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;text-transform:uppercase;font-size:10pt;font-style:normal;font-variant: normal;">CATALYST BIOSCIENCES INC. 2018 OMNIBUS INCENTIVE PLAN</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;text-transform:uppercase;font-size:10pt;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">STOCK OPTION AWARD AGREEMENT</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Grant of Option</font><font style="color:#000000;">.&nbsp;&nbsp;Catalyst Biosciences, Inc., a Delaware corporation (the &#8220;Company&#8221;), hereby grants to the Grantee (the &#8220;Grantee&#8221;) named in the Notice of Stock Option Award (the &#8220;Notice&#8221;), an option (the &#8220;Option&#8221;) to purchase the Total Number of Shares of Common Stock subject to the Option (the &#8220;Shares&#8221;) set forth in the Notice, at the Exercise Price per Share set forth in the Notice (the &#8220;Exercise Price&#8221;) subject to the terms and provisions of the Notice, this Stock Option Award Agreement (the &#8220;Option Agreement&#8221;) and the Company&#8217;s 2018 Omnibus Incentive Plan, as amended from time to time (the &#8220;Plan&#8221;), which are incorporated herein by reference.&nbsp;&nbsp;Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Option Agreement.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If designated in the Notice as an Incentive Stock Option, the Option is intended to qualify as an Incentive Stock Option as defined in Section&#160;422 of the Code.&nbsp;&nbsp;However, notwithstanding such designation, the Option will qualify as an Incentive Stock Option under the Code only to the extent the $100,000 limitation of Section&#160;422(d) of the Code is not exceeded.&nbsp;&nbsp;The $100,000 limitation of Section&#160;422(d) of the Code is calculated based on the aggregate Fair Market Value of the Shares subject to options designated as Incentive Stock Options which become exercisable for the first time by the Grantee during any calendar year (under all plans of the Company or any Parent or Subsidiary of the Company).&nbsp;&nbsp;For purposes of this calculation, Incentive Stock Options shall be taken into account in the order in which they were granted, and the Fair Market Value of the shares subject to such options shall be determined as of the grant date of the relevant option.</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Exercise of Option</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Right to Exercise</font><font style="color:#000000;">.&nbsp;&nbsp;The Option shall be exercisable during its term in accordance with the Vesting Schedule set out in the Notice and with the applicable provisions of the Plan and this Option Agreement.&nbsp;&nbsp;The Grantee shall be subject to reasonable limitations on the number of requested exercises during any monthly or weekly period as determined by the Administrator.&nbsp;&nbsp;In no event shall the Company issue fractional Shares.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Method of Exercise</font><font style="color:#000000;">.&nbsp;&nbsp;The Option shall be exercisable by delivery of an exercise notice (a form of which is attached as Exhibit&#160;A) or by such other procedure as specified from time to time by the Administrator which shall state the election to exercise the Option, the whole number of Shares in respect of which the Option is being exercised, and such other provisions as may be required by the Administrator.&nbsp;&nbsp;The exercise notice shall be delivered in person, by certified mail, or by such other method (including electronic transmission) as determined from time to time by the Administrator to the Company accompanied by payment of the Exercise Price.&nbsp;&nbsp;As a condition to the exercise of the Option, the Grantee must also make arrangements with the Company for payment of any tax withholding obligations.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Taxes</font><font style="color:#000000;">.&nbsp;&nbsp;The Company or any Related Entity shall be entitled, if necessary or desirable, to deduct and withhold (or, in the sole discretion of the Company, secure payment from the Grantee in lieu of withholding) the amount of any tax withholding due with respect to this Option.&nbsp;&nbsp;In the [Company&#8217;s] [Grantee&#8217;s] sole discretion, such tax withholding may be accomplished by the withholding of Shares which would otherwise be issued upon Option exercise to the Grantee in an amount whose Fair Market Value equal to the amount required to be withheld (provided the amount withheld does not exceed the maximum statutory tax rate for an employee in the applicable jurisdictions or such lesser amount as is necessary to avoid adverse accounting treatment).</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;">
<p style="margin-top:12pt;margin-bottom:0pt;line-height:10pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">3.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Method of Payment</font><font style="color:#000000;">.&nbsp;&nbsp;Payment of the Exercise Price shall be made by any of the following, or a combination thereof, at the election of the Grantee; provided, however, that such exercise method does not then violate any Applicable Law and, provided further, that the portion of the Exercise Price equal to the par value of the Shares must be paid in cash or other legal consideration permitted by the Delaware General Corporation Law:</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">cash;</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">check;</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">surrender of Shares held for the requisite period, if any, necessary to avoid a charge to the Company&#8217;s earnings for financial reporting purposes, or delivery of a properly executed form of attestation of ownership of Shares as the Administrator may require which have a Fair Market Value on the date of surrender or attestation equal to the aggregate Exercise Price of the Shares as to which the Option is being exercised;</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">payment through a &#8220;net exercise&#8221; such that, without the payment of any funds, the Grantee may exercise the Option and receive the net number of Shares equal to (i)&#160;the number of Shares as to which the Option is being exercised, multiplied by (ii)&#160;a fraction, the numerator of which is the Fair Market Value per Share (on such date as is determined by the Administrator) less the Exercise Price per Share, and the denominator of which is such Fair Market Value per Share (the number of net Shares to be received shall be rounded down to the nearest whole number of Shares); or</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">while the Common Stock is listed on a national stock exchange or a national market system, payment through a broker-dealer sale and remittance procedure pursuant to which the Grantee (i)&#160;shall provide written instructions to a Company-designated brokerage firm to effect the immediate sale of some or all of the purchased Shares and remit to the Company sufficient funds to cover the aggregate exercise price payable for the purchased Shares and (ii)&#160;shall provide written directives to the Company to deliver the certificates for the purchased Shares directly to such brokerage firm in order to complete the sale transaction.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Restrictions on Exercise</font><font style="color:#000000;">.&nbsp;&nbsp;The Option may not be exercised if the issuance of the Shares subject to the Option upon such exercise would constitute a violation of any Applicable Laws.&nbsp;&nbsp;If the exercise of the Option within the applicable time periods set forth in Section&#160;5, 6 and 7 of this Option Agreement is prevented by the provisions of this Section&#160;4, the Option shall remain exercisable until one (1)&#160;month after the date the Grantee is notified by the Company that the Option is exercisable, but in any event no later than the Expiration Date set forth in the Notice.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination or Change of Continuous Service</font><font style="color:#000000;">.&nbsp;&nbsp;In the event the Grantee&#8217;s Continuous Service terminates, the Grantee may, but only during the Post-Termination Exercise Period, exercise the portion of the Option that was vested at the date of such termination (the &#8220;Termination Date&#8221;).&nbsp;&nbsp;The Post-Termination Exercise Period shall commence on the Termination Date.&nbsp;&nbsp;In no event, however, shall the Option be exercised later than the Expiration Date set forth in the Notice.&nbsp;&nbsp;[In the event of the Grantee&#8217;s change in status from Employee, Director or Consultant to any other status of Employee, Director or Consultant, the Option shall remain in effect and the Option shall continue to vest in accordance with the Vesting Schedule set forth in the Notice; provided, however, that with respect to any Incentive Stock Option that shall remain in effect after a change in status from Employee to Director or Consultant, such Incentive Stock Option shall cease to be treated as an Incentive Stock Option and shall be treated as a Non-Qualified Stock Option on the day three (3)&#160;months and one (1)&#160;day following such change in status.]&nbsp;&nbsp;Except as provided in Sections 6 and 7 below, to the extent that the Option was unvested on the Termination Date, or if the Grantee does not exercise the vested portion of the Option within the Post-Termination Exercise Period, the Option shall terminate.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;">
<p style="margin-top:12pt;margin-bottom:0pt;line-height:10pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">6.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Disability of Grantee</font><font style="color:#000000;">.&nbsp;&nbsp;In the event the Grantee&#8217;s Continuous Service terminates as a result of his or her Disability, the Grantee may, but only within twelve (12)&#160;months commencing on the Termination Date (but in no event later than the Expiration Date), exercise the portion of the Option that was vested on the Termination Date; provided, however, that if such Disability is not a &#8220;disability&#8221; as such term is defined in Section&#160;22(e)(3) of the Code and the Option is an Incentive Stock Option, such Incentive Stock Option shall cease to be treated as an Incentive Stock Option and shall be treated as a Non-Qualified Stock Option on the day three (3)&#160;months and one (1)&#160;day following the Termination Date.&nbsp;&nbsp;To the extent that the Option was unvested on the Termination Date, or if the Grantee does not exercise the vested portion of the Option within the time specified herein, the Option shall terminate.&nbsp;&nbsp;Section&#160;22(e)(3) of the Code provides that an individual is permanently and totally disabled if he or she is unable to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can be expected to result in death or which has lasted or can be expected to last for a continuous period of not less than twelve (12)&#160;months.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Death of Grantee</font><font style="color:#000000;">.&nbsp;&nbsp;In the event of the termination of the Grantee&#8217;s Continuous Service as a result of his or her death, or in the event of the Grantee&#8217;s death during the Post-Termination Exercise Period, the person who acquired the right to exercise the Option pursuant to Section&#160;8 may exercise the portion of the Option that was vested at the date of termination within twelve (12)&#160;months commencing on the date of death (but in no event later than the Expiration Date).&nbsp;&nbsp;To the extent that the Option was unvested on the date of death, or if the vested portion of the Option is not exercised within the time specified herein, the Option shall terminate.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Transferability of Option</font><font style="color:#000000;">.&nbsp;&nbsp;The Option, if an Incentive Stock Option, may not be transferred in any manner other than by will or by the laws of descent and distribution and may be exercised during the lifetime of the Grantee only by the Grantee.&nbsp;&nbsp;The Option, if a Non-Qualified Stock Option, may not be transferred in any manner other than by will or by the laws of descent and distribution, provided, however, that a Non-Qualified Stock Option may be transferred during the lifetime of the Grantee to the extent and in the manner authorized by the Administrator.&nbsp;&nbsp;Notwithstanding the foregoing, the Grantee may designate one or more beneficiaries of the Grantee&#8217;s Incentive Stock Option or Non-Qualified Stock Option in the event of the Grantee&#8217;s death on a beneficiary designation form provided by the Administrator.&nbsp;&nbsp;Following the death of the Grantee, the Option, to the extent provided in Section&#160;7, may be exercised (a)&#160;by the person or persons designated under the deceased Grantee&#8217;s beneficiary designation or (b)&#160;in the absence of an effectively designated beneficiary, by the Grantee&#8217;s legal representative or by any person empowered to do so under the deceased Grantee&#8217;s will or under the then applicable laws of descent and distribution.&nbsp;&nbsp;The terms of the Option shall be binding upon the executors, administrators, heirs, successors and transferees of the Grantee.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Term of Option</font><font style="color:#000000;">.&nbsp;&nbsp;The Option must be exercised no later than the Expiration Date set forth in the Notice or such earlier date as otherwise provided herein.&nbsp;&nbsp;After the Expiration Date or such earlier date, the Option shall be of no further force or effect and may not be exercised.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Tax Consequences</font><font style="color:#000000;">.&nbsp;&nbsp;The Grantee may incur tax liability as a result of the Grantee&#8217;s purchase or disposition of the Shares.&nbsp;&nbsp;THE GRANTEE SHOULD CONSULT A TAX ADVISER BEFORE EXERCISING THE OPTION OR DISPOSING OF THE SHARES.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Entire Agreement:&nbsp;&nbsp;Governing Law</font><font style="color:#000000;">.&nbsp;&nbsp;The Notice, the Plan and this Option Agreement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and the Grantee with respect to the subject matter hereof, and may not be modified adversely to the Grantee&#8217;s interest except by means of a writing signed by the Company and the Grantee.&nbsp;&nbsp;Nothing in the Notice, the Plan and this Option Agreement (except as expressly provided therein) is </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;">
<p style="margin-top:12pt;margin-bottom:0pt;line-height:10pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">intended to confer any rights or remedies on any persons other than the parties.&nbsp;&nbsp;The Notice, the Plan and this Option Agreement are to be construed in accordance with and governed by the internal laws of the State of Delaware without giving effect to any choice of law rule that would cause the application of the laws of any jurisdiction other than the internal laws of the State of Delaware to the rights and duties of the parties.&nbsp;&nbsp;Should any provision of the Notice, the Plan or this Option Agreement be determined to be illegal or unenforceable, such provision shall be enforced to the fullest extent allowed by law and the other provisions shall nevertheless remain effective and shall remain enforceable.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Venue and Jurisdiction</font><font style="color:#000000;">.&nbsp;&nbsp;The parties agree that any suit, action, or proceeding arising out of or relating to the Notice, the Plan or this Option Agreement shall be brought exclusively in the United States District Court for Delaware (or should such court lack jurisdiction to hear such action, suit or proceeding, in a Delaware state court) and that the parties shall submit to the jurisdiction of such court.&nbsp;&nbsp;The parties irrevocably waive, to the fullest extent permitted by law, any objection the party may have to the laying of venue for any such suit, action or proceeding brought in such court.&nbsp;&nbsp;If any one or more provisions of this Section&#160;12 shall for any reason be held invalid or unenforceable, it is the specific intent of the parties that such provisions shall be modified to the minimum extent necessary to make it or its application valid and enforceable.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Construction</font><font style="color:#000000;">.&nbsp;&nbsp;The captions used in the Notice and this Option Agreement are inserted for convenience and shall not be deemed a part of the Option for construction or interpretation.&nbsp;&nbsp;Except when otherwise indicated by the context, the singular shall include the plural and the plural shall include the singular.&nbsp;&nbsp;Use of the term &#8220;or&#8221; is not intended to be exclusive, unless the context clearly requires otherwise.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Administration and Interpretation</font><font style="color:#000000;">.&nbsp;&nbsp;Any question or dispute regarding the administration or interpretation of the Notice, the Plan or this Option Agreement shall be submitted by the Grantee or by the Company to the Administrator.&nbsp;&nbsp;The resolution of such question or dispute by the Administrator shall be final and binding on all persons.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">15.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Notices</font><font style="color:#000000;">.&nbsp;&nbsp;Any notice required or permitted hereunder shall be given in writing and shall be deemed effectively given upon personal delivery, upon deposit for delivery by an internationally recognized express mail courier service or upon deposit in the United States mail by certified mail (if the parties are within the United States), with postage and fees prepaid, addressed to the other party at its address as shown in these instruments, or to such other address as such party may designate in writing from time to time to the other party.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">END OF AGREEMENT</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;">
<p style="margin-top:12pt;margin-bottom:0pt;line-height:10pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;text-transform:uppercase;font-size:10pt;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">EXHIBIT&#160;A</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;text-transform:uppercase;font-size:10pt;font-style:normal;font-variant: normal;">CATALYST BIOSCIENCES INC. 2018 OMNIBUS INCENTIVE PLAN</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;text-transform:uppercase;font-size:10pt;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">EXERCISE NOTICE</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[COMPANY<br />ADDRESS]<br /><font style="font-weight:normal;">Attention:&nbsp;&nbsp;Secretary</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Exercise of Option</font><font style="color:#000000;">.&nbsp;&nbsp;Effective as of today, [DATE], the undersigned (the &#8220;Grantee&#8221;) hereby elects to exercise the Grantee&#8217;s option to purchase shares of the Common Stock (the &#8220;Shares&#8221;) of Catalyst Biosciences, Inc. (the &#8220;Company&#8221;) under and pursuant to the Company&#8217;s 2018 Omnibus Incentive Plan, as amended from time to time (the &#8220;Plan&#8221;) and the Stock Option Award Agreement (the &#8220;Option Agreement&#8221;) and Notice of Stock Option Award (the &#8220;Notice&#8221;) dated [&#160;&#160;], 20[&#160;&#160;] and this Exercise Notice (the &#8220;Exercise Notice&#8221;).&nbsp;&nbsp;Unless otherwise defined herein, the terms defined in the Plan shall have the same defined meanings in this Exercise Notice.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Representations of the Grantee</font><font style="color:#000000;">.&nbsp;&nbsp;The Grantee acknowledges that the Grantee has received, read and understood the Notice, the Plan and the Option Agreement and agrees to abide by and be bound by their terms and conditions.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Rights as Stockholder</font><font style="color:#000000;">.&nbsp;&nbsp;Until the stock certificate evidencing such Shares is issued (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a stockholder shall exist with respect to the Shares, notwithstanding the exercise of the Option.&nbsp;&nbsp;The Company shall issue (or cause to be issued) such stock certificate promptly after the Option is exercised.&nbsp;&nbsp;No adjustment will be made for a dividend or other right for which the record date is prior to the date the stock certificate is issued, except as provided in Section&#160;10 of the Plan.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Delivery of Payment</font><font style="color:#000000;">.&nbsp;&nbsp;The Grantee herewith delivers to the Company the full Exercise Price for the Shares, which, to the extent selected, shall be deemed to be satisfied by use of the broker-dealer sale and remittance procedure to pay the Exercise Price provided in Section&#160;3(e) of the Option Agreement.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Tax Consultation</font><font style="color:#000000;">.&nbsp;&nbsp;The Grantee understands that the Grantee may suffer adverse tax consequences as a result of the Grantee&#8217;s purchase or disposition of the Shares.&nbsp;&nbsp;The Grantee represents that the Grantee has consulted with any tax consultants the Grantee deems advisable in connection with the purchase or disposition of the Shares and that the Grantee is not relying on the Company for any tax advice.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Taxes</font><font style="color:#000000;">.&nbsp;&nbsp;The Grantee agrees to satisfy all applicable foreign, federal, state and local income and employment tax withholding obligations and herewith delivers to the Company the full amount of such obligations or has made arrangements acceptable to the Company to satisfy such obligations.&nbsp;&nbsp;In the case of an Incentive Stock Option, the Grantee also agrees, as partial consideration for the designation of the Option as an Incentive Stock Option, to notify the Company in writing within thirty (30)&#160;days of any disposition of any shares acquired by exercise of the Option if such disposition occurs within two (2)&#160;years from the Grant Date or within one (1)&#160;year from the date the Shares were transferred to the Grantee.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Successors and Assigns</font><font style="color:#000000;">.&nbsp;&nbsp;The Company may assign any of its rights under this Exercise Notice to single or multiple assignees, and this Exercise Notice shall inure to the benefit of the successors and assigns of the Company.&nbsp;&nbsp;</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;">
<p style="margin-top:12pt;margin-bottom:0pt;line-height:10pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">This Exercise Notice shall be binding upon the Grantee and his or her heirs, executors, administrators, successors and assigns.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Construction</font><font style="color:#000000;">.&nbsp;&nbsp;The captions used in this Exercise Notice are inserted for convenience and shall not be deemed a part of this Exercise Notice for construction or interpretation.&nbsp;&nbsp;Except when otherwise indicated by the context, the singular shall include the plural and the plural shall include the singular.&nbsp;&nbsp;Use of the term &#8220;or&#8221; is not intended to be exclusive, unless the context clearly requires otherwise.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Administration and Interpretation</font><font style="color:#000000;">.&nbsp;&nbsp;The Grantee hereby agrees that any question or dispute regarding the administration or interpretation of this Exercise Notice shall be submitted by the Grantee or by the Company to the Administrator.&nbsp;&nbsp;The resolution of such question or dispute by the Administrator shall be final and binding on all persons.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Governing Law; Severability</font><font style="color:#000000;">.&nbsp;&nbsp;This Exercise Notice is to be construed in accordance with and governed by the internal laws of the State of Delaware without giving effect to any choice of law rule that would cause the application of the laws of any jurisdiction other than the internal laws of the State of Delaware to the rights and duties of the parties.&nbsp;&nbsp;Should any provision of this Exercise Notice be determined by a court of law to be illegal or unenforceable, such provision shall be enforced to the fullest extent allowed by law and the other provisions shall nevertheless remain effective and shall remain enforceable.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Notices</font><font style="color:#000000;">.&nbsp;&nbsp;Any notice required or permitted hereunder shall be given in writing and shall be deemed effectively given upon personal delivery, upon deposit for delivery by an internationally recognized express mail courier service or upon deposit in the United States mail by certified mail (if the parties are within the United States), with postage and fees prepaid, addressed to the other party at its address as shown below beneath its signature, or to such other address as such party may designate in writing from time to time to the other party.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Further Instruments</font><font style="color:#000000;">.&nbsp;&nbsp;The parties agree to execute such further instruments and to take such further action as may be reasonably necessary to carry out the purposes and intent of this agreement.</font></p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Entire Agreement</font><font style="color:#000000;">.&nbsp;&nbsp;The Notice, the Plan and the Option Agreement are incorporated herein by reference and together with this Exercise Notice constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and the Grantee with respect to the subject matter hereof, and may not be modified adversely to the Grantee&#8217;s interest except by means of a writing signed by the Company and the Grantee.&nbsp;&nbsp;Nothing in the Notice, the Plan, the Option Agreement and this Exercise Notice (except as expressly provided therein) is intended to confer any rights or remedies on any persons other than the parties.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Submitted by:</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accepted by:</p></td>
</tr>
<tr>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">GRANTEE:</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc.</p></td>
</tr>
<tr>
<td valign="top"  style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:45%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:45%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Signature)</p></td>
<td valign="top"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:45%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:45%;">
<p style="margin-bottom:12pt;margin-top:12pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Address</font>:</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:12pt;margin-top:12pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:9%;">
<p style="margin-bottom:12pt;margin-top:12pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Address</font>:</p></td>
<td valign="top"  style="width:45%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:12pt;margin-top:12pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:45%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
<td valign="top"  style="width:9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p></td>
<td valign="top"  style="width:45%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">[COMPANY ADDRESS]</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Arial;font-size:10pt;">
<p style="margin-top:12pt;margin-bottom:0pt;line-height:10pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>cbio-ex231_8.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cbio-ex231_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.1</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in the Registration Statements of Catalyst Biosciences, Inc. on Form S-8 (Nos. 333-133881, 333-133882, 333-160331, 333-185888, 333-189143, 333-206523, 333-206526, 333-212345, 333-219301, 333-225902, and 333-239712), and Form S-3 (Nos. 333-228970 and 333-253874) of our report dated March 31, 2022, on our audits of the financial statements as of December 31, 2021 and 2020, and for each of the years then ended, which report is included in this Annual Report on Form 10-K to be filed on or about March 31, 2022.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ EisnerAmper LLP</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EISNERAMPER LLP</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Iselin, New Jersey</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2022 </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>cbio-ex311_11.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cbio-ex311_11.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">Exhibit 31.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;">Rule 13<font style="text-transform:none;">a</font>-14(<font style="text-transform:none;">a</font>) or 15<font style="text-transform:none;">d</font>-14(<font style="text-transform:none;">a</font>) of the Securities Exchange Act of 1934<font style="text-transform:none;">,</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Nassim Usman, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this report on Form 10-K of Catalyst Biosciences, Inc.;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 31, 2022</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td style="width:40%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Nassim Usman, Ph.D.</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nassim Usman, Ph.D.</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>cbio-ex312_6.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cbio-ex312_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">Exhibit 31.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;">Rule 13<font style="text-transform:none;">a</font>-14(<font style="text-transform:none;">a</font>) or 15<font style="text-transform:none;">d</font>-14(<font style="text-transform:none;">a</font>) of the Securities Exchange Act of 1934<font style="text-transform:none;">,</font></p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Seline Miller, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this report on Form 10-K of Catalyst Biosciences, Inc.;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:10pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 31, 2022</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td style="width:40%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Seline Miller&#160;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Seline Miller&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interim Chief Financial Officer (Interim Financial and Principal Accounting Officer)</p></td>
</tr>
</table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>cbio-ex321_7.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cbio-ex321_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;"><br />Exhibit 32.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report on Form 10-K of Catalyst Biosciences, Inc. (the &#8220;Company&#8221;) for the year ended December&#160;31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Nassim Usman, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 31, 2022</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="middle"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Nassim Usman, Ph.D.</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nassim Usman, Ph.D.</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>cbio-ex322_10.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
cbio-ex322_10.htm
</title>
</head>
<!-- NG Converter v5.0.2.71 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;"><br />Exhibit 32.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:0%;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report on Form 10-K of Catalyst Biosciences, Inc. (the &#8220;Company&#8221;) for the year ended December&#160;31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Seline Miller, Interim Chief Financial Officer (Interim Financial and Principal Accounting Officer) of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 31, 2022</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="middle"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;white-space:nowrap;">
<p style="text-align:center;margin-bottom:1pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Seline Miller</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;Seline Miller</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interim Chief Financial Officer (Interim Financial and Principal Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>guycyz0ib1ig000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 guycyz0ib1ig000001.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" *C!94# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO,_C[^U/X"_9W\3
M^#?"?C'1]6NKGQQJQT_2VTV&)EBD#PINE+R)A<S)]T,>O% 'IE%%% !1110
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M^ /PRD\46,BW$/B:>*[M=-T73T:6.:2Y66ZD::9Y&MA$L?(VRDQR+DQ^M_\
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M96/L7_!1K_@X$^!LGP%_X0W]@'XE:MJ7C[6KRU\G7H?#\UM'H44<R22;EOH
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MD[K]K[3_ (5V\?Q'OHO+NO$PU"Y,DB_9UML>49?*'[E%3A.@SUYIOB+]BO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\?_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Q__P %0?\ DK'P!_[*
M /\ T?95]@5\?_\ !4'_ )*Q\ ?^R@#_ -'V5 'V!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YQ\0/^3B?A
M_P#]<-3_ /2<UZ/7G'Q _P"3B?A__P!<-3_])S7H] !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7FVJ_\G6:9_V)
MTG_H]Z])KS;5?^3K-,_[$Z3_ -'O0!Z31110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!YOI?_)U.I_]B?'_ .CT
MKTBO-]+_ .3J=3_[$^/_ -'I7I% !1110 4444 %%%% !1110 4444 %%%%
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M]#;IG_@?'_C1_P )KX._Z&W3/_ ^/_&CV=3^5_<'M:?\R^\TZ*S/^$U\'?\
M0VZ9_P"!\?\ C1_PFO@[_H;=,_\  ^/_ !H]G4_E?W![6G_,OO-.BLS_ (37
MP=_T-NF?^!\?^-'_  FO@[_H;=,_\#X_\:/9U/Y7]P>UI_S+[S3HK,_X37P=
M_P!#;IG_ ('Q_P"-'_":^#O^AMTS_P #X_\ &CV=3^5_<'M:?\R^\TZ*S/\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \WTO\ Y.IU/_L3X_\
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MW@Z:T^&/@77O"/BZ*W5M&\?:;XPU.34+"^0ADO DER86?>-S (H.6V>6=K*
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M@]XP^.O[ OQ#^'_@'3)K[6#I]O?V=C;Q&26Y^R74-T\4:*"SR-'"ZJH!+,5
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M_AYXDNK33+Z^<,]O8I:VDB6D><,_[V<I$I)),JQK@*JCP/PM\2/!_P#P5O\
MVAY?B[^VS^TIX.^'/PC\):D8_#OPZU/QQ:6-YJ!PK;-LDJ. RE?.N\ G)BAV
MX9H?T0^-'_!/#X!?&']ES2?V.[&?7/!_@?1[N">WL/!]Y%#)*(C(PCE>XBF\
MQ6ED\YV8%WE4.6)W9^>_^(=#]B7_ **C\5/_  =Z;_\ *^O6R_B+A/ZYC,PG
M*="O6G+D<8*3IP>[CT4YZW:NU?1WNWY.9<.<7_4\%ET(0KX>C"/.I3<54FME
M+JX0TY8NRE;WE:R7VA\&/%WP4\6> +-/V?O%GAG5O#.DQKIEBWA'4;>YLK58
M8U"VZF!F1=B%!L!X!7C&*ZJO)_V-_P!COX9_L0?">;X.?"C7=>U#2Y]9FU)I
M_$5U#-.)9$C1E#0PQ+MQ$N!MSDGD\8]8K\QQZPL<946&FYPN[2DK-KNUW/U+
M+Y8J6!IO$P4*EES1B[Q3[)]CY#_X+Q?\HI/BI_W _P#T^Z?6;H__  0:_P""
M85UI-K=3_ ?46>2W1V;_ (3?5N25!/\ R\U]$?M:_LP^ OVROV??$'[-WQ/U
M?6+#0_$?V3[==:#<117:?9[N&Z38TL<B#+P*#E#E2P&#@CP>+_@D5'#&L,7_
M  4V_:Z557"JOQHP /3_ (]*Y#L-_P",_P"RU\%/V0/^"8OQN^$GP"\+3:/H
M+?#/Q5?&SFU*XNV\^32I@[;YW=^0B\9P,<"K/_!/+PMX=T;_ ()5?#70],T:
MW@L[GX4PW%Q;1Q )))<6S33L1W+R22,WJ7)/6M;X:_\ !/K0? GPB^(WP7\5
M?M3_ !I\?Z7\2O#LFC:E<?$7QPNJW&E6\EO<02-8L\ 6!V6Y)8LKAC%%D$+@
M^G?"'X'>%/@M\!M!_9X\+:CJ-QHOAWPW#HMC=:A-&UT]O'"(E9V1%0OM&20@
M&>PZ4 ?E/>DM_P &KMD#_P!!(C_R\)*^Z/\ @K[X<T&S_P""6WQ6\/6NCVZ6
M-CX5MUL[-81Y<(BN;<Q!5Z#854KZ%1CI5Z7_ ():?L_R_L!1_P#!.4^,O&7_
M  A$4_FKJG]H6G]JEO[2.H_ZW[-Y./..W_4_<XZ_-7KG[2?P"\'_ +4GP,\2
M?L__ ! U/4K/1O%%A]DU"YT>:..ZC3>KYC:2.1 <J.J,,=J /ANY_:3\6^%?
M"_[(?[-_[,G[/7P_\5?&W7O@SI>H^'O%WQ$M3]E\+:=_942W$BR1*+C]['%<
M*PAD4XC *R[PM<'^V[HW[=>C?M(?LM:I^VQ\?/AW>RZI^T1H+:)\/_A[X?DC
MM;40WD(DO%N[K%U)@2QQM&04!E4YR!G[ ^,__!*_X#_&'P9\,="MOB'X^\(Z
M_P#"/08=%\'^/?!?B!+#6X[*.V6W,4LZQ%6#*H)*HI!9]NQ9'5N5M?\ @BS^
MSO<^)?#?Q(\=_'/XO^+_ !MX5\5:=K>D>.O%_C1-2U*(64CRPV ,\#1"T,K^
M8R+&'+ ?O ,@L#-T_2].U#_@X#OKN]LXY9++]EM9K1W7)AD.N1QEE]#L=USZ
M,1WK%_:3L[2+_@OA^SGJ$=M&L\WPVUZ*:8*-SHEMJ)52>X!=B/3<?6OJ&T_9
M4^'MG^U]<_MJQZUK1\577P_'@^33VN(?[/%B+Q;OS GE>9YWF*!N\S;MXV9Y
MJIXY_8Z^&?Q _:V\$_MEZSKNNQ^*/ >BWFF:/86MU"MA-#<QS1R-,C1&1F F
M;:5D0 @9!Y!0'SK_ ,$:5\.?\)K^U0;Y--'C(_M+:_\ \)#Y'E_:OLN__1=^
M/F\GS?MOEY^7/G;>=U<3_P %A?$W[,EQ^R#^T_X3^ MIIL?Q'L[CPG+\7Y--
MT>:.=D>]LC:>=<&,1R_N3P$=L?O=P#>97T!^T+_P2Z^$OQQ^-5[^T1X/^-OQ
M2^%?C'6+&.T\1:Q\*_&!TIM:CC"K%]I'EOO**BJ-NW(4;@Q (ZC]G3_@GO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#5NLVI:UJ6HV&GQ/($5YYDMHT4L>%!9AR>!7W=7Q_P#\%0?^2K_ '_LH _\
M1]E6E&I*C6C4CO%IKY:F=:G&M1E3EM)-/YZ'YQ_\.*_^"C/_ $3#1?\ PJ[/
M_P".4?\ #BO_ (*,_P#1+]%_\*NS_P#CE?NY17ZA_P 1@XI_DI?^ R_^3/RK
M_B#7"?\ /5_\"C_\@?A'_P .*_\ @HS_ -$OT7_PJ[/_ ..4?\.*_P#@HS_T
M2_1?_"KL_P#XY7[N44?\1@XI_DI?^ R_^3#_ (@UPG_/5_\  H__ "!^$?\
MPXK_ ."C/_1+]%_\*NS_ /CE'_#BO_@HS_T2_1?_  J[/_XY7[N44?\ $8.*
M?Y*7_@,O_DP_X@UPG_/5_P# H_\ R!^$?_#BO_@HS_T2_1?_  J[/_XY1_PX
MK_X*,_\ 1+]%_P#"KL__ (Y7[N44?\1@XI_DI?\ @,O_ ),/^(-<)_SU?_ H
M_P#R!^$?_#BO_@HS_P!$OT7_ ,*NS_\ CE'_  XK_P""C/\ T2_1?_"KL_\
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MB7Z+_P"%79__ !RC_AQ7_P %&?\ HE^B_P#A5V?_ ,<K]W**/^(P<4_R4O\
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MHHH **** "BBB@ HHHH **** /-]+_Y.IU/_ +$^/_T>E>D5YOI?_)U.I_\
M8GQ_^CTKTB@ HHHH **** "BBB@ HHHH **** "BBB@#.U;PAX3U^Y6\UWPO
MI]],J;%EO+*.1@N2=H+ \9)./<U7A^'7P^MYEN+?P+H\<D;!HY(]+B5E8=""
M%X-;-%:*K4C&RD_O,W2I.5W%?<%%%%9F@4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %?'_\ P5!_Y*Q\ ?\ LH _]'V5?8%?'_\ P5!_Y*Q\ ?\ LH _]'V5
M 'V!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!YQ\0/\ DXGX?_\ 7#4__2<UZ/7G'Q _Y.)^'_\ UPU/_P!)
MS7H] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !7FVJ_\G6:9_P!B=)_Z/>O2:\VU7_DZS3/^Q.D_]'O0!Z31110
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M^E]R6BBBO,/4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "OC_ /X*@_\ )6/@#_V4 ?\ H^RK[ KX_P#^"H/_
M "5CX _]E '_ */LJ /L"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#SCX@?\G$_#_P#ZX:G_ .DYKT>O./B!
M_P G$_#_ /ZX:G_Z3FO1Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV+3:KX%CU#Q+IY5E7$<&J7RW08D9*BUDG?:",M&G7&*^H/\ @N!_RC8\<_\
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MC5O'FHRQPZ;?+X7N(X=*42*TD\BW]NJ29C#HJA7^9@2 !S:_;+\6?M"^//\
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M;[6MJW9)GZOQEC,AR_*XXK-*:FH33A%NUZFO+U2[WO=)7;1Q'PQ\,_"OQ_\
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MJR_^/4?\1'O[,O\ T0?QW_WU9?\ QZOQVHH_XA7P?_SZE_X'+_,/^(L<:?\
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M_CO_ +ZLO_CU?CM11_Q"O@__ )]2_P# Y?YA_P 18XT_Y^Q_\ C_ )'[$_\
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M^CWKTFO-M5_Y.LTS_L3I/_1[T >DT444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 >;Z7_R=3J?_ &)\?_H]*](K
MS?2_^3J=3_[$^/\ ]'I7I% !1110 4444 %%%% !1110 4444 %%%% 'XN_\
M'%__ ">UX7_[)78_^G+4J^/?V9/^3DOA[_V/&D_^ED5?87_!Q?\ \GM>%_\
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MY+>XU&PL8H[C37F1S& [H,.&,;-"JEU1S*K]1'Q+\:O%O_!-CX'?#>'XH_\
M!,'P9\7? OQF\-WEG<:#K"Z7K3PZK&LT8N+6]2Z>2%H9(][L@159HU4C860_
M6G[0-_KG_!2_]KKX-_L@^,K[5/#_ ,+M1^"MM\5_B!X;L]1EM9_$"SW"P6^E
MSL@#K'%,(V8!@6#R$;9(XI%Z+QQ^U%_P5V^/>D6_PA^"/[!T_P 'O$D^H6Z:
MY\1/%GBK3]1T_1X5E4R-;Q>61>;U!7*JY56.U<D2)N?ME_ GX[:)^U#\/_VO
M/V.M=T'Q=\6O _A'^Q_&WPZUK7HM/N/%_AJ>=MKK\ZQ6S)<FXE5V58BXSEC
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MZ=X-\#^$X=;T]?"]KXLL[V_T2"?3I81>7CAU69[B6=0(X YB2##J#\S@C/\
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M+KX9?&C0O$/BJ\;4+>W58%DOKC4+E//:+=$L]V0D8W2["HPQ#&OO:D4?%_\
MP6:_Y!O[-O\ V=1X4_\ 0;JOM!NE?)__  5K^"'[0OQF^'OPIU;]FSX2_P#"
M;:UX#^-6C^*[S0?[>M--\ZULXKHL//NG5%W.T:<;F&_.T@&LG6OVMO\ @K[K
M&F3:5X3_ ."1VE:+J5Q&8[/5M<^.NDWMG9R$866:"!8Y)8U.&9$=68 @$$@T
M@/"/!UCIN@?';_@I9H/@^&./1Y/ Z7MQ'!]P7TVBZC).WLS3/.6]3UZ5K?\
M!)+_ ()L_LO_ !U_8V^'/[4?[0?@>]\4^-]1T>_LDOM3UZZ,%MI2&ZTR"QCM
MXY%A$(M5#<H7\R1V+YP!Z[\#_P#@G;\0O@'^P[\;O"_B/Q#:^-OC1\9M%UZ_
M\8:U9>7;V^H:M=VEPD-K 76)4@629]K.$&Z>1L1H51/3O^"8'P6^)?[/'[!W
MP[^#'QB\-?V/XET+3;F+5=-^V0W'D.UY/(H\R!WC;*.I^5CUQUR*KH(^?O\
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M02["5=7>XRH#\])_P5&_8@T_]L#]B[Q5\*OA_P"#=-_X2ZU2/5O!K)'% _\
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M6.FZ79Q6FGV=NN([>"- B1J.P50 /85(R[1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7Y_P#_  7Q_P"28^"_^XQ_Z)@K] *^*?\
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M?\1<X3_Z>?\ @"_^2#_B#_%W>G_X&_\ Y$_$&BOV^_XA_?V!O[WC?_PHT_\
MC-'_ !#^_L#?WO&__A1I_P#&:/\ B+G"?_3S_P  7_R0?\0?XN[T_P#P-_\
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M>;:K_P G6:9_V)TG_H]Z /2:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /-]+_P"3J=3_ .Q/C_\ 1Z5Z17F^
ME_\ )U.I_P#8GQ_^CTKTB@ HHHH **** "BBB@ HHHH **** "BBB@#\Z_\
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M8]J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *^/_P#@J#_R5CX _P#90!_Z/LJ^P*^/_P#@J#_R5CX _P#90!_Z
M/LJ /L"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#SCX@?\G$_#__ *X:G_Z3FO1Z\X^('_)Q/P__ .N&I_\
MI.:]'H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *\VU7_DZS3/\ L3I/_1[UZ37FVJ_\G6:9_P!B=)_Z/>@#TFBB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#S?2_^3J=3_P"Q/C_]'I7I%>;Z7_R=3J?_ &)\?_H]*](H **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *^/_P#@J#_R5CX _P#90!_Z/LJ^P*^/_P#@J#_R5CX _P#90!_Z
M/LJ /L"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#SCX@?\G$_#__ *X:G_Z3FO1Z\X^('_)Q/P__ .N&I_\
MI.:]'H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M $=#J7_@GT__ .1Z/^'P'_!2'_HZ'4O_  3Z?_\ (]'_ !!OB+_G_2^^?_R
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M_P $^G__ "/1_P 0;XB_Y_TOOG_\@'_$:N&_^?%;[H?_ "9_0117\^__  ^
M_P""D/\ T=#J7_@GT_\ ^1Z/^'P'_!2'_HZ'4O\ P3Z?_P#(]'_$&^(O^?\
M2^^?_P @'_$:N&_^?%;[H?\ R9_0117\^_\ P^ _X*0_]'0ZE_X)]/\ _D>C
M_A\!_P %(?\ HZ'4O_!/I_\ \CT?\0;XB_Y_TOOG_P#(!_Q&KAO_ )\5ONA_
M\F?T$45_/O\ \/@/^"D/_1T.I?\ @GT__P"1Z/\ A\!_P4A_Z.AU+_P3Z?\
M_(]'_$&^(O\ G_2^^?\ \@'_ !&KAO\ Y\5ONA_\F?T$45_/O_P^ _X*0_\
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MTNJ2;TO=*^]MK6;****\0]P**** "BBB@ HHHH **** "BBB@ HHHH ****
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M33O9Z:+?3' XO&9AF.23R^I!U/JTHN4[R2<8Q4[I-.4DTUNM=6]-?O/]F_\
M:R_9]_:V\*7'C']G_P")%KK]K9S+%J$2PR07%G(02HEAE59$!PVUBNUMK;2<
M''HU?EE_P3B\*Z;\"O\ @M7\8/@M\)PS>%?[+U0/8VK$6]D@N;69%VCC]P\A
MMU)Y =AG).?TS^).M:IX<^'FO>(=#@\R]L-&NKFSCVYWRI"S(,=\L!7Y[Q+D
MN'RG-84<+)RIU(0G#FMS)35TI6LKKT7H?HW"^>8C.,IG7Q<5&I3G.$^6_*W!
MV;C>[L_5^IX?\:O^"KO[!_[/_P 2+KX3_$?XW+'K>GS>3JEOINCW=ZEC)W22
M2")UWCHR*2RD$, >*^,_A'\0? _Q7_X.(IOB)\-_%%GK6AZMHR3Z=J>GS"2*
M9/\ A%H0<$="""I4X*L"I ((%G_@WQ^"_P )_B=X:^)GQ>^)7AO2_$GB9M:M
M[(S:Y9QW<MO!)$\DD@,H8@S.[!V_B\K&3S6)^SU\)? 'P._X.%M2^&WPOTZ&
MST.U:^N;.QMU58K5KG0OM4D,:H J1I),Z*@'R*JKVK]!PF4Y+D>)S; 89U'6
MIX6HI2DX\LKJ#;BDDXV=DKN5TWVN_P ZQF;YYGV%RC,,2J:HU<73<8Q4N>-G
M-)2;;4KJ[=E&S2[V7Z!?M/?\% /V3OV/=1L=!^//Q4BTO5-2M_M%GH]K8SW=
MTT.XKYK1P(QC0D, S[0Q1@N2K :W[,W[9G[-G[8&B7FM?L__ !-M=;_LV14U
M*Q:&2WNK0D?*7@F57"'D"0 HQ5@&)4@?D[X&^*WQ _X>X?&+XGG]DRY^.VM:
M7KVN6UCX=^T[6TR.WU".U@NQF"8$0P1I;J"G'FJ005&?6OV4O '[4I_X*O:/
M^TOHG["GBCX1>#_$,,UEXJT:WC)L%5[)U9W98(5"-<1P3E=G,J[B237F8W@7
M+<'ELN>HU5C1]KS.I2492MS>S5/^)JM%+9OIT/5P/'N9XW-(J%-.E*LZ7(J=
M5SC&_+[1U/X>CU<5JEUOJ?<O[2O_  4A_8Y_9*\51> _C9\6X[+7)8%G;2-/
MTZXO)X8VZ-*($819&" Y5F!R 1S6=X8_X*I_L#>,_%WA7P'X6_:$L[_6/&<E
MO'X?L;71K^1I99[AK>.*4K 5MI#(I&R8HP4JY 1E8_$?_!+_ ,#>"OC[_P %
M4?CGX\^.&E6>MZYH]_JEQI.FZU EP+=SJ?DF9%?/,"*D*\859 !C K%_;:^#
M7PH^#'_!<#X.V7PET"QTNWU[7O"VK:OINFQQQV\%ZVJO"VV*,!8M\<$4C+C+
M-(SG[].GP?PZL>\LJ2J^VA1]JY)QY&^7FY4G%M)76MW?5:;DU.,^))9>LTI1
MI>PG75)1:FYJ//R\S:DDV[/2RMH]=G^CWQ9_;L_91^!?Q7M_@E\6?BY!HGB6
MYT=M5CL;K2[LQBS5)G:5ITB,* +!*<,X/R=.1G%^$?\ P4K_ &,/C7X!\7?$
M_P %?&*)-!\"QP2>*-2U;3;FRCM$F+B$YGC7S#(T;JJ)N<MA=NYE!^ _^"M'
MPUT#XR?\%BOA7\*/%:2-I7B+3_#NGZHD,A1VMI=3N4E56'W24+ 'L>:^E_VQ
M?V;?^"7G[$7[(&I:+\2_A'JUCX.UKQ5:7']A^&]<OWO=5U18I%B4/)<C*I$)
M7V2R"$;2V#)LSP3X;X>HX' J7MY8C%1A)*"@TES6E9.S;:^%7T:NVUH>A#B;
MB2MC\>X^PAA\+*<6YN:;?+>%VKI)2^)VNT[12>IU>F_\%M_^";>I:TFCK\=[
MB%9) D=Y<^%M1C@))P,L8,J/=@ .I(%?2/B/XJ?#?PC\.YOBYXD\<:7:>%[?
M3EOY-?DO$^R?9F4,LHD!*LK KM*D[MR[<Y&?QR_;@^+&H?%C]B+2="^&7_!,
M:X^&_P ._#5Y82Z%\0M<*I<36KKY<?E PQ-*TY=6>023B3EVRQ$B^F?\%%?$
MGB/3O^"(?[/^DV=]/';:I_8$&I;)<":)-*N)(XG'\2[D1P.@,2GJ!7H8K@7+
MJE3!QH.=/VM5TY*4Z=1I)<U[P22DUO%W:;7S\["\?9E2IXV5=0J^QHJK%QA4
MIIMOEM:HVW%/:2LFD_E] ?M"?\%8OV"OCQ^S?\5OA-\//CC')K6I?#/Q!!I,
M.I:/=V4=]*=-N-L<<EQ$B[V. J,59V(5020*R?\ @WJO+/3?V$/$-_?W,<$$
M/Q&U"2::9PJ1H+&P)9B>  .23P*U?B;^QQ^RU#_P1UO-/TWX<^'Y5TOX/?\
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MQQ,YPE*[BW3YE&Z?\LTI1=K7B[]TVF%%%%?.GT@4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %?G_ /\ !?'_ ))CX+_[C'_H
MF"OT K\__P#@OC_R3'P7_P!QC_T3!79E_P#O]+_%'\T<>8?[A5_PR_)GXQT4
M45_<!_"(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7IG[(?[+?Q!_;%^/.B_ [X>PO')?2>;JVI^09(]+L4(\ZZDY'"@@
M$C>[(@(+BO.])TG5M?U6UT'0=+N+Z^OKA+>RLK.%I)KB9V"I&B*"S,S$ * 2
M20!7[X?\$JOV -,_8=^!*/XGLHW\?>*8XKKQ==B0.+? )BL8R/EV1!CN8$[Y
M&=MQ78%^+XXXKI<+Y2YP:=:=U37GUD_*/XNRZW7W' ?"-7BO-U"::H4[.H_+
MI%/O+;R5WTL^P\%_!7P%^SKXL^$/P3^&6G-:Z)X=TG4;:S60J9)#Y#,\TA4
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MZ[=$D0QR*&5AAE/>EHKQ<TS3&YQC98K%2O-VZ622T226B26B7ZGM93E.!R7
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M'&TI2=DI1_-'+CHRE@JL8J[<9?DS\5**^G/^'-G_  4I_P"C8[K_ ,*32_\
MY*H_X<V?\%*?^C8[K_PI-+_^2J_L;_6;AO\ Z#:/_@R'_P D?Q;_ *K<3?\
M0#6_\%3_ /D3YCHKZ<_X<V?\%*?^C8[K_P *32__ )*H_P"'-G_!2G_HV.Z_
M\*32_P#Y*H_UFX;_ .@VC_X,A_\ )!_JOQ-_T UO_!4__D3YCHKZ<_X<V?\
M!2G_ *-CNO\ PI-+_P#DJC_AS9_P4I_Z-CNO_"DTO_Y*H_UFX;_Z#:/_ (,A
M_P#)!_JOQ-_T UO_  5/_P"1/F.BOIS_ (<V?\%*?^C8[K_PI-+_ /DJC_AS
M9_P4I_Z-CNO_  I-+_\ DJC_ %FX;_Z#:/\ X,A_\D'^J_$W_0#6_P#!4_\
MY$^8Z*^G/^'-G_!2G_HV.Z_\*32__DJC_AS9_P %*?\ HV.Z_P#"DTO_ .2J
M/]9N&_\ H-H_^#(?_)!_JOQ-_P! -;_P5/\ ^1/F.BOIS_AS9_P4I_Z-CNO_
M  I-+_\ DJC_ (<V?\%*?^C8[K_PI-+_ /DJC_6;AO\ Z#:/_@R'_P D'^J_
M$W_0#6_\%3_^1/F.BOIS_AS9_P %*?\ HV.Z_P#"DTO_ .2J/^'-G_!2G_HV
M.Z_\*32__DJC_6;AO_H-H_\ @R'_ ,D'^J_$W_0#6_\ !4__ )$^8Z*^G/\
MAS9_P4I_Z-CNO_"DTO\ ^2J/^'-G_!2G_HV.Z_\ "DTO_P"2J/\ 6;AO_H-H
M_P#@R'_R0?ZK\3?] -;_ ,%3_P#D3YCHKZ<_X<V?\%*?^C8[K_PI-+_^2J/^
M'-G_  4I_P"C8[K_ ,*32_\ Y*H_UFX;_P"@VC_X,A_\D'^J_$W_ $ UO_!4
M_P#Y$^8Z*^G/^'-G_!2G_HV.Z_\ "DTO_P"2J/\ AS9_P4I_Z-CNO_"DTO\
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 ><?$#_DXGX?_ /7#4_\
MTG->CUYQ\0/^3B?A_P#]<-3_ /2<UZ/0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5YMJO\ R=9IG_8G2?\ H]Z]
M)KS;5?\ DZS3/^Q.D_\ 1[T >DT444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 >;Z7_ ,G4ZG_V)\?_ */2O2*\
MWTO_ ).IU/\ [$^/_P!'I7I% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Q_P#\%0?^2L? '_LH
M _\ 1]E7V!7Q_P#\%0?^2L? '_LH _\ 1]E0!]@4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ><?$#_DXGX?_
M /7#4_\ TG->CUYQ\0/^3B?A_P#]<-3_ /2<UZ/0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YMJO\ R=9IG_8G
M2?\ H]Z])KS;5?\ DZS3/^Q.D_\ 1[T >DT444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 >;Z7_ ,G4ZG_V)\?_
M */2O2*\WTO_ ).IU/\ [$^/_P!'I7I% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC9__ !RC^Q\V_P"@>?\ X!+_ "#^V<G_ .@BG_X''_,]@HKQ_P#X>"?L,?\
M1WWPW_\ "QL__CE'_#P3]AC_ *.^^&__ (6-G_\ '*/['S;_ *!Y_P#@$O\
M(/[9R?\ Z"*?_@<?\S9^('_)Q/P__P"N&I_^DYKT>OF+QQ^W3^Q?=_'7P1K5
MK^U5\/Y+.SAU 7=U'XLM3'#N@(7<V_ R>!GK7T%\/?B3X ^+/A:#QQ\,?&6F
M^(-%NF=;75=(O$N+>8HQ1MLB$JV&!4X/!!'4&L:^ QV%ASUJ4HK:[BTK_-&V
M'S# 8J?)1JQD][1DF[=[)FW1117(=@4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7FVJ_\ )UFF?]B=)_Z/>O2:\VU7_DZS
M3/\ L3I/_1[T >DT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 >;Z7_P G4ZG_ -B?'_Z/2O2*\WTO_DZG4_\
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M1110 4444 %?G_\ \%\?^28^"_\ N,?^B8*_0"OS_P#^"^/_ "3'P7_W&/\
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MJU,D,OB[5_#LL<EC?,+>9M0F62,F-PUNRHS@_/-G!+D$]9\3OVU/VIOVL_\
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MK:\J5WLTWI\UCN N(*F%C@:=>-2BJ*II2G4@HS5[SY()J=[Z<S=EHTTM9O\
M@CTMNG_!-SX7BVDW+_9UZ2?1O[0NMP_ Y%>.?\'$?AGQ!K/[%^@:[I5A<3VF
MC_$"UGU1H8RRP1/:742RN?X1YCI&#TW2J.XK[-^"/P0^&/[.?PUT_P"$'P<\
M./I'AW2VF.GZ:VH7%UY/FRM*X#W$CO@N[-@L0-W&!6UXQ\'>%?B#X6O_  1X
MX\/VNJZ1JEJ]MJ.FWT(DAN(F&&1E/!!%?&X?/Z6#XO>;TXMP]K*:3LFXRDW9
MV;2=GW:N?;8CAZMC.#5DU2:C/V,:;:NTI1BE=72;5UV3L?%_Q._;0_9?N/\
M@CQ>:I9?$CP_&^K_  ?/AVQ\.VNH0M=0ZI+IPM!9B#(?=%(X+87Y8T,GW #7
MQS\&O!_BGQA_P0%^)9\+)<2_V5\6%U#4;6VA:1I;6---$A(4'Y4W"9B<!5B9
MB0!7Z%^$O^".'_!.CP;J6H:GIG[/,,[:A87%D\6H:]?W*0PSQM'((Q).=C[6
M.V0?O$.&1E89KUKX#_LI? #]F?X<7WPB^"WP[ATKPWJ5[-=W^DW%]<7T<\LL
M212%C=22,59(T4KG;@=.3GZ2CQ7P_E.%E#+XU9R=>%;WU%*T7?ETE)WZ<UG=
MZV5M?F:O"7$6<8J,\QE2A%8>=']VY-WDK<VL8JU]>6ZLE:[OI^5GP-^&5SXH
M_8!3XB:[_P %B]0\*>$(?#]Q8Z]\-TTA;A[%29(GT\6XU%&E\T9V+Y:^8L@.
M "37HFG?L[>$/#?_  0E^*VB_LY_%?4_B-I.J>)E\0QZK)X/GT9O*MKK31=*
M(9Y',D<4=E)*9%8J2K+C<C"OJK6?^"*__!-[6_%$OBBX_9_,+3W!FEL;/Q%?
MPVI8DDA8DG C7)^XFU0.  .*]<^-5OXY^!?[,6K1?LF?"S1+S5O#.DHWAOP@
MUFR6L\,3H9;:..$J=[0B41A>LA3(;D'JQW&F&Q6)I+!2FVZ\*G+.%&E!<LDU
M&4H1<I-/>;DK+5ILY,#P/B,)A:SQT()+#SI\T)UJLWS1:<HQG)1BFMH*+N]$
MTCY-_P"":O\ P4)_9 ^$G_!-;P]!X_\ B[X<T?5O!FGW\&K>%)M0BCU&XE6X
MFE7R+9MKW!F21&#1JR[I&4ME'QX/_P $&3N^!G[33 ?\RSIW3M_HVK5ROPH_
M;>_X)@_#7Q3??$?XT?\ !-2\\/\ Q5T?5KDQ:/HJM)I,%R@^7?:7=TB6<BS;
MU*+;/Y.Q67+#:OT9_P $$?V4/'O@3]GSQ_XU^,GA"[TW3OB7+:6^GZ7J,,EO
M/=:?##/FYQPRQ2_:V"-P2(RX^5D8^[G6%PN3Y)FE>=*I3>(J4I+VC@^9JJYR
MC3Y6^915WS-ZIK16;?@9'BL5G6>950A5IU%AZ=:+]FIKE3I*$95.:*Y7)V7*
MEHT]7=)5?^#;SP]I-M^S_P#$3Q9#:H+Z]\8PVEQ.%&YX8;1'C4GK@-/*1_OG
MU-4?VNOVVOVHOBK_ ,%'+C]@3X5_M#Z7\&?#-FJ6E[XHO+.%KB[DDLHKHN))
M<%');RX4BDB+YR7)90OW1^SA^RA\ ?V1_"]]X+_9[\!?\(_INI:A]MO;;^U+
MJ[\R?8L>_=<RR,/E11@$#CIFN._:2_X)L_L;?M9>,H_B'\:OA&E[KJ6ZP2:K
M8:G<V<L\:_=67R)%$I X#,"P4!0< "OD/]9\CQ/%V*S/%4I2IU(M0O&$Y0E:
M*C)PD^27+9V3;6Q]E_JMGV%X/PF5X6K&-2E).=ISA&<;R<HJ<5SQYKJ[23W1
M^87A7PMIW@G_ (+(_"_PG-^UO??&6[L=:L$U;QI?7AF_TLF5OLD;&:8;8P47
M:)&"NSKP05'KGQ(\9>&?V=?^#B _$GXW7D.A^']<L[?^S=>U;]W;HDVA+9QS
M;\86/[3');F0X5<,6*J&-?:OA[_@EE^P1X3\2^%?&/A?]GJRTW5?!4T,WA[4
M+'6+Z&6*6*<SI)*4G'VIQ(<[I_,)7"'*@*.O_::_8O\ V:_VP='L='_:!^&=
MOK?]ER,^EWB74MM=6I888)-"ZOL/!*$E"54E25!'I8CCC)\1CH<\:CIRP\\/
M-\L(R]YWYXQB^7HO=T2V5[:^9A^!,YP^!FH2IJI'$PQ%-<TY1]U6Y)2DN?J_
M>U;W=KZ?FS_P<1_'/X2?$?QM\,_AUX"\9Z9K.K>';?5+K6O[+NEG6S2Z-H(8
MW="5#M]GD8IG<J[&( =29/\ @M%X5\0Z7_P4\^%_B_5OB->>!])U;1=+@TWQ
M\EHSQZ-)%?SB693N0,T'FQS. X*K*I)&17V\O_!'[_@G2? ]G\/[C]G*VDL;
M.]>[67^WM0CN99F4*6EGCN%DE  ^5&8HFYBJKN;/KG[0'[-/P._:D\#?\*Y^
M//P\L_$.E+,)H([AGCEMY1TDBEC99(FQD$HPR"5.02#.#XTR7*E@*&&A4E3H
M1K0DY*',U5<7S15Y1NFF^66EK*[U9>-X'SS-GF%?%3IQJ5Y4)P47/E3I*2Y9
M/EC*S32YHZWULM$?E;^UW^RY\.-:\7>#?AU^TM_P61U3QM?ZH7D\,6]G\/YM
M=:W,SPQC"VNH2NAF)39A3YGE'&2HSZ!_P6P\,:?XD_;?_9W\&>)$6]M;]K6R
MU!94&)XWU*%'!!S]X$Y'/6OL;X#?\$KOV&/V;_'5O\3/AG\%8UUZR.=/U'5M
M4N;UK1O[\232,B..SA=XYP1DUV_QF_8U_9N_:#^(?AOXK?%[X<_VOK_A"6.3
MP[?_ -L7EO\ 9&283*=D$R))B10WSJW3'3BICQQ@:.:8:KS5)TZ,*JOR4H/F
MJ*WNPI\J2VO>3;W275RX$Q];*<52Y*=.I6G2=O:5JBY:<D[2G4YFW:]DHI+9
MM].<_P""C.N? /0_V//%P_:?\.ZYJ/@:\CMK76E\.PAKJW+W$8@G3+*%*7'D
ML"25W!058$J?RZM?V5-/^&7[/.H?MC?L!_\ !2W^P]&6UGOM0\*:]KG]AZQ
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M2I"*4I/[32U>NK]7J]WJ%%%%>>>D%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7Y_P#_  7Q_P"28^"_^XQ_Z)@K] *_/_\
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M^KW_ .,4?\0XG[47_1<_ /\ WU>__&*_8RBC_B*G&'_/R/\ X!$/^(3<&?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#S?2_\ DZG4_P#L3X__ $>E>D5YOI?_ "=3J?\ V)\?_H]*](H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *^/_ /@J#_R5CX _]E '_H^RK[ KX_\ ^"H/_)6/@#_V4 ?^
MC[*@#[ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH \X^('_)Q/P__ .N&I_\ I.:]'KSCX@?\G$_#_P#ZX:G_
M .DYKT>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ KS;5?\ DZS3/^Q.D_\ 1[UZ37FVJ_\ )UFF?]B=)_Z/>@#T
MFBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#S?2_\ DZG4_P#L3X__ $>E>D5YOI?_ "=3J?\ V)\?_H]*](H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "O'_P!IW]DRV_:2\:?#_P 87'CJ31SX#UMM
M12W33Q-]M)DMWV$EU\O_ %&,X;[W3CGV"B@ &<<T444 %%%% !1110 4444
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MIET;6/M%WXD\,KI=I*=;2&ZMA]F\V6"66'>C/'NB(8;\C) HL%S]&Z*_(O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5ST%4=>_9;_9E\4Z!HOA3Q/^SIX$U+2_#<3Q>'=-O_"-E-;Z4CE2ZVT;Q%8
MQ1"0@4':N>@JN81^7/\ P5>P?^"_'[./_7QX+_\ 4CN:^W?^"U6C:KKW_!+W
MXN6.CV$MQ-'H]G<M'"A8B*'4+6:5^.RQH[$]@I/:O>/%'P%^!GC?QUI_Q0\:
M?!?PGK'B;23"=)\1:IX<M;B^LC#(9(O*GD0R1[)"77:PVL21@G-=1=6UM>VT
MEG>6\<T,T926*5 RNI&"I!X(([4KC/RY_P""77[67P"\:?\ !'?Q)^R3X=\=
M^?\ $+PC\)/&>HZ_X?;3+E/LUK)=7SI*)FC$,@(NH.$=F&_D#!QL?\&OV/\
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MOV=]#A_X)>^(M-\.ZUX9NHH)O"EOI.F+%>:4(O+6"V%Y"T,+0E8RL8,:F/>
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M6<9VD#?^KO[97@CQ1\2OV0/BM\-_ NCM?ZUX@^&NN:;H]A'(J-<W4^GSQ11
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/_V8OVIO^"^WA[]FKX>^'_@Y^PE\/=8\(V/@?2;?PKJU]GSKW34LXEMIY/\
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MJ-_PBT\.#<[/*!\TB/[WWR%ZG% '/?M=?%W]HG_@I3_P53NO^";?PH^-FN>
M?AOX1M95\77OAVZ:.;4?*@5[MY0I0N#+*EHD3,\:D><5;.P<)^U7X!^,W_!O
MS\8OAW\1/V9_CIXM\4?"GQ)?7,>K> ?%6I*T+21^2UQ&PC185DF1RT<Z0J\;
M1$-O7(?N?VL_A+^T?_P38_X*M7G_  4>^%OP,USQ]\-?%UO(WBJU\-VS2S6
MEMU2[27:KF,"6);I)&58VR(BZD%JX?\ :G\>_&3_ (."_C%\//AS^S-\#_%G
MA7X4^&;RYEUCX@>*M-585DE\E9W/ENT+21(FV.WCF9Y&E);8H+( ;'_!<S]I
M+7-1_;"^'/P5^+?Q>\=>&/V??$7@NWU'5G\!QCS-76>6<2.RNT:7&-ELICD,
M@B1C(L;,^QW?\$\?A[X)\%?MC>%9/^"77_!2_2?$'PV,\*^+/A7\3]<OK'5+
MR)R[7?V2Q-E%%=RI$K3)-&J%'7#ML9B_M'_!4_XG?M)?L_?%;PG8^,/V,/#/
MQ>_9DLK&%M1TN#P6+^]TLQV\EO()9I6F$#Q[DFCG$<*L L6\$2.WPO9? [X4
M_MR?M??#K5/^"07[+/Q$^'&BZ/K5O-XF\;:Q+)-:Z7<)<1RK>!GN)XX'@1&=
M4$^Z8[52-6'SG0#U+_@NU\"=>?\ X*>_#&]'QF\1JOQ%O-,3381=/M\+E9[:
MR+6/S_NR70W!V[?WK$]>:^ROVNOV2_VWO!G["7AG]G3]GO\ ;DL]'BT.\O;O
MXA?%SXE^,+O3]4GLC<23Q0B[CBF:.,&8J[F2,A+:) Q1Y%KP7_@XB\,>-_A]
M^T#\"/VN[7P5J6K>%_"%]G7+FQMG:.TD@O[:XCCEDV[(C-N*QEB-S(P[<\K_
M ,%L_'/QB_;L_9"^"O[6WP5^%7CAOA2UUK%YXB\/W5L8[BT9)UAM;R\@@>0*
MCPPW)CG^=(EFY<&=0YV ^??VT/#'[-W_  3QUSPU\1?^"<W_  4J\1>*OB+<
M7T<GC-M(UZ*\@NOE,OVHW%H@MWC,RX>UF>=CYOS9 ;=]=_\ !=/]KG]HC1/V
M7O@+XA\!>*_$7@_PK\2;5KWQ[JWA$2QS1LUK9RQ68F#I@,D]VPA:1?.\@Y.V
M-C7RK^V%I?PY_:U_9B\*1_\ !-?_ ()1^,/#GA;1-7276?'$?A$W-_?W#Q3)
M]DBN(C//>6Z,LA>1I&"LL098RR!ONW]M_P =_MT^ /V&O@[X@^ ?[.&B>/?"
M,W@[2(?B9\/?$?@674=2BQ;VSA'M7W?NL+)#*#"7A;YCG.8CL!\=? 3X5?LY
MZ+\2O!WB7_@D!_P5";POXRFN(6\2>$?C=JESH\.K2;T$=L/(LE@O"[ML-K^^
M)W91\K7UK_P<9?&+XR_![]E[X>ZY\+OB;K_A'4[SQMY.H7'A7Q!<6C2+]BF8
MQ&2$QM(@89&0,X!P#7P3^T[HG[)O[>6I:1X _P""8?\ P3H^(/A[XE2:^K^,
M@JL-/LXW#QM;F(7$D%K&)RI\YQ:I&L;!EP?D^SO^"Y?[./[0>M?\$^?@?\)-
M"\+>(OB%XH\+W]A:^)+[PYH]S?R7,T.DM#+=L(T9PKR@G<P&2XSR:.H&'_P7
M3_:6^/OPU\$_ /P+9?$OQ?X7^'?BO2Q-XZUSPC-C4-0*I;++#O+QEV6"65UA
M:5(YFD^?/EJR>1_LU_#3X+^%_C?X-U?_ ((W_P#!4"WT^^^W1S^(_AS\;]:O
M=)BUF<O&BVJ)#8I#?F528S$JM(F%>.0L 4^O/^"F_CW]MOX3?"+X8W/PT_97
M\.?%;X5+I>G?\+)\(ZGX._M2^22W:&5DDCD,@2&2)602BV<P.CL[ M$!^<_[
M1/@K]EO_ (* >*O#WA'_ ()/_L!?$'0?%DFJ,_C"ZG=AIT'F<+&5^T3PVL:O
MDB4M;HH&W8<C8(#^A:BLGP!HNN^&O FB>'/%'B%]7U/3])MK;4=6D7:U[.D2
MK).1V+L"WXUK5)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_C+_ (*5_%O1_#4/QC\.?LFZE<?#TS+"?$%[J+1&=CA2ZXB/EQ>8=BR,I#G
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M]?>'K_X>_$1IK"\DMYFBTFP*LR,5)&;T'&1QD"O2OV7O^"F7[+_[6'BH^ ?
MVJZII&OM&TEGHWB2S2WEO%49<PM'))&[ <E-^_:K,%*JQ'@'_!$U0?B?\?O^
MP]IG_H_5*Y3_ (+-^!_"_P"S]\8?A?\ M&?![0+'0?$TVH7<]U=Z?:I&MQ<6
MDMM-!,\8&UW#2.&8@EUVJQ(4 ?55,CR&MG4LGITY0J<J<9\]US<BG9Q<=%TT
M;?H?75<AX>KY[+):5*<*CBG&ISW7-[-3]Z+CHNFC;].GZ69 ZFC(]:^;/V\K
MS]MS4;_P_P"%/V9]=T;P?X7ES)XR^(&IZE:1M8H25V!)SN1%4&0O&"[,4 *!
M7W_.GP&_:O\ CK\'OV\?#7[.>I_M?Z3\:/!OBA8XY=5L?)F$$TJ.$Q(C-Y<J
M21C*++)&8Y,D!S\GS>#X=KX[ RQ%*K!M1E+DNV[1WNTG%-](MIL^8P/#.(S#
M+Y8FE6@Y*,I\EVY*,=[M)QBWNHMIM'UQ=?MQ_"BT_:_M?V*9?#OB+_A*KJ$R
MQZ@MI!_9X463WG+^=YF?+0C_ %?WL#I\U>S9'K7YXZX?^-_NC_\ 8.;_ -1R
M>ND^-G[1O[5'[4_[<.I?L9?LH_$^U\$Z+X3LW?Q1XDBMEFGG*& 3N-R[@8I)
M5A2.,H6;>SN5*^7VXKAV%2I05!J$70C5J2DW97;3>B;UT223=SOQ7#,*E3#K
M#R4(O#PK5)2;M&[:;T3>NB44F[_,^ZB>*\A_9[_;3^%W[2?Q-\;?"GP-H&OV
MFH> [YK75YM6M8(X9G$TL.83',[,-T3'YE4X(XZ@><_LBV?_  41^&/QPUCX
M3?M*3+XX\!K PT+Q_')9Q21R* Z;X]ZSL'5BCADD990-KF,,YQ_^"?/[3_QS
M^./[3'QJ^'WQ1\<?VIH_A+7)+?P_9_V9:P_9(Q>W407=#$K/\D:#+ECQGJ23
MQ?V-&EA\3/FA45.,)*49NR4I);<NKZ.,N5QWUZ\/]AQHX7%34H553C"2E&;L
ME*26W+J^CC+E<=]=+_7F1ZT9K\T_V+_CK_P4F_;W\*^)O"6B?M'Z;X?AT*:.
M6_\ %$WAZV%Y(9HI!#9PK!"B(A:)G>7_ %BY3:2,HWK7_!*O]J7]H#XC^(_B
M-\!_VE?$\>K:KX"O$2+5)HT6:/;)+!/#(ZA1(BO$K*[+O^=]S,-H7;'\*XO+
MZ5>4JL)2H\O-&+DVE*R3UBEUVO=+<VS#A'&9;1KRG6IRE1Y>>,7)M*5DGK%+
MJM+W2W/M+-&:_/7X9_%[]NC_ (*9_$'Q5XC^!7QKC^%WPZ\.W?V73&@T\/<W
MDI#M&7(^9I"NPR#S%2,-'M1SN)])_8$_:V^/FJ_'?Q=^Q)^UK<V-_P",O"<$
MEQ8^(;-8XUU"%'3*L%"!R4FBDC81JQCW&0!@<YXKAG%86C4;J0=2FE*<$WS1
M3MJ]+.UUS6;L98OA7&82A4DZD)5*24ITTWS03MJ]%%VNN9)NUT?8.1ZT @]#
M7YU?!7]H'_@H3^U?^T/\3_V=O WQVL-!TG0_$%UN\37/AVU>XTBQBNKB!;:W
M6.)?-DEW1_-(VY5MR5=6)#]A_P $U_VEOVH=0_:A\??L>?M'^,X_$TWA/3[F
MXM]89%\R.2WNXH&57"*TL<@N X,GS*$ X!(%XKA;&86C5G*K!RIQC.44W?EE
M:SUBEUU5[_>KZ8KA'&83#U9RK4W*G&,Y13ES<LK6>L4NNJO?[U?[EHS7PO\
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MV;BDU:]I1NC6EPC*EB,-.I5C4I5*L*4G#FWD[NS<4I*U[2C='VE\'?BGX?\
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M1-V[IGBY#Q7_ &+@EA_8N5JBJ)J;A?1+EDDGS+31-VONGL?EY^UIK^E^(_\
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ME1_FVE&^=K/X;?\ !<WPBMC\'-&^(_AZ^TN.&.!/&[W5C,+>/;C$CW$0NI"
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M9$UK7M(M[2?4=/\ LGD P>4EP^)FE*2>6NS)D 4 ^LJ* >*,@=30 449%&:
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M[F"VM+Y"AC2'SI)QF%VW1A223P*]J\)Z\/%'A;3?$PM?(_M"PAN?)+[O+\Q
MVW.!G&<9P* -"C:!VHR/6C- !11FC- !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !17B/QQ_X*$_LO?L\?%O3?@M\3?',EKK%\J-=-!9M
M)!I:2#]VUU(.(P_8#<5!#,%4AC[=716P>*P].%2K!QC-7BVFDUW7?_ANYU5L
M'B\-2A4JTW&,U>+::4EW7?\ X*[H;-/#;IYL\JHO]YFP*=GC-?$/_!PH0O\
MP3.\1$G_ )F31_\ TK6OH#_AX+^P3_T>[\(?_#E:7_\ 'ZYSE/7(IX9BPBE5
MMK8;:P.#Z4ZO@;_@DO\ %OX:>'-#_:V^.6I^-M/_ .$0L_VA/$^M3>(K6X$]
MJVGJ!-]I1XMPEC,7SJ4W;@1MSD5NO_P5X^*47@P?M(R_\$WOB<OP/:'[0OQ!
M_M"S_M'[*5WB]_LC/FBT\O\ >?:/-\O9\V<4[ ?;E%?-G[2W_!4/X!?LUR_"
MF[O]%U_Q1IOQBTV^N_!M]X3T\W;WK0V]O+;01P<2/+=O=6\,0P 'E'F%%#,/
M/+?_ (*_^)OA]X_F^$/[4_["OC_P+XOU;2EU#X<^'=)O(->F\6*TJ1K;1-;A
M%@NAOWO$Q*Q)&Y=U.Q75@/M:BOF;]E[_ (*#>,/BW^T=JW[(W[17[+&M_";X
M@67AW_A(-,TV^U^VU6TU+2_,2/SH[J *A?<^"BAU!20%]R,HY3Q-_P %4O'?
MC7QYXJ\-?L2_L0^+OC-HO@+5)=/\8>+K#7+;2[%;B$ SPV!F5VU&5 ?]7&%9
MLJ4W(Z.P!]B45\OW?_!5OX$-^P?XB_;RT7PAXDN-)\)ZI'I?B3PG<VT=OJVF
MZ@;VWM'M)D=]BR(;F*0C=]QAT)VCA_$O_!8O4_!-M9_'#QE^Q#\0=/\ @#J5
MY';V'QBDDCW-'+(L<-])I6T7$-E(71HYG8-(KILC9V$= 'VJ9X5D6%I5#M]U
M2W)I]?GE_P %%_CMI/P:_P""G_[,GQDTOP?KGC*-?"?B8:3HO@VT%Y>:K)<V
MGE0+ H8*P9I58OG:J;FY Y]G_9Z_X*0^*/&_[347['W[4O[*FN_!_P >:MI4
MVI^$[6^U^VU:RUJUC7>XCNK<*OG!%D<QJ&51#(&<, I=@/J(WEJ$>0W$>V-L
M2-O&%/H?2E,\(=8S*NZ3[B[N6^GK7YH?M?>+/V=O%/\ P3/_ &R8_P!G_P"%
M>H^&)M-^,=[9>.9-0U&2X&KZ\FK6'VJ^BWRR>5'(2N(UV*N.$6OHO7/%?[/N
MD_M%_LF>&/B'\+]0U3QYJWA;7?\ A7?B2WU"2.WT,1:) U_YT2RJLOG08C7<
MDFTC(VGFD!]3T5\G?$[_ (*5?$74/C7XH^ G[%/[&/B'XS:OX$N!;>--4C\3
M6FAZ387.T$VJ7=P'$UPIRK1!58%6QNP<>A_L1?MO^$/VU?"?B"\L?A]KW@WQ
M-X-UPZ/XP\'>)HT2\TV["!OX3\T;?,JLP1B8GRHP"0#VR:>&W3S)Y51?[S-@
M5''J.GRN(XKZ%F/15D!)KX?_ .#B3_E&CK7_ &-6D_\ H^O(?C;^R'_P;E^$
M_A#XE\1>$_B/X"LM6M-%N9-)O/"?QHNM2U*"Z$3&)[:V&H2^=*'VE4,;*6P"
M,9H _42BO"_^":$W[0T_["?PUE_:ICU)?')T C5O[:_X_3")I!:&X_B\\VOV
M<R>9^]WEO,_>;Z]TH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBOBW_@I=_P %+/BI^QI\5/#_ ,-/AG\/M#OOM^AKJFH:AKR3R(ZO/+$(8A%)
M'M9?)9F8ELB1?E&,GZR^%'CH_$_X7^&_B3_8TNG?\)!H-GJ?]GS-N>U\^!)?
M*8X&2N[:3@9(Z"O2Q64X[!X&EC*L4H5;\KNNG==#U,5D^/P>7T<;5BE3JWY7
M=-Z=UT,/]IO]H7P7^RE\"/$?[0GQ#TO5+S1?#%HEQ?VNBPQR74BM*D0$:RR1
MH3N<=77C/TKHOAKX\TCXI?#K0/B;X?MKF&P\1:+:ZI8PWB*LR0W$*RHKA690
MP5P" Q&<X)ZU\]_\%G/^48GQ<_[ -O\ ^EMO7D?[-W_!3#XP>%/V=_ 7A:R_
MX)@_'K5H=-\%Z7:PZMIOAV-K>]6.TB03Q'?S&X&Y3W!%><>6?5GPI_:O^'?Q
M?_:#^)G[-OAK1M:@UWX5-I2^(;J^MX5M+C[?;O/#]G996=]JH0^]$P<8W#FO
M3J_.'_@G]^TO!_PUC^VU^U3\3?A7XF\%VND:'X9UK6O"_B"S":G96]GI-ZSJ
M\8.-[1PEU&>0Z^M<SX'_ &N/VJOV@?ARO[0%U_P6K^ WPCU77;=M1T7X.W%G
MX>O(=-B*[K>UO+VXG-U%(XV^=^[9XBS84,/+4L%S]1**_-SXL_\ !5/]HOXC
M_P#!.KX&?M2_LX#2=+\>>+/C3IGA/Q3X>^S1SV-Y/LOEFLB9E=H8;AX;>0-&
M_FQQRA1+N#,;O[0GQ&_X*M?L/_%OX7V.L?M<^%?BS#\6_$DOA2UT'6OAW:Z)
M8Z%JERJ+:7/FV9>XGABD<LX)!:.)EQND#QE@/T6HKX7\/>-?V_OV3OV__@S\
M!OV@?VQM/^+GA+XP6GB*!HI/AO8Z'-I5QI]FMRLD9M6)?+-$F7=EVF3Y-VQP
MGA[XA?\ !0K]OSX[_%3_ (9O_:ETGX*_#GX7^.;OP98S1^ ++7K_ %S4K01_
M:Y)ENW B16<&-D*Y215*LRLU(#[IHKX.\#?MG_M9^ OA;^U%^SC^T#XRT?4/
MBO\  SX>WVO^%_B!HNEQPQZW:2Z7/<VEV]FT9A2:&18O,4*8B9 FUO+9Y,#P
M#9_\%H_B[^R-HW[8VA_MG>&]*U:Z\&VFNZ5\*U^&>GS6^L0);QR+Y]^V)(I[
MN,&1DC541Y@B&)>4=@/K[X[?M;?#C]GOXI?#7X1^,]%UNZU+XIZ]+I'A^;2[
M:%X+>:-48M<&25&1,2#!17/7BO4J_*_]LS]ISX@_M<:'^PW^T=\ -%TNR\6^
M+/&-Z--M-:$CV-AJ@\BUG,FP[WMX9TE;CYF2/IDXKUSQ7XZ_X*'_ +"/[3/P
M9M/CU^V%8_&;P)\4O&8\(ZII\OPZT_P_<:5>7(7[+<1-:EVDPVXMN;;M1EVE
MG5XRP'U!XQ_:NT#P$GQ<O_%?PC\>6>E_!_PVFMZEKUQH*1V/B&W^P27LB:5.
M\H6[DB6(QR!O+"2E5)P=PKZ/^U_X<\3> ?A3\2O"'P;^(6M:5\6ELI--GT?P
M\EP-!@N85F2XU0I*5M855P&=3( 00,]:^;?CA\>?BQX_U?\ X*#? WQ=XL^U
M^%?A]\'[(^$-+^PP1_8/MWA:\GNOWB1B27?* W[QGV]%VCBL?PW^T)\7_@K^
MS/\ L%>$OAEXN_LS3_'<WAO1O%5O_9]O-]NL6TZ F+=+&S1\_P 495O>@#]!
MJ*^+_P!IC6_V_M>^/?B267]LCPA^S#\*=%6WM?!NO>(-%T/5KCQ?.T8:XE9;
MNY_T98W!"J3&Q5U)0G)6?_@E?^UE\7_C7\2/C-\ /BO^T'X7^+D?PSU323H/
MQ.\+6%M;PZW:W\,\F"EH3!F(P[#LSABZEGV[J0'T=^TU^T)X,_93^!7B+]H/
MXAZ9JEYHOAFS6XO[7188Y+J16E2,"-99(T)RXZNO&?I7S79_\%L/A>WA*W^)
M.M_L._M,Z3X1FL8[YO&6H_"D#2XK)U#K=-/'=.#"5*L'7<"&!&0:[+_@LS_R
MC%^+O_8 @_\ 2VWKP3]G'_@IM\=OAM^QE\/?#7@[_@EO\;O%$NA_#?1[/3]1
MM=%VV&J^58PQK/'+&DK^3(%WJPC8E6'%,#[N^"GQM^%O[1?PPTGXR_!?QA;Z
M]X;URW,NFZE;*ZB0!BC*RN R.KJRLC ,K*00""*X_P#;0_;'^&O[#'P8_P"%
MX_%;PYX@U32_[6M].6S\,V<,]TTTV[9A)IHE(^4Y^;/3 ->'_P#!";P_X#T+
M]@^WN/!GQ$L=>O-4\6:C?^*+73;>:"'0M4E,9DTP13HDD1AC$.05 )<NA9'5
MC@_\'#,[6O\ P3]BN4MWE:/XA:,RQ1CYGPTAP/<T=0.L_P"'N.?^<8W[7G_A
ME_\ [JKTSXC?MY_#3X3V_P &_P#A/?ASXVTV\^-FLV6E>'])O-'AAN](NKE8
MB(]1BDG4V[(90KJGF,K*PP<<^4_\/4/C5_TB@_:'_P#"9C_^+KG_ /@KI_R<
MK^Q[_P!E\L?_ $=;4Q'T%IO[;_PEF_;'O/V'?$>A>(/#_C)=#75]!N-;M(([
M'Q%:[27:PE29FE9-LNY61&'D2X!",1:_:L_;+^%'[(FG^&H_'6GZSK6O>-->
MBT?PAX/\+VT4^J:Q=.RJ1#'++$FQ-Z%Y'=47>H)W.H;R?_@L)\ _!_C[]EZY
M_:(_X6-;^!O&WP;9O$_@?QM,P7['<Q%2;1N"76X98XPB@EI?)PKX,;^-_P#!
M'G7I?^"@/Q>\6?\ !2S]H/Q7X?U/QYHY7PKX7\$Z79NL?@FR6+,DRK,S.);H
MO)B1<@*;A1(?,>&%#/T51BR!BA7(SM;''Y5X=^UK_P %"_V=_P!CO6-'\"^.
MY]<\0^-O$2JWAWX>^"=';4M;U-#)Y8>.W4J%4L'"F1T#F.0)O9& ]R)P*^&_
M^"7WA6+XE_MC_M6?M6^.I;74/$T/Q?OO NDSM;CS=.TK3"$2-#U594^SAP,!
MFM@QYI =?X9_X+%_ /\ X3S1O WQU^ WQF^#:^(KC[+H>N_%WX?MI.G7=UN4
M" 3B:3:WS@EG"QJ.6=>,_6M?&?[?/[=W_!)GQ+IWBS]B3]L[XR-#)');Q^(-
M&A\-ZRTEM,OE7,+I<6UJZAA^[;*,1@E3D%EK%_;*_;^3PBOP4_9U_97_ &B/
M"W@&W^)_AF+75^,'Q&O/-CT/PXD"-!.(]3*FYN[D<+]I;<61@X#2>;$P/N:B
MOSK^$G[=OQ1^ 7[6'P]^$OQ*_P""C?PX_:4\(_%+4O["%[X3L=(L=3\+ZHQQ
M:N;?399!+;S.RQLSG*DY&W9MEF^$?Q+_ ."F7[97[2_QY^#?PQ_:[TOX;^%_
MAC\2+BSTWQ%)\/=/U>\FB=G2#38X9!''Y,:PO(\TA:8M)$H)7=A ?H=17P7\
M ?\ @HI\:_@?\%OVE-/_ &Q]5L_''B3]G/6/+A\1:?9Q:6/$L%TK_8(Y(H8V
MCMI'D559D5@BS*"KM&S2>3R?M;?M>O\ !5OVDF_X+:? &+Q5_9)U[_A1\>F>
M'VL@P'G?V1]M^T_:]QC_ '?3?YAV"3_EK3L!^IE?-?[0/_!26S_9\^).M_#W
M4/V'/VBO%5OH:1O/XJ\%_#,7VCW"- DQ>*Y-P@=4#[') "NCC^'->F?L@?M&
MZ'^UO^S/X-_:,\/Z4UA#XJT=;F;3VF\S[)<*S13P!]J[PDR2('VKN"@X&<#I
M/C)_R2'Q5_V+=]_Z3O2 ^5?AE_P6H\!?&30M.\7?##]@;]I_7-#U68QV/B#2
M?A9%=6,NV4Q.PGBO&1E1U=6()VE&!Y!%>_?!;]K+X=?'7XS?$SX&^$=$UNWU
M;X5:I9V/B&XU*VA2WN)+F*22,V[)*[.H$;;MZH02, ]1XG_P0=_Y12?"O_N.
M?^GW4*\#^!WPX_;'^*O_  4>_:R\-_LP?M*Z7\*=/M_%FBW.O>(YO!<&N7MU
M-]EF6WM8H+EUA2+:9WDD.7#)"J\,],1^G%%?#'[/?[=?[0'P#\(_M->!/VV_
M$5CXVU_]G/[+J%OXHT^T@TS_ (2.RU"TFN;"!H84\NWF81QJ2JL%-PJG>8R[
M^.:)^UK^UWXQ^#%O^T@/^"VGP!T7Q1J&DKKL/P1DTOP^EE;LP\Y-(DO9KK[9
M&Q3$;[@720LOF''FT6&?J517YW?'/_@I#^T5\8?@/^RW\4_V2/$%MX2U'XW^
M*I= UBUU32H+R"UN3NLY6_>HS-%;W0DE4J4:18E###%:])^)'@K_ (*M?"WX
M=:'\*_#W[5F@^*+S7O%5S=>+OCUX@\):1I4/@;0HK>W*Q)I0?9=SRR^>5D)=
M1C:_EAQ+&6 ^R**_.7X?_M>?M#? O]N#X3_!/Q1_P4R\"_M%>'_B)J5]I/B#
M2=$\+:1I]WX>F6$/;3YTZ60Y:0X(E.-JN I)#IU^N^,_^"CG[2'[?_QP_9J^
M O[4VE_#;P5\.Y/#ES#KUQX#LM8O+=[S2(IA9013!%>.20W$TLDKNZ%(5CVJ
MS!BP'W717P;\._CY^WMJ%K^T!^P1XM^,5A??'#X=>&X]>^&?Q"TGPS:6[>)[
M.5?.B#V4T9M8VW^5:R, 54W)QN:'S7Z?Q=_P4HFF_P""/4/[</A:^7_A,-:\
M(PZ=I5O;VL?F?\)3+)]@9(;>3<)1'>"241X8M%"3M(XI ?9=%<O\$=(^)F@_
M!WPOH_QH\5)KGC"WT&U3Q1JT4$44=UJ'E+]H=$B1$5#)NV@(ORXXS744 %%%
M% !1110!\2_\%(_^2Y:5_P!BG!_Z4W5>-?"__DIGAW_L.V?_ *.2O9?^"D?_
M "7+2O\ L4X/_2FZKQKX7_\ )3/#O_8=L_\ T<E:$_:/T_HHHK,H\!_;Z\>_
M'7P)X.T6Y^#YO;>SFO)1K>H:?;[YH2-GD)GDHCDODXY*JN1NPWIO[/\ K'Q'
MU_X.:#K'Q:TYK7Q#/9DZA#);B)\[V",Z#&QV0(S+@89B,+C ['&>HHKY[#9'
MB,/Q)7S1XJ<H5(1BJ3?N1:M[R7=V[+64M7=6]S$9Q0K9#1RY8:$94Y2DZJ7O
MR3O[K?97[[*.BL[YWB__ )%/5/\ L'3_ /HLU^8__!)7_A[C_P .^_A__P ,
MQ?\ #.7_  @W_$U_L/\ X3S^WO[6_P"0M>>=Y_V3]S_K_-V;/^6>S/S9K]/M
M>L9M3T.\TVW*B2XM9(HV;[H9E(&?;FO%/^":/[,7C[]C;]B7P5^S=\3]6TB^
MUSPW_:7VZZT&XEEM'^T:E=72;&ECC<X2= <H,,& R,$_0GAGR)\*?^&NO^'\
M'@O_ (;._P"%<?\ "4?\*)NO[/\ ^%8?;_L']G_;+W9YGV[]YY_F^?G'R;/+
MQSNKP^+]J#]B/]LOXD^//BK_ ,%%O''Q8UEH?%VHV/PU\&>&;34ETGPSI\16
M.VO8OL8"G4.&+.S,I.-R-P%_0[Q=^QY\3=>_X*I^%_VXK/6M#7PGHGPFD\+W
M6GR74PU%[QKJ[F#I&(C&8MLZ#<9 V0WR\ GR+0/@1_P42_X)W>//&NE?L9?!
M_P (_%KX8>.O%5[KVD^&K_Q$FCZEX5U"Z"E\R3$1362E0HC0F1L#'EG<7H1\
MSW?[9OQCU/\ X)9_M/>$/!WQL^(6IVOPS\3^'F^&_P 2?$$US8Z]-H^H:Q;A
M+>:;;'*\L0BFC:3.76;: J!5KMO^"AG[)/B?]BK]G+PK^WO\,/V@_&\WQZM?
M$6F1>*/'FJ>(99EUQ;QLR6DEK_J([..7;Y=ND>P1+Y;B3AA[?\4OV"_V[?VA
M/^">_P 5_@E\>/C]X=UOXE?$[Q%9ZE8V7VBYB\.>&+6'4K6Y%C:N87N-@CA?
MEE;DQKSM>:3U3_@I/^R%\3/VQ/V2H?@-\,=:T.QUB/7M*O6N-=NIHK;R[:0-
M(-T44C;B!\ORX)ZD4 ?-G[5/['_AS]@'XJ? /]I'X)_&#XA3^.O%OQV\/^$?
MB-X@USQ=-=MXPL+TS-*+Z.3,9*K (XUC5$16SM+JCKU7BSX5W/\ P4Q_X*)_
M%WX"_'WQ]KT?PC^"=AH-I#\.]!U::QMO$E[J-LUTUQJ#PLKRK&8V544KC$94
MK^]\WWS]OC]EOXA?M2V'PDM?A]JVCV;> _CAH/C+6/[8N)8Q-8V0N!+'#Y<<
MFZ8^:NU6VJ<'+KQGS7XV_LZ_ME_LY_M?^*/VU_V'/#?A_P =6/Q$TJPMOB3\
M+_$6L#3KB\NK)/)MKNPNV'E1,(B5993M&9#B0R+Y(!YKX(L_&O\ P3__ &O?
M&7["W@?XK>(M:^&GBKX'ZEXM\#6'B#4Y;F[\(WML9HC:6MP6W+:[$9E!Y!$?
M.Y9'EY_]BS_@F?\ \-H?L5^$/VC?VF/VDOB9J'Q0UC0DN? OBZ'QA<J_@N-)
M&6![1%<!WE1(VG:3<[DD*T;#S#ZCX _9:_:A\1^./B9^W]^W!<>']-\67GPG
MOO#?@OP#X5N3<6OAK2VC>>1;B=E_?W9DR&:-F3YY""59$B\6_P""<_B'_@K5
MI/\ P3W\"_#W]F_P#\/=>T/Q1I-TO@_XA:YKS6LG@N/[3,)1?VC*S7N'W_9S
M '"X7S491LH Y'XV?'#XU?MA?\$S_P!F/4O%'CC^S_B)%^U!I'AFZ\56]J',
M>H6YU"W@O]KDB20+Y,KYPKR!\!00!Z9^UW^R5X)_X)M?$;X'_M0?LZ_$SXA1
M^*/$GQIT'PI\1=0UKQE/J#^,K"Z6=IWU 3[EDF*P;5*!$7>65 ZHR^IZM_P2
MP\3^$?V5_P!GC]F_X2^---O)/A-\9='\:^+-8\02O"VJ>3+=3WIA$4+YD:6Y
M(B23&(U57E)7<WI__!1?]DOXC_M=>$/ACH/PVUC1;&;P7\9-%\6:HVN7,T:R
MV5I'<K)'%Y44A:8F9=JL%4X.6'&0#@/AWX^\=ZA_P5^^-WPYU#QKJT_A_3_A
M!I-UI^@S:E*UG;3OY6^6.$ML1VR<L "<\FOE;X$>//'/@/\ X)"?L6R^!O&>
MK:*VK?M.6.FZHVDZC+;&\LY=:USS+:7RV'F1/M7=&V5;:,@X%?<G@W]D?XD^
M'?\ @H?\3/VM;W6=$;PWXR^'MAH6EV<5S,;Z.Y@V;VE0Q"-8SM."LC$]U%>+
M^$/^"7?[0/A_]@_]G+]F"\\6>#V\0?"'XW6?C'Q+=Q:A=&SN;&+4-2N6CMG-
ML'>;9>1 *Z1KN5QO  )0S!_X*03_ +'[_M9-:_\ !23]LV;_ (5W_P (_;CP
MG\#?#$^J*]S<X/FW6IQZ<&=BSL# Y:+=C:#B-]^/_P $<OBYX;L_VT/B?^SG
M^S_XG^(=S\&X_!MGKG@?1_B,)Q)I>+@1,MBLQW+9L9F"D@,PB7=N92[>A>,?
MV?/VZ_V6_P!OKXB?M7?LS? GP7\6=$^+L>FP7L&L>)$TK5O#,EK;+#N\^92K
M69^\T<0>1PD8VKY09^F_9"_8Q_;(^'W[=OBW]L[]J/XC^!-:F\:_#^+2KW3O
M""7D,>E7<5S"8[>W2=#YEL(8=QF=UD:21@8\?,6(]E_;Q_:8LOV0/V1O'7[0
M<[Q_:]"T20:+%)'O6;4IB(+1&7()0SR1[\'(3<>U?D5XD_:F_8/^''_!-+X3
MZ7\$/VBH;SX]_"_Q;8>/(H;KP?J:-J.M3W DU"QGN6@6-HU60(S^;B9;",9^
M;C]0OV[OV0/B9^V/\0/@_P"%GUO08/AAX3\<+XE^(6EWSR->:O);)_H=K%&(
MFC>%BTRRAW7*R*0"R 'Z&UK1=(\1Z+=^'?$&EV]]I]_;26U]97D(DAN(74J\
M;HP(964D%2"""0:0S ^"/Q=\*?'SX/>&/C9X'D=M)\5:%:ZI8K+C?''-&K^6
M^"0'7.UAGAE([5\5ZY\*V_X*@_\ !03XO?!S]H'QYKR_"/X*+H^FV?PYT/5I
M["U\0WUY ]Q)<Z@\3AY1&\;*BJ4P!&5*XE\[VW_@F/\ LF_&;]B/X*:U^SK\
M1_&&D:YX<TKQA?W'PYN["ZD>XAT>>0R+!=(T$:I,)#)(VQI%W3L V%7/"_&;
M]G3]L[]F;]KSQ9^V=^PSX7\/^/M,^(^GV$7Q(^%OB#6$TVXN+RS3R;>[T^[=
M1%$?+)WK*2,M(<2%T\D \IL$\?\ [ W[0OQ9_84\"?&'Q-K/P]U?]G/5O''@
M*WU[4Y;B^\(W<'GVWV2UN<AA;X1G4'!4K'@[Q))+UG_!(S]DC1OB!\%_A5_P
M4#^,GQ4\=>*/BK<Z1=+_ &UJOBVXE@&EE9[2'33 3L:!4$=PVX&1KH-*TASM
MK:^&O[$?[6WQC\<_%#]K/]KS6/"^E^/O&OPHO/ _@7P3X?NI)=/\,:;.C2;;
MJXV,TTYG;+O'O49E*EE=(XO?/V"?@%XQ_9<_8_\  ?[/_P 0-1TV[UGPOHYM
M-0N='FDDM9'\V1\QM)'&Q&&'5%.>U,#S?_@M=_RB[^+7_8)LO_3C:UY'\()O
M^"Z4/[)_A%_A/;?LS3:;_P (#IP\.)_Q//[5%N;.,0,WG$6OV@(58[OW6\'@
MKP?IK_@H=^SKXW_:S_8T\<?L\?#C4]+L]:\36-O#876M3R1VL;1W<,Q,C11R
M.!MC8#"-R1]1X?\ #GP-_P %U_AA\.M!^&7AZ?\ 9.DL?#VBVNEV,UV_B9IF
MB@A6)&<J I<J@)(4#.< #BD!H?\ !#W4?A;I7['=S\'/!_AC5M$\6>!/%^H:
M3\4-+UZZAFNQX@#@W,I>'"O$3B.-L#"P["7*%VV/VTO&/CG]GO\ ;=_9\^/-
MIXTUF'P5XJUZX^'OC;0TU.1K*6XOHV?2K@6Q/E(ZW*R>9/\ ?V!$Y'%=9_P3
MM_8N\0?L>?#GQ+<_$_Q[;^*OB%\0_%UUXH\?>(+.T$%O-J%P<M% @5<1*=[#
M*J2TCD*BE47IOV[_ -FS4?VM/V6/%/P4\-ZU#I>OWD,-[X5UB9BBV.JVLZ7-
MI*7".T:^;$JNR*6$;N "3BCJ!\H^#/VJOC)J?_!7)O']UXSU";X/ZYXJUKX/
M:9IMQ-)#8:?K&FV%I?\ V@IO\J2XN+W[9;1R;=Y1&0$@ #SS]ICXS_&KQS^P
MC^US^W5X3^,?BC2]-U?X@:3X?^%:Z1XBN8[>STG2]7L;&34;)D=?*^VR-/Y@
M55/[L@E@QKWOQQ_P39^,^H?\$T_!O[.'A+XC:,?C!X+\467C+2_&.J74S6:^
M)AJ4E[=71D\AI'4_:KM4+0DG*;E SC>_:"_X)S>(?$W_  25_P"'=OP/U70;
M/5H/#VBV,.I:JTMO93W5MJ%K=W=R_E1RNIF>*>3A6^>7G R0Q'S_ /MQ_L@6
M7Q4_X*A_LXF]_:+^*VD/\3M)\0O=2Z#XP^SMX>-AH$&/[*)B;[)]HV?Z1G?Y
MN]ONYJ]X5_9#T#]KC_@KC^U/X1^)_C[Q)#X%TVW\'MXD\&Z'K$MA#XEEDT54
M@2\F@996MXU%P3"C*'>2-B<1[3[1^W?\!OVKH/C;\ /VK?V7_A-I/C[5?A F
MN6NL>#[KQ-%I<M_'J-C#:!X9YU$0$865B68-DQX1QNV^@?L[_LM_$;X6?MN_
M'K]IKQ/J6CMHGQ4C\,?V#8V=U*]Y:G3M/:WG%PK1*BY=LIL=\KR=IXH \;_X
M)B:-?_L[?MG_ +1?["'ASQWXBU?P#\/SX;O_  +IWB+4OM3:-'?6!N+BVB<J
M&$.Z2-43.%$6>7>1W[S_ (+7>./&OPW_ ."9/Q,\:?#OQAJF@ZQ9?V-]CU;1
M=0DM;J#?K5BC[)8F5UW(S*<$95B#P371? O]DWXC_#+_ (*"_'/]JW7M8T6;
MP[\3-/\ #T&@V=G<S->P-86"6\QG1HE1074E=COD==IXK0_X*7?LQ>/OVR?V
M)?&O[-WPPU;2+'7/$G]F_8;K7KB6*T3[/J5K=/O:*.1QE(' PA^8J#@9(749
M\T_M7^&_C'\?O^"P'@S]EK2?V@O&?A7P#KG[/\>H^-M+\,^()+1KV"/4[TD1
M'#"*626.UCDF0+*T DCWA7(,GP+^#6C?\$_O^"M_A_\ 9=_9U\3^(+/X8_$+
MX7WVL7'@/4M=GO+'2M0AF;]_:B9F92P@&2S,^9),L5V*GOE]^R+\2KK_ (*=
MZ#^VDFLZ'_PBVE_!8^$+BQ:YF_M!K[[?-<>8J>5Y9AV2*-QD#;@?DQR9/B#^
MR9\1_%?_  4L\ _MCZ=K&BIX7\*_#V_T+4+&:YF%_)<3O,R-&@B,9C D&29%
M/7"F@#Y#_88_X)Z?"G]M/4_VD+_]H3QKXLU+PK#^T=XML-.\!Z;X@GL=-@O]
M]O(VJNL+*9[D*\21B3,:")LH^_Y>?\0?%[]H#X>?\$:/VF_!T_Q[\5:AK7P=
M^.5QX-\+^,GUB6/51I]MK6E(H:Y1A(21-,OWN(W$8PBA1]S_ + G[+/Q"_98
MTSXM67Q"U?1[QO'GQNU[QCHYT>XED$-C>K;B*.;S(H]LP\IMRKN49&';G'AG
MQ%_X)A?'[Q=^Q?\ M-?LZ:;XK\(IKGQF^.5[XS\+W4VH70M;:PFU/3[I8[IA
M;%TF"6D@*QI(NYE <@DAB.+^//[/FN?M4_\ !8;P9\.Y_BKKWAO19/V4[2\\
M:2^']0:UOM7TX:U.K6*W !>)99WM_-92&:)94W#?FNN^&7PBG_X)I?\ !2+X
M9_LY_ KQIKL_PB^.&@^($M_ &M:W+=V_A?4M,@^W-<V33;G5)$<1E"VYC)([
MN^V()TG[0/['O[<6E_ML>&_VV?V6/%?@>1O"OP9MO"E]X2\1W5TG_"1R)?S3
MS6A=(@L$;1R+)%.7)%Q;QJ\?ELS#0_9X_9T_:^^/7[76C_MT_MV>&=#\&MX+
MT.^T[X7_  NT'6C?R:-+=EHKJ]O+J-O)EF>#]V FY&5T)6)XL, ?&G[1TOC7
MXT_\$=/VC/&'C_XM>+KVX\%_M,7_ /9L,VO2R17%L-1T^UCLIQ)N+VL8NFE2
M$%566*)Q]W!]M^*/PU^)7A*;]F__ ()D_#3]J;XDV.B_%IM5U[QMXXU#Q$;C
MQ MA9V$5S_9MK=!%$$+_ #J/E8KA =R;XY.PU7_@EQ\;-6_X)X?'K]DN^\9>
M&X_$'Q+^*&H>*_#=Y:W,\EK'"][97D$%PS0HT;L;0HQ575-X(+XQ4GB;]FK]
MO?\ :"^$OPA_:/3P%X;^%/[0'P3U">#1-!UC7DU31]?TZ6TAM[M+A[3>;<3A
M&V(LCM&NY3(&D$L0!R?Q]_9L\-_\$BOB%\*/C[^QSXQ\2:/X5\3?$O2_"7Q"
M^'.I:[<ZAI>K0WPD#:BJS.S1WB^43N!()V;0JB1)7)^S':_M[?\ !2_]I?X3
M?'[XP^.I_ ?@0>%Y=!\%Z7XJN;6S@U"\T@,EZBH^%>!X7E1<;#+)N=6Y5NQN
M?@+_ ,%!?V^_BW\/==_;/^&7A?X3?#?X;>++?Q&W@W1_$B:OJGB/6+4?Z/*\
M\0,,5GEF_=Y$@!=6#%DDB]I_9Y_9;^(7PF_;9_: _:0\1ZMH\VA_%5_#!\.V
MMC<2M=V_]G6$EM/]H5HE1-SN"FQWRN<[3Q0,^$?VV)_@CX*_;@\9:/\ \%8O
M"/Q>U3X6&VTJT^!^LZ1?7S>'])5;,"YNW>"=)'OA(%!.)G):0NA4Q&OMC_@E
MC<^$Y_V9YD^'?[:=W\<O#,?B:\'AOQ#J]NZ:EI-D=ACTR\:5C+)-%G?NE2)B
MDR;8TC\L5Q_Q8LO^"IO[//[0GB[QU\&/ VC_ !]^&?C.:*73_ ^M>++?1]3\
M+S"(B1(IIU6W:T8Y^7$DA_=\*5=Y>A_X)E_L6?$;]E32/B!X_P#C*_A>S\6?
M$_Q9_;>I>'/ L#Q:-HD85A%;6ZNJDL-[EVQ@G: 6V[V.@CZAHHHJ1A1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 ?,O[3'_!+#X!_M0_'6V^.GC+
M7=<LKF2.!->TW3[A!#JBPJ%3+%2\3% L;%#RJ+@*V7/TU1179B,PQF,HTZ5:
M;E&FK13Z+LON7R270[L5F6.QM&E1KU'*--6BG]E::+[E\DELD?$/_!PH ?\
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M!'V$;U #9'%(9^47Q!_Y1M?\% /^SG=<_P#3OIU?1_Q=/_&P+]@G_L5?&?\
MZC=O7UO<?L^_ 6[\->(/!EW\$O",NC^+-4DU+Q5I,GANU:VUF]=U=[F[B,>V
MXF9T1C)(&8E5).0*T;SX7?#34/$&@>+;_P"'FASZKX5BFB\+ZG-I,+7&CQS1
M"*9+60KNMU>,!&$94,H"G(&*8'Y[^"_C;^T-^V'\7OC5>Z1_P4%\&_LY^%?
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M?AGKGB33=<E@T;XZ?#;PC8FYN-9L20D.I6UHHR]S$<9\L@Y5"=L;W3G[EHH
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M?)E%O$(6*&1KI<.H5B/L2SO+74+2._L+F.:":-9(9H9 RR(1D,"."".01U%
M$E%?*][_ ,%,'EM_VDO$WA;X'R:AX9_9[C>W&O2:^T*^(]4@MVDO+%%-J1;F
M"1#&S[I?OQMMPV!9^-O_  4@_P"%.?L??!_]J_\ X4U_:7_"U]1\-VO]@_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG)-'[>7[$GCG]H/Q'X(_:&_9R^(]GX/^+WPQO)Y_"6L:E;M)8WT$R[9["\"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M ^)?^"D?_)<M*_[%.#_TINJ\:^%__)3/#O\ V';/_P!')7LO_!2/_DN6E?\
M8IP?^E-U7C7PO_Y*9X=_[#MG_P"CDK0G[1^G]%%%9E!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!\2_\%(_^2Y:5_P!BG!_Z4W5>-?"_
M_DIGAW_L.V?_ *.2O9?^"D?_ "7+2O\ L4X/_2FZKQKX7_\ )3/#O_8=L_\
MT<E:$_:/T_HHHK,H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** *=]X>T'5)A<:IHEG=2!=JR7%LKL%],D=.3^=11^#_"<3K+%X7T]65@5
M9;&,$'U'%:-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
%10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>guycyz0ib1ig000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 guycyz0ib1ig000002.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )= ET# 1$  A$! Q$!_\0
M'P !  (#  ,! 0$           <(!08) P0* 0(+_\0 <A   00" 0(" P0/
M#@X0 P4)! (#!08!!P ($1(3%!4A%A<Q00D8(CA14E9787B4EZ&WU2,R2%15
MAY66Q]'2T]36)#,V-T)8='>2DYBTMM<E-#538G%S=7:!D:6RL[C8"D/C&2A$
M<H*UP><F)Z*CL>+_Q  = 0$  04! 0$              0(#! 4&!P@)_\0
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MY1HUPV2#:MV]KN/>UK.20/\ (@GMU\!UKZ6^G7J[T[U#:\I5NB+KK^&M-IA
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M 'KY-\WC]/LSUJ;>IO<EPURW"56C9I<1/6JC[@M^+?L.6+B*Q$!ZMK49*D1
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M*W'%JPA"<94K.,8[\D>Z!QB2 -78DD  6&FDDGD  ++))/( =:'A3A\ DV&
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M>O0<;%9;4LP2IIVFZBME+7FQ9#2^WN?+4TI[K;8;4BE6.P[,]MY?]\<M;FX
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MX<:1_B-0_F;?]JI[S-J_3<']UF_D[C[E/$?Y7HWZ3>_[/I\.-(_Q&H?S-O\
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MNSJE>\5UG:D0_62(N/O=BJEAUQIW;9>P(>M-)J%2U[OBR3M3UO8K8[+2<5/
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MR"N\MYM0WM#8KDINFT[#1K:S0D)?H&!R4/$CKN$A[H:JUF'2;)-P .68KUG
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M!AWD@^OKR[NE5H>[PYBKK\M5<IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2OGO^3O\
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M R,;)!V*'K-RCX>[4R2RR-:J);8<.<I=@@3%F+)J4D$#N)'^\?;UU2P!!/>
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MQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*^>_Y._^A7_7P_<@Y<C[_D_72NPW1_\
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MS@G4'@Q9RV6C!G_0WS8N+,*"R.25&1S[K@3&GO;;R.[GMA*DPA?:LL9!212
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M<.7>'(E1*%3J[3QI,@-G(XC\@Q7HZ.:->%'4I@=TE#JV&59::4E&<IXI6_\
M%*<4IQ2L/89Z+JT%+V2:)P)$P<<7*2)&<95EH0)E;[V4-X^:==4E&4LLHQE;
MSJD--XRM:<9QKR[@L+2YO;I^SM[2&2XF?&=L<2%V( YLV!A5'-F(4 D@59N)
MXK6":XF;9%!&\LC=<(BEFP.I.!@ <V. ,DBN<-NZA7;CM2H:GN-NG-?2FQZU
M9K;1-;UQ$G&$3%=JS@"97%LO0+6,^OW!)#TW-5CI&+2J/%DG&TR28H]]'G4T
M^M:]$]Y=7%QI>F$J(]+L9C!<&.7)0ZC>Q8N&DD3^,M[9X88=PC=I7R:Y1Y-1
MU1#/<2S6-F2-EE:R&*8HV2IN[A2)2[#DT4)CC3(5B[>=410F\^EAFL5"[1;T
M5ZAO^W#M+5>>?JDF45-7L*PS%9>RX89'$22:^[*PABFKA(.(KSP;\?)>L_1)
M(-Y^B'AZRMGD6+3;59$C$\CO''),5*JV6EEWRN^""59R^<\L@TCTJTA9@EG
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MJS8;[#OQASY0EA?BF829LT5-6;XI3BE.*4XI3BE.*4XI3BE.*4XI3BE?/?\
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M6MV"CXL<-^+F)?0J:E#>D+_DJP [L5J6X>MA_>UYJ-H.Y([KMHQZ MVER0/
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M['Y*@G )\*XCW;?U6ONQL0FR=AP,C?"))B/"ISTAXX.KR4D(F1C*E'!JRN'
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ML=!RSW]WT=>7JS5/+.<GGUQRQS^7('4?JK;M/ZFS&/6FT7ZLMLR#VT9N_P!
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M>_I(_P G;:__ +BN;'R?C'\Z</?T/J'^V*X?WY_N9?\ ZO\ W:?_ ,:'!O\
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M(+9'NA!(/-FJ/4JY;"!YR8J> (^DV0Z!4B(S%VN" E8J1LB 9O?RJ1(1*I.
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M;988T?LEEEEI"6VFFFJ=*H;:;0G&$H;;0E*4(3C"4IQC&,8QCEU !M   &
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MYR O:2LJJJJJ@)%#&JQ0H-J*"69MYI^GPZ?"T<9>225^TN+B4@S7$I !=R
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MM2OLKMC/;V8Y?ROXR_+D'Y>7=6MPW@?8:]H'5&Y)1:6H_5%MPM6<8PN75"0
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M4$%H9U 60 AE(1U\Y #!%WB_.A)6F[OU>6Y 2HR@9ELJO.7S7DX-XT+3G)P
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M4AS;Y2[#4Q9:1VEK5T"-?G8PB.;.,:#EGBW!A5$8>>;&:<?6A"DM(4O.,9#
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M@X]3Y@:YRA>>)G!DV9GB:4)@;A'-]\6,-@B($C# E%SUN9DR-TBD^<!]\4L
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M9YF=S6G35;72AY%HYM]&@PJJD4D4>H7(SA9;N[)%S/-(1G =8E/F11JJBMM
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M_2#BA&/MX=?2/EKO'RS5^G%*<4KY[_D[_P"A7_7P_<@Y<C[_ )/UTKL-T?\
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M3EGA86TI0X$#&!N(+CS9!)SP49&QSZ\.DC1H(GE"LS^"0>?FG/K SGY.OS5
M^,,=,BNB$UL#K"%WC-5F!T%K*6TT+52C:[<Y/;TA!FSLXB4B&D(/>$HMB)@2
MV@"3.]9>J9 I.4.GA7@M(+D>[9Y8[\Y^WV]N.6;O//3E]O1R^V.AK</=CU2?
M6%U#_E'V+_V\<BII[L>J3ZPNH?\ */L7_MXXI6P=/U+M=#UOF'NXT*%9Y386
MYKW)1]=ERY^(C$[.W'?-D 18LT;#5XF37&1MK# +,7"QR7C!R%-#X9\M2I/,
M_(![!BH'+VGYR34U<BIIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*^>_Y._^A7_7
MP_<@Y<C[_D_72NPW1_\ .E]+OVNNDOQ:5GE#=3ZS]-0O0>H?15BN14TXI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE0[U!_P!9#:?_
M $)G?\R<YS?&'_!;7_\ HN[_ .Z:M1K_ /@75/\ 0I_^P:Y!]3-$V!L+;(]?
MI-:F9"3/Z>K2!3;LW;#*Y!:CV8=<H5FL;-?%P2.-)R=43AZ4:5%-2-KP*,[!
M@1K\-9)X@756DD<< 9W4 3H70H&:6,1G=&.1(#'ESPF>98,J@XD+*L:EB!AU
M)7:"70+YR\^@/(<\#GG((&=JN>AKO(YZB+%',.R<_L'<NIYZ)C\W24C7;+HZ
ME0^C%736(9F3,!51BW%5+9H'JM*8Z+FBK"\FPG"15BDSF(2>,>3J3M6."56/
M9AMD[F8)+C&6V!HCN&6 7S02H%0'7[V.@5'!.,X=C)M8^.T%#GF1CS1D"L13
M]$7N/LNC+7*U<1D:C;%WY(PT 38@YV4T]1-FQI;=.BQCBREB2S,*X$(R= P4
MA( 5M,N-6ZP])UFO#&XEYT*SH)">TC@#,$($TD9&\XP"">YF"EMI9L,Q!EG!
M60 Y++&"2,!V4C)[R,CF"0"V"6PS$5%>L>GGJ/IFK-I0DHN1G;G.ZUU_5)'W
M0;$85"[#O,3.2+FQ;]%(J1%8GLR-@@37UQ]CN-UJL[>2WHVK; BH:O0(TJ_=
MDN+9I8BN BRR,,1G,<94"-#N##:K 91$=8P"T99F*BIGC+*1R4.S#"\U4XVJ
M=VX<B!D*I"CFA+$BO3DNF[>SNE/<AZJF"CX[=%XN-3K8]QIK4?%U2Q4M8M9C
MIZK(5#5K,+&6>2D2BX>D7JJ6'7DIX+!K^TV4H!IZ8J%S )M^X8,*([;),LZN
M=[*W-]Q7&&D1ED!*R*N3MGM(]^X8!V!2VTY+ \R#S.2H&"RD,.3!>Z29O1N^
MI3?M0OLC*'D1XKNE3&9.L70*/@*1'T\=&=L5'*;1'S5V/C+N8F3[,Q@9:[]&
MV!J-N<[5"ZS#3S5I;B 021@ $B<89"6<OGLG\TA 4&!EB.S*Y0/N*U0'01E0
M!GS@<KEF)/F'D54;1SY_%(RJMDBNC^H_Z^4A_>H<_P!+PN86@?\ "J7_ /!]
MO_>,58^G?X=?_HD_^,6KA\]$KJJ<4IQ2G%*<4K2=E7</6>N;_L>1")DH_7])
MM5W.C@E-(,/#JD$?/%!"+?4EA!)3 "V&%/*2TEUQ&7%81C.<!S('C2HH:VAO
MEYMMU'3,;E#J$.(SG;VO\9\*TX4GOCO[,]LX[X^+E6%_&_U349SW'YOKK^_?
M,WW_ &LIGWW]?_O\87\;_5-,GP/S?76%L=MW1:H":K4UTOF$Q,]&&Q$BSC<&
MOTJ6(>.X,_Y:_;EMU*',J9=QCQ-.I0XGLI.,\D!000W0YZ'NH>8(P>?J^NN?
M,S5KOK;$=%;-KQ58+*;PF-D"2PI&)DFT^+#;&)V-=?BLS#+2,8-!R^V]E?8A
MEM3#[?:]D-DKS[R,=#]7A^XU9((^WV^7K6*P#%I#=&P& F/?RXX^/@<? ;V7
ME>-UQUK",,.9=7GQN*6G/C5GQ*SG/MY%16Y:_H%@W!,(KE3;=1#I=0Q9K@AK
M.8>O1V?#Z4V,7VP.?//#JRU&Q@JW%H>6DDS(PC+KJ1(7F>H/(=Y(_5G&?FYU
M(!)Q\_A5U=BW#J%UC==1:]TIT]P=ZU(X(J'L-Q,V /"OUX:)KDEZIAU168YT
MJ'PLJ/CT^Z=]FPQI.'<Q;P4>><*:W9 !R2V#ZOG_ '?+TS5WF, +R]?K^V?$
MUMWO@=1W]KI6?OZQO\P.,+^-_JFF6_%_UA3WP.H[^UTK/W]8W^8'&%_&_P!4
MTRWXO^L*WK3^Q2]H4UVR2-;54I4"W7^E3,!F79GFP9G7EXL%&E<C2XX@#1XA
M)U??+$?P$,K([[:5M86G.<P1@XSGIS]8S4@Y[L8.#4H<BIIQ2G%*K[N#5TW.
MR@%]HOH2[=&1RH>4A)!_T,"WU]+[A; "CO XF.F(PITA^&D'6U#9R64&=E(K
MR76.1XAT.ZN;B+5]*[(ZC!";:XM9G[.'4K,.TB0F7!$%S!(SO:SLI3[Y)%-]
M[?<FBU73IY98[^QV&[CC[&6"1MD=Y;ABZQE\$1S1.S-#(05\]T?"MN6"%R=H
M&5E@_5>TQ2V_F7F1Z>7,#I<Q[%89D81V0CBF_%C/@=8)5A:>RNR>_AQRQNKZ
M,[)M X@20<F5-->Y0'OVSVKS0R+G.&20Y'/ S6H-S<+YLFEZHKCDRK:-,H/H
MDA:2-QX%6(-?SZZG/K9[9^]Y8?Y-R/+;G\Q<1?T-=_U*>52_FW5OZ/G^JGKJ
M<^MGMG[WEA_DW'EMS^8N(OZ&N_ZE/*I?S;JW]'S_ %4]=3GUL]L_>\L/\FX\
MMN?S%Q%_0UW_ %*>52_FW5OZ/G^JGKJ=^+6>V<Y^+'O>SZ>^?BQW6.E./^-2
ML)Q\.<XQ[>/+;G\Q<1?T-=CYRH'MY4\JE_-FK?T?-^L5M]3UA;]@3$4?<X$F
MGT.'D!)C,%+NBN62WGQSZ"XP:2 "?+'A8 4YIHPL4LAV1DUCLC+%%%6ZM6PL
M-$U'6+FWEU*TDTW2;::*Y\DN6C-]J4L+B2!)X8GD2ULXY5622.21IIRB(T<:
M%C61;Z?=ZA-$]W UG80R+-V$Q0W-Y)&P:(2(C.L%NC@.R.QDE*JI15)-15O[
MITGHR?G+93ZVNY4VR2*IZ9K 0C4A+U^=<)0<6;'P[B5*EXLN2;1*-, )=D(R
M16ZL<10Z&G&O3E<$ $X(Y9/0CTX'7N]/+OKIV4YR!R\!W?;T56!+*2I1C#5=
MG"Y\=HD$4=JI3C\ZRV:X*X6"PQB+R<R@M\$)1(Z<(;?=#%6]A61VE(JQW\O7
MD>&?'I]NM4<^GS>FKH=/&@K&S9(_9.PXQR";A4O.T^J&*:7*>L"F'!E6"?9:
M6ZR"X*&\\U%1:G'#&"'W##/17QQV5T.PQ@<\]3Z/ ?/GNZ8S5Q%/4\O1\W/[
M?OOARU5RG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2OGO^3O\ Z%?]
M?#]R#ER/O^3]=*[#='_SI?2[]KKI+\6E9Y0W4^L_34+T'J'T58KD5-.*4XI3
MBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI6HWZIMWJE6BFN
MFKC6[+"'PZCVV$DK#P:PIG!"1U.LI?RUE6%^5EYKS,8RGS$=_%C7:OIZZMIE
M_IK2F 7UK-;&94#F/M4*[PA90^W.=NY<]-PZC$O[47UE=69<QBYADA,@7<4W
MJ5W;25W8SG&X9Z9'6H"QT_7U.,)QN(/MC&,8_P#Z;!?!C';ZJ><H.$M8  ^$
MD?+_ .Y(?VZM+[R:B/\ Z83^C8_VFOWY7^_?7B#^]L%_.GCX)ZQ_QDC_ *$A
M_;J>\NH_GA/Z-C_::?*_W[Z\0?WM@OYT\?!/6/\ C)'_ $)#^W4]Y=1_/"?T
M;'^TT^5_OWUX@_O;!?SIX^">L?\ &2/^A(?VZGO+J/YX3^C8_P!II\K_ '[Z
M\0?WM@OYT\?!/6/^,D?]"0_MU/>74?SPG]&Q_M-/E?[]]>(/[VP7\Z>/@GK'
M_&2/^A(?VZGO+J/YX3^C8_VFMRUMIN6I-N/M\W=TVHPNN>YM@=FLL5]H8;,F
MS**>4IJ6DLD.9=9PC"<I:PE*LYRI7;&,;'1>'+G3-1EU&ZU0:A+)9>1(BV*6
M:HAG6<L2MQ-O.Y< 87 )YGE65I^DS6EX]Y/>BZ=K;R95%LMN%3M1*2=LLFXY
M&.@Y'K4\<ZNMW3BE.*4XI3BE0#U7_.M=2G]X'<?XN['R5ZCUCZ:5.8'^T0O[
MD&_\E'(J%Z#U#Z*]OBIIQ2O1DHN,F0GXV8C@96.*1Y9($D(.<$0COW\#XI3;
MK#R.^,9\+C:L=_BXI42XZ=-%X*],QJRF^;X_,\K,2SD+Q=^_^YV>\?X?^!Z-
MX.WL\/;V<K[1^FX^W]?6J=J]<?;U=*Q4AO/5E/=75ZP'(V%<*I0A$1KBMYD(
MN&<;5G"@W#A\ 5L1]"_&EP)J1](8<2M+S#:O9GD[SC#1[:>2W@-YJD\3%)DT
MNU>\2%QU26YREHL@/(Q]OO4@JRJ1BM/-KUA#(T,7;WDL9*R+90-.L; X*O+Y
ML"L#D%>UW*0=P&*R-:W_ *]L,F)!ENS=/FI!U+,;'76&)@/6;ZO8D>.DEY(A
M#"E*[(;#8E%ENKSA+3#F>_:JRXMTB[GCM9#=:;=3,%@AU2UDM.W8YPD$YWVL
MLA(P(TG,C'DJ&JK?7;">58',UI/(<1QWL+6_:-^+'(=T#N>Y%E+GN4U-G.GK
M<4XI5=^F7^H>[_;$=47_ *B-F<D]?D7Z!5*_A?\ */ZJL1R*JIQ2G%*<4IQ2
MG%*<4K'2TO%P,:9,3<B%$Q4>RHDZ1D260PA&$=O$Z02^M#32.^<)QE2L>)2D
MI3W4K&,J56B0ZPM2"E*8CA[K8ADJRGUI"U9_U<O&,]E+8<EB8DDEK&<9\+HP
MKJ',?--*<3G"LUB-CX#UFJ-Z^FI;U[N'7NT$$)J,\V5(!-I=D(,X<F*G@&U*
MPGS28F0:'+R/XU)1Z8.A\++BDH22I><8Y!4KU'(]".8/J(JH,#R[_ ]:DWE-
M33BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7SW_)W_ -"O
M^OA^Y!RY'W_)^NE=ANC_ .=+Z7?M==)?BTK/*&ZGUGZ:A>@]0^BK%<BIJ"KY
ML*PUVQ$1D=D+ K8XKJ?/&RZYXGFL+7W7YJ>^/%GV8[>S'/'>,N.-<T/79M/L
M3:"WC@MI%[:W,C[I8@[9;M%R,GD,<A7H/#W#>FZEID5W<B<RO),I[.78N$D*
MKA=I[ASY\S6F^^];_IHS[BS_ !_.5^Z?Q/XZ?^B'^VK=_ S1?"Z_2/\ R5Z0
M^\)XLJ0!$D:^4;$NL,2@8Z&7BHUXH9HT5F0';*4\&Z2&^R6PV0AM;PSS3[>%
M-.(7FH^Z9Q4JHS"Q59 2C&R8*X5BK%"9<, P*D@D!@0>8(J!P;H9+ >4DJ0&
M N02I(# , F02I! .,@@]"*]WWWK?]-&?<6?X_E/W3^)_'3_ -$/]M4_ S1?
M"Z_2/_)3WWK?]-&?<6?X_C[I_$_CI_Z(?[:GP,T7PNOTC_R4]]ZW_31GW%G^
M.X^Z?Q1XZ?\ HA_M:? S1?"Z_2/_ "4]]ZW_ $T9]Q9_C^/NG\3^.G_HA_MJ
M? S1?"Z_2/\ R4]]ZW_31GW%G^/X^Z?Q/XZ?^B'^VI\#-%\+K](_\E/?>M_T
MT9]Q9_C^/NG\3^.G_HA_MJ? S1?"Z_2/_)5CZ\<_)P4/(D^#T@V-#*?\M/@1
MYK["'%^!/?/A3XE9[8[Y[8]G?//>-$O)M0T?2[ZXV]O=V%K<3;%VIVDT*.^U
M<G:NYC@9.!RS7F.I6\=KJ%[;1;NR@NIHH]QW-LCD95R<#)P!DXYUF.;2L&G%
M*P4S:*S74X5/V&#A$Y3XDYEI4&.\2?BRG!;[.5=^W;'AQGOGV8[YY<2&67^+
MBDD_Y",W_9!K(AM;JX_O>VGGYX^\PR2<_P#V%:M+7NO4R%^#.P*QG.,]NZ))
MIQOO\']-1XF^WV?'V^/OS(&GWIY^2S?*C#YCSK,&B:N1D:?=?+$0?8<'YJV>
M&O5*L*TM05MK<N\OV)'CIJ.+)[Y^+(S)"WTJ_P""IO&?L<LR6]Q%SE@EC'B\
M;J/:0!\]8LUC>VX)GM+F%1^%+!*B_P IE"_/6U<LUBTXI3BE.*4XI3BE.*4X
MI3BE.*4XI7A(('$9<)*?9&'93E;KY#J&66D8^%3CKBDH0G'QJ4K&,?1XI4;2
M&[-/13BF3]HT =]&<X6QFVP:WV\X^'#C+1RW49^PM&,\G:W@?8:C</$>VO+&
M;FU',NI8B]G4(PA>>R!FK9!^DKS\'9 RCDOJ]OL^9;SQM;KM./'!IN7Q'MJ1
MVW6WFT.LN(=:<2E;;K:TN-N(5CNE:%ISE*DJQG&4J3G.,XSWQGMR*FO[XI3B
ME.*5 /5?\ZUU*?W@=Q_B[L?)7J/6/II4Y@?[1"_N0;_R4<BH7H/4/HKV^*FG
M%*<4JO/4/8I(6%K5)AS2(TO84T1%2,D(XI@P.KQ<:1*V' 3Z/FQS)!IL6':?
M3CQL-R3SS:D.MMJQQ_&%W,MM8Z5;R/"^LW+V\\\;%)(K"W@>XO.R<'*2S*L=
MLK@$HL[N,,JFM%KL\@BMK*)VC?4)FBDD0[72UBB>6XV,#E7D55A##FHE+ A@
M#5 HK?@(VXI_0U5I-?''H=CJ]3/+,V-4:[)+Q/TJL7QV0KM%*PJPSP<;#6AE
M+SHR<.'2 ,DVA65,K=SJX=/AM;.$0JL,*QMV4,4+=FBH[1[2RC8I+*2222<[
MF))S6+';1P01K$HCC5?,C1"%558KC(Y Y!)SDG.2<FL9K7J'%W-&ZI%O&HIF
MFUCJ'H[=QU?*2,]7+-%SK#U6#NZ*_+(BB6I6MVQ53)(L,<TH @%3$%.81-BR
M( 8YZ^TV":&YMYC'<Q(>RN(F1AR+% ZD_BN!M=65T8HRX/,1<VL4L<L,H2:/
MFLB,".C8##([FQA@0RMM( ZCHYT^V:5EZM-5J>-?DY;7]B>J_K,M>7392&7'
M1\S7CCG<_P!..Q$R; !;ZOS0D@!PIW*G'U*5N.$+VXGL;JQNY6GN-'O&L.WD
M.99[8PPW5E+*?PI?)KA(I&ZN\3.V68DYFA7$LEO/:SNTLNGW#6O:OS>6$QQS
M6[N?PI.QE5';JS(6/-B:F=4U#)4I*I:,2I.<I4E1XN%)5C/;*58R[C.,XSC.
M,XSCOC/LSSI3<VP)!N( 0<$&6,$$=01NY$5MS-""09H@1R(,B9!\#SJO735+
M1;%)NR'Y*/94KJ$ZG7DI=,&;4IE_J$V2\PZG"W,9RV\RM#K3F,92XVM#B,J2
MK&<R;JVS_?$'1?\ UT?@/\JJ5GA\[[]%\8_^L3ZZL)Z\A?U8B_V0$_CN1Y5;
M?E$'\]'_ %JJ[>#_ !T7\XGUT]>0OZL1?[("?QW'E5M^40?ST?\ 6IV\'^.B
M_G$^NGKR%_5B+_9 3^.X\JMORB#^>C_K4[>#_'1?SB?73UY"_JQ%_L@)_'<>
M56WY1!_/1_UJ=O!_CHOYQ/KIZ\A?U8B_V0$_CN/*K;\H@_GH_P"M3MX/\=%_
M.)]=/7D+^K$7^R G\=QY5;?E$'\]'_6IV\'^.B_G$^NGKR%_5B+_ &0$_CN/
M*K;\H@_GH_ZU.W@_QT7\XGUUSEZI;R_<-AIH[!B'JG208HXD)AY+HDM:9@=1
M[9A?EJ4T2U#Q3@;8++GBPP68:]GNOR_+RX61D$B,K!B<.C!@0#@@$$CJ"#Z1
MCJ"*@N'YJP9>XJ00?'!'+ET]&#7+*"ZN$S] SL0*A@.Q)2M?C1,:)LVGG3JY
M'9-^JU!KH=AC!?&[5$-F6=!TF3)J4@)F/*'\#I&48Y6"".7HY<N7LZ4(\3SY
M^/=G/,CY/6:F_56XI&U2=GF(2*)I>Q=.V@2,(RS,1%CC\R!5;A[4,.).0)3H
MDG%2<-.#@3<2<V":PMPEDN.]%=CS3)ZY!Z9P1G'@<\L^@],\NZHZ8(/I!'U'
MT\O5[*[TTZQL6^I5BUC-Y9'LM?AYYEC*O$IA$M'CGI84KMCNMGS_ "EY[8^:
M1GV8Y8(P2/ XJ\#D ^-;'R*FG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4KY[_D[_ .A7_7P_<@Y<C[_D_72NPW1_\Z7TN_:ZZ2_%I6>4-U/K
M/TU"]!ZA]%6*Y%354=L_U9E_W&!_FZ>?-ONE_P#"NZ_T6R_[A:]@X/\ \!P?
M\]<_]ZU1KS@:ZBJ5W'6&SI*S;F<@F[/"QM^WITXR>)>J6U54F9+6M?B]<1&S
ME"S4-,QL]$#IBXJPQ9R0RHZ<(%2^J$RI]T-_/1V][9)!IPE,,CVNFZPG9SV_
M;QI>3/=R66Z.2-XI#O>)UW*\0;':\@PK52V]PTEV4[1%GN[%MT<O9NT$:P+<
M8=75T&U74X*N1G8<X-1<%J;J3@Z3=(Z)L&W'YVQZKV)#LFS&W9.PR8%KC-OO
M#:N)KQEAMDDS79K&I",^DS45Z"Y.9&'-NIDI:TK)<S6O]'EN;=WBL!%#?6LA
M5-/CB1H'T\&\$RQ6Z&:,WXY12;A%DK;+'!YHQEM;Z..94DNBSVTZ O=-(PE6
MZ(MBA>1A&_DQYNNW?@&<M)S.U06H=WUNVSCL'8MIO1)<SO:O1"[9N.U6Z,!I
M4K3(8S5I21+-;IQ[!XE^Q*JCK*\*3=HT1UZ+,DVJVV  S9EU#3)H(A+#8B18
M]+FD$&GP6[O<I<2+?*6@MXQL:UV!X05MG8!U0S%W-Q+:\CE<H]P5+WD:]K=2
MRJ(6A5K<XEED(83[MLF#,JDJ2(\*/4#A.HZ^5N2#EX;;=$;++Z/85]@K8$+#
MV1^-K5\8<ZC9.+F*5>9(N':DZRLP.8D0I>.GK$"QZ1"*)><CGU29-(M9E9)+
M"Z*IQ!("MK))"))K5O>A'CN+5%D*3!6C1HWBA8[90HWK0)?3Q,'2Z@).EH09
MT20B.<&^9'AF?:&C+*[*RO(H\S)VFM4V+K[JJ32*+!5R6V2Y'0%BZJ(\Y$3:
M).?V 2,1M8U/2Y+R-C3OK3TQ-QH&K&"AB"[;?;0/F2E:Z3L:HS) \A+UV_:7
M>A^4W4LL=F'EAT-U,D*16JL+!??R-(3I>H1QNU\5*K;VL#;(YELYXU*1RV9X
M-3[&%(VGVI)J2G;(TDY4W+>]KF3RZU=PML""99Y?.>,W$3D,\?1BN,S ]>@1
M["6@^?8AHMF</;'9$0;,- L(DRT"C+<'&02:E]Y([#CC+.%X;:6I"4JSR,QC
M,LIA4K$9',2DEBL98E%+'!8A< DC)QD\ZWR!@B!SN<*H=@  6 &X@#D,G)P.
M0Z"LSRW5562I>RZVW$Q</(N/1A (0P?G$-Y6&]EAI+6%I?9\>6O'X?%G#[;:
M$=^WF*^'GO7"O'^@QZ;IVEWSS:?/9VEO:&:>/?:RM#$L>]9HMYB#;23V\<:)
MG':'K7E^N<+:H]Y=WMLL=U%<3RS]G&P6>,2.7VF.3:'QG [-G9NNP5+XQ0IK
M*" R&"F%^U#X[K;S2_\ \KC:E(SV^/MGV<]0M[FWNHEGM9X;F%QE)8)4FC8>
M*O&S*?D-<7+#+ [13120R+\:.5&C=?6K ,/E%5!N6S;'=CSP:W+%5NF!EDQ[
M9T4YZ//69P-Y8Q1C<EC&7(B'40TML)(/ER!C2%$NE,-O-CHZ&"UBMU5I4$L[
M*K%7&8H=P#*NW_UDF"-V[**3M"D@FNOL=*MK*..2YB2YO71)#'*-UO:AU#HI
MCZ33;2"^\M&A\P(Q!8U&"W!K1NX$04;4+C*@LW;.NY3: ]2)F:8+L+!:8QVM
M'69Y\B=)(&FU)KLG8!XPRH1%G\VN2]C!G!3 ![S7+L=I=]N=OFY$:G.-H5<*
M.?+DNT'D3GE6<U_*Y$9>7LU;LQL&R!6SC8%3:HPV%)5-@?S2P8$#,5GJ(U?.
M#64F4.-UV)5(6I6B1?VB G7P_N.OQE@CZ3:L.V%X1H&+LQ]5L(00,PJ+L(9<
M6Z/,P<8\^&@F@2 Y))& "2W+D<@'GW'!ZX([P*LB>,[BQ*;0K$R^9YKE@C>=
MC 8JP ;# C#*.6=/OW4-J> .L[!M0M%VA*51(#9MONM+K<5:*U7J19&;&9&6
M+)XDLB7E!U1M4G)17N7C9DK( B7AFWW'V&G*A<-&3M>084,Q4G&TYZ\^8P">
MAJL7[PD['FVI&LC-&V8Q&VX@D;_.&$8X56Y#H>56KJ][L](8%E("5-M%24PT
M6]690UV1\<6XVE[#]8E2U.FA$('5YHP3SY$<5C/E>2PXM#R8DAANN3JD4I/F
MSH H)/3M44!64G&7 #CKEAD51<6-EJ(VRQQVURW\7=PH(P7/Q1<Q* CH3C=(
MJK*HYY8#:;L14Q'S,/'SP!"78N3CQI00E6<-I4$6.@IIU?BSCR^S*\*<2O.,
MMYPI*^V4Y[:-XW21HV!#HY1EZG<IVD#'7F,#'6N(FB>"66&4;9(9'C=?!T8J
MPSW\P<'OZUY8R4C)N/$EH:1 EXL]E) ,E&%CGQYHZ^_@?$,%<=&(95VSX767
M%H5VSV5GMQ)')$[1RH\4B':\<BLCHPZAE8!E/H(!JW7O<HI3BE.*4XI3BE.*
M4XI5;.H/>).KAHNO5@00^\60<DH-4AA:XR B!G$#OSD@PTIMTQ:R7,"Q<>AQ
ME)1*'W'WD,"+;?K10>9Z#YSX?6>>.7+G5+-CIU/S5SAM4O*6A9$YL6SR5G6,
MAXX@FQ'X1"1S3+:G2'18="F(&(#9;PMQ>& VD--X4IQS/92LW>70# ]'7'I/
M4X]-6LGO.?7S^FJ_P^_M8EAN&C1%QC(YZN.6VME%:VM0+5VKS9D5'X.IC"8?
M)<P\^9.PC8<1D46;-8E@9 2->C7%&(;L^//GSSZO;^KIRH1CP]OV^W+KRK<X
M78NM[5$!2CDA%QB)">E:HW&6X=BO3";1"2+T3+5U<5.)&)=E1#V%LX8&00@Q
MI3!@#I8)0I+S/I[\=>_&,>O'+U4P1]/R>-2[5YRT4(E)M"LTM574+\Q8 A"R
MJ\8KQ=\HD*X8IV))0K'B3EQL=@IO"E*8):7V5@0",$ _,1CP/T^- 2.AQ72?
M0FYO?;@I)N5!8B;C5WA!+)'B+6N/(0<TZY'3<2IU2GDQLHD8I*1B%K(!*%)$
M=<>2VT2_:==I&.A&>?4>(/I'SU=5LY\1X?34U R\5)O20\;)Q\@_#'YBIA@$
MT8MZ*D\""GYC9)L=UQ8)^ 3@C,AE):(P(8*1EOR2&5KHJJLAQ2H!ZK_G6NI3
M^\#N/\7=CY*]1ZQ]-*G,#_:(7]R#?^2CD5"]!ZA]%>WQ4TXI3BE5[ZA:W*&P
ME;ND($1*'Z]FGY8Z+$;4\8?692.(BK$@ =&/&0>$P\-+CCISA9&(UT9I*WGF
MDYY#B^RGDMK+4[6)YY='N7N)8(P6EFL9X'M[U84'-Y8D9+E$R"_8%!EF53HM
M=@E:*VO84:1]/F:62)!EY+:6-HK@(.K.BLLRJ.;=D5&2152*+K:C"6W8.UHI
MR.L<CM.SP=O1*O1\:0]!KAM>4_7C,?#R.&,G,CN!U!L\AIUU#[$A(GL*0A./
M!C317L=Y;6[V\JRV_9D1R1.2DBM(\A)'<P9RK*0&4KM8!@16%'<)<11O$ZO$
M4\QE.0069B3SQD%L$8!&,'G41ZVZ>A-,1FJ2KSMN8N=:Z>J.U2]71<A 5VM1
MD(RU5PJ2W/2F8IA^6LUO]R@A%>CG/3QP<,3LYY<$1('"$!7+[4X((;FXF[.V
MBD;M)Y&=F)\XN(T!//<Y&U%5I'8*JY/(S<W<4,<LTI2%"2[L23WEMB@\R6;&
M$ +,P &>AZ/]/U7EH6K3%BGPGXR:O]A?M+D64GRS8F)P !#UZ..;[_F1R(B,
M&,-9SV<&+.?%=QA;&4IW/"-C<6UC=7MY$T%SJ]Z]^8)!B6WMA##;64,H_!E%
MM DLJ=8Y)6C;FA SM"MI8K::YG1HIM0N&NC$^0\479QPV\<@[I!#$KN.JLY0
M_%JF] H=)E*E%2$E4JZ><5F0<),+AP""7W/6AJ?&\\ZPIQQ7A2E/B6K.>V,8
M[]L<\ZT?2-*GTVWFGTVQFED[9GEEM87D<^42C+.R%F. !DD\A7+:=IUA+9P2
M2V=M)(X=G=X49V/:/S9BI)/K-;C[VFO/J'JG[ QG\FYL_>+1?S3IWZ';_P!G
M6;[UZ;^06GZ/'_5I[VFO/J'JG[ QG\FX]XM%_-.G?H=O_9T]Z]-_(+3]'C_J
MU!M]L^LJ=:3Z7 Z!G=J66!J<?>K;&:YJNO7G:G5IDZ=CH ^25<K33429UA+J
MUH;A*[5E6&RFXKYZ_5#:'8]1U^/AO174.VFZ5$K,40R6<7GNH4L!L@? 7<NY
MGVJ-PY]<5KH^FL 3962@DJ"T"<R "0-L;8QE<EMH&>M?MCMNGJQ9:;!R.EIK
M$3="*3'!W9W7\#$UB-F]B''1U4KT@+83H:Y%SKY8243D=7*E/.4M@T$Z[YK@
M#KI3)>&M'978:9I64[0E/)8"Q$0!=@5B*!0#YI9EWX(3<>5!I&FL"1961(!.
MT0QDD#JW)",#N)(W?@YKPUG8W3#;A+]F$CJ(38-:F[5$ME%P+3G+T UJ"Y3M
M(LTDJMC'OEM1ADI!I,A2S%">D14[6RI!$8[,,C)EN&=+3LRVCZ?ME$15_(H=
MGWY5=1N[+J V&QGF& SBAT?3P5SI]J VW#>3Q[3O4,.>SP/,>(/A6@Q.]M$$
M5*[6^SZ)L&OA*1J6+W>3'6JOZD.D)G6\NW*K#FXI^C; N4&$]E4.8VY%6F9K
M<HG.,/8$4*V20/6W"VD!HU73=)D,DIA!6SC 61<9#=I;H2/.'-0P]/,9J.BZ
M=E0ME9-N8ID6Z@!A@D'=&I/7JH(]-6,J$9HG8,1[H*('K&YP7I9(&9BKMUN>
MC4G!Y3@H-1L9@D=)0^5MY>'4YAUM+C:EHPEQ&58S\/Z1&=LFC6"-@':]C IP
M>AP8P<5;.DZ<IPVGVH/@;>,'V%:VGWM->?4/5/V!C/Y-RGWBT7\TZ=^AV_\
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MER8S^-&CGLHV\'2,,.YA5A^=+6XKG7K+^H>"_P#RR'_[5.YY!H/^";3U3?\
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MCI8@]]MP*.S'Q4?B32K)V:HI5(D*(&;>V"[R$LP50?.<@8484 <SDFRS;MH
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M:RNE@(R59;9I>\KF@ZZS9358PJ6LM&L%:L%.EIU>&WIP(2#E2V_6!AKCDG&
M1WYR.X']_7% >9'>/G!^KH:MYRFIK&R$S$Q2<JDI($'';OC!13+*U8_X#:UX
M<7G/Q80E6<_%CFOO=5TS3EW7^H6=F,9 N+B*)FZ_%1F#N>1P%4D]PK*MK&\O
M#BUM;BX],43NH_Y3*I51Z6(%5(N.W'X6<RE^\BPX$Y95P570?) QR9>1,481
M&0T0@[++A\D4&(0\+'#8=->8%(<;94EAW*?GO5>+^(IM5U5M+U>^DL([N[EM
M^P!,<=BL["*3'9;DA5&C 9P -RACDBO5[+A_28[&Q%[86ZW300)+VC89KDQ
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M(%;7[OKC]4!_^$W_ !?+'PSXI_/=[_*3^I5SX.Z)^;;?V/\ UJQ<EMJ6A1Y
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M8+2XFC)6$!@'CC925/(@'(/(UZOPG>V<.BPQS7=M%()K@E)9XHW ,I()5W#
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M[HW\JL<Q+$J#RV,)B Y@WIVVR0PL2T32*[1L=R%6YUYH_IFHT9:I>YB:S/\
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M%B)R&F+,TI9VE8!G=RSLWG%LDFI#BZ7(PL9'0\76I4.,B01(V.$;C9#+8H(
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M4VS.9F _'ET0A":)ED:%DBD$,C E)3&)-AZ!MC%0W?R) Z<ZJC*"0-(G:(I
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M$E) *(E(B+-GFFSCWW  9'7\FF2$P<BJ"\TRRMWMD\@NF0ZR!<S:9'-),X2
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ML@&ZV]Y_)P6 8,1Y6J (1N#*L@7: XBJM::W]2-34NGT)=AK\Y#=+74=6_\
M9&_>N&XS=-ILVKI'6*W39>>G?-D618^ZK@IM*)*%JS:S&'EB,R#8)V;-J.E7
M-_<W%T(I8I-;T>;S+7LB^FP0WR7H"QQ180L]L)8O,DG(4@,4+ICI:7L-K%#;
MEXV33KZ,;I]^V[D>W:W)9W<E@%FV/YR1 D<@P5LC<*KN(O7D3"4&B;T@XPO;
M;YIH%QW9)6W8494&]9NCMD/R$)U#46S$5Z1V!CT1BO\ RPY#T4>XBW%L$5I:
M:U$T6\^GK=R275UIDKK8!5:WTV."T>X-X"5"2:3=0+*EJ=QE]Z '4&W4K,.V
MDJEBNV@1((KR-3=%F66\:2=8?)B,EDOH)"AGY=F+\E6^^X,?WM-29U/U%*IA
MLW(Q-Y>W;8/D=4#JTNR#;&CVVQ.H*"C)M^5 ,\%W9BT6F4LD\*?"7@ $J.;<
M$FGW;1%X?[260;[21<K&DEJ--AXNDOEA:S<EM)EDC",N;8R&".&(K);.RMAH
MP(7QYEI;:_[(NRS&\?0H[9I!<+@7R*Y=3]^"]JTD@9)U4J-KDRKD;I??JF[L
M]0:YEL?8OJC.V094:TIV(.G3K.B$:C'C#Z81K+W8I\RY.[)0>6W)>]X_,XD"
M@9Q-V17QUP8>O$^F^](C)L^T\A:-H/)"=0.IF_+I<B]\GY6XL]BE/*Q'M5HO
M)C*>U;*[*[\M+XGV>4AA)VX\E\C\E"-$;?M<]KY1N;<8"VXAQ-V8[-?>Z=]<
M[@I-A@3;K+7T]B?U0KW=9N.RI.^AB;1&NCKT=B)C):T3HD'E%7/)8?S4Q8^$
M/&$ :DW"9 ,926J7FGW*,MLEJC1:@ODWD]E':LUDUNH<R/'!$TOW] 0)V:12
MSE J,:6<%U"RM,T[![4]MVMPTX%P)25V*TCA/O;$'L@J$!0Q+**O[[S_ %<_
MVY,1_DU4O^>7/K#*_B_ZQKPRGO/]7/\ ;DQ'^352_P">7&5_%_UC2GO/]7/]
MN3$?Y-5+_GEQE?Q?]8TI[S_5S_;DQ'^352_YY<97\7_6-*XE_)C*;N"K?*Z>
M^CND/:_I_ON^H_1=90>OO4'HOO8>L_,]4S,MZW]:>D1_A](]'] ]7*\KS?37
M/+K0@YP,=._/C4'/=CY1G]8KO3T?_.E]+OVNNDOQ:5GEMNI]9^FB]!ZA]%6*
MY%33BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5H5DVEK:GN+8
MM%\J4&4C.<*"D9Z-8D.^/AQB/41Z:K./CPEC/;V=_AQR0">@-02!U(K1?EG-
M#>/P>^5"9SW[>/#,KEKZ'?S\1_D]O^%YG;M[>_;V\J[-_P 4U&]?'YC]5;O7
M-KZRM[J!ZS?JC-%N9QA (,_&NR*LY^#'J[)"3L=\^S'<?'?/?&/;C/(*L.JD
M8]'+QZ^JIW*>\?1]-2!RFIIQ2G%*<4IQ2G%*<4J!>JGYU_J0_O"[@_%[8N2O
M4>L?34-T/J/T5-<5_N7&_P!P!_YNWR*FO?XI3BE.*4XI4 ]5_P ZUU*?W@=Q
M_B[L?)7J/6/II4Y@?[1"_N0;_P E'(J%Z#U#Z*]OBIIQ2G%*BW;NP7]>U=HN
M+$8D;//R8U<J<<2I:1'YHUM]_P!*/RUGSDQD2"*9*R.6_"M8X>1VW&W2&UXT
M/$6KOH]BKV\:3W]Y.EEI\#DB-[J57;M)L$-Y/;Q1R7$^WSBD90%6=6&LU6_:
MPM@T2+)=7$JVUI&Q(5II QW28YB**-7ED(Y[4*@@L#7/:RWC1H]W#J>Y-SZY
MG]MRS\8T-5M@W^JASSY<^ZAB'!K6NI&78Q'CRI+B1X0&,ALO'K6AMMTU]>5*
MX4Z&;[-WJJW&MW!W,]S>1M+;QGJZVUJ ;2UA4D[4CC!4'SW8Y:N=]ZQ<9GOA
M)J,W-GFN%+PIWD108["",<\*J@@?&8\S7L:^NFGK-*2;G3CN+7R[? MMER8F
MKKU6[-'LMY>4RRU<*C 2Q\>]%DD-J&4HT$<A+B5>AELD-X[/>6336%SI/;Z)
M= Y1X$>.SG(P>RNK)@+:XB; W#LQ*OQHY$8 T][3:'MK#M--FZJT09;>4C\"
M>V/WF6,XY^:'7JCJ>=="M4W[.Q:DS,E!HC)R/.-K]HBFEJ=:C;%$K0V<R.ZK
MNIT(IMP>2CG%*4M<<<+EQ67/'SOM U8ZSIRW,D0@NX99;._MU)98+RW($J(Q
MYM$ZLDT+$DF&6,DYS72:7?>7VHE=!%/'(]O=1 Y$=Q$0)%4GF48%9(R>9C="
M>9-5.K>N]U5J&$@_>T&D, +,0DUJ\5P=LE#IQ)#;J6759=;PI#R?F',^/';Y
MK&,^S'!6.D<36-K':>\B3=B9 )5U2S0.&E=PP5O.7(8<CS\:YJULM9M8([?W
MM23LMRB07T"AP79@0I!(R#T//QK.8K.ZL^W&J6<X[YQ[+]6,^W&<XSCX?AQG
M&<9Q\6<9QGV\R_(^)OS O]+6-9'9:S^:E_I"W_JU^^YC=7UJ&OV^UC]_CR/B
M;\P+_2UC3LM9_-2_TA;_ -6GN8W5]:AK]OM8_?X\CXF_,"_TM8T[+6?S4O\
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MP+96+-8*K(Q%^!CZ4'6):WZTV*57)B:B:I;7)UB#LM+L=7M=SB\LJ=JUB;Q
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M'EX]?L?55)<8.#S[N1^JI*UQU':8KE.J52F=G6"8EH&OQ$/(VFYUBVA2%BD
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MW1IU,"L0LN&C)!7$-Q/LNKA;A62V:'9&B1F*=6M;:8[6P9,RM,PB82$#*<F
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M?$+0XE*T*2M"TX4A:%84E258[I4E6,YPI.<9QG&<9SC.,]\9YVBLKJKHRNC
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M&R2L-,QQS^Y732P1C>6862X-M$P-S()7$<$NY>QM92J[;B,%9 DJON1XU9&
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MH&,RUPUK)S91DY7UTT4^9J233(.0@L1,;'S!OUC[DGNT:=8:;;\.<43>3K;
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MN&M08"(H]GLU^) 6V3<"KC*3<W8[2;(S8K PC41&L@#Q^Z34!;+*MC'+:F2
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M\1 U"DL#IA@RBI'-DL]PN"6.-[;^$)*HGAEG<B4MN08^*T8 CB7<H"L7<G)
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MD.12I>Z:/ZT,1_TFV/\ C'MG-WP1_P '8/\ 3];_ /?6H5F<.?X*C_TK4O\
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MP,UKPM?TC_R4]]ZH?3R7W#\/_P#F_P#]\?=/X7_&O_T3_P"+3X%ZUX6O\_\
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M@PTA'D$$/-H998.#><6ELEE2\F.SNYE5X;6YE1F"J\<$KJS$L JLJD%B58
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M3ZS]-%Z#U#Z*L5R*FG%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4KTI&-CI<(B-E@
MI2.+;RT6!("L&A$M9[9RV0*2AQAYO.<8SE#B%)SG&/9[. 2.8.#XBE5WG.DS
M3,LZX_'1$Q4'WE*4YFHS\A&"Y5GXVXDE9\*QC'Q('C6D?13GE>]NG(^L?5CV
M5047TCY?KS5>9GIHKL?N[7VM!KQ?\P-NUCMV[GEO%UAR7&D=?6G2D'%"!DXJ
MZ!D@F"[*F'9#! 1!"WPHQ0Y Z$%ME3O."<#J.X]X/B2?MZJCLQXFIVB.C_4
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MBFHVV:]![6B1@;MKVP1IL6MU^#L]1FH:3FH$AY"4O+%29B+46$3A"$GQCXQ
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M99>);B0321$B7B#3DLE1"BC,=JR EF\Z9<L%C+;%M1:;.J*LDT1*1Z/"FQ'
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M0A(P"5# '  Y<N59EK";>VMX&8,T$$,)89 8QQJA8 \P"5R,\ZZ'4+^HZO\
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MVQ1(S8(^D*P7=]HD4J/V),V&Q!:^?@F=67+8.9$F(<[3T#.MS-2<J:8LF4E
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MA"$XYZ_[GFMWO$'"NFW^I,DFH1RW^G7EQ&H2*\GTK4+G36O8U4! +L6HN'5
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M,GFS,?36DN;B:[GDN;A^TFF;?(^U$W-@#.U%5!R Y*H'HKW.956*^>_Y._\
MH5_U\/W(.7(^_P"3]=*[#='_ ,Z7TN_:ZZ2_%I6>4-U/K/TU"]!ZA]%6*Y%3
M56M[[W]Y@>?L$S(-@UJ!"C'7?*B")B3+-E2!8Z,B8J.!:(D):9FYDX&'A(@
M=\Z3E3@X\-ET@AM"O(>*N+.(]/XE?1])>V[,PP2(LT$1V[H.VFDDFD952*-5
M>21W(6.-69B%4FN^T/0=(N]'2_OEFW]I*K&.1QG$O9QHD: EG<E455!9W8*
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MQ/S3*'4,29K3V]/&^B3P]F>(M%$9BBB;^%Z=!*\4*QK%'+)F.>1(UCB"K*S
M=FG+*#&L'#=_'(7]Z-1+AWD'\'O)(UDD+,[HA#Q*S%V)9%!\YN?,YB'J'VMT
M#Z;#D9#?6T=;ZS-MUFC+VT6C84M4+X?:X&M,4<"QTPJF3<=>(^1&J@N:N093
M'0L/PQ4I&R*G19>5;,WO#LVH\42-%PI:ZAQ,;5#!*-%TVXUFUA623MA#=S06
M]Q8Q;Y6$B+>2H"VUP1M4K@:G;6^EH'UAK?2A*PF4ZA=1Z?,Y1>S[6%9I8;AM
MB HQ@4X7<#G<0<ATL=771KU$/0&F.FKJ TU&CPL<)!0-+9MD;$[#?A8H9([8
ME*U]./!V*1PP*SA+DLX,5Y"59,>:(?5XE[>Y]S?W4=2FF&J</ZEP;I+2,+[6
M]42"?4Y48_?!IMG9RW4%K+*"1'>:C/&L0)DBM970*,%>*>$;""-[/4+7B"Z5
M<6UA8&1+!&4>8;R[F2)Y40\WM[2-VD*['GC5BU7KZF(:/KW2_L.$BF/1X^-K
M(0PS7BRM6$(FHS*G'7%?-.O/.96\^ZKNMUYQQQ><J7G//5M&TFQT+3;#2-,A
M$%CI\$=O;Q9+,$7F7D=LM)-*Y:6:5B7EE=Y')9B:\]U&^N=3N[J_O).UN;J1
MY97P%&YA@*BCDD:*%2-%PJ(JHH  JSO-C6)3BE.*4XI3BE.*4XI3BE.*4XI3
MBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7SW_)W_T*_P"OA^Y!RY'W
M_)^NE=ANC_YTOI=^UUTE^+2L\H;J?6?IJ%Z#U#Z*L5R*FJ"]7&N\[3$G:@S,
M>YZ3]+H%KK<]D#$LS"W'7EJKVP:5+&1&2X_UQ'1]MJ\*7)Q&)".5*Q[1,>B0
M!41@MGYYX[N_(>-9[@Q]LGD,4$T6_LS);W=A):7,:R;7[-W@GD5)-C]FY5]C
M;=I]8X9@\IX<BBW;&\IDEC?;N"2P7:SPLR97>JRQH63<N]05W+G(K)-ZCVKL
M:!DXW:=^J!K9-]T':HFL5>F/B5*%C],[<K>T)M+CLS+2=BFYW8F(+$,<^=(L
MP, $) MQL"\4+/REFX^*_L;.5'LK6X4K:ZK!)-/<!IY'U'3YK*(@1QI%%%9F
M7M4"H996:4O* T20] ]K<SHRW$\9S/92K''$1&@M+J.Y?FSM([W 0(Q9@D8"
M!4)#M+%]ZZ/)2R"Q;L5= V)&,MO4M+I!,>V) 0!,+U(73-ND63,ZUV!1I\N1
MK3C H:AR9ER#LP!MD!- CB)<.6A\VUX@2%I!);LR/!H\>Y1:2RK)H]MY.FWR
MRTNHE28%FRL8DA=865G$923'FTLR!"LHW+)J#8;MT0KJ$W:L"+>XA=FCY+@N
M4D5I 54N&3<E]*P*)^+E1YJ-]%AY+IK*"8+AB3B\"=/.+%@,9<C(2QQSKLFJ
M=R\ 66685%OH????D2"7'\XXUQNRD1HG+21ZPC%9 B[M6,19@J1JH"=EAU55
M608 "* *N^]R]H&WKA6L&4%"Q L=^T;F8L2V_D225YD[B36D3O1]8RJ:]3(:
M]5I@2S:=O.C+B9,T\R2(CJG=;;+V7,_04CV )N'L<</-E@K%DL'1<D<#5IA[
M+"*PF+ELF+7X5N!<2VLS-#J%MJ=NL=PJ!Y[>".'L;K=$_:0N8U;<FV1$:>,9
M[;?'9?2G,)A29 )+6:SE9XBQ6*:5Y-\($@".H<KAMRL5C8X[,*V^73I]NTV1
MMMROWB&C!=B[?UGML)E^)EQY0-RG:^H6OYZMO66*F1YF'S)L:ZA)N#M]3<A[
M+"&E'B)<>8RE]>+;:K;1BP[6VE=K/3[RP8B2,HPN+NZNXIA"\9CD"->21RV]
MP)(955&P#RJ]+8RL;HQS*HN+JWNL%6##LH(('C[17#KN%NCK+'MD1BR\QS,:
MN]%]A(I.EZL3L.">-TA?+QM:%DGZD?*HL]VGMK%;"K\397+-9;#/OT , \L.
MPP[]@D;#-6D6I7=%H%FZ3&N&YGPBA%SJ,XM)0NI6MM8R*)TC,-M%8K:3/"(8
M8HA=.R*T4BQ)#' UQ;&!HKEPECWJ<Q6D9N%W6<\URC&(OVDSW)GC60R2.YA4
M,P=2YD>413"57A7=N^R.F&;MX-K]3VJ*!EIW=4GMB,/?Q=80Z!1*ZG U>Z#'
M3M(N%;EFRVT#$&GM&YE*S9H0PZISM<='/]:!8UGK44#0=I!(R1::E@Z@V\BR
MF._:]#O%<V\R%22%0KLG@E59XI@4V->N-/>59-DBJ[W9N58]JC)NMA;X5X98
MV!&"QSNCD0M$\9#;UL11XFXUQL"KSA\7.0%=U]0(D&S,QK$-,S]PCTV&/NA\
MA#QSV(6*C"0PJC(1$;% BC@E2$T*V\0*R&R'J;F2WF+SQH\4LUW=2-"7,D<5
MN_9/;(DCCM9'5FN$D>1F+*D3$!BQ;.A65 L;LKHD,*B0*$=Y5WK*Q1?,12!$
MRJH 4LXY@ #HK3OZE*Y_S+&_YJUSZGX6_P"#>@_]$V'_ (:.O$=;_P ,:G_I
MUS_WK5LG-]6KK"3]D@:M'KE;%+@0T>VK",DGD(82MS.,Y2RPE6?,((7C&?+'
M'0X^YVSA#:L\N1Q23-LB1I&ZX4$D#Q..@'>3@#O-7[>VN+N016T,DTA&=L:E
MB .K,1R51WLQ"CO(J%S^H6$RI2*W4[78D^W*#G1A*[&O(_L5M.SA(T@M"O8K
M&<1?;*<X4GQ?!S.739 ,RS0Q'\4,97'?S$89!_+Z^NMW'PY<8S<W5I;'&3&'
M>XE!_%(@5XP1W@R\CR.*C\O9^#K;#WHG2L*1;*_"S==A;"1<AO7$;!V0J&.F
MXX9Q-:<0AF0*K\0Z]CS5*1D12&7&VR"DD7/>Z'']]GY+<XR,]YE![_#Y*O\
MP>MN_4VSZ+%B/D)N0<?^R#Z*W</J%8;5C$_0K/'-Y]F2(@B*L;+?T5.-,%!2
M.4XQ[?S$!Y><^Q+><\I;321][N86/XKAXB?42K)[7'UVGX=<_P![W]K(?Q9E
MEMF/J+(\6?\ E2*/34O52]U*[,NNUJ;%D5C8QZ8%V=%DP<J[8Q@Z+,;'D!.Z
ML^%*GQD(6K&<-J7V[\PIK>:W($L;*#G:W(HV/Q77*M\A/IK3W=A>6+!;J!X@
MWQ'Y/%)U_BYD+1/TY[7)'>!6W<L5ATXI3BE:-,ZQUM8GU%3VOZ5,E+5E2RI2
MKPAQ2E9SWRI1)(+CV<YS[<YROV_'WYJKG0]%O',EWI&F74C'+27%A:S2$^)>
M2)F)]9K"FTW3KABT]A93.>KRVL#N?_:9"WSUD(&C4JK+RY6:A5ZZYE.4Y<@X
M"*B7%)SC.,X4X (PM6,XSGOW5GOWSW[]^7K32M,L#FQTZPLSC&;6TM[<X(P1
MF&-#S'(\^=5P65G:G-M:6UN<8S!!%$<>N-%/KK:>9]955RTE_7/ZP?MA:I_Z
M3NF/DGHOJ_6:@=6]?ZA5C>14TXI3BE8BPS0=;@)RQ2'C] @(B2FCO*QA3GH<
M4$^<3Y:<YQA2_)87X,9SC&5=L9SCX>!S('C0\@3X5Q^N-ULVV9--DNY:RF75
M^E0E60ZXJNUH1W&5##B@9\+!DDEE:4FS!;3AA+V,X;4P.AEE&1@+R Z<B<<R
M?$]?IY=/'-@DD_;E46;(O(>M:<=:2(TJ66P=78&'A(]8[!4U9;A9(BG5*#8?
M*6T('F8L\]$1F325I&!;*46_W:87C+D/1]=.OVSR%0Q==[WW6T,R[>=6047/
M2MK@JS6E1VQI&:H\YF8@[183'<6076[=P"/K\?4)7,K&+UH^V\Z7"HB)"32:
M8N,C/+NSX9_=GIZ*8'CR^?N[LX'7J34^U*<8M]2KMC2N"+'L4%&2^'*],XLU
M=?;D@V2L*AYY4?%XFXI>'>X4FJ, R</Y9"@ALN991([C]'ZJ@_;/*I*H>RY_
M29_N@@"WO<JP[Z7:Z>X_GU)(1:5>.2, &=7@>'FAAL+)&/#\A#RV4L'MD#+6
MCD$!NO7Q[_1XG'H^CK4AB/5X5>&N=<?2!:7)MN,ZD-/#^H)3U0:Y/7RO5=HD
MS 8QJG(9RR'129^.0T6TUF9A/3X=1:"0FSEEAELLV=K>!]E7LCQ'MK9_EMNE
M3^V:Z?/OSZX_G)Q@^!]AID>(]HJM6K'$.Z_K#K2T.-. NN-N-JPM#B%F$J0M
M"TYRE2%)SA25)SG"L9QG&<XSSQ[0/\#V/_-O_P!])7#Z3_@ZU_Y#?]X]58@M
M%;/K.]]F7]NMQ4_6[UMD"\ '-=5F^:0*! JH%"IIXLWH>"I9VIK1*#/UB4,0
MF7/(:G1WXUB1.$R,WD3IFGB:"*/>59(BA'DL#DMVDC@K.S"51YP'F@;2"0#G
MGM^T7LPG,$*0?O,39.YF&)"_: $$= ,'/+OJ !NA39H<$$,4%INQ3K%VG;5%
MR9\Q;,+U_5[AH#:NJ@]04TR9JME.30]&V2UUB0U?Z)FMLS<&B3+.KU3L\;@Z
MSY!OHBQP9D78JE0J>>R3Q2F9PK*-\ZHRR [RK8PSJ<+69ER<;P"H4@;<,1(K
M;VP5&7 .\<\'&"PY"4H_H<AV[I3&Y*GZE-U'7V:PY):_=BL%0QTG&:GV;4YJ
M0<K!%;]0R14C=[P/9U&2*LE&E9D+&8I%@;8P_:-Z=CD22B5BV) 2" 98F W
MY $<97 Z#"CETH[4X8Y<.<X.>8RR, #NR  I7&<#D/BU$;?0[O% ,@QB3UJJ
MP6#00>LK=;Y2P/SQL]/L=.=:U6MZ/D"]1C['KS+MZKH4J>XK9<U29"M1^9=O
M5@-]GS9.)O&^@R/XS:MQVJ*%VA5\H:7! E,;>8Q ^]!PQ ,I10#69D\&P)-Z
M@#&!VA?GYY4G!(^*&SRWE1@V^T?I2RZXOUHG)NJ:Q0Y)F;3*.VI"RDX5LW9.
M+SLWW:5=FY@.5Z%C!&*? *7 81(35U>%=9#$IQ-5KJ9&+D\.>=98T4/+YHB
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MK$_&54J!LSJ,V)>KQ8[2)>]K'P\EL+9NT]G6J#@''@ S(V/+*>G+"7'Q,#!
M$RT;%0%6B%!141'Y#C(B.:&&PE/[$:7HW"WN<:/I]G8Z<((VFBL(!IVFR7%U
M<W<L<DNV."TBEE =899" ,84O*[R,SO^5>O<3<5^Z7JU]/=WY\GABFO1:76H
MQVNG6-E%)'&&DDN98H995:6)&GDS+([80)$J11XO8>D9:"AAK#/)K$S",V\J
ML0UMJ%LA+"PQ;8*!J]N(<KMBK4@0^,9$@VN">3+Q9361)3)(39*3XXMIG<M-
MHO$:R:;=V<DCM9+=R6FHV$]K<16MQ<W=G'(4N8HY87DELKC: 5D,827'9RHS
M:*UEX@X4FCU73=0%MMO'M$NM-OX+JUGN+>WM+N2%Q!++!=1)%>0;UD62'M"\
M1^^1.J_3%\C9ZZ-A]3_0IU-Z.W?8C;GM[IFCZ0*-L"8=\Z?V)J6]R#V:'-6<
MI?A7+7&OGU:RU2S37@\Z79CX";E7")J8D3"OA3W7^!X>"N)A'8C;INHJUS:I
M@ 1$%>T10  J>>   %[191&JQA$7[M]S3C+X:\+V^IRHL=]"7M+^-"2BW4(P
MY3))VR(4G12S,D<L:.[NK.WTT\\DKT2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4
MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2OGO\ D[_Z%?\ 7P_<@Y<C[_D_
M72NPW1_\Z7TN_:ZZ2_%I6>4-U/K/TU"]!ZA]%6*Y%37.WJBG92*WAH:- 9<=
M#LVQ96(FG$$S#*1X\30VV[ PZZU&R(8!:%2T+&,88L LM%H<>;*&"9FQXF2
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M^.GQ>!E\L1IUY#659RK+.'5+\E2LY4IKP*S[<YYI+B(0SS1 [A'(Z GJ0K$
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M+LJ9QN*JS 9P">502P&?-^>J+3LE.W.879;Q*OV6?=4I2'C,YS'Q2%YPKT&
MC,YR)$@LYQA*$CM)?>SC+Q3SSZUKSK>6, ;1CIW_ "GO-6R2>IS]N[P^:J_V
M':MWS:[G6]:ZU!OB-;BPJ[DY(7ENGR94K.1>+ -5Z. _69F,G; W7GH^0=S9
MI^C0&")J& ]?8PY*F0T>H=/D]GV ]/7#'>3U^7Y3S^W.M9B.I2/,O]\K,M%P
MD'7:0[91VY!R;MLE>;&]4D134\NOT*/UL['3C0,G(NQSH=;O,_84Y; (5 81
M+B(PSS/+D/7X9Z8^C)Z<L&F#R/C]>/UCKBIHJ%UJFRHF1,@\F%#1<P;79J-G
MZ_,U^4BIJ/;&?*C92"LL=&R8CZ1C0RV<OAI:*",%-$<?%(9>7(.>8/LR#]8H
M00>?K^WU&K,:*VK8-:6VMUM4@7(:^LLW'5TF!-?<*;K9LT4V!&2M?<>4MT 1
M$B^PW)1;:E N#/O$,#M%-I7FEE!4] 0"<^/>03Z!TY=V,U*M@^@]?K^O_=5X
M=S]1VD^GP:OD;?V% TI5JDV8FNB23ZU'RI+I0HCK[(8Z'GV8J/<,'7+SA:1X
M6'8=2_*'B-*2K-H GH,XJZ2!C/?R%8/Y;[I2_ME=#_?9HOY=Y.Q_Q6_DGZJ9
M'B/:*?+?=*7]LKH?[[-%_+O&Q_Q6_DGZJ9'B/:*CRQ[CZ K<ZLBR[5Z6)@MS
M.<N'F7K6:I%6<^W.<R*)5!WMS[<]B/;GVY]OMY4!*.@<8]#8\.GJJ#L/7;[1
M49:IJ/3!MC?FU8[7N=>;$U_6-2:2/&34+,Q9X")N%AN.^Q['APJ'ES!VY,V%
M@*AZ4"0]GRA!8]YL=K!*W'Q9P!DD$DGF,9Z8/3Q[Z@*I)Y9'+O[^>>_U5=^M
M:OUQ3G$OU:BU.!*1^=-C(&-&/]GLQXCT#X,7VQ\&5OJ[=\_1SR@LQZDGUDX]
ME5!0.X5O?(J:<4IQ2N6)5*.LFJ9#5-XU3M@N*FH22KEA9C:=,>$@(U\A)"!#
MFF\XREQIS'@>0G*<XSWQWQGV^.:1)J.FV=K!)H6O=O;;@2FESO'N$CL"K# 8
M8(((Y'U5P-A)=6EM!#)IFJ=I"""4LI&7(=F!#9 8<QSZ'U5MT)#@5H4$&N:%
MNT %%BR848'":E<BA8X*:+&/F! 1P0V&A!98X(,V3''0VT>6(,04AUYAI:,Y
MK^^<DMHG$;$X)+:7<DDKD DDG. 2!X9..M99NYSDG3=7).,DV4ISCD,Y/<.0
MKT8VJ5Z& CXN(Z=+1%1D1,.V**CHW32 0(RP/M/L/3L>&+'M#A3#S)1++LF,
MVT:XT2^VM_*'G,*DZA?DDG1>)"67:Q.EW)++^*23S7D.1Y<J&\N#G.FZN<C!
MS92\QX'GS'(<O17I-4*F,18,(STRS;,+&3:K-&Q#6D!6XN.L:N_BL ("(S @
MDVKQ*\4J.TV?GOGN1GOGD^^.H9)]YN)<E=I/O9=9*_BDYR5]'3T5/EEQG/O;
MK&2-I/D4N2OAG/3T=*]T>J5T0\R4%Z=+0-)R, S59"1'TTAD\ZKCCM!L5LPQ
MN/203 ,",,"LP[SBXYL=EIA Z6FT)Q'OA?D '1>)" VX#WLN<!CU8#. Q\>O
MIJ#>7!QG3=7.#N&;*7DWB.?(^GK7KM4BIL"5D!GIKL#(-*,<D::$UI,=L2I2
M#KV"'3ZR,B-PS F./XP^X5%($?6]C#JEY7CQ<GWQU#+'WFXERXPY][+K+#P;
MGYP]!S3RRX\[_P!&ZOYWQOX%+YW_ "N?/Y:D>KL6:<V=JU_% V!$!0EFE).3
MDI^J2,1'"B*IUECT*<,)3AI*W"S1F6T*SC*UN82GNK.,9BR%[=ZWH+#2-7MH
MK6_GN)Y[RPEMX8XSIE_""TC^:"9)8U .,E@!SY5$)N+C4M+(L+^%(+F6662X
MM7BC5#9W,8)<Y )=U4 XR2 .?*KW\]4KM*@O:D/1@GVYTZ4DJ]:CT>0)[FVF
MS)6P9'3C"&B8)UIX640,C.$9-)0-Z*C*&W)%AO#:>>-^Z1I?!UG-'K-UJ.H:
M%Q+?+V-L>'XH[O4]=,"X2*XT62*:VU)+=2%\KN(X#;*4C>_ACV)7H7!]]Q#<
M1MIUO:6FIZ/;-VD_OJ[06>F"5LL\6HH\<UFTK#/81-*)B&9;61]QJOCH&QI1
M2T-S(\3'*SV0LL,5F9=:S\;[,<X:.*M6,_-8&DDN(S^=6C/LQXD]E[H6I%T3
M5H-*L&/WM[FUMHM6DB/,=K%8/>0VSL"-P@U!)4(P&4Y ]+2YX7M K/8RWET.
M;+#/,]BCCNC>Z6WEF4'IVMHR,.H(Z[_7RKI68Y$9"3D!&B86M]QMBJJ?622[
MV\\HPLV<(,-*>RG'FD$/J=4E*48RE"$)3VVB2\7</6":=I&M:)I]LKO*\</#
M+3//<2',MS=W5WK,]U=W$I [2>>5I6"JNX*JJO-ZE#H.K737>H:?J5W,56-6
MDU@1K%"F1'#!#!I\4$$,8)V111A 26P69BW%#J5^0C:9W'=['LS5EQD>GRV6
MLHR6L$%KZ(C?>KF+"<ZI\VP.ZZG&IH6#D3G\^8<S1Y:GQ9CV7"GP%&OOEN>[
M\'_W2WNZ<$P1V<5_PCQ/I\9&+75-.U/2[G8#_%Q7D&H:E!&2.0D>PED)VAI-
M@ 'E7%GN'>Y)QK(;C4]*UG3K_:$2^L;VVFD ')>U46UC+.B?@1R7+1IEBB*S
M%JC?07R!30X-JB_ELNH3:FRHQ!C*F:)7ZQ!Z9US;7/'C"8>R6N G[?<2@#$^
M)MZ-!LU&*,SE+:2G$+4,OTB7^[.X@XA5-$UK33P'=WS"VBN))H=0TF\EDRJP
M6NMV\-M%'-+S5+?4[>U[481(I9& KB+'^YBX2X:E.KZ)$G$YL_OV;@S^^-H$
M(8SMI,\DL;+$=K"XM/*7B(W]I&%)KO\ [^I50UOTD7"A4"LPE-I50I4/ 5>J
MUN-%B(& A8V3B1@8R*C FF10PQF4)0VTRVE..V59[J4I6=!)-+<3///(\TTL
MADEED8O)(['+,S,26)/4DUT 543:H"JJX50,  #  '<!5L.6JKIQ2G%*<4IQ
M2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4KY[_D[
M_P"A7_7P_<@Y<C[_ )/UTKHKTK=,737/],'3A.SO3UHZ:G)K0NGY:9F9;4U"
MDI66E9+7M=,D9.3D3(!XL^0/+>>*--*>=)*)==??=<=<4K-))R>9ZGO/C5(
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M$5.</9:E*CP/E9:B2[* J0AZ]8XQ^K6@@5M&7'O-J=@&C; *\*A.5%C%1K)
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M^K,O^XP/\W3SYM]TO_A7=?Z+9?\ <+7L'!_^ X/^>N?^]:HUYP-=13BE0#U
MNW!J*H&8!V\CU)>PVD;:)UH&9(7L>@>XF[K!5 "Q 4A97,.;)1KUB:550B)Y
MNO/2RVDM1^)$AG::4+<R77:BV,XM";!;QE2U-UY3;!A*TC)"/X&;LQ]NPB[4
M1Y\_8#A7O:[8.S,HB,X\J, +3"#L9L=F$#2<[CL _9@N(RY&!DBL5E*ZI%;'
MU7B*-VE'5C-/T&J/:D*O#SDC(3CMODD[Q;VZY3WXO747.9IB89,^[+2,;  #
M/%&Z:8D+JP3&.[J%=$\CO@ZV33^4:KN*3R1HD0MT][#8>4B2[>+RCM.R"(\S
ML NH%+9E<8$AU'RBWVM<+%V5EMW1J[LYE;RSRKL=MNK]CL$FYE106-INE!6M
M\UMK^Z16Q=?RDC6Y,./C-J];TP>6^QA+(L7L#;!<S2SGE>+/A8LD4M!T8OMG
MSQU87G"?@YC7=W;/9WB),C.]CPU&B@\V>TL5CN5'IA<%7'<:O00RK/;LT;!5
MN-79B1R"SW3/$3Z)$\Y?$5=_G-5MJ<4IQ2KJ4[^I2N?\RQO^:M<^LN%O^#>@
M_P#1-A_X:.O"];_PQJ?^G7/_ 'K5LG-]6KKEQOS3YIE#N>FIF1S66)]MWW 7
MHD)4A!K-!EF;%57I)G! 31),1, QZ9VNOGQKTP$.^T$:VT<@IKH RWD9DB(+
M[5[6/D7C=0 6VY!:-B-P8<@#M;!&*[Y9$UBV,T# S&-/*H!SE@F0*#((\YD@
M=E#JRY !*/M(-0O<=:[NVE&^+9M5Z<K5$Q,O5)"(T]-NV:TTB=?BF+*//V&6
MO,I2A3X>6DT3<2N!B'-<7*$@&8 T4U5B*LK4O6;95C\8(<$84YQD9R2<9!\/
M-(&._/*P\<L@^^) P#*1$VYE. P9BY0%6.X8'9N%"D$G?E8+C.C#:H%FUD:5
M;*+(1=%L6F;$V:VEZ.E8B.U[>#;1+42-\5)D;1882.BI8^M4&3G=E!QT37&6
M(1^C#EFR5C>H$3 KS&%VGT\CG;\7) !PI+<ARV@Y:K(M9=T9+(0C1-W@@(Y8
MH/,+,JABL9:0 +A2F<L9)T-T?.Z.,T'*A3(M@,I&D ]0[.!LD[;K7%N'AUR#
M:Q<=1-6DN531'3IR%?B)^NQ U>@K#490#TL9@RH0X)521[-F#G"[6!)([CN7
M.<<Q@@8!!_R0#<AMNR,)!W%8A%(&9F&0H&Z+<3LR1AE 564C(!0 V(U!2IVI
M5\_7$,L2TVV5V)N6X,HBL/JCHB/V;N"];#C7I\IUK"8UJ&C;8(')9>QC))XK
M[,<DI+K"U7D58D,DS=G$&=MQY%\LS!(QU9STY9"G)8@"LR-$M83<7CB&V625
MRY^-+OE>18H$.&ED8,%.T%4YLS!1D]+Z?7FZG5:]66G\DI@H>/B\DJQX<D+#
M&;9=(\'?/@P\XE;F&^^<-X5A&,YPGOS1SRF::64C!DD9\>&XDX^3.,]]</>7
M!N[NYNBH0SS22[1S"AW+!<]^T$#/?C-;'RU6-3BE.*5^9QA6,I5C&4YQG&<9
MQC.,XSCMG&<9]F<9Q[,XS[,XXI47SND=0V5Y9,UK:F&%N9RITU,!'B'.JS[<
MJ=."9'+<5W]N,K>5G&<Y[9QWSRH,PZ,?;4;5/</H^BM:;Z9=#MK\>-:0+F<9
M[^!]<B2U_P 66"#G6<X^QEO./B[=N-[>/T?-X5&U?#Z:DNMT.DTY.4U2H5JM
M^).4K7"0D;&.NXS\/G/!C-.O9SVQXE.K6I7;'?.>023U)/K)-2 !T K:^14T
MXI3BE>L88)'C/FGE# AC-Y=)+,?:&&':3^><??>4AIIM/QK<6E./CSQ2H(F^
MJ+1T*\X,F[,SI3:E)RS5(N8M#:E)^'"3H4 R,SV^R=CO\7?'?.*MC>&.G4@<
MCW\^ZJ=Z^.?0!58X*^=+4!U 77J/CZU?6-CWNDUVC3,IFEEY%Q'P13SKT@PT
MC&3$R4T(/6HV4>7A:5 U*%;8:97DY9591L8RN 3W^C/U_*<> %.Y<YY_-CZ?
MMS\:M) ]36D+ ^T(U>@8@QU6$)&M(4I55>8KV);P18 8X%Q:L^Q*62G/$K.$
MX[J]G*"C#/+./#!^7E50=3WX]?VQ4YL/LDLM$#/-$#OMI=9?8<0ZR\TO&%(<
M:=;RI#C:TYPI*T*RE6,XSC.<9Y355>7BE.*4XI3BE.*4XI3BE.*4XI3BE1M<
M];A6<I,U&G.U^S-,)'Q*#LH)&/';[Y:$F8Y:VVSV&LJ5Y#J71S1O%^8DI1CR
ML\!Q7P%:\0W*ZOI][+H?$,4*P#4H(4N+>]MT),=KJU@[)'?0QEF[&19(+NWS
M]YN50=F>JT+BF?283875NFIZ2\AE-G+(T4MM*V-\UA<J&:VD? [1"DD$N/OD
M)8[Q#<U2KL@4J,GZ3'6^));4R7F%*CSPS6%>W*"H&P9!=4E7;'C'2H]&,X]C
MB\8QG/F]QHG'NDM_"N'(]82,Y\OX9U*W<L.YO>W59-/O(WQUCAENPK9 E8 ,
M>RBU3A>_7[SJSV#/R-MK-I, /$>5V*7<#KGHSQP$CF44\JP[ Q0'HS0^NK<%
MZ$+B/#;%II/@$!3EKL$,L%IQA@-/DLYPPRXEC'DMYPG\S3VUKWNK*2)>$>-0
MQ.6 X=OI\MSZR6XFB8\SYW:$<\YYUFB'3R R:]PX1C /OM;1D+X;)3'(!R'F
ME0>G*O:#AK$1Z.U#:TFV\C+>6,J0$B*\*(HI2U$N-K/+:?94^IQQ;^1Q5N/9
M<7E:5J5G&;\2<57S;-/X*XCD=L#M-3%AHMN #C+OJ%ZD^% SA+61\ !49N56
MI)-"M1NNN(M(51GS;(W.HRY.<[4M;=H\DDC+3(N>9;'.O1G':;6GDM[FV/5J
MXQ\RXY1H&1?/F36L]EX:E%BLJG'A5I[)='C(D=LC"LH]-<1GPJZ;3?<SUK6&
M1^+[ZVMM-)#2</:%)._EB9SV&J:U+';3/"0"D]KI]O;+,I93=,F0=)><:Z=I
MX9= MIIKP A=5U-(E\G;&.ULM.C::-9 ?.BFNY93&0"( W,>I>>H#IJO-0D]
M>V6MS]SHTJ(* =!>X&:1"EA@$#%@M)'/8BUH;$*#$(%PAMM3#H[*T83EO';V
MNWM8[6&&WMHHK>"WCCA@AB5(XH8HE"1QQ(@")'&BA$10%50  !BO-I9VFDDE
MF=YI97>265V+O)([%G=W8[F=V)9F))))).:WF/ZN-*D*0T;)6.OISV2ER8IM
MC9&3\&,84^!'GL-)Q[,96XM#:,?GEIQRX8VY=#GP(JC>OI'K'U9J<*K>J9>!
M5&4^T05D';PG+^8B2%-=%RK\ZDP=EQ1 ;F?]Z*:9<]N/F?;CE)!'4$?K]7C5
M0(/0UM?(J:<4IQ2G%*<4JBT6ZNY3\Y?K!GTV97/6&%AQB<^:W4X6$FC8@:(C
MV%X\ 13R0LF2Q+;;9)I9*\NJRREI&/&;5CJU]>:Y>_?;MKV_L[6.3SETRSL[
MN:TCM($/**1Q#VMU(JK)-+(VX[ HKWV]4:'IVG\.::/)[$:=IE_?2Q#8VLW]
M_8P7TE[<R*=UQ#&;@0643L\5O#$NP!R[&)MLVR\/[1U1INE6-BAJO]9VE=IN
M]*A(^P2@L=K(G748U5*R!->;!,V"Q&[('F%2$O'3;(]<J-C8'B%&%L2T1OHD
M3LIIG4OV;1(J;BHS*)#O8CSBJB/;A2N6=26P"K<S,\AFA@C;L^T2:1I-H9@(
M3$NQ WFAG,P;+!@$C<!<D,M+]L=2NY*)-6^,SL9<^!K32,5:9BX:9UE3;=3B
M;JK;.[]>2!FQ7K7:1F*+%Q>-<0H=X&;M$;#TN;!OJIFQ0D3"J/"SH;:&0(>R
M"F68J$FE='"=C!(!'L4F0GM6*':6=3'M4LV#@S74\9<=J6$, =G@AC=#)VUQ
M$3+O<=FJ]DHD =5C82[G4+D2Y5^K>0L'4SK71DC/ZOB"<TFQ1NRJ^)/AF625
MW1&U:F6DR+I@;YZ)!JD5L66DQ Y=\0Q^X2.9=D3T$>EEDS=E[,+:R3A96\]3
M$Q4A1 7= SD#&]B%.W(V#'7> MY+TM=Q6Y:$'LW65 V7,X2.0B,9R(T#, Q!
M,AW 8[(EKOV"O!3PS>'EN!2(*_2X:<#7D>5@I!OYIB1C3492\.\RXE*UI2O#
M3Z$Y9?2MI2DYT-_80WT8#EH9X3VMI>0DQW-E.O-)[>52KHR, 2 P6104D#(2
M*Z33-4N--F8QA9[6X'8WVGSKVMGJ%LW*2VNK=@4E1U)525+QL0\95P#5E-3V
M>0N6N*?99;#?K.4AV7#W&48;9**86X(\<PWC&,-L2"Q\FL-IQX4-$(2GNG&,
M\] X8U&XU;0-*U"[ %S<VB-.RKM221&:)ID4<E2<IVR <@D@ Y8KS'C'2;;0
M^)];TJS+>26=](ENKMODBBD59DMY'.2TELL@MY&/-GC8MS)J0^;ZN:KD#UZ:
M?F]M=3&B6!J9K6U5^$U'N]R5*W'JPO:FNXF6D;%I%$$EZ+;EX$./MAXP<ZNO
MDD2K1+\4!:& V'4>EOB^-<<ZA'8:IJ):YO()9;?01&NG7RV-W)&AUSM<2&.5
MF@4M$)5"$!WA9C\4-Z)PS:M=65H!%;R1I)JA8W5L;F!'8Z9L\S>@$I42&,E@
M2JR <LD5<G-5;EU&=#)UW<=CS!NINFK7E?%DHBH1<Q%[.GH79<@X=6)$:?@[
MG(#@)@5E-M0-<L ]HBX$X)Q=C?> %DE\+%?:=?K)Y7;V<:WVL7<K+).\;V44
MED@6=#%+;(SF4*3++$87E5AV(#L@Z5[>[M67L);AS;:? @*Q*R7#I<-NC82)
M*0.SR-D<@E6-A]\RJM6YO[%Z@G.J^*K<;%;"QJUS84_69H.5J1.*4S40]"S]
MFB+*-.B:41'A1LCM*/@8P.S+W[.2!1\K(UDNA1F4LM1.,+32O>*29WM/+A:1
M31,DX\I:X;58H9(6B;42[.EB\KM![U1*J1I.MU)DM)>,]][Y)&JS^3&=XW#1
M'LA$+&219 XM JJURL:B3RUV+NT1A7D$B.@;IW_.P5R'#M^T[':Q]'].5ZLX
M,IJ" !.H=@OVR;)#;ID]-1X>O(OWS8RN4:$G)36S;:-IUZR2%=CFH6=OCD@<
M,_GW>G:5%+;EK>QAMVU+6+:!TU"9UN8K6SADTU-1=KN3R)YKF6)+PGR&:%)7
M,D5J$5ABP7=Z\<P$MS)*+33YI%:U13 \\\JWC6BB!?*%CA1FMP/*4D:,!'G+
M$&2B+QN[%=C<FV7>4=KM6V+S%";/AM*#RF[Y.B Z^%D::]-ZSSJ237&1I>R7
M;17V)WWJ(PB5AJW3'RW66K:3+RF&+;3>V?;#ICW8L+9VLI-2*::ETUV4N!'>
M^7H'=;,0S&+RYUCDFN0H)MU2/),UWL7,EVL'E,RBX2T#7C0B -$7M_)6VJ;C
MM$#^3 ND<)/*4LV]XO&Z\[QUMK+)LNQ7K_2Z[MB2EI"N58&6JL'180V#VK2S
MQ143 $?)3][L.EW@V7#IPMH6S;-8@)UL2K13C6-Y+IOO9>7NU#-:7,M@D:33
MO'/+=2K+8W*,QC9TBM8=25B$B4M#9-+&6G<&[VUWY9;V^6$<\*7+,R1JT20H
M4N8F WJK/-):;06<XDN>SD B4B (Z?W_ $S3&LX8:=W^!(1NN]XN%2L?IM%Q
MNE@WC V^-9U[3+C'G:NE4Q](EQ2K&]'V1F*KL-:!11BU;)"%2$3-;5XM*N-1
MO9&BTIT>[TT+&VH&WMH=,EMW-W<VSK?(7NHRL(:!GFEA9BOD;L66/"5[V*SM
MT#WH=8+S+K:]K-)>1RJ((I5:V;;"P,A60+&DBJ"9U !>;H^Z[^9ZGX"OS0]O
M*U[,,QS$I#P]4>$I53\6HWIN2/+M)>JI**LL5G8(K\:S.A;VKUE F"XZKKU1
M+0WBM9FL>WTHZ+++&;=;N,NR223AKF?^'B)$6%;U)(9/)&#F)M,FA>-7G%_'
M)_!URUFO??%(V$I@8*&18\119MBY8R&V994[92HD6\CD5V6,VK)]]:+8"V]1
M=9&Z/(UF*O042=J'IS V)0:YJ]JLAQEDE3(^'V.J66-IJSUB"&K$2ZRJ=HAM
MJZ?L4:&CR)*KR-J-7FK1.=+!I$S<0,7MFD74-7>TNYKTSEX8U>2S[/.HPS2M
M/("(KI8-5\ID=4G2!?X0^-'+?QKI2[)E4VE@+B".W$2K(Y5)]V+26-!$N"\!
MEL>Q12T32L>S3OU0OZCJ_P#\WM_^-?/=^#/^"VB?Z$G_ &WKS'B+_#>I?Z0?
M^PE;=SIZTM?/?\G?_0K_ *^'[D'+D??\GZZ5V&Z/_G2^EW[7727XM*SRANI]
M9^FH7H/4/HJQ7(J:JCMG^K,O^XP/\W3SYM]TO_A7=?Z+9?\ <+7L'!_^ X/^
M>N?^]:JN;CW! :6K<=9;""0>-*3P]=%::GZ)5V$'$QTI)MK-G=CV^D5<%A3,
M2^PRE^<286<^&&"&4\_V1R&GZ?+J,SPQ,%9(C,Q,5S,=JNB$+%:07,[',@)Q
M%M50S.R@5O[JZ2TC61U+!G$8 >&/SBK,,O<2PQ@84@#?N+$!02:T>M]3-;NW
MO?N4:C;%N EYUSJW;!Q<.!5D8HE&W&=(1U(EK:+)6Z/D"7"7H.ROR05+$MY$
M5'U>:-*3AOU3B5R9M&FMO*Q<W5G;M:WE]8JLC3_PJZTY4>YCMV2W9%"B2$(U
MRUN'>>)1SW]G9CU".;L##%/*)K>VN25$7WF&[9EA:4-*K'.R0L(A*4$3EOP=
MV)IG4)+VAZOMR50D:\5-;RW[J4"(]%A9A^PAZ<]\; <D%*#7@82OO2N*/E#S
MLH)(^.6:-BDQH$06#;FZ[G28X!*4N$E6/3-*OWDW2QB)M0\CW(R&V9I1'Y3R
M",F(RLF]Y%:W-,5Z\FS=$T9>\O;95PC&1;4W 5E83 (7[$9+@^=N7:JE91YF
M^K/7!=%FMAQ<;8S:[ P.JYB1*+?IE8&#D=L-,F1U3E):XW"NP,!9JG$GP4S>
MA+#*Q0,*#8X5@.0EI8AZ,'CWAO%NH[1WB2:66^C15%Q.S)8$J\Z1V]O-++#/
M(DL=LT,<C2O#(66.,!S(U*!H7G57,:);.Q)BC :Y *Q,TLL:))$C(\P=E"+(
MF&9B5&'K/54%?)C5>:=4)=ZH[&H?4'9S["874S'*K+Z'MU9I,E'/M0UQ+CY\
M$J?E)0)$G5I.;CI'.((Z*D788V1EHRY-H;6L=]Y1/&+BSNM)A6%5G43QZI!-
M<HX,ENKQ,L2(Q2=(W3[ZLB"14C>B+41.]L(HG[.XAOI#(QB/9/9310,I"2E7
M4R.P#1,ZMYA5BC,R^X#U55M$;3BBZQ<YH*2I>EK5=;E#0];BZS1T;O*1%4YR
M=B)2^%V-&#)+#A,I'U1N^YJD4X.7,2SPJD'/4MH<V^X59K>-DN-1@MK>229Y
MKDZ:"]P(I([80^:F C3FU[=P5C0-E1(U*/$1,<SAHK2265$C6.'RP[8MZM,9
M.;9++%VW9*078@[CM5.ZB8&Y;!70F*5?(5#\UM6N0EOFF:BFKV.<TW9F*O=
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MM^J8>W5Y]-TW_P"#L[^'R]_\VO\ [\_ZA4^?_D_/3MU>?3=-_P#@[._A\?\
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M]5DTN&P@5W;L+03IDHEO'DS,NT=DGA'CYC=,]K;NUW-<7$SO-I#N)[M=ES-
M[,6M9)T\V1K8Q%@J9YQQE;(U_A=1"JSRJL$<,4:K'?JIB@;=#'(  )EB;F@F
M$F,N.CN&VB(Z1P8*4'F(VI.-'!7^W[/C\OW.7.%C+K?HR3B;A*1D>=8"8^.%
MG!YN:)*@@Q6:^W+S$G.BQ8\T<0>Y9DX)XYE0QO9P%6M+>R?%SI:L]M:NDENC
MNKAW:(QQJLK,93'&D3.8U5!<3B3AM&#+<R9$TMPN8;U@LLRLLK*K(54.'<E
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M66*%$=0Z$JP# C<I*GJ"17E>J3QW.HWUQ"Q:*>ZGEC8@J61Y&93M8!AD$'!
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MF%7IBY6$M\6.K5+KJ&G)NQRYYHD<,PTI]2!HV)#?-9,L=B/6W%5J$:,F9-U
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MMV+K4,-F3L,DVWG*5O, (6V@<1*DJ1D^1(" PXE362O-QX.2JENG0=2>@H6
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MG0.""%@C8@G;*N0:R9=0BU.)1JMG9ZQ!(BD/=0!+P1LH(,-_"(KV)BI!!,K
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MT@$2BX3!B+;")(2JDH8R9;\=H8I9F5B\<L:@&:6666-T)\U7E+DQ'(< ME)
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M4@J\<444%N'5@&20P&:)@&CE4Y)[L]2%:KU-Z3M@5&I0D56:M6-?!5^N5V"
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MA>=V0OC>"B':5!4DJ"0#FK;'3 CR+'9RK')'')V*02%'ED6)0P7.T[FY@X.
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MC,K8;_[0_H:_MJ](_M[A_P"/Y1\,.%OS_I?Z7%_6K._^3)_="?\ U.>Z!_\
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M]34!^P\=_)N*8'@/8*>Y2K?4U ?L/'?R;BF!X#V"GN4JWU-0'[#QW\FXI@>
M]@I[E*M]34!^P\=_)N*8'@/8*>Y2K?4U ?L/'?R;BF!X#V"GN4JWU-0'[#QW
M\FXI@> ]@I[E*M]34!^P\=_)N*8'@/8*>Y2K?4U ?L/'?R;BF!X#V"GN4JWU
M-0'[#QW\FXI@> ]@I[E*M]34!^P\=_)N*8'@/8*>Y2K?4U ?L/'?R;BF!X#V
M"GN4JWU-0'[#QW\FXI@> ]@I[E*M]34!^P\=_)N*8'@/8*U2\5RO"5.<)$@H
M84AD3Q-/CQ8++S2O.:QXFW6V$K0KMG..Z58SVSG'?MGG*\;_ /!36O\ 15_[
M^*MWPV -<T[  ^_GH/\ -O54>?+->W5#&_+79Z9KIV:JI"HPE=JH41-V1$/F
MP+IM/GKM PURN:(?RGV255FM'2<K@HX8N'A?1\S\\$=!Q4B&_L=*@@N;P13C
M>.PNI(H>T[+RFXBMI9+>V,F05[:943:I623/91,LLB,,6\DDB@+QG:>TA5Y-
MF_LHGF1)9=N"#V<99LL"B8[216164T+?W)MFD:&KSE8MEGE+-9]G=8$Q%7&0
MH[;+5I$KFY[^70(Y:YZ.GUQ_NLCI*(?J5,JM#FIJ^P8C[=!?J\7&)?<Z@:=8
M7.J3":"&.&"RX?C>W6Y),+3:;:+=/B)HM_8.CB>YGNHHK65AY4L[R872FZNH
M;).SED:22XU5DE:$8E$=U.;=<NK[>U4J8HHH'>=%/8=DJYJ5I?9?459+%7"8
M&>S3X*2!Z8QC(L378LNC#VYVK,SLB5Q(S."262J8V)$&5UK*E1\)((<7;PK)
M&F)C&\&.STB&&998O*)4;6F61KMHSC3C";./9'@%;C=(LQ^/*A MWA==YRGN
M+YWC*,8D9=/!40!O[[[47#;GR0T.$,?+;&P^_+*K;!'.S.I7?E6H% .CEGHO
M(M%M5FF G:&,)%W^4J5Z<K2 <X6)8)HTZ0@8HJ<F*A2("O/0X<JU:CKU7JV.
MT-G+LM'TJ>ZNE<*;9KJ""-A=,SVJ3VPFW?&BC1%ED6.*XN9IA(T9@6VFF)8V
M+B_O(X(2NX3K!)(RF$!9VBF,>WXKNS,B%WBA2,HK]J9HXUP9BE-U;% ZF*Q0
M#K$Y#Q4[O$O7@>O':"^\%,:S8Z;;/L\6_B7M0G?,J;L"$*BUD,2GJ5H"++J>
M(--BCI68=UZ:=:/HT]TL0D>+35NVNQ= -'>G6(+)K1K7=\1;617 *=H6D6?M
M>R>.,9+W<ZZA% 9"BR79@6 P':]N+"2Y$PF(YL9T*9#; JF+9VBN]?G25N/=
MVS9V98VHQ#B?_P EQ%@GJT-'3 TIK&_&S,@)):]((]QD)%LCQP;*AU1$[8;#
M<FR(G-A2>?6[+%K!:]I^FV44;6+2-_"9(HIR\92]M5C1DNPOE$CEG8AC)%%%
M;XD['8DT+AFF75Y<,PN0BGLE>2,*X:WF+L&@SV*+A0,%7DDE!3M 6BE0K>KG
M,UN*WO7=>CK+8,@2>'E"M OF9;9=\G+BVGAVTH<7A.5X;SAY658;4VOOA/9>
M,=\9[+@;1+'7];-GJ(E:WCLYKK9%(8B[QRP(J.X!?LR)6)",CY"X< $'G^)=
M2N=+TWRBT,8E:XCAW2)O"JZ2,6520N\%!@L&7&<J<@BU$7!Q$*UY,5'"@HSC
M"5*9:QAUS&/@\Y]7B?>SCZ9UQ>?L\^C-.T?2])C[+3;&VLU(PQAC42./\[,<
MS2GD.<CN>0Y\A7D=WJ%[?OOO+F:X(.0)')1?^1&,1IU/)%4<ZK-UE?UGQ/[X
MFO?](Q>>B\"?X;E_Z*U3_P *]<#QU_@)?^DM-_\ %)7.2VU:$O-4L]*LHJSJ
MY<*]-5:?";((#69"6"-)B945!8;K!8JR 2WV4D"O,D,97AUAUMU*5X]"EC2:
M.2&0;HY4>.1<D;D=2K#*D$94D9!!'4$&O-8I7@EBFC.V2&1)8R0" \;!U)!!
M!PP!P00>A&*T%O1.LF)>8GQ((D"8G+18+D=( S<T*0FQ6BHD4F9/"4R>G$=@
MF%-D'FQ0,#AC3DE)6,8=J<D##WK/D=N&9PA#O(\I8.X/:21&%V4AO-RA8A5P
MH=FD #LS&^;ZY*)&T@9$BCA561".SBE$R*V5\[#JH);)**L9)15499C4.NA5
M4_(M8"':HM/E]?UT5E3Z F:5.@0D=*U@\+#OHTO#EC5N!RL.5:,;2_%!D(PE
MYOQYJ%M O98C4"&)H8P,X$+A%:,C.'0B./(<-S13U&:H-W<'M<R,3/,EQ(3C
M<9D9V656ZJX,DG-2.3$&L=1])T37TL/-P:+*;(QT ]4X!ZTW2V7#%6JI!,>8
M37:PW9YB51"QI9$3$+.]$PDN0;AH48XH@6&BV Z8;2&!]Z=H6"=DADEEE[.(
ME28XQ([;%)1"V.;;$#$A% JGO9[A"C]DJM()9!%#%#VLH#*))#$BEV 9]N?-
M4NY507<F3#/]LUW_ *;4+_36!YG1=+G_ $#4O_=]S6$WQ[7_ $_3O_'VU=+>
MJ_45BWOH&^:IJAT)&S]I55,@F6-\X:&9Q!7:MV4O!C\;'2QJ/-!AR61_)CR,
M+*<80[Y3*G'V_FGB'3IM6TB[T^W>*.:X-OL>8NL0[&Z@G;<421AE(F"X0Y8@
M' R1]H^XWQKIGN=^Z1PYQCK-O?W6FZ.-9%Q!I<=O+?.=1T#5=*A,$=U=64#;
M+B^BDE[2YCQ"LC)O<+&T^>K8[](!?<K'\7S;[$_%7^2/JKSCRJY_*)_YZ3^M
M3U;'?I +[E8_B^-B?BK_ "1]5/*KG\HG_GI/ZU58Z@>GPV\E"W:@Y %M\?'I
MC)"%+4D&,M,4.\\2*SZ4A&6XZ:!=()2"<\VH8AI_(ARV66VGV;L;*H*D84G(
MP!R/CCED'EGU<JQY2\IWN[.^,9=BQ('098D\NZN6NTM2CE6*,D;GC8FH;O$Q
MTE7F9V+/(JII\!*OB%2,*J56.?6YZ+=, &+ -9R4=$E-/%P,A%OEFK(NX!Z'
M/JSZN8[C\XSRJUS7J/;TY?;Y^=1HUTSZB4DL$"2LX]0E8^KQ<Y1(^ZFIJ%CC
MJC"Q]?B0[".EQ<K,BOQ,8&).CG3+P]E9P0U8&Y)DXYLF ,?,#\G3T]WC49R,
M$ XSSYYY_+6=D]-:]=E929D[;;D/%8M+D(RY?3AV:2==)(>9LTG3G$O-G1YL
MC)BM/,(,+DPX@-9<%!!QM>DI*(,G;X@^//N_=R/S]U,^KP/+K]O1CQ/.IKTQ
MI.QE1ZX/5U;L,^W+2QLW-WRU*>%B9"8E%H]-FIBQ$"!C'N-LM"C#1=9 <9!B
M@P(F(C08T,0=F"0O7V=Y^G'K/+ECNQ4X+?1Z!Z.?ZL^VNLVF-4 ZCJ/J-LW,
MO,R9KDS99M36&/6<P^RRPKT9CQ+R+'!##L!1XN5KRVPSYKF5$/OK5:=MQST
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M,C,)6XM;BDM-)PI:U+SC*E9SFN2629VDFD>61SEI)'9W8@  L[$L2  .9/(
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M9%D5R77?+(2VX9+,\SECWY& ,"L-2]&4;5M^-V*/N'94K.S ->B[ +;+76;
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M<4M/LPN.B0 EX_\ UC,-J]OQY[]\_'S<Z=PYP_I#!M*T+1],8='T_3+*S?\
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M/5D-&RI;-AD:F8V&34=GW5H%0EDCO4R6[ N$=E#3H]$$W+((4MN!M(S@ >)
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M2,<T$8L5QU(A&6YPO@OS5&6\3[36"L/43J>'"V9X-BUNSS6I:E;+I>*15[3
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=.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>guycyz0ib1ig000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 guycyz0ib1ig000003.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" *C!94# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO,_C[^U/X"_9W\3
M^#?"?C'1]6NKGQQJQT_2VTV&)EBD#PINE+R)A<S)]T,>O% 'IE%%% !1110
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M^ /PRD\46,BW$/B:>*[M=-T73T:6.:2Y66ZD::9Y&MA$L?(VRDQR+DQ^M_\
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M96/L7_!1K_@X$^!LGP%_X0W]@'XE:MJ7C[6KRU\G7H?#\UM'H44<R22;EOH
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MD[K]K[3_ (5V\?Q'OHO+NO$PU"Y,DB_9UML>49?*'[E%3A.@SUYIOB+]BO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\?_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Q__P %0?\ DK'P!_[*
M /\ T?95]@5\?_\ !4'_ )*Q\ ?^R@#_ -'V5 'V!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YQ\0/^3B?A
M_P#]<-3_ /2<UZ/7G'Q _P"3B?A__P!<-3_])S7H] !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7FVJ_\G6:9_V)
MTG_H]Z])KS;5?^3K-,_[$Z3_ -'O0!Z31110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!YOI?_)U.I_]B?'_ .CT
MKTBO-]+_ .3J=3_[$^/_ -'I7I% !1110 4444 %%%% !1110 4444 %%%%
M!17Y6_\ !<+]M+]J;]G#]K#P_P""/@?\:]8\-Z3=?#NTOKBQT]H]CW#7]_&T
MAW*3DI%&OT45\Q_ /_@IK^WIXI^.W@KPSX@_:=\1W5AJ'B[3;:]M9&BVS0R7
M4:.A^3H5)'XU^E9;X8YQF>3PS&G6IJ,H\R3YKVU[1M?3N?F.9^*63Y7G4\MJ
M4:CG&7*VN6U].\KVU['[W44#CBBOS4_3@HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *^/_\ @J#_ ,E8^ /_ &4 ?^C[*OL"OCW_ (*C2Q0?%/X!SSR*B)X^
MW.[-@*!/9<DT ?85%9G_  FO@W_H;=,_\#X_\:/^$U\'?]#;IG_@?'_C6GLZ
MG\K^XS]K3_F7WFG169_PFO@[_H;=,_\  ^/_ !H_X37P=_T-NF?^!\?^-'LZ
MG\K^X/:T_P"9?>:=%9G_  FO@[_H;=,_\#X_\:/^$U\'?]#;IG_@?'_C1[.I
M_*_N#VM/^9?>:=%9G_":^#O^AMTS_P #X_\ &C_A-?!W_0VZ9_X'Q_XT>SJ?
MRO[@]K3_ )E]YIT5F?\ ":^#O^AMTS_P/C_QH_X37P=_T-NF?^!\?^-'LZG\
MK^X/:T_YE]YIT5F?\)KX._Z&W3/_  /C_P :/^$U\'?]#;IG_@?'_C1[.I_*
M_N#VM/\ F7WFG169_P )KX._Z&W3/_ ^/_&C_A-?!W_0VZ9_X'Q_XT>SJ?RO
M[@]K3_F7WFG169_PFO@[_H;=,_\  ^/_ !H_X37P=_T-NF?^!\?^-'LZG\K^
MX/:T_P"9?>:=%9G_  FO@[_H;=,_\#X_\:/^$U\'?]#;IG_@?'_C1[.I_*_N
M#VM/^9?>:=%9G_":^#O^AMTS_P #X_\ &C_A-?!W_0VZ9_X'Q_XT>SJ?RO[@
M]K3_ )E]YIT5F?\ ":^#O^AMTS_P/C_QH_X37P=_T-NF?^!\?^-'LZG\K^X/
M:T_YE]YIT5F?\)KX._Z&W3/_  /C_P :/^$U\'?]#;IG_@?'_C1[.I_*_N#V
MM/\ F7WFG169_P )KX._Z&W3/_ ^/_&C_A-?!W_0VZ9_X'Q_XT>SJ?RO[@]K
M3_F7WG%_$#_DXGX?_P#7#4__ $G->CUY/X^\8>$F_:%\ RKXITTJL.I;F%]'
M@?Z.>O->B_\ ":^#O^AMTS_P/C_QH]G4_E?W![6G_,OO-.BLS_A-?!W_ $-N
MF?\ @?'_ (T?\)KX._Z&W3/_  /C_P :/9U/Y7]P>UI_S+[S3HK,_P"$U\'?
M]#;IG_@?'_C1_P )KX._Z&W3/_ ^/_&CV=3^5_<'M:?\R^\TZ*S/^$U\'?\
M0VZ9_P"!\?\ C1_PFO@[_H;=,_\  ^/_ !H]G4_E?W![6G_,OO-.BLS_ (37
MP=_T-NF?^!\?^-'_  FO@[_H;=,_\#X_\:/9U/Y7]P>UI_S+[S3HK,_X37P=
M_P!#;IG_ ('Q_P"-'_":^#O^AMTS_P #X_\ &CV=3^5_<'M:?\R^\TZ*S/\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \WTO\ Y.IU/_L3X_\
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MW@Z:T^&/@77O"/BZ*W5M&\?:;XPU.34+"^0ADO DER86?>-S (H.6V>6=K*
M?:E%?GG^U9HW[7/A?_@A+\0O"'[;5QI]WXYT?2X;.75K#5!=MJ5HFHVOD3S.
M$4>=M.QOO%M@=FW.P%G]CK_@BS_P3.^*?[(WPL^)_CO]FO[?KGB3X<Z'JFM7
MW_"9:S%]HN[BPAEFDV1WBHFYW8[54*,X  P* /T#HKY&_:4_9(_9\_8T_P""
M7'QV^&7[-OP__P"$;T/4/!FMZI=V/]JW=YYEV]@(FDWW4LCC*0Q+M#!?ESC)
M)/K?_!/K_DPGX(_]DA\-?^FNVH ]>HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ K\__P#@OC_R3#P7_P!QC_T1!7Z 5^?_ /P7Q_Y)CX+_ .XQ_P"B8*[,
MO_W^E_BC^:./,/\ <*O^&7Y,_&.BBBO[@/X1"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** #WQ1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1170?"CX6^.OC
M=\2-%^$WPRT";5->UZ_2TTVSA7[SMU9CT1%4%W<X5$5F8@*345*E.C3=2;2B
ME=MZ));M^AI3I5*U2-.G&\FTDDKMMZ)+S9[;_P $R?V$-:_;L_:"C\,:@TEK
MX-\.B*^\::BBMGR"^$M(V'"S3E6522-J)*XW&/:W[=67A_0_"7[1OA_PKX8T
MBWT_3=-\!BUT^QLX1'#;0QRLJ1HHX554  #@ 56_8@_9$\$_L3_L^:3\$_"$
MOVJXCS=^(-7:,*VI:A(J^;.0/NK\JHB\E8XT!+$%CJZK_P G6:9_V)TG_H]Z
M_D[CKBRIQ1FS=-OV%.Z@N_>3\Y?@K+>]_P"O. >$:?"N4)5$G7J6=1]NT5Y1
M_%W>UK>DT445\.?=!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'F^E_P#)U.I_]B?'_P"CTKTBO-]+_P"3J=3_ .Q/
MC_\ 1Z5Z10 4444 %%%% !1110 4444 %%%% !1110!^+O\ P<7_ /)[7A?_
M +)78_\ IRU*OCW]F3_DY+X>_P#8\:3_ .ED5?87_!Q?_P GM>%_^R5V/_IR
MU*OCW]F3_DY+X>_]CQI/_I9%7];<)_\ )!X?_KT_R9_'_&'_ "7V(_Z^K_VT
M_IDHHHK^23^P#P__ (* _MB7G[#GP*C^-\7PDNO&%N-<M["^L[;4A:"TCE23
M%P\ABDPN]4CQMY:5>:^8O#O['W_!(3]OC]GV/]H_3=$T+X=7%QI4%SXKD\)^
M*X[#_A&9U7,UO-#*!:Q!65U\QK=!(@$B\,#7WC\2OAKX%^,/@35/AE\3/#-K
MK&@ZU:-;:EIMXI*31GW!!5@0&5U(96564A@"/B/7/^#=G]BC5-8GU'3OB%\1
MM-MYIB\=A;:Q9/' I/W$:6T9\#MN9CZDU]SPWF>2X/ N,\15PN(4K^TIWDIP
M_EE'F2NG>SM;O?8^#XFRO/,9CU*&'I8K#N-O9U.6+A/^:,N5NS5KJ]^UMSPS
M_@A%XIUGP/\ MN?%#]GCX<_$2Y\0_#J#3=2NK.ZVD6]Y);7\%O;7ZKR(VE@<
MYQ]X%<Y\M<8W_!';XS>%?V!/VN?BA^RQ^TWK>G^&;C5)(K,:YJUU]GM$O=/E
MG"(7D 58YXKB21)7*J=B 9,BU^DG['O[#?[/W[#W@JZ\'_!'P_<+-J4BR:QK
MFJS+-?ZBR@A/-D"JH503MC1412S$+N=B>9_;&_X)@_LJ?MN:A#XF^*7A[4-+
M\10QK$/$_AFZ2VO)8EZ1R[TDCF4< %T9E PK*,@^[BN,<BS'-,;1Q$)K#8F%
M.+FDN?FIZQJ.*LM7NM[)>AX.%X+S_+<JP-;#S@\3AIU)*#;Y.6KI*FI.[T2T
M>UV_4^>?VZ_^"N_PTT#P#\:_V6?&_P (_%'A_P 22^']1T?PA<WUN'M/$%O<
M@V:WL3C!1"))9ER"C1PD;_,(CKH_^#?CX3^*?A]^Q5?^,?$^F26J^,/%UQJ.
MDK+P9;)(8;=9<=0&DBFQD#*A6&0P)R[;_@W2_8O@@N!+\3OB1/+);LD#3:K8
M[87(XDPMF-Q![$X->[?\$Z?V3?CI^Q]\-=:^%_Q@_:$N/'6GPZLB>#8Y$81Z
M;IL<*JJ@2 R1,QR# ))(HUC3RR"TF>?-LPX3H\)U<!D]1\TIPE-34DY65O<W
MMK[S4I=[7T2Z,GRWBZMQ=2Q^<TERQA.,'"46H7=_?MRMZ>ZG&/:]M6W?\%5O
M@]XP^.O[ OQ#^'_@'3)K[6#I]O?V=C;Q&26Y^R74-T\4:*"SR-'"ZJH!+,5
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M_AYXDNK33+Z^<,]O8I:VDB6D><,_[V<I$I)),JQK@*JCP/PM\2/!_P#P5O\
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M2^%?C'6+&.T\1:Q\*_&!TIM:CC"K%]I'EOO**BJ-NW(4;@Q (ZC]G3_@GO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#5NLVI:UJ6HV&GQ/($5YYDMHT4L>%!9AR>!7W=7Q_P#\%0?^2K_ '_LH _\
M1]E6E&I*C6C4CO%IKY:F=:G&M1E3EM)-/YZ'YQ_\.*_^"C/_ $3#1?\ PJ[/
M_P".4?\ #BO_ (*,_P#1+]%_\*NS_P#CE?NY17ZA_P 1@XI_DI?^ R_^3/RK
M_B#7"?\ /5_\"C_\@?A'_P .*_\ @HS_ -$OT7_PJ[/_ ..4?\.*_P#@HS_T
M2_1?_"KL_P#XY7[N44?\1@XI_DI?^ R_^3#_ (@UPG_/5_\  H__ "!^$?\
MPXK_ ."C/_1+]%_\*NS_ /CE'_#BO_@HS_T2_1?_  J[/_XY7[N44?\ $8.*
M?Y*7_@,O_DP_X@UPG_/5_P# H_\ R!^$?_#BO_@HS_T2_1?_  J[/_XY1_PX
MK_X*,_\ 1+]%_P#"KL__ (Y7[N44?\1@XI_DI?\ @,O_ ),/^(-<)_SU?_ H
M_P#R!^$?_#BO_@HS_P!$OT7_ ,*NS_\ CE'_  XK_P""C/\ T2_1?_"KL_\
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MB7Z+_P"%79__ !RC_AQ7_P %&?\ HE^B_P#A5V?_ ,<K]W**/^(P<4_R4O\
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MHHH **** "BBB@ HHHH **** /-]+_Y.IU/_ +$^/_T>E>D5YOI?_)U.I_\
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M444 %%%% !7FVJ_\G6:9_P!B=)_Z/>O2:\VU7_DZS3/^Q.D_]'O0!Z31110
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M^E]R6BBBO,/4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "OC_ /X*@_\ )6/@#_V4 ?\ H^RK[ KX_P#^"H/_
M "5CX _]E '_ */LJ /L"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#SCX@?\G$_#_P#ZX:G_ .DYKT>O./B!
M_P G$_#_ /ZX:G_Z3FO1Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV+3:KX%CU#Q+IY5E7$<&J7RW08D9*BUDG?:",M&G7&*^H/\ @N!_RC8\<_\
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MC5O'FHRQPZ;?+X7N(X=*42*TD\BW]NJ29C#HJA7^9@2 !S:_;+\6?M"^//\
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M;[6MJW9)GZOQEC,AR_*XXK-*:FH33A%NUZFO+U2[WO=)7;1Q'PQ\,_"OQ_\
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MJR_^/4?\1'O[,O\ T0?QW_WU9?\ QZOQVHH_XA7P?_SZE_X'+_,/^(L<:?\
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M_CO_ +ZLO_CU?CM11_Q"O@__ )]2_P# Y?YA_P 18XT_Y^Q_\ C_ )'[$_\
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M^CWKTFO-M5_Y.LTS_L3I/_1[T >DT444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 >;Z7_R=3J?_ &)\?_H]*](K
MS?2_^3J=3_[$^/\ ]'I7I% !1110 4444 %%%% !1110 4444 %%%% 'XN_\
M'%__ ">UX7_[)78_^G+4J^/?V9/^3DOA[_V/&D_^ED5?87_!Q?\ \GM>%_\
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MY+>XU&PL8H[C37F1S& [H,.&,;-"JEU1S*K]1'Q+\:O%O_!-CX'?#>'XH_\
M!,'P9\7? OQF\-WEG<:#K"Z7K3PZK&LT8N+6]2Z>2%H9(][L@159HU4C860_
M6G[0-_KG_!2_]KKX-_L@^,K[5/#_ ,+M1^"MM\5_B!X;L]1EM9_$"SW"P6^E
MSL@#K'%,(V8!@6#R$;9(XI%Z+QQ^U%_P5V^/>D6_PA^"/[!T_P 'O$D^H6Z:
MY\1/%GBK3]1T_1X5E4R-;Q>61>;U!7*JY56.U<D2)N?ME_ GX[:)^U#\/_VO
M/V.M=T'Q=\6O _A'^Q_&WPZUK7HM/N/%_AJ>=MKK\ZQ6S)<FXE5V58BXSEC
ML$@!\]_ML_\ !/?X8?L6?M#?LPZW^R])JGAWP#K?[17AJ'Q#X'F\075[9G5U
MN@;;4(EN7D=)3!]IBD._:56'"@@DZGC+]ESX<?MA_P#!=/XL?!SXX0ZEJ'@B
M'X8Z3J^K>';'6)K*'5;J&*RAMDN&@9)6CC-S+,%5U'F1QDY"[3S7[;?Q%_;D
M^+W[8'[*.K?M+_ G2OA7H\/QRTI=!\ V?C*+7=0U&:.\LY+G4YI;4"$011LD
M:* '0R3%_E=#7U;\*?V:/C;X:_X+"?%#]J;6O!7D^ _$7PQL=)T;7?[2MF^T
M7D9LM\7DK(9DQY,GS,@4[>"<C(,\B_;L_9R_X)U_!/6/AQX*_;%_:D;PW\$?
M"/AEK#PO\!+-M0)U"^+3?\32XELIGO+A5!*AC&H611^]_>21R^-?L;>-_P!C
MSP/_ ,%7_A+X>_X)F6?C/P_\.O'GA_6[#QM9ZE'J2:3KD]GI]U=P30'4':62
M6-MFX\!%*;0/-DW>[_M*_!S]I[]GO_@I[=?M[>!?V5)?C?X9UWP'#H=KI^GZ
MI;Q:AX4ND,8,D"3AB5<(YW1@?\?,P9DZ2P:7\)O^"CGQ^_X*6?!7]M+XS?LX
MZ=X-\#^$X=;T]?"]KXLL[V_T2"?3I81>7CAU69[B6=0(X YB2##J#\S@C/\
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M+KX9?&C0O$/BJ\;4+>W58%DOKC4+E//:+=$L]V0D8W2["HPQ#&OO:D4?%_\
MP6:_Y!O[-O\ V=1X4_\ 0;JOM!NE?)__  5K^"'[0OQF^'OPIU;]FSX2_P#"
M;:UX#^-6C^*[S0?[>M--\ZULXKHL//NG5%W.T:<;F&_.T@&LG6OVMO\ @K[K
M&F3:5X3_ ."1VE:+J5Q&8[/5M<^.NDWMG9R$866:"!8Y)8U.&9$=68 @$$@T
M@/"/!UCIN@?';_@I9H/@^&./1Y/ Z7MQ'!]P7TVBZC).WLS3/.6]3UZ5K?\
M!)+_ ()L_LO_ !U_8V^'/[4?[0?@>]\4^-]1T>_LDOM3UZZ,%MI2&ZTR"QCM
MXY%A$(M5#<H7\R1V+YP!Z[\#_P#@G;\0O@'^P[\;O"_B/Q#:^-OC1\9M%UZ_
M\8:U9>7;V^H:M=VEPD-K 76)4@629]K.$&Z>1L1H51/3O^"8'P6^)?[/'[!W
MP[^#'QB\-?V/XET+3;F+5=-^V0W'D.UY/(H\R!WC;*.I^5CUQUR*KH(^?O\
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M02["5=7>XRH#\])_P5&_8@T_]L#]B[Q5\*OA_P"#=-_X2ZU2/5O!K)'% _\
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M6.FZ79Q6FGV=NN([>"- B1J.P50 /85(R[1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7Y_P#_  7Q_P"28^"_^XQ_Z)@K] *^*?\
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M?\1<X3_Z>?\ @"_^2#_B#_%W>G_X&_\ Y$_$&BOV^_XA_?V!O[WC?_PHT_\
MC-'_ !#^_L#?WO&__A1I_P#&:/\ B+G"?_3S_P  7_R0?\0?XN[T_P#P-_\
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M>;:K_P G6:9_V)TG_H]Z /2:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /-]+_P"3J=3_ .Q/C_\ 1Z5Z17F^
ME_\ )U.I_P#8GQ_^CTKTB@ HHHH **** "BBB@ HHHH **** "BBB@#\Z_\
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M8]J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *^/_P#@J#_R5CX _P#90!_Z/LJ^P*^/_P#@J#_R5CX _P#90!_Z
M/LJ /L"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#SCX@?\G$_#__ *X:G_Z3FO1Z\X^('_)Q/P__ .N&I_\
MI.:]'H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *\VU7_DZS3/\ L3I/_1[UZ37FVJ_\G6:9_P!B=)_Z/>@#TFBB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@#S?2_^3J=3_P"Q/C_]'I7I%>;Z7_R=3J?_ &)\?_H]*](H **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *^/_P#@J#_R5CX _P#90!_Z/LJ^P*^/_P#@J#_R5CX _P#90!_Z
M/LJ /L"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#SCX@?\G$_#__ *X:G_Z3FO1Z\X^('_)Q/P__ .N&I_\
MI.:]'H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M $=#J7_@GT__ .1Z/^'P'_!2'_HZ'4O_  3Z?_\ (]'_ !!OB+_G_2^^?_R
M?\1JX;_Y\5ONA_\ )G]!%%?S[_\ #X#_ (*0_P#1T.I?^"?3_P#Y'H_X? ?\
M%(?^CH=2_P#!/I__ ,CT?\0;XB_Y_P!+[Y__ " ?\1JX;_Y\5ONA_P#)G]!%
M%?S[_P##X#_@I#_T=#J7_@GT_P#^1Z/^'P'_  4A_P"CH=2_\$^G_P#R/1_Q
M!OB+_G_2^^?_ ,@'_$:N&_\ GQ6^Z'_R9_0117\^_P#P^ _X*0_]'0ZE_P""
M?3__ )'H_P"'P'_!2'_HZ'4O_!/I_P#\CT?\0;XB_P"?]+[Y_P#R ?\ $:N&
M_P#GQ6^Z'_R9_0117\^__#X#_@I#_P!'0ZE_X)]/_P#D>C_A\!_P4A_Z.AU+
M_P $^G__ "/1_P 0;XB_Y_TOOG_\@'_$:N&_^?%;[H?_ "9_0117\^__  ^
M_P""D/\ T=#J7_@GT_\ ^1Z/^'P'_!2'_HZ'4O\ P3Z?_P#(]'_$&^(O^?\
M2^^?_P @'_$:N&_^?%;[H?\ R9_0117\^_\ P^ _X*0_]'0ZE_X)]/\ _D>C
M_A\!_P %(?\ HZ'4O_!/I_\ \CT?\0;XB_Y_TOOG_P#(!_Q&KAO_ )\5ONA_
M\F?T$45_/O\ \/@/^"D/_1T.I?\ @GT__P"1Z/\ A\!_P4A_Z.AU+_P3Z?\
M_(]'_$&^(O\ G_2^^?\ \@'_ !&KAO\ Y\5ONA_\F?T$45_/O_P^ _X*0_\
M1T.I?^"?3_\ Y'H_X? ?\%(?^CH=2_\ !/I__P CT?\ $&^(O^?]+[Y__(!_
MQ&KAO_GQ6^Z'_P F?T$45_/O_P /@/\ @I#_ -'0ZE_X)]/_ /D>C_A\!_P4
MA_Z.AU+_ ,$^G_\ R/1_Q!OB+_G_ $OOG_\ (!_Q&KAO_GQ6^Z'_ ,F?T$45
M_/O_ ,/@/^"D/_1T.I?^"?3_ /Y'H_X? ?\ !2'_ *.AU+_P3Z?_ /(]'_$&
M^(O^?]+[Y_\ R ?\1JX;_P"?%;[H?_)G]!%%?S[_ /#X#_@I#_T=#J7_ ()]
M/_\ D>C_ (? _P#!2'_HZ'4O_!/I_P#\CT?\0;XB_P"?]+[Y_P#R ?\ $:N&
M_P#GQ6^Z'_R9^X/Q _Y.)^'_ /UPU/\ ])S7H]?D]_P2C^.'[='[7_[2_A[X
MC_'#XW:I?>#] N+VWAW:;:Q?;[O[(SM;JT<*_*JM&\G.<,BC[Y*_K".E?GW$
M&25.'LQ>"JU8SG%+FY+M)OHVTM;:NVU][W2_1>'<]I<1Y;''4J4Z<)-\O.DF
MTNJ2;TO=*^]MK6;****\0]P**** "BBB@ HHHH **** "BBB@ HHHH ****
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M33O9Z:+?3' XO&9AF.23R^I!U/JTHN4[R2<8Q4[I-.4DTUNM=6]-?O/]F_\
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M/Q&U"2::9PJ1H+&P)9B>  .23P*U?B;^QQ^RU#_P1UO-/TWX<^'Y5TOX/?\
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MQQ,YPE*[BW3YE&Z?\LTI1=K7B[]TVF%%%%?.GT@4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %?G_ /\ !?'_ ))CX+_[C'_H
MF"OT K\__P#@OC_R3'P7_P!QC_T3!79E_P#O]+_%'\T<>8?[A5_PR_)GXQT4
M45_<!_"(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7IG[(?[+?Q!_;%^/.B_ [X>PO')?2>;JVI^09(]+L4(\ZZDY'"@@
M$C>[(@(+BO.])TG5M?U6UT'0=+N+Z^OKA+>RLK.%I)KB9V"I&B*"S,S$ * 2
M20!7[X?\$JOV -,_8=^!*/XGLHW\?>*8XKKQ==B0.+? )BL8R/EV1!CN8$[Y
M&=MQ78%^+XXXKI<+Y2YP:=:=U37GUD_*/XNRZW7W' ?"-7BO-U"::H4[.H_+
MI%/O+;R5WTL^P\%_!7P%^SKXL^$/P3^&6G-:Z)X=TG4;:S60J9)#Y#,\TA4
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MZ[=$D0QR*&5AAE/>EHKQ<TS3&YQC98K%2O-VZ622T226B26B7ZGM93E.!R7
MQPF$C:$;]6VV]6VWJVWJW^ED?G*?^"3W[<'[*_QP\3>,O^":7[37AOPCX5\5
M*KW6B^*%>1[/$KLML%DM+N.=(@W[N=MLH61D.?F>38_97_X)&_';]G+_ (*%
M6_[5&N?&?1?%F@B.[GU/4-0FGCUC4+Z[L&2YG: 0F%%:[EE95\YB(]N2S9S^
M@5%>_4XXSZMAZE.;@_:0=.<N2//.+22YI6YFTM$V^KW9\_3X#X?HXBG5@II4
MYJI"//+DA)-M\L&^5)O5I+HMD?"?[2?_  2Y_:,T?]JV_P#VR?\ @GA\?=*\
M#>*/$2R+XDTSQ!"?LCM*H\^1"MO.LBRNL<C0RQ,!*#*K@[%3I/V&O^">G[2'
MPN_: UO]K3]LO]HX>+O&FI+)%!IGAJZGATSYH(H?M,RA+=)7$2>6L/D"- JN
M"SA#']D45S5.+LXK9?\ 5).+O!4W/DC[1P6T'.W-R^5SJI\'Y+1S'ZY!25IN
MHH<\O9JH]YJ%^7F\['Y7_%KX-_#'QA_P4?USQ7_P38_;JTWP/\8[S6KVV\3^
M#=>T&^AMFNXV?^T#'.]J\-QN>/S#;NDB.X>17P$5?,?B!^SQJWPW_P""RWPA
M\"W7Q\O_ (I>,;C7-'UKQWXANE19([Z*^FE:$0HS_9TBL;>W(C+':O(VJ51?
MT!_:K_X)%_L:_M<^+[SXC^./#>KZ'XEU!HSJ&O>%M2%O-<[  "\<J20EBH +
M^7N(ZG(!%_\ 9"_X)7_LC?L7>)%\=_#+PSJ6J>)DADA@\2>)[Y;JZMXY!AQ$
M$2.*(D94ND8<JS+NVLP/VV'XURO"Y?S1JU)5/8NER2IT^9R:LKUE:3IQ^S%J
M_5W=K?#XC@?-L7F7+*C3A3]NJO/&I4Y>5.[M1E>*J2^U)/EZ*RO?SO\ :E_X
M)S?&WXX?\%)?AS^V+X5\5>%;?PSX0_L?^TK'4+VY6^E^R7DL\GEHENT9RL@"
M[I%R0<X'->A?\%._V#I_V^/@/:^ _#WBJVT7Q%H6J?VEH-[?*[6TK^4\;6\V
MS)5'#*?,5692BX!!93](45\%'B;-H5L+5A)*6&7+!I+1>?>]VGY'Z!+A?)ZE
M#%T9P;CB7S5$V]79;=K637F?FKX__P""6/\ P4^_:*^ UQ\(/VE_VT_"^I6O
MA^WLV\#Z'86[&VGN(L1E[^Z%C%.P2#>%)6=GDDWL05._WR?_ ()S:A\9_P#@
MFYX:_8J_:3\1:7#XA\.Z?'%IOB/PQYEQ!87-L\B6EQ&LRQ-+_H[".5&";A)*
M%93M<?5U%=6)XPSK$1IQBX4_9S]I'DA&'+*UM+*S3W=[W>^FAQX7@O),-.I*
M2G4=2G[.?/.4^:-[I.[NFMDU:RVUU/S7T3_@EY_P5-\2_ .]_96^+7[:WA=?
MAY9^&YK;0=#TE'FEN+B+YK*TGN9+&.>*T60+NQ)*5CC$:QD$%/6_V-_^"76K
M?#C]@7QG^Q/^T]K6D:E#XN\07-\]YX4O9G6W1HK3R)%::&,^;'-:B0 H4.U<
M[@2M?9M%7B^-,[Q=!TO<@G-5/<A&#YXNZE>*7O7U;=V[(G!\$Y'@ZZK>_-J$
MJ?OSE-<DE9QM)OW4M$E9*[/S'M/^"67_  5D\#_"35/V3?AS^VIX-_X53>M<
M6OV*[CFANI+&9\RI@64LD <%BT"7)0[W4L0[9^E?%G_!/KQ%I?\ P39UK]B+
MX>?$N36M>U33@DGB?Q=>3*ES=M=1SR2,%$S0Q_*52-0^T!<EF+.?J.BIQG&&
M<8R5.4N2/)-5/=A&/-46TIV2YGW[_=:L'P7DN!A4C#GESTW2]ZI*7+3>\87;
MY5V[???Q'_@G9^S7XY_9&_9$\,_ 'XD:MI-]K&BS7[W5SHDTLELPGO9ITVM+
M'&QPLB@Y4<@XR.3\Q>*/^"4O[8O[._Q_\2_&#_@F?^TIX=\&Z9XQ:5M5\/>)
M+$"*R4R"5885^R7,4B*YD\MC'&\2'RP7#.Q_0NBN;#<3YIA<=B,4N67MVW4C
M**E"5WS:Q::T;NNWI<ZL5PME.*P&'PK4H_5TE3E&3C.-DHZ233U2L^_K8^+/
MV(/^"9GQ@^&O[3.K?MN_MI_&'2_&GQ,O(G@L6T.W*VMKNMUMS<%S%#F3R 85
MC6)$1"W+EAL^TZ**X,US;&YSBE7Q+5TE%))1C&,=HQBK))=$CNRG)\#DN%=#
M"IV<G*3;<I2E+>4I.[;?5L****\T]0**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "OS__ ."^/_),?!?_ '&/_1,%?H!7P=_P
M7(\,ZYXU\+_#GP;X8L#=:EJU_J5EI]J)%7SIY4MTC3+$*,LP&20!GDBNK RC
M'&TI2=DI1_-'+CHRE@JL8J[<9?DS\5**^G/^'-G_  4I_P"C8[K_ ,*32_\
MY*H_X<V?\%*?^C8[K_PI-+_^2J_L;_6;AO\ Z#:/_@R'_P D?Q;_ *K<3?\
M0#6_\%3_ /D3YCHKZ<_X<V?\%*?^C8[K_P *32__ )*H_P"'-G_!2G_HV.Z_
M\*32_P#Y*H_UFX;_ .@VC_X,A_\ )!_JOQ-_T UO_!4__D3YCHKZ<_X<V?\
M!2G_ *-CNO\ PI-+_P#DJC_AS9_P4I_Z-CNO_"DTO_Y*H_UFX;_Z#:/_ (,A
M_P#)!_JOQ-_T UO_  5/_P"1/F.BOIS_ (<V?\%*?^C8[K_PI-+_ /DJC_AS
M9_P4I_Z-CNO_  I-+_\ DJC_ %FX;_Z#:/\ X,A_\D'^J_$W_0#6_P#!4_\
MY$^8Z*^G/^'-G_!2G_HV.Z_\*32__DJC_AS9_P %*?\ HV.Z_P#"DTO_ .2J
M/]9N&_\ H-H_^#(?_)!_JOQ-_P! -;_P5/\ ^1/F.BOIS_AS9_P4I_Z-CNO_
M  I-+_\ DJC_ (<V?\%*?^C8[K_PI-+_ /DJC_6;AO\ Z#:/_@R'_P D'^J_
M$W_0#6_\%3_^1/F.BOIS_AS9_P %*?\ HV.Z_P#"DTO_ .2J/^'-G_!2G_HV
M.Z_\*32__DJC_6;AO_H-H_\ @R'_ ,D'^J_$W_0#6_\ !4__ )$^8Z*^G/\
MAS9_P4I_Z-CNO_"DTO\ ^2J/^'-G_!2G_HV.Z_\ "DTO_P"2J/\ 6;AO_H-H
M_P#@R'_R0?ZK\3?] -;_ ,%3_P#D3YCHKZ<_X<V?\%*?^C8[K_PI-+_^2J/^
M'-G_  4I_P"C8[K_ ,*32_\ Y*H_UFX;_P"@VC_X,A_\D'^J_$W_ $ UO_!4
M_P#Y$^8Z*^G/^'-G_!2G_HV.Z_\ "DTO_P"2J/\ AS9_P4I_Z-CNO_"DTO\
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 ><?$#_DXGX?_ /7#4_\
MTG->CUYQ\0/^3B?A_P#]<-3_ /2<UZ/0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5YMJO\ R=9IG_8G2?\ H]Z]
M)KS;5?\ DZS3/^Q.D_\ 1[T >DT444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 >;Z7_ ,G4ZG_V)\?_ */2O2*\
MWTO_ ).IU/\ [$^/_P!'I7I% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Q_P#\%0?^2L? '_LH
M _\ 1]E7V!7Q_P#\%0?^2L? '_LH _\ 1]E0!]@4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ><?$#_DXGX?_
M /7#4_\ TG->CUYQ\0/^3B?A_P#]<-3_ /2<UZ/0 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YMJO\ R=9IG_8G
M2?\ H]Z])KS;5?\ DZS3/^Q.D_\ 1[T >DT444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 >;Z7_ ,G4ZG_V)\?_
M */2O2*\WTO_ ).IU/\ [$^/_P!'I7I% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC9__ !RC^Q\V_P"@>?\ X!+_ "#^V<G_ .@BG_X''_,]@HKQ_P#X>"?L,?\
M1WWPW_\ "QL__CE'_#P3]AC_ *.^^&__ (6-G_\ '*/['S;_ *!Y_P#@$O\
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M10 4444 %%%% !1110 4444 >;Z7_P G4ZG_ -B?'_Z/2O2*\WTO_DZG4_\
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M1110 4444 %?G_\ \%\?^28^"_\ N,?^B8*_0"OS_P#^"^/_ "3'P7_W&/\
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MJU,D,OB[5_#LL<EC?,+>9M0F62,F-PUNRHS@_/-G!+D$]9\3OVU/VIOVL_\
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MK:\J5WLTWI\UCN N(*F%C@:=>-2BJ*II2G4@HS5[SY()J=[Z<S=EHTTM9O\
M@CTMNG_!-SX7BVDW+_9UZ2?1O[0NMP_ Y%>.?\'$?AGQ!K/[%^@:[I5A<3VF
MC_$"UGU1H8RRP1/:742RN?X1YCI&#TW2J.XK[-^"/P0^&/[.?PUT_P"$'P<\
M./I'AW2VF.GZ:VH7%UY/FRM*X#W$CO@N[-@L0-W&!6UXQ\'>%?B#X6O_  1X
MX\/VNJZ1JEJ]MJ.FWT(DAN(F&&1E/!!%?&X?/Z6#XO>;TXMP]K*:3LFXRDW9
MV;2=GW:N?;8CAZMC.#5DU2:C/V,:;:NTI1BE=72;5UV3L?%_Q._;0_9?N/\
M@CQ>:I9?$CP_&^K_  ?/AVQ\.VNH0M=0ZI+IPM!9B#(?=%(X+87Y8T,GW #7
MQS\&O!_BGQA_P0%^)9\+)<2_V5\6%U#4;6VA:1I;6---$A(4'Y4W"9B<!5B9
MB0!7Z%^$O^".'_!.CP;J6H:GIG[/,,[:A87%D\6H:]?W*0PSQM'((Q).=C[6
M.V0?O$.&1E89KUKX#_LI? #]F?X<7WPB^"WP[ATKPWJ5[-=W^DW%]<7T<\LL
M212%C=22,59(T4KG;@=.3GZ2CQ7P_E.%E#+XU9R=>%;WU%*T7?ETE)WZ<UG=
MZV5M?F:O"7$6<8J,\QE2A%8>=']VY-WDK<VL8JU]>6ZLE:[OI^5GP-^&5SXH
M_8!3XB:[_P %B]0\*>$(?#]Q8Z]\-TTA;A[%29(GT\6XU%&E\T9V+Y:^8L@.
M "37HFG?L[>$/#?_  0E^*VB_LY_%?4_B-I.J>)E\0QZK)X/GT9O*MKK31=*
M(9Y',D<4=E)*9%8J2K+C<C"OJK6?^"*__!-[6_%$OBBX_9_,+3W!FEL;/Q%?
MPVI8DDA8DG C7)^XFU0.  .*]<^-5OXY^!?[,6K1?LF?"S1+S5O#.DHWAOP@
MUFR6L\,3H9;:..$J=[0B41A>LA3(;D'JQW&F&Q6)I+!2FVZ\*G+.%&E!<LDU
M&4H1<I-/>;DK+5ILY,#P/B,)A:SQT()+#SI\T)UJLWS1:<HQG)1BFMH*+N]$
MTCY-_P"":O\ P4)_9 ^$G_!-;P]!X_\ B[X<T?5O!FGW\&K>%)M0BCU&XE6X
MFE7R+9MKW!F21&#1JR[I&4ME'QX/_P $&3N^!G[33 ?\RSIW3M_HVK5ROPH_
M;>_X)@_#7Q3??$?XT?\ !-2\\/\ Q5T?5KDQ:/HJM)I,%R@^7?:7=TB6<BS;
MU*+;/Y.Q67+#:OT9_P $$?V4/'O@3]GSQ_XU^,GA"[TW3OB7+:6^GZ7J,,EO
M/=:?##/FYQPRQ2_:V"-P2(RX^5D8^[G6%PN3Y)FE>=*I3>(J4I+VC@^9JJYR
MC3Y6^915WS-ZIK16;?@9'BL5G6>950A5IU%AZ=:+]FIKE3I*$95.:*Y7)V7*
MEHT]7=)5?^#;SP]I-M^S_P#$3Q9#:H+Z]\8PVEQ.%&YX8;1'C4GK@-/*1_OG
MU-4?VNOVVOVHOBK_ ,%'+C]@3X5_M#Z7\&?#-FJ6E[XHO+.%KB[DDLHKHN))
M<%');RX4BDB+YR7)90OW1^SA^RA\ ?V1_"]]X+_9[\!?\(_INI:A]MO;;^U+
MJ[\R?8L>_=<RR,/E11@$#CIFN._:2_X)L_L;?M9>,H_B'\:OA&E[KJ6ZP2:K
M8:G<V<L\:_=67R)%$I X#,"P4!0< "OD/]9\CQ/%V*S/%4I2IU(M0O&$Y0E:
M*C)PD^27+9V3;6Q]E_JMGV%X/PF5X6K&-2E).=ISA&<;R<HJ<5SQYKJ[23W1
M^87A7PMIW@G_ (+(_"_PG-^UO??&6[L=:L$U;QI?7AF_TLF5OLD;&:8;8P47
M:)&"NSKP05'KGQ(\9>&?V=?^#B _$GXW7D.A^']<L[?^S=>U;]W;HDVA+9QS
M;\86/[3');F0X5<,6*J&-?:OA[_@EE^P1X3\2^%?&/A?]GJRTW5?!4T,WA[4
M+'6+Z&6*6*<SI)*4G'VIQ(<[I_,)7"'*@*.O_::_8O\ V:_VP='L='_:!^&=
MOK?]ER,^EWB74MM=6I888)-"ZOL/!*$E"54E25!'I8CCC)\1CH<\:CIRP\\/
M-\L(R]YWYXQB^7HO=T2V5[:^9A^!,YP^!FH2IJI'$PQ%-<TY1]U6Y)2DN?J_
M>U;W=KZ?FS_P<1_'/X2?$?QM\,_AUX"\9Z9K.K>';?5+K6O[+NEG6S2Z-H(8
MW="5#M]GD8IG<J[&( =29/\ @M%X5\0Z7_P4\^%_B_5OB->>!])U;1=+@TWQ
M\EHSQZ-)%?SB693N0,T'FQS. X*K*I)&17V\O_!'[_@G2? ]G\/[C]G*VDL;
M.]>[67^WM0CN99F4*6EGCN%DE  ^5&8HFYBJKN;/KG[0'[-/P._:D\#?\*Y^
M//P\L_$.E+,)H([AGCEMY1TDBEC99(FQD$HPR"5.02#.#XTR7*E@*&&A4E3H
M1K0DY*',U5<7S15Y1NFF^66EK*[U9>-X'SS-GF%?%3IQJ5Y4)P47/E3I*2Y9
M/EC*S32YHZWULM$?E;^UW^RY\.-:\7>#?AU^TM_P61U3QM?ZH7D\,6]G\/YM
M=:W,SPQC"VNH2NAF)39A3YGE'&2HSZ!_P6P\,:?XD_;?_9W\&>)$6]M;]K6R
MU!94&)XWU*%'!!S]X$Y'/6OL;X#?\$KOV&/V;_'5O\3/AG\%8UUZR.=/U'5M
M4N;UK1O[\232,B..SA=XYP1DUV_QF_8U_9N_:#^(?AOXK?%[X<_VOK_A"6.3
MP[?_ -L7EO\ 9&283*=D$R))B10WSJW3'3BICQQ@:.:8:KS5)TZ,*JOR4H/F
MJ*WNPI\J2VO>3;W275RX$Q];*<52Y*=.I6G2=O:5JBY:<D[2G4YFW:]DHI+9
MM].<_P""C.N? /0_V//%P_:?\.ZYJ/@:\CMK76E\.PAKJW+W$8@G3+*%*7'D
ML"25W!058$J?RZM?V5-/^&7[/.H?MC?L!_\ !2W^P]&6UGOM0\*:]KG]AZQ
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M2I"*4I/[32U>NK]7J]WJ%%%%>>>D%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7Y_P#_  7Q_P"28^"_^XQ_Z)@K] *_/_\
MX+X_\DQ\%_\ <8_]$P5V9?\ [_2_Q1_-''F'^X5?\,OR9^,=%%%?W ?PB%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 9QUK
M]>/^"$G_  3Q;X=>%XOVT_B[HVW7M>LV3P-I]U;8:PT^08:]^;D23J2J$ 8@
M).6$Y"_)'_!(3_@G?<?MF_&7_A/OB/HT_P#PKCPA=))K#M'B/5[P8:/3U8]1
M@AYL9*QE5^4S(P_=F&&*"-888U554!55<  =@*_$?%3C#V--Y+A)>])?O6NB
M>T/5[R\K+J[?NGA/P9[>HL\QD?=C_"3ZOK/T6T?.[TLK^=?$#_DXCX?_ /7#
M4_\ TG->CUYQ\0/^3B?A_P#]<-3_ /2<UZ/7X"?T,%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>;:K_R=9IG_8G2
M?^CWKTFO-M5_Y.LTS_L3I/\ T>] 'I-%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% 'F^E_\G4ZG_V)\?\ Z/2O
M2*\WTO\ Y.IU/_L3X_\ T>E>D4 %%%% !1110 4444 %%%% !1110 4444 ?
MB[_P<7_\GM>%_P#LE=C_ .G+4J^/?V9/^3DOA[_V/&D_^ED5?=G_  7V^!GQ
MM^)_[8GAO7OAK\'?%7B&QA^&EG;S7NA^'KF[A28:AJ+&,O$C*&"LIVYSA@>X
MKY0_9T_96_:@TC]H/P'JNJ_LW^/K6UMO&6ERW%Q<>#[U(XHUNXRSLQBPJ@ D
MD\ "OZMX5QF#AP/0A*I%/V3TNK]>ES^2.+<%C:G'F(G&G)KVJU2=NGD?T3T4
M45_*1_6X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M &!Z48 Z"BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OAG_ (+5>"=0
M^)=I\+?AQI-W#;W7B#6K[3;:>XSY<<DXMHE9L G:"P)P"<5]S5\?_P#!4'_D
MK'P!_P"R@#_T?95I3J2HU(U([IIKU1G5IQK4Y4Y;--/T9\9C_@W$_:B(_P"2
MY> ?^^KW_P",4?\ $.)^U%_T7/P#_P!]7O\ \8K]C**_0O\ B*G&'_/R/_@$
M3\Y_XA-P9_SZE_X'(_'/_B'$_:B_Z+GX!_[ZO?\ XQ1_Q#B?M1?]%S\ _P#?
M5[_\8K]C**/^(J<8?\_(_P#@$0_XA-P9_P ^I?\ @<C\<_\ B'$_:B_Z+GX!
M_P"^KW_XQ1_Q#B?M1?\ 1<_ /_?5[_\ &*_8RBC_ (BIQA_S\C_X!$/^(3<&
M?\^I?^!R/QS_ .(<3]J+_HN?@'_OJ]_^,4?\0XG[47_1<_ /_?5[_P#&*_8R
MBC_B*G&'_/R/_@$0_P"(3<&?\^I?^!R/QS_XAQ/VHO\ HN?@'_OJ]_\ C%'_
M !#B?M1?]%S\ _\ ?5[_ /&*_8RBC_B*G&'_ #\C_P" 1#_B$W!G_/J7_@<C
M\<_^(<3]J+_HN?@'_OJ]_P#C%'_$.)^U%_T7/P#_ -]7O_QBOV,HH_XBIQA_
MS\C_ . 1#_B$W!G_ #ZE_P"!R/QS_P"(<3]J+_HN?@'_ +ZO?_C%'_$.)^U%
M_P!%S\ _]]7O_P 8K]C**/\ B*G&'_/R/_@$0_XA-P9_SZE_X'(_'/\ XAQ/
MVHO^BY^ ?^^KW_XQ1_Q#B?M1?]%S\ _]]7O_ ,8K]C**/^(J<8?\_(_^ 1#_
M (A-P9_SZE_X'(_'/_B'$_:B_P"BY^ ?^^KW_P",4?\ $.)^U%_T7/P#_P!]
M7O\ \8K]C**/^(J<8?\ /R/_ (!$/^(3<&?\^I?^!R/QS_XAQ/VHO^BY^ ?^
M^KW_ .,4?\0XG[47_1<_ /\ WU>__&*_8RBC_B*G&'_/R/\ X!$/^(3<&?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#S?2_\ DZG4_P#L3X__ $>E>D5YOI?_ "=3J?\ V)\?_H]*](H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *^/_ /@J#_R5CX _]E '_H^RK[ KX_\ ^"H/_)6/@#_V4 ?^
MC[*@#[ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH \X^('_)Q/P__ .N&I_\ I.:]'KSCX@?\G$_#_P#ZX:G_
M .DYKT>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ KS;5?\ DZS3/^Q.D_\ 1[UZ37FVJ_\ )UFF?]B=)_Z/>@#T
MFBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#S?2_\ DZG4_P#L3X__ $>E>D5YOI?_ "=3J?\ V)\?_H]*](H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "O'_P!IW]DRV_:2\:?#_P 87'CJ31SX#UMM
M12W33Q-]M)DMWV$EU\O_ %&,X;[W3CGV"B@ &<<T444 %%%% !1110 4444
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MIET;6/M%WXD\,KI=I*=;2&ZMA]F\V6"66'>C/'NB(8;\C) HL%S]&Z*_(O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5ST%4=>_9;_9E\4Z!HOA3Q/^SIX$U+2_#<3Q>'=-O_"-E-;Z4CE2ZVT;Q%8
MQ1"0@4':N>@JN81^7/\ P5>P?^"_'[./_7QX+_\ 4CN:^W?^"U6C:KKW_!+W
MXN6.CV$MQ-'H]G<M'"A8B*'4+6:5^.RQH[$]@I/:O>/%'P%^!GC?QUI_Q0\:
M?!?PGK'B;23"=)\1:IX<M;B^LC#(9(O*GD0R1[)"77:PVL21@G-=1=6UM>VT
MEG>6\<T,T926*5 RNI&"I!X(([4KC/RY_P""77[67P"\:?\ !'?Q)^R3X=\=
M^?\ $+PC\)/&>HZ_X?;3+E/LUK)=7SI*)FC$,@(NH.$=F&_D#!QL?\&OV/\
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MOV=]#A_X)>^(M-\.ZUX9NHH)O"EOI.F+%>:4(O+6"V%Y"T,+0E8RL8,:F/>
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M6<9VD#?^KO[97@CQ1\2OV0/BM\-_ NCM?ZUX@^&NN:;H]A'(J-<W4^GSQ11
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/_V8OVIO^"^WA[]FKX>^'_@Y^PE\/=8\(V/@?2;?PKJU]GSKW34LXEMIY/\
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MJ-_PBT\.#<[/*!\TB/[WWR%ZG% '/?M=?%W]HG_@I3_P53NO^";?PH^-FN>
M?AOX1M95\77OAVZ:.;4?*@5[MY0I0N#+*EHD3,\:D><5;.P<)^U7X!^,W_!O
MS\8OAW\1/V9_CIXM\4?"GQ)?7,>K> ?%6I*T+21^2UQ&PC185DF1RT<Z0J\;
M1$-O7(?N?VL_A+^T?_P38_X*M7G_  4>^%OP,USQ]\-?%UO(WBJU\-VS2S6
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_C+_ (*5_%O1_#4/QC\.?LFZE<?#TS+"?$%[J+1&=CA2ZXB/EQ>8=BR,I#G
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M]?>'K_X>_$1IK"\DMYFBTFP*LR,5)&;T'&1QD"O2OV7O^"F7[+_[6'BH^ ?
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M:SUBEUU5[_>KZ8KA'&83#U9RK4W*G&,Y13ES<LK6>L4NNJO?[U?[EHS7PO\
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MV;BDU:]I1NC6EPC*EB,-.I5C4I5*L*4G#FWD[NS<4I*U[2C='VE\'?BGX?\
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M1-V[IGBY#Q7_ &+@EA_8N5JBJ)J;A?1+EDDGS+31-VONGL?EY^UIK^E^(_\
M@BY\%[[2)=\<7B:RM9#SQ+#:ZE#(.?1T:O1O^"C?_*)3X8_]>_AG_P!-KU]_
M44X\4*%2C)4?X=6=7XM^9WY?AZ=^O9%0XLC3K49JA_#K3JVYM^9WY;\NEN_7
MLC\\/V\K'XL7O_!)/X/M\/UOFT>'PWX>D\6QZ=YFXV@TI=C3;.#;B7:6W?*'
M\H]LCY@_:*UK]DSQM^SE83?LA_LL^+-%.CZI:OXT\;:]NF1'\EXTMA-YTJYE
MDE+D 1 ^4F$(P$_:ZDV@'(KIRWC'^SZ<8^Q;Y9RGI-Q3YG>TDE[UNC>W8ZLK
MXV_LVG&/L&^6I*>E1Q3YG=J:4?>:^RWMIIT?*_ GQ!I?BKX)^#_$VAR;[/4/
M"^GW%JQSS&]M&R]>^"*^.O\ @JMIUIX%_:W_ &=?CSJD[0:99>+(;;5[V;B&
MUCAOK6<%F[$H\Y^D1]*^\*\A_;A_99TW]K[]GK5OA-)<06VJJZ7WAN_NF81V
MNH1!O+9]H)V,K21,=K$)*S!2P6O&R/,*.#SJ-:II"3E&76T9IQ;\[7OMK;8\
M/(,QP^"SR->KI3DY1EUM&:<6_/EO?;6VQX+_ ,%WSG]DGPV?^JC6O_I!?U](
M?L<#_C$3X5\?\TWT/_T@@KI/A!8_$?2OA?H.D_%Z]L+KQ-::5#!KEYIEP\D%
MS<(@5YE9XXV^<C>04&"Q'(&3TE9XK,N;*:>7<O\ #G*7,G=.^FBM^-]>QGBL
MTYLGIY9RK]W.4N9.ZE?316V\[Z]CX<_X+S?\FR^$_P#L>X__ $BNJK?\% ?V
MR=1^"G[*'@G]GGX6SW#^./'O@^QA7[&NZ6RT]X4B9U RWFS-NACVC(Q*P*LB
M9^[**Z\'GV'H8?#4:U#G5&4I?%92<K6NN5Z)J_6^VAV8'B##X?#86C7P_M%0
ME*=N:RDY6M=<KT35VM;[:'Y@_&;_ ()-^(?@[^Q'H?Q9\#3WB_%'PG(VO>)C
M8W6U_*8([Q0%3P]H$5U96RQ6=ER6C4?6?[!_[='AS]IG]F6X^(_BZ]CM_$'@
M^S,?CB'<@PT<1<7:JN-L<R(S#@!761!D)N/T77E_[8_PU^+_ ,9/V=O$GPG^
M"6LZ/IVL^([3^SYK[7)W2&*SD.+D?)#*2SQ;XQ\HQYA8,"HK:MGTL\HQPV/2
M<O:751NW)&3]Z+5G>/5*ZM96OL;5^()9_1CA<Q2<G4YHU6[<D9/WHM6=X]4K
MIJRM>UCYI_X(0^ KG2/V?O%OQ*O()HF\1>*_(MQ)&0LD-M"N)$/<>9/,A([Q
MD=J^YJXW]GSX*^&?V=O@QX=^#/A([K/0=.6 W!7:;F8DO-.1DX:25GD(S@%\
M#@"NRKR\\S".:9O6Q4=I2T]%HOP2/)X@S&.;9U7Q<=I2T]%HOP2"OSD_X+]3
MBVOOA!<,N?+?7&QZX.G&OT;HHR/-/[%S2GC.3GY;Z7M>\7'>S[WV#(,V_L/-
MJ>-Y.?DYO=O:]XN.]G;>^Q^<_P 1?^"ROB?X]>"M6^$G[-7[,GB2Z\4:YI<]
MK;S1S&[DLT==C3I!!&S2,H8XR54-M)W %3V'P6_9'_:"_98_X)@>.M!\&VMQ
M'\3O$MM)J<MII(W7=I&1$AM8F0DO,MNDK+L^82RE4R0K'[HHKTJG$.&IT8T,
M%AE3ASQG).3FYN+NDVTO=\K'J5>),+2H1P^ PJI4^>,Y)R<W-Q=TFVE[ODE^
MM_Q4^$WB#]EO4/V5M<\!>&/V6?$OBCXU+H.I2ZIXBFMS/8:=:B5R]V%,Y$1A
MMMN&\D'S0!N^8&O=X==T?5O^" S:?IFIPW$VEZI]EU&**0,UM,?$(F$;C^%C
M%+$^#SMD4]"*_3,*!2UZ.*XRCB:D)>Q?NUHU=:CEK&_NJ\=(ZZ)+3LST\9QQ
M'%5(2]A+W:T:VM5RUC?W5>.D==$E[O9GY]?'']GKX@?M"_\ !'SX8V/PQT:7
M4]6\-Z?IVLC2[9"T]Y EO-#)'$H^](!-Y@7JPC*J"Q53G:5_P69O!\$O#?PE
M^"OP/UW5/BQ#:66F/8ZII7G6,D\2JDQ1+>=;B5F"';'M3:6R20F&_18C(Q3=
MBUP0XBPM2DZ>+PRJ)5)3C[SC9R=W%V3YE>W8\ZGQ+@ZE)T\9A55BJDJD%SN/
M*YN[C*R?-&]NW^7YK_\ !2[QY\8/V@_$'P5_8>UY--L_&FNM9:KXTM=-AW6>
MGZA<Y@BC^62:0+ C73/\S!D9'&1C&U=?\$'M7FT@Z6?VRM0D@6,*EK+X3;RL
M+]U<?;2  0.W&*_1"BJAQAF.#PE+#X!*DHW;LHRYI-WO[T=$MDKNRZLJGQIF
M>#P=+#9>E14;N5E&7-*3NW[T7RI;))NRZL^"?^")?QA\0Z/IOC;]C?XCM);Z
MUX-U2:[L-/N)2[V\?F^3>0#&558KD*QP>7NF(SUK[VHHKQLXS"GFF83Q4:?)
MSV;5[J]M6M%N];=WN>)G694\VS*IC(T_9\]FU>ZO;5K1;O6VNKW"BBBO,/*"
MBBB@#P?]O3]ACPC^VW\.[/1+W7GT7Q#H4TD_AW6EA\U(C)M$L,L>1OCD"+T(
M961&!(#(_P Y>+?V$_\ @K+\5_ D/P6^*O[8/A6\\)/Y4-\JW,TEU-"A'^LD
M%C'+<GC)66;#D?,W>OT%HKWL#Q%F.7X>-&'+*,&W'FBI.#>[BVKK77UU/H,O
MXFS/+L/&A#EE&#;ASPC)P;W<6U=7>OKJ?-?B7]@BT\+_ /!/O5OV-_@IJ-BN
MH:A91^9K&L!H$O;TW$4LUQ,8E=ER(]JC#E56-,D+FO%?A'^QK_P6#^!7P[T_
MX5?"O]J'X=:7H.E^=]@L/LZS^5YLKS/\\VE.[9DD=N6.,X&  *^_J*>'XDS"
MC1G3FH5%.;F^>"E[S5KZZ;?J5A^*,RHT:E*I&%13FZC]I!3]YJU]=%I^;/C;
M]C+_ ()U_&KX=_M+:E^UQ^UI\5]+\4>+YHIET_\ LF2:11))$(3.[O'"%VP[
MX5A6/8JL,$;54?7^MR:S%HUTWAZ"VFU 6LAL8[R5DA>;:=@D959E0MC) ) S
M@'I5JBN#,,SQ6:8A5J]FTE%)))**V22V1Y^99KB\VQ2KXBS:2BDDE%16T4EL
MC\V?!'_!,S_@IY\.OBMJWQQ\(?M!_#ZW\6:X9CJ>M2W4T\LOFN'DQYNG,J9(
M'W , 8''%?3W[.?P#_:UU#X=^._AK^WC\6=&\96'BC3UL-/706VM;V\D4\=R
M"1:P;6821[3\V"F>._T117I8[B;'YA3Y:L*:>EI*"4ERM-6ENK6Z=-#T\PXJ
MS#,J?+5A33TM)0BI+E::M+=6MTZ:'YKZ9^PK_P %1O@/X=UG]ECX&_$3P_J'
MP[\6372W6M2S01"RAF7RI#(LJ-<0M)& &6 3!2<JP8EC]B?L<_LK6_[('[.%
MK\(O#NI07NL,9K[5M3PR1W6HRJ 7P<E454BC'&2L0)&XFO9**SS+B+'YI0]E
M544FU*7+%1<Y+1.5MW]R\KD9IQ-F.;8?V-50BFU*7+%1<Y)64IVW=O1=;7/F
MW_@F;^QGXS_8V^%&O^&_B;=:#>>(-;\2->2:CH5Q-,LEHL$211N\L4;963[0
MV,$#S,YR2!:_X*(_LM?&3]I+P#HM]\!?BC=>'_$OAG46N[6S;5)+:SU%#L;;
M)L!S*CQ1M$S J"7!QOW+]$45SO.L=+-O[1;3J7OJKK:UK=K:'*\\Q\LX_M-M
M.K>^JNMK6MVMI^1\$_"/]A[]MK]I#X^>$?V@/^"@7BW3K>S\%SK+I?A6SDMY
M)9)8I%D3<EL#;I')(%>1MSR.L8C*JNTIW?\ P4 _8G^-7Q#^+'AK]KK]DWQ-
M#9_$#PG;+"VFW5PD27\4;.T?ELP">8?,DC=)2(Y(W ++M(?Z[HKKEQ-F'UV&
M(BH14$XJ"C:'*]X\O5.^MW?S.V7%69?7H8F,814(N*@HI4^67Q1Y>J=];N_G
MHC\[_CO^P)_P43_;-U?PO\5_C=XS\ :1J.FOB+P?;7%S';Z5!^Z9B'C2<23R
M,K;_ )V4"./:[ [4_0*_\-^'-7G^UZIX?LKJ7;M\RXM4=L>F2#Q5ZBN3,,YQ
M>8TZ5.:C&-._*HKE24FFU^'77NVSBS+/,9F5*E2FHQC2YN517*DI--K\.NO=
MMZG@W[='["?@C]LGX36G@Z*^AT#6]!FDN/#.K16H:.W9\>;"\8QF*4*N=I!5
ME1_FVE&^=K/X;?\ !<WPBMC\'-&^(_AZ^TN.&.!/&[W5C,+>/;C$CW$0NI"
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M9$UK7M(M[2?4=/\ LGD P>4EP^)FE*2>6NS)D 4 ^LJ* >*,@=30 449%&:
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M[F"VM+Y"AC2'SI)QF%VW1A223P*]J\)Z\/%'A;3?$PM?(_M"PAN?)+[O+\Q
MVW.!G&<9P* -"C:!VHR/6C- !11FC- !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !17B/QQ_X*$_LO?L\?%O3?@M\3?',EKK%\J-=-!9M
M)!I:2#]VUU(.(P_8#<5!#,%4AC[=716P>*P].%2K!QC-7BVFDUW7?_ANYU5L
M'B\-2A4JTW&,U>+::4EW7?\ X*[H;-/#;IYL\JHO]YFP*=GC-?$/_!PH0O\
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M;E&FK13Z+LON7R270[L5F6.QM&E1KU'*--6BG]E::+[E\DELD?$/_!PH ?\
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M!'V$;U #9'%(9^47Q!_Y1M?\% /^SG=<_P#3OIU?1_Q=/_&P+]@G_L5?&?\
MZC=O7UO<?L^_ 6[\->(/!EW\$O",NC^+-4DU+Q5I,GANU:VUF]=U=[F[B,>V
MXF9T1C)(&8E5).0*T;SX7?#34/$&@>+;_P"'FASZKX5BFB\+ZG-I,+7&CQS1
M"*9+60KNMU>,!&$94,H"G(&*8'Y[^"_C;^T-^V'\7OC5>Z1_P4%\&_LY^%?
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M?AGKGB33=<E@T;XZ?#;PC8FYN-9L20D.I6UHHR]S$<9\L@Y5"=L;W3G[EHH
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M?)E%O$(6*&1KI<.H5B/L2SO+74+2._L+F.:":-9(9H9 RR(1D,"."".01U%
M$E%?*][_ ,%,'EM_VDO$WA;X'R:AX9_9[C>W&O2:^T*^(]4@MVDO+%%-J1;F
M"1#&S[I?OQMMPV!9^-O_  4@_P"%.?L??!_]J_\ X4U_:7_"U]1\-VO]@_\
M"1>3_9?]JV9N=WG_ &=O/\K&W'EQ[^N4Z4 ?3]%?+'[87_!0?XQ_ ']J/PA^
MR;\!_P!D+_A:/B7QAX9GUFSB_P"$^M]$\M(7E$B9N('C.$B+9,BD] ">O)>)
M_P#@J5^TE^SR]KXM_;H_X)K^*/AKX#DNH;?4?'&@^.++Q/!I1ED$:2W45G&K
M11;V4%LEB6541W948L!]DZ_H>E^)]"O?#6N6OGV.H6DEM>0[V7S(I%*NN5((
MRI(R"".QK"^"OP7^&G[._P +](^#'P=\-?V/X:T&%XM*TW[9-<>0C2-(P\R=
MWD;+NQ^9B><=,"IO$WQ4\">%?A1J'QMO_$=K-X9TWP_+KDVKVDRRPO81P&<S
MHZDJZ&(;@P.".17SYXU_X*A>#?A3^QM\._VE_B=\+=0C\5_%73[63P'\*_#-
M]_:FI:O<W:J]M!"XBC+ QRP-(_E_(950+)(T:2 'U+17Q=J7[;?_  58\+Z5
M-X_\3?\ !)#S=!MX#<7&FZ/\6K&[U:.$#)*PQQ%IY ,_ND3>Q^4 &NS^+'_!
M4#X9>&?^"<4__!1[X/\ @ZZ\6:"L%F]MH-]>_P!FW'F2ZC%82P2N(YA')#([
M[MJNK&/Y6*LKT ?3U%-BD\V)9<8W*#BG9H **,T9STH ***,T %%&:,CUH *
M*,CUHS0 449'K1D>M !11FOD7Q__ ,%5;7PGJ0?0?@;+J6DR?M*VWP?M=2N/
M$!MGFN3"#=Z@(_LSCRX9]\*QASYOEEM\?W: /KJBBO"_^">_[:?_  W?\#;[
MXS_\*U_X17['XJOM&_LW^V/MV_[/Y?[WS/)BQNW_ '=IQCJ<T >Z449HS0 4
M49STK.\7Z_\ \(KX3U3Q1]D^T?V;IT]UY'F;?,\N-GVYP<9QC.#CT- &C17S
MO^SY^VE\6?VFOV5?A;^TS\)_V7_[0/CSQ0EGXCT/_A-H(O\ A&M*%W<V]QJ?
MG30I]L\KR$;[.B+(_FX4_*2=[X0_M?\ _"U?VR_B[^R/_P *\^P?\*KL]#G_
M .$@_M;S?[4_M&S6YQY'E+Y'E[MN?,?=C/R]* /:J*,T9H **,T4 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG)-'[>7[$GCG]H/Q'X(_:&_9R^(]GX/^+WPQO)Y_"6L:E;M)8WT$R[9["\"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M ^)?^"D?_)<M*_[%.#_TINJ\:^%__)3/#O\ V';/_P!')7LO_!2/_DN6E?\
M8IP?^E-U7C7PO_Y*9X=_[#MG_P"CDK0G[1^G]%%%9E!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!\2_\%(_^2Y:5_P!BG!_Z4W5>-?"_
M_DIGAW_L.V?_ *.2O9?^"D?_ "7+2O\ L4X/_2FZKQKX7_\ )3/#O_8=L_\
MT<E:$_:/T_HHHK,H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** *=]X>T'5)A<:IHEG=2!=JR7%LKL%],D=.3^=11^#_"<3K+%X7T]65@5
M9;&,$'U'%:-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
%10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>cbio-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-31T02:21:01.8282556+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : ef934a25c5c94284985388408cc8aae1 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:cbio="http://www.catalystbiosciences.com/20211231" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.catalystbiosciences.com/20211231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" namespace="http://xbrl.sec.gov/country/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" namespace="http://xbrl.sec.gov/currency/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4" />
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" namespace="http://xbrl.sec.gov/exch/2021" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" namespace="http://xbrl.sec.gov/naics/2021" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" namespace="http://xbrl.sec.gov/sic/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd" namespace="http://fasb.org/srt-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" namespace="http://fasb.org/srt-types/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" namespace="http://xbrl.sec.gov/stpr/2021" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" namespace="http://fasb.org/us-roles/2021-01-31" />
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" namespace="http://fasb.org/us-types/2021-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.catalystbiosciences.com/20211231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cbio-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cbio-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cbio-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cbio-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" id="Role_StatementConsolidatedStatementsOfOperations">
        <link:definition>100030 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>100040 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" id="Role_StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100050 - Statement - Consolidated Statements of Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" id="Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
        <link:definition>100060 - Statement - Consolidated Statements of Stockholders&apos; Equity (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100070 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureNatureOfOperations" id="Role_DisclosureNatureOfOperations">
        <link:definition>100080 - Disclosure - Nature of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLiquidity" id="Role_DisclosureLiquidity">
        <link:definition>100090 - Disclosure - Liquidity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100110 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFinancialInstruments" id="Role_DisclosureFinancialInstruments">
        <link:definition>100120 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureOtherAccruedLiabilities" id="Role_DisclosureOtherAccruedLiabilities">
        <link:definition>100130 - Disclosure - Other Accrued Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100140 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedParties" id="Role_DisclosureRelatedParties">
        <link:definition>100150 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100160 - Disclosure - Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100170 - Disclosure - Stock Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100180 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborations" id="Role_DisclosureCollaborations">
        <link:definition>100190 - Disclosure - Collaborations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureInterestAndOtherIncomeExpenseNet" id="Role_DisclosureInterestAndOtherIncomeExpenseNet">
        <link:definition>100200 - Disclosure - Interest and Other Income (Expense), Net</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>100210 - Disclosure - Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholders">
        <link:definition>100220 - Disclosure - Net Loss per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuring" id="Role_DisclosureRestructuring">
        <link:definition>100230 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEvent" id="Role_DisclosureSubsequentEvent">
        <link:definition>100240 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100250 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100260 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsTables" id="Role_DisclosureFinancialInstrumentsTables">
        <link:definition>100270 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureOtherAccruedLiabilitiesTables" id="Role_DisclosureOtherAccruedLiabilitiesTables">
        <link:definition>100280 - Disclosure - Other Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100290 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100300 - Disclosure - Stock Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100310 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureInterestAndOtherIncomeExpenseNetTables" id="Role_DisclosureInterestAndOtherIncomeExpenseNetTables">
        <link:definition>100320 - Disclosure - Interest and Other Income (Expense), Net (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables">
        <link:definition>100330 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringTables" id="Role_DisclosureRestructuringTables">
        <link:definition>100340 - Disclosure - Restructuring (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureNatureOfOperationsAdditionalInformationDetail" id="Role_DisclosureNatureOfOperationsAdditionalInformationDetail">
        <link:definition>100350 - Disclosure - Nature of Operations - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail" id="Role_DisclosureLiquidityAdditionalInformationDetail">
        <link:definition>100360 - Disclosure - Liquidity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100370 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail" id="Role_DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail">
        <link:definition>100380 - Disclosure - Assets and Liabilities Measured at Fair Value - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail" id="Role_DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail">
        <link:definition>100390 - Disclosure - Assets and Liabilities Measured at Fair Value (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail" id="Role_DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail">
        <link:definition>100400 - Disclosure - Cash Equivalents, Restricted Cash and Short-Term Investments Classified as Available-for-sale Securities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail" id="Role_DisclosureFinancialInstrumentsAdditionalInformationDetail">
        <link:definition>100410 - Disclosure - Financial Instruments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail" id="Role_DisclosureScheduleOfOtherAccruedLiabilitiesDetail">
        <link:definition>100420 - Disclosure - Schedule of Other Accrued Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>100430 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail" id="Role_DisclosureRelatedPartiesAdditionalInformationDetail">
        <link:definition>100440 - Disclosure - Related Parties - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" id="Role_DisclosureLeasesAdditionalInformationDetail">
        <link:definition>100450 - Disclosure - Leases - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail" id="Role_DisclosureSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail">
        <link:definition>100460 - Disclosure - Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail" id="Role_DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail">
        <link:definition>100470 - Disclosure - Schedule of Maturity of Operating Lease Liabilities - (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2" id="Role_DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2">
        <link:definition>100480 - Disclosure - Schedule of Maturity of Operating Lease Liabilities - (Detail)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationDetails" id="Role_DisclosureScheduleOfSupplementalCashFlowInformationDetails">
        <link:definition>100490 - Disclosure - Schedule of Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetail">
        <link:definition>100500 - Disclosure - Stock Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail" id="Role_DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail">
        <link:definition>100510 - Disclosure - Summary of Option Activity Under Company&apos;s Equity Incentive Plans (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail" id="Role_DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail">
        <link:definition>100520 - Disclosure - Fair Values of Stock Options Estimated Using Black-Scholes Valuation Model (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail" id="Role_DisclosureSummaryOfStockBasedCompensationRecognizedDetail">
        <link:definition>100530 - Disclosure - Summary of Stock-Based Compensation Recognized (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail" id="Role_DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail">
        <link:definition>100540 - Disclosure - Summary of Stock-Based Compensation Recognized (Parenthetical) (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail" id="Role_DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail">
        <link:definition>100550 - Disclosure - Reconciliation of Statutory Federal Income Tax (benefit) Rate to Company&apos;s Effective Tax Rate (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail" id="Role_DisclosureComponentsOfCompanySDeferredTaxAssetsDetail">
        <link:definition>100560 - Disclosure - Components of the Company&apos;s Deferred Tax Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100570 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureUnrecognizedTaxBenefitDetail" id="Role_DisclosureUnrecognizedTaxBenefitDetail">
        <link:definition>100580 - Disclosure - Unrecognized tax benefit (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail" id="Role_DisclosureCollaborationsAdditionalInformationDetail">
        <link:definition>100590 - Disclosure - Collaborations - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeExpenseNetDetail" id="Role_DisclosureDetailOfInterestAndOtherIncomeExpenseNetDetail">
        <link:definition>100600 - Disclosure - Detail of Interest and Other Income (Expense), Net (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" id="Role_DisclosureStockholdersEquityAdditionalInformationDetail">
        <link:definition>100610 - Disclosure - Stockholders&apos; Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail" id="Role_DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail">
        <link:definition>100620 - Disclosure - Anti-dilutive Security not Included In Diluted per Share Calculations (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail" id="Role_DisclosureRestructuringAdditionalInformationDetail">
        <link:definition>100630 - Disclosure - Restructuring - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail" id="Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail">
        <link:definition>100640 - Disclosure - Restructuring - Summary of Restructuring Charges Recorded in Component of Operating Expenses (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" id="Role_DisclosureSubsequentEventAdditionalInformationDetails">
        <link:definition>100650 - Disclosure - Subsequent Event - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" name="AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_SaleSecuritiesAvailable" name="SaleSecuritiesAvailable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_InterestAndOtherIncomeExpenseNet" name="InterestAndOtherIncomeExpenseNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_LicenseRevenueMember" name="LicenseRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_CollaborationRevenueMember" name="CollaborationRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_CostOfLicenseMember" name="CostOfLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_CostOfCollaborationMember" name="CostOfCollaborationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" name="StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares" name="StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" name="IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_PaymentsToAcquireShortTermAndLongInvestments" name="PaymentsToAcquireShortTermAndLongInvestments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" name="ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises" name="ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities" name="NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_NonCashOrPartNonCashRemeasurementOfRightOfUseAssetDueToOperatingLeaseModification" name="NonCashOrPartNonCashRemeasurementOfRightOfUseAssetDueToOperatingLeaseModification" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock" name="CostOfLicenseAndCollaborationRevenuePolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" name="AccruedResearchAndDevelopmentExpensesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_ConcentrationRiskCreditRiskPolicyTextBlock" name="ConcentrationRiskCreditRiskPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_SaleSecuritiesAvailableTextBlock" name="SaleSecuritiesAvailableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" name="SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_LiquidityAbstract" name="LiquidityAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_CostOfCollaborationRevenue" name="CostOfCollaborationRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_LongTermInvestmentsMember" name="LongTermInvestmentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_AmortizedCostAvailableForSaleSecurities" name="AmortizedCostAvailableForSaleSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_FederalAgencySecuritiesMember" name="FederalAgencySecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_GrossRealizedGainLossNetAvailableForSalesSecurities" name="GrossRealizedGainLossNetAvailableForSalesSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_AvailableForSaleDebtSecuritiesContractualMaturity" name="AvailableForSaleDebtSecuritiesContractualMaturity" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_FinancialInstrumentLineItems" name="FinancialInstrumentLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_FinancialInstrumentsTable" name="FinancialInstrumentsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_AccruedManufacturingExpensesCurrent" name="AccruedManufacturingExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_AccruedCollaborationExpensesCurrent" name="AccruedCollaborationExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_AccruedPreClinicalExpensesCurrent" name="AccruedPreClinicalExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_AccruedClinicalExpensesCurrent" name="AccruedClinicalExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_AccruedAndOtherCurrentLiabilities" name="AccruedAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_FirmWorkOrderSupportingClinicalTrials" name="FirmWorkOrderSupportingClinicalTrials" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="cbio_CostOfServicesAsPerAgreement" name="CostOfServicesAsPerAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_CostOfManufacturingServices" name="CostOfManufacturingServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" name="ChargesRelatedToWriteOffOfPrepaidManufacturingCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_CommitmentsAndContingenciesDisclosureLineItems" name="CommitmentsAndContingenciesDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_CommitmentsAndContingenciesDisclosureTable" name="CommitmentsAndContingenciesDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_AGCBiologicsIncMember" name="AGCBiologicsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_MarzeptacogAlfaActivatedMember" name="MarzeptacogAlfaActivatedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_IntegrityBioMember" name="IntegrityBioMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" name="MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_DalcinonacogAlfaMember" name="DalcinonacogAlfaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_GMPMember" name="GMPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement" name="UpfrontFeeReveivedFromLicenseAndCollaborationAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_SublicenseFee" name="SublicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" name="MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_MosaicBiosciencesIncMember" name="MosaicBiosciencesIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_BiogenCollaborationMember" name="BiogenCollaborationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_IntravitrealAntiComplementFactor3Member" name="IntravitrealAntiComplementFactor3Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_LesseeOperatingLeaseRenewalTermDescription" name="LesseeOperatingLeaseRenewalTermDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_LeaseLabAndOfficeSpaceMember" name="LeaseLabAndOfficeSpaceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_SubleaseArrangementMember" name="SubleaseArrangementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" name="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_PrepaidCashPaymentForLeaseLiabilities" name="PrepaidCashPaymentForLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_TwoThousandEighteenOmnibusIncentivePlanMember" name="TwoThousandEighteenOmnibusIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_PerformanceBasedStockOptionGrantsMember" name="PerformanceBasedStockOptionGrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember" name="TwoThousandEighteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_IssuanceOfOptionGrantsToPurchaseCommonStockShares" name="IssuanceOfOptionGrantsToPurchaseCommonStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences" name="EffectiveIncomeTaxRateReconciliationPermanentDifferences" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_EffectiveIncomeTaxRateReconciliationDerecognition" name="EffectiveIncomeTaxRateReconciliationDerecognition" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_DeferredTaxAssetsFixedAssetsAndIntangibles" name="DeferredTaxAssetsFixedAssetsAndIntangibles" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_IncomeTaxLineItems" name="IncomeTaxLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_IncomeTaxTable" name="IncomeTaxTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_OperatingLossCarryforwardsWithIndefiniteLife" name="OperatingLossCarryforwardsWithIndefiniteLife" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards" name="DeferredTaxAssetsStateNetOperatingLossCarryForwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" name="ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_MaximumAmountOfTaxOffsetPerYear" name="MaximumAmountOfTaxOffsetPerYear" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_RequiredMinimumTaxableIncome" name="RequiredMinimumTaxableIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" name="UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_RegulatoryAndDevelopmentMilestonePayment" name="RegulatoryAndDevelopmentMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_CommercialMilestonePayments" name="CommercialMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_CollaborationAgreementsAbstract" name="CollaborationAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_IsuAbxisMember" name="IsuAbxisMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_AmendedAndRestatedLicenseAgreementMember" name="AmendedAndRestatedLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_BiogenMember" name="BiogenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_LicenseAndCollaborationAgreementMember" name="LicenseAndCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_ExclusiveLicenseMember" name="ExclusiveLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember" name="TransferOfExclusiveLicenseAndRelatedKnowHowMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" name="ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_ResearchServicesAgreementTerm" name="ResearchServicesAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_ResearchServicesAgreementOptionToExtend" name="ResearchServicesAgreementOptionToExtend" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="cbio_DevelopmentMilestonesPaymentReceivable" name="DevelopmentMilestonesPaymentReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_MiscellaneousIncomeExpense" name="MiscellaneousIncomeExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_UnderwritingCommissionsAndOfferingExpensesPayable" name="UnderwritingCommissionsAndOfferingExpensesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_StockholdersEquityDisclosureLineItems" name="StockholdersEquityDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_StockholdersEquityDisclosureTable" name="StockholdersEquityDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_UnderwritersOverallotmentOptionMember" name="UnderwritersOverallotmentOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_TwoThousandTwentyOneATMProgramMember" name="TwoThousandTwentyOneATMProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_PercentageOfCommissionForSharesSold" name="PercentageOfCommissionForSharesSold" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="cbio_LegalExpensesIncurred" name="LegalExpensesIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="cbio_OptionsToPurchaseCommonStockMember" name="OptionsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_CommonStockWarrantsMember" name="CommonStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_RestructuringLiability" name="RestructuringLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_BiogenAgreementMember" name="BiogenAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_AdvisorAgreementMember" name="AdvisorAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_RaymondJamesAndAssociatesMember" name="RaymondJamesAndAssociatesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="cbio_AdvisoryFeesPayable" name="AdvisoryFeesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="cbio_ReimbursementOfAdvisoryFee" name="ReimbursementOfAdvisoryFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>cbio-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-31T02:21:01.8282556+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : ef934a25c5c94284985388408cc8aae1 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="cbio-20211231.xsd#TemplateLink" roleURI="http://www.catalystbiosciences.com/20211231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="cbio-20211231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments" xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10240.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="cbio-20211231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_InterestAndOtherIncomeExpenseNet" xlink:type="locator" xlink:label="cbio_InterestAndOtherIncomeExpenseNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="cbio_InterestAndOtherIncomeExpenseNet" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10080.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="cbio-20211231.xsd#Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="cbio-20211231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" xlink:type="locator" xlink:label="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_PaymentsToAcquireShortTermAndLongInvestments" xlink:type="locator" xlink:label="cbio_PaymentsToAcquireShortTermAndLongInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises" xlink:type="locator" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" xlink:type="locator" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="cbio_PaymentsToAcquireShortTermAndLongInvestments" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10120.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10130.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10170.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail">
    <link:loc xlink:href="cbio-20211231.xsd#cbio_SaleSecuritiesAvailable" xlink:type="locator" xlink:label="cbio_SaleSecuritiesAvailable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" xlink:type="locator" xlink:label="cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AmortizedCostAvailableForSaleSecurities" xlink:type="locator" xlink:label="cbio_AmortizedCostAvailableForSaleSecurities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cbio_AmortizedCostAvailableForSaleSecurities" xlink:to="cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cbio_AmortizedCostAvailableForSaleSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cbio_AmortizedCostAvailableForSaleSecurities" xlink:to="cbio_SaleSecuritiesAvailable" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureScheduleOfOtherAccruedLiabilitiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail">
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AccruedAndOtherCurrentLiabilities" xlink:type="locator" xlink:label="cbio_AccruedAndOtherCurrentLiabilities" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AccruedClinicalExpensesCurrent" xlink:type="locator" xlink:label="cbio_AccruedClinicalExpensesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AccruedPreClinicalExpensesCurrent" xlink:type="locator" xlink:label="cbio_AccruedPreClinicalExpensesCurrent" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AccruedCollaborationExpensesCurrent" xlink:type="locator" xlink:label="cbio_AccruedCollaborationExpensesCurrent" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AccruedManufacturingExpensesCurrent" xlink:type="locator" xlink:label="cbio_AccruedManufacturingExpensesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="cbio_AccruedManufacturingExpensesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="cbio_AccruedCollaborationExpensesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="cbio_AccruedPreClinicalExpensesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="cbio_AccruedClinicalExpensesCurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="cbio_AccruedAndOtherCurrentLiabilities" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2" xlink:href="cbio-20211231.xsd#Role_DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationDetails" xlink:href="cbio-20211231.xsd#Role_DisclosureScheduleOfSupplementalCashFlowInformationDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationDetails">
    <link:loc xlink:href="cbio-20211231.xsd#cbio_PrepaidCashPaymentForLeaseLiabilities" xlink:type="locator" xlink:label="cbio_PrepaidCashPaymentForLeaseLiabilities" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:type="locator" xlink:label="cbio_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="cbio_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="cbio_PrepaidCashPaymentForLeaseLiabilities" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_EffectiveIncomeTaxRateReconciliationDerecognition" xlink:type="locator" xlink:label="cbio_EffectiveIncomeTaxRateReconciliationDerecognition" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:type="locator" xlink:label="cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="cbio_EffectiveIncomeTaxRateReconciliationDerecognition" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="10070.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureComponentsOfCompanySDeferredTaxAssetsDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_DeferredTaxAssetsFixedAssetsAndIntangibles" xlink:type="locator" xlink:label="cbio_DeferredTaxAssetsFixedAssetsAndIntangibles" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="cbio_DeferredTaxAssetsFixedAssetsAndIntangibles" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10050.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeExpenseNetDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureDetailOfInterestAndOtherIncomeExpenseNetDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeExpenseNetDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_MiscellaneousIncomeExpense" xlink:type="locator" xlink:label="cbio_MiscellaneousIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_InterestAndOtherIncomeExpenseNet" xlink:type="locator" xlink:label="cbio_InterestAndOtherIncomeExpenseNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cbio_InterestAndOtherIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cbio_InterestAndOtherIncomeExpenseNet" xlink:to="cbio_MiscellaneousIncomeExpense" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="cbio_InterestAndOtherIncomeExpenseNet" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges" xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>cbio-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-31T02:21:01.8282556+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : ef934a25c5c94284985388408cc8aae1 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="cbio-20211231.xsd#TemplateLink" roleURI="http://www.catalystbiosciences.com/20211231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="cbio-20211231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_InterestAndOtherIncomeExpenseNet" xlink:type="locator" xlink:label="cbio_InterestAndOtherIncomeExpenseNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CostOfCollaborationMember" xlink:type="locator" xlink:label="cbio_CostOfCollaborationMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CostOfLicenseMember" xlink:type="locator" xlink:label="cbio_CostOfLicenseMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CollaborationRevenueMember" xlink:type="locator" xlink:label="cbio_CollaborationRevenueMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_LicenseRevenueMember" xlink:type="locator" xlink:label="cbio_LicenseRevenueMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10090.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_LicenseRevenueMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_CollaborationRevenueMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_CostOfLicenseMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_CostOfCollaborationMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cbio_InterestAndOtherIncomeExpenseNet" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10900.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="cbio-20211231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares" xlink:type="locator" xlink:label="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" xlink:type="locator" xlink:label="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11360.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGrossCurrent" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CostOfCollaborationRevenue" xlink:type="locator" xlink:label="cbio_CostOfCollaborationRevenue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:type="locator" xlink:label="us-gaap_LeasePracticalExpedientsPackage" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="cbio_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="cbio_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cbio_SummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LeasePracticalExpedientsPackage" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cbio_CostOfCollaborationRevenue" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10790.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_LongTermInvestmentsMember" xlink:type="locator" xlink:label="cbio_LongTermInvestmentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="cbio_LongTermInvestmentsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10180.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestmentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10580.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail">
    <link:loc xlink:href="cbio-20211231.xsd#cbio_SaleSecuritiesAvailable" xlink:type="locator" xlink:label="cbio_SaleSecuritiesAvailable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" xlink:type="locator" xlink:label="cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AmortizedCostAvailableForSaleSecurities" xlink:type="locator" xlink:label="cbio_AmortizedCostAvailableForSaleSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestmentsMember" xlink:type="locator" xlink:label="us-gaap_OtherLongTermInvestmentsMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_FederalAgencySecuritiesMember" xlink:type="locator" xlink:label="cbio_FederalAgencySecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestmentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10040.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="cbio_FederalAgencySecuritiesMember" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_OtherLongTermInvestmentsMember" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="cbio_AmortizedCostAvailableForSaleSecurities" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="cbio_SaleSecuritiesAvailable" order="11010.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureFinancialInstrumentsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail">
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AvailableForSaleDebtSecuritiesContractualMaturity" xlink:type="locator" xlink:label="cbio_AvailableForSaleDebtSecuritiesContractualMaturity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_GrossRealizedGainLossNetAvailableForSalesSecurities" xlink:type="locator" xlink:label="cbio_GrossRealizedGainLossNetAvailableForSalesSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_FinancialInstrumentsTable" xlink:type="locator" xlink:label="cbio_FinancialInstrumentsTable" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_FinancialInstrumentLineItems" xlink:type="locator" xlink:label="cbio_FinancialInstrumentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cbio_FinancialInstrumentLineItems" xlink:to="cbio_FinancialInstrumentsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_FinancialInstrumentsTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_FinancialInstrumentLineItems" xlink:to="cbio_GrossRealizedGainLossNetAvailableForSalesSecurities" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_FinancialInstrumentLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_FinancialInstrumentLineItems" xlink:to="cbio_AvailableForSaleDebtSecuritiesContractualMaturity" order="10180.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" xlink:type="locator" xlink:label="cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CostOfManufacturingServices" xlink:type="locator" xlink:label="cbio_CostOfManufacturingServices" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CostOfServicesAsPerAgreement" xlink:type="locator" xlink:label="cbio_CostOfServicesAsPerAgreement" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_FirmWorkOrderSupportingClinicalTrials" xlink:type="locator" xlink:label="cbio_FirmWorkOrderSupportingClinicalTrials" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceAgreementsMember" xlink:type="locator" xlink:label="us-gaap_ServiceAgreementsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_GMPMember" xlink:type="locator" xlink:label="cbio_GMPMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_DalcinonacogAlfaMember" xlink:type="locator" xlink:label="cbio_DalcinonacogAlfaMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" xlink:type="locator" xlink:label="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_IntegrityBioMember" xlink:type="locator" xlink:label="cbio_IntegrityBioMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_MarzeptacogAlfaActivatedMember" xlink:type="locator" xlink:label="cbio_MarzeptacogAlfaActivatedMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AGCBiologicsIncMember" xlink:type="locator" xlink:label="cbio_AGCBiologicsIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CommitmentsAndContingenciesDisclosureTable" xlink:type="locator" xlink:label="cbio_CommitmentsAndContingenciesDisclosureTable" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:type="locator" xlink:label="cbio_CommitmentsAndContingenciesDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="cbio_CommitmentsAndContingenciesDisclosureTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_AGCBiologicsIncMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_MarzeptacogAlfaActivatedMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_IntegrityBioMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_ProductOrServiceAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_DalcinonacogAlfaMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_GMPMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_RangeAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ServiceAgreementsMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="cbio_FirmWorkOrderSupportingClinicalTrials" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="cbio_CostOfServicesAsPerAgreement" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="cbio_CostOfManufacturingServices" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ContractualObligation" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" order="10720.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureRelatedPartiesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail">
    <link:loc xlink:href="cbio-20211231.xsd#cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" xlink:type="locator" xlink:label="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_SublicenseFee" xlink:type="locator" xlink:label="cbio_SublicenseFee" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement" xlink:type="locator" xlink:label="cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_IntravitrealAntiComplementFactor3Member" xlink:type="locator" xlink:label="cbio_IntravitrealAntiComplementFactor3Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_BiogenCollaborationMember" xlink:type="locator" xlink:label="cbio_BiogenCollaborationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_MosaicBiosciencesIncMember" xlink:type="locator" xlink:label="cbio_MosaicBiosciencesIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cbio_MosaicBiosciencesIncMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cbio_BiogenCollaborationMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ProductOrServiceAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_IntravitrealAntiComplementFactor3Member" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="cbio_SublicenseFee" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" order="10520.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_LesseeOperatingLeaseRenewalTermDescription" xlink:type="locator" xlink:label="cbio_LesseeOperatingLeaseRenewalTermDescription" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_SubleaseArrangementMember" xlink:type="locator" xlink:label="cbio_SubleaseArrangementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_LeaseLabAndOfficeSpaceMember" xlink:type="locator" xlink:label="cbio_LeaseLabAndOfficeSpaceMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cbio_LeaseLabAndOfficeSpaceMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cbio_SubleaseArrangementMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="cbio_LesseeOperatingLeaseRenewalTermDescription" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="10470.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_IssuanceOfOptionGrantsToPurchaseCommonStockShares" xlink:type="locator" xlink:label="cbio_IssuanceOfOptionGrantsToPurchaseCommonStockShares" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_PerformanceBasedStockOptionGrantsMember" xlink:type="locator" xlink:label="cbio_PerformanceBasedStockOptionGrantsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_TwoThousandEighteenOmnibusIncentivePlanMember" xlink:type="locator" xlink:label="cbio_TwoThousandEighteenOmnibusIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="cbio_TwoThousandEighteenOmnibusIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="cbio_PerformanceBasedStockOptionGrantsMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cbio_IssuanceOfOptionGrantsToPurchaseCommonStockShares" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11210.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" xlink:type="locator" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:type="locator" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10260.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureSummaryOfStockBasedCompensationRecognizedDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10220.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_RequiredMinimumTaxableIncome" xlink:type="locator" xlink:label="cbio_RequiredMinimumTaxableIncome" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_MaximumAmountOfTaxOffsetPerYear" xlink:type="locator" xlink:label="cbio_MaximumAmountOfTaxOffsetPerYear" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" xlink:type="locator" xlink:label="cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards" xlink:type="locator" xlink:label="cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_OperatingLossCarryforwardsWithIndefiniteLife" xlink:type="locator" xlink:label="cbio_OperatingLossCarryforwardsWithIndefiniteLife" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="cbio_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_IncomeTaxTable" xlink:type="locator" xlink:label="cbio_IncomeTaxTable" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_IncomeTaxLineItems" xlink:type="locator" xlink:label="cbio_IncomeTaxLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cbio_IncomeTaxLineItems" xlink:to="cbio_IncomeTaxTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_IncomeTaxTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="stpr_CA" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_IncomeTaxLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_IncomeTaxLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_IncomeTaxLineItems" xlink:to="cbio_OperatingLossCarryforwardsExpirationYear" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_IncomeTaxLineItems" xlink:to="cbio_OperatingLossCarryforwardsWithIndefiniteLife" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_IncomeTaxLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_IncomeTaxLineItems" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_IncomeTaxLineItems" xlink:to="cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_IncomeTaxLineItems" xlink:to="cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_IncomeTaxLineItems" xlink:to="cbio_MaximumAmountOfTaxOffsetPerYear" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_IncomeTaxLineItems" xlink:to="cbio_RequiredMinimumTaxableIncome" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_IncomeTaxLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_IncomeTaxLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" order="11160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureCollaborationsAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_DevelopmentMilestonesPaymentReceivable" xlink:type="locator" xlink:label="cbio_DevelopmentMilestonesPaymentReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ResearchServicesAgreementOptionToExtend" xlink:type="locator" xlink:label="cbio_ResearchServicesAgreementOptionToExtend" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ResearchServicesAgreementTerm" xlink:type="locator" xlink:label="cbio_ResearchServicesAgreementTerm" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CommercialMilestonePayments" xlink:type="locator" xlink:label="cbio_CommercialMilestonePayments" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_RegulatoryAndDevelopmentMilestonePayment" xlink:type="locator" xlink:label="cbio_RegulatoryAndDevelopmentMilestonePayment" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_MilestonePayments" xlink:type="locator" xlink:label="cbio_MilestonePayments" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" xlink:type="locator" xlink:label="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CollaborationRevenueMember" xlink:type="locator" xlink:label="cbio_CollaborationRevenueMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember" xlink:type="locator" xlink:label="cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_LicenseRevenueMember" xlink:type="locator" xlink:label="cbio_LicenseRevenueMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ExclusiveLicenseMember" xlink:type="locator" xlink:label="cbio_ExclusiveLicenseMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_LicenseAndCollaborationAgreementMember" xlink:type="locator" xlink:label="cbio_LicenseAndCollaborationAgreementMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_BiogenMember" xlink:type="locator" xlink:label="cbio_BiogenMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AmendedAndRestatedLicenseAgreementMember" xlink:type="locator" xlink:label="cbio_AmendedAndRestatedLicenseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_IsuAbxisMember" xlink:type="locator" xlink:label="cbio_IsuAbxisMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_IsuAbxisMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_TransactionTypeAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain_2" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="cbio_AmendedAndRestatedLicenseAgreementMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_RangeAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_BiogenMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="cbio_LicenseAndCollaborationAgreementMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransactionDomain" xlink:to="cbio_ExclusiveLicenseMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_ProductOrServiceAxis" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_LicenseRevenueMember" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_ExclusiveLicenseMember" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_CollaborationRevenueMember" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_MilestonePayments" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_RegulatoryAndDevelopmentMilestonePayment" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_CommercialMilestonePayments" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_ResearchServicesAgreementTerm" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_ResearchServicesAgreementOptionToExtend" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_DevelopmentMilestonesPaymentReceivable" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" order="11560.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail">
    <link:loc xlink:href="cbio-20211231.xsd#cbio_LegalExpensesIncurred" xlink:type="locator" xlink:label="cbio_LegalExpensesIncurred" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_PercentageOfCommissionForSharesSold" xlink:type="locator" xlink:label="cbio_PercentageOfCommissionForSharesSold" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_UnderwritingCommissionsAndOfferingExpensesPayable" xlink:type="locator" xlink:label="cbio_UnderwritingCommissionsAndOfferingExpensesPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_TwoThousandTwentyOneATMProgramMember" xlink:type="locator" xlink:label="cbio_TwoThousandTwentyOneATMProgramMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_UnderwritersOverallotmentOptionMember" xlink:type="locator" xlink:label="cbio_UnderwritersOverallotmentOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_StockholdersEquityDisclosureTable" xlink:type="locator" xlink:label="cbio_StockholdersEquityDisclosureTable" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_StockholdersEquityDisclosureLineItems" xlink:type="locator" xlink:label="cbio_StockholdersEquityDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="cbio_StockholdersEquityDisclosureTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_StockholdersEquityDisclosureTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="cbio_StockholdersEquityDisclosureTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cbio_UnderwritersOverallotmentOptionMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cbio_TwoThousandTwentyOneATMProgramMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_SharePrice" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="cbio_UnderwritingCommissionsAndOfferingExpensesPayable" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="10800.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="cbio_PercentageOfCommissionForSharesSold" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="cbio_LegalExpensesIncurred" order="10840.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CommonStockWarrantsMember" xlink:type="locator" xlink:label="cbio_CommonStockWarrantsMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_OptionsToPurchaseCommonStockMember" xlink:type="locator" xlink:label="cbio_OptionsToPurchaseCommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="cbio_OptionsToPurchaseCommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="cbio_CommonStockWarrantsMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges" xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" order="10200.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" xlink:href="cbio-20211231.xsd#Role_DisclosureSubsequentEventAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges" xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ReimbursementOfAdvisoryFee" xlink:type="locator" xlink:label="cbio_ReimbursementOfAdvisoryFee" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AdvisoryFeesPayable" xlink:type="locator" xlink:label="cbio_AdvisoryFeesPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_RaymondJamesAndAssociatesMember" xlink:type="locator" xlink:label="cbio_RaymondJamesAndAssociatesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AdvisorAgreementMember" xlink:type="locator" xlink:label="cbio_AdvisorAgreementMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_BiogenAgreementMember" xlink:type="locator" xlink:label="cbio_BiogenAgreementMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_SubleaseArrangementMember" xlink:type="locator" xlink:label="cbio_SubleaseArrangementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cbio_SubleaseArrangementMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cbio_BiogenAgreementMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cbio_AdvisorAgreementMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_2" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="cbio_RaymondJamesAndAssociatesMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceived" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="cbio_AdvisoryFeesPayable" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="cbio_ReimbursementOfAdvisoryFee" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RestructuringCharges" order="10800.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>cbio-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-31T02:21:01.8282556+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : ef934a25c5c94284985388408cc8aae1 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" xlink:type="locator" xlink:label="cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" />
    <link:label xml:lang="en-US" xlink:label="cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accumulated gross unrealized gain before tax available for sale securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" xlink:to="cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_SaleSecuritiesAvailable" xlink:type="locator" xlink:label="cbio_SaleSecuritiesAvailable" />
    <link:label xml:lang="en-US" xlink:label="cbio_SaleSecuritiesAvailable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale securities available.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_SaleSecuritiesAvailable" xlink:to="cbio_SaleSecuritiesAvailable_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:type="locator" xlink:label="dei_AuditorFirmId" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorFirmId_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorFirmId_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm Id</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:type="locator" xlink:label="dei_AuditorName" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:type="locator" xlink:label="dei_AuditorLocation" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorLocation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AuditorLocation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments" xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Investments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets, noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Employee Benefits Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies (Note 7)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value, 5,000,000 shares authorized; zero shares issued and outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value, 100,000,000 shares authorized; 31,409,707 and 22,097,820 shares issued and outstanding at December 31, 2021 and 2020, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_InterestAndOtherIncomeExpenseNet" xlink:type="locator" xlink:label="cbio_InterestAndOtherIncomeExpenseNet" />
    <link:label xml:lang="en-US" xlink:label="cbio_InterestAndOtherIncomeExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest and other income (expense), net.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_InterestAndOtherIncomeExpenseNet" xlink:to="cbio_InterestAndOtherIncomeExpenseNet_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_LicenseRevenueMember" xlink:type="locator" xlink:label="cbio_LicenseRevenueMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_LicenseRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License revenue member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_LicenseRevenueMember" xlink:to="cbio_LicenseRevenueMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_LicenseRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_LicenseRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Revenue [Member]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CollaborationRevenueMember" xlink:type="locator" xlink:label="cbio_CollaborationRevenueMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_CollaborationRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration revenue member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CollaborationRevenueMember" xlink:to="cbio_CollaborationRevenueMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_CollaborationRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CollaborationRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Revenue [Member]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CostOfLicenseMember" xlink:type="locator" xlink:label="cbio_CostOfLicenseMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of license member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CostOfLicenseMember" xlink:to="cbio_CostOfLicenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of license</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of License [Member]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CostOfCollaborationMember" xlink:type="locator" xlink:label="cbio_CostOfCollaborationMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfCollaborationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of collaboration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CostOfCollaborationMember" xlink:to="cbio_CostOfCollaborationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfCollaborationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of collaboration</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfCollaborationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Collaboration [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and collaboration revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of license and collaboration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Goods And Services Sold</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_InterestAndOtherIncomeExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and other income (expense), net</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_InterestAndOtherIncomeExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest And Other Income Expense Net</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares used to compute net loss per share attributable to common stockholders, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Income And Comprehensive Income [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Period Change [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss on available-for-sale debt securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" xlink:type="locator" xlink:label="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" />
    <link:label xml:lang="en-US" xlink:label="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period from ESPP purchases and stock options exercised value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" xlink:to="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares" xlink:type="locator" xlink:label="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares" />
    <link:label xml:lang="en-US" xlink:label="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period from ESPP purchases and stock options exercised shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares" xlink:to="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from ESPP purchases and stock option exercises</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period From E S P P Purchases And Stock Options Exercised Value</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from ESPP purchases and stock option exercises, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period From E S P P Purchases And Stock Options Exercised Shares</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for public offering, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for public offering, net of issuance costs, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in shares)</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs of issuance of common stock for public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Stock Issued Issuance Costs</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" xlink:type="locator" xlink:label="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase Decrease in operating lease liability and right-of-use asset.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" xlink:to="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_PaymentsToAcquireShortTermAndLongInvestments" xlink:type="locator" xlink:label="cbio_PaymentsToAcquireShortTermAndLongInvestments" />
    <link:label xml:lang="en-US" xlink:label="cbio_PaymentsToAcquireShortTermAndLongInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments to acquire short term and long investments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_PaymentsToAcquireShortTermAndLongInvestments" xlink:to="cbio_PaymentsToAcquireShortTermAndLongInvestments_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" xlink:type="locator" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock for secondary public offering, net of issuance costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" xlink:to="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises" xlink:type="locator" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises" />
    <link:label xml:lang="en-US" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock from ESPP purchases and stock option exercises.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises" xlink:to="cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities" xlink:type="locator" xlink:label="cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Right-of-use assets obtained in exchange for operating lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities" xlink:to="cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_NonCashOrPartNonCashRemeasurementOfRightOfUseAssetDueToOperatingLeaseModification" xlink:type="locator" xlink:label="cbio_NonCashOrPartNonCashRemeasurementOfRightOfUseAssetDueToOperatingLeaseModification" />
    <link:label xml:lang="en-US" xlink:label="cbio_NonCashOrPartNonCashRemeasurementOfRightOfUseAssetDueToOperatingLeaseModification_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Remeasurement of right-of-use asset due to operating lease modification.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_NonCashOrPartNonCashRemeasurementOfRightOfUseAssetDueToOperatingLeaseModification" xlink:to="cbio_NonCashOrPartNonCashRemeasurementOfRightOfUseAssetDueToOperatingLeaseModification_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and other accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability and right-of-use asset</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liability And Right Of Use Asset</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Contract With Customer Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash flows used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Maturity And Collection Of Shortterm Investments</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_PaymentsToAcquireShortTermAndLongInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of short-term and long-term investments</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_PaymentsToAcquireShortTermAndLongInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Short Term And Long Investments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Investments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash flows provided by investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for public offering, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock For Public Offering Net Of Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from ESPP purchase and stock option exercises</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock From E S P P Purchases And Stock Option Exercises</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash flows provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of the period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Disclosure of Non-Cash Investing and Financing Activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing And Financing Items [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained in exchange for operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Or Part Non Cash Right Of Use Assets Obtained In Exchange For Operating Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_NonCashOrPartNonCashRemeasurementOfRightOfUseAssetDueToOperatingLeaseModification_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remeasurement of right-of-use asset due to operating lease modification</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_NonCashOrPartNonCashRemeasurementOfRightOfUseAssetDueToOperatingLeaseModification_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Or Part Non Cash Remeasurement Of Right Of Use Asset Due To Operating Lease Modification</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Operations</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:type="locator" xlink:label="us-gaap_LiquidationBasisOfAccountingTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiquidationBasisOfAccountingTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:to="us-gaap_LiquidationBasisOfAccountingTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiquidationBasisOfAccountingTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liquidation Basis Of Accounting [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments All Other Investments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_InvestmentsAllOtherInvestmentsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Income And Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndOtherIncomeTextBlock" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncomeTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestAndOtherIncomeTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and Other Income (Expense), Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncomeTextBlock" xlink:to="us-gaap_InterestAndOtherIncomeTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestAndOtherIncomeTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest And Other Income [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share Attributable to Common Stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring And Related Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring And Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Pronouncements Recently Adopted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Financial Instruments Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Policy [Text Block]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock" xlink:type="locator" xlink:label="cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of license and collaboration revenue policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock" xlink:to="cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of License and Collaboration Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of License And Collaboration Revenue Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:type="locator" xlink:label="cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:to="cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses Policy [Text Block]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ConcentrationRiskCreditRiskPolicyTextBlock" xlink:type="locator" xlink:label="cbio_ConcentrationRiskCreditRiskPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="cbio_ConcentrationRiskCreditRiskPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Concentration Risk Credit Risk</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ConcentrationRiskCreditRiskPolicyTextBlock" xlink:to="cbio_ConcentrationRiskCreditRiskPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_ConcentrationRiskCreditRiskPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ConcentrationRiskCreditRiskPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="locator" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable, net and Allowance for Doubtful Accounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Receivables Trade And Other Accounts Receivable Allowance For Doubtful Accounts Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:type="locator" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Charges</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:to="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Costs Associated With Exit Or Disposal Activities Or Restructurings Policy</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis [Text Block]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_SaleSecuritiesAvailableTextBlock" xlink:type="locator" xlink:label="cbio_SaleSecuritiesAvailableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="cbio_SaleSecuritiesAvailableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale securities available text block.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_SaleSecuritiesAvailableTextBlock" xlink:to="cbio_SaleSecuritiesAvailableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_SaleSecuritiesAvailableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents, Restricted Cash and Short-Term Investments Classified as Available-for-sale Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_SaleSecuritiesAvailableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Securities Available [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Other Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" xlink:type="locator" xlink:label="cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of present value assumptions of lease payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" xlink:to="cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Present Value Assumptions Of Lease Payments Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Maturity of Operating Lease Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Supplemental Cash Flow Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Cash Flow Supplemental Disclosures Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Option Activity Under Company&apos;s Equity Incentive Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted Average Valuation Assumptions Used to Estimate Fair Value of Employee Stock Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation Recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Federal Income Tax Rate to Company&apos;s Effective Tax Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of the Company&apos;s Deferred Tax Assets (Liabilities)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized Tax Benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Detail of Interest and Other Income (Expense), Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Other Nonoperating Income Expense Table [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive Security not Included in Diluted per Share Calculations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restructuring Charges Recorded in Component of Operating Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Restructuring And Related Costs [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_LiquidityAbstract" xlink:type="locator" xlink:label="cbio_LiquidityAbstract" />
    <link:label xml:lang="en-US" xlink:label="cbio_LiquidityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_LiquidityAbstract" xlink:to="cbio_LiquidityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_LiquidityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Short Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="cbio_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="cbio_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cbio_SummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="cbio_SummaryOfSignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="cbio_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:to="cbio_SummaryOfSignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AS 2016-02</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201602 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Software Intangible Asset [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:type="locator" xlink:label="us-gaap_LeasePracticalExpedientsPackage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasePracticalExpedientsPackage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease practical expedients</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasePracticalExpedientsPackage" xlink:to="us-gaap_LeasePracticalExpedientsPackage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasePracticalExpedientsPackage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Practical Expedients Package</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful lives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CostOfCollaborationRevenue" xlink:type="locator" xlink:label="cbio_CostOfCollaborationRevenue" />
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfCollaborationRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of collaboration revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CostOfCollaborationRevenue" xlink:to="cbio_CostOfCollaborationRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfCollaborationRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of collaboration revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfCollaborationRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Collaboration Revenue</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGrossCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Gross Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_LongTermInvestmentsMember" xlink:type="locator" xlink:label="cbio_LongTermInvestmentsMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_LongTermInvestmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term investments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_LongTermInvestmentsMember" xlink:to="cbio_LongTermInvestmentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_LongTermInvestmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_LongTermInvestmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Investments [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Agency Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale, debt securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Inputs, Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal Agency Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestmentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-Term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestmentsMember" xlink:to="us-gaap_ShortTermInvestmentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShortTermInvestmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Investments [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets, fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AmortizedCostAvailableForSaleSecurities" xlink:type="locator" xlink:label="cbio_AmortizedCostAvailableForSaleSecurities" />
    <link:label xml:lang="en-US" xlink:label="cbio_AmortizedCostAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortized cost available for sale securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_AmortizedCostAvailableForSaleSecurities" xlink:to="cbio_AmortizedCostAvailableForSaleSecurities_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Debt And Equity Securities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_FederalAgencySecuritiesMember" xlink:type="locator" xlink:label="cbio_FederalAgencySecuritiesMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_FederalAgencySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal agency securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_FederalAgencySecuritiesMember" xlink:to="cbio_FederalAgencySecuritiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_FederalAgencySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal Agency Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_FederalAgencySecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Federal Agency Securities [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestmentsMember" xlink:type="locator" xlink:label="us-gaap_OtherLongTermInvestmentsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLongTermInvestmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Long-term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermInvestmentsMember" xlink:to="us-gaap_OtherLongTermInvestmentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLongTermInvestmentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Long Term Investments [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AmortizedCostAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AmortizedCostAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortized Cost Available For Sale Securities</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Gross Unrealized Gain Before Tax Available For Sale Securities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_SaleSecuritiesAvailable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_SaleSecuritiesAvailable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Securities Available</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_GrossRealizedGainLossNetAvailableForSalesSecurities" xlink:type="locator" xlink:label="cbio_GrossRealizedGainLossNetAvailableForSalesSecurities" />
    <link:label xml:lang="en-US" xlink:label="cbio_GrossRealizedGainLossNetAvailableForSalesSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Gross realized gain loss net available for sales securities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_GrossRealizedGainLossNetAvailableForSalesSecurities" xlink:to="cbio_GrossRealizedGainLossNetAvailableForSalesSecurities_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AvailableForSaleDebtSecuritiesContractualMaturity" xlink:type="locator" xlink:label="cbio_AvailableForSaleDebtSecuritiesContractualMaturity" />
    <link:label xml:lang="en-US" xlink:label="cbio_AvailableForSaleDebtSecuritiesContractualMaturity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Available for sale debt securities contractual maturity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_AvailableForSaleDebtSecuritiesContractualMaturity" xlink:to="cbio_AvailableForSaleDebtSecuritiesContractualMaturity_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_FinancialInstrumentLineItems" xlink:type="locator" xlink:label="cbio_FinancialInstrumentLineItems" />
    <link:label xml:lang="en-US" xlink:label="cbio_FinancialInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_FinancialInstrumentLineItems" xlink:to="cbio_FinancialInstrumentLineItems_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_FinancialInstrumentsTable" xlink:type="locator" xlink:label="cbio_FinancialInstrumentsTable" />
    <link:label xml:lang="en-US" xlink:label="cbio_FinancialInstrumentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial instruments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_FinancialInstrumentsTable" xlink:to="cbio_FinancialInstrumentsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_FinancialInstrumentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_FinancialInstrumentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_FinancialInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_FinancialInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_GrossRealizedGainLossNetAvailableForSalesSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Material realized gains or losses on available-for-sale securities</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_GrossRealizedGainLossNetAvailableForSalesSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gross Realized Gain Loss Net Available For Sales Securities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale debt securities current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AvailableForSaleDebtSecuritiesContractualMaturity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available for sale debt securities contractual maturities</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AvailableForSaleDebtSecuritiesContractualMaturity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Contractual Maturity</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AccruedManufacturingExpensesCurrent" xlink:type="locator" xlink:label="cbio_AccruedManufacturingExpensesCurrent" />
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedManufacturingExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued manufacturing expenses current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_AccruedManufacturingExpensesCurrent" xlink:to="cbio_AccruedManufacturingExpensesCurrent_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AccruedCollaborationExpensesCurrent" xlink:type="locator" xlink:label="cbio_AccruedCollaborationExpensesCurrent" />
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedCollaborationExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued collaboration expenses current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_AccruedCollaborationExpensesCurrent" xlink:to="cbio_AccruedCollaborationExpensesCurrent_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AccruedPreClinicalExpensesCurrent" xlink:type="locator" xlink:label="cbio_AccruedPreClinicalExpensesCurrent" />
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedPreClinicalExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Pre Clinical Expenses Current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_AccruedPreClinicalExpensesCurrent" xlink:to="cbio_AccruedPreClinicalExpensesCurrent_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AccruedClinicalExpensesCurrent" xlink:type="locator" xlink:label="cbio_AccruedClinicalExpensesCurrent" />
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedClinicalExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical expenses current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_AccruedClinicalExpensesCurrent" xlink:to="cbio_AccruedClinicalExpensesCurrent_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AccruedAndOtherCurrentLiabilities" xlink:type="locator" xlink:label="cbio_AccruedAndOtherCurrentLiabilities" />
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedAndOtherCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued and other current liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_AccruedAndOtherCurrentLiabilities" xlink:to="cbio_AccruedAndOtherCurrentLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedManufacturingExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedManufacturingExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Manufacturing Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedCollaborationExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Biogen</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedCollaborationExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Collaboration Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedPreClinicalExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-clinical</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedPreClinicalExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Pre Clinical Expenses Current</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional and consulting services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedClinicalExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedClinicalExpensesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedAndOtherCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AccruedAndOtherCurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued And Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other accrued liabilities</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_FirmWorkOrderSupportingClinicalTrials" xlink:type="locator" xlink:label="cbio_FirmWorkOrderSupportingClinicalTrials" />
    <link:label xml:lang="en-US" xlink:label="cbio_FirmWorkOrderSupportingClinicalTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Firm work order supporting clinical trials.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_FirmWorkOrderSupportingClinicalTrials" xlink:to="cbio_FirmWorkOrderSupportingClinicalTrials_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CostOfServicesAsPerAgreement" xlink:type="locator" xlink:label="cbio_CostOfServicesAsPerAgreement" />
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfServicesAsPerAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of services as per agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CostOfServicesAsPerAgreement" xlink:to="cbio_CostOfServicesAsPerAgreement_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CostOfManufacturingServices" xlink:type="locator" xlink:label="cbio_CostOfManufacturingServices" />
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfManufacturingServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of manufacturing services related company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CostOfManufacturingServices" xlink:to="cbio_CostOfManufacturingServices_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" xlink:type="locator" xlink:label="cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" />
    <link:label xml:lang="en-US" xlink:label="cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Charges related to write off of prepaid manufacturing costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" xlink:to="cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:type="locator" xlink:label="cbio_CommitmentsAndContingenciesDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="cbio_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="cbio_CommitmentsAndContingenciesDisclosureLineItems_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CommitmentsAndContingenciesDisclosureTable" xlink:type="locator" xlink:label="cbio_CommitmentsAndContingenciesDisclosureTable" />
    <link:label xml:lang="en-US" xlink:label="cbio_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CommitmentsAndContingenciesDisclosureTable" xlink:to="cbio_CommitmentsAndContingenciesDisclosureTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CommitmentsAndContingenciesDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AGCBiologicsIncMember" xlink:type="locator" xlink:label="cbio_AGCBiologicsIncMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_AGCBiologicsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">AGC Biologics Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_AGCBiologicsIncMember" xlink:to="cbio_AGCBiologicsIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_AGCBiologicsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AGC Biologics, Inc</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AGCBiologicsIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">A G C Biologics Inc [Member]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_MarzeptacogAlfaActivatedMember" xlink:type="locator" xlink:label="cbio_MarzeptacogAlfaActivatedMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_MarzeptacogAlfaActivatedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Marzeptacog alfa (activated).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_MarzeptacogAlfaActivatedMember" xlink:to="cbio_MarzeptacogAlfaActivatedMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_MarzeptacogAlfaActivatedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marzeptacog Alfa Activated</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_MarzeptacogAlfaActivatedMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marzeptacog Alfa Activated [Member]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_IntegrityBioMember" xlink:type="locator" xlink:label="cbio_IntegrityBioMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_IntegrityBioMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Integrity bio .</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_IntegrityBioMember" xlink:to="cbio_IntegrityBioMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_IntegrityBioMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Catalent Indiana, LLC.</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_IntegrityBioMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Integrity Bio [Member]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" xlink:type="locator" xlink:label="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Marzeptacog alfa activated and dalcinonacog alfa.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" xlink:to="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marzeptacog Alfa Activated and Dalcinonacog Alfa</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marzeptacog Alfa Activated And Dalcinonacog Alfa [Member]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_DalcinonacogAlfaMember" xlink:type="locator" xlink:label="cbio_DalcinonacogAlfaMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_DalcinonacogAlfaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Dalcinonacog alfa.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_DalcinonacogAlfaMember" xlink:to="cbio_DalcinonacogAlfaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_DalcinonacogAlfaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dalcinonacog Alfa</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_DalcinonacogAlfaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dalcinonacog Alfa [Member]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_GMPMember" xlink:type="locator" xlink:label="cbio_GMPMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_GMPMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">GMP manufacturing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_GMPMember" xlink:to="cbio_GMPMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_GMPMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dalcinonacog alfa.</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_GMPMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">G M P [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceAgreementsMember" xlink:type="locator" xlink:label="us-gaap_ServiceAgreementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ServiceAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Service Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServiceAgreementsMember" xlink:to="us-gaap_ServiceAgreementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ServiceAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Service Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CommitmentsAndContingenciesDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_FirmWorkOrderSupportingClinicalTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Firm work order supporting clinical trials</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_FirmWorkOrderSupportingClinicalTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Firm Work Order Supporting Clinical Trials</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfServicesAsPerAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of services as per agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfServicesAsPerAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Services As Per Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfManufacturingServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of Manufacturing Services</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CostOfManufacturingServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Manufacturing Services</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractualObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual obligation payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractualObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Charges related to write off of prepaid manufacturing cost</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Charges Related To Write Off Of Prepaid Manufacturing Cost</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement" xlink:type="locator" xlink:label="cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement" />
    <link:label xml:lang="en-US" xlink:label="cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront fee reveived from license and collaboration agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement" xlink:to="cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_SublicenseFee" xlink:type="locator" xlink:label="cbio_SublicenseFee" />
    <link:label xml:lang="en-US" xlink:label="cbio_SublicenseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublicense fee entitled to pay.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_SublicenseFee" xlink:to="cbio_SublicenseFee_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" xlink:type="locator" xlink:label="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" />
    <link:label xml:lang="en-US" xlink:label="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment .</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" xlink:to="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_MosaicBiosciencesIncMember" xlink:type="locator" xlink:label="cbio_MosaicBiosciencesIncMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_MosaicBiosciencesIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Mosaic Biosciences, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_MosaicBiosciencesIncMember" xlink:to="cbio_MosaicBiosciencesIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_MosaicBiosciencesIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Mosaic Biosciences Inc</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_MosaicBiosciencesIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Mosaic Biosciences Inc [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_BiogenCollaborationMember" xlink:type="locator" xlink:label="cbio_BiogenCollaborationMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_BiogenCollaborationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Biogen collaboration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_BiogenCollaborationMember" xlink:to="cbio_BiogenCollaborationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_BiogenCollaborationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Biogen Collaboration</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_BiogenCollaborationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Biogen Collaboration [Member]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_IntravitrealAntiComplementFactor3Member" xlink:type="locator" xlink:label="cbio_IntravitrealAntiComplementFactor3Member" />
    <link:label xml:lang="en-US" xlink:label="cbio_IntravitrealAntiComplementFactor3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Intravitreal anti-complement factor 3.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_IntravitrealAntiComplementFactor3Member" xlink:to="cbio_IntravitrealAntiComplementFactor3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_IntravitrealAntiComplementFactor3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intravitreal Anti-Complement Factor 3</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_IntravitrealAntiComplementFactor3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intravitreal Anti Complement Factor3 [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront license fee received from collaboration agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Fee Reveived From License And Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_SublicenseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment related to collaboration</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_SublicenseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sublicense Fee</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One Time Expense related to collaboration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction Expenses From Transactions With Related Party</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone Payment Related To Regulatory And Clinical Development Events</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Related To Regulatory And Clinical Development Events</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_LesseeOperatingLeaseRenewalTermDescription" xlink:type="locator" xlink:label="cbio_LesseeOperatingLeaseRenewalTermDescription" />
    <link:label xml:lang="en-US" xlink:label="cbio_LesseeOperatingLeaseRenewalTermDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease renewal term description.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_LesseeOperatingLeaseRenewalTermDescription" xlink:to="cbio_LesseeOperatingLeaseRenewalTermDescription_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Table]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_LeaseLabAndOfficeSpaceMember" xlink:type="locator" xlink:label="cbio_LeaseLabAndOfficeSpaceMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_LeaseLabAndOfficeSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease lab and office space.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_LeaseLabAndOfficeSpaceMember" xlink:to="cbio_LeaseLabAndOfficeSpaceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_LeaseLabAndOfficeSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Lab And Office Space</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_LeaseLabAndOfficeSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Lab And Office Space [Member]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_SubleaseArrangementMember" xlink:type="locator" xlink:label="cbio_SubleaseArrangementMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_SubleaseArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_SubleaseArrangementMember" xlink:to="cbio_SubleaseArrangementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_SubleaseArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease Arrangement</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_SubleaseArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Arrangement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Lease Description [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_LesseeOperatingLeaseRenewalTermDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee operating lease renewal term description</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_LesseeOperatingLeaseRenewalTermDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Term Description</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset and lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Asset Obtained In Exchange For Operating Lease Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Undiscounted future payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, option to extend</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Option To Extend</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease commenced description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Description</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease not yet commenced description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Lease Not Yet Commenced Description</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease term of contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liabilities Payments Due [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total operating lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:type="locator" xlink:label="cbio_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="cbio_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid for amounts included in the measurement of lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:to="cbio_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_PrepaidCashPaymentForLeaseLiabilities" xlink:type="locator" xlink:label="cbio_PrepaidCashPaymentForLeaseLiabilities" />
    <link:label xml:lang="en-US" xlink:label="cbio_PrepaidCashPaymentForLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid Cash Payment For Lease Liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_PrepaidCashPaymentForLeaseLiabilities" xlink:to="cbio_PrepaidCashPaymentForLeaseLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid For Amounts Included In The Measurement Of Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_PrepaidCashPaymentForLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid cash payment for lease</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_PrepaidCashPaymentForLeaseLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Cash Payment For Lease Liabilities</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash paid for operating leases that were included in operating cash outflows</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_TwoThousandEighteenOmnibusIncentivePlanMember" xlink:type="locator" xlink:label="cbio_TwoThousandEighteenOmnibusIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_TwoThousandEighteenOmnibusIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand eighteen omnibus incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_TwoThousandEighteenOmnibusIncentivePlanMember" xlink:to="cbio_TwoThousandEighteenOmnibusIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_TwoThousandEighteenOmnibusIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Omnibus Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_TwoThousandEighteenOmnibusIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Omnibus Incentive Plan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_PerformanceBasedStockOptionGrantsMember" xlink:type="locator" xlink:label="cbio_PerformanceBasedStockOptionGrantsMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_PerformanceBasedStockOptionGrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance based stock option grants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_PerformanceBasedStockOptionGrantsMember" xlink:to="cbio_PerformanceBasedStockOptionGrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_PerformanceBasedStockOptionGrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Based Stock Option Grants</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_PerformanceBasedStockOptionGrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Performance Based Stock Option Grants [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand eighteen employee stock purchase plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:to="cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Increase in number of shares of common stock reserved for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_IssuanceOfOptionGrantsToPurchaseCommonStockShares" xlink:type="locator" xlink:label="cbio_IssuanceOfOptionGrantsToPurchaseCommonStockShares" />
    <link:label xml:lang="en-US" xlink:label="cbio_IssuanceOfOptionGrantsToPurchaseCommonStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of option grants to purchase common stock shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_IssuanceOfOptionGrantsToPurchaseCommonStockShares" xlink:to="cbio_IssuanceOfOptionGrantsToPurchaseCommonStockShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_IssuanceOfOptionGrantsToPurchaseCommonStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of option grants to purchase common stock shares</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_IssuanceOfOptionGrantsToPurchaseCommonStockShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Option Grants To Purchase Common Stock Shares</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares Underlying Outstanding Options, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options, Options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Underlying Outstanding Options, Options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Underlying Outstanding Options, Options forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Underlying Outstanding Options, Options expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares Underlying Outstanding Options, Ending Balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options, Exercisable- December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available to be granted - December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted- Average Exercise Price, Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Options forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Options expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted- Average Exercise Price, Ending Balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Exercise Price, Exercisable - December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term (Years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term (Years), Outstanding Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term, Exercisable - December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Additional General Disclosures [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of options vested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:type="locator" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" />
    <link:label xml:lang="en-US" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award fair value assumptions Black-Scholes method used.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" xlink:type="locator" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" />
    <link:label xml:lang="en-US" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black-Scholes Method Used [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" xlink:to="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black Scholes Method Used [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black Scholes Method Used [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black Scholes Method Used [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black Scholes Method Used [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of common stock issued to certain board members in lieu of cash compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Issued For Services</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized employee stock based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized employee stock based compensation expense, period for recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of fair market value of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum employee subscription rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of common stock available for future grant</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock authorized for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock stock issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from Issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Or Sale Of Equity</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:type="locator" xlink:label="cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences" />
    <link:label xml:lang="en-US" xlink:label="cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation, permanent differences.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_EffectiveIncomeTaxRateReconciliationDerecognition" xlink:type="locator" xlink:label="cbio_EffectiveIncomeTaxRateReconciliationDerecognition" />
    <link:label xml:lang="en-US" xlink:label="cbio_EffectiveIncomeTaxRateReconciliationDerecognition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation derecognition.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_EffectiveIncomeTaxRateReconciliationDerecognition" xlink:to="cbio_EffectiveIncomeTaxRateReconciliationDerecognition_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax at statutory federal rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">State Tax (benefit)&#8212;net of federal benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Permanent differences</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Permanent Differences</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Credits</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_EffectiveIncomeTaxRateReconciliationDerecognition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Derecognition due to Sec. 382 and 383 limitations</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_EffectiveIncomeTaxRateReconciliationDerecognition_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Derecognition</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense Other</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_DeferredTaxAssetsFixedAssetsAndIntangibles" xlink:type="locator" xlink:label="cbio_DeferredTaxAssetsFixedAssetsAndIntangibles" />
    <link:label xml:lang="en-US" xlink:label="cbio_DeferredTaxAssetsFixedAssetsAndIntangibles_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets fixed assets and intangibles.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_DeferredTaxAssetsFixedAssetsAndIntangibles" xlink:to="cbio_DeferredTaxAssetsFixedAssetsAndIntangibles_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals and reserves</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carry forwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carry forwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_DeferredTaxAssetsFixedAssetsAndIntangibles_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed and intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_DeferredTaxAssetsFixedAssetsAndIntangibles_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Fixed Assets And Intangibles</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_IncomeTaxLineItems" xlink:type="locator" xlink:label="cbio_IncomeTaxLineItems" />
    <link:label xml:lang="en-US" xlink:label="cbio_IncomeTaxLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_IncomeTaxLineItems" xlink:to="cbio_IncomeTaxLineItems_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_IncomeTaxTable" xlink:type="locator" xlink:label="cbio_IncomeTaxTable" />
    <link:label xml:lang="en-US" xlink:label="cbio_IncomeTaxTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income Tax [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_IncomeTaxTable" xlink:to="cbio_IncomeTaxTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_IncomeTaxTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_IncomeTaxTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal Income Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State Income Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:label xml:lang="en-US" xlink:label="stpr_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CALIFORNIA</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl" />
    <link:label xml:lang="en-US" xlink:label="stpr_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">CALIFORNIA</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_IncomeTaxLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_IncomeTaxLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (decrease) in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:to="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowances And Reserves Period Increase Decrease</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="cbio_OperatingLossCarryforwardsExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="cbio_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_OperatingLossCarryforwardsExpirationYear" xlink:to="cbio_OperatingLossCarryforwardsExpirationYear_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_OperatingLossCarryforwardsWithIndefiniteLife" xlink:type="locator" xlink:label="cbio_OperatingLossCarryforwardsWithIndefiniteLife" />
    <link:label xml:lang="en-US" xlink:label="cbio_OperatingLossCarryforwardsWithIndefiniteLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards with indefinite life.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_OperatingLossCarryforwardsWithIndefiniteLife" xlink:to="cbio_OperatingLossCarryforwardsWithIndefiniteLife_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_OperatingLossCarryforwardsWithIndefiniteLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards having indefinite life</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_OperatingLossCarryforwardsWithIndefiniteLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards With Indefinite Life</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforwards available to offset future federal tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Amount</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit carryforward, expire period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardExpirationDate" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Date</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards" xlink:type="locator" xlink:label="cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards" />
    <link:label xml:lang="en-US" xlink:label="cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets state net operating loss carry forwards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards" xlink:to="cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforward, derecognized</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets State Net Operating Loss Carry Forwards</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" xlink:type="locator" xlink:label="cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" />
    <link:label xml:lang="en-US" xlink:label="cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development tax credit carry forwards derecognized.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" xlink:to="cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross federal R&amp;D tax credit-related deferred tax assets derecognized</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Tax Credit Carry Forwards Derecognized</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_MaximumAmountOfTaxOffsetPerYear" xlink:type="locator" xlink:label="cbio_MaximumAmountOfTaxOffsetPerYear" />
    <link:label xml:lang="en-US" xlink:label="cbio_MaximumAmountOfTaxOffsetPerYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum amount of tax offset per year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_MaximumAmountOfTaxOffsetPerYear" xlink:to="cbio_MaximumAmountOfTaxOffsetPerYear_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_RequiredMinimumTaxableIncome" xlink:type="locator" xlink:label="cbio_RequiredMinimumTaxableIncome" />
    <link:label xml:lang="en-US" xlink:label="cbio_RequiredMinimumTaxableIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The minimum taxable income required to support realizing the company&apos;s.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_RequiredMinimumTaxableIncome" xlink:to="cbio_RequiredMinimumTaxableIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_MaximumAmountOfTaxOffsetPerYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum amount of tax offset per year</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_MaximumAmountOfTaxOffsetPerYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Amount Of Tax Offset Per Year</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_RequiredMinimumTaxableIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Required Minimum Taxable Income</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_RequiredMinimumTaxableIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Required Minimum Taxable Income</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrecognized tax benefits increase (decrease) resulting from tax positions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:to="cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase/(Decrease) of unrecognized tax benefits taken in prior years</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase/(Decrease) of unrecognized tax benefits related to current year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balance</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax-related penalties or interest recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination Penalties And Interest Accrued</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liability For Uncertain Tax Positions Current</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_MilestonePayments" xlink:type="locator" xlink:label="cbio_MilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="cbio_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_MilestonePayments" xlink:to="cbio_MilestonePayments_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_RegulatoryAndDevelopmentMilestonePayment" xlink:type="locator" xlink:label="cbio_RegulatoryAndDevelopmentMilestonePayment" />
    <link:label xml:lang="en-US" xlink:label="cbio_RegulatoryAndDevelopmentMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory and development milestone payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_RegulatoryAndDevelopmentMilestonePayment" xlink:to="cbio_RegulatoryAndDevelopmentMilestonePayment_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CommercialMilestonePayments" xlink:type="locator" xlink:label="cbio_CommercialMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="cbio_CommercialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CommercialMilestonePayments" xlink:to="cbio_CommercialMilestonePayments_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CollaborationAgreementsAbstract" xlink:type="locator" xlink:label="cbio_CollaborationAgreementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="cbio_CollaborationAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CollaborationAgreementsAbstract" xlink:to="cbio_CollaborationAgreementsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_CollaborationAgreementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreements [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition Multiple Deliverable Arrangements [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Multiple Deliverable Arrangements [Table]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_IsuAbxisMember" xlink:type="locator" xlink:label="cbio_IsuAbxisMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_IsuAbxisMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">ISU Abxis.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_IsuAbxisMember" xlink:to="cbio_IsuAbxisMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_IsuAbxisMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ISU Abxis</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_IsuAbxisMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Isu Abxis [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transaction Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransactionDomain" xlink:to="us-gaap_TransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transaction [Domain]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AmendedAndRestatedLicenseAgreementMember" xlink:type="locator" xlink:label="cbio_AmendedAndRestatedLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_AmendedAndRestatedLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended and restated license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_AmendedAndRestatedLicenseAgreementMember" xlink:to="cbio_AmendedAndRestatedLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_AmendedAndRestatedLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended and Restated License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AmendedAndRestatedLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amended And Restated License Agreement [Member]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_BiogenMember" xlink:type="locator" xlink:label="cbio_BiogenMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_BiogenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Biogen.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_BiogenMember" xlink:to="cbio_BiogenMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_BiogenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Biogen</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_BiogenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Biogen [Member]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_LicenseAndCollaborationAgreementMember" xlink:type="locator" xlink:label="cbio_LicenseAndCollaborationAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_LicenseAndCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License and Collaboration Agreement (the &#8220;Biogen Agreement&#8221;), .</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_LicenseAndCollaborationAgreementMember" xlink:to="cbio_LicenseAndCollaborationAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_LicenseAndCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and Collaboration Agreement (the &#8220;Biogen Agreement&#8221;)</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_LicenseAndCollaborationAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License And Collaboration Agreement [Member]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ExclusiveLicenseMember" xlink:type="locator" xlink:label="cbio_ExclusiveLicenseMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_ExclusiveLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exclusive license.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ExclusiveLicenseMember" xlink:to="cbio_ExclusiveLicenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_ExclusiveLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exclusive License</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ExclusiveLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exclusive License [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ExclusiveLicenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exclusive License</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others By Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others Type [Domain]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember" xlink:type="locator" xlink:label="cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Transfer of Exclusive License and Related Know-How.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember" xlink:to="cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfer of Exclusive License and Related Know-How</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transfer Of Exclusive License And Related Know How [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CollaborationRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Collaboration</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" xlink:type="locator" xlink:label="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursable Out-of-Pocket and Personnel Costs Incurred Related to Research Services.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" xlink:to="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursable Out-of-Pocket and Personnel Costs Incurred Related to Research Services</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursable Out Of Pocket And Personnel Costs Incurred Related To Research Services [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition Multiple Deliverable Arrangements [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Multiple Deliverable Arrangements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_MilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_RegulatoryAndDevelopmentMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regulatory and development milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_RegulatoryAndDevelopmentMilestonePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory And Development Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CommercialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CommercialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Milestone Payments</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ResearchServicesAgreementTerm" xlink:type="locator" xlink:label="cbio_ResearchServicesAgreementTerm" />
    <link:label xml:lang="en-US" xlink:label="cbio_ResearchServicesAgreementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research services.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ResearchServicesAgreementTerm" xlink:to="cbio_ResearchServicesAgreementTerm_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ResearchServicesAgreementOptionToExtend" xlink:type="locator" xlink:label="cbio_ResearchServicesAgreementOptionToExtend" />
    <link:label xml:lang="en-US" xlink:label="cbio_ResearchServicesAgreementOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research services agreement option to extend.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ResearchServicesAgreementOptionToExtend" xlink:to="cbio_ResearchServicesAgreementOptionToExtend_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_ResearchServicesAgreementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research services</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ResearchServicesAgreementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Services Agreement Term</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ResearchServicesAgreementOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research services option to extend</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ResearchServicesAgreementOptionToExtend_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Services Agreement Option To Extend</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_DevelopmentMilestonesPaymentReceivable" xlink:type="locator" xlink:label="cbio_DevelopmentMilestonesPaymentReceivable" />
    <link:label xml:lang="en-US" xlink:label="cbio_DevelopmentMilestonesPaymentReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestones payment Receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_DevelopmentMilestonesPaymentReceivable" xlink:to="cbio_DevelopmentMilestonesPaymentReceivable_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Up-front payments received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From License Fees Received</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_DevelopmentMilestonesPaymentReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and sales milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_DevelopmentMilestonesPaymentReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestones Payment Receivable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueRevenueRecognized1" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Revenue Recognized1</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_MiscellaneousIncomeExpense" xlink:type="locator" xlink:label="cbio_MiscellaneousIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="cbio_MiscellaneousIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Miscellaneous income (expense).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_MiscellaneousIncomeExpense" xlink:to="cbio_MiscellaneousIncomeExpense_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income Expense Nonoperating Net</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_MiscellaneousIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Miscellaneous income</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_MiscellaneousIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Miscellaneous Income Expense</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_InterestAndOtherIncomeExpenseNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total interest and other income (expense), net</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_UnderwritingCommissionsAndOfferingExpensesPayable" xlink:type="locator" xlink:label="cbio_UnderwritingCommissionsAndOfferingExpensesPayable" />
    <link:label xml:lang="en-US" xlink:label="cbio_UnderwritingCommissionsAndOfferingExpensesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting commissions and offering expenses payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_UnderwritingCommissionsAndOfferingExpensesPayable" xlink:to="cbio_UnderwritingCommissionsAndOfferingExpensesPayable_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_StockholdersEquityDisclosureLineItems" xlink:type="locator" xlink:label="cbio_StockholdersEquityDisclosureLineItems" />
    <link:label xml:lang="en-US" xlink:label="cbio_StockholdersEquityDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stockholders equity disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="cbio_StockholdersEquityDisclosureLineItems_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_StockholdersEquityDisclosureTable" xlink:type="locator" xlink:label="cbio_StockholdersEquityDisclosureTable" />
    <link:label xml:lang="en-US" xlink:label="cbio_StockholdersEquityDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stockholders equity disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_StockholdersEquityDisclosureTable" xlink:to="cbio_StockholdersEquityDisclosureTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_StockholdersEquityDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders Equity Disclosure [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_StockholdersEquityDisclosureTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Disclosure [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_UnderwritersOverallotmentOptionMember" xlink:type="locator" xlink:label="cbio_UnderwritersOverallotmentOptionMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_UnderwritersOverallotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriters overallotment option.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_UnderwritersOverallotmentOptionMember" xlink:to="cbio_UnderwritersOverallotmentOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_UnderwritersOverallotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters&apos; Overallotment Option</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_UnderwritersOverallotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Underwriters Overallotment Option [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_TwoThousandTwentyOneATMProgramMember" xlink:type="locator" xlink:label="cbio_TwoThousandTwentyOneATMProgramMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_TwoThousandTwentyOneATMProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one ATM program.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_TwoThousandTwentyOneATMProgramMember" xlink:to="cbio_TwoThousandTwentyOneATMProgramMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_TwoThousandTwentyOneATMProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 ATM Program</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_TwoThousandTwentyOneATMProgramMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One A T M Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_StockholdersEquityDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders Equity Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_StockholdersEquityDisclosureLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Disclosure [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock price, per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_UnderwritingCommissionsAndOfferingExpensesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts, commissions and offering expenses payable</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_UnderwritingCommissionsAndOfferingExpensesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Commissions And Offering Expenses Payable</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from sale of common stock after deducting underwriting commissions and offering expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock warrants issued</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock warrants outstanding</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants exercise price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants And Rights Outstanding Maturity Date</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_PercentageOfCommissionForSharesSold" xlink:type="locator" xlink:label="cbio_PercentageOfCommissionForSharesSold" />
    <link:label xml:lang="en-US" xlink:label="cbio_PercentageOfCommissionForSharesSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of Commission for shares sold.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_PercentageOfCommissionForSharesSold" xlink:to="cbio_PercentageOfCommissionForSharesSold_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_LegalExpensesIncurred" xlink:type="locator" xlink:label="cbio_LegalExpensesIncurred" />
    <link:label xml:lang="en-US" xlink:label="cbio_LegalExpensesIncurred_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Legal expenses incurred.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_LegalExpensesIncurred" xlink:to="cbio_LegalExpensesIncurred_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_PercentageOfCommissionForSharesSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of commission for shares sold</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_PercentageOfCommissionForSharesSold_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Commission For Shares Sold</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_LegalExpensesIncurred_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal expenses incurred</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_LegalExpensesIncurred_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Legal Expenses Incurred</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_OptionsToPurchaseCommonStockMember" xlink:type="locator" xlink:label="cbio_OptionsToPurchaseCommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_OptionsToPurchaseCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to purchase common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_OptionsToPurchaseCommonStockMember" xlink:to="cbio_OptionsToPurchaseCommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_OptionsToPurchaseCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options To Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_OptionsToPurchaseCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Options To Purchase Common Stock [Member]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CommonStockWarrantsMember" xlink:type="locator" xlink:label="cbio_CommonStockWarrantsMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_CommonStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_CommonStockWarrantsMember" xlink:to="cbio_CommonStockWarrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_CommonStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_CommonStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti dilutive securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_RestructuringLiability" xlink:type="locator" xlink:label="cbio_RestructuringLiability" />
    <link:label xml:lang="en-US" xlink:label="cbio_RestructuringLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Restructuring liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_RestructuringLiability" xlink:to="cbio_RestructuringLiability_lbl" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percent of employees terminated</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring And Related Cost Number Of Positions Eliminated Period Percent</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1" xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Severance costs and expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeveranceCosts1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Severance Costs1</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_RestructuringLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring liability</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_RestructuringLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Liability</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Restructuring And Related Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Restructuring And Related Costs [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restructuring Cost And Reserve [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Cost And Reserve [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges" xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total restructuring charges</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restructuring Charges</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_BiogenAgreementMember" xlink:type="locator" xlink:label="cbio_BiogenAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_BiogenAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Biogen agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_BiogenAgreementMember" xlink:to="cbio_BiogenAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_BiogenAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Biogen Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_BiogenAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Biogen Agreement [Member]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AdvisorAgreementMember" xlink:type="locator" xlink:label="cbio_AdvisorAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_AdvisorAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Advisor Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_AdvisorAgreementMember" xlink:to="cbio_AdvisorAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_AdvisorAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advisor Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AdvisorAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Advisor Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_RaymondJamesAndAssociatesMember" xlink:type="locator" xlink:label="cbio_RaymondJamesAndAssociatesMember" />
    <link:label xml:lang="en-US" xlink:label="cbio_RaymondJamesAndAssociatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Raymond James and Associates.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_RaymondJamesAndAssociatesMember" xlink:to="cbio_RaymondJamesAndAssociatesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_RaymondJamesAndAssociatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Raymond James &amp; Associates</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_RaymondJamesAndAssociatesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Raymond James And Associates [Member]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease Payments Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceived_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessor Operating Lease Payments To Be Received</link:label>
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AdvisoryFeesPayable" xlink:type="locator" xlink:label="cbio_AdvisoryFeesPayable" />
    <link:label xml:lang="en-US" xlink:label="cbio_AdvisoryFeesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Advisory fees payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_AdvisoryFeesPayable" xlink:to="cbio_AdvisoryFeesPayable_lbl" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ReimbursementOfAdvisoryFee" xlink:type="locator" xlink:label="cbio_ReimbursementOfAdvisoryFee" />
    <link:label xml:lang="en-US" xlink:label="cbio_ReimbursementOfAdvisoryFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reimbursement of advisory fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cbio_ReimbursementOfAdvisoryFee" xlink:to="cbio_ReimbursementOfAdvisoryFee_lbl" />
    <link:label xml:lang="en-US" xlink:label="cbio_AdvisoryFeesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advisory fees payable</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_AdvisoryFeesPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Advisory Fees Payable</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ReimbursementOfAdvisoryFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursement of advisory fee</link:label>
    <link:label xml:lang="en-US" xlink:label="cbio_ReimbursementOfAdvisoryFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reimbursement Of Advisory Fee</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestructuringCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total expenses</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>cbio-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2022-03-31T02:21:01.8292552+00:00 -->
<!-- Version            : 5.0.1.728 -->
<!-- Package ID         : ef934a25c5c94284985388408cc8aae1 -->
<!-- Copyright (c) 2022 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/role/TemplateLink" xlink:href="cbio-20211231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="cbio-20211231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:type="locator" xlink:label="dei_AuditorLocation" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:type="locator" xlink:label="dei_AuditorName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:type="locator" xlink:label="dei_AuditorFirmId" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="12170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="cbio-20211231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments" xlink:type="locator" xlink:label="us-gaap_LongTermInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="cbio-20211231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="cbio-20211231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_InterestAndOtherIncomeExpenseNet" xlink:type="locator" xlink:label="cbio_InterestAndOtherIncomeExpenseNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CostOfCollaborationMember" xlink:type="locator" xlink:label="cbio_CostOfCollaborationMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CostOfLicenseMember" xlink:type="locator" xlink:label="cbio_CostOfLicenseMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CollaborationRevenueMember" xlink:type="locator" xlink:label="cbio_CollaborationRevenueMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_LicenseRevenueMember" xlink:type="locator" xlink:label="cbio_LicenseRevenueMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_LicenseRevenueMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_CollaborationRevenueMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_CostOfLicenseMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_CostOfCollaborationMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cbio_InterestAndOtherIncomeExpenseNet" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="cbio-20211231.xsd#Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="cbio-20211231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares" xlink:type="locator" xlink:label="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" xlink:type="locator" xlink:label="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:href="cbio-20211231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="cbio-20211231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="cbio-20211231.xsd#cbio_NonCashOrPartNonCashRemeasurementOfRightOfUseAssetDueToOperatingLeaseModification" xlink:type="locator" xlink:label="cbio_NonCashOrPartNonCashRemeasurementOfRightOfUseAssetDueToOperatingLeaseModification" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities" xlink:type="locator" xlink:label="cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises" xlink:type="locator" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" xlink:type="locator" xlink:label="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireInvestments" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_PaymentsToAcquireShortTermAndLongInvestments" xlink:type="locator" xlink:label="cbio_PaymentsToAcquireShortTermAndLongInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" xlink:type="locator" xlink:label="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="cbio_PaymentsToAcquireShortTermAndLongInvestments" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="cbio_NonCashOrPartNonCashRemeasurementOfRightOfUseAssetDueToOperatingLeaseModification" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureNatureOfOperations" xlink:href="cbio-20211231.xsd#Role_DisclosureNatureOfOperations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureNatureOfOperations">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLiquidity" xlink:href="cbio-20211231.xsd#Role_DisclosureLiquidity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLiquidity">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiquidationBasisOfAccountingTextBlock" xlink:type="locator" xlink:label="us-gaap_LiquidationBasisOfAccountingTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_LiquidationBasisOfAccountingTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="cbio-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurements" xlink:href="cbio-20211231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurements">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFinancialInstruments" xlink:href="cbio-20211231.xsd#Role_DisclosureFinancialInstruments" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFinancialInstruments">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentsDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="us-gaap_FinancialInstrumentsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureOtherAccruedLiabilities" xlink:href="cbio-20211231.xsd#Role_DisclosureOtherAccruedLiabilities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureOtherAccruedLiabilities">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="cbio-20211231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedParties" xlink:href="cbio-20211231.xsd#Role_DisclosureRelatedParties" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedParties">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeases" xlink:href="cbio-20211231.xsd#Role_DisclosureLeases" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeases">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="cbio-20211231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensation">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="cbio-20211231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborations" xlink:href="cbio-20211231.xsd#Role_DisclosureCollaborations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborations">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureInterestAndOtherIncomeExpenseNet" xlink:href="cbio-20211231.xsd#Role_DisclosureInterestAndOtherIncomeExpenseNet" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureInterestAndOtherIncomeExpenseNet">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndOtherIncomeTextBlock" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncomeTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestAndOtherIncomeTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquity" xlink:href="cbio-20211231.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquity">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:href="cbio-20211231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuring" xlink:href="cbio-20211231.xsd#Role_DisclosureRestructuring" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuring">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEvent" xlink:href="cbio-20211231.xsd#Role_DisclosureSubsequentEvent" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEvent">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="cbio-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:type="locator" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="locator" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ConcentrationRiskCreditRiskPolicyTextBlock" xlink:type="locator" xlink:label="cbio_ConcentrationRiskCreditRiskPolicyTextBlock" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:type="locator" xlink:label="cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock" xlink:type="locator" xlink:label="cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cbio_ConcentrationRiskCreditRiskPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables" xlink:href="cbio-20211231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsTables" xlink:href="cbio-20211231.xsd#Role_DisclosureFinancialInstrumentsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsTables">
    <link:loc xlink:href="cbio-20211231.xsd#cbio_SaleSecuritiesAvailableTextBlock" xlink:type="locator" xlink:label="cbio_SaleSecuritiesAvailableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsAllOtherInvestmentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="cbio_SaleSecuritiesAvailableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureOtherAccruedLiabilitiesTables" xlink:href="cbio-20211231.xsd#Role_DisclosureOtherAccruedLiabilitiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureOtherAccruedLiabilitiesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesTables" xlink:href="cbio-20211231.xsd#Role_DisclosureLeasesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" xlink:type="locator" xlink:label="cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="cbio-20211231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="cbio-20211231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureInterestAndOtherIncomeExpenseNetTables" xlink:href="cbio-20211231.xsd#Role_DisclosureInterestAndOtherIncomeExpenseNetTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureInterestAndOtherIncomeExpenseNetTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:href="cbio-20211231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringTables" xlink:href="cbio-20211231.xsd#Role_DisclosureRestructuringTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringTables">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureNatureOfOperationsAdditionalInformationDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureNatureOfOperationsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureNatureOfOperationsAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureLiquidityAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_LiquidityAbstract" xlink:type="locator" xlink:label="cbio_LiquidityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_LiquidityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_LiquidityAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_LiquidityAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableGrossCurrent" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CostOfCollaborationRevenue" xlink:type="locator" xlink:label="cbio_CostOfCollaborationRevenue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:type="locator" xlink:label="us-gaap_LeasePracticalExpedientsPackage" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="cbio_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="locator" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="cbio_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="cbio_SummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesTable" xlink:to="cbio_SummaryOfSignificantAccountingPoliciesLineItems" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LeasePracticalExpedientsPackage" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="cbio_CostOfCollaborationRevenue" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_LongTermInvestmentsMember" xlink:type="locator" xlink:label="cbio_LongTermInvestmentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="cbio_LongTermInvestmentsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestmentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail">
    <link:loc xlink:href="cbio-20211231.xsd#cbio_SaleSecuritiesAvailable" xlink:type="locator" xlink:label="cbio_SaleSecuritiesAvailable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" xlink:type="locator" xlink:label="cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AmortizedCostAvailableForSaleSecurities" xlink:type="locator" xlink:label="cbio_AmortizedCostAvailableForSaleSecurities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLongTermInvestmentsMember" xlink:type="locator" xlink:label="us-gaap_OtherLongTermInvestmentsMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_FederalAgencySecuritiesMember" xlink:type="locator" xlink:label="cbio_FederalAgencySecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:type="locator" xlink:label="us-gaap_ShortTermInvestmentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashAndCashEquivalentsMember" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_ShortTermInvestmentsMember" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="10060.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="10060.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="cbio_FederalAgencySecuritiesMember" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_OtherLongTermInvestmentsMember" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="cbio_AmortizedCostAvailableForSaleSecurities" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="cbio_SaleSecuritiesAvailable" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureFinancialInstrumentsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail">
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AvailableForSaleDebtSecuritiesContractualMaturity" xlink:type="locator" xlink:label="cbio_AvailableForSaleDebtSecuritiesContractualMaturity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_GrossRealizedGainLossNetAvailableForSalesSecurities" xlink:type="locator" xlink:label="cbio_GrossRealizedGainLossNetAvailableForSalesSecurities" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_FinancialInstrumentLineItems" xlink:type="locator" xlink:label="cbio_FinancialInstrumentLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_FinancialInstrumentsTable" xlink:type="locator" xlink:label="cbio_FinancialInstrumentsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="cbio_FinancialInstrumentsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_FinancialInstrumentsTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_FinancialInstrumentsTable" xlink:to="cbio_FinancialInstrumentLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_FinancialInstrumentLineItems" xlink:to="cbio_GrossRealizedGainLossNetAvailableForSalesSecurities" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_FinancialInstrumentLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_FinancialInstrumentLineItems" xlink:to="cbio_AvailableForSaleDebtSecuritiesContractualMaturity" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureScheduleOfOtherAccruedLiabilitiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AccruedAndOtherCurrentLiabilities" xlink:type="locator" xlink:label="cbio_AccruedAndOtherCurrentLiabilities" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AccruedClinicalExpensesCurrent" xlink:type="locator" xlink:label="cbio_AccruedClinicalExpensesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AccruedPreClinicalExpensesCurrent" xlink:type="locator" xlink:label="cbio_AccruedPreClinicalExpensesCurrent" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AccruedCollaborationExpensesCurrent" xlink:type="locator" xlink:label="cbio_AccruedCollaborationExpensesCurrent" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AccruedManufacturingExpensesCurrent" xlink:type="locator" xlink:label="cbio_AccruedManufacturingExpensesCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="cbio_AccruedManufacturingExpensesCurrent" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="cbio_AccruedCollaborationExpensesCurrent" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="cbio_AccruedPreClinicalExpensesCurrent" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="cbio_AccruedClinicalExpensesCurrent" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="cbio_AccruedAndOtherCurrentLiabilities" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" xlink:type="locator" xlink:label="cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CostOfManufacturingServices" xlink:type="locator" xlink:label="cbio_CostOfManufacturingServices" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CostOfServicesAsPerAgreement" xlink:type="locator" xlink:label="cbio_CostOfServicesAsPerAgreement" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_FirmWorkOrderSupportingClinicalTrials" xlink:type="locator" xlink:label="cbio_FirmWorkOrderSupportingClinicalTrials" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:type="locator" xlink:label="cbio_CommitmentsAndContingenciesDisclosureLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceAgreementsMember" xlink:type="locator" xlink:label="us-gaap_ServiceAgreementsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_GMPMember" xlink:type="locator" xlink:label="cbio_GMPMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_DalcinonacogAlfaMember" xlink:type="locator" xlink:label="cbio_DalcinonacogAlfaMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" xlink:type="locator" xlink:label="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_IntegrityBioMember" xlink:type="locator" xlink:label="cbio_IntegrityBioMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_MarzeptacogAlfaActivatedMember" xlink:type="locator" xlink:label="cbio_MarzeptacogAlfaActivatedMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AGCBiologicsIncMember" xlink:type="locator" xlink:label="cbio_AGCBiologicsIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CommitmentsAndContingenciesDisclosureTable" xlink:type="locator" xlink:label="cbio_CommitmentsAndContingenciesDisclosureTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="cbio_CommitmentsAndContingenciesDisclosureTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_AGCBiologicsIncMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_MarzeptacogAlfaActivatedMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_IntegrityBioMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_ProductOrServiceAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_DalcinonacogAlfaMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_GMPMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_CommitmentsAndContingenciesDisclosureTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_CommitmentsAndContingenciesDisclosureTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_ServiceAgreementsMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_CommitmentsAndContingenciesDisclosureTable" xlink:to="cbio_CommitmentsAndContingenciesDisclosureLineItems" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="cbio_FirmWorkOrderSupportingClinicalTrials" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="cbio_CostOfServicesAsPerAgreement" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="cbio_CostOfManufacturingServices" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="us-gaap_ContractualObligation" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_CommitmentsAndContingenciesDisclosureLineItems" xlink:to="cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureRelatedPartiesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail">
    <link:loc xlink:href="cbio-20211231.xsd#cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" xlink:type="locator" xlink:label="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_SublicenseFee" xlink:type="locator" xlink:label="cbio_SublicenseFee" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement" xlink:type="locator" xlink:label="cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_IntravitrealAntiComplementFactor3Member" xlink:type="locator" xlink:label="cbio_IntravitrealAntiComplementFactor3Member" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_BiogenCollaborationMember" xlink:type="locator" xlink:label="cbio_BiogenCollaborationMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_MosaicBiosciencesIncMember" xlink:type="locator" xlink:label="cbio_MosaicBiosciencesIncMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cbio_MosaicBiosciencesIncMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cbio_BiogenCollaborationMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_ProductOrServiceAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_IntravitrealAntiComplementFactor3Member" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="cbio_SublicenseFee" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureLeasesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_LesseeOperatingLeaseRenewalTermDescription" xlink:type="locator" xlink:label="cbio_LesseeOperatingLeaseRenewalTermDescription" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_SubleaseArrangementMember" xlink:type="locator" xlink:label="cbio_SubleaseArrangementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_LeaseLabAndOfficeSpaceMember" xlink:type="locator" xlink:label="cbio_LeaseLabAndOfficeSpaceMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:type="locator" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="cbio_LeaseLabAndOfficeSpaceMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cbio_SubleaseArrangementMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="cbio_LesseeOperatingLeaseRenewalTermDescription" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationDetails" xlink:href="cbio-20211231.xsd#Role_DisclosureScheduleOfSupplementalCashFlowInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_PrepaidCashPaymentForLeaseLiabilities" xlink:type="locator" xlink:label="cbio_PrepaidCashPaymentForLeaseLiabilities" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:type="locator" xlink:label="cbio_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="cbio_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="cbio_PrepaidCashPaymentForLeaseLiabilities" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_IssuanceOfOptionGrantsToPurchaseCommonStockShares" xlink:type="locator" xlink:label="cbio_IssuanceOfOptionGrantsToPurchaseCommonStockShares" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_PerformanceBasedStockOptionGrantsMember" xlink:type="locator" xlink:label="cbio_PerformanceBasedStockOptionGrantsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_TwoThousandEighteenOmnibusIncentivePlanMember" xlink:type="locator" xlink:label="cbio_TwoThousandEighteenOmnibusIncentivePlanMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="cbio_TwoThousandEighteenOmnibusIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="cbio_PerformanceBasedStockOptionGrantsMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="cbio_IssuanceOfOptionGrantsToPurchaseCommonStockShares" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_li0l2" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="12110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="12210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="12910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="13110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="13410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" order="13510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="13710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:type="locator" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" xlink:type="locator" xlink:label="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable" xlink:to="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureSummaryOfStockBasedCompensationRecognizedDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_EffectiveIncomeTaxRateReconciliationDerecognition" xlink:type="locator" xlink:label="cbio_EffectiveIncomeTaxRateReconciliationDerecognition" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:type="locator" xlink:label="cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="cbio_EffectiveIncomeTaxRateReconciliationDerecognition" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureComponentsOfCompanySDeferredTaxAssetsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_DeferredTaxAssetsFixedAssetsAndIntangibles" xlink:type="locator" xlink:label="cbio_DeferredTaxAssetsFixedAssetsAndIntangibles" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="cbio_DeferredTaxAssetsFixedAssetsAndIntangibles" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_RequiredMinimumTaxableIncome" xlink:type="locator" xlink:label="cbio_RequiredMinimumTaxableIncome" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_MaximumAmountOfTaxOffsetPerYear" xlink:type="locator" xlink:label="cbio_MaximumAmountOfTaxOffsetPerYear" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" xlink:type="locator" xlink:label="cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards" xlink:type="locator" xlink:label="cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardExpirationDate" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardExpirationDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_OperatingLossCarryforwardsWithIndefiniteLife" xlink:type="locator" xlink:label="cbio_OperatingLossCarryforwardsWithIndefiniteLife" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="cbio_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_IncomeTaxLineItems" xlink:type="locator" xlink:label="cbio_IncomeTaxLineItems" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_IncomeTaxTable" xlink:type="locator" xlink:label="cbio_IncomeTaxTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="cbio_IncomeTaxTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="stpr_CA" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxTable" xlink:to="cbio_IncomeTaxLineItems" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxLineItems" xlink:to="cbio_OperatingLossCarryforwardsExpirationYear" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxLineItems" xlink:to="cbio_OperatingLossCarryforwardsWithIndefiniteLife" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxLineItems" xlink:to="us-gaap_TaxCreditCarryforwardExpirationDate" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxLineItems" xlink:to="cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxLineItems" xlink:to="cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxLineItems" xlink:to="cbio_MaximumAmountOfTaxOffsetPerYear" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxLineItems" xlink:to="cbio_RequiredMinimumTaxableIncome" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_IncomeTaxLineItems" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureUnrecognizedTaxBenefitDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureUnrecognizedTaxBenefitDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureUnrecognizedTaxBenefitDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits_li0l2" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_li0l2" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureCollaborationsAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_DevelopmentMilestonesPaymentReceivable" xlink:type="locator" xlink:label="cbio_DevelopmentMilestonesPaymentReceivable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="locator" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ResearchServicesAgreementOptionToExtend" xlink:type="locator" xlink:label="cbio_ResearchServicesAgreementOptionToExtend" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ResearchServicesAgreementTerm" xlink:type="locator" xlink:label="cbio_ResearchServicesAgreementTerm" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CommercialMilestonePayments" xlink:type="locator" xlink:label="cbio_CommercialMilestonePayments" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_RegulatoryAndDevelopmentMilestonePayment" xlink:type="locator" xlink:label="cbio_RegulatoryAndDevelopmentMilestonePayment" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_MilestonePayments" xlink:type="locator" xlink:label="cbio_MilestonePayments" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" xlink:type="locator" xlink:label="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CollaborationRevenueMember" xlink:type="locator" xlink:label="cbio_CollaborationRevenueMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember" xlink:type="locator" xlink:label="cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_LicenseRevenueMember" xlink:type="locator" xlink:label="cbio_LicenseRevenueMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ExclusiveLicenseMember" xlink:type="locator" xlink:label="cbio_ExclusiveLicenseMember_li0l2" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ExclusiveLicenseMember" xlink:type="locator" xlink:label="cbio_ExclusiveLicenseMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_LicenseAndCollaborationAgreementMember" xlink:type="locator" xlink:label="cbio_LicenseAndCollaborationAgreementMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_BiogenMember" xlink:type="locator" xlink:label="cbio_BiogenMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AmendedAndRestatedLicenseAgreementMember" xlink:type="locator" xlink:label="cbio_AmendedAndRestatedLicenseAgreementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionDomain" xlink:type="locator" xlink:label="us-gaap_TransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransactionTypeAxis" xlink:type="locator" xlink:label="us-gaap_TransactionTypeAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_IsuAbxisMember" xlink:type="locator" xlink:label="cbio_IsuAbxisMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CollaborationAgreementsAbstract" xlink:type="locator" xlink:label="cbio_CollaborationAgreementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_CollaborationAgreementsAbstract" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_IsuAbxisMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_TransactionTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionTypeAxis" xlink:to="us-gaap_TransactionDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="cbio_AmendedAndRestatedLicenseAgreementMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cbio_BiogenMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="cbio_LicenseAndCollaborationAgreementMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="cbio_ExclusiveLicenseMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransactionDomain" xlink:to="cbio_ExclusiveLicenseMember_li0l2" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="srt_ProductOrServiceAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_LicenseRevenueMember" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_ExclusiveLicenseMember" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="cbio_CollaborationRevenueMember" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable" xlink:to="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_MilestonePayments" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_RegulatoryAndDevelopmentMilestonePayment" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_CommercialMilestonePayments" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_ResearchServicesAgreementTerm" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_ResearchServicesAgreementOptionToExtend" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="cbio_DevelopmentMilestonesPaymentReceivable" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeExpenseNetDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureDetailOfInterestAndOtherIncomeExpenseNetDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeExpenseNetDetail">
    <link:loc xlink:href="cbio-20211231.xsd#cbio_InterestAndOtherIncomeExpenseNet" xlink:type="locator" xlink:label="cbio_InterestAndOtherIncomeExpenseNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_MiscellaneousIncomeExpense" xlink:type="locator" xlink:label="cbio_MiscellaneousIncomeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="cbio_MiscellaneousIncomeExpense" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="cbio_InterestAndOtherIncomeExpenseNet" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail">
    <link:loc xlink:href="cbio-20211231.xsd#cbio_LegalExpensesIncurred" xlink:type="locator" xlink:label="cbio_LegalExpensesIncurred" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_PercentageOfCommissionForSharesSold" xlink:type="locator" xlink:label="cbio_PercentageOfCommissionForSharesSold" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_UnderwritingCommissionsAndOfferingExpensesPayable" xlink:type="locator" xlink:label="cbio_UnderwritingCommissionsAndOfferingExpensesPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_StockholdersEquityDisclosureLineItems" xlink:type="locator" xlink:label="cbio_StockholdersEquityDisclosureLineItems" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_TwoThousandTwentyOneATMProgramMember" xlink:type="locator" xlink:label="cbio_TwoThousandTwentyOneATMProgramMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:type="locator" xlink:label="us-gaap_WarrantMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_UnderwritersOverallotmentOptionMember" xlink:type="locator" xlink:label="cbio_UnderwritersOverallotmentOptionMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_StockholdersEquityDisclosureTable" xlink:type="locator" xlink:label="cbio_StockholdersEquityDisclosureTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="cbio_StockholdersEquityDisclosureTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_StockholdersEquityDisclosureTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_StockholdersEquityDisclosureTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cbio_UnderwritersOverallotmentOptionMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="cbio_TwoThousandTwentyOneATMProgramMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_StockholdersEquityDisclosureTable" xlink:to="cbio_StockholdersEquityDisclosureLineItems" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_SharePrice" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="cbio_UnderwritingCommissionsAndOfferingExpensesPayable" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="cbio_PercentageOfCommissionForSharesSold" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cbio_StockholdersEquityDisclosureLineItems" xlink:to="cbio_LegalExpensesIncurred" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_CommonStockWarrantsMember" xlink:type="locator" xlink:label="cbio_CommonStockWarrantsMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_OptionsToPurchaseCommonStockMember" xlink:type="locator" xlink:label="cbio_OptionsToPurchaseCommonStockMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="cbio_OptionsToPurchaseCommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="cbio_CommonStockWarrantsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureRestructuringAdditionalInformationDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail">
    <link:loc xlink:href="cbio-20211231.xsd#cbio_RestructuringLiability" xlink:type="locator" xlink:label="cbio_RestructuringLiability" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" xlink:type="locator" xlink:label="cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1" xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_SeveranceCosts1" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="cbio_RestructuringLiability" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail" xlink:href="cbio-20211231.xsd#Role_DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges" xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails" xlink:href="cbio-20211231.xsd#Role_DisclosureSubsequentEventAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges" xlink:type="locator" xlink:label="us-gaap_RestructuringCharges" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_ReimbursementOfAdvisoryFee" xlink:type="locator" xlink:label="cbio_ReimbursementOfAdvisoryFee" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AdvisoryFeesPayable" xlink:type="locator" xlink:label="cbio_AdvisoryFeesPayable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="locator" xlink:label="us-gaap_LessorOperatingLeasePaymentsToBeReceived" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_RaymondJamesAndAssociatesMember" xlink:type="locator" xlink:label="cbio_RaymondJamesAndAssociatesMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_AdvisorAgreementMember" xlink:type="locator" xlink:label="cbio_AdvisorAgreementMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_BiogenAgreementMember" xlink:type="locator" xlink:label="cbio_BiogenAgreementMember" />
    <link:loc xlink:href="cbio-20211231.xsd#cbio_SubleaseArrangementMember" xlink:type="locator" xlink:label="cbio_SubleaseArrangementMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cbio_SubleaseArrangementMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cbio_BiogenAgreementMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="cbio_AdvisorAgreementMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="cbio_RaymondJamesAndAssociatesMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LessorOperatingLeasePaymentsToBeReceived" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="cbio_AdvisoryFeesPayable" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="cbio_ReimbursementOfAdvisoryFee" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RestructuringCharges" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850045187272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 25, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CBIO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Catalyst Biosciences, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001124105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,477,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,045,079<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-51173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">56-2020050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">611 Gateway Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">871-0761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">EISNERAMPER LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Philadelphia, Pennsylvania<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the Registrant's proxy statement for its 2022 Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8221;), to be filed with the U.S. Securities and Exchange Commission, no later than 120 days after the Registrant&#8217;s fiscal year ended December 31, 2021, are incorporated by reference to Part III of this Annual Report on Form 10-K.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850045584568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 44,347<span></span>
</td>
<td class="nump">$ 30,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">2,504<span></span>
</td>
<td class="nump">48,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">1,818<span></span>
</td>
<td class="nump">3,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">2,807<span></span>
</td>
<td class="nump">6,843<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">51,476<span></span>
</td>
<td class="nump">89,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, noncurrent</a></td>
<td class="nump">472<span></span>
</td>
<td class="nump">528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">2,744<span></span>
</td>
<td class="nump">1,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">970<span></span>
</td>
<td class="nump">433<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">55,662<span></span>
</td>
<td class="nump">94,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,419<span></span>
</td>
<td class="nump">5,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation</a></td>
<td class="nump">1,467<span></span>
</td>
<td class="nump">2,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">1,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">4,072<span></span>
</td>
<td class="nump">6,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">1,977<span></span>
</td>
<td class="nump">663<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">14,165<span></span>
</td>
<td class="nump">17,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, noncurrent</a></td>
<td class="nump">408<span></span>
</td>
<td class="nump">981<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">14,573<span></span>
</td>
<td class="nump">18,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 5,000,000 shares authorized; zero shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 100,000,000 shares authorized; 31,409,707 and 22,097,820 shares issued and outstanding at December 31, 2021 and 2020, respectively</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">443,752<span></span>
</td>
<td class="nump">390,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(402,694)<span></span>
</td>
<td class="num">(314,761)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">41,089<span></span>
</td>
<td class="nump">76,069<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 55,662<span></span>
</td>
<td class="nump">$ 94,846<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850049708936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">31,409,707<span></span>
</td>
<td class="nump">22,097,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">31,409,707<span></span>
</td>
<td class="nump">22,097,820<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850045481688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="nump">$ 7,338<span></span>
</td>
<td class="nump">$ 20,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">68,889<span></span>
</td>
<td class="nump">52,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">18,963<span></span>
</td>
<td class="nump">16,180<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">95,232<span></span>
</td>
<td class="nump">78,318<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(87,894)<span></span>
</td>
<td class="num">(57,370)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_InterestAndOtherIncomeExpenseNet', window );">Interest and other income (expense), net</a></td>
<td class="num">(39)<span></span>
</td>
<td class="nump">1,129<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (87,933)<span></span>
</td>
<td class="num">$ (56,241)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders, basic and diluted</a></td>
<td class="num">$ (2.87)<span></span>
</td>
<td class="num">$ (2.93)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used to compute net loss per share attributable to common stockholders, basic and diluted</a></td>
<td class="nump">30,640,977<span></span>
</td>
<td class="nump">19,179,299<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cbio_LicenseRevenueMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cbio_CollaborationRevenueMember', window );">Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="nump">$ 7,338<span></span>
</td>
<td class="nump">5,848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cbio_CostOfLicenseMember', window );">Cost of license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of license and collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cbio_CostOfCollaborationMember', window );">Cost of collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of license and collaboration</a></td>
<td class="nump">$ 7,380<span></span>
</td>
<td class="nump">$ 6,061<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_InterestAndOtherIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and other income (expense), net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_InterestAndOtherIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cbio_LicenseRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cbio_LicenseRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cbio_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cbio_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cbio_CostOfLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cbio_CostOfLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cbio_CostOfCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cbio_CostOfCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850049489832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement Of Income And Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (87,933)<span></span>
</td>
<td class="num">$ (56,241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available-for-sale debt securities</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (87,938)<span></span>
</td>
<td class="num">$ (56,270)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850045375240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 68,336<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 326,810<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="num">$ (258,520)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,040,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue', window );">Issuance of common stock from ESPP purchases and stock option exercises</a></td>
<td class="nump">435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares', window );">Issuance of common stock from ESPP purchases and stock option exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for public offering, net of issuance costs</a></td>
<td class="nump">59,941<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">59,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for public offering, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,923,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available-for-sale debt securities</a></td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(56,241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56,241)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">76,069<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">390,803<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(314,761)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,097,820<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue', window );">Issuance of common stock from ESPP purchases and stock option exercises</a></td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares', window );">Issuance of common stock from ESPP purchases and stock option exercises, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock for public offering, net of issuance costs</a></td>
<td class="nump">49,250<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">49,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for public offering, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on available-for-sale debt securities</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(87,933)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(87,933)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 41,089<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 443,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (402,694)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,409,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period from ESPP purchases and stock options exercised shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period from ESPP purchases and stock options exercised value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850129545320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement Of Stockholders Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs of issuance of common stock for public offering</a></td>
<td class="nump">$ 3,563<span></span>
</td>
<td class="nump">$ 4,559<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850045071960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (87,933)<span></span>
</td>
<td class="num">$ (56,241)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">3,405<span></span>
</td>
<td class="nump">3,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">290<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">1,495<span></span>
</td>
<td class="nump">11,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other assets</a></td>
<td class="nump">3,880<span></span>
</td>
<td class="num">(3,043)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">1,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued compensation and other accrued liabilities</a></td>
<td class="num">(3,680)<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset', window );">Operating lease liability and right-of-use asset</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(1,753)<span></span>
</td>
<td class="num">(13,017)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows used in operating activities</a></td>
<td class="num">(83,755)<span></span>
</td>
<td class="num">(55,048)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Proceeds from maturities of short-term investments</a></td>
<td class="nump">49,028<span></span>
</td>
<td class="nump">107,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_PaymentsToAcquireShortTermAndLongInvestments', window );">Purchase of short-term and long-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97,635)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of property and equipment</a></td>
<td class="num">(839)<span></span>
</td>
<td class="num">(267)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows provided by investing activities</a></td>
<td class="nump">48,189<span></span>
</td>
<td class="nump">9,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts', window );">Issuance of common stock for public offering, net of issuance costs</a></td>
<td class="nump">49,250<span></span>
</td>
<td class="nump">59,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises', window );">Issuance of common stock from ESPP purchase and stock option exercises</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows provided by financing activities</a></td>
<td class="nump">49,553<span></span>
</td>
<td class="nump">60,376<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">13,987<span></span>
</td>
<td class="nump">14,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of the period</a></td>
<td class="nump">30,360<span></span>
</td>
<td class="nump">15,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of the period</a></td>
<td class="nump">44,347<span></span>
</td>
<td class="nump">30,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosure of Non-Cash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities', window );">Right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">1,850<span></span>
</td>
<td class="nump">$ 476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_NonCashOrPartNonCashRemeasurementOfRightOfUseAssetDueToOperatingLeaseModification', window );">Remeasurement of right-of-use asset due to operating lease modification</a></td>
<td class="nump">$ 624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease in operating lease liability and right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_NonCashOrPartNonCashRemeasurementOfRightOfUseAssetDueToOperatingLeaseModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remeasurement of right-of-use asset due to operating lease modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_NonCashOrPartNonCashRemeasurementOfRightOfUseAssetDueToOperatingLeaseModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-of-use assets obtained in exchange for operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_PaymentsToAcquireShortTermAndLongInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to acquire short term and long investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_PaymentsToAcquireShortTermAndLongInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock for secondary public offering, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock from ESPP purchases and stock option exercises.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850048520504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p id="NOTES_TO_CONSOLIDATED" style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Nature of Operations</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc. and its subsidiary (the &#8220;Company&#8221; or &#8220;Catalyst&#8221;) is a <span style="color:#000000;">fully integrated research and clinical development biopharmaceutical company with expertise in protease engineering, discovery, translational research, clinical development, and manufacturing. The Company is focused on advancing its protease product candidates in the fields of hemostasis and complement regulation.</span> <span style="color:#000000;">The Company is located in South San Francisco, California and operates in</span> one segment. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850048362488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiquidationBasisOfAccountingTextBlock', window );">Liquidity</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Liquidity<span style="font-weight:normal;"> </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had a net loss of $87.9 million for the year ended December 31, 2021 and an accumulated deficit of $402.7 million as of December 31, 2021. The Company expects to continue to incur losses for the next several years. As of December 31, 2021, the Company had $46.9 million of cash, cash equivalents and short-term  investments. Its primary uses of cash are to fund operating expenses, including research and development expenditures and general and administrative expenditures. Based on the current status of its research and development plans, the Company believes that its existing cash, cash equivalents and investments as of December 31, 2021 will be sufficient to fund its cash requirements for at least the next 12 months from the date of the filing of this report. If, at any time, the Company&#8217;s prospects for financing its research and development programs decline, the Company may decide to reduce research and development expenses by delaying, discontinuing or reducing its funding of one or more of its research or development programs. Alternatively, the Company might raise funds through strategic collaborations, public or private financings or other arrangements. Such funding, if needed, may not be available on favorable terms, or at all. The Company will continue to evaluate the impact of the novel coronavirus disease (&#8220;COVID-19&#8221;) pandemic on our business, operations, and cash requirements. For recent financing, see Note 14,<span style="color:#000000;"> </span><span style="font-style:italic;color:#000000;">Stockholders&#8217; Equity</span>.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiquidationBasisOfAccountingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the liquidation basis of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 30<br> -URI http://asc.fasb.org/subtopic&amp;trid=35686142<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiquidationBasisOfAccountingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850048307800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Summary of Significant Accounting Policies</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements include the accounts of the Company and its subsidiary. Intercompany accounts and transactions, if applicable, have been eliminated in consolidation. The Company&#8217;s consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;GAAP&#8221;). &#160;&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowance of doubtful accounts, operating lease right-of-use assets and liabilities, accrued expenses, income taxes and stock-based compensation. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounting Pronouncements Recently Adopted</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update&#160;(&#8220;ASU&#8221;) 2019-12, <span style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. </span>The amendments in ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes.&#160;ASU 2019-12&#160;removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The Company adopted ASU 2019-12 as of January 1, 2021, on a prospective transition basis. <span style="color:#000000;">The adoption of ASU 2019-12 did not have a material impact on the Company&#8217;s consolidated financial statements.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">New Accounting Pronouncements &#8211; Issued But Not Yet Adopted</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13,<span style="font-style:italic;">&#160;Measurement of Credit Losses on Financial Instruments</span>. The main objective of ASU 2016-13 is to provide financial statement users with more decision-useful information about an entity's expected credit losses on financial instruments and other commitments to extend credit at each reporting date. To achieve this objective, the amendments in this update replace the incurred loss impairment methodology currently used today with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates. ASU 2016-13 will be effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, using a modified retrospective approach. Early adoption is permitted.&#160;The Company plans to adopt ASU 2016-13&#160;and related updates&#160;as of January 1, 2023.&#160;The Company will assess the impact of adoption of this standard on its consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2021, the FASB issued ASU 2021-04, <span style="font-style:italic;">Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</span>. The amendments in ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The Company plans to adopt ASU 2021-04 and related updates on January 1, 2022, and does not expect the adoption to have a material impact on its consolidated financial statements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company invests its excess cash in bank deposits, consisting primarily of money market mutual funds. The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value hierarchy requires that an entity maximize the use of observable inputs when estimating fair value. The fair value hierarchy includes the following three-level classification which is based on the market observability of the inputs used for estimating the fair value of the assets or liabilities being measured:</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 1<span style="font-style:normal;"> &#8211; Quoted prices in active markets for identical assets or liabilities.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 2<span style="font-style:normal;"> &#8211; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 3<span style="font-style:normal;"> &#8211; Inputs that are generally unobservable and typically reflect management&#8217;s estimate of assumptions that market participants would use in pricing the asset or liability.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, which are three years for computer equipment and software, and three to seven years for furniture and leasehold improvements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investments</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company invests its excess cash in investment grade, short to intermediate-term, fixed income securities and recognizes purchased securities on the settlement date. All investments have been classified as &#8220;available-for-sale&#8221; and are carried at estimated fair value based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments at the time of purchase and reevaluates such designation as of each consolidated balance sheet date. Unrealized gains and losses on available-for-sale debt securities are excluded from earnings and are reported as a component of comprehensive loss. Realized gains and losses and declines in fair value determined to be other-than-temporary, if any, on available-for-sale debt securities are included in interest and other income (expense), net. The cost of securities sold is based on the specific-identification method. Interest on short-term investments is included in interest and other income (expense), net.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">License and Collaboration Arrangements </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.21%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may enter into collaboration arrangements that fall under the scope Collaborative Arrangements (Topic 808). The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808 to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. The accounting for some of the activities under collaboration arrangements may be analogized to ASC 606 for distinct units of account that are reflective of a vendor-customer relationship.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, in determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when the Company satisfies each performance obligation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues attributed to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of each arrangement that contain development milestones, the Company evaluates whether the development milestones included are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not generally considered probable of being achieved until those approvals are received.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the end of each reporting period, the Company re-evaluates the probability of achievement of any development milestones, and if necessary, adjusts its estimate of the transaction price. Any such adjustments </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would be recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For research and development services, the Company elected the practical expedient to recognize revenue as the research and development services are invoiced.&#160;&#160;As the Company has a right to consideration from the collaboration agreement with Biogen International GmbH (&#8220;Biogen&#8221;), in an amount that corresponds directly with the value of the Company&#8217;s performance completed to date for the research services, the Company recognized revenue related to the research services as invoiced, in line with the practical expedient in ASC 606-10-55-18.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price is allocated to each performance obligation on a relative stand-alone selling price (&#8220;SSP&#8221;) basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the timing of recognition and the SSP for each performance obligation identified in the contract.&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SSP for licenses are calculated using the residual approach if the Company has not yet established a price for such license and the license has not previously been sold on a standalone basis.&#160;Otherwise, selling prices for licenses are determined using an income approach model and include key assumptions such as: development timeline, revenue forecast, commercialization expenses, discount rate and probabilities of technical and regulatory success. To estimate the SSP for research and development services, the Company uses a cost-plus margin approach. </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cost of License and Collaboration</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of license revenue includes sublicense fees paid or payable to Mosaic Biosciences, Inc. (&#8220;Mosaic&#8221;), incurred in the period, under the terms of the Mosaic collaboration agreement, and fees for patent development and protection paid or payable to other third-party vendors corresponding to the recognition of license revenue from the Company&#8217;s collaboration agreement with Biogen. See<span style="color:#000000;"> Notes 8 and 12, </span><span style="font-style:italic;color:#000000;">Related Parties </span><span style="color:#000000;">and</span><span style="font-style:italic;color:#000000;"> Collaborations, </span><span style="color:#000000;">respectively. Cost of license revenue does not include any allocated overhead costs.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of collaboration revenue includes fees for research and development services paid or payable to Mosaic and other third-party vendors and personnel cost, incurred in the period pertaining to the Company&#8217;s agreement with Biogen. See<span style="color:#000000;"> Notes 8 and 12, </span><span style="font-style:italic;color:#000000;">Related Parties </span><span style="color:#000000;">and</span><span style="font-style:italic;color:#000000;"> Collaborations, </span><span style="color:#000000;">respectively. Cost of collaboration revenue does not include any allocated overhead costs.</span></p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services used in research and development are initially deferred and capitalized in prepaid and other current assets. The capitalized amounts are then expensed as the related goods are delivered or services are performed, or until it is no longer expected that the goods or services will be delivered. Research and development costs consist of payroll and other personnel-related expenses, laboratory supplies and reagents, contract research and development services, materials, and consulting costs, as well as allocations of facilities and other overhead costs. Under the Company&#8217;s collaboration agreement with Biogen, certain specific expenditures are reimbursed by third parties. During the years ended December 31, 2021 and 2020, $6.5 million and $5.4 million, respectively, of research and development expense was recorded as cost of collaboration revenue related to the collaboration agreement with Biogen signed in December 2019.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.81%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses include estimated costs of research and development activities conducted by external service providers, which include the conduct of preclinical studies and clinical trials and contract manufacturing activities. The Company records the estimated costs of research and development activities </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">based upon the estimated </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">amount</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of services provided but not yet invoiced and includes these costs in</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> other</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> accrued liabilities in the consolidated balance sheet and within research and development expense in the consolidated statement of operations. These costs are a significant component of the research and development expenses. The Company records accrued expenses for these costs based on the estimated amount of work completed and in accordance with agreements established with these external service providers.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, investments and accounts receivable. The Company&#8217;s investment policy restricts cash investments to high credit quality, investment grade investments. The Company believes that it has established guidelines for investment of its excess cash that maintain safety and liquidity through its policies on high quality of investment and investment duration. The Company is exposed to credit risk in the event of default by the institutions holding the cash and cash equivalents to the extent beyond the amount insured by the federal depository insurance corporation. The Company&#8217;s accounts receivable as of December 31, 2021 of $1.8 million as well as its total license and collaboration revenue of $7.3 million and $20.9 million for the years ended December 31, 2021 and 2020, respectively, are from one party, see Note 12, <span style="font-style:italic;">Collaborations</span>.&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounts Receivable and Allowance for Doubtful Accounts</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. Customer payments are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under the arrangements. The Company continuously monitors collections and payments from its customers and maintains a provision for estimated credit losses. The Company determines its allowance for doubtful accounts by considering a number of factors, including the length of time balances are past due, the Company&#8217;s previous loss history, the customer&#8217;s current ability to pay its obligations to the Company and the condition of the general economy and the industry as a whole. The Company writes off accounts receivable when they are determined to be uncollectible. For the years ended December 31, 2021 and 2020, there were no allowance for doubtful accounts deemed necessary.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes are computed using the liability method. Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company follows the authoritative guidance on accounting for uncertainty in income taxes. This guidance prescribes a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken in the Company&#8217;s income tax returns. This interpretation also provides guidance on accounting for interest and penalties and associated with tax positions, accounting for income taxes in interim periods and income tax disclosures.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s policy is to include penalties and interest expense related to income taxes as a component of other expense and interest expense, respectively, as necessary.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures the cost of employee, non-employee and director services received in exchange for an award of equity instruments based on the fair value of the award on the date of grant and recognizes the related expense over the period during which the employee, non-employee or director is required to provide service in exchange for the award on a straight-line basis. The estimated fair value of equity awards that contain performance conditions is expensed over the term of the award once the Company has determined that it is probable that performance conditions will be satisfied.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the Black-Scholes option-pricing valuation model to estimate the grant-date fair value of stock-based awards. The determination of fair value for stock-based awards on the date of grant using an option-pricing model requires management to make certain assumptions regarding </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a number of</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> variables. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he Company </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">elected to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">account for forfeitures when they occur. As such, the Company recognizes stock-based compensation expense, over their requisite service period, based on the vesting provisions of the individual grants.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restructuring Charges</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs and liabilities associated with restructuring are recorded in the period management commits to a restructuring or cost reduction plan, or executes specific actions contemplated by the plan and all criteria for liability recognition have been met. One-time employee termination costs are recognized at the time of communication to employees, unless future service is required, in which case the costs are recognized ratably over the future service period. Restructuring charges are recognized as an operating expense within the consolidated statements of operations and related liabilities are recorded within accrued compensation on the consolidated balance sheets. The Company periodically evaluates and, if necessary, adjusts its estimates based on currently available information.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has elected to combine lease and non-lease components as a single component. The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the consolidated balance sheet as right-of-use assets, operating lease liabilities, current and operating lease liabilities, non-current. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss per Share Attributable to Common Stockholders</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss of the Company for all periods presented.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850048331064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Fair Value Measurements</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For a description of the fair value hierarchy and fair value methodology, see Note 3,<span style="font-style:italic;"> Summary of Significant Accounting Policies</span>. As of December 31, 2021 and 2020, the Company&#8217;s highly liquid money market funds included within cash equivalents and U.S. government agency securities are valued using Level&#160;1 inputs. The Company classifies its federal agency securities as Level 2. There were no transfers in or out of Level 1 and Level 2 during the periods presented. U.S. government agency securities are bonds issued by the U.S. government and are fully backed by the U.S. government. Given the frequency at which U.S. government agency securities trade and the accessibility of observable, quoted prices for such assets in active markets, they are recognized as Level 1 assets. Federal agency securities are bonds and notes issued by government-sponsored enterprises, including Fannie Mae, Freddie Mac and the Federal Home Loan Bank. Since Federal agency securities typically do not trade as U.S. government agency securities and no exchange exists to price such investments, they are recognized as Level 2 assets. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present the fair value hierarchy for assets measured at fair value on a recurring basis as of December 31, 2021 and 2020 <span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,347</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,347</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">2)</sup></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,504</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,504</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,851</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,851</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,360</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,360</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">2)</sup></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,837</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,837</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal agency securities<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">2)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,700</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,700</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,197</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,700</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,897</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Included in cash and cash equivalents on accompanying consolidated balance sheet.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Included in short-term investments on accompanying consolidated balance sheet and are classified as available-for-sale debt securities. $2.5 million of U.S. government agency securities as of December 31, 2020 are included in long-term investments on the accompanying consolidated balance sheets due to the maturity being more than 12 months. &#160;</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-0.43%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of cash, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to the short-term maturity of these instruments.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850049861432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Instruments</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents and investments (debt securities) which are classified as available-for-sale securities, consisted of the following <span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds (cash equivalents)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,504</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,504</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,851</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,851</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Classified as:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,504</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,851</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds (cash equivalents)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,360</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,360</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,835</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,837</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal agency securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,697</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,700</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,892</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,897</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Classified as:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,360</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,994</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,543</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,897</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no material realized gains or losses on available-for-sale debt securities for the periods presented. As of December 31, 2021, the remaining contractual maturities of $2.5 million of available-for-sale debt securities were less than one year. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850048469640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Other Accrued Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6.</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Other Accrued Liabilities </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued liabilities consisted of the following <span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,381</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,238</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biogen</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">868</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-clinical</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">773</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional and consulting services</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">509</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,979</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">361</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">235</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other accrued liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,072</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,743</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850049828264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Commitments and Contingencies </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Manufacturing Agreements</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 20, 2016, the Company signed a development and manufacturing services agreement with AGC Biologics, Inc. (&#8220;AGC&#8221;), pursuant to which AGC will conduct manufacturing development of agreed upon product candidates. The Company had firm work orders with AGC to manufacture MarzAA and DalcA to support its clinical trials totaling $15.8 million and the payment obligations were fully paid off as of December 31, 2021. The Company also signed an agreement with AGC to perform certain manufacturing services related to the Company&#8217;s collaboration agreement with Biogen, which includes firm work orders totaling $0.7 million and the payment obligations remaining as of December 31, 2021 were $0.3 million.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2021, the Company entered into two separate agreements, one for additional clinical trial services for MarzAA, and another for the Company&#8217;s screening and natural history of disease clinical studies related to CFI deficiency, with total payments of up to $3.2 million and $6.5 million, respectively. In November 2021, the Company provided notice of intent to terminate its MarzAA manufacturing agreements and incurred charges of $3.8 million to write-off prepaid manufacturing costs that will no longer be used for the clinical development of MarzAA, see Note 16, <span style="font-style:italic;">Restructuring</span>. The Company can terminate the CFI agreement at its discretion and upon termination will be responsible to pay for those services incurred prior to termination plus reasonable wind-down expenses.</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 16, 2021, the Company signed a Manufacturing and Research and Development Studies Agreement to support the lyophilized drug product, CB4332. The agreement will cover analytical method qualification to support good manufacturing practices (&#8220;GMP&#8221;) manufacturing. The Company currently has firm work orders related to this agreement totaling $0.2 million and the payment obligations were fully paid off as of December 31, 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">COVID-19</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current COVID-19 pandemic has presented a substantial public health and economic challenge around the world and is affecting the Company&#8217;s employees, potential trial participants and business operations. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#8217;s business, results of operations and financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact and the economic impact on local, regional, national, and international markets. The COVID-19 pandemic may disrupt the operations of the Company&#8217;s manufacturers or disrupt supply logistics, which could impact the timing of deliveries and potentially increase expenses under our agreements. </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is actively monitoring the impact of COVID-19 and the possible effects on its financial condition, liquidity, operations, clinical trials, suppliers, </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">industry</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and workforce.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850129740968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Related Parties</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 24, 2017, the Company announced a strategic research collaboration with Mosaic to develop intravitreal anti-complement factor C3 products for the treatment of dry AMD and other retinal diseases. <span style="color:#000000;">Dr. Usman, the Company&#8217;s Chief Executive Officer and a member of the Company&#8217;s board of directors, and Mr. Lawlor, a member of the Company&#8217;s board of directors, were also members of the board of directors of Mosaic. On December 21, 2018, the Company amended its collaboration agreement with Mosaic to, among other things, include certain additional products. According to the Mosaic collaboration agreement, as amended, the Company and Mosaic co-funded certain research.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 18, 2019, the Company entered into the second amendment to the Mosaic collaboration agreement following completion of the co-funded research. Pursuant to the second amendment, any future services provided by Mosaic will be performed on a fee-for-service basis. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Company&#8217;s collaboration agreement with Biogen, the Company received a $15.0 million upfront license fee on January 10, 2020, see Note 12, <span style="font-style:italic;">Collaborations</span>. As a result, the Company paid Mosaic a $3.0 million sublicense fee and recorded such payment as cost of license revenue for the year ended December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 8, 2020, the Company entered into a subsequent amendment to the Mosaic collaboration agreement. As part of this amendment, the Company paid a one-time $0.8 million cash payment to Mosaic, and Mosaic is eligible to receive up to $4.0 million in potential future milestone payments related to regulatory and clinical development events for CB 2782-PEG and an additional anti-complement product candidate in lieu of the Company&#8217;s obligations to pay Mosaic a double-digit percentage of funds the Company receives from Biogen or any other amounts the Company receives related to sublicense fees, research and development payments, or any other research, regulatory, clinical or commercial milestones and royalties on any other development candidates. The Company now owns one hundred percent of all future payment streams related to these product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2020, Mosaic was no longer a related party.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850129798280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Leases</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. In calculating the present value of the lease payments, the Company has elected to utilize its incremental borrowing rate based on the original lease term and not the remaining lease term. The lease includes non-lease components (<span style="font-style:italic;">e.g.</span>, common area maintenance) that are paid separately from rent based on actual costs incurred and, therefore, were not included in the right-of-use asset and lease liability but are reflected as an expense in the period incurred.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office space for its corporate headquarters, located in South San Francisco, CA. The lease term is through April 30, 2023 and there are no stated renewal options. On July 17, 2020, the Company entered into an amendment to its existing lease agreement to lease additional office space for an aggregated undiscounted future monthly payment of $0.5 million. The amendment was treated as a separate lease with a lease term of 2.6 years and commenced during the fourth quarter of 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2021, the Company entered into a license agreement (the &#8220;License Agreement&#8221;) for the use of laboratory facilities in South San Francisco, CA, for an aggregated undiscounted future payment of $1.9 million. This License Agreement has an original lease term of one year and a renewal period of six months. This License Agreement commenced during the second quarter of 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2021, the Company amended the License Agreement to extend the lease term for a period of one year. The amendment was not accounted for as a separate </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">lease, and</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> resulted in an adjustment to the right-of-use asset</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and lease liability of $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.6</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The amended lease will expire at the end of April 2023.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2021 and 2020, the Company&#8217;s operating lease expense was $1.7 million and $0.7 million, respectively. The present value assumptions used in calculating the present value of the lease payments were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3 years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3 years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maturity of the Company&#8217;s operating lease liabilities as of&#160;December&#160;31, 2021 were as follows&#160;<span style="font-style:italic;">(in thousands):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,044</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">410</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,454</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(69</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liability</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,385</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. The Company did not incur significant variable lease costs for the years ended December 31, 2021 and 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information related to operating leases was as follows&#160;<span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,641</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">602</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid cash payment for lease</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">208</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for operating leases that were included in operating cash outflows</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,849</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">602</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850049858648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Based Compensation</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stock Based Compensation</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2018 Omnibus Incentive Plan </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, stockholders of the Company approved the Company&#8217;s 2018 Omnibus Incentive Plan (the &#8220;2018 Plan&#8221;). The 2018 Plan had previously been approved by the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) and the Compensation Committee (the &#8220;Committee&#8221;) of the Board, subject to stockholder approval. The 2018 Plan became effective on June 13, 2018. On June 9, 2021, the stockholders of the Company approved an amendment previously approved by the Board to increase the number of shares of common stock reserved for issuance under the 2018 Plan by 2,500,000 to a total of 5,300,000 shares. The amendment became effective immediately upon stockholder approval.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Performance-Based Stock Option Grants</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021, the Committee approved the issuance of option grants to purchase 647,000 shares of common stock for executive officers pursuant to the 2018 Plan, which will vest upon (a) the achievement of specified performance goals and (b) the grantees&#8217; continued employment during the service period specified in each grant. For the year ended December 31, 2021, no expense has been recognized related to these awards. In </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">addition, the options </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">never vested and expired </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">since the performance conditions were not satisfied as of December 31, 2021.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity under the Company&#8217;s 2018 Plan and related information:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,577,541</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.85</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000407">8.15</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,350</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,091,250</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.26</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44,605</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.04</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(250,641</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.32</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options expired</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,930</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51.12</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,355,615</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.59</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000408">7.96</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,337</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,493,238</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.31</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.63</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options forfeited</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,239,630</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.26</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options expired</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(593</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">566.33</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,603,630</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.70</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000409">7.46</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable &#8212; December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,513,039</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.37</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000410">6.35</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available to be granted &#8212; December 31,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,333,791</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.07%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average grant date fair value of options granted during the years ended December 31, 2021 and 2020 was $4.00 and $5.20, respectively.</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.07%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value of options exercised during the years ended December 31, 2021 and 2020 was $3,000 and $0.1 million, respectively.</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.07%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of options vested during the years ended December 31, 2021 and 2020 was $2.6 million and $3.0 million, respectively.</p>
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Valuation Assumptions</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimated the fair value of stock options granted using the Black-Scholes option-pricing formula and a single option award approach. Due to its limited history as a public company and limited number of sales of its common stock, the Company estimated its volatility considering a number of factors including the use of the volatility of comparable public companies. The expected term of options granted under the Plan, all of which qualify as &#8220;plain vanilla&#8221; per SEC Staff Accounting Bulletin 107, is determined based on the simplified method due to the Company&#8217;s limited operating history. The risk-free rate is based on the yield of a U.S. Treasury security with a term consistent with the option. This fair value is being amortized ratably over the requisite service periods of the awards, which is generally the vesting period.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of employee stock options was estimated using the following&#160;weighted-average assumptions:<span style="color:#000000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee Stock Options:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000419">6.00</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000420">5.81</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.84</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.91</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93.25</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113.36</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation recognized was as follows <span style="font-style:italic;">(in thousands):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,202</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,487</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative<sup style="font-size:85%;line-height:120%;vertical-align:top"> (1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,203</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,140</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,405</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,627</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:8pt;color:#000000;">Included in general and administrative stock-based compensation for the years ended December 31, 2021 and 2020 is $0.3 million and $0.3 million in expense related to 56,912 shares and 51,056 shares of common stock, respectively, issued to certain board members in lieu of their cash compensation.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.19%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the Company had unrecognized employee stock-based compensation expense of $3.9 million, related to unvested stock option awards, which is expected to be recognized over an estimated weighted-average period of 2.49 years.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:8pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, the Company&#8217;s stockholders approved the 2018 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP had previously been approved by the Board and the Compensation Committee of the Board, subject to stockholder approval which became effective as of June 13, 2018. Under the ESPP, employees meeting certain specific employment qualifications are eligible to participate and can purchase shares of common stock semi-annually on February 9<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> and August 9<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> of each year, through payroll deductions. The purchase price is 85% of the lower of the fair market value of the stock at the commencement or end of the offering period. The ESPP permits eligible employees to purchase shares of common stock through payroll deductions for up to 15% of qualified compensation.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s ESPP is subject to an Evergreen provision which shares may be added to the pool as needed. As of December 31, 2021, a total of 359,545 shares of common stock may be granted in accordance with the terms of the ESPP.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2021, a total of 64,975 shares of common stock for $0.3 million have been issued to employees participating in the two ESPP purchases during 2021 and 235,469 shares are available for issuance under the ESPP as of December 31, 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense for the ESPP was $0.1 million and $0.1 million for the years ended December 31, 2021 and 2020, respectively, and is included in total stock-based compensation recognized.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850048337384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Income Taxes </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred cumulative net operating losses since inception and, consequently, has not recorded any income tax expense for the years ended December 31, 2021 and 2020 due to its net operating loss position. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reconciliation of the federal statutory income tax rate to the Company&#8217;s effective tax rate for the years ended December 31, 2021 and 2020 are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax at statutory federal rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-21.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-21.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State Tax (benefit)&#8212;net of federal benefit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.35</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.58</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-5.86</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-12.26</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition due to Sec. 382 and 383 limitations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.55</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.26</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-12.25</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.25</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.38</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective tax rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s deferred tax assets as of December 31, 2021 and 2020 consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals and reserves</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,095</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carry forwards</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,541</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,505</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credit carry forwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,939</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,789</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed and intangible assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61,483</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,396</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the available objective evidence at December 31, 2021, the Company does not believe it is more likely than not that the net deferred tax assets will be realizable. Accordingly, the Company has provided a full valuation allowance against its net deferred tax assets at December 31, 2021 and 2020. The net valuation allowance increased by approximately $23.1 million and decreased approximately $6.9 million during the years ended December 31, 2021 and 2020, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, after consideration of certain limitations (see below), the Company had approximately $226.4 million federal and $8.0 million state net operating loss carryforwards (&#8220;NOL&#8221;) available to reduce future taxable income which, if unused, will begin to expire in 2037 for federal and 2032 for state tax purposes. The federal net operating loss carryforward includes $218.9 million that have an indefinite life.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the Company also had tax credit carry forwards available to offset future tax liabilities of approximately $11.4 million for federal and $7.5 million for state. If unused, the federal credit will begin to expire in 2040 and the state tax credit does not expire. &#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Company experiences a greater than 50 percentage point aggregate change in ownership over a three-year period (a Section 382 ownership change), utilization of its pre-change NOL carry forwards are subject to annual limitation under Section 382 of the Internal Revenue Code (California has similar provisions). The annual limitation is determined by multiplying the value of the Company's stock at the time of such ownership change by the applicable long-term tax-exempt rate. Such limitations may result in expiration of a portion of the NOL carryforwards before utilization. The Company determined that ownership changes occurred December 21, 2007, August 20, 2015, April 13, 2017, February 15, 2018, and February 18, 2020. Approximately $156.3 million and $70.8 million of the NOLs will expire unutilized for federal and California purposes, respectively. The Company has derecognized NOL related deferred tax assets in the tax affected amounts of $32.8 million and $0 for federal and California purposes, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of the federal tax credits could expire unutilized as well, whereas none of the California tax credits are subject to expiration. Approximately $15.2 million of gross federal tax credit-related deferred tax assets were derecognized due to the Section 383 limitation. The ability of the Company to use its remaining NOL and tax credit carry forwards may be further limited if the Company experiences a Section 382 ownership change as a result of future changes in its stock ownership. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 27, 2020, the &#8220;Coronavirus Aid, Relief and Economic Security (CARES) Act&#8221; (the &#8220;Act&#8221;) was signed into law. The Act includes provisions relating to refundable payroll tax credits, deferment of the employer portion of certain payroll taxes, net operating loss carryback periods, alternative minimum tax credit refunds, and modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The Company analyzed the provisions of the Act and determined there was no significant impact to its 2020 tax provision.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 29, 2020, the California Governor signed Assembly Bill 85 (&#8220;A.B. 85&#8221;), which now becomes California law. A.B. 85, which includes several tax measures, provides for a three-year suspension of the use of net operating losses for medium and large businesses and a three-year cap on the use of business incentive tax credits to offset no more than $5.0 million of tax per year. Generally, A.B. 85 suspends the use of net operating losses for taxable years 2020, 2021, and 2022 for taxpayers with taxable income of $1.0 million or more. Since the Company is not expected to generate California source taxable income of more than $1.0 million, no material impact is anticipated at this time.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 27, 2020, the &#8220;Consolidated Appropriations Act, 2021&#8221; (the &#8220;CAA&#8221;) was signed into law. The CAA includes provisions meant to clarify and modify certain items put forth in CARES Act, while providing aid to businesses affected by the pandemic.&#160;&#160;The CAA allows deductions for expenses paid for by Paycheck Protection Program (&#8220;PPP&#8221;) and Economic Injury Disaster Loan (&#8220;EIDL&#8221;) Program, clarifies forgiveness of EIDL advances, and other business provisions.&#160;&#160;The Company analyzed the provisions of the CAA and determined there was no significant impact to its 2021 tax provision.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounting for Uncertainty in Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company only recognizes tax benefits if it is more likely than not that they will be sustained upon audit by the relevant tax authority based upon their technical merits. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had approximately $4.7 million and $3.0 million of unrecognized tax benefits as of December 31, 2021 and 2020, respectively. As the Company has a full valuation allowance on its deferred tax assets, the unrecognized tax benefits have reduced the deferred tax assets and the valuation allowance in the same amount. The Company does not expect the amount of unrecognized tax benefits to materially change in the next twelve months.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the beginning and ending balance of the unrecognized tax benefits is as follows <span style="font-style:italic;">(in thousands)</span>: </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Beginning Balance at January 1, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1,871</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase/(Decrease) of unrecognized tax benefits taken</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; in prior years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(295</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase/(Decrease) of unrecognized tax benefits</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related to current year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,379</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ending Balance at December&#160;31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2,955</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase/(Decrease) of unrecognized tax benefits taken</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; in prior years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase/(Decrease) of unrecognized tax benefits</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related to current year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,749</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ending Balance at December&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4,704</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and penalties related to unrecognized tax benefits would be included as income tax expense in the Company&#8217;s consolidated statements of operations. As of December 31, 2021 and 2020, the Company had not recognized any tax-related penalties or interest in its consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files income tax returns in the United States federal, California, Kansas, Missouri and New Jersey state jurisdictions. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. As of December 31, 2021 and 2020, the Company had no uncertain tax positions which affected its financial position and its results of operations or its cash flow, and will continue to evaluate for uncertain positions in the future. The Company is subject to United States federal and state income tax examinations by authorities for all tax years due to accumulated net operating losses that are being carried forward for tax purposes.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850049858088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborations</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Collaborations</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Mosaic</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2017, the Company entered into a strategic research collaboration with Mosaic to develop intravitreal anti-complement factor 3 (C3) products for the treatment of dry Age-related Macular Degeneration (AMD) and other retinal diseases. The Company entered into two amendments to the Mosaic research collaboration agreements in December 2019 and May 2020. See Note 8, <span style="font-style:italic;">Related Parties</span>.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ISU Abxis</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2018, the Company entered into an amended and restated license agreement with ISU Abxis (the &#8220;A&amp;R ISU Abxis Agreement&#8221;), which amended and restated its previous license and collaboration agreement with ISU Abxis previously entered into in September 2013, as subsequently amended in October 2014 and December 2016 <span style="color:#000000;">(the &#8220;Original ISU Abxis Agreement&#8221;)</span>. Under the A&amp;R ISU Abxis Agreement, <span style="color:#000000;">ISU Abxis will receive commercialization rights in South Korea to the Company&#8217;s engineered Factor IX dalcinonacog alfa - DalcA and the Company will receive clinical development and commercialization rights in the rest of world (excluding South Korea) and manufacturing development and manufacturing rights worldwide (including South Korea)</span>. <span style="color:#000000;">The </span>A&amp;R ISU Abxis Agreement <span style="color:#000000;">eliminates the profit-sharing arrangement in the Original ISU Abxis Agreement and</span> p<span style="color:#000000;">rovides for a low single-digit royalty payment to ISU Abxis, on a country-by-country basis, for net product sales of DalcA by the Company or its affiliates in each country other than South Korea. Pursuant to the A&amp;R </span>ISU Abxis Agreement<span style="color:#000000;">, the Company will also pay up to an aggregate of</span> <span style="color:#000000;">$19.5 million in milestone payments to ISU Abxis, including $2.5&#160;million in regulatory and development milestone payments and up to $17.0&#160;million in commercial milestone payments, if the applicable milestones are met. As of December 31, 2021, no milestones have been met.</span><span style="letter-spacing:-0.2pt;"> </span>&#160;&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Biogen</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 18, 2019, the Company and Biogen entered into a License and Collaboration Agreement (the &#8220;Biogen Agreement&#8221;), under which the Company granted Biogen a worldwide, royalty-bearing, exclusive, with the right to sublicense, license (&#8220;Exclusive License&#8221;) to develop and commercialize CB 2782-PEG and other anti-C3 proteases for potential treatment of dry AMD and other disorders. Pursuant to the Biogen Agreement, the Company will perform certain pre-clinical and manufacturing activities (&#8220;Research Services&#8221;), and Biogen will be solely responsible for funding the pre-clinical and manufacturing activities and performing IND-enabling activities, worldwide clinical development, and commercialization. The Company will provide the Research Services over a term of <span style="color:#000000;">thirty months</span> with Biogen having the option to extend the term for two additional <span style="color:#000000;"><span style="-sec-ix-hidden:F_000509">twelve-month</span></span> periods.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Biogen Agreement, the Company received an up-front payment for the transfer of the Exclusive License (inclusive of certain know-how) of <span style="color:#000000;">$15.0</span> million in January 2020. The Company is eligible to receive development milestones and sales milestones of up to $340.0 million. In addition, the Company is eligible to receive royalties in the range of single-digit to low double-digit percentage rates of annual net sales on a product-by-product and country-by-country basis. The Company will also receive reimbursements for costs associated with the performance of the Research Services.<span style="color:#000000;">   </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the performance obligations under the Biogen Agreement were the Exclusive License and the Research Services. For the Exclusive License, the Company used the residual approach in determining the standalone selling price, or SSP, which includes the upfront payments, milestones and royalties. For the Research Services, the Company used the historical pricing approach for determining the SSP, which includes the reimbursement of personnel and out-of-pocket costs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Biogen Agreement will continue on a product-by-product and country-by-country basis until the tenth anniversary of the first commercial sale of the first product in a country, unless terminated earlier by either party as specified under the agreement. In March 2022, the Company received written notice from Biogn to terminate the Biogen Agreement effective in May 2022. See Note 17, <span style="font-style:italic;">Subsequent Event</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2021, the Company recognized no license revenue from the Biogen Agreement. For the year ended December 31, 2020, the Company recognized the $15.0 million in license revenue upon the transfer of the Exclusive License and the related know-how, and $0.1 million in license revenue for reimbursable out-of-pocket costs incurred.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2021 and 2020, the Company recognized $7.3 million and $5.8 million in collaboration revenue for reimbursable out-of-pocket and personnel costs incurred related to Research Services.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December 31, 2021, the Company recognized $2.0 million in collaboration revenue from the beginning of period deferred revenue balance.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850045156920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interest and Other Income (Expense), Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income And Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncomeTextBlock', window );">Interest and Other Income (Expense), Net</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">13.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Interest and Other Income (Expense), Net </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table shows the detail of interest and other income (expense), net as follows <span style="font-style:italic;">(in thousands):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">561</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Miscellaneous income</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">659</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(87</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(91</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total interest and other income (expense), net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,129</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for interest and other income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI http://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850048337384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:15pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">14.</span></p></td>
<td valign="top">
<p style="margin-top:15pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stockholders&#8217; Equity</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the first quarter of 2021, the Company issued and sold an aggregate of 9,185,000 registered shares of its common stock (including 485,000 shares sold pursuant to the exercise of the underwriters&#8217; overallotment option) at a price of $5.75 per share. The net proceeds to the Company, after deducting $3.6 million in underwriting discounts and commissions, and offering expenses, were approximately $49.3 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had 85 issued and outstanding common stock warrants as of December 31, 2021 and 2020, respectively, with a weighted-average exercise price of $392.70. The warrants expire in <span style="-sec-ix-hidden:F_000537">August 2022</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">2021 ATM Program </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On October 15, 2021, the Company entered into an Equity Distribution Agreement (the &#8220;ATM Agreement&#8221;) with Piper Sandler &amp; Co. (&#8220;Piper Sandler&#8221;), as sales agent, pursuant to which the Company may offer and sell, from time to time, through Piper Sandler, shares of the Company&#8217;s common stock, par value of $0.001 per </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">share, with aggregate gross sales proceeds of up to $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50.0</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million through an &#8220;at the market&#8221; equity offering program (the &#8220;ATM Program&#8221;). The Company will pay Piper Sandler a commission of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.0</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">% of the gross proceeds of any shares sold. The Company also agreed to reimburse Piper Sandler for certain expenses incurred in connection with its services under the ATM Agreement, including up to $</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,000</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for legal expenses in connection with the establishment of the ATM Program.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of shares of common stock under the ATM Program will be made pursuant to the registration statement on Form S-3 (File No. 333-253874), which was declared effective by the SEC on May 3, 2021, and a related prospectus supplement file with the SEC on October 15, 2021. For the year ended December 31, 2021, no shares of common stock were sold under the ATM Program. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850048473864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Net Loss per Share Attributable to Common Stockholders</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,603,630</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,355,615</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,603,715</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,355,700</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850048541208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring And Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:15pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16.</span></p></td>
<td valign="top">
<p style="margin-top:15pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Restructuring</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2021, the Board approved a restructuring of its business based on its decision to stop the clinical development of MarzAA and focus solely on its complement programs and protease medicines platform. The restructuring included a reduction-in-force whereby approximately 35% of employees were terminated. During the year ended December 31, 2021, the Company recorded charges of $0.4 million related to one-time severance costs and related expenses in connection with the workforce reduction, and charges of $3.8 million related to the write-off of prepaid manufacturing costs that will no longer be used for the clinical development of MarzAA. <span style="color:#000000;">As of December 31, 2021, the remaining restructuring liability was $0.2 million, which the Company expects to pay in the first quarter of 2022.</span></p>
<p style="margin-bottom:6pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes restructuring charges recorded in each component of operating expenses in the Company&#8217;s consolidated statements of operations (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total restructuring charges</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,168</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850048475544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Subsequent Event</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.81%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Biogen Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.76%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2022, the Company received written notice that Biogn is terminating the Biogen Agreement. Pursuant to the terms of the Biogen Agreement, termination will be effective in <span style="-sec-ix-hidden:F_000557">May 2022</span>. As a result of the termination, Biogen will no longer have an exclusive license to develop, manufacture and commercialize CB 2782-PEG and other anti-C3 proteases for potential treatment of dry AMD and other disorders.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sublease</span><span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> Agreement</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.76%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2022, the Company entered into a sublease agreement for one of its leased facilities that commences in April 2022. Under the terms of the sublease agreement, the Company will receive $0.2 million in base lease payments over the term of the sublease, which ends in <span style="-sec-ix-hidden:F_000556">April 2023</span>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Advisor Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.76%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2022, the Company entered into a financial advisor agreement with Raymond James &amp; Associates, Inc. (&#8220;Raymond James&#8221;) to help the Company evaluate the possible sale or merger of the Company with various third-parties. Raymond James will be paid an advisory fee of up to $1.0 million upon the effective sale or merger of the Company and will be reimbursed up to $20,000 for reasonable legal, travel and out-of-pocket expenses. </p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Event</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.76%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2022, the Company announced that it intends to further reduce its workforce as part of its restructuring plan. Under the restructuring plan, the Company will provide employees one-time severance payments upon termination, continued benefits for a specific period, and outplacement services. The Company expects to incur total expenses of approximately $0.8 million, which is expected to be paid out during the second quarter of 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850046224152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying consolidated financial statements include the accounts of the Company and its subsidiary. Intercompany accounts and transactions, if applicable, have been eliminated in consolidation. The Company&#8217;s consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;GAAP&#8221;). &#160;&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowance of doubtful accounts, operating lease right-of-use assets and liabilities, accrued expenses, income taxes and stock-based compensation. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Pronouncements Recently Adopted</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounting Pronouncements Recently Adopted</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update&#160;(&#8220;ASU&#8221;) 2019-12, <span style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. </span>The amendments in ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes.&#160;ASU 2019-12&#160;removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The Company adopted ASU 2019-12 as of January 1, 2021, on a prospective transition basis. <span style="color:#000000;">The adoption of ASU 2019-12 did not have a material impact on the Company&#8217;s consolidated financial statements.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">New Accounting Pronouncements &#8211; Issued But Not Yet Adopted</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU 2016-13,<span style="font-style:italic;">&#160;Measurement of Credit Losses on Financial Instruments</span>. The main objective of ASU 2016-13 is to provide financial statement users with more decision-useful information about an entity's expected credit losses on financial instruments and other commitments to extend credit at each reporting date. To achieve this objective, the amendments in this update replace the incurred loss impairment methodology currently used today with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates. ASU 2016-13 will be effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, using a modified retrospective approach. Early adoption is permitted.&#160;The Company plans to adopt ASU 2016-13&#160;and related updates&#160;as of January 1, 2023.&#160;The Company will assess the impact of adoption of this standard on its consolidated financial statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2021, the FASB issued ASU 2021-04, <span style="font-style:italic;">Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options</span>. The amendments in ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The Company plans to adopt ASU 2021-04 and related updates on January 1, 2022, and does not expect the adoption to have a material impact on its consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company invests its excess cash in bank deposits, consisting primarily of money market mutual funds. The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value hierarchy requires that an entity maximize the use of observable inputs when estimating fair value. The fair value hierarchy includes the following three-level classification which is based on the market observability of the inputs used for estimating the fair value of the assets or liabilities being measured:</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 1<span style="font-style:normal;"> &#8211; Quoted prices in active markets for identical assets or liabilities.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 2<span style="font-style:normal;"> &#8211; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Level 3<span style="font-style:normal;"> &#8211; Inputs that are generally unobservable and typically reflect management&#8217;s estimate of assumptions that market participants would use in pricing the asset or liability.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, which are three years for computer equipment and software, and three to seven years for furniture and leasehold improvements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investments</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company invests its excess cash in investment grade, short to intermediate-term, fixed income securities and recognizes purchased securities on the settlement date. All investments have been classified as &#8220;available-for-sale&#8221; and are carried at estimated fair value based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments at the time of purchase and reevaluates such designation as of each consolidated balance sheet date. Unrealized gains and losses on available-for-sale debt securities are excluded from earnings and are reported as a component of comprehensive loss. Realized gains and losses and declines in fair value determined to be other-than-temporary, if any, on available-for-sale debt securities are included in interest and other income (expense), net. The cost of securities sold is based on the specific-identification method. Interest on short-term investments is included in interest and other income (expense), net.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">License and Collaboration Arrangements </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.21%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may enter into collaboration arrangements that fall under the scope Collaborative Arrangements (Topic 808). The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808 to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. The accounting for some of the activities under collaboration arrangements may be analogized to ASC 606 for distinct units of account that are reflective of a vendor-customer relationship.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under ASC 606, in determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when the Company satisfies each performance obligation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues attributed to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of each arrangement that contain development milestones, the Company evaluates whether the development milestones included are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not generally considered probable of being achieved until those approvals are received.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the end of each reporting period, the Company re-evaluates the probability of achievement of any development milestones, and if necessary, adjusts its estimate of the transaction price. Any such adjustments </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">would be recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For research and development services, the Company elected the practical expedient to recognize revenue as the research and development services are invoiced.&#160;&#160;As the Company has a right to consideration from the collaboration agreement with Biogen International GmbH (&#8220;Biogen&#8221;), in an amount that corresponds directly with the value of the Company&#8217;s performance completed to date for the research services, the Company recognized revenue related to the research services as invoiced, in line with the practical expedient in ASC 606-10-55-18.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price is allocated to each performance obligation on a relative stand-alone selling price (&#8220;SSP&#8221;) basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the timing of recognition and the SSP for each performance obligation identified in the contract.&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The SSP for licenses are calculated using the residual approach if the Company has not yet established a price for such license and the license has not previously been sold on a standalone basis.&#160;Otherwise, selling prices for licenses are determined using an income approach model and include key assumptions such as: development timeline, revenue forecast, commercialization expenses, discount rate and probabilities of technical and regulatory success. To estimate the SSP for research and development services, the Company uses a cost-plus margin approach. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock', window );">Cost of License and Collaboration Revenue</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cost of License and Collaboration</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of license revenue includes sublicense fees paid or payable to Mosaic Biosciences, Inc. (&#8220;Mosaic&#8221;), incurred in the period, under the terms of the Mosaic collaboration agreement, and fees for patent development and protection paid or payable to other third-party vendors corresponding to the recognition of license revenue from the Company&#8217;s collaboration agreement with Biogen. See<span style="color:#000000;"> Notes 8 and 12, </span><span style="font-style:italic;color:#000000;">Related Parties </span><span style="color:#000000;">and</span><span style="font-style:italic;color:#000000;"> Collaborations, </span><span style="color:#000000;">respectively. Cost of license revenue does not include any allocated overhead costs.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of collaboration revenue includes fees for research and development services paid or payable to Mosaic and other third-party vendors and personnel cost, incurred in the period pertaining to the Company&#8217;s agreement with Biogen. See<span style="color:#000000;"> Notes 8 and 12, </span><span style="font-style:italic;color:#000000;">Related Parties </span><span style="color:#000000;">and</span><span style="font-style:italic;color:#000000;"> Collaborations, </span><span style="color:#000000;">respectively. Cost of collaboration revenue does not include any allocated overhead costs.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services used in research and development are initially deferred and capitalized in prepaid and other current assets. The capitalized amounts are then expensed as the related goods are delivered or services are performed, or until it is no longer expected that the goods or services will be delivered. Research and development costs consist of payroll and other personnel-related expenses, laboratory supplies and reagents, contract research and development services, materials, and consulting costs, as well as allocations of facilities and other overhead costs. Under the Company&#8217;s collaboration agreement with Biogen, certain specific expenditures are reimbursed by third parties. During the years ended December 31, 2021 and 2020, $6.5 million and $5.4 million, respectively, of research and development expense was recorded as cost of collaboration revenue related to the collaboration agreement with Biogen signed in December 2019.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock', window );">Accrued Research and Development Expenses</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.81%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses include estimated costs of research and development activities conducted by external service providers, which include the conduct of preclinical studies and clinical trials and contract manufacturing activities. The Company records the estimated costs of research and development activities </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">based upon the estimated </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">amount</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of services provided but not yet invoiced and includes these costs in</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> other</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> accrued liabilities in the consolidated balance sheet and within research and development expense in the consolidated statement of operations. These costs are a significant component of the research and development expenses. The Company records accrued expenses for these costs based on the estimated amount of work completed and in accordance with agreements established with these external service providers.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_ConcentrationRiskCreditRiskPolicyTextBlock', window );">Concentration Risk Credit Risk</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, investments and accounts receivable. The Company&#8217;s investment policy restricts cash investments to high credit quality, investment grade investments. The Company believes that it has established guidelines for investment of its excess cash that maintain safety and liquidity through its policies on high quality of investment and investment duration. The Company is exposed to credit risk in the event of default by the institutions holding the cash and cash equivalents to the extent beyond the amount insured by the federal depository insurance corporation. The Company&#8217;s accounts receivable as of December 31, 2021 of $1.8 million as well as its total license and collaboration revenue of $7.3 million and $20.9 million for the years ended December 31, 2021 and 2020, respectively, are from one party, see Note 12, <span style="font-style:italic;">Collaborations</span>.&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Accounts Receivable, net and Allowance for Doubtful Accounts</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accounts Receivable and Allowance for Doubtful Accounts</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. Customer payments are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under the arrangements. The Company continuously monitors collections and payments from its customers and maintains a provision for estimated credit losses. The Company determines its allowance for doubtful accounts by considering a number of factors, including the length of time balances are past due, the Company&#8217;s previous loss history, the customer&#8217;s current ability to pay its obligations to the Company and the condition of the general economy and the industry as a whole. The Company writes off accounts receivable when they are determined to be uncollectible. For the years ended December 31, 2021 and 2020, there were no allowance for doubtful accounts deemed necessary.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income taxes are computed using the liability method. Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company follows the authoritative guidance on accounting for uncertainty in income taxes. This guidance prescribes a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken in the Company&#8217;s income tax returns. This interpretation also provides guidance on accounting for interest and penalties and associated with tax positions, accounting for income taxes in interim periods and income tax disclosures.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s policy is to include penalties and interest expense related to income taxes as a component of other expense and interest expense, respectively, as necessary.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures the cost of employee, non-employee and director services received in exchange for an award of equity instruments based on the fair value of the award on the date of grant and recognizes the related expense over the period during which the employee, non-employee or director is required to provide service in exchange for the award on a straight-line basis. The estimated fair value of equity awards that contain performance conditions is expensed over the term of the award once the Company has determined that it is probable that performance conditions will be satisfied.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the Black-Scholes option-pricing valuation model to estimate the grant-date fair value of stock-based awards. The determination of fair value for stock-based awards on the date of grant using an option-pricing model requires management to make certain assumptions regarding </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a number of</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> variables. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he Company </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">elected to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">account for forfeitures when they occur. As such, the Company recognizes stock-based compensation expense, over their requisite service period, based on the vesting provisions of the individual grants.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy', window );">Restructuring Charges</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restructuring Charges</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs and liabilities associated with restructuring are recorded in the period management commits to a restructuring or cost reduction plan, or executes specific actions contemplated by the plan and all criteria for liability recognition have been met. One-time employee termination costs are recognized at the time of communication to employees, unless future service is required, in which case the costs are recognized ratably over the future service period. Restructuring charges are recognized as an operating expense within the consolidated statements of operations and related liabilities are recorded within accrued compensation on the consolidated balance sheets. The Company periodically evaluates and, if necessary, adjusts its estimates based on currently available information.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss per Share Attributable to Common Stockholders</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss of the Company for all periods presented.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_ConcentrationRiskCreditRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk Credit Risk</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_ConcentrationRiskCreditRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of license and collaboration revenue policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850048383976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables present the fair value hierarchy for assets measured at fair value on a recurring basis as of December 31, 2021 and 2020 <span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,347</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,347</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">2)</sup></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,504</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,504</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,851</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,851</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,360</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,360</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">2)</sup></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,837</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,837</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal agency securities<sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup><sup style="font-size:85%;line-height:120%;vertical-align:top">2)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,700</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,700</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68,197</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,700</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,897</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Included in cash and cash equivalents on accompanying consolidated balance sheet.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Included in short-term investments on accompanying consolidated balance sheet and are classified as available-for-sale debt securities. $2.5 million of U.S. government agency securities as of December 31, 2020 are included in long-term investments on the accompanying consolidated balance sheets due to the maturity being more than 12 months. &#160;</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-0.43%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of cash, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to the short-term maturity of these instruments.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850129726824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract', window );"><strong>Investments All Other Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SaleSecuritiesAvailableTextBlock', window );">Cash Equivalents, Restricted Cash and Short-Term Investments Classified as Available-for-sale Securities</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents and investments (debt securities) which are classified as available-for-sale securities, consisted of the following <span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds (cash equivalents)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,504</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,504</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,851</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,851</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Classified as:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,347</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,504</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46,851</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds (cash equivalents)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,360</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,360</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government agency securities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,835</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,837</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal agency securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,697</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,700</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total financial assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,892</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,897</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Classified as:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,360</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,994</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term investments</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,543</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,897</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_SaleSecuritiesAvailableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale securities available text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_SaleSecuritiesAvailableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAllOtherInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAllOtherInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850048323176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Other Accrued Liabilities</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued liabilities consisted of the following <span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,381</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,238</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biogen</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">868</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-clinical</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">773</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional and consulting services</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">509</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,979</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">361</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">180</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">235</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other accrued liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,072</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,743</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850046260696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock', window );">Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments</a></td>
<td class="text">The present value assumptions used in calculating the present value of the lease payments were as follows:
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3 years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.3 years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.7</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Operating Lease Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:2pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The maturity of the Company&#8217;s operating lease liabilities as of&#160;December&#160;31, 2021 were as follows&#160;<span style="font-style:italic;">(in thousands):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ending December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,044</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">410</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total undiscounted lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,454</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="middle">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(69</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liability</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,385</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Supplemental Cash Flow Information</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:2pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. The Company did not incur significant variable lease costs for the years ended December 31, 2021 and 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental cash flow information related to operating leases was as follows&#160;<span style="font-style:italic;">(in thousands)</span>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,641</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">602</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid cash payment for lease</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">208</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for operating leases that were included in operating cash outflows</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,849</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">602</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of present value assumptions of lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850129649896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Option Activity Under Company's Equity Incentive Plans</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes stock option activity under the Company&#8217;s 2018 Plan and related information:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number&#160;of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Underlying</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,577,541</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.85</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000407">8.15</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,350</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,091,250</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.26</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(44,605</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.04</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options forfeited</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(250,641</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.32</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options expired</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,930</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51.12</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,355,615</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.59</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000408">7.96</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,337</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,493,238</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.31</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.63</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options forfeited</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,239,630</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.26</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options expired</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(593</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">566.33</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding &#8212; December 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,603,630</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.70</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000409">7.46</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable &#8212; December 31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,513,039</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.37</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000410">6.35</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available to be granted &#8212; December 31,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,333,791</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Weighted Average Valuation Assumptions Used to Estimate Fair Value of Employee Stock Options</a></td>
<td class="text">The fair value of employee stock options was estimated using the following&#160;weighted-average assumptions:
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee Stock Options:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000419">6.00</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000420">5.81</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.84</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.91</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93.25</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113.36</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Recognized</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation recognized was as follows <span style="font-style:italic;">(in thousands):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,202</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,487</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative<sup style="font-size:85%;line-height:120%;vertical-align:top"> (1)</sup></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,203</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,140</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,405</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,627</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:5.24%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:8pt;color:#000000;">Included in general and administrative stock-based compensation for the years ended December 31, 2021 and 2020 is $0.3 million and $0.3 million in expense related to 56,912 shares and 51,056 shares of common stock, respectively, issued to certain board members in lieu of their cash compensation.</span></p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850129505128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Federal Income Tax Rate to Company's Effective Tax Rate</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The reconciliation of the federal statutory income tax rate to the Company&#8217;s effective tax rate for the years ended December 31, 2021 and 2020 are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax at statutory federal rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-21.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-21.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State Tax (benefit)&#8212;net of federal benefit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permanent differences</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.35</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.58</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-5.86</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-12.26</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Derecognition due to Sec. 382 and 383 limitations</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44.55</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.26</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-12.25</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.25</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.38</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective tax rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of the Company's Deferred Tax Assets (Liabilities)</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s deferred tax assets as of December 31, 2021 and 2020 consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals and reserves</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,095</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carry forwards</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,541</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,505</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credit carry forwards</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,939</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,789</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed and intangible assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(61,483</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,396</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Unrecognized Tax Benefits</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the beginning and ending balance of the unrecognized tax benefits is as follows <span style="font-style:italic;">(in thousands)</span>: </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Beginning Balance at January 1, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1,871</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase/(Decrease) of unrecognized tax benefits taken</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; in prior years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(295</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase/(Decrease) of unrecognized tax benefits</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related to current year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,379</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ending Balance at December&#160;31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2,955</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase/(Decrease) of unrecognized tax benefits taken</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; in prior years</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Increase/(Decrease) of unrecognized tax benefits</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; related to current year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,749</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Ending Balance at December&#160;31, 2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4,704</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850048368248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interest and Other Income (Expense), Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income And Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Detail of Interest and Other Income (Expense), Net</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table shows the detail of interest and other income (expense), net as follows <span style="font-style:italic;">(in thousands):</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">561</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Miscellaneous income</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">659</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(87</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(91</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total interest and other income (expense), net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,129</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850048323176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Anti-dilutive Security not Included in Diluted per Share Calculations</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options to purchase common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,603,630</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,355,615</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,603,715</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,355,700</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850048524312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring And Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Summary of Restructuring Charges Recorded in Component of Operating Expenses</a></td>
<td class="text">
<p style="margin-bottom:6pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes restructuring charges recorded in each component of operating expenses in the Company&#8217;s consolidated statements of operations (in thousands):</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,025</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total restructuring charges</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,168</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850048518824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850045410872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_LiquidityAbstract', window );"><strong>Liquidity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 402,694<span></span>
</td>
<td class="nump">$ 314,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">46,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 87,933<span></span>
</td>
<td class="nump">$ 56,241<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_LiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_LiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850042356440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="nump">7,338<span></span>
</td>
<td class="nump">$ 20,948<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_CostOfCollaborationRevenue', window );">Cost of collaboration revenue</a></td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="nump">$ 5,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_CostOfCollaborationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of collaboration revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_CostOfCollaborationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850050022088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=cbio_LongTermInvestmentsMember', window );">Long Term Investments | U.S. Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale, debt securities</a></td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=cbio_LongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=cbio_LongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850045253368">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 46,851<span></span>
</td>
<td class="nump">$ 81,897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">44,347<span></span>
</td>
<td class="nump">30,360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">46,851<span></span>
</td>
<td class="nump">68,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 | Money Market Funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">44,347<span></span>
</td>
<td class="nump">30,360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government Agency Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">2,504<span></span>
</td>
<td class="nump">37,837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government Agency Securities | Fair Value, Inputs, Level 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 2,504<span></span>
</td>
<td class="nump">37,837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-Term Investments | Federal Agency Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-Term Investments | Fair Value, Inputs, Level 2 | Federal Agency Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,700<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Included in cash and cash equivalents on accompanying consolidated balance sheet.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Included in short-term investments on accompanying consolidated balance sheet and are classified as available-for-sale debt securities. $2.5 million of U.S. government agency securities as of December 31, 2020 are included in long-term investments on the accompanying consolidated balance sheets due to the maturity being more than 12 months.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850042166088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents, Restricted Cash and Short-Term Investments Classified as Available-for-sale Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_AmortizedCostAvailableForSaleSecurities', window );">Amortized Cost</a></td>
<td class="nump">$ 46,851<span></span>
</td>
<td class="nump">$ 81,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SaleSecuritiesAvailable', window );">Estimated Fair Value</a></td>
<td class="nump">46,851<span></span>
</td>
<td class="nump">81,897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=cbio_FederalAgencySecuritiesMember', window );">Federal Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_AmortizedCostAvailableForSaleSecurities', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SaleSecuritiesAvailable', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds | Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_AmortizedCostAvailableForSaleSecurities', window );">Amortized Cost</a></td>
<td class="nump">44,347<span></span>
</td>
<td class="nump">30,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SaleSecuritiesAvailable', window );">Estimated Fair Value</a></td>
<td class="nump">44,347<span></span>
</td>
<td class="nump">30,360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Government Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_AmortizedCostAvailableForSaleSecurities', window );">Amortized Cost</a></td>
<td class="nump">2,504<span></span>
</td>
<td class="nump">37,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SaleSecuritiesAvailable', window );">Estimated Fair Value</a></td>
<td class="nump">2,504<span></span>
</td>
<td class="nump">37,837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SaleSecuritiesAvailable', window );">Estimated Fair Value</a></td>
<td class="nump">44,347<span></span>
</td>
<td class="nump">30,360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-Term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SaleSecuritiesAvailable', window );">Estimated Fair Value</a></td>
<td class="nump">$ 2,504<span></span>
</td>
<td class="nump">48,994<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember', window );">Other Long-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SaleSecuritiesAvailable', window );">Estimated Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,543<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated gross unrealized gain before tax available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_AmortizedCostAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_AmortizedCostAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_SaleSecuritiesAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale securities available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_SaleSecuritiesAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=cbio_FederalAgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=cbio_FederalAgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_OtherLongTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850049487080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_FinancialInstrumentLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_GrossRealizedGainLossNetAvailableForSalesSecurities', window );">Material realized gains or losses on available-for-sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available-for-sale debt securities current</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_FinancialInstrumentLineItems', window );"><strong>Financial Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_AvailableForSaleDebtSecuritiesContractualMaturity', window );">Available for sale debt securities contractual maturities</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_AvailableForSaleDebtSecuritiesContractualMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available for sale debt securities contractual maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_AvailableForSaleDebtSecuritiesContractualMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_FinancialInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_FinancialInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_GrossRealizedGainLossNetAvailableForSalesSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross realized gain loss net available for sales securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_GrossRealizedGainLossNetAvailableForSalesSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850042218616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Other Accrued Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_AccruedManufacturingExpensesCurrent', window );">Manufacturing</a></td>
<td class="nump">$ 1,381<span></span>
</td>
<td class="nump">$ 2,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_AccruedCollaborationExpensesCurrent', window );">Biogen</a></td>
<td class="nump">868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_AccruedPreClinicalExpensesCurrent', window );">Pre-clinical</a></td>
<td class="nump">773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional and consulting services</a></td>
<td class="nump">509<span></span>
</td>
<td class="nump">3,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_AccruedClinicalExpensesCurrent', window );">Clinical</a></td>
<td class="nump">361<span></span>
</td>
<td class="nump">291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_AccruedAndOtherCurrentLiabilities', window );">Other</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Total other accrued liabilities</a></td>
<td class="nump">$ 4,072<span></span>
</td>
<td class="nump">$ 6,743<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_AccruedAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_AccruedAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_AccruedClinicalExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_AccruedClinicalExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_AccruedCollaborationExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued collaboration expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_AccruedCollaborationExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_AccruedManufacturingExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued manufacturing expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_AccruedManufacturingExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_AccruedPreClinicalExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Pre Clinical Expenses Current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_AccruedPreClinicalExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850042241080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost', window );">Charges related to write off of prepaid manufacturing cost</a></td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_AGCBiologicsIncMember', window );">AGC Biologics, Inc | Marzeptacog Alfa Activated and Dalcinonacog Alfa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_FirmWorkOrderSupportingClinicalTrials', window );">Firm work order supporting clinical trials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_AGCBiologicsIncMember', window );">AGC Biologics, Inc | Marzeptacog Alfa Activated and Dalcinonacog Alfa | Service Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_CostOfManufacturingServices', window );">Cost of Manufacturing Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_MarzeptacogAlfaActivatedMember', window );">Marzeptacog Alfa Activated | Marzeptacog Alfa Activated and Dalcinonacog Alfa | Maximum | Service Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_CostOfServicesAsPerAgreement', window );">Cost of services as per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_MarzeptacogAlfaActivatedMember', window );">Marzeptacog Alfa Activated | Dalcinonacog Alfa | Maximum | Service Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_CostOfServicesAsPerAgreement', window );">Cost of services as per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_IntegrityBioMember', window );">Catalent Indiana, LLC. | Dalcinonacog alfa.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_CommitmentsAndContingenciesDisclosureLineItems', window );"><strong>Commitments And Contingencies Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_FirmWorkOrderSupportingClinicalTrials', window );">Firm work order supporting clinical trials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Charges related to write off of prepaid manufacturing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_CommitmentsAndContingenciesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_CommitmentsAndContingenciesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_CostOfManufacturingServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of manufacturing services related company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_CostOfManufacturingServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_CostOfServicesAsPerAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of services as per agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_CostOfServicesAsPerAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_FirmWorkOrderSupportingClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Firm work order supporting clinical trials.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_FirmWorkOrderSupportingClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cbio_AGCBiologicsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cbio_AGCBiologicsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cbio_MarzeptacogAlfaActivatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cbio_MarzeptacogAlfaActivatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cbio_DalcinonacogAlfaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cbio_DalcinonacogAlfaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cbio_IntegrityBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cbio_IntegrityBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cbio_GMPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cbio_GMPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850042203912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties - Additional Information (Detail) - Mosaic Biosciences Inc - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 08, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 10, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">One Time Expense related to collaboration</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cbio_MosaicBiosciencesIncMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents', window );">Milestone Payment Related To Regulatory And Clinical Development Events</a></td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cbio_MosaicBiosciencesIncMember', window );">Intravitreal Anti-Complement Factor 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_SublicenseFee', window );">Payment related to collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cbio_MosaicBiosciencesIncMember', window );">Biogen Collaboration | Intravitreal Anti-Complement Factor 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement', window );">Upfront license fee received from collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_SublicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sublicense fee entitled to pay.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_SublicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront fee reveived from license and collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cbio_MosaicBiosciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cbio_MosaicBiosciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cbio_IntravitrealAntiComplementFactor3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cbio_IntravitrealAntiComplementFactor3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cbio_BiogenCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cbio_BiogenCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850046248584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 17, 2020</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_LesseeOperatingLeaseRenewalTermDescription', window );">Lessee operating lease renewal term description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">no stated renewal options<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset and lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Undiscounted future payment</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription', window );">Operating lease not yet commenced description</a></td>
<td class="text">commenced during the fourth quarter of 2020.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term of contract</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cbio_LeaseLabAndOfficeSpaceMember', window );">Lease Lab And Office Space | Sublease Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Undiscounted future payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">This License Agreement has an original lease term of one year and a renewal period of six months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating lease commenced description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">commenced during the second quarter of 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_LesseeOperatingLeaseRenewalTermDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease renewal term description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_LesseeOperatingLeaseRenewalTermDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease that has not yet commenced. Including, but not limited to, nature of involvement with construction or design of underlying asset for lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cbio_LeaseLabAndOfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cbio_LeaseLabAndOfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cbio_SubleaseArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cbio_SubleaseArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850138614568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850045376024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Maturity of Operating Lease Liabilities - (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jul. 17, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease Liabilities Payments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 2,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">2,454<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(69)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">$ 2,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850050142056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease Liabilities Payments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 1,641<span></span>
</td>
<td class="nump">$ 602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_PrepaidCashPaymentForLeaseLiabilities', window );">Prepaid cash payment for lease</a></td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating leases that were included in operating cash outflows</a></td>
<td class="nump">$ 1,849<span></span>
</td>
<td class="nump">$ 602<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in the measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_PrepaidCashPaymentForLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Cash Payment For Lease Liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_PrepaidCashPaymentForLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850043637176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 09, 2021</div></th>
<th class="th"><div>Jun. 13, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable', window );"><strong>Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="nump">$ 5.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common stock available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,405,000<span></span>
</td>
<td class="nump">3,627,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable', window );"><strong>Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized employee stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized employee stock based compensation expense, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 5 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cbio_TwoThousandEighteenOmnibusIncentivePlanMember', window );">2018 Omnibus Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable', window );"><strong>Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease', window );">Increase in number of shares of common stock reserved for issuance</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance</a></td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cbio_TwoThousandEighteenOmnibusIncentivePlanMember', window );">2018 Omnibus Incentive Plan | Performance Based Stock Option Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable', window );"><strong>Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_IssuanceOfOptionGrantsToPurchaseCommonStockShares', window );">Issuance of option grants to purchase common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">647,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember', window );">2018 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable', window );"><strong>Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Maximum employee subscription rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of common stock available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of common stock authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of common stock stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember', window );">2018 Employee Stock Purchase Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable', window );"><strong>Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percentage of fair market value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_IssuanceOfOptionGrantsToPurchaseCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of option grants to purchase common stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_IssuanceOfOptionGrantsToPurchaseCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of information about share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cbio_TwoThousandEighteenOmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cbio_TwoThousandEighteenOmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cbio_PerformanceBasedStockOptionGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cbio_PerformanceBasedStockOptionGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850048614120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Option Activity Under Company's Equity Incentive Plans (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares Underlying Outstanding Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Underlying Outstanding Options, Beginning Balance</a></td>
<td class="nump">2,355,615<span></span>
</td>
<td class="nump">1,577,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares Underlying Outstanding Options, Options granted</a></td>
<td class="nump">1,493,238<span></span>
</td>
<td class="nump">1,091,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares Underlying Outstanding Options, Options exercised</a></td>
<td class="num">(5,000)<span></span>
</td>
<td class="num">(44,605)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares Underlying Outstanding Options, Options forfeited</a></td>
<td class="num">(1,239,630)<span></span>
</td>
<td class="num">(250,641)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Shares Underlying Outstanding Options, Options expired</a></td>
<td class="num">(593)<span></span>
</td>
<td class="num">(17,930)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Underlying Outstanding Options, Ending Balance</a></td>
<td class="nump">2,603,630<span></span>
</td>
<td class="nump">2,355,615<span></span>
</td>
<td class="nump">1,577,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares Underlying Outstanding Options, Exercisable- December 31, 2020</a></td>
<td class="nump">1,513,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available to be granted - December 31, 2020</a></td>
<td class="nump">3,333,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 8.59<span></span>
</td>
<td class="nump">$ 10.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Options granted</a></td>
<td class="nump">5.31<span></span>
</td>
<td class="nump">6.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Options exercised</a></td>
<td class="nump">4.63<span></span>
</td>
<td class="nump">5.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Options forfeited</a></td>
<td class="nump">6.26<span></span>
</td>
<td class="nump">10.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Options expired</a></td>
<td class="nump">566.33<span></span>
</td>
<td class="nump">51.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Ending Balance</a></td>
<td class="nump">7.70<span></span>
</td>
<td class="nump">$ 8.59<span></span>
</td>
<td class="nump">$ 10.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercisable - December 31, 2020</a></td>
<td class="nump">$ 9.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term (Years), Outstanding Balance</a></td>
<td class="text">7 years 5 months 15 days<span></span>
</td>
<td class="text">7 years 11 months 15 days<span></span>
</td>
<td class="text">8 years 1 month 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Exercisable - December 31, 2020</a></td>
<td class="text">6 years 4 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,337<span></span>
</td>
<td class="nump">$ 1,350<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850042111176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Values of Stock Options Estimated Using Black-Scholes Valuation Model (Detail) - Employee Stock Option<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black Scholes Method Used [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">5 years 9 months 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.84%<span></span>
</td>
<td class="nump">0.91%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">93.25%<span></span>
</td>
<td class="nump">113.36%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions Black-Scholes method used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850042045448">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Summary of Stock-Based Compensation Recognized (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,405<span></span>
</td>
<td class="nump">$ 3,627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,202<span></span>
</td>
<td class="nump">1,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 2,203<span></span>
</td>
<td class="nump">$ 2,140<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:8pt;color:#000000;">Included in general and administrative stock-based compensation for the years ended December 31, 2021 and 2020 is $0.3 million and $0.3 million in expense related to 56,912 shares and 51,056 shares of common stock, respectively, issued to certain board members in lieu of their cash compensation.</span></p></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850049739624">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Summary of Stock-Based Compensation Recognized (Parenthetical) (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Number of shares of common stock issued to certain board members in lieu of cash compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">56,912<span></span>
</td>
<td class="nump">51,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,405<span></span>
</td>
<td class="nump">$ 3,627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,203<span></span>
</td>
<td class="nump">2,140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative | Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;"/><span style="font-size:8pt;color:#000000;">Included in general and administrative stock-based compensation for the years ended December 31, 2021 and 2020 is $0.3 million and $0.3 million in expense related to 56,912 shares and 51,056 shares of common stock, respectively, issued to certain board members in lieu of their cash compensation.</span></p></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850045284776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reconciliation of Statutory Federal Income Tax (benefit) Rate to Company's Effective Tax Rate (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax at statutory federal rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State Tax (benefit)&#8212;net of federal benefit</a></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences', window );">Permanent differences</a></td>
<td class="nump">0.35%<span></span>
</td>
<td class="nump">0.58%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="num">(5.86%)<span></span>
</td>
<td class="num">(12.26%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_EffectiveIncomeTaxRateReconciliationDerecognition', window );">Derecognition due to Sec. 382 and 383 limitations</a></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="nump">44.55%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">26.26%<span></span>
</td>
<td class="num">(12.25%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.38%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_EffectiveIncomeTaxRateReconciliationDerecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation derecognition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_EffectiveIncomeTaxRateReconciliationDerecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation, permanent differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850042267752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Components of the Company's Deferred Tax Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
<td class="nump">47,541<span></span>
</td>
<td class="nump">29,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Tax credit carry forwards</a></td>
<td class="nump">12,939<span></span>
</td>
<td class="nump">7,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_DeferredTaxAssetsFixedAssetsAndIntangibles', window );">Fixed and intangible assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">$ (61,483)<span></span>
</td>
<td class="num">$ (38,396)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_DeferredTaxAssetsFixedAssetsAndIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets fixed assets and intangibles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_DeferredTaxAssetsFixedAssetsAndIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850041832984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2007</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease', window );">Increase (decrease) in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (23,100,000)<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized', window );">Gross federal R&amp;D tax credit-related deferred tax assets derecognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,704,000<span></span>
</td>
<td class="nump">2,955,000<span></span>
</td>
<td class="nump">$ 1,871,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Tax-related penalties or interest recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Uncertain tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal Income Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 226,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_OperatingLossCarryforwardsWithIndefiniteLife', window );">Net operating loss carryforwards having indefinite life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 218,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards available to offset future federal tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardExpirationDate', window );">Credit carryforward, expire period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards', window );">Net operating loss carryforward, derecognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State Income Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards available to offset future federal tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=stpr_CA', window );">CALIFORNIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_IncomeTaxLineItems', window );"><strong>Income Tax [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards', window );">Net operating loss carryforward, derecognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_MaximumAmountOfTaxOffsetPerYear', window );">Maximum amount of tax offset per year</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_RequiredMinimumTaxableIncome', window );">Required Minimum Taxable Income</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets state net operating loss carry forwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_IncomeTaxLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_IncomeTaxLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_MaximumAmountOfTaxOffsetPerYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of tax offset per year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_MaximumAmountOfTaxOffsetPerYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_OperatingLossCarryforwardsWithIndefiniteLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards with indefinite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_OperatingLossCarryforwardsWithIndefiniteLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_RequiredMinimumTaxableIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum taxable income required to support realizing the company's.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_RequiredMinimumTaxableIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development tax credit carry forwards derecognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of the tax credit carryforward, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850045124392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Unrecognized tax benefit (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning Balance</a></td>
<td class="nump">$ 2,955<span></span>
</td>
<td class="nump">$ 1,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions', window );">Increase/(Decrease) of unrecognized tax benefits taken in prior years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(295)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase/(Decrease) of unrecognized tax benefits related to current year</a></td>
<td class="nump">1,749<span></span>
</td>
<td class="nump">1,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending Balance</a></td>
<td class="nump">$ 4,704<span></span>
</td>
<td class="nump">$ 2,955<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized tax benefits increase (decrease) resulting from tax positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850042499560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 18, 2019</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,338<span></span>
</td>
<td class="nump">$ 20,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Deferred revenue, recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cbio_LicenseRevenueMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cbio_LicenseRevenueMember', window );">License | Transfer of Exclusive License and Related Know-How</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cbio_ExclusiveLicenseMember', window );">Exclusive License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cbio_CollaborationRevenueMember', window );">Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,338<span></span>
</td>
<td class="nump">5,848<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=cbio_CollaborationRevenueMember', window );">Collaboration | Reimbursable Out-of-Pocket and Personnel Costs Incurred Related to Research Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,300<span></span>
</td>
<td class="nump">$ 5,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_IsuAbxisMember', window );">ISU Abxis | Amended and Restated License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_RegulatoryAndDevelopmentMilestonePayment', window );">Regulatory and development milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_IsuAbxisMember', window );">ISU Abxis | Amended and Restated License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_MilestonePayments', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_CommercialMilestonePayments', window );">Commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_BiogenMember', window );">Biogen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_BiogenMember', window );">Biogen | License and Collaboration Agreement (the &#8220;Biogen Agreement&#8221;)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_ResearchServicesAgreementTerm', window );">Research services</a></td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_ResearchServicesAgreementOptionToExtend', window );">Research services option to extend</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_BiogenMember', window );">Biogen | Exclusive License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Up-front payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=cbio_BiogenMember', window );">Biogen | Exclusive License | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems', window );"><strong>Revenue Recognition Multiple Deliverable Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_DevelopmentMilestonesPaymentReceivable', window );">Development and sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_CommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercial milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_CommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_DevelopmentMilestonesPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development milestones payment Receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_DevelopmentMilestonesPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_RegulatoryAndDevelopmentMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Regulatory and development milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_RegulatoryAndDevelopmentMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_ResearchServicesAgreementOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research services agreement option to extend.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_ResearchServicesAgreementOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_ResearchServicesAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_ResearchServicesAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRevenueRecognized1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously reported as deferred or unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueRevenueRecognized1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cbio_LicenseRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cbio_LicenseRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cbio_ExclusiveLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cbio_ExclusiveLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=cbio_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=cbio_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cbio_IsuAbxisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cbio_IsuAbxisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=cbio_AmendedAndRestatedLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=cbio_AmendedAndRestatedLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cbio_BiogenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cbio_BiogenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=cbio_LicenseAndCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=cbio_LicenseAndCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TransactionTypeAxis=cbio_ExclusiveLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TransactionTypeAxis=cbio_ExclusiveLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850045559736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Detail of Interest and Other Income (Expense), Net (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income And Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_MiscellaneousIncomeExpense', window );">Miscellaneous income</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other</a></td>
<td class="num">(87)<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_InterestAndOtherIncomeExpenseNet', window );">Total interest and other income (expense), net</a></td>
<td class="num">$ (39)<span></span>
</td>
<td class="nump">$ 1,129<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_InterestAndOtherIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and other income (expense), net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_InterestAndOtherIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_MiscellaneousIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Miscellaneous income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_MiscellaneousIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850043525016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 15, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_StockholdersEquityDisclosureLineItems', window );"><strong>Stockholders Equity Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_UnderwritingCommissionsAndOfferingExpensesPayable', window );">Underwriting discounts, commissions and offering expenses payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from sale of common stock after deducting underwriting commissions and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,409,707<span></span>
</td>
<td class="nump">22,097,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,409,707<span></span>
</td>
<td class="nump">22,097,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=cbio_TwoThousandTwentyOneATMProgramMember', window );">2021 ATM Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_StockholdersEquityDisclosureLineItems', window );"><strong>Stockholders Equity Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance</a></td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_PercentageOfCommissionForSharesSold', window );">Percentage of commission for shares sold</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_LegalExpensesIncurred', window );">Legal expenses incurred</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_StockholdersEquityDisclosureLineItems', window );"><strong>Stockholders Equity Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for public offering, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,185,000<span></span>
</td>
<td class="nump">9,185,000<span></span>
</td>
<td class="nump">9,923,076<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock price, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Underwriters' Overallotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_StockholdersEquityDisclosureLineItems', window );"><strong>Stockholders Equity Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock for public offering, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">485,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_StockholdersEquityDisclosureLineItems', window );"><strong>Stockholders Equity Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 392.70<span></span>
</td>
<td class="nump">$ 392.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrant expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_LegalExpensesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Legal expenses incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_LegalExpensesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_PercentageOfCommissionForSharesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Commission for shares sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_PercentageOfCommissionForSharesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_StockholdersEquityDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders equity disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_StockholdersEquityDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_UnderwritingCommissionsAndOfferingExpensesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriting commissions and offering expenses payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_UnderwritingCommissionsAndOfferingExpensesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cbio_TwoThousandTwentyOneATMProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cbio_TwoThousandTwentyOneATMProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=cbio_UnderwritersOverallotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=cbio_UnderwritersOverallotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850045282408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Anti-dilutive Security not Included In Diluted per Share Calculations (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti dilutive securities</a></td>
<td class="nump">2,603,715<span></span>
</td>
<td class="nump">2,355,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cbio_OptionsToPurchaseCommonStockMember', window );">Options To Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti dilutive securities</a></td>
<td class="nump">2,603,630<span></span>
</td>
<td class="nump">2,355,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cbio_CommonStockWarrantsMember', window );">Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti dilutive securities</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cbio_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cbio_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cbio_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cbio_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850041948616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Additional Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring And Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Percent of employees terminated</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance costs and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost', window );">Charges related to write off of prepaid manufacturing cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_RestructuringLiability', window );">Restructuring liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Charges related to write off of prepaid manufacturing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_RestructuringLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_RestructuringLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850042138984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Summary of Restructuring Charges Recorded in Component of Operating Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost And Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 68,889<span></span>
</td>
<td class="nump">$ 52,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">18,963<span></span>
</td>
<td class="nump">$ 16,180<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total restructuring charges</a></td>
<td class="nump">4,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost And Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">4,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost And Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139850049764568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 30,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,168,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total expenses</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Sublease Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Lease Payments Receivable</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">Apr. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Biogen Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">May 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Advisor Agreement | Raymond James &amp; Associates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_AdvisoryFeesPayable', window );">Advisory fees payable</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Advisor Agreement | Raymond James &amp; Associates | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cbio_ReimbursementOfAdvisoryFee', window );">Reimbursement of advisory fee</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_AdvisoryFeesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advisory fees payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_AdvisoryFeesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cbio_ReimbursementOfAdvisoryFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of advisory fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cbio_ReimbursementOfAdvisoryFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cbio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cbio_SubleaseArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cbio_SubleaseArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cbio_BiogenAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cbio_BiogenAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cbio_AdvisorAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cbio_AdvisorAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=cbio_RaymondJamesAndAssociatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=cbio_RaymondJamesAndAssociatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>cbio-10k_20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cbio="http://www.catalystbiosciences.com/20211231"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="cbio-20211231.xsd" xlink:type="simple"/>
    <context id="C_0001124105_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_20220325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2022-03-25</instant>
        </period>
    </context>
    <context id="C_0001124105_20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_0001124105_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_srtProductOrServiceAxis_cbioLicenseRevenueMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:LicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtProductOrServiceAxis_cbioCostOfLicenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CostOfLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtProductOrServiceAxis_cbioCostOfCollaborationMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CostOfCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtProductOrServiceAxis_cbioCostOfCollaborationMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CostOfCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapComputerSoftwareIntangibleAssetMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_cbioLongTermInvestmentsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">cbio:LongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapFinancialInstrumentAxis_cbioFederalAgencySecuritiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">cbio:FederalAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapOtherLongTermInvestmentsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:OtherLongTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_srtRangeAxis_srtMaximumMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioAGCBiologicsIncMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:AGCBiologicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioMarzeptacogAlfaActivatedMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapServiceAgreementsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:MarzeptacogAlfaActivatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioMarzeptacogAlfaActivatedMember_srtProductOrServiceAxis_cbioDalcinonacogAlfaMember_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapServiceAgreementsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:MarzeptacogAlfaActivatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:DalcinonacogAlfaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioIntegrityBioMember_srtProductOrServiceAxis_cbioGMPMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:IntegrityBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:GMPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioAGCBiologicsIncMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapServiceAgreementsMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:AGCBiologicsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_20211101_20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtProductOrServiceAxis_cbioIntravitrealAntiComplementFactor3Member_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_us-gaapTypeOfArrangementAxis_cbioBiogenCollaborationMember_20200110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:IntravitrealAntiComplementFactor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbio:MosaicBiosciencesIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cbio:BiogenCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-10</instant>
        </period>
    </context>
    <context id="C_0001124105_srtProductOrServiceAxis_cbioIntravitrealAntiComplementFactor3Member_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:IntravitrealAntiComplementFactor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbio:MosaicBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200508_20200508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbio:MosaicBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-08</startDate>
            <endDate>2020-05-08</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200508_20200508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbio:MosaicBiosciencesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-08</startDate>
            <endDate>2020-05-08</endDate>
        </period>
    </context>
    <context id="C_0001124105_20211001_20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioLeaseLabAndOfficeSpaceMember_us-gaapTypeOfArrangementAxis_cbioSubleaseArrangementMember_20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbio:LeaseLabAndOfficeSpaceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cbio:SubleaseArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioLeaseLabAndOfficeSpaceMember_us-gaapTypeOfArrangementAxis_cbioSubleaseArrangementMember_20210401_20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">cbio:LeaseLabAndOfficeSpaceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cbio:SubleaseArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="C_0001124105_20200716_20200717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2020-07-16</startDate>
            <endDate>2020-07-17</endDate>
        </period>
    </context>
    <context id="C_0001124105_20200717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <instant>2020-07-17</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenOmnibusIncentivePlanMember_20210609_20210609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenOmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-09</startDate>
            <endDate>2021-06-09</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenOmnibusIncentivePlanMember_20210609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenOmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-09</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapAwardTypeAxis_cbioPerformanceBasedStockOptionGrantsMember_us-gaapPlanNameAxis_cbioTwoThousandEighteenOmnibusIncentivePlanMember_20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cbio:PerformanceBasedStockOptionGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenOmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="C_0001124105_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20180613_20180613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-13</startDate>
            <endDate>2018-06-13</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20180613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-13</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cbio:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20071231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2007-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_stprCA_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_stprCA_20200629_20200629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-06-29</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapIncomeTaxAuthorityAxis_stprCA_20200629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-29</instant>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:IsuAbxisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:IsuAbxisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:IsuAbxisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:IsuAbxisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:AmendedAndRestatedLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_us-gaapTransactionTypeAxis_cbioLicenseAndCollaborationAgreementMember_20191218_20191218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:BiogenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:LicenseAndCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-18</startDate>
            <endDate>2019-12-18</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_us-gaapTransactionTypeAxis_cbioExclusiveLicenseMember_20200101_20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:BiogenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:ExclusiveLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioExclusiveLicenseMember_20200101_20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:BiogenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TransactionTypeAxis">cbio:ExclusiveLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cbio:BiogenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtProductOrServiceAxis_cbioLicenseRevenueMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cbioTransferOfExclusiveLicenseAndRelatedKnowHowMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:LicenseRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cbio:TransferOfExclusiveLicenseAndRelatedKnowHowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtProductOrServiceAxis_cbioExclusiveLicenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:ExclusiveLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cbioReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CollaborationRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cbio:ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cbioReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">cbio:CollaborationRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">cbio:ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_cbioUnderwritersOverallotmentOptionMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cbio:UnderwritersOverallotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001124105_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapSubsidiarySaleOfStockAxis_cbioTwoThousandTwentyOneATMProgramMember_20211015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cbio:TwoThousandTwentyOneATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-15</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapSubsidiarySaleOfStockAxis_cbioTwoThousandTwentyOneATMProgramMember_20211015_20211015">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">cbio:TwoThousandTwentyOneATMProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-15</startDate>
            <endDate>2021-10-15</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioOptionsToPurchaseCommonStockMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cbio:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioOptionsToPurchaseCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cbio:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioCommonStockWarrantsMember_20210101_20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cbio:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioCommonStockWarrantsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cbio:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_20211130_20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
        </entity>
        <period>
            <startDate>2021-11-30</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_cbioSubleaseArrangementMember_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cbio:SubleaseArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_0001124105_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_cbioSubleaseArrangementMember_20220301_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cbio:SubleaseArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_cbioBiogenAgreementMember_20220301_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cbio:BiogenAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapRelatedPartyTransactionAxis_cbioRaymondJamesAndAssociatesMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_cbioAdvisorAgreementMember_20220301_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cbio:RaymondJamesAndAssociatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cbio:AdvisorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionAxis_cbioRaymondJamesAndAssociatesMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_cbioAdvisorAgreementMember_20220301_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">cbio:RaymondJamesAndAssociatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cbio:AdvisorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0001124105_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220301_20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001124105</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_cbioSegment">
        <measure>cbio:Segment</measure>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="C_0001124105_20210101_20211231" id="F_000001">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0001124105_20210101_20211231" id="F_000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="C_0001124105_20210101_20211231" id="F_000007">0001124105</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_0001124105_20210101_20211231" id="F_000008">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001124105_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20211231"
      id="F_000280">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001124105_srtRangeAxis_srtMinimumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210101_20211231"
      id="F_000282">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:TaxCreditCarryforwardExpirationDate
      contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231"
      id="F_000482">2040-12-31</us-gaap:TaxCreditCarryforwardExpirationDate>
    <cbio:ResearchServicesAgreementOptionToExtend
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_us-gaapTransactionTypeAxis_cbioLicenseAndCollaborationAgreementMember_20191218_20191218"
      id="F_000509">P12M</cbio:ResearchServicesAgreementOptionToExtend>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20211231"
      id="F_000537">2022-08-31</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001124105_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_cbioBiogenAgreementMember_20220301_20220331"
      id="F_000557">2022-05-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001124105_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_cbioSubleaseArrangementMember_20220301_20220331"
      id="F_000556">2023-04-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001124105_20211231"
      id="F_000072"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001124105_20201231"
      id="F_000073"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001124105_20211231"
      id="F_000074"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001124105_20201231"
      id="F_000075"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001124105_20190101_20191231" id="F_000407">P8Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001124105_20200101_20201231" id="F_000408">P7Y11M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001124105_20210101_20211231" id="F_000409">P7Y5M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="C_0001124105_20210101_20211231" id="F_000410">P6Y4M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231"
      id="F_000419">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      id="F_000420">P5Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <dei:DocumentType contextRef="C_0001124105_20210101_20211231" id="F_000000">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="C_0001124105_20210101_20211231" id="F_000032">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="C_0001124105_20210101_20211231" id="F_000002">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="C_0001124105_20210101_20211231" id="F_000003">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_0001124105_20210101_20211231" id="F_000033">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0001124105_20210101_20211231" id="F_000022">000-51173</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0001124105_20210101_20211231" id="F_000006">Catalyst Biosciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001124105_20210101_20211231" id="F_000023">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001124105_20210101_20211231" id="F_000024">56-2020050</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001124105_20210101_20211231" id="F_000025">611 Gateway Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_0001124105_20210101_20211231" id="F_000026">Suite 710</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_0001124105_20210101_20211231" id="F_000027">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001124105_20210101_20211231" id="F_000028">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001124105_20210101_20211231" id="F_000029">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001124105_20210101_20211231" id="F_000030">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001124105_20210101_20211231" id="F_000031">871-0761</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0001124105_20210101_20211231" id="F_000020">Common stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001124105_20210101_20211231" id="F_000005">CBIO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001124105_20210101_20211231" id="F_000021">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="C_0001124105_20210101_20211231" id="F_000009">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="C_0001124105_20210101_20211231" id="F_000011">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="C_0001124105_20210101_20211231" id="F_000010">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0001124105_20210101_20211231" id="F_000019">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="C_0001124105_20210101_20211231" id="F_000012">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0001124105_20210101_20211231" id="F_000014">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001124105_20210101_20211231" id="F_000015">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="C_0001124105_20210101_20211231" id="F_000018">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="C_0001124105_20210101_20211231" id="F_000013">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0001124105_20220325"
      decimals="INF"
      id="F_000016"
      unitRef="U_xbrlishares">31477053</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityPublicFloat
      contextRef="C_0001124105_20210630"
      decimals="0"
      id="F_000017"
      unitRef="U_iso4217USD">135045079</dei:EntityPublicFloat>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000222">
&lt;p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Portions of the Registrant's proxy statement for its 2022 Annual Meeting of Stockholders (the &#x201c;Proxy Statement&#x201d;), to be filed with the U.S. Securities and Exchange Commission, no later than 120 days after the Registrant&#x2019;s fiscal year ended December 31, 2021, are incorporated by reference to Part III of this Annual Report on Form 10-K.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId contextRef="C_0001124105_20210101_20211231" id="F_000034">274</dei:AuditorFirmId>
    <dei:AuditorName contextRef="C_0001124105_20210101_20211231" id="F_000035">EISNERAMPER LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="C_0001124105_20210101_20211231" id="F_000036">Philadelphia, Pennsylvania</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000037"
      unitRef="U_iso4217USD">44347000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000038"
      unitRef="U_iso4217USD">30360000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">2504000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">48994000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">1818000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">3313000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">2807000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">6843000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">51476000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">89510000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">2543000</us-gaap:LongTermInvestments>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">472000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">528000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">2744000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">1832000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">970000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000053"
      unitRef="U_iso4217USD">433000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Assets
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000054"
      unitRef="U_iso4217USD">55662000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000055"
      unitRef="U_iso4217USD">94846000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000056"
      unitRef="U_iso4217USD">6419000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000057"
      unitRef="U_iso4217USD">5931000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000058"
      unitRef="U_iso4217USD">1467000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000059"
      unitRef="U_iso4217USD">2476000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000060"
      unitRef="U_iso4217USD">230000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000061"
      unitRef="U_iso4217USD">1983000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000062"
      unitRef="U_iso4217USD">4072000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000063"
      unitRef="U_iso4217USD">6743000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000064"
      unitRef="U_iso4217USD">1977000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000065"
      unitRef="U_iso4217USD">663000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000066"
      unitRef="U_iso4217USD">14165000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000067"
      unitRef="U_iso4217USD">17796000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000068"
      unitRef="U_iso4217USD">408000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000069"
      unitRef="U_iso4217USD">981000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000070"
      unitRef="U_iso4217USD">14573000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000071"
      unitRef="U_iso4217USD">18777000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001124105_20211231"
      decimals="INF"
      id="F_000087"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001124105_20201231"
      decimals="INF"
      id="F_000088"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001124105_20211231"
      decimals="INF"
      id="F_000089"
      unitRef="U_xbrlishares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001124105_20201231"
      decimals="INF"
      id="F_000090"
      unitRef="U_xbrlishares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001124105_20211231"
      decimals="INF"
      id="F_000091"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001124105_20201231"
      decimals="INF"
      id="F_000092"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001124105_20211231"
      decimals="INF"
      id="F_000093"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001124105_20201231"
      decimals="INF"
      id="F_000094"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001124105_20211231"
      decimals="INF"
      id="F_000095"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001124105_20201231"
      decimals="INF"
      id="F_000096"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001124105_20211231"
      decimals="INF"
      id="F_000097"
      unitRef="U_xbrlishares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001124105_20201231"
      decimals="INF"
      id="F_000098"
      unitRef="U_xbrlishares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001124105_20211231"
      decimals="INF"
      id="F_000099"
      unitRef="U_xbrlishares">31409707</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001124105_20211231"
      decimals="INF"
      id="F_000101"
      unitRef="U_xbrlishares">31409707</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001124105_20201231"
      decimals="INF"
      id="F_000100"
      unitRef="U_xbrlishares">22097820</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001124105_20201231"
      decimals="INF"
      id="F_000102"
      unitRef="U_xbrlishares">22097820</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000076"
      unitRef="U_iso4217USD">31000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000077"
      unitRef="U_iso4217USD">22000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000078"
      unitRef="U_iso4217USD">443752000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000079"
      unitRef="U_iso4217USD">390803000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000080"
      unitRef="U_iso4217USD">5000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000081"
      unitRef="U_iso4217USD">-402694000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000082"
      unitRef="U_iso4217USD">-314761000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000083"
      unitRef="U_iso4217USD">41089000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000084"
      unitRef="U_iso4217USD">76069000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000085"
      unitRef="U_iso4217USD">55662000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000086"
      unitRef="U_iso4217USD">94846000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001124105_srtProductOrServiceAxis_cbioLicenseRevenueMember_20200101_20201231"
      decimals="-3"
      id="F_000103"
      unitRef="U_iso4217USD">15100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_20210101_20211231"
      decimals="-3"
      id="F_000104"
      unitRef="U_iso4217USD">7338000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_20200101_20201231"
      decimals="-3"
      id="F_000105"
      unitRef="U_iso4217USD">5848000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000106"
      unitRef="U_iso4217USD">7338000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000107"
      unitRef="U_iso4217USD">20948000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_0001124105_srtProductOrServiceAxis_cbioCostOfLicenseMember_20200101_20201231"
      decimals="-3"
      id="F_000108"
      unitRef="U_iso4217USD">3102000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_0001124105_srtProductOrServiceAxis_cbioCostOfCollaborationMember_20210101_20211231"
      decimals="-3"
      id="F_000109"
      unitRef="U_iso4217USD">7380000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="C_0001124105_srtProductOrServiceAxis_cbioCostOfCollaborationMember_20200101_20201231"
      decimals="-3"
      id="F_000110"
      unitRef="U_iso4217USD">6061000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000111"
      unitRef="U_iso4217USD">68889000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000112"
      unitRef="U_iso4217USD">52975000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000113"
      unitRef="U_iso4217USD">18963000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000114"
      unitRef="U_iso4217USD">16180000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000115"
      unitRef="U_iso4217USD">95232000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000116"
      unitRef="U_iso4217USD">78318000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000117"
      unitRef="U_iso4217USD">-87894000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000118"
      unitRef="U_iso4217USD">-57370000</us-gaap:OperatingIncomeLoss>
    <cbio:InterestAndOtherIncomeExpenseNet
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000119"
      unitRef="U_iso4217USD">-39000</cbio:InterestAndOtherIncomeExpenseNet>
    <cbio:InterestAndOtherIncomeExpenseNet
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000120"
      unitRef="U_iso4217USD">1129000</cbio:InterestAndOtherIncomeExpenseNet>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000121"
      unitRef="U_iso4217USD">-87933000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000122"
      unitRef="U_iso4217USD">-56241000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001124105_20210101_20211231"
      decimals="2"
      id="F_000123"
      unitRef="U_iso4217USD_xbrlishares">-2.87</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001124105_20200101_20201231"
      decimals="2"
      id="F_000124"
      unitRef="U_iso4217USD_xbrlishares">-2.93</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001124105_20210101_20211231"
      decimals="0"
      id="F_000125"
      unitRef="U_xbrlishares">30640977</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001124105_20200101_20201231"
      decimals="0"
      id="F_000126"
      unitRef="U_xbrlishares">19179299</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000127"
      unitRef="U_iso4217USD">-87933000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000128"
      unitRef="U_iso4217USD">-56241000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000129"
      unitRef="U_iso4217USD">-5000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000130"
      unitRef="U_iso4217USD">-29000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000131"
      unitRef="U_iso4217USD">-87938000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000132"
      unitRef="U_iso4217USD">-56270000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="INF"
      id="F_000133"
      unitRef="U_xbrlishares">12040835</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="-3"
      id="F_000134"
      unitRef="U_iso4217USD">12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231"
      decimals="-3"
      id="F_000135"
      unitRef="U_iso4217USD">326810000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231"
      decimals="-3"
      id="F_000136"
      unitRef="U_iso4217USD">34000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231"
      decimals="-3"
      id="F_000137"
      unitRef="U_iso4217USD">-258520000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000138"
      unitRef="U_iso4217USD">68336000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000139"
      unitRef="U_xbrlishares">51056</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000140"
      unitRef="U_iso4217USD">3627000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000141"
      unitRef="U_iso4217USD">3627000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000142"
      unitRef="U_xbrlishares">82853</cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares>
    <cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000143"
      unitRef="U_iso4217USD">435000</cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue>
    <cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000144"
      unitRef="U_iso4217USD">435000</cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000179"
      unitRef="U_iso4217USD">4559000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000145"
      unitRef="U_xbrlishares">9923076</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-3"
      id="F_000146"
      unitRef="U_iso4217USD">10000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000147"
      unitRef="U_iso4217USD">59931000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000148"
      unitRef="U_iso4217USD">59941000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231"
      decimals="-3"
      id="F_000149"
      unitRef="U_iso4217USD">-29000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000150"
      unitRef="U_iso4217USD">-29000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231"
      decimals="-3"
      id="F_000151"
      unitRef="U_iso4217USD">-56241000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000152"
      unitRef="U_iso4217USD">-56241000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000153"
      unitRef="U_xbrlishares">22097820</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000154"
      unitRef="U_iso4217USD">22000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="-3"
      id="F_000155"
      unitRef="U_iso4217USD">390803000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231"
      decimals="-3"
      id="F_000156"
      unitRef="U_iso4217USD">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="-3"
      id="F_000157"
      unitRef="U_iso4217USD">-314761000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000158"
      unitRef="U_iso4217USD">76069000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000159"
      unitRef="U_xbrlishares">56912</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000160"
      unitRef="U_iso4217USD">3405000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000161"
      unitRef="U_iso4217USD">3405000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000162"
      unitRef="U_xbrlishares">69975</cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares>
    <cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000163"
      unitRef="U_iso4217USD">303000</cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue>
    <cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000164"
      unitRef="U_iso4217USD">303000</cbio:StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000178"
      unitRef="U_iso4217USD">3563000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000165"
      unitRef="U_xbrlishares">9185000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="-3"
      id="F_000166"
      unitRef="U_iso4217USD">9000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20211231"
      decimals="-3"
      id="F_000167"
      unitRef="U_iso4217USD">49241000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000168"
      unitRef="U_iso4217USD">49250000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20210101_20211231"
      decimals="-3"
      id="F_000169"
      unitRef="U_iso4217USD">-5000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000170"
      unitRef="U_iso4217USD">-5000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20211231"
      decimals="-3"
      id="F_000171"
      unitRef="U_iso4217USD">-87933000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000172"
      unitRef="U_iso4217USD">-87933000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="INF"
      id="F_000173"
      unitRef="U_xbrlishares">31409707</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20211231"
      decimals="-3"
      id="F_000174"
      unitRef="U_iso4217USD">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20211231"
      decimals="-3"
      id="F_000175"
      unitRef="U_iso4217USD">443752000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20211231"
      decimals="-3"
      id="F_000176"
      unitRef="U_iso4217USD">-402694000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000177"
      unitRef="U_iso4217USD">41089000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000180"
      unitRef="U_iso4217USD">-87933000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000181"
      unitRef="U_iso4217USD">-56241000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000182"
      unitRef="U_iso4217USD">3405000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000183"
      unitRef="U_iso4217USD">3627000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000184"
      unitRef="U_iso4217USD">290000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000185"
      unitRef="U_iso4217USD">138000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000186"
      unitRef="U_iso4217USD">-1495000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000187"
      unitRef="U_iso4217USD">-11687000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000188"
      unitRef="U_iso4217USD">-3880000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000189"
      unitRef="U_iso4217USD">3043000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000190"
      unitRef="U_iso4217USD">500000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000191"
      unitRef="U_iso4217USD">1652000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000192"
      unitRef="U_iso4217USD">-3680000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000193"
      unitRef="U_iso4217USD">82000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <cbio:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000194"
      unitRef="U_iso4217USD">41000</cbio:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset>
    <cbio:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000195"
      unitRef="U_iso4217USD">67000</cbio:IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000196"
      unitRef="U_iso4217USD">-1753000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000197"
      unitRef="U_iso4217USD">-13017000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000198"
      unitRef="U_iso4217USD">-83755000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000199"
      unitRef="U_iso4217USD">-55048000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000200"
      unitRef="U_iso4217USD">49028000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000201"
      unitRef="U_iso4217USD">107565000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <cbio:PaymentsToAcquireShortTermAndLongInvestments
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000202"
      unitRef="U_iso4217USD">97635000</cbio:PaymentsToAcquireShortTermAndLongInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000203"
      unitRef="U_iso4217USD">839000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000204"
      unitRef="U_iso4217USD">267000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000205"
      unitRef="U_iso4217USD">48189000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000206"
      unitRef="U_iso4217USD">9663000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <cbio:ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000207"
      unitRef="U_iso4217USD">49250000</cbio:ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts>
    <cbio:ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000208"
      unitRef="U_iso4217USD">59941000</cbio:ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts>
    <cbio:ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000209"
      unitRef="U_iso4217USD">303000</cbio:ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises>
    <cbio:ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000210"
      unitRef="U_iso4217USD">435000</cbio:ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000211"
      unitRef="U_iso4217USD">49553000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000212"
      unitRef="U_iso4217USD">60376000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000213"
      unitRef="U_iso4217USD">13987000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000214"
      unitRef="U_iso4217USD">14991000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000215"
      unitRef="U_iso4217USD">30360000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000216"
      unitRef="U_iso4217USD">15369000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000217"
      unitRef="U_iso4217USD">44347000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000218"
      unitRef="U_iso4217USD">30360000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <cbio:NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000219"
      unitRef="U_iso4217USD">1850000</cbio:NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities>
    <cbio:NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000220"
      unitRef="U_iso4217USD">476000</cbio:NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities>
    <cbio:NonCashOrPartNonCashRemeasurementOfRightOfUseAssetDueToOperatingLeaseModification
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000221"
      unitRef="U_iso4217USD">624000</cbio:NonCashOrPartNonCashRemeasurementOfRightOfUseAssetDueToOperatingLeaseModification>
    <us-gaap:NatureOfOperations contextRef="C_0001124105_20210101_20211231" id="F_000223">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p id="NOTES_TO_CONSOLIDATED" style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Nature of Operations&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Catalyst Biosciences, Inc. and its subsidiary (the &#x201c;Company&#x201d; or &#x201c;Catalyst&#x201d;) is a &lt;span style="color:#000000;"&gt;fully integrated research and clinical development biopharmaceutical company with expertise in protease engineering, discovery, translational research, clinical development, and manufacturing. The Company is focused on advancing its protease product candidates in the fields of hemostasis and complement regulation.&lt;/span&gt; &lt;span style="color:#000000;"&gt;The Company is located in South San Francisco, California and operates in&lt;/span&gt; one segment. &lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0001124105_20210101_20211231"
      decimals="INF"
      id="F_000274"
      unitRef="U_cbioSegment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:LiquidationBasisOfAccountingTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000224">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="font-weight:normal;"/&gt;Liquidity&lt;span style="font-weight:normal;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had a net loss of $87.9 million for the year ended December 31, 2021 and an accumulated deficit of $402.7 million as of December 31, 2021. The Company expects to continue to incur losses for the next several years. As of December 31, 2021, the Company had $46.9 million of cash, cash equivalents and short-term  investments. Its primary uses of cash are to fund operating expenses, including research and development expenditures and general and administrative expenditures. Based on the current status of its research and development plans, the Company believes that its existing cash, cash equivalents and investments as of December 31, 2021 will be sufficient to fund its cash requirements for at least the next 12 months from the date of the filing of this report. If, at any time, the Company&#x2019;s prospects for financing its research and development programs decline, the Company may decide to reduce research and development expenses by delaying, discontinuing or reducing its funding of one or more of its research or development programs. Alternatively, the Company might raise funds through strategic collaborations, public or private financings or other arrangements. Such funding, if needed, may not be available on favorable terms, or at all. The Company will continue to evaluate the impact of the novel coronavirus disease (&#x201c;COVID-19&#x201d;) pandemic on our business, operations, and cash requirements. For recent financing, see Note 14,&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Stockholders&#x2019; Equity&lt;/span&gt;.&lt;/p&gt;</us-gaap:LiquidationBasisOfAccountingTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001124105_20210101_20211231"
      decimals="-5"
      id="F_000277"
      unitRef="U_iso4217USD">-87900000</us-gaap:NetIncomeLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001124105_20211231"
      decimals="-5"
      id="F_000275"
      unitRef="U_iso4217USD">-402700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_0001124105_20211231"
      decimals="-5"
      id="F_000276"
      unitRef="U_iso4217USD">46900000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000225">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Summary of Significant Accounting Policies&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its subsidiary. Intercompany accounts and transactions, if applicable, have been eliminated in consolidation. The Company&#x2019;s consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;GAAP&#x201d;). &#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowance of doubtful accounts, operating lease right-of-use assets and liabilities, accrued expenses, income taxes and stock-based compensation. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accounting Pronouncements Recently Adopted&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update&#160;(&#x201c;ASU&#x201d;) 2019-12, &lt;span style="font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. &lt;/span&gt;The amendments in ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes.&#160;ASU 2019-12&#160;removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The Company adopted ASU 2019-12 as of January 1, 2021, on a prospective transition basis. &lt;span style="color:#000000;"&gt;The adoption of ASU 2019-12 did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;New Accounting Pronouncements &#x2013; Issued But Not Yet Adopted&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU 2016-13,&lt;span style="font-style:italic;"&gt;&#160;Measurement of Credit Losses on Financial Instruments&lt;/span&gt;. The main objective of ASU 2016-13 is to provide financial statement users with more decision-useful information about an entity's expected credit losses on financial instruments and other commitments to extend credit at each reporting date. To achieve this objective, the amendments in this update replace the incurred loss impairment methodology currently used today with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates. ASU 2016-13 will be effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, using a modified retrospective approach. Early adoption is permitted.&#160;The Company plans to adopt ASU 2016-13&#160;and related updates&#160;as of January 1, 2023.&#160;The Company will assess the impact of adoption of this standard on its consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2021, the FASB issued ASU 2021-04, &lt;span style="font-style:italic;"&gt;Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options&lt;/span&gt;. The amendments in ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The Company plans to adopt ASU 2021-04 and related updates on January 1, 2022, and does not expect the adoption to have a material impact on its consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company invests its excess cash in bank deposits, consisting primarily of money market mutual funds. The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value hierarchy requires that an entity maximize the use of observable inputs when estimating fair value. The fair value hierarchy includes the following three-level classification which is based on the market observability of the inputs used for estimating the fair value of the assets or liabilities being measured:&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;span style="font-style:normal;"&gt; &#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;span style="font-style:normal;"&gt; &#x2013; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;span style="font-style:normal;"&gt; &#x2013; Inputs that are generally unobservable and typically reflect management&#x2019;s estimate of assumptions that market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, which are three years for computer equipment and software, and three to seven years for furniture and leasehold improvements.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Investments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company invests its excess cash in investment grade, short to intermediate-term, fixed income securities and recognizes purchased securities on the settlement date. All investments have been classified as &#x201c;available-for-sale&#x201d; and are carried at estimated fair value based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments at the time of purchase and reevaluates such designation as of each consolidated balance sheet date. Unrealized gains and losses on available-for-sale debt securities are excluded from earnings and are reported as a component of comprehensive loss. Realized gains and losses and declines in fair value determined to be other-than-temporary, if any, on available-for-sale debt securities are included in interest and other income (expense), net. The cost of securities sold is based on the specific-identification method. Interest on short-term investments is included in interest and other income (expense), net.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;License and Collaboration Arrangements &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.21%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company may enter into collaboration arrangements that fall under the scope Collaborative Arrangements (Topic 808). The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808 to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. The accounting for some of the activities under collaboration arrangements may be analogized to ASC 606 for distinct units of account that are reflective of a vendor-customer relationship.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under ASC 606, in determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when the Company satisfies each performance obligation.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues attributed to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the inception of each arrangement that contain development milestones, the Company evaluates whether the development milestones included are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not generally considered probable of being achieved until those approvals are received.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the end of each reporting period, the Company re-evaluates the probability of achievement of any development milestones, and if necessary, adjusts its estimate of the transaction price. Any such adjustments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;would be recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For research and development services, the Company elected the practical expedient to recognize revenue as the research and development services are invoiced.&#160;&#160;As the Company has a right to consideration from the collaboration agreement with Biogen International GmbH (&#x201c;Biogen&#x201d;), in an amount that corresponds directly with the value of the Company&#x2019;s performance completed to date for the research services, the Company recognized revenue related to the research services as invoiced, in line with the practical expedient in ASC 606-10-55-18.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The transaction price is allocated to each performance obligation on a relative stand-alone selling price (&#x201c;SSP&#x201d;) basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the timing of recognition and the SSP for each performance obligation identified in the contract.&#160;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The SSP for licenses are calculated using the residual approach if the Company has not yet established a price for such license and the license has not previously been sold on a standalone basis.&#160;Otherwise, selling prices for licenses are determined using an income approach model and include key assumptions such as: development timeline, revenue forecast, commercialization expenses, discount rate and probabilities of technical and regulatory success. To estimate the SSP for research and development services, the Company uses a cost-plus margin approach. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cost of License and Collaboration&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of license revenue includes sublicense fees paid or payable to Mosaic Biosciences, Inc. (&#x201c;Mosaic&#x201d;), incurred in the period, under the terms of the Mosaic collaboration agreement, and fees for patent development and protection paid or payable to other third-party vendors corresponding to the recognition of license revenue from the Company&#x2019;s collaboration agreement with Biogen. See&lt;span style="color:#000000;"&gt; Notes 8 and 12, &lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Related Parties &lt;/span&gt;&lt;span style="color:#000000;"&gt;and&lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt; Collaborations, &lt;/span&gt;&lt;span style="color:#000000;"&gt;respectively. Cost of license revenue does not include any allocated overhead costs.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of collaboration revenue includes fees for research and development services paid or payable to Mosaic and other third-party vendors and personnel cost, incurred in the period pertaining to the Company&#x2019;s agreement with Biogen. See&lt;span style="color:#000000;"&gt; Notes 8 and 12, &lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Related Parties &lt;/span&gt;&lt;span style="color:#000000;"&gt;and&lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt; Collaborations, &lt;/span&gt;&lt;span style="color:#000000;"&gt;respectively. Cost of collaboration revenue does not include any allocated overhead costs.&lt;/span&gt;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services used in research and development are initially deferred and capitalized in prepaid and other current assets. The capitalized amounts are then expensed as the related goods are delivered or services are performed, or until it is no longer expected that the goods or services will be delivered. Research and development costs consist of payroll and other personnel-related expenses, laboratory supplies and reagents, contract research and development services, materials, and consulting costs, as well as allocations of facilities and other overhead costs. Under the Company&#x2019;s collaboration agreement with Biogen, certain specific expenditures are reimbursed by third parties. During the years ended December 31, 2021 and 2020, $6.5 million and $5.4 million, respectively, of research and development expense was recorded as cost of collaboration revenue related to the collaboration agreement with Biogen signed in December 2019.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.81%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accrued Research and Development Expenses&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses include estimated costs of research and development activities conducted by external service providers, which include the conduct of preclinical studies and clinical trials and contract manufacturing activities. The Company records the estimated costs of research and development activities &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;based upon the estimated &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;amount&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; of services provided but not yet invoiced and includes these costs in&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; other&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; accrued liabilities in the consolidated balance sheet and within research and development expense in the consolidated statement of operations. These costs are a significant component of the research and development expenses. The Company records accrued expenses for these costs based on the estimated amount of work completed and in accordance with agreements established with these external service providers.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, investments and accounts receivable. The Company&#x2019;s investment policy restricts cash investments to high credit quality, investment grade investments. The Company believes that it has established guidelines for investment of its excess cash that maintain safety and liquidity through its policies on high quality of investment and investment duration. The Company is exposed to credit risk in the event of default by the institutions holding the cash and cash equivalents to the extent beyond the amount insured by the federal depository insurance corporation. The Company&#x2019;s accounts receivable as of December 31, 2021 of $1.8 million as well as its total license and collaboration revenue of $7.3 million and $20.9 million for the years ended December 31, 2021 and 2020, respectively, are from one party, see Note 12, &lt;span style="font-style:italic;"&gt;Collaborations&lt;/span&gt;.&#160;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accounts Receivable and Allowance for Doubtful Accounts&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts payable to the Company are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. Customer payments are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under the arrangements. The Company continuously monitors collections and payments from its customers and maintains a provision for estimated credit losses. The Company determines its allowance for doubtful accounts by considering a number of factors, including the length of time balances are past due, the Company&#x2019;s previous loss history, the customer&#x2019;s current ability to pay its obligations to the Company and the condition of the general economy and the industry as a whole. The Company writes off accounts receivable when they are determined to be uncollectible. For the years ended December 31, 2021 and 2020, there were no allowance for doubtful accounts deemed necessary.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income taxes are computed using the liability method. Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company follows the authoritative guidance on accounting for uncertainty in income taxes. This guidance prescribes a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken in the Company&#x2019;s income tax returns. This interpretation also provides guidance on accounting for interest and penalties and associated with tax positions, accounting for income taxes in interim periods and income tax disclosures.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s policy is to include penalties and interest expense related to income taxes as a component of other expense and interest expense, respectively, as necessary.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures the cost of employee, non-employee and director services received in exchange for an award of equity instruments based on the fair value of the award on the date of grant and recognizes the related expense over the period during which the employee, non-employee or director is required to provide service in exchange for the award on a straight-line basis. The estimated fair value of equity awards that contain performance conditions is expensed over the term of the award once the Company has determined that it is probable that performance conditions will be satisfied.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company uses the Black-Scholes option-pricing valuation model to estimate the grant-date fair value of stock-based awards. The determination of fair value for stock-based awards on the date of grant using an option-pricing model requires management to make certain assumptions regarding &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;a number of&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; variables. &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;T&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;he Company &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;elected to &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;account for forfeitures when they occur. As such, the Company recognizes stock-based compensation expense, over their requisite service period, based on the vesting provisions of the individual grants.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Restructuring Charges&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs and liabilities associated with restructuring are recorded in the period management commits to a restructuring or cost reduction plan, or executes specific actions contemplated by the plan and all criteria for liability recognition have been met. One-time employee termination costs are recognized at the time of communication to employees, unless future service is required, in which case the costs are recognized ratably over the future service period. Restructuring charges are recognized as an operating expense within the consolidated statements of operations and related liabilities are recorded within accrued compensation on the consolidated balance sheets. The Company periodically evaluates and, if necessary, adjusts its estimates based on currently available information.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has elected to combine lease and non-lease components as a single component. The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the consolidated balance sheet as right-of-use assets, operating lease liabilities, current and operating lease liabilities, non-current. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss per Share Attributable to Common Stockholders&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss of the Company for all periods presented.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000240">
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying consolidated financial statements include the accounts of the Company and its subsidiary. Intercompany accounts and transactions, if applicable, have been eliminated in consolidation. The Company&#x2019;s consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;GAAP&#x201d;). &#160;&#160;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="C_0001124105_20210101_20211231" id="F_000241">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowance of doubtful accounts, operating lease right-of-use assets and liabilities, accrued expenses, income taxes and stock-based compensation. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000242">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accounting Pronouncements Recently Adopted&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update&#160;(&#x201c;ASU&#x201d;) 2019-12, &lt;span style="font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. &lt;/span&gt;The amendments in ASU 2019-12 are intended to simplify various aspects related to accounting for income taxes.&#160;ASU 2019-12&#160;removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The Company adopted ASU 2019-12 as of January 1, 2021, on a prospective transition basis. &lt;span style="color:#000000;"&gt;The adoption of ASU 2019-12 did not have a material impact on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;New Accounting Pronouncements &#x2013; Issued But Not Yet Adopted&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU 2016-13,&lt;span style="font-style:italic;"&gt;&#160;Measurement of Credit Losses on Financial Instruments&lt;/span&gt;. The main objective of ASU 2016-13 is to provide financial statement users with more decision-useful information about an entity's expected credit losses on financial instruments and other commitments to extend credit at each reporting date. To achieve this objective, the amendments in this update replace the incurred loss impairment methodology currently used today with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to develop credit loss estimates. ASU 2016-13 will be effective for the Company for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, using a modified retrospective approach. Early adoption is permitted.&#160;The Company plans to adopt ASU 2016-13&#160;and related updates&#160;as of January 1, 2023.&#160;The Company will assess the impact of adoption of this standard on its consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2021, the FASB issued ASU 2021-04, &lt;span style="font-style:italic;"&gt;Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options&lt;/span&gt;. The amendments in ASU 2021-04 provide guidance to clarify and reduce diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. The Company plans to adopt ASU 2021-04 and related updates on January 1, 2022, and does not expect the adoption to have a material impact on its consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000243">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company invests its excess cash in bank deposits, consisting primarily of money market mutual funds. The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="C_0001124105_20210101_20211231" id="F_000244">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company applies fair value accounting for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value hierarchy requires that an entity maximize the use of observable inputs when estimating fair value. The fair value hierarchy includes the following three-level classification which is based on the market observability of the inputs used for estimating the fair value of the assets or liabilities being measured:&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;span style="font-style:normal;"&gt; &#x2013; Quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;span style="font-style:normal;"&gt; &#x2013; Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;span style="font-style:normal;"&gt; &#x2013; Inputs that are generally unobservable and typically reflect management&#x2019;s estimate of assumptions that market participants would use in pricing the asset or liability.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000245">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost, less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets, which are three years for computer equipment and software, and three to seven years for furniture and leasehold improvements.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001124105_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapComputerEquipmentMember_20210101_20211231"
      id="F_000278">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001124105_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapComputerSoftwareIntangibleAssetMember_20210101_20211231"
      id="F_000279">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20210101_20211231"
      id="F_000281">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20210101_20211231"
      id="F_000283">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:MarketableSecuritiesPolicy contextRef="C_0001124105_20210101_20211231" id="F_000246">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Investments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company invests its excess cash in investment grade, short to intermediate-term, fixed income securities and recognizes purchased securities on the settlement date. All investments have been classified as &#x201c;available-for-sale&#x201d; and are carried at estimated fair value based upon quoted market prices or pricing models for similar securities. Management determines the appropriate classification of its investments at the time of purchase and reevaluates such designation as of each consolidated balance sheet date. Unrealized gains and losses on available-for-sale debt securities are excluded from earnings and are reported as a component of comprehensive loss. Realized gains and losses and declines in fair value determined to be other-than-temporary, if any, on available-for-sale debt securities are included in interest and other income (expense), net. The cost of securities sold is based on the specific-identification method. Interest on short-term investments is included in interest and other income (expense), net.&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000247">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;License and Collaboration Arrangements &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.21%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company may enter into collaboration arrangements that fall under the scope Collaborative Arrangements (Topic 808). The Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808 to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. This assessment is performed throughout the life of the arrangement based on changes in the responsibilities of all parties in the arrangement. The accounting for some of the activities under collaboration arrangements may be analogized to ASC 606 for distinct units of account that are reflective of a vendor-customer relationship.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under ASC 606, in determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when the Company satisfies each performance obligation.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues attributed to the license when the license is transferred to the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the inception of each arrangement that contain development milestones, the Company evaluates whether the development milestones included are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not generally considered probable of being achieved until those approvals are received.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the end of each reporting period, the Company re-evaluates the probability of achievement of any development milestones, and if necessary, adjusts its estimate of the transaction price. Any such adjustments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;would be recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For research and development services, the Company elected the practical expedient to recognize revenue as the research and development services are invoiced.&#160;&#160;As the Company has a right to consideration from the collaboration agreement with Biogen International GmbH (&#x201c;Biogen&#x201d;), in an amount that corresponds directly with the value of the Company&#x2019;s performance completed to date for the research services, the Company recognized revenue related to the research services as invoiced, in line with the practical expedient in ASC 606-10-55-18.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The transaction price is allocated to each performance obligation on a relative stand-alone selling price (&#x201c;SSP&#x201d;) basis. The Company recognizes revenue as or when the performance obligations under the contract are satisfied. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the timing of recognition and the SSP for each performance obligation identified in the contract.&#160;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The SSP for licenses are calculated using the residual approach if the Company has not yet established a price for such license and the license has not previously been sold on a standalone basis.&#160;Otherwise, selling prices for licenses are determined using an income approach model and include key assumptions such as: development timeline, revenue forecast, commercialization expenses, discount rate and probabilities of technical and regulatory success. To estimate the SSP for research and development services, the Company uses a cost-plus margin approach. &lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <cbio:CostOfLicenseAndCollaborationRevenuePolicyTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000248">
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cost of License and Collaboration&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of license revenue includes sublicense fees paid or payable to Mosaic Biosciences, Inc. (&#x201c;Mosaic&#x201d;), incurred in the period, under the terms of the Mosaic collaboration agreement, and fees for patent development and protection paid or payable to other third-party vendors corresponding to the recognition of license revenue from the Company&#x2019;s collaboration agreement with Biogen. See&lt;span style="color:#000000;"&gt; Notes 8 and 12, &lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Related Parties &lt;/span&gt;&lt;span style="color:#000000;"&gt;and&lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt; Collaborations, &lt;/span&gt;&lt;span style="color:#000000;"&gt;respectively. Cost of license revenue does not include any allocated overhead costs.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of collaboration revenue includes fees for research and development services paid or payable to Mosaic and other third-party vendors and personnel cost, incurred in the period pertaining to the Company&#x2019;s agreement with Biogen. See&lt;span style="color:#000000;"&gt; Notes 8 and 12, &lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt;Related Parties &lt;/span&gt;&lt;span style="color:#000000;"&gt;and&lt;/span&gt;&lt;span style="font-style:italic;color:#000000;"&gt; Collaborations, &lt;/span&gt;&lt;span style="color:#000000;"&gt;respectively. Cost of collaboration revenue does not include any allocated overhead costs.&lt;/span&gt;&lt;/p&gt;</cbio:CostOfLicenseAndCollaborationRevenuePolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_0001124105_20210101_20211231" id="F_000249">
&lt;p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services used in research and development are initially deferred and capitalized in prepaid and other current assets. The capitalized amounts are then expensed as the related goods are delivered or services are performed, or until it is no longer expected that the goods or services will be delivered. Research and development costs consist of payroll and other personnel-related expenses, laboratory supplies and reagents, contract research and development services, materials, and consulting costs, as well as allocations of facilities and other overhead costs. Under the Company&#x2019;s collaboration agreement with Biogen, certain specific expenditures are reimbursed by third parties. During the years ended December 31, 2021 and 2020, $6.5 million and $5.4 million, respectively, of research and development expense was recorded as cost of collaboration revenue related to the collaboration agreement with Biogen signed in December 2019.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <cbio:CostOfCollaborationRevenue
      contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231"
      decimals="-5"
      id="F_000284"
      unitRef="U_iso4217USD">6500000</cbio:CostOfCollaborationRevenue>
    <cbio:CostOfCollaborationRevenue
      contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231"
      decimals="-5"
      id="F_000285"
      unitRef="U_iso4217USD">5400000</cbio:CostOfCollaborationRevenue>
    <cbio:AccruedResearchAndDevelopmentExpensesPolicyTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000250">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.81%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accrued Research and Development Expenses&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses include estimated costs of research and development activities conducted by external service providers, which include the conduct of preclinical studies and clinical trials and contract manufacturing activities. The Company records the estimated costs of research and development activities &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;based upon the estimated &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;amount&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; of services provided but not yet invoiced and includes these costs in&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; other&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; accrued liabilities in the consolidated balance sheet and within research and development expense in the consolidated statement of operations. These costs are a significant component of the research and development expenses. The Company records accrued expenses for these costs based on the estimated amount of work completed and in accordance with agreements established with these external service providers.&lt;/span&gt;&lt;/p&gt;</cbio:AccruedResearchAndDevelopmentExpensesPolicyTextBlock>
    <cbio:ConcentrationRiskCreditRiskPolicyTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000251">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, investments and accounts receivable. The Company&#x2019;s investment policy restricts cash investments to high credit quality, investment grade investments. The Company believes that it has established guidelines for investment of its excess cash that maintain safety and liquidity through its policies on high quality of investment and investment duration. The Company is exposed to credit risk in the event of default by the institutions holding the cash and cash equivalents to the extent beyond the amount insured by the federal depository insurance corporation. The Company&#x2019;s accounts receivable as of December 31, 2021 of $1.8 million as well as its total license and collaboration revenue of $7.3 million and $20.9 million for the years ended December 31, 2021 and 2020, respectively, are from one party, see Note 12, &lt;span style="font-style:italic;"&gt;Collaborations&lt;/span&gt;.&#160;&lt;/p&gt;</cbio:ConcentrationRiskCreditRiskPolicyTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="C_0001124105_20211231"
      decimals="-5"
      id="F_000286"
      unitRef="U_iso4217USD">1800000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001124105_20210101_20211231"
      decimals="-5"
      id="F_000287"
      unitRef="U_iso4217USD">7300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy contextRef="C_0001124105_20210101_20211231" id="F_000252">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accounts Receivable and Allowance for Doubtful Accounts&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amounts payable to the Company are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. Customer payments are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligations under the arrangements. The Company continuously monitors collections and payments from its customers and maintains a provision for estimated credit losses. The Company determines its allowance for doubtful accounts by considering a number of factors, including the length of time balances are past due, the Company&#x2019;s previous loss history, the customer&#x2019;s current ability to pay its obligations to the Company and the condition of the general economy and the industry as a whole. The Company writes off accounts receivable when they are determined to be uncollectible. For the years ended December 31, 2021 and 2020, there were no allowance for doubtful accounts deemed necessary.&lt;/p&gt;</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000253">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income taxes are computed using the liability method. Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company follows the authoritative guidance on accounting for uncertainty in income taxes. This guidance prescribes a more-likely-than-not threshold for financial statement recognition and measurement of a tax position taken in the Company&#x2019;s income tax returns. This interpretation also provides guidance on accounting for interest and penalties and associated with tax positions, accounting for income taxes in interim periods and income tax disclosures.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s policy is to include penalties and interest expense related to income taxes as a component of other expense and interest expense, respectively, as necessary.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="C_0001124105_20210101_20211231" id="F_000254">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures the cost of employee, non-employee and director services received in exchange for an award of equity instruments based on the fair value of the award on the date of grant and recognizes the related expense over the period during which the employee, non-employee or director is required to provide service in exchange for the award on a straight-line basis. The estimated fair value of equity awards that contain performance conditions is expensed over the term of the award once the Company has determined that it is probable that performance conditions will be satisfied.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company uses the Black-Scholes option-pricing valuation model to estimate the grant-date fair value of stock-based awards. The determination of fair value for stock-based awards on the date of grant using an option-pricing model requires management to make certain assumptions regarding &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;a number of&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; variables. &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;T&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;he Company &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;elected to &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;account for forfeitures when they occur. As such, the Company recognizes stock-based compensation expense, over their requisite service period, based on the vesting provisions of the individual grants.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy contextRef="C_0001124105_20210101_20211231" id="F_000255">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Restructuring Charges&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs and liabilities associated with restructuring are recorded in the period management commits to a restructuring or cost reduction plan, or executes specific actions contemplated by the plan and all criteria for liability recognition have been met. One-time employee termination costs are recognized at the time of communication to employees, unless future service is required, in which case the costs are recognized ratably over the future service period. Restructuring charges are recognized as an operating expense within the consolidated statements of operations and related liabilities are recorded within accrued compensation on the consolidated balance sheets. The Company periodically evaluates and, if necessary, adjusts its estimates based on currently available information.&lt;/p&gt;</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000257">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000258">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss per Share Attributable to Common Stockholders&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss of the Company for all periods presented.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000226">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Fair Value Measurements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For a description of the fair value hierarchy and fair value methodology, see Note 3,&lt;span style="font-style:italic;"&gt; Summary of Significant Accounting Policies&lt;/span&gt;. As of December 31, 2021 and 2020, the Company&#x2019;s highly liquid money market funds included within cash equivalents and U.S. government agency securities are valued using Level&#160;1 inputs. The Company classifies its federal agency securities as Level 2. There were no transfers in or out of Level 1 and Level 2 during the periods presented. U.S. government agency securities are bonds issued by the U.S. government and are fully backed by the U.S. government. Given the frequency at which U.S. government agency securities trade and the accessibility of observable, quoted prices for such assets in active markets, they are recognized as Level 1 assets. Federal agency securities are bonds and notes issued by government-sponsored enterprises, including Fannie Mae, Freddie Mac and the Federal Home Loan Bank. Since Federal agency securities typically do not trade as U.S. government agency securities and no exchange exists to price such investments, they are recognized as Level 2 assets. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables present the fair value hierarchy for assets measured at fair value on a recurring basis as of December 31, 2021 and 2020 &lt;span style="font-style:italic;"&gt;(in thousands)&lt;/span&gt;:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(&lt;/sup&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency securities&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(&lt;/sup&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,504&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,504&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,851&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,851&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(&lt;/sup&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency securities&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(&lt;/sup&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,837&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,837&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal agency securities&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(&lt;/sup&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68,197&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,897&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:6pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"&gt;Included in cash and cash equivalents on accompanying consolidated balance sheet.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"&gt;Included in short-term investments on accompanying consolidated balance sheet and are classified as available-for-sale debt securities. $2.5 million of U.S. government agency securities as of December 31, 2020 are included in long-term investments on the accompanying consolidated balance sheets due to the maturity being more than 12 months. &#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-0.43%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts of cash, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to the short-term maturity of these instruments.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000259">
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables present the fair value hierarchy for assets measured at fair value on a recurring basis as of December 31, 2021 and 2020 &lt;span style="font-style:italic;"&gt;(in thousands)&lt;/span&gt;:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(&lt;/sup&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency securities&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(&lt;/sup&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,504&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,504&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,851&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,851&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(&lt;/sup&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency securities&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(&lt;/sup&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,837&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,837&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal agency securities&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(&lt;/sup&gt;&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;68,197&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,897&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:6pt;font-family:Times New Roman;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"&gt;Included in cash and cash equivalents on accompanying consolidated balance sheet.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;"&gt;Included in short-term investments on accompanying consolidated balance sheet and are classified as available-for-sale debt securities. $2.5 million of U.S. government agency securities as of December 31, 2020 are included in long-term investments on the accompanying consolidated balance sheets due to the maturity being more than 12 months. &#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:-0.43%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts of cash, accounts receivable, accounts payable and accrued liabilities approximate their fair values due to the short-term maturity of these instruments.&lt;/p&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231"
      decimals="-3"
      id="F_000289"
      unitRef="U_iso4217USD">44347000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20211231"
      decimals="-3"
      id="F_000290"
      unitRef="U_iso4217USD">44347000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000291"
      unitRef="U_iso4217USD">2504000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000292"
      unitRef="U_iso4217USD">2504000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20211231"
      decimals="-3"
      id="F_000293"
      unitRef="U_iso4217USD">46851000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000294"
      unitRef="U_iso4217USD">46851000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231"
      decimals="-3"
      id="F_000295"
      unitRef="U_iso4217USD">30360000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000296"
      unitRef="U_iso4217USD">30360000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000297"
      unitRef="U_iso4217USD">37837000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000298"
      unitRef="U_iso4217USD">37837000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231"
      decimals="-3"
      id="F_000299"
      unitRef="U_iso4217USD">13700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231"
      decimals="-3"
      id="F_000300"
      unitRef="U_iso4217USD">13700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231"
      decimals="-3"
      id="F_000301"
      unitRef="U_iso4217USD">68197000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_20201231"
      decimals="-3"
      id="F_000302"
      unitRef="U_iso4217USD">13700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000303"
      unitRef="U_iso4217USD">81897000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_cbioLongTermInvestmentsMember_20211231"
      decimals="-5"
      id="F_000288"
      unitRef="U_iso4217USD">2500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000227">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Financial Instruments&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents and investments (debt securities) which are classified as available-for-sale securities, consisted of the following &lt;span style="font-style:italic;"&gt;(in thousands)&lt;/span&gt;:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds (cash equivalents)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,504&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,504&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,851&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,851&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Classified as:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,504&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,851&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds (cash equivalents)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,835&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,837&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,697&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,892&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,897&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Classified as:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,994&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,543&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,897&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There have been no material realized gains or losses on available-for-sale debt securities for the periods presented. As of December 31, 2021, the remaining contractual maturities of $2.5 million of available-for-sale debt securities were less than one year. &lt;/p&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <cbio:SaleSecuritiesAvailableTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000260">
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents and investments (debt securities) which are classified as available-for-sale securities, consisted of the following &lt;span style="font-style:italic;"&gt;(in thousands)&lt;/span&gt;:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds (cash equivalents)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,504&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,504&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,851&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,851&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Classified as:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44,347&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,504&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;46,851&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds (cash equivalents)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,835&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,837&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal agency securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,697&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,892&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,897&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Classified as:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,360&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Short-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;48,994&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-term investments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,543&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;81,897&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</cbio:SaleSecuritiesAvailableTextBlock>
    <cbio:AmortizedCostAvailableForSaleSecurities
      contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231"
      decimals="-3"
      id="F_000304"
      unitRef="U_iso4217USD">44347000</cbio:AmortizedCostAvailableForSaleSecurities>
    <cbio:SaleSecuritiesAvailable
      contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20211231"
      decimals="-3"
      id="F_000307"
      unitRef="U_iso4217USD">44347000</cbio:SaleSecuritiesAvailable>
    <cbio:AmortizedCostAvailableForSaleSecurities
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000305"
      unitRef="U_iso4217USD">2504000</cbio:AmortizedCostAvailableForSaleSecurities>
    <cbio:SaleSecuritiesAvailable
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20211231"
      decimals="-3"
      id="F_000308"
      unitRef="U_iso4217USD">2504000</cbio:SaleSecuritiesAvailable>
    <cbio:AmortizedCostAvailableForSaleSecurities
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000306"
      unitRef="U_iso4217USD">46851000</cbio:AmortizedCostAvailableForSaleSecurities>
    <cbio:SaleSecuritiesAvailable
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000309"
      unitRef="U_iso4217USD">46851000</cbio:SaleSecuritiesAvailable>
    <cbio:SaleSecuritiesAvailable
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20211231"
      decimals="-3"
      id="F_000310"
      unitRef="U_iso4217USD">44347000</cbio:SaleSecuritiesAvailable>
    <cbio:SaleSecuritiesAvailable
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20211231"
      decimals="-3"
      id="F_000311"
      unitRef="U_iso4217USD">2504000</cbio:SaleSecuritiesAvailable>
    <cbio:SaleSecuritiesAvailable
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000312"
      unitRef="U_iso4217USD">46851000</cbio:SaleSecuritiesAvailable>
    <cbio:AmortizedCostAvailableForSaleSecurities
      contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000313"
      unitRef="U_iso4217USD">30360000</cbio:AmortizedCostAvailableForSaleSecurities>
    <cbio:SaleSecuritiesAvailable
      contextRef="C_0001124105_us-gaapCashAndCashEquivalentsAxis_us-gaapCashEquivalentsMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20201231"
      decimals="-3"
      id="F_000320"
      unitRef="U_iso4217USD">30360000</cbio:SaleSecuritiesAvailable>
    <cbio:AmortizedCostAvailableForSaleSecurities
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000314"
      unitRef="U_iso4217USD">37835000</cbio:AmortizedCostAvailableForSaleSecurities>
    <cbio:AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000317"
      unitRef="U_iso4217USD">2000</cbio:AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities>
    <cbio:SaleSecuritiesAvailable
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_20201231"
      decimals="-3"
      id="F_000321"
      unitRef="U_iso4217USD">37837000</cbio:SaleSecuritiesAvailable>
    <cbio:AmortizedCostAvailableForSaleSecurities
      contextRef="C_0001124105_us-gaapFinancialInstrumentAxis_cbioFederalAgencySecuritiesMember_20201231"
      decimals="-3"
      id="F_000315"
      unitRef="U_iso4217USD">13697000</cbio:AmortizedCostAvailableForSaleSecurities>
    <cbio:AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities
      contextRef="C_0001124105_us-gaapFinancialInstrumentAxis_cbioFederalAgencySecuritiesMember_20201231"
      decimals="-3"
      id="F_000318"
      unitRef="U_iso4217USD">3000</cbio:AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities>
    <cbio:SaleSecuritiesAvailable
      contextRef="C_0001124105_us-gaapFinancialInstrumentAxis_cbioFederalAgencySecuritiesMember_20201231"
      decimals="-3"
      id="F_000322"
      unitRef="U_iso4217USD">13700000</cbio:SaleSecuritiesAvailable>
    <cbio:AmortizedCostAvailableForSaleSecurities
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000316"
      unitRef="U_iso4217USD">81892000</cbio:AmortizedCostAvailableForSaleSecurities>
    <cbio:AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000319"
      unitRef="U_iso4217USD">5000</cbio:AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities>
    <cbio:SaleSecuritiesAvailable
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000323"
      unitRef="U_iso4217USD">81897000</cbio:SaleSecuritiesAvailable>
    <cbio:SaleSecuritiesAvailable
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapCashAndCashEquivalentsMember_20201231"
      decimals="-3"
      id="F_000324"
      unitRef="U_iso4217USD">30360000</cbio:SaleSecuritiesAvailable>
    <cbio:SaleSecuritiesAvailable
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapShortTermInvestmentsMember_20201231"
      decimals="-3"
      id="F_000325"
      unitRef="U_iso4217USD">48994000</cbio:SaleSecuritiesAvailable>
    <cbio:SaleSecuritiesAvailable
      contextRef="C_0001124105_us-gaapInvestmentTypeAxis_us-gaapOtherLongTermInvestmentsMember_20201231"
      decimals="-3"
      id="F_000326"
      unitRef="U_iso4217USD">2543000</cbio:SaleSecuritiesAvailable>
    <cbio:SaleSecuritiesAvailable
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000327"
      unitRef="U_iso4217USD">81897000</cbio:SaleSecuritiesAvailable>
    <cbio:GrossRealizedGainLossNetAvailableForSalesSecurities
      contextRef="C_0001124105_20210101_20211231"
      decimals="INF"
      id="F_000328"
      unitRef="U_iso4217USD">0</cbio:GrossRealizedGainLossNetAvailableForSalesSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001124105_20211231"
      decimals="-5"
      id="F_000329"
      unitRef="U_iso4217USD">2500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <cbio:AvailableForSaleDebtSecuritiesContractualMaturity
      contextRef="C_0001124105_srtRangeAxis_srtMaximumMember_20210101_20211231"
      id="F_000330">P1Y</cbio:AvailableForSaleDebtSecuritiesContractualMaturity>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000228">
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.&lt;/span&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Other Accrued Liabilities &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other accrued liabilities consisted of the following &lt;span style="font-style:italic;"&gt;(in thousands)&lt;/span&gt;:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Manufacturing&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,381&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,238&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Biogen&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;868&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pre-clinical&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;773&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional and consulting services&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;509&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,979&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Clinical&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;361&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;291&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;180&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;235&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total other accrued liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,072&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,743&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000261">
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other accrued liabilities consisted of the following &lt;span style="font-style:italic;"&gt;(in thousands)&lt;/span&gt;:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Manufacturing&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,381&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,238&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Biogen&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;868&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pre-clinical&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;773&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Professional and consulting services&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;509&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,979&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Clinical&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;361&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.9%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;291&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;180&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;235&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.46%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total other accrued liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4.68%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,072&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.9%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,743&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <cbio:AccruedManufacturingExpensesCurrent
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000331"
      unitRef="U_iso4217USD">1381000</cbio:AccruedManufacturingExpensesCurrent>
    <cbio:AccruedManufacturingExpensesCurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000332"
      unitRef="U_iso4217USD">2238000</cbio:AccruedManufacturingExpensesCurrent>
    <cbio:AccruedCollaborationExpensesCurrent
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000333"
      unitRef="U_iso4217USD">868000</cbio:AccruedCollaborationExpensesCurrent>
    <cbio:AccruedPreClinicalExpensesCurrent
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000334"
      unitRef="U_iso4217USD">773000</cbio:AccruedPreClinicalExpensesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000335"
      unitRef="U_iso4217USD">509000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000336"
      unitRef="U_iso4217USD">3979000</us-gaap:AccruedProfessionalFeesCurrent>
    <cbio:AccruedClinicalExpensesCurrent
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000337"
      unitRef="U_iso4217USD">361000</cbio:AccruedClinicalExpensesCurrent>
    <cbio:AccruedClinicalExpensesCurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000338"
      unitRef="U_iso4217USD">291000</cbio:AccruedClinicalExpensesCurrent>
    <cbio:AccruedAndOtherCurrentLiabilities
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000339"
      unitRef="U_iso4217USD">180000</cbio:AccruedAndOtherCurrentLiabilities>
    <cbio:AccruedAndOtherCurrentLiabilities
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000340"
      unitRef="U_iso4217USD">235000</cbio:AccruedAndOtherCurrentLiabilities>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000341"
      unitRef="U_iso4217USD">4072000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000342"
      unitRef="U_iso4217USD">6743000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000229">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Commitments and Contingencies &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Manufacturing Agreements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On May 20, 2016, the Company signed a development and manufacturing services agreement with AGC Biologics, Inc. (&#x201c;AGC&#x201d;), pursuant to which AGC will conduct manufacturing development of agreed upon product candidates. The Company had firm work orders with AGC to manufacture MarzAA and DalcA to support its clinical trials totaling $15.8 million and the payment obligations were fully paid off as of December 31, 2021. The Company also signed an agreement with AGC to perform certain manufacturing services related to the Company&#x2019;s collaboration agreement with Biogen, which includes firm work orders totaling $0.7 million and the payment obligations remaining as of December 31, 2021 were $0.3 million.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2021, the Company entered into two separate agreements, one for additional clinical trial services for MarzAA, and another for the Company&#x2019;s screening and natural history of disease clinical studies related to CFI deficiency, with total payments of up to $3.2 million and $6.5 million, respectively. In November 2021, the Company provided notice of intent to terminate its MarzAA manufacturing agreements and incurred charges of $3.8 million to write-off prepaid manufacturing costs that will no longer be used for the clinical development of MarzAA, see Note 16, &lt;span style="font-style:italic;"&gt;Restructuring&lt;/span&gt;. The Company can terminate the CFI agreement at its discretion and upon termination will be responsible to pay for those services incurred prior to termination plus reasonable wind-down expenses.&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 16, 2021, the Company signed a Manufacturing and Research and Development Studies Agreement to support the lyophilized drug product, CB4332. The agreement will cover analytical method qualification to support good manufacturing practices (&#x201c;GMP&#x201d;) manufacturing. The Company currently has firm work orders related to this agreement totaling $0.2 million and the payment obligations were fully paid off as of December 31, 2021.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;COVID-19&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The current COVID-19 pandemic has presented a substantial public health and economic challenge around the world and is affecting the Company&#x2019;s employees, potential trial participants and business operations. The full extent to which the COVID-19 pandemic will directly or indirectly impact the Company&#x2019;s business, results of operations and financial condition will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19, the actions taken to contain it or treat its impact and the economic impact on local, regional, national, and international markets. The COVID-19 pandemic may disrupt the operations of the Company&#x2019;s manufacturers or disrupt supply logistics, which could impact the timing of deliveries and potentially increase expenses under our agreements. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is actively monitoring the impact of COVID-19 and the possible effects on its financial condition, liquidity, operations, clinical trials, suppliers, &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;industry&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and workforce.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <cbio:FirmWorkOrderSupportingClinicalTrials
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioAGCBiologicsIncMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_20211231"
      decimals="-5"
      id="F_000343"
      unitRef="U_iso4217USD">15800000</cbio:FirmWorkOrderSupportingClinicalTrials>
    <cbio:CostOfManufacturingServices
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioAGCBiologicsIncMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapServiceAgreementsMember_20211231"
      decimals="-5"
      id="F_000347"
      unitRef="U_iso4217USD">700000</cbio:CostOfManufacturingServices>
    <us-gaap:ContractualObligation
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioAGCBiologicsIncMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapServiceAgreementsMember_20211231"
      decimals="-5"
      id="F_000348"
      unitRef="U_iso4217USD">300000</us-gaap:ContractualObligation>
    <cbio:CostOfServicesAsPerAgreement
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioMarzeptacogAlfaActivatedMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapServiceAgreementsMember_20211231"
      decimals="-5"
      id="F_000344"
      unitRef="U_iso4217USD">3200000</cbio:CostOfServicesAsPerAgreement>
    <cbio:CostOfServicesAsPerAgreement
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioMarzeptacogAlfaActivatedMember_srtProductOrServiceAxis_cbioDalcinonacogAlfaMember_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapServiceAgreementsMember_20211231"
      decimals="-5"
      id="F_000345"
      unitRef="U_iso4217USD">6500000</cbio:CostOfServicesAsPerAgreement>
    <cbio:ChargesRelatedToWriteOffOfPrepaidManufacturingCost
      contextRef="C_0001124105_20211101_20211130"
      decimals="-5"
      id="F_000349"
      unitRef="U_iso4217USD">3800000</cbio:ChargesRelatedToWriteOffOfPrepaidManufacturingCost>
    <cbio:FirmWorkOrderSupportingClinicalTrials
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIntegrityBioMember_srtProductOrServiceAxis_cbioGMPMember_20211231"
      decimals="-5"
      id="F_000346"
      unitRef="U_iso4217USD">200000</cbio:FirmWorkOrderSupportingClinicalTrials>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000230">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;8&lt;/span&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Related Parties&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 24, 2017, the Company announced a strategic research collaboration with Mosaic to develop intravitreal anti-complement factor C3 products for the treatment of dry AMD and other retinal diseases. &lt;span style="color:#000000;"&gt;Dr. Usman, the Company&#x2019;s Chief Executive Officer and a member of the Company&#x2019;s board of directors, and Mr. Lawlor, a member of the Company&#x2019;s board of directors, were also members of the board of directors of Mosaic. On December 21, 2018, the Company amended its collaboration agreement with Mosaic to, among other things, include certain additional products. According to the Mosaic collaboration agreement, as amended, the Company and Mosaic co-funded certain research.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On December 18, 2019, the Company entered into the second amendment to the Mosaic collaboration agreement following completion of the co-funded research. Pursuant to the second amendment, any future services provided by Mosaic will be performed on a fee-for-service basis. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the Company&#x2019;s collaboration agreement with Biogen, the Company received a $15.0 million upfront license fee on January 10, 2020, see Note 12, &lt;span style="font-style:italic;"&gt;Collaborations&lt;/span&gt;. As a result, the Company paid Mosaic a $3.0 million sublicense fee and recorded such payment as cost of license revenue for the year ended December 31, 2020.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On May 8, 2020, the Company entered into a subsequent amendment to the Mosaic collaboration agreement. As part of this amendment, the Company paid a one-time $0.8 million cash payment to Mosaic, and Mosaic is eligible to receive up to $4.0 million in potential future milestone payments related to regulatory and clinical development events for CB 2782-PEG and an additional anti-complement product candidate in lieu of the Company&#x2019;s obligations to pay Mosaic a double-digit percentage of funds the Company receives from Biogen or any other amounts the Company receives related to sublicense fees, research and development payments, or any other research, regulatory, clinical or commercial milestones and royalties on any other development candidates. The Company now owns one hundred percent of all future payment streams related to these product candidates.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of June 30, 2020, Mosaic was no longer a related party.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <cbio:UpfrontFeeReveivedFromLicenseAndCollaborationAgreement
      contextRef="C_0001124105_srtProductOrServiceAxis_cbioIntravitrealAntiComplementFactor3Member_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_us-gaapTypeOfArrangementAxis_cbioBiogenCollaborationMember_20200110"
      decimals="-5"
      id="F_000350"
      unitRef="U_iso4217USD">15000000.0</cbio:UpfrontFeeReveivedFromLicenseAndCollaborationAgreement>
    <cbio:SublicenseFee
      contextRef="C_0001124105_srtProductOrServiceAxis_cbioIntravitrealAntiComplementFactor3Member_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200101_20201231"
      decimals="-5"
      id="F_000351"
      unitRef="U_iso4217USD">3000000.0</cbio:SublicenseFee>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="C_0001124105_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200508_20200508"
      decimals="-5"
      id="F_000352"
      unitRef="U_iso4217USD">800000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <cbio:MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents
      contextRef="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200508_20200508"
      decimals="-5"
      id="F_000353"
      unitRef="U_iso4217USD">4000000.0</cbio:MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000231">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Leases&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. In calculating the present value of the lease payments, the Company has elected to utilize its incremental borrowing rate based on the original lease term and not the remaining lease term. The lease includes non-lease components (&lt;span style="font-style:italic;"&gt;e.g.&lt;/span&gt;, common area maintenance) that are paid separately from rent based on actual costs incurred and, therefore, were not included in the right-of-use asset and lease liability but are reflected as an expense in the period incurred.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company leases office space for its corporate headquarters, located in South San Francisco, CA. The lease term is through April 30, 2023 and there are no stated renewal options. On July 17, 2020, the Company entered into an amendment to its existing lease agreement to lease additional office space for an aggregated undiscounted future monthly payment of $0.5 million. The amendment was treated as a separate lease with a lease term of 2.6 years and commenced during the fourth quarter of 2020.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2021, the Company entered into a license agreement (the &#x201c;License Agreement&#x201d;) for the use of laboratory facilities in South San Francisco, CA, for an aggregated undiscounted future payment of $1.9 million. This License Agreement has an original lease term of one year and a renewal period of six months. This License Agreement commenced during the second quarter of 2021.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2021, the Company amended the License Agreement to extend the lease term for a period of one year. The amendment was not accounted for as a separate &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;lease, and&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; resulted in an adjustment to the right-of-use asset&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and lease liability of $&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.6&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. The amended lease will expire at the end of April 2023.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the years ended December 31, 2021 and 2020, the Company&#x2019;s operating lease expense was $1.7 million and $0.7 million, respectively. The present value assumptions used in calculating the present value of the lease payments were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average remaining lease term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.3 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The maturity of the Company&#x2019;s operating lease liabilities as of&#160;December&#160;31, 2021 were as follows&#160;&lt;span style="font-style:italic;"&gt;(in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,044&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;410&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,454&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(69&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,385&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. The Company did not incur significant variable lease costs for the years ended December 31, 2021 and 2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental cash flow information related to operating leases was as follows&#160;&lt;span style="font-style:italic;"&gt;(in thousands)&lt;/span&gt;:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,641&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;602&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid cash payment for lease&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;208&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for operating leases that were included in operating cash outflows&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,849&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;602&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LeaseExpirationDate1 contextRef="C_0001124105_20210101_20211231" id="F_000354">2023-04-30</us-gaap:LeaseExpirationDate1>
    <cbio:LesseeOperatingLeaseRenewalTermDescription contextRef="C_0001124105_20210101_20211231" id="F_000355">no stated renewal options</cbio:LesseeOperatingLeaseRenewalTermDescription>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0001124105_20200717"
      decimals="-5"
      id="F_000362"
      unitRef="U_iso4217USD">500000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="C_0001124105_20200717" id="F_000361">P2Y7M6D</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedDescription contextRef="C_0001124105_20200716_20200717" id="F_000360">commenced during the fourth quarter of 2020.</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedDescription>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0001124105_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioLeaseLabAndOfficeSpaceMember_us-gaapTypeOfArrangementAxis_cbioSubleaseArrangementMember_20210430"
      decimals="-5"
      id="F_000357"
      unitRef="U_iso4217USD">1900000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_0001124105_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioLeaseLabAndOfficeSpaceMember_us-gaapTypeOfArrangementAxis_cbioSubleaseArrangementMember_20210401_20210430"
      id="F_000358">This License Agreement has an original lease term of one year and a renewal period of six months</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_0001124105_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioLeaseLabAndOfficeSpaceMember_us-gaapTypeOfArrangementAxis_cbioSubleaseArrangementMember_20210401_20210430"
      id="F_000359">commenced during the second quarter of 2021</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0001124105_20211001_20211031"
      decimals="-5"
      id="F_000356"
      unitRef="U_iso4217USD">600000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001124105_20210101_20211231"
      decimals="-5"
      id="F_000363"
      unitRef="U_iso4217USD">1700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001124105_20200101_20201231"
      decimals="-5"
      id="F_000364"
      unitRef="U_iso4217USD">700000</us-gaap:OperatingLeaseExpense>
    <cbio:SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000262">The present value assumptions used in calculating the present value of the lease payments were as follows:
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average remaining lease term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.3 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.84%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.3 years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.84%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;</cbio:SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001124105_20211231" id="F_000365">P1Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001124105_20201231" id="F_000366">P2Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001124105_20211231"
      decimals="3"
      id="F_000367"
      unitRef="U_xbrlipure">0.048</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001124105_20201231"
      decimals="3"
      id="F_000368"
      unitRef="U_xbrlipure">0.057</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000263">
&lt;p style="margin-bottom:0pt;margin-top:2pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The maturity of the Company&#x2019;s operating lease liabilities as of&#160;December&#160;31, 2021 were as follows&#160;&lt;span style="font-style:italic;"&gt;(in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ending December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,044&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;410&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,454&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="middle"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(69&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,385&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000369"
      unitRef="U_iso4217USD">2044000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000370"
      unitRef="U_iso4217USD">410000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000371"
      unitRef="U_iso4217USD">2454000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000372"
      unitRef="U_iso4217USD">69000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000373"
      unitRef="U_iso4217USD">2385000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000264">
&lt;p style="margin-bottom:0pt;margin-top:2pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. The Company did not incur significant variable lease costs for the years ended December 31, 2021 and 2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental cash flow information related to operating leases was as follows&#160;&lt;span style="font-style:italic;"&gt;(in thousands)&lt;/span&gt;:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,641&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;602&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid cash payment for lease&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;208&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for operating leases that were included in operating cash outflows&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,849&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;602&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <cbio:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000374"
      unitRef="U_iso4217USD">1641000</cbio:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities>
    <cbio:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000375"
      unitRef="U_iso4217USD">602000</cbio:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities>
    <cbio:PrepaidCashPaymentForLeaseLiabilities
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000376"
      unitRef="U_iso4217USD">208000</cbio:PrepaidCashPaymentForLeaseLiabilities>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000377"
      unitRef="U_iso4217USD">1849000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000378"
      unitRef="U_iso4217USD">602000</us-gaap:OperatingLeasePayments>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000232">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Stock Based Compensation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;2018 Omnibus Incentive Plan &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2018, stockholders of the Company approved the Company&#x2019;s 2018 Omnibus Incentive Plan (the &#x201c;2018 Plan&#x201d;). The 2018 Plan had previously been approved by the Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;) and the Compensation Committee (the &#x201c;Committee&#x201d;) of the Board, subject to stockholder approval. The 2018 Plan became effective on June 13, 2018. On June 9, 2021, the stockholders of the Company approved an amendment previously approved by the Board to increase the number of shares of common stock reserved for issuance under the 2018 Plan by 2,500,000 to a total of 5,300,000 shares. The amendment became effective immediately upon stockholder approval.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Performance-Based Stock Option Grants&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2021, the Committee approved the issuance of option grants to purchase 647,000 shares of common stock for executive officers pursuant to the 2018 Plan, which will vest upon (a) the achievement of specified performance goals and (b) the grantees&#x2019; continued employment during the service period specified in each grant. For the year ended December 31, 2021, no expense has been recognized related to these awards. In &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;addition, the options &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;never vested and expired &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;since the performance conditions were not satisfied as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes stock option activity under the Company&#x2019;s 2018 Plan and related information:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&#160;of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Underlying&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding &#x2014; December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,577,541&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000407"&gt;8.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,350&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,091,250&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.26&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(44,605&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.04&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(250,641&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.32&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options expired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17,930&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51.12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding &#x2014; December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,355,615&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.59&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000408"&gt;7.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,337&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,493,238&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.31&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.63&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,239,630&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.26&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options expired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(593&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;566.33&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding &#x2014; December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,603,630&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.70&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000409"&gt;7.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable &#x2014; December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,513,039&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000410"&gt;6.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares available to be granted &#x2014; December 31,&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,333,791&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.07%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average grant date fair value of options granted during the years ended December 31, 2021 and 2020 was $4.00 and $5.20, respectively.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.07%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate intrinsic value of options exercised during the years ended December 31, 2021 and 2020 was $3,000 and $0.1 million, respectively.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.07%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of options vested during the years ended December 31, 2021 and 2020 was $2.6 million and $3.0 million, respectively.&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Valuation Assumptions&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company estimated the fair value of stock options granted using the Black-Scholes option-pricing formula and a single option award approach. Due to its limited history as a public company and limited number of sales of its common stock, the Company estimated its volatility considering a number of factors including the use of the volatility of comparable public companies. The expected term of options granted under the Plan, all of which qualify as &#x201c;plain vanilla&#x201d; per SEC Staff Accounting Bulletin 107, is determined based on the simplified method due to the Company&#x2019;s limited operating history. The risk-free rate is based on the yield of a U.S. Treasury security with a term consistent with the option. This fair value is being amortized ratably over the requisite service periods of the awards, which is generally the vesting period.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of employee stock options was estimated using the following&#160;weighted-average assumptions:&lt;span style="color:#000000;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee Stock Options:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000419"&gt;6.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000420"&gt;5.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.84&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.91&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;93.25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;113.36&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation recognized was as follows &lt;span style="font-style:italic;"&gt;(in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,202&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,487&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt; (1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,203&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,140&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,405&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,627&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:8pt;color:#000000;"&gt;Included in general and administrative stock-based compensation for the years ended December 31, 2021 and 2020 is $0.3 million and $0.3 million in expense related to 56,912 shares and 51,056 shares of common stock, respectively, issued to certain board members in lieu of their cash compensation.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.19%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, the Company had unrecognized employee stock-based compensation expense of $3.9 million, related to unvested stock option awards, which is expected to be recognized over an estimated weighted-average period of 2.49 years.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Employee Stock Purchase Plan&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2018, the Company&#x2019;s stockholders approved the 2018 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). The ESPP had previously been approved by the Board and the Compensation Committee of the Board, subject to stockholder approval which became effective as of June 13, 2018. Under the ESPP, employees meeting certain specific employment qualifications are eligible to participate and can purchase shares of common stock semi-annually on February 9&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;th&lt;/sup&gt; and August 9&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;th&lt;/sup&gt; of each year, through payroll deductions. The purchase price is 85% of the lower of the fair market value of the stock at the commencement or end of the offering period. The ESPP permits eligible employees to purchase shares of common stock through payroll deductions for up to 15% of qualified compensation.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s ESPP is subject to an Evergreen provision which shares may be added to the pool as needed. As of December 31, 2021, a total of 359,545 shares of common stock may be granted in accordance with the terms of the ESPP.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the year ended December 31, 2021, a total of 64,975 shares of common stock for $0.3 million have been issued to employees participating in the two ESPP purchases during 2021 and 235,469 shares are available for issuance under the ESPP as of December 31, 2021.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense for the ESPP was $0.1 million and $0.1 million for the years ended December 31, 2021 and 2020, respectively, and is included in total stock-based compensation recognized.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease
      contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenOmnibusIncentivePlanMember_20210609_20210609"
      decimals="INF"
      id="F_000379"
      unitRef="U_xbrlishares">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenOmnibusIncentivePlanMember_20210609"
      decimals="INF"
      id="F_000380"
      unitRef="U_xbrlishares">5300000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <cbio:IssuanceOfOptionGrantsToPurchaseCommonStockShares
      contextRef="C_0001124105_us-gaapAwardTypeAxis_cbioPerformanceBasedStockOptionGrantsMember_us-gaapPlanNameAxis_cbioTwoThousandEighteenOmnibusIncentivePlanMember_20210228"
      decimals="INF"
      id="F_000381"
      unitRef="U_xbrlishares">647000</cbio:IssuanceOfOptionGrantsToPurchaseCommonStockShares>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000265">
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes stock option activity under the Company&#x2019;s 2018 Plan and related information:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&#160;of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Underlying&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding &#x2014; December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,577,541&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000407"&gt;8.15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,350&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,091,250&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.26&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(44,605&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.04&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(250,641&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.32&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options expired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17,930&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51.12&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding &#x2014; December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,355,615&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.59&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000408"&gt;7.96&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,337&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,493,238&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.31&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.63&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,239,630&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.26&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options expired&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(593&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;566.33&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding &#x2014; December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,603,630&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.70&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000409"&gt;7.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable &#x2014; December 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,513,039&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000410"&gt;6.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares available to be granted &#x2014; December 31,&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,333,791&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001124105_20191231"
      decimals="INF"
      id="F_000382"
      unitRef="U_xbrlishares">1577541</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001124105_20191231"
      decimals="2"
      id="F_000395"
      unitRef="U_iso4217USD_xbrlishares">10.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000411"
      unitRef="U_iso4217USD">1350000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001124105_20200101_20201231"
      decimals="INF"
      id="F_000383"
      unitRef="U_xbrlishares">1091250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001124105_20200101_20201231"
      decimals="2"
      id="F_000396"
      unitRef="U_iso4217USD_xbrlishares">6.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001124105_20200101_20201231"
      decimals="INF"
      id="F_000384"
      unitRef="U_xbrlishares">44605</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001124105_20200101_20201231"
      decimals="2"
      id="F_000397"
      unitRef="U_iso4217USD_xbrlishares">5.04</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001124105_20200101_20201231"
      decimals="INF"
      id="F_000385"
      unitRef="U_xbrlishares">250641</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0001124105_20200101_20201231"
      decimals="2"
      id="F_000398"
      unitRef="U_iso4217USD_xbrlishares">10.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_0001124105_20200101_20201231"
      decimals="INF"
      id="F_000386"
      unitRef="U_xbrlishares">17930</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001124105_20200101_20201231"
      decimals="2"
      id="F_000399"
      unitRef="U_iso4217USD_xbrlishares">51.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001124105_20201231"
      decimals="INF"
      id="F_000387"
      unitRef="U_xbrlishares">2355615</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001124105_20201231"
      decimals="2"
      id="F_000400"
      unitRef="U_iso4217USD_xbrlishares">8.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000412"
      unitRef="U_iso4217USD">1337000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001124105_20210101_20211231"
      decimals="INF"
      id="F_000388"
      unitRef="U_xbrlishares">1493238</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001124105_20210101_20211231"
      decimals="2"
      id="F_000401"
      unitRef="U_iso4217USD_xbrlishares">5.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001124105_20210101_20211231"
      decimals="INF"
      id="F_000389"
      unitRef="U_xbrlishares">5000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001124105_20210101_20211231"
      decimals="2"
      id="F_000402"
      unitRef="U_iso4217USD_xbrlishares">4.63</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001124105_20210101_20211231"
      decimals="INF"
      id="F_000390"
      unitRef="U_xbrlishares">1239630</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0001124105_20210101_20211231"
      decimals="2"
      id="F_000403"
      unitRef="U_iso4217USD_xbrlishares">6.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_0001124105_20210101_20211231"
      decimals="INF"
      id="F_000391"
      unitRef="U_xbrlishares">593</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001124105_20210101_20211231"
      decimals="2"
      id="F_000404"
      unitRef="U_iso4217USD_xbrlishares">566.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001124105_20211231"
      decimals="INF"
      id="F_000392"
      unitRef="U_xbrlishares">2603630</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001124105_20211231"
      decimals="2"
      id="F_000405"
      unitRef="U_iso4217USD_xbrlishares">7.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0001124105_20211231"
      decimals="INF"
      id="F_000393"
      unitRef="U_xbrlishares">1513039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0001124105_20211231"
      decimals="2"
      id="F_000406"
      unitRef="U_iso4217USD_xbrlishares">9.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001124105_20211231"
      decimals="INF"
      id="F_000394"
      unitRef="U_xbrlishares">3333791</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001124105_20210101_20211231"
      decimals="2"
      id="F_000413"
      unitRef="U_iso4217USD_xbrlishares">4.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001124105_20200101_20201231"
      decimals="2"
      id="F_000414"
      unitRef="U_iso4217USD_xbrlishares">5.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001124105_20210101_20211231"
      decimals="0"
      id="F_000415"
      unitRef="U_iso4217USD">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001124105_20200101_20201231"
      decimals="-5"
      id="F_000416"
      unitRef="U_iso4217USD">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_0001124105_20210101_20211231"
      decimals="-5"
      id="F_000417"
      unitRef="U_iso4217USD">2600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_0001124105_20200101_20201231"
      decimals="-5"
      id="F_000418"
      unitRef="U_iso4217USD">3000000.0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000266">The fair value of employee stock options was estimated using the following&#160;weighted-average assumptions:
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee Stock Options:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000419"&gt;6.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000420"&gt;5.81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.84&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.91&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;93.25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;113.36&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231"
      decimals="4"
      id="F_000421"
      unitRef="U_xbrlipure">0.0084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="4"
      id="F_000422"
      unitRef="U_xbrlipure">0.0091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231"
      decimals="2"
      id="F_000423"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="2"
      id="F_000424"
      unitRef="U_xbrlipure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231"
      decimals="4"
      id="F_000425"
      unitRef="U_xbrlipure">0.9325</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="4"
      id="F_000426"
      unitRef="U_xbrlipure">1.1336</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000267">
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation recognized was as follows &lt;span style="font-style:italic;"&gt;(in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,202&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,487&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt; (1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,203&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,140&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,405&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,627&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:80.77%;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"/&gt;&lt;span style="font-size:8pt;color:#000000;"&gt;Included in general and administrative stock-based compensation for the years ended December 31, 2021 and 2020 is $0.3 million and $0.3 million in expense related to 56,912 shares and 51,056 shares of common stock, respectively, issued to certain board members in lieu of their cash compensation.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231"
      decimals="-3"
      id="F_000427"
      unitRef="U_iso4217USD">1202000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000428"
      unitRef="U_iso4217USD">1487000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231"
      decimals="-3"
      id="F_000429"
      unitRef="U_iso4217USD">2203000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000430"
      unitRef="U_iso4217USD">2140000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000431"
      unitRef="U_iso4217USD">3405000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000432"
      unitRef="U_iso4217USD">3627000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20211231"
      decimals="-5"
      id="F_000435"
      unitRef="U_iso4217USD">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="-5"
      id="F_000436"
      unitRef="U_iso4217USD">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_0001124105_20210101_20211231"
      decimals="INF"
      id="F_000433"
      unitRef="U_xbrlishares">56912</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_0001124105_20200101_20201231"
      decimals="INF"
      id="F_000434"
      unitRef="U_xbrlishares">51056</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20211231"
      decimals="-5"
      id="F_000437"
      unitRef="U_iso4217USD">3900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231"
      id="F_000438">P2Y5M26D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20180613_20180613"
      decimals="INF"
      id="F_000439"
      unitRef="U_xbrlipure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20180613"
      decimals="INF"
      id="F_000440"
      unitRef="U_xbrlipure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20211231"
      decimals="INF"
      id="F_000442"
      unitRef="U_xbrlishares">359545</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20210101_20211231"
      decimals="INF"
      id="F_000443"
      unitRef="U_xbrlishares">64975</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20210101_20211231"
      decimals="-5"
      id="F_000444"
      unitRef="U_iso4217USD">300000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20211231"
      decimals="INF"
      id="F_000441"
      unitRef="U_xbrlishares">235469</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20210101_20211231"
      decimals="-5"
      id="F_000445"
      unitRef="U_iso4217USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001124105_us-gaapPlanNameAxis_cbioTwoThousandEighteenEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="-5"
      id="F_000446"
      unitRef="U_iso4217USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000233">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Income Taxes &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has incurred cumulative net operating losses since inception and, consequently, has not recorded any income tax expense for the years ended December 31, 2021 and 2020 due to its net operating loss position. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The reconciliation of the federal statutory income tax rate to the Company&#x2019;s effective tax rate for the years ended December 31, 2021 and 2020 are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax at statutory federal rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-21.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-21.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State Tax (benefit)&#x2014;net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.58&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-5.86&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-12.26&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derecognition due to Sec. 382 and 383 limitations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44.55&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26.26&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-12.25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.38&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant components of the Company&#x2019;s deferred tax assets as of December 31, 2021 and 2020 consist of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accruals and reserves&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,095&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carry forwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,541&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,505&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credit carry forwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,939&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,789&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed and intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(61,483&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(38,396&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Based on the available objective evidence at December 31, 2021, the Company does not believe it is more likely than not that the net deferred tax assets will be realizable. Accordingly, the Company has provided a full valuation allowance against its net deferred tax assets at December 31, 2021 and 2020. The net valuation allowance increased by approximately $23.1 million and decreased approximately $6.9 million during the years ended December 31, 2021 and 2020, respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, after consideration of certain limitations (see below), the Company had approximately $226.4 million federal and $8.0 million state net operating loss carryforwards (&#x201c;NOL&#x201d;) available to reduce future taxable income which, if unused, will begin to expire in 2037 for federal and 2032 for state tax purposes. The federal net operating loss carryforward includes $218.9 million that have an indefinite life.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2021, the Company also had tax credit carry forwards available to offset future tax liabilities of approximately $11.4 million for federal and $7.5 million for state. If unused, the federal credit will begin to expire in 2040 and the state tax credit does not expire. &#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;If the Company experiences a greater than 50 percentage point aggregate change in ownership over a three-year period (a Section 382 ownership change), utilization of its pre-change NOL carry forwards are subject to annual limitation under Section 382 of the Internal Revenue Code (California has similar provisions). The annual limitation is determined by multiplying the value of the Company's stock at the time of such ownership change by the applicable long-term tax-exempt rate. Such limitations may result in expiration of a portion of the NOL carryforwards before utilization. The Company determined that ownership changes occurred December 21, 2007, August 20, 2015, April 13, 2017, February 15, 2018, and February 18, 2020. Approximately $156.3 million and $70.8 million of the NOLs will expire unutilized for federal and California purposes, respectively. The Company has derecognized NOL related deferred tax assets in the tax affected amounts of $32.8 million and $0 for federal and California purposes, respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All of the federal tax credits could expire unutilized as well, whereas none of the California tax credits are subject to expiration. Approximately $15.2 million of gross federal tax credit-related deferred tax assets were derecognized due to the Section 383 limitation. The ability of the Company to use its remaining NOL and tax credit carry forwards may be further limited if the Company experiences a Section 382 ownership change as a result of future changes in its stock ownership. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 27, 2020, the &#x201c;Coronavirus Aid, Relief and Economic Security (CARES) Act&#x201d; (the &#x201c;Act&#x201d;) was signed into law. The Act includes provisions relating to refundable payroll tax credits, deferment of the employer portion of certain payroll taxes, net operating loss carryback periods, alternative minimum tax credit refunds, and modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property. The Company analyzed the provisions of the Act and determined there was no significant impact to its 2020 tax provision.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June 29, 2020, the California Governor signed Assembly Bill 85 (&#x201c;A.B. 85&#x201d;), which now becomes California law. A.B. 85, which includes several tax measures, provides for a three-year suspension of the use of net operating losses for medium and large businesses and a three-year cap on the use of business incentive tax credits to offset no more than $5.0 million of tax per year. Generally, A.B. 85 suspends the use of net operating losses for taxable years 2020, 2021, and 2022 for taxpayers with taxable income of $1.0 million or more. Since the Company is not expected to generate California source taxable income of more than $1.0 million, no material impact is anticipated at this time.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On December 27, 2020, the &#x201c;Consolidated Appropriations Act, 2021&#x201d; (the &#x201c;CAA&#x201d;) was signed into law. The CAA includes provisions meant to clarify and modify certain items put forth in CARES Act, while providing aid to businesses affected by the pandemic.&#160;&#160;The CAA allows deductions for expenses paid for by Paycheck Protection Program (&#x201c;PPP&#x201d;) and Economic Injury Disaster Loan (&#x201c;EIDL&#x201d;) Program, clarifies forgiveness of EIDL advances, and other business provisions.&#160;&#160;The Company analyzed the provisions of the CAA and determined there was no significant impact to its 2021 tax provision.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accounting for Uncertainty in Income Taxes&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company only recognizes tax benefits if it is more likely than not that they will be sustained upon audit by the relevant tax authority based upon their technical merits. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had approximately $4.7 million and $3.0 million of unrecognized tax benefits as of December 31, 2021 and 2020, respectively. As the Company has a full valuation allowance on its deferred tax assets, the unrecognized tax benefits have reduced the deferred tax assets and the valuation allowance in the same amount. The Company does not expect the amount of unrecognized tax benefits to materially change in the next twelve months.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the beginning and ending balance of the unrecognized tax benefits is as follows &lt;span style="font-style:italic;"&gt;(in thousands)&lt;/span&gt;: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Beginning Balance at January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,871&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase/(Decrease) of unrecognized tax benefits taken&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; in prior years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(295&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase/(Decrease) of unrecognized tax benefits&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; related to current year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,379&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ending Balance at December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,955&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase/(Decrease) of unrecognized tax benefits taken&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; in prior years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase/(Decrease) of unrecognized tax benefits&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; related to current year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,749&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ending Balance at December&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,704&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest and penalties related to unrecognized tax benefits would be included as income tax expense in the Company&#x2019;s consolidated statements of operations. As of December 31, 2021 and 2020, the Company had not recognized any tax-related penalties or interest in its consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company files income tax returns in the United States federal, California, Kansas, Missouri and New Jersey state jurisdictions. The Company is not currently under examination by income tax authorities in federal, state or other jurisdictions. As of December 31, 2021 and 2020, the Company had no uncertain tax positions which affected its financial position and its results of operations or its cash flow, and will continue to evaluate for uncertain positions in the future. The Company is subject to United States federal and state income tax examinations by authorities for all tax years due to accumulated net operating losses that are being carried forward for tax purposes.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000268">
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The reconciliation of the federal statutory income tax rate to the Company&#x2019;s effective tax rate for the years ended December 31, 2021 and 2020 are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax at statutory federal rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-21.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-21.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State Tax (benefit)&#x2014;net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.35&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.58&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-5.86&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-12.26&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derecognition due to Sec. 382 and 383 limitations&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44.55&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26.26&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-12.25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.38&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.00&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001124105_20210101_20211231"
      decimals="INF"
      id="F_000447"
      unitRef="U_xbrlipure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001124105_20200101_20201231"
      decimals="INF"
      id="F_000448"
      unitRef="U_xbrlipure">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001124105_20210101_20211231"
      decimals="4"
      id="F_000449"
      unitRef="U_xbrlipure">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001124105_20200101_20201231"
      decimals="4"
      id="F_000450"
      unitRef="U_xbrlipure">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <cbio:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="C_0001124105_20210101_20211231"
      decimals="4"
      id="F_000451"
      unitRef="U_xbrlipure">-0.0035</cbio:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <cbio:EffectiveIncomeTaxRateReconciliationPermanentDifferences
      contextRef="C_0001124105_20200101_20201231"
      decimals="4"
      id="F_000452"
      unitRef="U_xbrlipure">-0.0058</cbio:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_0001124105_20210101_20211231"
      decimals="4"
      id="F_000453"
      unitRef="U_xbrlipure">0.0586</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_0001124105_20200101_20201231"
      decimals="4"
      id="F_000454"
      unitRef="U_xbrlipure">0.1226</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <cbio:EffectiveIncomeTaxRateReconciliationDerecognition
      contextRef="C_0001124105_20210101_20211231"
      decimals="4"
      id="F_000455"
      unitRef="U_xbrlipure">0.0000</cbio:EffectiveIncomeTaxRateReconciliationDerecognition>
    <cbio:EffectiveIncomeTaxRateReconciliationDerecognition
      contextRef="C_0001124105_20200101_20201231"
      decimals="4"
      id="F_000456"
      unitRef="U_xbrlipure">-0.4455</cbio:EffectiveIncomeTaxRateReconciliationDerecognition>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001124105_20210101_20211231"
      decimals="4"
      id="F_000457"
      unitRef="U_xbrlipure">-0.2626</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001124105_20200101_20201231"
      decimals="4"
      id="F_000458"
      unitRef="U_xbrlipure">0.1225</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_0001124105_20210101_20211231"
      decimals="4"
      id="F_000459"
      unitRef="U_xbrlipure">-0.0025</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
      contextRef="C_0001124105_20200101_20201231"
      decimals="4"
      id="F_000460"
      unitRef="U_xbrlipure">-0.0038</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001124105_20210101_20211231"
      decimals="4"
      id="F_000461"
      unitRef="U_xbrlipure">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001124105_20200101_20201231"
      decimals="4"
      id="F_000462"
      unitRef="U_xbrlipure">0.0000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000269">
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant components of the Company&#x2019;s deferred tax assets as of December 31, 2021 and 2020 consist of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accruals and reserves&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,095&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carry forwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,541&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29,505&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credit carry forwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,939&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,789&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed and intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(61,483&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(38,396&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000463"
      unitRef="U_iso4217USD">1000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000464"
      unitRef="U_iso4217USD">1095000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000465"
      unitRef="U_iso4217USD">47541000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000466"
      unitRef="U_iso4217USD">29505000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000467"
      unitRef="U_iso4217USD">12939000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000468"
      unitRef="U_iso4217USD">7789000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <cbio:DeferredTaxAssetsFixedAssetsAndIntangibles
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000469"
      unitRef="U_iso4217USD">3000</cbio:DeferredTaxAssetsFixedAssetsAndIntangibles>
    <cbio:DeferredTaxAssetsFixedAssetsAndIntangibles
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000470"
      unitRef="U_iso4217USD">7000</cbio:DeferredTaxAssetsFixedAssetsAndIntangibles>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000471"
      unitRef="U_iso4217USD">61483000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000472"
      unitRef="U_iso4217USD">38396000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease
      contextRef="C_0001124105_20210101_20211231"
      decimals="-5"
      id="F_000473"
      unitRef="U_iso4217USD">-23100000</us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease>
    <us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease
      contextRef="C_0001124105_20200101_20201231"
      decimals="-5"
      id="F_000474"
      unitRef="U_iso4217USD">6900000</us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231"
      decimals="-5"
      id="F_000475"
      unitRef="U_iso4217USD">226400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231"
      decimals="-5"
      id="F_000476"
      unitRef="U_iso4217USD">8000000.0</us-gaap:OperatingLossCarryforwards>
    <cbio:OperatingLossCarryforwardsExpirationYear
      contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20210101_20211231"
      id="F_000477">2037</cbio:OperatingLossCarryforwardsExpirationYear>
    <cbio:OperatingLossCarryforwardsExpirationYear
      contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20210101_20211231"
      id="F_000478">2032</cbio:OperatingLossCarryforwardsExpirationYear>
    <cbio:OperatingLossCarryforwardsWithIndefiniteLife
      contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231"
      decimals="-5"
      id="F_000479"
      unitRef="U_iso4217USD">218900000</cbio:OperatingLossCarryforwardsWithIndefiniteLife>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231"
      decimals="-5"
      id="F_000480"
      unitRef="U_iso4217USD">11400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20211231"
      decimals="-5"
      id="F_000481"
      unitRef="U_iso4217USD">7500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20071231"
      decimals="-5"
      id="F_000483"
      unitRef="U_iso4217USD">156300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_stprCA_20211231"
      decimals="-5"
      id="F_000484"
      unitRef="U_iso4217USD">70800000</us-gaap:OperatingLossCarryforwards>
    <cbio:DeferredTaxAssetsStateNetOperatingLossCarryForwards
      contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20211231"
      decimals="-5"
      id="F_000485"
      unitRef="U_iso4217USD">32800000</cbio:DeferredTaxAssetsStateNetOperatingLossCarryForwards>
    <cbio:DeferredTaxAssetsStateNetOperatingLossCarryForwards
      contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_stprCA_20211231"
      decimals="-6"
      id="F_000486"
      unitRef="U_iso4217USD">0</cbio:DeferredTaxAssetsStateNetOperatingLossCarryForwards>
    <cbio:ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized
      contextRef="C_0001124105_20210101_20211231"
      decimals="-5"
      id="F_000487"
      unitRef="U_iso4217USD">15200000</cbio:ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized>
    <cbio:MaximumAmountOfTaxOffsetPerYear
      contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_stprCA_20200629_20200629"
      decimals="-5"
      id="F_000488"
      unitRef="U_iso4217USD">5000000.0</cbio:MaximumAmountOfTaxOffsetPerYear>
    <cbio:RequiredMinimumTaxableIncome
      contextRef="C_0001124105_us-gaapIncomeTaxAuthorityAxis_stprCA_20200629"
      decimals="-5"
      id="F_000489"
      unitRef="U_iso4217USD">1000000.0</cbio:RequiredMinimumTaxableIncome>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001124105_20211231"
      decimals="-5"
      id="F_000490"
      unitRef="U_iso4217USD">4700000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001124105_20201231"
      decimals="-5"
      id="F_000491"
      unitRef="U_iso4217USD">3000000.0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000270">
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the beginning and ending balance of the unrecognized tax benefits is as follows &lt;span style="font-style:italic;"&gt;(in thousands)&lt;/span&gt;: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Beginning Balance at January 1, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,871&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase/(Decrease) of unrecognized tax benefits taken&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; in prior years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(295&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase/(Decrease) of unrecognized tax benefits&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; related to current year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,379&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ending Balance at December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,955&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase/(Decrease) of unrecognized tax benefits taken&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; in prior years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Increase/(Decrease) of unrecognized tax benefits&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; related to current year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,749&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ending Balance at December&#160;31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,704&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001124105_20191231"
      decimals="-3"
      id="F_000492"
      unitRef="U_iso4217USD">1871000</us-gaap:UnrecognizedTaxBenefits>
    <cbio:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000493"
      unitRef="U_iso4217USD">-295000</cbio:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000494"
      unitRef="U_iso4217USD">1379000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001124105_20201231"
      decimals="-3"
      id="F_000495"
      unitRef="U_iso4217USD">2955000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000496"
      unitRef="U_iso4217USD">1749000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001124105_20211231"
      decimals="-3"
      id="F_000497"
      unitRef="U_iso4217USD">4704000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_0001124105_20211231"
      decimals="INF"
      id="F_000498"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="C_0001124105_20201231"
      decimals="INF"
      id="F_000499"
      unitRef="U_iso4217USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="C_0001124105_20211231"
      decimals="INF"
      id="F_000500"
      unitRef="U_iso4217USD">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent
      contextRef="C_0001124105_20201231"
      decimals="INF"
      id="F_000501"
      unitRef="U_iso4217USD">0</us-gaap:LiabilityForUncertainTaxPositionsCurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000234">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Collaborations&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Mosaic&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2017, the Company entered into a strategic research collaboration with Mosaic to develop intravitreal anti-complement factor 3 (C3) products for the treatment of dry Age-related Macular Degeneration (AMD) and other retinal diseases. The Company entered into two amendments to the Mosaic research collaboration agreements in December 2019 and May 2020. See Note 8, &lt;span style="font-style:italic;"&gt;Related Parties&lt;/span&gt;.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;ISU Abxis&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2018, the Company entered into an amended and restated license agreement with ISU Abxis (the &#x201c;A&amp;amp;R ISU Abxis Agreement&#x201d;), which amended and restated its previous license and collaboration agreement with ISU Abxis previously entered into in September 2013, as subsequently amended in October 2014 and December 2016 &lt;span style="color:#000000;"&gt;(the &#x201c;Original ISU Abxis Agreement&#x201d;)&lt;/span&gt;. Under the A&amp;amp;R ISU Abxis Agreement, &lt;span style="color:#000000;"&gt;ISU Abxis will receive commercialization rights in South Korea to the Company&#x2019;s engineered Factor IX dalcinonacog alfa - DalcA and the Company will receive clinical development and commercialization rights in the rest of world (excluding South Korea) and manufacturing development and manufacturing rights worldwide (including South Korea)&lt;/span&gt;. &lt;span style="color:#000000;"&gt;The &lt;/span&gt;A&amp;amp;R ISU Abxis Agreement &lt;span style="color:#000000;"&gt;eliminates the profit-sharing arrangement in the Original ISU Abxis Agreement and&lt;/span&gt; p&lt;span style="color:#000000;"&gt;rovides for a low single-digit royalty payment to ISU Abxis, on a country-by-country basis, for net product sales of DalcA by the Company or its affiliates in each country other than South Korea. Pursuant to the A&amp;amp;R &lt;/span&gt;ISU Abxis Agreement&lt;span style="color:#000000;"&gt;, the Company will also pay up to an aggregate of&lt;/span&gt; &lt;span style="color:#000000;"&gt;$19.5 million in milestone payments to ISU Abxis, including $2.5&#160;million in regulatory and development milestone payments and up to $17.0&#160;million in commercial milestone payments, if the applicable milestones are met. As of December 31, 2021, no milestones have been met.&lt;/span&gt;&lt;span style="letter-spacing:-0.2pt;"&gt; &lt;/span&gt;&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Biogen&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On December 18, 2019, the Company and Biogen entered into a License and Collaboration Agreement (the &#x201c;Biogen Agreement&#x201d;), under which the Company granted Biogen a worldwide, royalty-bearing, exclusive, with the right to sublicense, license (&#x201c;Exclusive License&#x201d;) to develop and commercialize CB 2782-PEG and other anti-C3 proteases for potential treatment of dry AMD and other disorders. Pursuant to the Biogen Agreement, the Company will perform certain pre-clinical and manufacturing activities (&#x201c;Research Services&#x201d;), and Biogen will be solely responsible for funding the pre-clinical and manufacturing activities and performing IND-enabling activities, worldwide clinical development, and commercialization. The Company will provide the Research Services over a term of &lt;span style="color:#000000;"&gt;thirty months&lt;/span&gt; with Biogen having the option to extend the term for two additional &lt;span style="color:#000000;"&gt;&lt;span style="-sec-ix-hidden:F_000509"&gt;twelve-month&lt;/span&gt;&lt;/span&gt; periods.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the Biogen Agreement, the Company received an up-front payment for the transfer of the Exclusive License (inclusive of certain know-how) of &lt;span style="color:#000000;"&gt;$15.0&lt;/span&gt; million in January 2020. The Company is eligible to receive development milestones and sales milestones of up to $340.0 million. In addition, the Company is eligible to receive royalties in the range of single-digit to low double-digit percentage rates of annual net sales on a product-by-product and country-by-country basis. The Company will also receive reimbursements for costs associated with the performance of the Research Services.&lt;span style="color:#000000;"&gt;   &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined that the performance obligations under the Biogen Agreement were the Exclusive License and the Research Services. For the Exclusive License, the Company used the residual approach in determining the standalone selling price, or SSP, which includes the upfront payments, milestones and royalties. For the Research Services, the Company used the historical pricing approach for determining the SSP, which includes the reimbursement of personnel and out-of-pocket costs.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Biogen Agreement will continue on a product-by-product and country-by-country basis until the tenth anniversary of the first commercial sale of the first product in a country, unless terminated earlier by either party as specified under the agreement. In March 2022, the Company received written notice from Biogn to terminate the Biogen Agreement effective in May 2022. See Note 17, &lt;span style="font-style:italic;"&gt;Subsequent Event&lt;/span&gt;.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the year ended December 31, 2021, the Company recognized no license revenue from the Biogen Agreement. For the year ended December 31, 2020, the Company recognized the $15.0 million in license revenue upon the transfer of the Exclusive License and the related know-how, and $0.1 million in license revenue for reimbursable out-of-pocket costs incurred.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the years ended December 31, 2021 and 2020, the Company recognized $7.3 million and $5.8 million in collaboration revenue for reimbursable out-of-pocket and personnel costs incurred related to Research Services.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For the year ended December 31, 2021, the Company recognized $2.0 million in collaboration revenue from the beginning of period deferred revenue balance.&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <cbio:MilestonePayments
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231"
      decimals="-5"
      id="F_000503"
      unitRef="U_iso4217USD">19500000</cbio:MilestonePayments>
    <cbio:RegulatoryAndDevelopmentMilestonePayment
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231"
      decimals="-5"
      id="F_000505"
      unitRef="U_iso4217USD">2500000</cbio:RegulatoryAndDevelopmentMilestonePayment>
    <cbio:CommercialMilestonePayments
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20181201_20181231"
      decimals="-5"
      id="F_000507"
      unitRef="U_iso4217USD">17000000.0</cbio:CommercialMilestonePayments>
    <cbio:MilestonePayments
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20210101_20211231"
      decimals="-6"
      id="F_000502"
      unitRef="U_iso4217USD">0</cbio:MilestonePayments>
    <cbio:RegulatoryAndDevelopmentMilestonePayment
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20210101_20211231"
      decimals="-6"
      id="F_000504"
      unitRef="U_iso4217USD">0</cbio:RegulatoryAndDevelopmentMilestonePayment>
    <cbio:CommercialMilestonePayments
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioIsuAbxisMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioAmendedAndRestatedLicenseAgreementMember_20210101_20211231"
      decimals="-6"
      id="F_000506"
      unitRef="U_iso4217USD">0</cbio:CommercialMilestonePayments>
    <cbio:ResearchServicesAgreementTerm
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_us-gaapTransactionTypeAxis_cbioLicenseAndCollaborationAgreementMember_20191218_20191218"
      id="F_000508">P30M</cbio:ResearchServicesAgreementTerm>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_us-gaapTransactionTypeAxis_cbioExclusiveLicenseMember_20200101_20200131"
      decimals="-5"
      id="F_000510"
      unitRef="U_iso4217USD">15000000.0</us-gaap:ProceedsFromLicenseFeesReceived>
    <cbio:DevelopmentMilestonesPaymentReceivable
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_srtRangeAxis_srtMaximumMember_us-gaapTransactionTypeAxis_cbioExclusiveLicenseMember_20200101_20200131"
      decimals="-5"
      id="F_000511"
      unitRef="U_iso4217USD">340000000.0</cbio:DevelopmentMilestonesPaymentReceivable>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001124105_srtCounterpartyNameAxis_cbioBiogenMember_20210101_20211231"
      decimals="-3"
      id="F_000512"
      unitRef="U_iso4217USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001124105_srtProductOrServiceAxis_cbioLicenseRevenueMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cbioTransferOfExclusiveLicenseAndRelatedKnowHowMember_20200101_20201231"
      decimals="-5"
      id="F_000513"
      unitRef="U_iso4217USD">15000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001124105_srtProductOrServiceAxis_cbioExclusiveLicenseMember_20200101_20201231"
      decimals="-5"
      id="F_000514"
      unitRef="U_iso4217USD">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cbioReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_20210101_20211231"
      decimals="-5"
      id="F_000515"
      unitRef="U_iso4217USD">7300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001124105_srtProductOrServiceAxis_cbioCollaborationRevenueMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_cbioReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember_20200101_20201231"
      decimals="-5"
      id="F_000516"
      unitRef="U_iso4217USD">5800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DeferredRevenueRevenueRecognized1
      contextRef="C_0001124105_20210101_20211231"
      decimals="-5"
      id="F_000517"
      unitRef="U_iso4217USD">2000000.0</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:InterestAndOtherIncomeTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000235">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Interest and Other Income (Expense), Net &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table shows the detail of interest and other income (expense), net as follows &lt;span style="font-style:italic;"&gt;(in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;561&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Miscellaneous income&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;659&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(87&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(91&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total interest and other income (expense), net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(39&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,129&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;"&gt;&#160;&lt;/p&gt;</us-gaap:InterestAndOtherIncomeTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000271">
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table shows the detail of interest and other income (expense), net as follows &lt;span style="font-style:italic;"&gt;(in thousands):&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;561&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Miscellaneous income&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;659&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(87&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(91&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total interest and other income (expense), net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(39&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,129&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000518"
      unitRef="U_iso4217USD">39000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000519"
      unitRef="U_iso4217USD">561000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <cbio:MiscellaneousIncomeExpense
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000520"
      unitRef="U_iso4217USD">9000</cbio:MiscellaneousIncomeExpense>
    <cbio:MiscellaneousIncomeExpense
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000521"
      unitRef="U_iso4217USD">659000</cbio:MiscellaneousIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000522"
      unitRef="U_iso4217USD">-87000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000523"
      unitRef="U_iso4217USD">-91000</us-gaap:OtherNonoperatingIncomeExpense>
    <cbio:InterestAndOtherIncomeExpenseNet
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000524"
      unitRef="U_iso4217USD">-39000</cbio:InterestAndOtherIncomeExpenseNet>
    <cbio:InterestAndOtherIncomeExpenseNet
      contextRef="C_0001124105_20200101_20201231"
      decimals="-3"
      id="F_000525"
      unitRef="U_iso4217USD">1129000</cbio:InterestAndOtherIncomeExpenseNet>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000236">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:15pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:15pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Stockholders&#x2019; Equity&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the first quarter of 2021, the Company issued and sold an aggregate of 9,185,000 registered shares of its common stock (including 485,000 shares sold pursuant to the exercise of the underwriters&#x2019; overallotment option) at a price of $5.75 per share. The net proceeds to the Company, after deducting $3.6 million in underwriting discounts and commissions, and offering expenses, were approximately $49.3 million.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had 85 issued and outstanding common stock warrants as of December 31, 2021 and 2020, respectively, with a weighted-average exercise price of $392.70. The warrants expire in &lt;span style="-sec-ix-hidden:F_000537"&gt;August 2022&lt;/span&gt;.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;2021 ATM Program &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On October 15, 2021, the Company entered into an Equity Distribution Agreement (the &#x201c;ATM Agreement&#x201d;) with Piper Sandler &amp;amp; Co. (&#x201c;Piper Sandler&#x201d;), as sales agent, pursuant to which the Company may offer and sell, from time to time, through Piper Sandler, shares of the Company&#x2019;s common stock, par value of $0.001 per &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;share, with aggregate gross sales proceeds of up to $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50.0&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million through an &#x201c;at the market&#x201d; equity offering program (the &#x201c;ATM Program&#x201d;). The Company will pay Piper Sandler a commission of &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.0&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;% of the gross proceeds of any shares sold. The Company also agreed to reimburse Piper Sandler for certain expenses incurred in connection with its services under the ATM Agreement, including up to $&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;50,000&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; for legal expenses in connection with the establishment of the ATM Program.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sales of shares of common stock under the ATM Program will be made pursuant to the registration statement on Form S-3 (File No. 333-253874), which was declared effective by the SEC on May 3, 2021, and a related prospectus supplement file with the SEC on October 15, 2021. For the year ended December 31, 2021, no shares of common stock were sold under the ATM Program. &lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="INF"
      id="F_000526"
      unitRef="U_xbrlishares">9185000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_cbioUnderwritersOverallotmentOptionMember_20210101_20210331"
      decimals="INF"
      id="F_000527"
      unitRef="U_xbrlishares">485000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331"
      decimals="2"
      id="F_000528"
      unitRef="U_iso4217USD_xbrlishares">5.75</us-gaap:SharePrice>
    <cbio:UnderwritingCommissionsAndOfferingExpensesPayable
      contextRef="C_0001124105_20210101_20210331"
      decimals="-5"
      id="F_000529"
      unitRef="U_iso4217USD">3600000</cbio:UnderwritingCommissionsAndOfferingExpensesPayable>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001124105_20210101_20210331"
      decimals="-5"
      id="F_000530"
      unitRef="U_iso4217USD">49300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20211231"
      decimals="INF"
      id="F_000531"
      unitRef="U_xbrlishares">85</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20201231"
      decimals="INF"
      id="F_000532"
      unitRef="U_xbrlishares">85</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20211231"
      decimals="INF"
      id="F_000533"
      unitRef="U_xbrlishares">85</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20201231"
      decimals="INF"
      id="F_000534"
      unitRef="U_xbrlishares">85</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20211231"
      decimals="2"
      id="F_000535"
      unitRef="U_iso4217USD_xbrlishares">392.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001124105_us-gaapStatementEquityComponentsAxis_us-gaapWarrantMember_20201231"
      decimals="2"
      id="F_000536"
      unitRef="U_iso4217USD_xbrlishares">392.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001124105_us-gaapSubsidiarySaleOfStockAxis_cbioTwoThousandTwentyOneATMProgramMember_20211015"
      decimals="3"
      id="F_000538"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_0001124105_us-gaapSubsidiarySaleOfStockAxis_cbioTwoThousandTwentyOneATMProgramMember_20211015_20211015"
      decimals="-5"
      id="F_000539"
      unitRef="U_iso4217USD">50000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <cbio:PercentageOfCommissionForSharesSold
      contextRef="C_0001124105_us-gaapSubsidiarySaleOfStockAxis_cbioTwoThousandTwentyOneATMProgramMember_20211015"
      decimals="3"
      id="F_000540"
      unitRef="U_xbrlipure">0.030</cbio:PercentageOfCommissionForSharesSold>
    <cbio:LegalExpensesIncurred
      contextRef="C_0001124105_us-gaapSubsidiarySaleOfStockAxis_cbioTwoThousandTwentyOneATMProgramMember_20211015_20211015"
      decimals="0"
      id="F_000541"
      unitRef="U_iso4217USD">50000</cbio:LegalExpensesIncurred>
    <us-gaap:EarningsPerShareTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000237">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;15.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Net Loss per Share Attributable to Common Stockholders&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,603,630&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,355,615&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,603,715&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,355,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000272">
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods as the inclusion of all potential common shares outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,603,630&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,355,615&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;85&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,603,715&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,355,700&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioOptionsToPurchaseCommonStockMember_20210101_20211231"
      decimals="INF"
      id="F_000542"
      unitRef="U_xbrlishares">2603630</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioOptionsToPurchaseCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000543"
      unitRef="U_xbrlishares">2355615</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioCommonStockWarrantsMember_20210101_20211231"
      decimals="INF"
      id="F_000544"
      unitRef="U_xbrlishares">85</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001124105_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cbioCommonStockWarrantsMember_20200101_20201231"
      decimals="INF"
      id="F_000545"
      unitRef="U_xbrlishares">85</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001124105_20210101_20211231"
      decimals="INF"
      id="F_000546"
      unitRef="U_xbrlishares">2603715</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001124105_20200101_20201231"
      decimals="INF"
      id="F_000547"
      unitRef="U_xbrlishares">2355700</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000238">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:15pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:15pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Restructuring&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2021, the Board approved a restructuring of its business based on its decision to stop the clinical development of MarzAA and focus solely on its complement programs and protease medicines platform. The restructuring included a reduction-in-force whereby approximately 35% of employees were terminated. During the year ended December 31, 2021, the Company recorded charges of $0.4 million related to one-time severance costs and related expenses in connection with the workforce reduction, and charges of $3.8 million related to the write-off of prepaid manufacturing costs that will no longer be used for the clinical development of MarzAA. &lt;span style="color:#000000;"&gt;As of December 31, 2021, the remaining restructuring liability was $0.2 million, which the Company expects to pay in the first quarter of 2022.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:6pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes restructuring charges recorded in each component of operating expenses in the Company&#x2019;s consolidated statements of operations (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;143&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total restructuring charges&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,168&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="C_0001124105_20211130_20211130"
      decimals="2"
      id="F_000548"
      unitRef="U_xbrlipure">0.35</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:SeveranceCosts1
      contextRef="C_0001124105_20210101_20211231"
      decimals="-5"
      id="F_000549"
      unitRef="U_iso4217USD">400000</us-gaap:SeveranceCosts1>
    <cbio:ChargesRelatedToWriteOffOfPrepaidManufacturingCost
      contextRef="C_0001124105_20210101_20211231"
      decimals="-5"
      id="F_000550"
      unitRef="U_iso4217USD">3800000</cbio:ChargesRelatedToWriteOffOfPrepaidManufacturingCost>
    <cbio:RestructuringLiability
      contextRef="C_0001124105_20210101_20211231"
      decimals="-5"
      id="F_000551"
      unitRef="U_iso4217USD">200000</cbio:RestructuringLiability>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000273">
&lt;p style="margin-bottom:6pt;margin-top:12pt;margin-left:5.24%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes restructuring charges recorded in each component of operating expenses in the Company&#x2019;s consolidated statements of operations (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.08%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,025&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;143&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.08%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total restructuring charges&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,168&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231"
      decimals="-3"
      id="F_000552"
      unitRef="U_iso4217USD">4025000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20211231"
      decimals="-3"
      id="F_000553"
      unitRef="U_iso4217USD">143000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:RestructuringCharges
      contextRef="C_0001124105_20210101_20211231"
      decimals="-3"
      id="F_000554"
      unitRef="U_iso4217USD">4168000</us-gaap:RestructuringCharges>
    <us-gaap:SubsequentEventsTextBlock contextRef="C_0001124105_20210101_20211231" id="F_000239">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:5.24%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/span&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7&lt;/span&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Subsequent Event&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.81%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Biogen Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.76%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2022, the Company received written notice that Biogn is terminating the Biogen Agreement. Pursuant to the terms of the Biogen Agreement, termination will be effective in &lt;span style="-sec-ix-hidden:F_000557"&gt;May 2022&lt;/span&gt;. As a result of the termination, Biogen will no longer have an exclusive license to develop, manufacture and commercialize CB 2782-PEG and other anti-C3 proteases for potential treatment of dry AMD and other disorders.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Sublease&lt;/span&gt;&lt;span style="font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt; Agreement&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.76%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2022, the Company entered into a sublease agreement for one of its leased facilities that commences in April 2022. Under the terms of the sublease agreement, the Company will receive $0.2 million in base lease payments over the term of the sublease, which ends in &lt;span style="-sec-ix-hidden:F_000556"&gt;April 2023&lt;/span&gt;.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Advisor Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.76%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2022, the Company entered into a financial advisor agreement with Raymond James &amp;amp; Associates, Inc. (&#x201c;Raymond James&#x201d;) to help the Company evaluate the possible sale or merger of the Company with various third-parties. Raymond James will be paid an advisory fee of up to $1.0 million upon the effective sale or merger of the Company and will be reimbursed up to $20,000 for reasonable legal, travel and out-of-pocket expenses. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:4.76%;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Other Event&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:4.76%;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2022, the Company announced that it intends to further reduce its workforce as part of its restructuring plan. Under the restructuring plan, the Company will provide employees one-time severance payments upon termination, continued benefits for a specific period, and outplacement services. The Company expects to incur total expenses of approximately $0.8 million, which is expected to be paid out during the second quarter of 2022.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="C_0001124105_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_cbioSubleaseArrangementMember_20220331"
      decimals="-5"
      id="F_000555"
      unitRef="U_iso4217USD">200000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <cbio:AdvisoryFeesPayable
      contextRef="C_0001124105_us-gaapRelatedPartyTransactionAxis_cbioRaymondJamesAndAssociatesMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_cbioAdvisorAgreementMember_20220301_20220331"
      decimals="-5"
      id="F_000558"
      unitRef="U_iso4217USD">1000000.0</cbio:AdvisoryFeesPayable>
    <cbio:ReimbursementOfAdvisoryFee
      contextRef="C_0001124105_srtRangeAxis_srtMaximumMember_us-gaapRelatedPartyTransactionAxis_cbioRaymondJamesAndAssociatesMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapTypeOfArrangementAxis_cbioAdvisorAgreementMember_20220301_20220331"
      decimals="0"
      id="F_000559"
      unitRef="U_iso4217USD">20000</cbio:ReimbursementOfAdvisoryFee>
    <us-gaap:RestructuringCharges
      contextRef="C_0001124105_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220301_20220331"
      decimals="-5"
      id="F_000560"
      unitRef="U_iso4217USD">800000</us-gaap:RestructuringCharges>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_000290"
          xlink:label="F_000290"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000295"
          xlink:label="F_000295"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000296"
          xlink:label="F_000296"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000289"
          xlink:label="F_000289"
          xlink:type="locator"/>
        <link:footnote id="FNT_000000" xlink:label="FNT_000000" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Included in cash and cash equivalents on accompanying consolidated balance sheet.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000290"
          xlink:to="FNT_000000"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000295"
          xlink:to="FNT_000000"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000296"
          xlink:to="FNT_000000"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000289"
          xlink:to="FNT_000000"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_000299"
          xlink:label="F_000299"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000291"
          xlink:label="F_000291"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000297"
          xlink:label="F_000297"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000298"
          xlink:label="F_000298"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000300"
          xlink:label="F_000300"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000292"
          xlink:label="F_000292"
          xlink:type="locator"/>
        <link:footnote id="FNT_000001" xlink:label="FNT_000001" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Included in short-term investments on accompanying consolidated balance sheet and are classified as available-for-sale debt securities. $2.5 million of U.S. government agency securities as of December 31, 2020 are included in long-term investments on the accompanying consolidated balance sheets due to the maturity being more than 12 months.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000299"
          xlink:to="FNT_000001"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000291"
          xlink:to="FNT_000001"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000297"
          xlink:to="FNT_000001"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000298"
          xlink:to="FNT_000001"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000300"
          xlink:to="FNT_000001"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000292"
          xlink:to="FNT_000001"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_000430"
          xlink:label="F_000430"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_000429"
          xlink:label="F_000429"
          xlink:type="locator"/>
        <link:footnote id="FNT_000002" xlink:label="FNT_000002" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="text-align:left;margin-bottom:0pt;margin-top:2pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><xhtml:span style="Background-color:#auto;text-decoration:none;"/><xhtml:span style="color:#000000;"/><xhtml:span style="font-size:8pt;color:#000000;">Included in general and administrative stock-based compensation for the years ended December 31, 2021 and 2020 is $0.3 million and $0.3 million in expense related to 56,912 shares and 51,056 shares of common stock, respectively, issued to certain board members in lieu of their cash compensation.</xhtml:span></xhtml:p></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000430"
          xlink:to="FNT_000002"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_000429"
          xlink:to="FNT_000002"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>82
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M!K,@B&:V)^VE@MJE8C:I+XD;G<J"B\?EE,$H"F?./>VE@]JEXYC?%_)*IUI
M7"]PQ@@-9F$PV"BG& <=@UTTMJ(HLF-ITB@<]$TZR[R, 2]Z_9=0' 5OC,"M
MCG6;?B7W+.;7"^C#):\.?+%!IO+G?W!T&GPO2=0N27=*Q%]3D2>\DK_^$E(2
MO&TD7CW9E(GVRD3MR@05=4NJ4L^T1*_P)<8$A*I"T$?5?(F\)<98_R&9,@@/
ML5I!+Y/]X,E;](-7XOG[3$I-?$UQ7BNIX '6R;@P5E _LS#_W=%IXGK%I';%
MU+M2E/-9(\><S>4-6FH71\L !TV^*%WB*%B&%-N3B9A"T)+SXAZ4YKFK/WJ
M_GP)RBCWO+F>R8U<3@U=&1F?8X-ZS]2HM-=N:M?N=TF2Z:("V$9W<!=9"?WZ
M/@/V,<*<"C3TZ8$WED>#G1/A$,_H#NVEG-JE'.JANJCSYFJF;32A,JIXJF_1
M#AS:)7@W%2!;:FCG9M#T<DWM<CU$D_!=%F=F'9E*\(6+J1^-^Q"3H:-[SCD]
MZ?6:GJ/7<I:TC+ -S1W!X;CR-9@%/O8C,V2GEVW'+ML3"6R.T\^%T$XQO#$R
M]2T&,U/?LAK<*>H+W3]9]9"5$LJ*'8S#EP'DH#K>D1Y?E-@WUXSW0BE1-(\I
M9P!=&\#O.P$:V;[HF\ONIGKS+U!+ P04    "  I:']4E.2O;+X"  !%"0
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M$Y:;Z+DZ4-'18>V'WC1UDF2\;!:K9>"%@0/I27OWWT=F35Y<3'8N3N>.O G
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M*,FIT ;P?<>Y>OVA)^AOF:__!U!+ P04    "  I:']4]-O"K1 #  !^!@
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M9XDG'CD6P'EN$4.W8 ?]HW'Q+U!+ P04    "  I:']4\7!''5\:   T4
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MEAKNK/\<K.XMYU;@^$Q;\U$+D<9V:SJ)+H:*;3XI*.\HKD$LMEX9QG;,YAN
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M!>T<T%XJ98^"2]"MY/EO4$L#!!0    ( "EH?U38$5F>>P8  +X/   9
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MA/2 8EZ [TN+;#0/[*"[LI_]#U!+ P04    "  I:']4;9B.G!P%  !T#
M&0   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6R=5\ER&S<0O><KNAA73ER'
M<L0XDJJT.(Y=4:SRDAQ2.8 S31)E#$ #&-'\^[S&+!K*DLKQ11K,H%^_?KT
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MVL[5%?)A(DS!^I3W4F>2R)K%;\'8ZEXGY*\4+X\LT^^:5B1&>7!:J$PK[(7
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MJW>$Y]#<YQX!$H=*O@G+B,-R..N+RVJ)9D\0!$?#T10WUJ7.Q&C,O['@6[5
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MF7J+IPIR_A;>Y')FK.08N>N!ATY^,DAJ^;LH/SX@/QJ+)Z/]PHG/.J5T6\$
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M(GP@&7@CJHVTY!=RJV;ZXKFRKI(1'6ML.K/[M@AD[@P[(ZI2U$0P1SSFL,?
M3D8?^Q<8_7G.Z8=]_$36C:8F FXG!)MDG8RW1:$5'(M:785 MZM@CU8^$C&=
MC"[[P[:B35WN$02"++@IRQ(D(F<Y;4Y!K<4E^;Z8Q, WS=W,_*[0IGU^(=$A
M,R(=I>Z4P8 07UO4RL3*'+T=7(9?']Z9?7]K,=O6)&T58IME:BU[N+0"9]F:
M4=NVYZAZ)M1:4FYZJ=O4;V]&H46Z(G2M P]T(Y^&QN86Y-"#)&LB[JX9^;3&
M];D1;#Q:4UYK8._2"$#>B?'EU;CW_/G7UF@-L_S^C#O#A]D:>J7$!1X@SV^'
M]]-#2QP3V5@$P[VM_=WP[>F!DBR_8(B$K,>;! ^2WIH4WQ)4V.55&+9-+%Z:
MB3XE^XIHN$V26H40C,U(8 DD#!W09XG]27&%LK<9\LGZ(Y&]%P(_K!W@)X^_
M/?1(H^JWCW5;?+J/[[O["7][PXG!B@094+YQ6YA73J9 P1><*;]0%F19Q"7=
M+RE_I5ZX$M]"\8;%#(==//W_TE6/+%X<0 Z]S$+5FHHWBY[4+H/R6N6;0JTG
M2KB%,TW:OVNS["W,\D,DO@N03MO[E!@HIBZ/4NECFF+@L;-#$V(^KU?B:NW<
MKC]B"2XX *N9TF_"VA=?:M_>"&W'IW*4-J-9I1773HF$\<R @XT'39%A[]+8
M&9@]\:8:*J:T4-OET3.=/C?;6J3T>L16Y5;445EM=@T#E!E&M5&_<>@ ZH6"
M'AMJDX&$$F[P<W9W'3B$T9(J9N !:A@#>7)&:XJ]A%'9,UFO-,EW#./$.%^O
M\F^3Q16?P%VE*XK3O9[=/-V;,1Y;9__01REXE==USG4OM4;ZK),\OV.!9LHZ
MWYYJO!=L/VQ,J=:"P0, D7<B!B7LT ASKE!Z6"5(!6HL)7<@+[PE)2I3.+2I
MSO4NW>>WA:>0(TS!\8&N6UKEX05&I$<6!0JA"#'3@6P;%/OKGK*,PD<0]J%^
ME1FW7F7XC7&ZWLG%YU?^VQ30"GZ)N*+OF=@[6($'@R;E0=[,++P9$&<P(-X'
MK_\>4\.#IOAV9(S6FK)KO +;OY.@&B9H7D\;:HHT?3+LCXX9XE9I6B#L/WL*
MGANFLEA+MCUWAZ(<#!^-P<EE_VR-*L"\Z%]MKVWM9>>=8.OQ5G?O-O1U>%!]
M1SCS#Q4/EM?A.\ W]30CO%4$7HILHPPON,AQA!E/SV3.DZ*_[S/.H/45#30P
M#]\*76SU^$%M?7?].7(2O\)MCL=OF6AC@,$K-&40'?8O+SIQHVLNO"G#-[F9
M\=X4X>>")#B!#^!Y9M"0]04;6'^DO?T?4$L#!!0    ( "EH?U1\K(NS?0(
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M/X^X&;9NAL'-\#]\XN/D=-"+WDJ'AQ)A911WH=1K(+%4"*XT.P=LQ#\R":G
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M(.:L,;Z@QY9(AD\9!&Q*<*<$Z:.YZGU'IL,= 3KA6&6$3:>\YTZY>R6]3W6
MIR;6C<Y+TJ2N *Z;O;0_34;]Z2BAT6@RZ4^'D][ZS("ZJC71,+W+B7L^*\M$
MZW5!ML'K(DF>._7QF=94J/=>40T1:*0-LM.M=J*]#%KU:!X4_Y;I/:=$!.[(
M-1E<D$;JH*)A8E7ME2M3EG30#TOZ\:!V!K2_4]2^=N("=+^RQ1]02P,$%
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M7N3R2OD58&'CU6@P1?\9TPVCKH(0/6?Y-&)*44#0O++@FKL0NQ#LY/@1,S0
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M#&+P[9VF3ECE)/JHP8GS"#Q(6W(@ U9@A2\@H!$B/'^6WC!!7AN!%+I5,#=
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M:7"*N66)?QM 604\+Z0TVXUUT/T1F?X'4$L#!!0    ( "EH?U3)9DCRJ0(
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M=OI.IJH =L<?P+#V'5_F8#H3WV)H,O#3.LR\"A,="1-&[+V2=F/8I<P@>Q[
M1TX-L6A/;!Z=C+B M,?BL,NB( I/Q(N;1&,7+_[/1-E"F#17IM3 _IHMC=4H
MC;]/0"0-1.(@DB,0-Y JF8I<<"<XM6)7D('F.3L O^$6F%7L0A5;+A]_PHJM
M5N"TV>R_5O_3T'<;P"/R$M[BUU5-P5AN2ZOT(Q,5&8M@NB9#AC6A'[\;1>'P
MK6'0T&HL<08XTT?@&@VHTPS[!,42=-,KQF5&BX!Q+# WZ)7CT3=GWI_H5NGC
MF9='7O03>%0 ;@^X[MD3O/<F"GM!X/WPM+BU1(N\VDN0L!*VX_A';R7.,ZS
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MKI6E=O;+DOY/U,Z [@NE['[C"+H?>?X/4$L#!!0    ( "EH?U2;Z?4&(@,
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M QE<7AFK5-.QF@G*I;OT,XFFA;AA:9H\*!M@]N=2XF9B"W2_C>$?4$L#!!0
M   ( "EH?U37V'2<L@,  .4/   9    >&PO=V]R:W-H965T<R]S:&5E=#,X
M+GAM;+U736_;.!#]*X300PMT(XGR5PK;0&*GV  )&L3;W<.B!UH:640I4B4I
M.P7ZXTM2CN0V-NT"@2^Q2''>O'D<OWC&&R&_J@) HZ>2<34)"JVK#V&HT@)*
MHBY$!=R\R84LB39+N0I5)8%D+JAD(8ZB05@2RH/IV.T]R.E8U)I1#@\2J;HL
MB?Q^#4QL)D$</&\\TE6A[48X'5=D!0O0GZL':59ABY+1$KBB@B,)^22XBC_,
M\, &N!/_4MBHG6=D2UD*\=4N;K-)$%E&P"#5%H*8CS7,@#&+9'A\VX(&;4X;
MN/O\C/[1%6^*61(%,\'^HYDN)L$H0!GDI&;Z46S^AFU!?8N7"J;<7[39GHT"
ME-9*BW(;;!B4E#>?Y&DKQ$Y /#@0@+<!^/> WH& 9!N0N$(;9JZL.=%D.I9B
M@Z0];=#L@]/&19MJ*+?7N-#2O*4F3D\7S?4AD:,%77&:TY1PC:[25-1<4[Y"
M#X+1E()"?Z&K+*-6?,+0+6]:R%[%VSEH0MD[<^+S8H[>OGF'WB#*T3^%J!7A
MF1J'VE"U"<-T2^NZH84/T(HQNA=<%PK=\ RR7P%"4V-;*'XN]!I[$>>07J D
M?H]PA.,]A&:GAT<>.DFK>^+PDB.Z?SJN^_]W)A;=:BC5%T_F7INYYS+W#F3>
MIE#F2Y@"79,E@WWWTX ,'(CU@O4T'D6F\O6>U/TV==^;^HZFQ@  F9Y IG$9
M60K9M)"$-?!Z+Y$&LK]#9)@DHY9(<WG]%VQQ=-D;[:<[:.D.O'0?00&1:>'X
MS@U#)BKC8!K=/%6V#L]E#-L4PS.WP:C-//(6-Q-*VV_]R?<P>B'QH+_3$,T]
MO#S4[QWJFLN6Z:67Z4+D>D.D3^XXZNPN.K/@\8[5QMY";I2FQC(A0[6"O&:(
MF?]@^\W1#Y2@[Z8QE8\4[DCA(WU05K4&B>!;35U[^V [>XO/[6]Q9W"QW^'^
M0&<_T DZ=]87^[WO8RTYU;4$] /=4T[+NO3A=AX5#\XM=&=>\?"UA/8#G2!T
MYVNQW]A^$9H\'1.Z<Z'X\LQ"X\ZU</1*0A\!&AX5&G=VAOTN= ?FYW,A6(9H
M64FQ!FL>ZJ3VQIT]87QNU3L/P\EKJ>X'.M[>N#,W[/>DPZH?[77<F17NGUOU
MSM"P_U?7'ZCN!_+T>K@S,)4@5VZ.5,A5UXP4[6X[JUZY">VW_6LSPS839P?3
M#,#W1*XH5XA!;B"CBZ%17#8S9;/0HG)CV5)H,^2YQ\+,X2#M ?,^%T(_+VR"
M=K*?_@102P,$%     @ *6A_5)I"4Y-3 @  Q00  !D   !X;"]W;W)K<VAE
M971S+W-H965T,SDN>&UL?53?;]HP$/Y73E$?6JD0"'0_JA )BKHAP8;*VCU,
M>S#) 58=F]D7:*7]\3L[:<0>Z$OB.]]]]]WGL].CL<]NATCP4BKM1M&.:'\;
MQR[?82E<U^Q1\\[&V%(0FW8;N[U%482D4L5)K_<A+H74498&W])FJ:E(28U+
M"ZXJ2V%?)ZC,<13UHS?'@]SNR#OB+-V++:Z0'O=+RU;<HA2R1.VDT6!Q,XK&
M_=O)T,>'@">)1W>R!M_)VIAG;\R*4=3SA%!A3AY!\.^ =ZB4!V(:?QK,J"WI
M$T_7;^CWH7?N92T<WAGU4Q:T&T6?(BAP(RI%#^;X%9M^;CQ>;I0+7S@VL;T(
M\LJ1*9MD9E!*7?_%2Z/#24+2/Y.0- E)X%T7"BRG@D266G,$ZZ,9S2]"JR&;
MR4GM#V5%EG<EYU$V=@[)@= %S*582R5)HH,%"E=9+$ 0W MIX4FH"J$#XZ*0
M7DZA8*;KF?#B7DZ1A%17< %2PT(JQ5Z7QL04?:$X;^A,:CK)&3I3S+LPZ%]#
MTDOZCZLI7%Y<_8\2<X-METG;91)@AV=@YT9OX0?:DDD?T!%/%3?]%QZ[JRY\
M,0>TVKM@O$6=O\(*\\H&(=ZI/6AK#T+MP9G:)_(U8H_/B?U=PX,O;273]5'?
MC+:M8R*<=/!KSO@P(RS=[W?8#5MVPW>5&1_XV,1:88</L^.$PFL>ZC6!.Z-!
M?8HUZ.< ZN_](4NZ-VE\.&42GTREO^ +8;=2.U"XX:Q>]^--!+:^-+5!9A\&
M=6V(QSXL=_S.H/4!O+\QAMX,/_OMRY7] U!+ P04    "  I:']4:79DL\0$
M  "+%@  &0   'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6S-6-]/XS@0_E>L
M:A]V)6ACI[] I1)0<8<$=X@N>P]H']QTVEHX=M=VVD7:/_YL-R2!)FF7Y:$O
M$#OSC6?FR\RX,UA+]:07  ;]C+G09XV%,<O35DM'"XBI;LHE"/MF)E5,C5VJ
M>4LO%="I!\6\18*@VXHI$XWAP._=J>% )H8S 7<*Z22.J7J^ "[79PW<>-FX
M9_.%<1NMX6!)YS &\["\4W;5RK1,60Q",RF0@ME9XQR?CL+  ;S$-P9K77A&
MSI6)E$]N<3T]:P3.(N 0&:>"VG\KN 3.G29KQX]4:2,[TP&+SR_:K[SSUID)
MU7 I^7]L:A9GC7X#36%&$V[NY?IO2!WJ.'V1Y-K_1>M4-FB@*-%&QBG86A S
ML?E/?Z:!V = 4@!Y \#M"D"8 L)] >T4T/:1V;CBXS"BA@X'2JZ1<M)6FWOP
MP?1HZSX3CO>Q4?8MLS@S/-<:C$943-$-HQ/&F6&@T2U0G2B8(FK0%64*?:,\
M ?1Y!(8R_@4=HX?Q"'W^] 5]0DR@KPN9:*M##UK&&N54MZ+4@,N- :3"@!%$
M313B(T0"@DO@H_WAP6MXRX8BBP?)XD&\OK!"7\'9-#3G5:'Y5Z![B!*EF)A[
MJ7^D4-G&!=5,H\<;JQ]=&XCU]QKKPLRZT%O7KF7K",V<E2MG95G -SJZ7H?+
M^]6PW>UW;'!7Q;AN2_5Q_Z272;TRL)T9V*XU\%8*>$:W5#W9DG65;'T1KY1V
M,J6= ^2DFUG7_7-.+NIU/.+O941N0)TBD>VPW7M#Y+94&(3=H)S(7N95K]:B
M/.9'Z%HL$^?A#:R (UP3LWZFO7^ C)YDUIU\0):=;)-3DF7;4MT^KLHR'.15
M.W@O/>@7^JTLQ(56@0^0-9R7;DP^(!-W**E(Q12U*Q=+Q&J2$>=U']<7_FJ^
M25WH\K*-VX=(;=X!<.?/J1VE2HK1QV$OJ(I^7N%Q?7E^:(Z;Z"^Y B7LE=>@
M\SF(Z!F-G=<^.G4^YA47]PZ1@[QFX_Y'I%>]DD=2GE[]+>9()VB_S:YMJ;#7
M#ZNJ:5[O<7W!W\FOK:GO:X@DK^@D.$#V25[\"?X ]G<HJ6 _177KV4^E]F2?
M%&[\]15_O)#*''\%%5MB5Z"-^P8\Y3 %1?EOI3O)2SH)#Y'PO"60^JO\GH37
M*RDG?)2B]BS4)&\3I+Y-5%-9W3_?2W3>/4CW$(G.^PZIO^KO272]DBJB>UN9
M74>TZT6O=_(:3NIK>/F][6('ZEI$/)G:R#.!(JH7?A#B'^!'PFPP_/?CYU.1
MC)=4/#LB(BFTY&Q*C45.**<B N1G,,VZ'_EY+PCK;_?EP;S8@2KZHGTB&)<(
MK) (^SOB T$5H(A3K=F,N5F01G1%&:<3#L<SJ8ZUC0^:PL0@G:5,$WTBS0Z*
M&>=NKB=GR'?7>=Y=Z2;+<HA3;.5&$$$\ 96-<_SYK. 5EV)>ZI19P+Z.:32U
MB6BDQ\34.!N>T00<*I;V0+.@ F%B%\(L="FAK<*\+08U]W-+;0]-A-G,2K+=
M;#9ZX4>(;_=)__32?O7;;^R':]^<E+T)@]/+S:"UE1^^&=/:GWQS)C3B,+.&
M!,V>+9=J,_G<+(Q<^EG@1!HC8_^X &JKGQ.P[V=2FI>%.R";/P__!U!+ P04
M    "  I:']4"0RO:_@#  !;$0  &0   'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6R]F-]OVCH4Q_\5*]K#)@T2.P'"!$@=77LK;5I5UMV'J_O@@B%6DYC9
M#JQ7]X^_QR%-@"2^5*UX@82<7_[ZY),31ELA'U7$F$:_DSA58R?2>OW)==4\
M8@E57;%F*5Q9"IE0#:=RY:JU9'21.R6Q2SRO[R:4I\YDE/]V*R<CD>F8I^Q6
M(I4E"95/GUDLMF,'.\\_W/%5I,T/[F2TIBLV8_I^?2OAS"VC+'C"4L5%BB1;
MCIT+_&E*0N.06_SD;*OVCI%9RH,0C^;D9C%V/%,1B]E<FQ 4OC9LRN+81((Z
M?A5!G3*G<=P_?HY^E2\>%O- %9N*^$^^T-'8"1VT8$N:Q?I.;/]@Q8)Z)MY<
MQ"K_1-O"UG/0/%-:)(4S5)#P=/=-?Q="[#G@H,6!% [D5 >_</#SA>XJRY=U
M236=C*38(FFL(9HYR+7)O6$U/#7;.-,2KG+PTY,I51'Z\BOC&QJS5*N/Z(XI
M+?E<LP7*+])T@6:1D+KS@\D$W:0;,$B,+9K&5"F^Y&!*%;K84![3AYAUH+LZ
M"N*A&9MGDFO.%'I_R31<_X ZZ'YVB=Z_^X#>(9ZB'Y'(%.10(U?#>DQ5[KRH
M_?.N=M)2^R6;=Y&//R+B$=S@/CW=W3MT=T'%4DI22DGR>'Y+O!G<8HL,5OU]
M66F!H-G0[$B+O[Z"*[K1+%%_6Q+[96(_3QRT)+Y(8'?X/V;#A-)-.N[\^[F_
MN;$WDZ ?]D"SS;Y<=:L0AT-26AT4%Y3%!=;BKJ50"MVGP)@XK_$:V-*TV=-=
MG-Y>^EYSZEZ9NF=-_45I#C<ZY+RB7**?-,Y8DSJ]6N(F=>I61IU!<XG]LL2^
MM<0KMF"2QNABQ=+YTUZ/6-IB4,8>G+<?PS)Q^+I^G(8U+;'?;]-R6*8=OE&G
M#6OI_>;4V*LPZKU%KTV+,(=+'WA>2_X]C&-K_F\B94_H&Y6/\.B_RH"GZ%]T
M#'?+WN**<OC,F,,5Y_!K05<$.+B7 S\8'-W+#6:^Y_?;=J%B';;#[E3BX#KK
M&LNLF]G*K+B([6"\[\ZZZ%ILF$S-@_Q%],$5VG#_S(U2D0\/7MLH@YJTI.<%
MQQM0M_('H=_R7,(5(+&=D*>C"M=1V?) QA4GL1V4)W=IG9--&C70%#1J@3FI
MB$KL1"V'SQ=0C%2\)/B\S4GVQD3R)O(78?X/$@UF%DB0"K;$#MOFF=^F0(5)
M$IQ9_ I]Y&UFPB),W][[I&%T#(?#H$7["IW$/A9^UQ&3Z*M(5QW]@@VH^$C.
M/!J2"GW$CKY3!Z4BS.$&!,=SFKOWYFO^=H !: 4D13%;@IO7'<#6R-V;_.Y$
MBW7^,OP@-+Q:YX<1HS"$&P.XOA1"/Y^8]^OR_Y3)?U!+ P04    "  I:']4
M^DY,ZH4"  "*!@  &0   'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6RU5<EN
MVS 0_15"Z"$!FFAQO""P!=AQ@P9H@"!!VD/1 RV-+2)<7')D)_WZ#BE;=1%'
M;0_UP>(R\][C&W$TWAK[Y"H 9,]*:C>)*L3U91R[H@+%W;E9@Z:=I;&*(TWM
M*G9K"[P,24K&69(,8L6%CO)Q6+NS^=C4*(6&.\M<K12W+S.09CN)TFB_<"]6
M%?J%.!^O^0H> !_7=Y9F<8M2"@7:":.9A>4DFJ:7LY&/#P&?!6S=P9CYDRR,
M>?*3FW(2)5X02"C0(W!Z;. *I/1 )./[#C-J*7WBX7B/?AW.3F=9< =71GX1
M)5:3:!2Q$I:\EGAOMA]A=YZ^QRN,=.&?;9O8P3!B1>W0J%TR*5!"-T_^O//A
M("%+WTC(=@E9T-T0!95SCCP?6[-EUD<3FA^$HX9L$B>T+\H#6MH5E(?YM=!<
M%X)+=J,=VIK\1L?.V+0LA;<M;#2U]R:>S &YD*?C&(G<0\3%CFC6$&5O$*49
MNS4:*\<^Z!+*WP%B4MU*S_;29UDGXAR*<]9+W[,LR=+'ASD[>7?: =MK'>D%
MV-X_.,*^?J(H=H.@W+<.CHN6XR)P7+S!<<L1K*>@>R3%#RC9BNZ/8\8R:9P#
M&M$+NR&G^4+"&?E_YK@$YJ"H+=4%W+$"-)R#P.DOXR9/QO'FB,Q^*[/?*7/Z
M6D$)"SR00:^HM630,3G]5W*R?N)_QT4-6E&#/WCW+%2M.JHP;)&&_ZW2HY9C
M]'<6,K*0';>0KH6E[E23$+IF'07NIDK9"W![3'-\T!\4V%7H@IZXUMBTBG:U
M;;33IK_\"F^Z]"VW*_^F2EA2:G(^I"K;IO,U$S3KT&T6!JEWA6%%'PNP/H#V
ME\;@?N()VL]/_A-02P,$%     @ *6A_5..XA,7$ @  T <  !D   !X;"]W
M;W)K<VAE971S+W-H965T-#,N>&ULC55=;]HP%/TK5M2'5EJ;+R!)!4@4-&W2
MJJ'2;@_3'DQR0ZPZ-K,=:/_];"?-* FL+XD_[KGGW.OKZ_&>BV=9 "CT4E(F
M)TZAU/;6=65:0(GE#=\"TSLY%R56>BHVKMP*P)D%E=0-/&_DEI@P9SJV:TLQ
M'?-*4<)@*9"LRA*+USN@?#]Q?.=MX8%L"F46W.EXBS>P O6T70H]<ULO&2F!
M2<(9$I!/G)E_.T^,O37X06 O#\;(1++F_-E,OF83QS."@$*JC >L?SN8 Z7&
MD9;QI_'IM)0&>#A^\_[9QJYC66,)<TY_DDP5$R=V4 8YKJAZX/LOT,0S-/Y2
M3J7]HGUM&P4.2BNI>-F M8*2L/J/7YH\' #\P0E T ""CP+"!A#:0&ME-JP%
M5G@Z%GR/A+'6WLS YL:B=32$F5-<*:%WB<:IZ4J715910#Q'WU4! LW25%20
MH6\$KPDEBH!$EPM0F- K=(V>5@MT>7&%+A!AZ+'@E<0LDV-7:3'&I9LVQ'<U
M<7""> 'I#0K]3RCP K\'/O\XW'L/=W4*VCP$;1X"ZR\\X6^)7_&:ZE!G+*M3
M@*E$OV9KJ80NM=]G*,*6(K04@Q,4]YA5N?95"<(V?0FKX2,+-[=O-_7#6.=F
M=YB6KE$0A'%K]$[9H%4V.*OLCO -L#Y)-6YXP!:/3I -6[+A6;*E@.M4+Y(4
MTS[*88<RBL)^RE%+.?H/)<]!FL:#*=+EBE+.I+[G^AR0!+$C*?16\*@C9>@E
M1^?1M0F3*.G7&[5ZH[-ZYV?2$W7Y1L<UTK4)$K]?4MQ*BL]*LKVA3T_<X?)C
M[TA/UR8(A_UZDE9/<E;/(U?Z++GM6+CI6/1?Q^I3FG1NSL"+@B.I7:-1-#@N
M/_>@WYJW[AZ+#6$24<@US+N)=*BB?C_JB>);VX+77.F&;H>%?G)!& .]GW.N
MWB:FJ[>/^/0O4$L#!!0    ( "EH?U2$M/LCR ,  !<.   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0T+GAM;+U7WV_;-A#^5PY"'UH@LT0Y=I+"-N#(ZQ8@
M'H(&W1Z&/3 2+1.E2(VD[738'[\C)4MV*BM;M_G!MG[P[KZ[[^XS.=DI_=FL
M&;/P7 AIIL':VO)]&)ITS0IJ!JID$M^LE"ZHQ5N=AZ;4C&;>J!!A'$7CL*!<
M!K.)?_:@9Q.UL8)+]J#!;(J"ZB^W3*C=-"#!_L%'GJ^M>Q#.)B7-V2.SG\H'
MC7=AXR7C!9.&*PF:K:;!G+Q/XL@9^!4_<[8S!]?@4GE2ZK.[N<NF0>00,<%2
MZUQ0_-FRA GA/"&.WVNG01/3&1Y>[[U_\,EC,D_4L$2)7WAFU]/@.H",K>A&
MV(]J]R.K$QHY?ZD2QG_#KEX;!9!NC%5%;8P("BZK7_I<%^+  /UT&\2U0?S2
M8'S"8%@;#'VB%3*?UH):.IMHM0/M5J,W=^%KXZTQ&RX=C8]6XUN.=G:6J*+@
M%GFQ!JC,(%'2<IDSF7)FX#N89QEW]:8"[F35-:[Z;Q?,4B[>X8I/CPMX^^8=
MO $N8<F%P/=F$EH$YT*$:0WDM@(2GP!"8(FAUP:^EQG+.NR35^SC'@<A5J4I
M3;POS6W<Z_$GM1W ,+J .(I)%Z!^\P5+T9QTF1_!&39,#;V_X=]@:OX54PMN
M4J',1C/X]1XMX<ZRPOS6$_>RB7OIXUZ>BKNF.L<(F@EJ6096P4YSRT"M5O@!
M5(^2\@R;4FY6.)4;C:@@5<9V-4$5Z\;'<A*SG0T'UY-P>UC7_C5'28R:)$:]
M2<Q_2."6*Z%RGIH+;.44_H0EU7^PTM)4Y3 7*PISIRD^23<*"RI2+K'U]^][
MBCEN<(S/2N)5$_>J-_\/7!=>4$'IC#D9+TNEK6<*U_(4Y]MJ3D77Y":5;Q(=
M,$)&IRBY;B!=__^4H,DCTUN>,ICGFC%?V9YZW33@;L[*$XE:/8[ZQPT'QXW5
M\FB<ZB0[V:D='M$3#:ZZV2$'?PSD%2#2:@< 6T,]"9Y7RE_2+QU%KI&0+B3#
M$TCB%DG<BZ2G*;ZI8Y;TF1>;XI_V#FF5FIQ7JDFKU>05L:Z[Q]3] M1 B?-.
M]PEVTG;Y-6W#07R"ME9R2;_F]M+V7_+2BB\YK_J25GY)O_Y^&R\=NCL>C$[P
MTNHNZ1?>!/>) D.BY&:<2GH!]_?)X"4G%#D9].7>2BDYKY;&K9;&_5KZ[_[U
M:N<W1V+V<BK"@ZUWP7"CY$XD!K<_&VFK77CSM#GUS/U>/VR75T<FG)><2P."
MK= 4%1S'2U>GD.K&JM)OY)^4Q6.!OUSCR8UIMP#?KY2R^QL7H#D+SOX"4$L#
M!!0    ( "EH?U0-;CG:$@,  #L)   9    >&PO=V]R:W-H965T<R]S:&5E
M=#0U+GAM;+56;6_3,!#^*Z>(#T."YJW;NJFMM+4@BJBH]@(?$!^\Y-I:.':P
MW7:5^/&<G304UD8@M"^)'=]S]]QS]CG]C=+?S!+1PF,AI!D$2VO+RS TV1(+
M9CJJ1$DK<Z4+9FFJ%Z$I-;+<@PH1)E%T%A:,RV#8]]]F>MA7*RNXQ)D&LRH*
MIK?7*-1F$,3![L,-7RRM^Q .^R5;X"W:^W*F:18V7G)>H#1<2= X'P17\>4X
M3AS 6WSBN#%[8W"I/"CUS4TF^2"('",4F%GG@M%KC2,4PGDB'M]KIT$3TP'W
MQSOO;WWRE,P#,SA2XC//[7(0] +(<<Y6PMZHS3NL$SIU_C(EC'_"IK:- LA6
MQJJB!A.#@LOJS1YK(?8 <7H$D-2 Y$] ]P@@K0'IWP*Z-:#KE:E2\3J,F67#
MOE8;T,Z:O+F!%].C*7TN7=UOK:953C@[O$'!+.8P8]IR-/ :KO*<NY(P 1-9
M;2Q7H),Q6L;%2[*8*L-X!M=<F8RCS @VD1DMW-^.X>3%2W@!7,*4"T% TP\M
M\731PJSF=%UQ2HYPFK(M1+U7D$1)=  ]:D>/,>M &A^%C]OA[YGL0!P=@H>D
M;2-PT@B<>'_I7PB\A3O-I&'5EO_R@4QA8K$P7UL"I4V@U ?J'@GTD9S=T9&$
M-X_4% S2J:PB6P6T2P1[4-J7\E!!*M<7WK5K%>MAU.GUP_4!/MV&3[>5SY0]
M\F)5M&1VVG@Z?5X)SYI 9^V4N4 Z<>1RQK;4W"SL0M\I&BY6-%%Z"U<RAQ&!
M>4:'9(QKZIZE-W^SIN?!'5\%/ML3N'M8WO.&ZWDKUXFTFJVYI68OB)#EKT>J
M* 5Z'F])'Z4A;=&DU\3I/:_X%TV@B]:$=I+_P[8=73Q1-3VL:AS]ZH=1*PWJ
M:@N4,-H/#3_@?^6.]QIR_+R"Q[]:4YRTYGI?SK4B_H)GOF/,T76-#.DFSH&6
MBM\K &RAT6=\L*TF3XH1G_Y1C7#OHG*_%5.F%UP:$#@G4-0YIT:@JYNZFEA5
M^KOK05FZ"?UP27\WJ)T!K<^5LKN)NPZ;_Z7A3U!+ P04    "  I:']46H5L
MD>4#  #U#   &0   'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6RU5\MNVS@4
M7;=?<2%TT0*-]; M)X5MP(D;-(,,$M3-S&(P"UJB+*(2J9)4' /S\7-)*8KC
MR&P*S&QL/7C./?=):KH5\KO**=7P4!9<S;Q<Z^J3[ZLDIR51 U%1CF\R(4NB
M\59N?%5)2E(+*@L_"H+8+PGCWGQJG]W*^534NF"<WDI0=5D2N3NGA=C.O-![
M?/"5;7)M'OCS:44V=$7U774K\<[O6%)64JZ8X"!I-O,6X:?+<&0 =L4?C&[5
MWC485]9"?#<W5^G,"XPB6M!$&PJ"?_?T@A:%84(=/UI2K[-I@/O7C^R7UGET
M9DT4O1#%GRS5^<P[]2"E&:D+_55LO]#6H;'A2T2A["]LF[5Q[$%2*RW*%HP*
M2L:;?_+0!F(/,!H? 40M(#H 8&3Z <,6,#P G 9' *,6,#H 1,=\&+> \6LE
MQ2T@MK%O@F4CO22:S*=2;$&:U<AF+FRZ+!H#S+BIK)66^)8A3L^O*:9%P0DL
MTI297),"KGA3L2;S[Y=4$U9\P!5WJR6\?_<!W@'C\"T7M2(\55-?HPQ#YB>M
MR?/&9'3$Y&]U,8!P\A&B( IZX!=N^$VB!S ,+3SL@2_=\$4E$1X<A7]VPY<T
M<5J_?#W\P'<?,]>E+^K2%UF^X='T*44IV"S"DJI$LLKF[:]K7 E7FI;J;X>=
M86=G:.V,7&4"]*%BLJF+E&C:%STWS6/PW[YY@P$8.H2-.F&CGPBS <!):X3Q
M#116J:2<;K&4-94E#IHN+GV2W0:X *71V;3C%)9).<2/._%C)[>=XR<B.ZE1
M,D%'-&!+M2X4C*Q9P?2NKT4:WMCRFLWC?AX'6$_W/6+B3DSL%'/'4Z8247/C
M:U;K6E*HR YW$=W7X_$+!>,]!4UD7ZZ)1N-1O\Q))W/BE'ESD&DN-.PP<(DH
M46J"VMWI/G?3[]'4TEC1.85,U%+G\*,F$@L*1&;;=^"H@-/.F]-?\L;6*_(G
M@FN)NVZ? V[&"*-!I(()E,B1*XBQ5W>N:CWKM)[]DE:<!GC"Z)T"9R\2'TX.
MJ^/RY:+)L1H.@Z?M+'C%H+HF:UA@)]UD&4LHK"J"O__ JEXWTA=2$KZA+VO[
MN=6]333\7\=P^#3OP^@_[-)ER_8L$V='H_RT&X3N.7Y0"A_;F0A:8%5HRM->
M+6[.;SE3<(WIXB9!&TEM>B G"H<B",DVS!Q.GO>)P.B:>K=SDW0C&N4QD9H%
MBCVTC> *_]-N$[IW@\,>>.W46?Z$MW?L*(IC(#T8.V&?'_[> =!\$/Q.)$9+
MH<@,S06#">X7LCEC-S=:5/9,N!8:3YCV,L?O$BK- GR?":$?;\PQL_O2F?\+
M4$L#!!0    ( "EH?U3>>13+2P(  +<%   9    >&PO=V]R:W-H965T<R]S
M:&5E=#0W+GAM;)5486_:,!#]*Z=(DS9I(R&!%56 1$'3)G42*EK[8=H'DQS$
MJA-G]J64?[^S$R**@&U?$I]][_G>L\_CG3;/-D<D>"U4:2=!3E3=AJ%-<RR$
M[>D*2U[9:%,(XM!L0UL9%)D'%2J,H^AS6 A9!M.QGUN:Z5C7I&2)2P.V+@IA
M]G>H]&X2](/#Q(/<YN0FPNFX$EM<(?VHEH:CL&/)9(&EE;H$@YM),.O?S@<N
MWR<\2MS9HS$X)6NMGUWP+9L$D2L(%:;D& 3_7G".2CDB+N-WRQET6SK@\?C
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M!8.1J4(U$Z]9H*S<T%A*-"/(A1OSD0!E+YCSE93XNK!SJ/OL3'X#4$L#!!0
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MBL?9Y098 $(WP/<KSM7Q1G\J*[_6SOX!4$L#!!0    ( "EH?U3/QY%U[P0
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MY9D55WG%@Z#K_')K1H6@:3Y<$2S/VLI ?K^@5!P>5(+J0G7T&U!+ P04
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M)ZKJ2-7$R-)=ZB_24(MPPXR:."H;0.\74IK=Q'Z@^5LP_@-02P,$%     @
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M5U1V ZVOI#3[%WM ,Q"/_P-02P,$%     @ *6A_5)*78&*_ P  * P  !D
M  !X;"]W;W)K<VAE971S+W-H965T-30N>&ULS5=9;R(Y$/XK5BL/&8G0%Y!#
M@,2Q1Z29%0IS/(SFP707M!6WS=KN$%;[X[?L;CI &C([FH=Y"7:UO_)7AZLJ
M_8U4CSH#,.0YYT(/O,R8]9WOZR2#G.JV7(/ +TNI<FIPJU:^7BN@J0/EW(^"
MH.?GE EOV'>RF1KV96$X$S!31!=Y3M5V#%QN!E[H[00/;)49*_"'_35=P1S,
MI_5,X<ZOM:0L!Z&9%$3!<N"-PKMI&%N ._&9P4;OK8DU92'EH]W<IP,OL(R
M0V*L"HH_3S !SJTFY/%WI=2K[[3 _?5.^^_.>#1F035,)/_"4I,-O!N/I+"D
M!3</<O,G5 9UK;Y$<NW^DDUU-O!(4F@C\PJ,#'(FRE_Z7#GB>P!1!8B. &'O
M!""N /$QH',"T*D '>>9TA3GARDU=-A7<D.4/8W:[,(YTZ'1?"9LW.=&X5>&
M.#.<E_$F<DGF1B:/5V-T8DHF,L?,TM3%Y@$2N1+L'Y1?SJ@"83(P+*'\';F<
M@J$,%U?DTWQ*+B_>D0O"!/F8R4)3D>J^;Y"EO<M/*D:3DE%T@E$8D0\2K]#D
M-Y%">JC 1_-J&Z.=C9/HK,8I)&T2ART2!5'80&CZ_?#@#)VX=GGL],6G7)ZA
M#Z\6K_T\4HJ*%>"K,F2Q)?OG9G3KQ*,-56GK$#:1VI"O[_$6<F\@U]_.<.S4
M'#N.8^<$Q[^*? '*9H6V++1=)3+/\3IMTX0PK0OD921)0&$*"+*02(WD8(':
MY@!G4#@<U9D%UXR;<J*DTW5T;*UZ&G9[MV'4]Y_V ]5P*@RZO?K4@:W=VM;N
M65L_2D-Y:5;E[;?(EOIZ>S3B3M ]XMIPJ!==-U/MU51[9ZG^ 0(4DL67148I
ME@.FC:*V<IZ)^76M_/J7S<N;FN/-SXW5^+R^K^&WI@#?O,JS* KBHP W' H[
M07. ;VO[;G\PP.1?ZUW[ %V=/N/+,'BI_<$O&_%PKT.%/_E]5@H/WEX0'(7O
MC4.'9&VK.92\5/LP_H$4&[^!NA<)+[#]V4*ZVDL*>I@4I[Q"<"(DV*;)%BA6
M8["=E& C<]6Y[H5.H^UJ6,[)1=".<<+@W(UC^.% @#3@V:H'G/8X-67M[_9:
M6*1W/<*"NF$+"_*)KM%"K%Z#&_7XMO5_F@C:PM3K5M)NRC!_;QS*0:W<6*D1
M5PA3ML!:6H^N8S>P'<DG=J1MD(_"Z&X2-B$PK/C%S7+^R]7E#/V!JA43FG!8
M(HV@?8VE0Y5C:;DQ<NT&M84T./:Y98:C/"A[ +\OI32[C;V@_N=@^!]02P,$
M%     @ *6A_5";:ZS%- P  % L  !D   !X;"]W;W)K<VAE971S+W-H965T
M-34N>&ULG5;;;MLX$/T50D6Z#E!8-]MQ6MM 8K=H'XH-DF[WH>@#+8TLHA3I
M)4=U\O=+4K)B9V6ZVQ=)O)PS<SBCX<QV4OW0)0"2QXH+/0]*Q.W;,-19"175
M0[D%858*J2J*9J@VH=XJH+D#53Q,HF@25I2)8#%S<W=J,9,U<B;@3A%=5Q55
M3[? Y6X>Q,%^XIYM2K03X6*VI1MX /QK>Z?,*.Q8<E:!T$P*HJ"8!S?QVV7L
M &['5P8[??!-K)2UE#_LX%,^#R+K$7#(T%)0\_H)2^#<,AD__FE)@\ZF!1Y^
M[]D_./%&S)IJ6$K^-\NQG ?3@.10T)KCO=Q]A%;0V/)EDFOW)+MV;Q20K-8H
MJQ9L/*B8:-[TL3V( T \.0%(6D#R$C Z 4A;0.J$-IXY62N*=#%3<D>4W6W8
M[(<[&X<V:IBP87Q 95:9P>'B'C(I,L89=:<J"_* %&N4ZHE\@!P4Y>23R&0%
MY M])(,U""@87I)[BD!0DJ6LME0\_:')^Z( %Q2WTZT/5H"4\<M9B,97:S',
M6K]N&[^2$W[%"?DL!9:&5N20'Q.$1F2G--DKO4V\C"O(AB2-WY D2N(>AY:_
M#H\\[J3=P:>.+SW!=W"H*Z8S+G6M@'R[66M4)K>_>TR,.A,C9V)TPH3EIDAT
M%]"B#:@RL>D+B9]ND,3#*+KH"^;R=Y!'FL:=IK&7RF;GBU1\_6J:Q,D[86J>
M2=^]QG:U3Z;?PB ZJ?(W@$<B)YW(B9?I#DR!$B"0Y,S\5 I$!KI/B9\F&J;C
MBSX=YV#CZ85'Q56GXNIL^F4*<H:]OOO!@_%P.NF/PAE@G R3_R"/!$P[ 5,O
MU<J<?"8W@KG2F->NWCVX.C!-"!6Y>:>$LXJAJYZ],OTF/,GF!XY&P_'+X!Z)
MO.Y$7GN)EB45&R!,D)^4U\TM0+FYW:E)NCY!?KID8D^_3X\?Y\(V]H8MCI[O
MM,A+]B>6H'KO'#\NLB[T^7X6EWK_F/C@-HZ]3,]W*)J_YU2=/D/B<JI7QO_&
M-3+"@_ZB K5Q;9<FF:P%-A=P-]NU=C>NH7DQ?VM;/M>W/-,T_>)GJC9,:,*A
M,)31\,K46M6T8,T Y=9U,6N)IB=RGZ5I6T'9#6:]D!+W VN@:X07_P)02P,$
M%     @ *6A_5!M_^R*E @  % <  !D   !X;"]W;W)K<VAE971S+W-H965T
M-38N>&ULC97;;N(P$(9?Q8I6VE;:-B>20 5(+:C:O=A5U=->FV1"K#HV:YM#
MWW['3AI1"*@WQ';F__EF[(S'6ZG>= 5@R*[F0D^\RIC5C>_KO(*:ZFNY H%O
M2JEJ:G"JEKY>*:"%$]7<CX(@]6O*A#<=N[4'-1W+M>%,P(,B>EW75+W? 9?;
MB1=Z'PN/;%D9N^!/QRNZA"<P+ZL'A3._<RE8#4(S*8B"<N+=AC>SS,:[@%<&
M6[TW)C:3A91O=O*KF'B!!0(.N;$.%!\;F 'GU@@Q_K6>7O>75K@__G"_=[EC
M+@NJ82;Y7U:8:N(-/5) 2=?</,KM3VCS2:Q?+KEVOV3;Q@8>R=?:R+H5(T'-
M1/.DN[8.>X)P<$(0M8+HJX*X%<0NT8;,I36GAD['2FZ)LM'H9@>N-DZ-V3!A
M=_')*'S+4&>F,UFOI !A-)$E,140NT+%^W=-YE""4E"09[HCMUH#!EW,P5#&
M+\D5>7F:DXMOE^0;88(\5W*MJ2CTV#>(9<W]O$6X:Q"B$PASR*])'/X@41"%
M/?+9U^7!9[F/Q>@J$G45B9Q??-*OS=I@UM1E?7/&-NYL8V<[.&%[F^=J3;DF
M6"0\_AK4!GJ+U=BDSL9^@YMI& 28V&:_)'U!HZ0+^D0XZ @'9PG_8,_ [J"H
M86))N-2:Y%2I=X*]8DM5_]8VELD>R"!+!N$![G%4-$J"$[Q)QYN<Y;6G,L>-
M8N8+G,D101B-XM$!YW%4E@U'_9AIAYF>Q;QG.SQ,=M>9,%0LV8)#>Z[Z0-,C
MA/@ \C@BZR?,.L+L+.$KY6O:-%6.79V*'/K(LJ,S=Y6&@^$A7D]8/(Q'Z0&C
MO]>S['WQFZHE$YIP*%$87&>8H&IZ<#,Q<N7:V$(:;(IN6.&U!<H&X/M22O,Q
ML9VQNPBG_P%02P,$%     @ *6A_5*86 ,JA!   ]Q(  !D   !X;"]W;W)K
M<VAE971S+W-H965T-3<N>&ULM5A14^,V$'Z^_@I-IM,Y9@!;2FPGUY 9()<V
MG>/*P-$^=/J@Q&NB.=O*R4H"_?5=V<8.V%$R!\<#V):^W4^[JV^%AANIOF8+
M $T>DCC-SCH+K9<?'">;+R#AV:E<0HHCD50)U_BJ[IULJ8"'.2B)'>:ZOI-P
MD79&P_S;M1H-Y4K'(H5K1;)5DG#U> &QW)QU:.?IPXVX7VCSP1D-E_P>;D'?
M+:\5OCF5E5 DD&9"ID1!=-8YIQ\FS#> ?,9? C;9UC,Q2YE)^=6\3,.SCFL8
M00QS;4QP_+.&2XAC8PEY?"N-=BJ?!KC]_&1]DB\>%S/C&5S*^&\1ZL59I]\A
M(41\%>L;N?D=R@5YQMY<QEG^FVR*N8'?(?-5IF52@I%!(M+B+W\H [$%H+T=
M %8"V*& ;@GHO@3LHM0K ;U#/7@EP#L4X)> /)E.$:P\TF.N^6BHY(8H,QNM
MF8<\73D: RQ24UFW6N&H0)P>3=.Y3(!\X0^0D1-R'H;"9)S'9)H6=6OR_WX,
MFHOX"&?<W8[)^Y^/AHY&[\:&,R\]712>V Y/?ZS24\(&QX2YS&V!7]KA8YB?
MDB[-X;0%/CX<WN;]X\%P.FB!3PZ&N\%SN(,)J[+&JJRQW%YW;];(/Y]PC$PU
M)-F_%LO=RG(WM]S;;1D%*@/R/H3BZ8B(E*QYO"I*@<<H1CR=0UL*"]M^;MMH
MVGITPKK4-3]#9[V=K>9,?_!\WC/ZO8I^STK_-R6SC$00@L(2OOF%)\M?QT1C
MG' Q6-HG"F*N(33B PH_Y6,\RT!G^$W!7-ZGXC\(VU97N/:V.%./64A[%6G/
M2OHNK?WF?&:00B1T&P>OP:$7N+UF?)OSV,#S&O,^>HT\T'Y =R[)KY;D6Y>$
ME5F%&IL@C[5 ?9$*:TECE#--[*'V&_1?+M VXQGEH*(<[,G"'!2J7)JG8"FS
M7 BS-G;!7G9!(ZP[V/4K=GTKNTE9TO7.MVSV065T\,8R0MVZK[A6PI_Q5(3G
M'X6JD=Z3V&S+.5?J$9O*AJNP-:ZER>VP,>;W6O1CTC*5>G[7LAOI5DNDKZ).
MX&$I5"&'C\!5ZU+L+IC;M?4!6C<"RE['=<'79D2DJ'@B%1I(+*)6\2X]/8L^
M[=M4F=9=A=K;RI=*@5_0XVL\5_!9#$1+(J,(A9A$*[U24*FXV8ZQX#,1"Z,B
MK=2[36FF/1OSNJ%0>T>Y;+(^+@H 4-F4D&WZ-=YC].D\\-.[=PS5VU8)=1.A
M]BZRIQ*.][8WVNP97=:W!;'N!M3>#FXU=H+#M(O6>DV#MU:O6FVI76Z_2[WZ
MC?U31&]7^&J9IH,?+TAV%RA(S'8PK76?V77_!^]TUM3]P+,$F=6JS^R2?'G^
M:3KY\^;S]-P6AZT3^EL?T5FMILRNIM]3G:PID8%KV]VLEDAF5[-7*T]I_X#C
M$JOED-GE\(H_B&25$)[(58K\HKRZRKI#LKLVR@5K'HD]VS9FM0HRNPK>P+>5
M,/]S7&$C-MRP./(-4=1**QF_><QI)>-L70&8*Z$KKNY%FI$8(D2ZIP&N2A6W
M+,6+ELO\5F FM99)_K@ CIDR$W \DE(_O9B+ANJN:_0_4$L#!!0    ( "EH
M?U3M=7PJN0(  "H'   9    >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;*U5
M36_;, S]*X310PML=6PG<5LD 9IDPWHH4/1C.PP[*#83"Y6E3)*;=K]^E)QX
M:>)D.^QBBQ3Y^$A1U&"E]+,I$"V\ED*:85!8N[P*0Y,56#)SKI8H:6>N=,DL
MB7H1FJ5&EGNG4H1QI],/2\9E,!IXW9T>#51E!9=XI\%49<GTVQB%6@V#*-@H
M[OFBL$X1C@9+ML 'M$_+.TU2V*#DO$1IN)*@<3X,KJ.K2>KLO<%7CBNSM0:7
MR4RI9R?<Y,.@XPBAP,PZ!$:_%YR@$ Z(:/Q<8P9-2.>XO=Z@?_:Y4RXS9G"B
MQ#>>VV(87 20XYQ5PMZKU1=<Y]-S>)D2QG]A5=NF20!99:PJU\[$H.2R_K/7
M=1VV'*+^ 8=X[1#O.G0/."1KA\0G6C/S:4V99:.!5BO0SIK0W,+7QGM3-ERZ
M4WRPFG8Y^=G1D]28J87DOS 'RUYAAA+GW,+I%"WCX@P^PM/#%$Y/SN $N(3'
M0E6&R=P,0DOQ'4J8K6.-ZUCQ@5A1#+=*VL+ )YEC_AX@).(-^WC#?AP?19QB
M=@Y)] 'B3ARU$)K\NWOG")VD*6;B\9(#>#<R4R7"(Y5QRDTFE*DTPO?KF;&:
M^O7'D1#=)D37A^@>"#'&!9>2RP6,F6 RP[9CJ"'Z'L)=XY=1?-GK#<*7[=+L
M&T47:=08O6/7:]CUCK*C M H,1A2]]2K,U!SJ XTF2'A&:5KJZ7F2L,;,MW6
M6),Z;&^+[$=*J9ULOR';_[]D-0IFG5+1S=0:I?6$VTZ@O\<W2KN7.R?08I2D
ME^U)I4U2Z=&DZ&;]I3G2O7/OIIWN#K5]HW<=5%,+M\9.B7KAI[&!3%72UG>X
MT38#_]K/N1W]F!Z">F[_@:E?D5NFJ=\-")P39.<\I6KI>C+7@E5+/]QFRM*H
M],N"'C/4SH#VYTK9C> "-,_CZ#=02P,$%     @ *6A_5&7/,K4;!0  Z!@
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M=E^Q36A@^3+!E/N%71L;!9#52HNR!1L%)>7-DSRV1G0 \? 50-("DD/ Z2N
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MW.&7!90-P/-<2G/:V%G4?JN2/U!+ P04    "  I:']49*=^7?P"   V"0
M&0   'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6R]5LENVS 0_15"R"$!VFBS
M93FP#7A)VP -&L1)>RAZ8*2Q)40B59*RT[_OD)+EW? AR,46R9DW;S8.>TLN
M7F4"H,A;GC'9MQ*EBAO;EE$".977O "&)S,N<JIP*>:V+ 30V"CEF>TY3F#G
M-&76H&?V'L2@QTN5I0P>!)%EGE/Q;P097_8MUUIM/*;S1.D->] KZ!RFH)Z+
M!X$KNT&)TQR83#DC F9]:^C>C%U/*QB)GRDLY<8WT:Z\</ZJ%W=QWW(T(\@@
M4AJ"XM\"QI!E&@EY_*U!K<:F5MS\7J%_,<ZC,R]4PIAGO])8)7TKM$@,,UIF
MZI$OOT'M4%OC13R3YI<L:UG'(E$I%<]K9620IZSZIV]U(#84W."(@E<K>+L*
MK2,*?JW@&T<K9L:M"55TT!-\28261C3]86)CM-&;E.DT3I7 TQ3UU. 1I!)E
MI$J1LCGY3*95.@F?D>VC<4+%'"3N1ES$$).4D3'/"\Z *2W^HP!!E1:]?<,B
MDRA[.0%%T^P*<9^G$W)Y<44NM-Y3PDM)62Q[MD(?-!,[JOF.*K[>$;ZN1^XY
M4XDDMPQ9; /8Z'P3 6\5@9%W$G$"T37QW4_$<SSW *'Q^>K."3I^DQ#?X/EG
M)63,I2)#%NMD@%@ ^?T=Y<F=@ES^.6&MU5AK&6NMX]: BB@AF VL_@6V=8%-
MJ@XEID(*#)*^'1:#( S#;L]>;$9K7ZKM=3OM1FJ+9KNAV3Y)\RLP+*[,L*0Q
MMD&*0:+Z CA$M,)J;U!PPV[@[Q!M[Q%U S=T#A,-&J+!2:)/7"%-L97#J.J<
M0TR#/:8M-P@/4^@T%#KGIW2R3NFJ+4]43=B8"#^@1KN-M>Z[U6AW/Z".=Z3X
M7&=]1SIGE]_P1/EMPV]<P>X'A-/UUO:\=^RF&FRK45K^3DCMC0F4 Y:['LR2
M1+QDJKJ*F]UF^ _-R-O9'^E'@9EL:YCJ17&/790R23*8(:1SW<$LBVI(5PO%
M"S/G7KC"J6D^$WS8@- ">#[C7*T6VD#S5!K\!U!+ P04    "  I:']4P >-
MI&H#   6#0  &0   'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6RU5]%NVS84
M?>Z^@A"&H06Z2*0=Q^UL W;28BD:('#6[6'8 RU=VT1%424I.P;V\;VD',EH
M;,;&YA=;I'@.[SV7/+@:K)7^:I8 ECS*O###:&EM^3Z.3;H$R<V%*J' -W.E
M);<XU(O8E!IXYD$RCUF2]&+)11&-!G[N7H\&JK*Y*.!>$U-)R?5F KE:#R,:
M/4U,Q6)IW40\&I1\ 0]@OY3W&D=QPY()"841JB :YL-H3-]?,P_P*_X4L#8[
MS\2E,E/JJQO<9L,H<1%!#JEU%!S_5G ->>Z8,(YO6]*HV=,!=Y^?V#_ZY#&9
M&3=PK?*_1&:7PZ@?D0SFO,KM5*U_AVU"EXXO5;GQOV1=K[WJ122MC%5R"\8(
MI"CJ?_ZX%6('0 \!V!; C@5TMH".3[2.S*=UPRT?#;1:$^U6(YM[\-IX-&8C
M"E?&!ZOQK4"<'3U4,P/?*B@L^;!RO[^2<98))S'/R6U1'Q0G^.L;L%SDY@TN
M^?)P0U[__&806PS!$<7I=KM)O1T[L!TE=ZJP2T,^%!ED>_#7+^!9@"#&W!L!
MV), $Q9DO./Z@G3H6\(2QO8%%(;?0-K :2"<3E./CN?K'%N/OS_C"G)K09I_
M OS=AK_K^;L'^#\#GGD"CZ70=5DS;F%?VF&:<>E42][^].H5)MX)!';9!'89
M9/Q#63QP&!A:!)A]$=7XGL<[=UJ-NK373Y)D$*_V;-QK-NX%-_Y1\4 N5PWE
MU5F*V&_X^_]-JTG_F59.J$-2O6OV?7>25.1?@E.Y/U)CK7FQ !E6D":M+R5G
MT9#N.!\]XBK<\XV+V9 II"!6'-/9:VOTF:(LH"AE;13L?[F0DQ=XCK^1M/4B
MVCFUWA.A%E"0\4+#B[5N/8EVSU/KUEQHV%V.5SG,<\<WSNUKD5DHM-9^Z&G^
M@R*/LY4P2K<JX]P4SZDJ,O*)2S#D%R[+W\C8&)4*S,2$(FE=BY['MFCK6S1L
M7-O$-F0.F$3)-P>OVW,#HTGHOK461D_VL-/EQ@5W_%'(2H8ZD-;KV'F\CK5>
MQ\)>-P4A9Y4V=7IJ3OA.)?85@!WPNQ_DCW<Z3PEZX1MR0U)5%;9N0IO9IND?
M^U8W;I?77PS8B"U$84@.<X0F%U=X$W7=A-<#JTK?Q\Z4Q:[8/R[QPP6T6X#O
MYTK9IX';H/D4&GT'4$L#!!0    ( "EH?U0 =$*&)@,   P3   -    >&PO
M<W1Y;&5S+GAM;-U846_:,!#^*Y$[39TT-4!&2E9 VI J3=JF2NW#WBI#'+#D
MV)EC.NBOGR\."5 ?8GW88(D@]GV^[S[[+MAB6)JU8/<+QDRPRH4L1V1A3/$Q
M#,O9@N6TO%(%DQ;)E,ZIL5T]#\M",YJ6X)2+L-?IQ&%.N23CH5SFM[DI@YE:
M2C,B_<84N,>7=$2Z\0<2.+J)2MF(/%Z^_;E4YN9-X)X7[R\N.H_O;O;MEQ7P
MCH1>TOX1I%>=#DX,($8>'T=^B!NCOCZ*^@ S1CS8)6Z)=AS#.F7C8:9DF[F(
M.(-EICD+GJ@8D0D5?*HY>&4TYV+MS#TPS)10.C"V9&RH+EC*9P=W70^JJ>;)
MN52ZBNTBN.]I/7P/V/1 (!>B$=@CSC >%M08IN6M[52#*^,+**C;#^O"*IQK
MNN[V^J1UJ!XVR%3IE.DF3)=L3..A8!G(T7R^@*=110B@,2JWC933N9*TTK#Q
MJ!N6=L:$N(=7[4>VP[W*MG+6@8S)IFD%U4U'XSK O\WFN+=I>Z_B#0K^I,SG
MI9V.K/I09.Q.LXROJOXJ:P1@[%V<G1:%6'\2?"YSYB9_=,#QD&[\@H72_-E&
M@U*960/3)'ABVO#9MN67IL4#6YE-.:TR7'/O##7_W76>,\DT%=NB;>V?\BJ_
M6G%T_:\D5[\J^X*]&NO]\]1%]L]!9'P.(L^B)@>G+S)*3E)C6._?6X>$G2-"
M8PW@*#8BW^%0)]J@P73)A>&R[BUXFC+YXJ1@Z0V=VJ/^#K\=G[*,+H5Y:, 1
M:=O?6,J7>=*,NH.%J$>U[:\PO6[<G -M+"Y3MF+II.[J^;1J!K9AH]87..PC
MM]7E1S ?A_D1P+ XF +,QWEA<?ZG^0S0^3@,TS;P(@/49X#Z."\?,JEN+([?
M)[&7?Z9)$D5QC*WH9.)5,,'6+8[AXV?#M($'%@<B_=E:X]G&*^1P'6 Y/50A
MV$SQ2L1FBJ\U(/YU X\D\6<;BP,>6!:PVH'X_CA04WZ?*(*L8MJP-QA'D@1#
MH!;]-1K'R.K$</OS@[TE490D?@0POX(HPA!X&W$$4P :,"2*JGUP;S\*-_M4
MV/[_-?X-4$L#!!0    ( "EH?U27BKL<P    !,"   +    7W)E;',O+G)E
M;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]
M/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>-8?20$3;8T.P6BP^
M0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS#O#-TG\R]_,,-47E
M2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<
M8R6,<6*T_C6"R0_L?@!02P,$%     @ *6A_5';;%<."!0  "2L   \   !X
M;"]W;W)K8F]O:RYX;6S%FMM2XS@00']%E9=AJY8-\24S0P%5+)==JAB@",/K
MEF(K1(4M9229V]=/RTYFVB1T[4O#"^ +SDG;ZM,M>>_1NONIM??BJ:Z,WQ_,
M0UCL#H>^F*M:^K_L0ADX,K.NE@$VW=W0+YR2I9\K%>IJF.SLC(>UU&9PL+>Z
MUI4;X@T;5!&T-; S[KC5ZM'_/AXWQ8/V>JHK'9[W!^W?E1J(6AM=ZQ=5[@]V
M!L+/[>._UND7:X*L)H6S5;4_&'4';I4+NEC;/8F0-W+JVSU!3J\E@.P/QCMP
MP9EV/K1GM->7P/B@X.1NJPGV5%=!N6,9U#_.-@MM[N)EX%L,T==HX[#ZW05Q
MU_V?,-K93!?JV!9-K4SHXNA4%0&-G^N%'P@C:[4_6)TBI"G%B0D0)'%FNDO!
MN?&;PD>?E=VW#H"+8NAV-1QP9V4+S@=Y!-NVTB5\>BG^EI4TA1)M<#T"3 C
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M+5!D+5!D+5!D+5!D+?Y3UF=KEW\</SSSUM3=(9\-__^:O0%02P$"% ,4
M"  I:']4!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( "EH?U0%815 [0   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( "EH?U297)PC
M$ 8  )PG   3              "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ *6A_5)0&JB@C!P  H1P  !@              ("!# @
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( "EH?U21&8\2
MO04  +46   8              " @64/  !X;"]W;W)K<VAE971S+W-H965T
M,BYX;6Q02P$"% ,4    "  I:']4E.2O;+X"  !%"0  &
M@(%8%0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ *6A_
M5-/1ED90!   .A   !@              ("!3!@  'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;%!+ 0(4 Q0    ( "EH?U3], 7EL0(  .\&   8
M      " @=(<  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M"  I:']4]X9[ ]D$  !\%0  &               @(&Y'P  >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL4$L! A0#%     @ *6A_5,]??1IG @  8P4  !@
M             ("!R"0  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4
M Q0    ( "EH?U1.O];Z_P4  '$6   8              " @64G  !X;"]W
M;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  I:']4]-O"K1 #  !^
M!@  &               @(&:+0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
M4$L! A0#%     @ *6A_5(HD5%R9!   0 H  !D              ("!X#
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  I:']4\7!'
M'5\:   T4   &0              @(&P-0  >&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;%!+ 0(4 Q0    ( "EH?U3#'C/E(@0  "<*   9
M  " @490  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @
M*6A_5)NZ=$K/ P  :@D  !D              ("!GU0  'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6Q02P$"% ,4    "  I:']4H(GAF9L"  ">!0  &0
M            @(&E6   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4
M Q0    ( "EH?U38$5F>>P8  +X/   9              " @7=;  !X;"]W
M;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ *6A_5&V8CIP<!0
M= P  !D              ("!*6(  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6Q02P$"% ,4    "  I:']4JDN;,1D&  !;#P  &0              @(%\
M9P  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( "EH?U1#
M!A2T/@H  $@;   9              " @<QM  !X;"]W;W)K<VAE971S+W-H
M965T,3@N>&UL4$L! A0#%     @ *6A_5$HXH44Y#0  4"0  !D
M     ("!07@  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "EH?U2$2L^-]0,  *X(   9              "
M@4&9  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ *6A_
M5-V"8+M*!   ZPD  !D              ("!;9T  'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6Q02P$"% ,4    "  I:']4Q.=Y[DX;  !R6   &0
M        @('NH0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0
M   ( "EH?U3PI=WW_P,  +\)   9              " @7.]  !X;"]W;W)K
M<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ *6A_5)XOVL5R P  E @
M !D              ("!J<$  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q0
M2P$"% ,4    "  I:']4R69(\JD"  "6!0  &0              @(%2Q0
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( "EH?U0$><KR
M- 0  %@*   9              " @3+(  !X;"]W;W)K<VAE971S+W-H965T
M,S N>&UL4$L! A0#%     @ *6A_5-Y$W):"!0  ^0P  !D
M ("!G<P  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  I
M:']4M,E@-YH$  "_"P  &0              @(%6T@  >&PO=V]R:W-H965T
M<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( "EH?U2X]$WTA0(  )T%   9
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M970S-RYX;6Q02P$"% ,4    "  I:']4U]ATG+(#  #E#P  &0
M    @($RY0  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (
M "EH?U2:0E.34P(  ,4$   9              " @1OI  !X;"]W;W)K<VAE
M971S+W-H965T,SDN>&UL4$L! A0#%     @ *6A_5&EV9+/$!   BQ8  !D
M             ("!I>L  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"
M% ,4    "  I:']4"0RO:_@#  !;$0  &0              @(&@\   >&PO
M=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( "EH?U3Z3DSJA0(
M (H&   9              " @<_T  !X;"]W;W)K<VAE971S+W-H965T-#(N
M>&UL4$L! A0#%     @ *6A_5..XA,7$ @  T <  !D              ("!
MB_<  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    "  I:']4
MA+3[(\@#   7#@  &0              @(&&^@  >&PO=V]R:W-H965T<R]S
M:&5E=#0T+GAM;%!+ 0(4 Q0    ( "EH?U0-;CG:$@,  #L)   9
M      " @87^  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%
M  @ *6A_5%J%;)'E P  ]0P  !D              ("!S@$! 'AL+W=O<FMS
M:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    "  I:']4WGD4RTL"  "W!0
M&0              @('J!0$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+
M 0(4 Q0    ( "EH?U3VM:M&AP(  ((&   9              " @6P( 0!X
M;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ *6A_5"/Q5VO
M @  R 8  !D              ("!*@L! 'AL+W=O<FMS:&5E=',O<VAE970T
M.2YX;6Q02P$"% ,4    "  I:']4??OY.#,%  "Y%0  &0
M@($A#@$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( "EH
M?U3/QY%U[P0  %P5   9              " @8L3 0!X;"]W;W)K<VAE971S
M+W-H965T-3$N>&UL4$L! A0#%     @ *6A_5)^4R?3Q @  (@@  !D
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M=#4V+GAM;%!+ 0(4 Q0    ( "EH?U2F%@#*H00  /<2   9
M  " @?LI 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @
M*6A_5.UU?"JY @  *@<  !D              ("!TRX! 'AL+W=O<FMS:&5E
M=',O<VAE970U."YX;6Q02P$"% ,4    "  I:']49<\RM1L%  #H&   &0
M            @('#,0$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4
M Q0    ( "EH?U2PM&+$HP(   T'   9              " @14W 0!X;"]W
M;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ *6A_5!!7V[2=!
MCQ(  !D              ("![SD! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX
M;6Q02P$"% ,4    "  I:']4-WBP&,D"  "E"   &0              @('#
M/@$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( "EH?U1:
MM[?<EP(  +<&   9              " @<-! 0!X;"]W;W)K<VAE971S+W-H
M965T-C,N>&UL4$L! A0#%     @ *6A_5&2G?EW\ @  -@D  !D
M     ("!D40! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( "EH?U2U<6!\%@(  *HF   :
M          "  4Y5 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( "EH?U32-&04[ $   <F   3              "  9Q7 0!;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@    !) $D ]A,  +E9 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>134</ContextCount>
  <ElementCount>298</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>65</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureNatureOfOperations</Role>
      <ShortName>Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLiquidity</Role>
      <ShortName>Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Other Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureOtherAccruedLiabilities</Role>
      <ShortName>Other Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Stock Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Collaborations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborations</Role>
      <ShortName>Collaborations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Interest and Other Income (Expense), Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureInterestAndOtherIncomeExpenseNet</Role>
      <ShortName>Interest and Other Income (Expense), Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Net Loss per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFinancialInstruments</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Other Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureOtherAccruedLiabilitiesTables</Role>
      <ShortName>Other Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureOtherAccruedLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Stock Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Interest and Other Income (Expense), Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureInterestAndOtherIncomeExpenseNetTables</Role>
      <ShortName>Interest and Other Income (Expense), Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureInterestAndOtherIncomeExpenseNet</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringTables</Role>
      <ShortName>Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuring</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Nature of Operations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureNatureOfOperationsAdditionalInformationDetail</Role>
      <ShortName>Nature of Operations - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Liquidity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail</Role>
      <ShortName>Liquidity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Assets and Liabilities Measured at Fair Value - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Assets and Liabilities Measured at Fair Value (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Cash Equivalents, Restricted Cash and Short-Term Investments Classified as Available-for-sale Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail</Role>
      <ShortName>Cash Equivalents, Restricted Cash and Short-Term Investments Classified as Available-for-sale Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Financial Instruments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail</Role>
      <ShortName>Financial Instruments - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Schedule of Other Accrued Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail</Role>
      <ShortName>Schedule of Other Accrued Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Related Parties - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail</Role>
      <ShortName>Related Parties - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail</Role>
      <ShortName>Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Schedule of Maturity of Operating Lease Liabilities - (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail</Role>
      <ShortName>Schedule of Maturity of Operating Lease Liabilities - (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Schedule of Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationDetails</Role>
      <ShortName>Schedule of Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Stock Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Summary of Option Activity Under Company's Equity Incentive Plans (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail</Role>
      <ShortName>Summary of Option Activity Under Company's Equity Incentive Plans (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Fair Values of Stock Options Estimated Using Black-Scholes Valuation Model (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail</Role>
      <ShortName>Fair Values of Stock Options Estimated Using Black-Scholes Valuation Model (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Summary of Stock-Based Compensation Recognized (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail</Role>
      <ShortName>Summary of Stock-Based Compensation Recognized (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Summary of Stock-Based Compensation Recognized (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail</Role>
      <ShortName>Summary of Stock-Based Compensation Recognized (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Reconciliation of Statutory Federal Income Tax (benefit) Rate to Company's Effective Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail</Role>
      <ShortName>Reconciliation of Statutory Federal Income Tax (benefit) Rate to Company's Effective Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Components of the Company's Deferred Tax Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail</Role>
      <ShortName>Components of the Company's Deferred Tax Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Unrecognized tax benefit (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureUnrecognizedTaxBenefitDetail</Role>
      <ShortName>Unrecognized tax benefit (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Collaborations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail</Role>
      <ShortName>Collaborations - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Detail of Interest and Other Income (Expense), Net (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeExpenseNetDetail</Role>
      <ShortName>Detail of Interest and Other Income (Expense), Net (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Anti-dilutive Security not Included In Diluted per Share Calculations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail</Role>
      <ShortName>Anti-dilutive Security not Included In Diluted per Share Calculations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Restructuring - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail</Role>
      <ShortName>Restructuring - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Restructuring - Summary of Restructuring Charges Recorded in Component of Operating Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail</Role>
      <ShortName>Restructuring - Summary of Restructuring Charges Recorded in Component of Operating Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="cbio-10k_20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Subsequent Event - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails</Role>
      <ShortName>Subsequent Event - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="cbio-10k_20211231.htm">cbio-10k_20211231.htm</File>
    <File>cbio-20211231.xsd</File>
    <File>cbio-20211231_cal.xml</File>
    <File>cbio-20211231_def.xml</File>
    <File>cbio-20211231_lab.xml</File>
    <File>cbio-20211231_pre.xml</File>
    <File>cbio-ex108_9.htm</File>
    <File>cbio-ex231_8.htm</File>
    <File>cbio-ex311_11.htm</File>
    <File>cbio-ex312_6.htm</File>
    <File>cbio-ex321_7.htm</File>
    <File>cbio-ex322_10.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>guycyz0ib1ig000001.jpg</File>
    <File>guycyz0ib1ig000002.jpg</File>
    <File>guycyz0ib1ig000003.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="414">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>88
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cbio-10k_20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 23,
   "contextCount": 134,
   "dts": {
    "calculationLink": {
     "local": [
      "cbio-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cbio-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cbio-10k_20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cbio-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cbio-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cbio-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 494,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 16,
    "http://www.catalystbiosciences.com/20211231": 1,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 21
   },
   "keyCustom": 59,
   "keyStandard": 239,
   "memberCustom": 34,
   "memberStandard": 28,
   "nsprefix": "cbio",
   "nsuri": "http://www.catalystbiosciences.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiquidationBasisOfAccountingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Liquidity",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLiquidity",
     "shortName": "Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiquidationBasisOfAccountingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Fair Value Measurements",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Financial Instruments",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Other Accrued Liabilities",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureOtherAccruedLiabilities",
     "shortName": "Other Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Commitments and Contingencies",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Related Parties",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Leases",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Stock Based Compensation",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensation",
     "shortName": "Stock Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Income Taxes",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Collaborations",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborations",
     "shortName": "Collaborations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestAndOtherIncomeTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Interest and Other Income (Expense), Net",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureInterestAndOtherIncomeExpenseNet",
     "shortName": "Interest and Other Income (Expense), Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestAndOtherIncomeTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Stockholders' Equity",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Net Loss per Share Attributable to Common Stockholders",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders",
     "shortName": "Net Loss per Share Attributable to Common Stockholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Restructuring",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuring",
     "shortName": "Restructuring",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Subsequent Event",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEvent",
     "shortName": "Subsequent Event",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cbio:SaleSecuritiesAvailableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cbio:SaleSecuritiesAvailableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Other Accrued Liabilities (Tables)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureOtherAccruedLiabilitiesTables",
     "shortName": "Other Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cbio:SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Leases (Tables)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cbio:SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Stock Based Compensation (Tables)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InterestAndOtherIncomeTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Interest and Other Income (Expense), Net (Tables)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureInterestAndOtherIncomeExpenseNetTables",
     "shortName": "Interest and Other Income (Expense), Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InterestAndOtherIncomeTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables",
     "shortName": "Net Loss per Share Attributable to Common Stockholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Restructuring (Tables)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringTables",
     "shortName": "Restructuring (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_cbioSegment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Nature of Operations - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureNatureOfOperationsAdditionalInformationDetail",
     "shortName": "Nature of Operations - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_cbioSegment",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Liquidity - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail",
     "shortName": "Liquidity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LiquidationBasisOfAccountingTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20211231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "cbio:ConcentrationRiskCreditRiskPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20211231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "cbio:ConcentrationRiskCreditRiskPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20211231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_cbioLongTermInvestmentsMember_20211231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Assets and Liabilities Measured at Fair Value - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail",
     "shortName": "Assets and Liabilities Measured at Fair Value - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "link:footnote",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_us-gaapFairValueByAssetClassAxis_us-gaapUSGovernmentAgenciesDebtSecuritiesMember_us-gaapInvestmentTypeAxis_cbioLongTermInvestmentsMember_20211231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated Statements of Operations",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OperatingExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Assets and Liabilities Measured at Fair Value (Detail)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail",
     "shortName": "Assets and Liabilities Measured at Fair Value (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "cbio:SaleSecuritiesAvailableTextBlock",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cbio:AmortizedCostAvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Cash Equivalents, Restricted Cash and Short-Term Investments Classified as Available-for-sale Securities (Detail)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail",
     "shortName": "Cash Equivalents, Restricted Cash and Short-Term Investments Classified as Available-for-sale Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "cbio:SaleSecuritiesAvailableTextBlock",
       "us-gaap:FinancialInstrumentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cbio:AmortizedCostAvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cbio:GrossRealizedGainLossNetAvailableForSalesSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Financial Instruments - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail",
     "shortName": "Financial Instruments - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cbio:GrossRealizedGainLossNetAvailableForSalesSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cbio:AccruedManufacturingExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Schedule of Other Accrued Liabilities (Detail)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail",
     "shortName": "Schedule of Other Accrued Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cbio:AccruedManufacturingExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20211101_20211130",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "cbio:ChargesRelatedToWriteOffOfPrepaidManufacturingCost",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_srtCounterpartyNameAxis_cbioAGCBiologicsIncMember_srtProductOrServiceAxis_cbioMarzeptacogAlfaActivatedAndDalcinonacogAlfaMember_20211231",
      "decimals": "-5",
      "lang": null,
      "name": "cbio:FirmWorkOrderSupportingClinicalTrials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200508_20200508",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Related Parties - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail",
     "shortName": "Related Parties - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_cbioMosaicBiosciencesIncMember_20200508_20200508",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseExpirationDate1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Leases - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "lang": "en-US",
      "name": "cbio:LesseeOperatingLeaseRenewalTermDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail",
     "shortName": "Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Schedule of Maturity of Operating Lease Liabilities - (Detail)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail",
     "shortName": "Schedule of Maturity of Operating Lease Liabilities - (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cbio:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Schedule of Supplemental Cash Flow Information (Details)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationDetails",
     "shortName": "Schedule of Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cbio:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Stock Based Compensation - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Summary of Option Activity Under Company's Equity Incentive Plans (Detail)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail",
     "shortName": "Summary of Option Activity Under Company's Equity Incentive Plans (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Fair Values of Stock Options Estimated Using Black-Scholes Valuation Model (Detail)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail",
     "shortName": "Fair Values of Stock Options Estimated Using Black-Scholes Valuation Model (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20211231",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Summary of Stock-Based Compensation Recognized (Detail)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail",
     "shortName": "Summary of Stock-Based Compensation Recognized (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "link:footnote",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Summary of Stock-Based Compensation Recognized (Parenthetical) (Detail)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail",
     "shortName": "Summary of Stock-Based Compensation Recognized (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "link:footnote",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Reconciliation of Statutory Federal Income Tax (benefit) Rate to Company's Effective Tax Rate (Detail)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail",
     "shortName": "Reconciliation of Statutory Federal Income Tax (benefit) Rate to Company's Effective Tax Rate (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Components of the Company's Deferred Tax Assets (Detail)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail",
     "shortName": "Components of the Company's Deferred Tax Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Unrecognized tax benefit (Detail)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureUnrecognizedTaxBenefitDetail",
     "shortName": "Unrecognized tax benefit (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "cbio:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Collaborations - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
     "shortName": "Collaborations - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:DeferredRevenueRevenueRecognized1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:InterestAndOtherIncomeTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestIncomeExpenseNonoperatingNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Detail of Interest and Other Income (Expense), Net (Detail)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeExpenseNetDetail",
     "shortName": "Detail of Interest and Other Income (Expense), Net (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:InterestAndOtherIncomeTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestIncomeExpenseNonoperatingNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20210331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "cbio:UnderwritingCommissionsAndOfferingExpensesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Stockholders' Equity - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
     "shortName": "Stockholders' Equity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20210331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "cbio:UnderwritingCommissionsAndOfferingExpensesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Anti-dilutive Security not Included In Diluted per Share Calculations (Detail)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail",
     "shortName": "Anti-dilutive Security not Included In Diluted per Share Calculations (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20211130_20211130",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Restructuring - Additional Information (Detail)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail",
     "shortName": "Restructuring - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20211130_20211130",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Restructuring - Summary of Restructuring Charges Recorded in Component of Operating Expenses (Detail)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail",
     "shortName": "Restructuring - Summary of Restructuring Charges Recorded in Component of Operating Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20211231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseExpirationDate1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Subsequent Event - Additional Information (Details)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
     "shortName": "Subsequent Event - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220301_20220331",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical",
     "shortName": "Consolidated Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Nature of Operations",
     "role": "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureNatureOfOperations",
     "shortName": "Nature of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "cbio-10k_20211231.htm",
      "contextRef": "C_0001124105_20210101_20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 65,
   "tag": {
    "cbio_AGCBiologicsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AGC Biologics Inc.",
        "label": "A G C Biologics Inc [Member]",
        "terseLabel": "AGC Biologics, Inc"
       }
      }
     },
     "localname": "AGCBiologicsIncMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_AccruedAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued and other current liabilities.",
        "label": "Accrued And Other Current Liabilities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AccruedAndOtherCurrentLiabilities",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_AccruedClinicalExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical expenses current.",
        "label": "Accrued Clinical Expenses Current",
        "terseLabel": "Clinical"
       }
      }
     },
     "localname": "AccruedClinicalExpensesCurrent",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_AccruedCollaborationExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued collaboration expenses current.",
        "label": "Accrued Collaboration Expenses Current",
        "terseLabel": "Biogen"
       }
      }
     },
     "localname": "AccruedCollaborationExpensesCurrent",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_AccruedManufacturingExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued manufacturing expenses current.",
        "label": "Accrued Manufacturing Expenses Current",
        "terseLabel": "Manufacturing"
       }
      }
     },
     "localname": "AccruedManufacturingExpensesCurrent",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_AccruedPreClinicalExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Pre Clinical Expenses Current.",
        "label": "Accrued Pre Clinical Expenses Current",
        "terseLabel": "Pre-clinical"
       }
      }
     },
     "localname": "AccruedPreClinicalExpensesCurrent",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_AccruedResearchAndDevelopmentExpensesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses.",
        "label": "Accrued Research And Development Expenses Policy [Text Block]",
        "terseLabel": "Accrued Research and Development Expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpensesPolicyTextBlock",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cbio_AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail": {
       "order": 10010.0,
       "parentTag": "cbio_AmortizedCostAvailableForSaleSecurities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated gross unrealized gain before tax available for sale securities.",
        "label": "Accumulated Gross Unrealized Gain Before Tax Available For Sale Securities",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AccumulatedGrossUnrealizedGainBeforeTaxAvailableForSaleSecurities",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_AdvisorAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advisor Agreement.",
        "label": "Advisor Agreement [Member]",
        "terseLabel": "Advisor Agreement"
       }
      }
     },
     "localname": "AdvisorAgreementMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_AdvisoryFeesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advisory fees payable.",
        "label": "Advisory Fees Payable",
        "terseLabel": "Advisory fees payable"
       }
      }
     },
     "localname": "AdvisoryFeesPayable",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_AmendedAndRestatedLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended and restated license agreement.",
        "label": "Amended And Restated License Agreement [Member]",
        "terseLabel": "Amended and Restated License Agreement"
       }
      }
     },
     "localname": "AmendedAndRestatedLicenseAgreementMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_AmortizedCostAvailableForSaleSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost available for sale securities.",
        "label": "Amortized Cost Available For Sale Securities",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AmortizedCostAvailableForSaleSecurities",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_AvailableForSaleDebtSecuritiesContractualMaturity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available for sale debt securities contractual maturity.",
        "label": "Available For Sale Debt Securities Contractual Maturity",
        "terseLabel": "Available for sale debt securities contractual maturities"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesContractualMaturity",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "cbio_BiogenAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biogen agreement.",
        "label": "Biogen Agreement [Member]",
        "terseLabel": "Biogen Agreement"
       }
      }
     },
     "localname": "BiogenAgreementMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_BiogenCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biogen collaboration.",
        "label": "Biogen Collaboration [Member]",
        "terseLabel": "Biogen Collaboration"
       }
      }
     },
     "localname": "BiogenCollaborationMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_BiogenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biogen.",
        "label": "Biogen [Member]",
        "terseLabel": "Biogen"
       }
      }
     },
     "localname": "BiogenMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_OperatingLeasePayments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for amounts included in the measurement of lease liabilities.",
        "label": "Cash Paid For Amounts Included In The Measurement Of Lease Liabilities",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_ChargesRelatedToWriteOffOfPrepaidManufacturingCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Charges related to write off of prepaid manufacturing costs.",
        "label": "Charges Related To Write Off Of Prepaid Manufacturing Cost",
        "terseLabel": "Charges related to write off of prepaid manufacturing cost"
       }
      }
     },
     "localname": "ChargesRelatedToWriteOffOfPrepaidManufacturingCost",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_CollaborationAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreements.",
        "label": "Collaboration Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAgreementsAbstract",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "xbrltype": "stringItemType"
    },
    "cbio_CollaborationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration revenue member.",
        "label": "Collaboration Revenue [Member]",
        "terseLabel": "Collaboration",
        "verboseLabel": "Collaboration"
       }
      }
     },
     "localname": "CollaborationRevenueMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_CommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial milestone payments.",
        "label": "Commercial Milestone Payments",
        "terseLabel": "Commercial milestone payments"
       }
      }
     },
     "localname": "CommercialMilestonePayments",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_CommitmentsAndContingenciesDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies disclosure.",
        "label": "Commitments And Contingencies Disclosure [Line Items]",
        "terseLabel": "Commitments And Contingencies Disclosure [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureLineItems",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbio_CommitmentsAndContingenciesDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies disclosure.",
        "label": "Commitments And Contingencies Disclosure [Table]",
        "terseLabel": "Commitments And Contingencies Disclosure [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTable",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbio_CommonStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants.",
        "label": "Common Stock Warrants [Member]",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "localname": "CommonStockWarrantsMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_ConcentrationRiskCreditRiskPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk Credit Risk",
        "label": "Concentration Risk Credit Risk Policy [Text Block]",
        "terseLabel": "Concentration Risk Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRiskPolicyTextBlock",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cbio_CostOfCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of collaboration.",
        "label": "Cost Of Collaboration [Member]",
        "terseLabel": "Cost of collaboration"
       }
      }
     },
     "localname": "CostOfCollaborationMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_CostOfCollaborationRevenue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of collaboration revenue.",
        "label": "Cost Of Collaboration Revenue",
        "terseLabel": "Cost of collaboration revenue"
       }
      }
     },
     "localname": "CostOfCollaborationRevenue",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_CostOfLicenseAndCollaborationRevenuePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of license and collaboration revenue policy.",
        "label": "Cost Of License And Collaboration Revenue Policy [Text Block]",
        "terseLabel": "Cost of License and Collaboration Revenue"
       }
      }
     },
     "localname": "CostOfLicenseAndCollaborationRevenuePolicyTextBlock",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cbio_CostOfLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of license member.",
        "label": "Cost Of License [Member]",
        "terseLabel": "Cost of license"
       }
      }
     },
     "localname": "CostOfLicenseMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_CostOfManufacturingServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of manufacturing services related company.",
        "label": "Cost Of Manufacturing Services",
        "terseLabel": "Cost of Manufacturing Services"
       }
      }
     },
     "localname": "CostOfManufacturingServices",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_CostOfServicesAsPerAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of services as per agreement.",
        "label": "Cost Of Services As Per Agreement",
        "terseLabel": "Cost of services as per agreement"
       }
      }
     },
     "localname": "CostOfServicesAsPerAgreement",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_DalcinonacogAlfaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dalcinonacog alfa.",
        "label": "Dalcinonacog Alfa [Member]",
        "terseLabel": "Dalcinonacog Alfa"
       }
      }
     },
     "localname": "DalcinonacogAlfaMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_DeferredTaxAssetsFixedAssetsAndIntangibles": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets fixed assets and intangibles.",
        "label": "Deferred Tax Assets Fixed Assets And Intangibles",
        "terseLabel": "Fixed and intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsFixedAssetsAndIntangibles",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_DeferredTaxAssetsStateNetOperatingLossCarryForwards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets state net operating loss carry forwards.",
        "label": "Deferred Tax Assets State Net Operating Loss Carry Forwards",
        "terseLabel": "Net operating loss carryforward, derecognized"
       }
      }
     },
     "localname": "DeferredTaxAssetsStateNetOperatingLossCarryForwards",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_DevelopmentMilestonesPaymentReceivable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development milestones payment Receivable.",
        "label": "Development Milestones Payment Receivable",
        "terseLabel": "Development and sales milestone payments"
       }
      }
     },
     "localname": "DevelopmentMilestonesPaymentReceivable",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_EffectiveIncomeTaxRateReconciliationDerecognition": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation derecognition.",
        "label": "Effective Income Tax Rate Reconciliation Derecognition",
        "negatedLabel": "Derecognition due to Sec. 382 and 383 limitations"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDerecognition",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "cbio_EffectiveIncomeTaxRateReconciliationPermanentDifferences": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation, permanent differences.",
        "label": "Effective Income Tax Rate Reconciliation Permanent Differences",
        "negatedLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferences",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "cbio_ExclusiveLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive license.",
        "label": "Exclusive License [Member]",
        "terseLabel": "Exclusive License",
        "verboseLabel": "Exclusive License"
       }
      }
     },
     "localname": "ExclusiveLicenseMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_FederalAgencySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal agency securities.",
        "label": "Federal Agency Securities [Member]",
        "terseLabel": "Federal Agency Securities"
       }
      }
     },
     "localname": "FederalAgencySecuritiesMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_FinancialInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument.",
        "label": "Financial Instrument [Line Items]",
        "terseLabel": "Financial Instrument [Line Items]"
       }
      }
     },
     "localname": "FinancialInstrumentLineItems",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbio_FinancialInstrumentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instruments.",
        "label": "Financial Instruments [Table]",
        "terseLabel": "Financial Instruments [Table]"
       }
      }
     },
     "localname": "FinancialInstrumentsTable",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbio_FirmWorkOrderSupportingClinicalTrials": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Firm work order supporting clinical trials.",
        "label": "Firm Work Order Supporting Clinical Trials",
        "terseLabel": "Firm work order supporting clinical trials"
       }
      }
     },
     "localname": "FirmWorkOrderSupportingClinicalTrials",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_GMPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GMP manufacturing.",
        "label": "G M P [Member]",
        "terseLabel": "Dalcinonacog alfa."
       }
      }
     },
     "localname": "GMPMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_GrossRealizedGainLossNetAvailableForSalesSecurities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross realized gain loss net available for sales securities.",
        "label": "Gross Realized Gain Loss Net Available For Sales Securities",
        "terseLabel": "Material realized gains or losses on available-for-sale securities"
       }
      }
     },
     "localname": "GrossRealizedGainLossNetAvailableForSalesSecurities",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_IncomeTaxLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax.",
        "label": "Income Tax [Line Items]",
        "terseLabel": "Income Tax [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxLineItems",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbio_IncomeTaxTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax [Table]",
        "label": "Income Tax [Table]",
        "terseLabel": "Income Tax [Table]"
       }
      }
     },
     "localname": "IncomeTaxTable",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbio_IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Decrease in operating lease liability and right-of-use asset.",
        "label": "Increase Decrease In Operating Lease Liability And Right Of Use Asset",
        "terseLabel": "Operating lease liability and right-of-use asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_IntegrityBioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Integrity bio .",
        "label": "Integrity Bio [Member]",
        "terseLabel": "Catalent Indiana, LLC."
       }
      }
     },
     "localname": "IntegrityBioMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_InterestAndOtherIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeExpenseNetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10020.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest and other income (expense), net.",
        "label": "Interest And Other Income Expense Net",
        "terseLabel": "Interest and other income (expense), net",
        "totalLabel": "Total interest and other income (expense), net"
       }
      }
     },
     "localname": "InterestAndOtherIncomeExpenseNet",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeExpenseNetDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_IntravitrealAntiComplementFactor3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intravitreal anti-complement factor 3.",
        "label": "Intravitreal Anti Complement Factor3 [Member]",
        "terseLabel": "Intravitreal Anti-Complement Factor 3"
       }
      }
     },
     "localname": "IntravitrealAntiComplementFactor3Member",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_IssuanceOfOptionGrantsToPurchaseCommonStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of option grants to purchase common stock shares.",
        "label": "Issuance Of Option Grants To Purchase Common Stock Shares",
        "terseLabel": "Issuance of option grants to purchase common stock shares"
       }
      }
     },
     "localname": "IssuanceOfOptionGrantsToPurchaseCommonStockShares",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "cbio_IsuAbxisMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISU Abxis.",
        "label": "Isu Abxis [Member]",
        "terseLabel": "ISU Abxis"
       }
      }
     },
     "localname": "IsuAbxisMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_LeaseLabAndOfficeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease lab and office space.",
        "label": "Lease Lab And Office Space [Member]",
        "terseLabel": "Lease Lab And Office Space"
       }
      }
     },
     "localname": "LeaseLabAndOfficeSpaceMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_LegalExpensesIncurred": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal expenses incurred.",
        "label": "Legal Expenses Incurred",
        "terseLabel": "Legal expenses incurred"
       }
      }
     },
     "localname": "LegalExpensesIncurred",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_LesseeOperatingLeaseRenewalTermDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease renewal term description.",
        "label": "Lessee Operating Lease Renewal Term Description",
        "terseLabel": "Lessee operating lease renewal term description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTermDescription",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbio_LicenseAndCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and Collaboration Agreement (the \u201cBiogen Agreement\u201d), .",
        "label": "License And Collaboration Agreement [Member]",
        "terseLabel": "License and Collaboration Agreement (the \u201cBiogen Agreement\u201d)"
       }
      }
     },
     "localname": "LicenseAndCollaborationAgreementMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_LicenseRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License revenue member.",
        "label": "License Revenue [Member]",
        "terseLabel": "License"
       }
      }
     },
     "localname": "LicenseRevenueMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_LiquidityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity.",
        "label": "Liquidity [Abstract]"
       }
      }
     },
     "localname": "LiquidityAbstract",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "xbrltype": "stringItemType"
    },
    "cbio_LongTermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term investments.",
        "label": "Long Term Investments [Member]",
        "terseLabel": "Long Term Investments"
       }
      }
     },
     "localname": "LongTermInvestmentsMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marzeptacog alfa activated and dalcinonacog alfa.",
        "label": "Marzeptacog Alfa Activated And Dalcinonacog Alfa [Member]",
        "terseLabel": "Marzeptacog Alfa Activated and Dalcinonacog Alfa"
       }
      }
     },
     "localname": "MarzeptacogAlfaActivatedAndDalcinonacogAlfaMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_MarzeptacogAlfaActivatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marzeptacog alfa (activated).",
        "label": "Marzeptacog Alfa Activated [Member]",
        "terseLabel": "Marzeptacog Alfa Activated"
       }
      }
     },
     "localname": "MarzeptacogAlfaActivatedMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_MaximumAmountOfTaxOffsetPerYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of tax offset per year.",
        "label": "Maximum Amount Of Tax Offset Per Year",
        "terseLabel": "Maximum amount of tax offset per year"
       }
      }
     },
     "localname": "MaximumAmountOfTaxOffsetPerYear",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment .",
        "label": "Milestone Payment Related To Regulatory And Clinical Development Events",
        "terseLabel": "Milestone Payment Related To Regulatory And Clinical Development Events"
       }
      }
     },
     "localname": "MilestonePaymentRelatedToRegulatoryAndClinicalDevelopmentEvents",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_MilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "Milestone Payments",
        "terseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_MiscellaneousIncomeExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeExpenseNetDetail": {
       "order": 10020.0,
       "parentTag": "cbio_InterestAndOtherIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Miscellaneous income (expense).",
        "label": "Miscellaneous Income Expense",
        "terseLabel": "Miscellaneous income"
       }
      }
     },
     "localname": "MiscellaneousIncomeExpense",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeExpenseNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_MosaicBiosciencesIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mosaic Biosciences, Inc.",
        "label": "Mosaic Biosciences Inc [Member]",
        "terseLabel": "Mosaic Biosciences Inc"
       }
      }
     },
     "localname": "MosaicBiosciencesIncMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_NonCashOrPartNonCashRemeasurementOfRightOfUseAssetDueToOperatingLeaseModification": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remeasurement of right-of-use asset due to operating lease modification.",
        "label": "Non Cash Or Part Non Cash Remeasurement Of Right Of Use Asset Due To Operating Lease Modification",
        "terseLabel": "Remeasurement of right-of-use asset due to operating lease modification"
       }
      }
     },
     "localname": "NonCashOrPartNonCashRemeasurementOfRightOfUseAssetDueToOperatingLeaseModification",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-use assets obtained in exchange for operating lease liabilities.",
        "label": "Non Cash Or Part Non Cash Right Of Use Assets Obtained In Exchange For Operating Lease Liabilities",
        "terseLabel": "Right-of-use assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "NonCashOrPartNonCashRightOfUseAssetsObtainedInExchangeForOperatingLeaseLiabilities",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Net operating loss carryforwards expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "gYearItemType"
    },
    "cbio_OperatingLossCarryforwardsWithIndefiniteLife": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards with indefinite life.",
        "label": "Operating Loss Carryforwards With Indefinite Life",
        "terseLabel": "Net operating loss carryforwards having indefinite life"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsWithIndefiniteLife",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_OptionsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to purchase common stock.",
        "label": "Options To Purchase Common Stock [Member]",
        "terseLabel": "Options To Purchase Common Stock"
       }
      }
     },
     "localname": "OptionsToPurchaseCommonStockMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_PaymentsToAcquireShortTermAndLongInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to acquire short term and long investments.",
        "label": "Payments To Acquire Short Term And Long Investments",
        "negatedLabel": "Purchase of short-term and long-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermAndLongInvestments",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_PercentageOfCommissionForSharesSold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Commission for shares sold.",
        "label": "Percentage Of Commission For Shares Sold",
        "terseLabel": "Percentage of commission for shares sold"
       }
      }
     },
     "localname": "PercentageOfCommissionForSharesSold",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "cbio_PerformanceBasedStockOptionGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance based stock option grants.",
        "label": "Performance Based Stock Option Grants [Member]",
        "terseLabel": "Performance Based Stock Option Grants"
       }
      }
     },
     "localname": "PerformanceBasedStockOptionGrantsMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_PrepaidCashPaymentForLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_OperatingLeasePayments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Cash Payment For Lease Liabilities.",
        "label": "Prepaid Cash Payment For Lease Liabilities",
        "terseLabel": "Prepaid cash payment for lease"
       }
      }
     },
     "localname": "PrepaidCashPaymentForLeaseLiabilities",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock for secondary public offering, net of issuance costs.",
        "label": "Proceeds From Issuance Of Common Stock For Public Offering Net Of Issuance Costs",
        "terseLabel": "Issuance of common stock for public offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockForPublicOfferingNetOfIssuanceCosts",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock from ESPP purchases and stock option exercises.",
        "label": "Proceeds From Issuance Of Common Stock From E S P P Purchases And Stock Option Exercises",
        "terseLabel": "Issuance of common stock from ESPP purchase and stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockFromESPPPurchasesAndStockOptionExercises",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_RaymondJamesAndAssociatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Raymond James and Associates.",
        "label": "Raymond James And Associates [Member]",
        "terseLabel": "Raymond James &amp; Associates"
       }
      }
     },
     "localname": "RaymondJamesAndAssociatesMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_RegulatoryAndDevelopmentMilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory and development milestone payment.",
        "label": "Regulatory And Development Milestone Payment",
        "terseLabel": "Regulatory and development milestone payment"
       }
      }
     },
     "localname": "RegulatoryAndDevelopmentMilestonePayment",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursable Out-of-Pocket and Personnel Costs Incurred Related to Research Services.",
        "label": "Reimbursable Out Of Pocket And Personnel Costs Incurred Related To Research Services [Member]",
        "terseLabel": "Reimbursable Out-of-Pocket and Personnel Costs Incurred Related to Research Services"
       }
      }
     },
     "localname": "ReimbursableOutOfPocketAndPersonnelCostsIncurredRelatedToResearchServicesMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_ReimbursementOfAdvisoryFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement of advisory fee.",
        "label": "Reimbursement Of Advisory Fee",
        "terseLabel": "Reimbursement of advisory fee"
       }
      }
     },
     "localname": "ReimbursementOfAdvisoryFee",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_RequiredMinimumTaxableIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum taxable income required to support realizing the company's.",
        "label": "Required Minimum Taxable Income",
        "terseLabel": "Required Minimum Taxable Income"
       }
      }
     },
     "localname": "RequiredMinimumTaxableIncome",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development tax credit carry forwards derecognized.",
        "label": "Research And Development Tax Credit Carry Forwards Derecognized",
        "terseLabel": "Gross federal R&amp;D tax credit-related deferred tax assets derecognized"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_ResearchServicesAgreementOptionToExtend": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research services agreement option to extend.",
        "label": "Research Services Agreement Option To Extend",
        "terseLabel": "Research services option to extend"
       }
      }
     },
     "localname": "ResearchServicesAgreementOptionToExtend",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "cbio_ResearchServicesAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research services.",
        "label": "Research Services Agreement Term",
        "terseLabel": "Research services"
       }
      }
     },
     "localname": "ResearchServicesAgreementTerm",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "cbio_RestructuringLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring liability.",
        "label": "Restructuring Liability",
        "terseLabel": "Restructuring liability"
       }
      }
     },
     "localname": "RestructuringLiability",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_SaleSecuritiesAvailable": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail": {
       "order": 10030.0,
       "parentTag": "cbio_AmortizedCostAvailableForSaleSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale securities available.",
        "label": "Sale Securities Available",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "SaleSecuritiesAvailable",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_SaleSecuritiesAvailableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale securities available text block.",
        "label": "Sale Securities Available [Text Block]",
        "terseLabel": "Cash Equivalents, Restricted Cash and Short-Term Investments Classified as Available-for-sale Securities"
       }
      }
     },
     "localname": "SaleSecuritiesAvailableTextBlock",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award fair value assumptions Black-Scholes method used.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black Scholes Method Used [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black Scholes Method Used [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedLineItems",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbio_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black-Scholes Method Used [Table]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black Scholes Method Used [Table]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Black Scholes Method Used [Table]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsBlackScholesMethodUsedTable",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period from ESPP purchases and stock options exercised shares.",
        "label": "Stock Issued During Period From E S P P Purchases And Stock Options Exercised Shares",
        "terseLabel": "Issuance of common stock from ESPP purchases and stock option exercises, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedShares",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "cbio_StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period from ESPP purchases and stock options exercised value.",
        "label": "Stock Issued During Period From E S P P Purchases And Stock Options Exercised Value",
        "terseLabel": "Issuance of common stock from ESPP purchases and stock option exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodFromESPPPurchasesAndStockOptionsExercisedValue",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_StockholdersEquityDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders equity disclosure.",
        "label": "Stockholders Equity Disclosure [Line Items]",
        "terseLabel": "Stockholders Equity Disclosure [Line Items]"
       }
      }
     },
     "localname": "StockholdersEquityDisclosureLineItems",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbio_StockholdersEquityDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders equity disclosure.",
        "label": "Stockholders Equity Disclosure [Table]",
        "terseLabel": "Stockholders Equity Disclosure [Table]"
       }
      }
     },
     "localname": "StockholdersEquityDisclosureTable",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbio_SubleaseArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease arrangement.",
        "label": "Sublease Arrangement [Member]",
        "terseLabel": "Sublease Arrangement"
       }
      }
     },
     "localname": "SubleaseArrangementMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_SublicenseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublicense fee entitled to pay.",
        "label": "Sublicense Fee",
        "terseLabel": "Payment related to collaboration"
       }
      }
     },
     "localname": "SublicenseFee",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of present value assumptions of lease payments.",
        "label": "Summary Of Present Value Assumptions Of Lease Payments Table [Text Block]",
        "terseLabel": "Summary of Present Value Assumptions used in Calculating Present Value of Lease Payments"
       }
      }
     },
     "localname": "SummaryOfPresentValueAssumptionsOfLeasePaymentsTableTextBlock",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cbio_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbio_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "cbio_TransferOfExclusiveLicenseAndRelatedKnowHowMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer of Exclusive License and Related Know-How.",
        "label": "Transfer Of Exclusive License And Related Know How [Member]",
        "terseLabel": "Transfer of Exclusive License and Related Know-How"
       }
      }
     },
     "localname": "TransferOfExclusiveLicenseAndRelatedKnowHowMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_TwoThousandEighteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eighteen employee stock purchase plan.",
        "label": "Two Thousand Eighteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2018 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandEighteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_TwoThousandEighteenOmnibusIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eighteen omnibus incentive plan.",
        "label": "Two Thousand Eighteen Omnibus Incentive Plan [Member]",
        "terseLabel": "2018 Omnibus Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandEighteenOmnibusIncentivePlanMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_TwoThousandTwentyOneATMProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one ATM program.",
        "label": "Two Thousand Twenty One A T M Program [Member]",
        "terseLabel": "2021 ATM Program"
       }
      }
     },
     "localname": "TwoThousandTwentyOneATMProgramMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_UnderwritersOverallotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriters overallotment option.",
        "label": "Underwriters Overallotment Option [Member]",
        "terseLabel": "Underwriters' Overallotment Option"
       }
      }
     },
     "localname": "UnderwritersOverallotmentOptionMember",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "cbio_UnderwritingCommissionsAndOfferingExpensesPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting commissions and offering expenses payable.",
        "label": "Underwriting Commissions And Offering Expenses Payable",
        "terseLabel": "Underwriting discounts, commissions and offering expenses payable"
       }
      }
     },
     "localname": "UnderwritingCommissionsAndOfferingExpensesPayable",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized tax benefits increase (decrease) resulting from tax positions.",
        "label": "Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions",
        "terseLabel": "Increase/(Decrease) of unrecognized tax benefits taken in prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureUnrecognizedTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cbio_UpfrontFeeReveivedFromLicenseAndCollaborationAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront fee reveived from license and collaboration agreement.",
        "label": "Upfront Fee Reveived From License And Collaboration Agreement",
        "terseLabel": "Upfront license fee received from collaboration agreement"
       }
      }
     },
     "localname": "UpfrontFeeReveivedFromLicenseAndCollaborationAgreement",
     "nsuri": "http://www.catalystbiosciences.com/20211231",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r550",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm Id",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r550",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r550",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r550",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r550",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r45",
      "r47",
      "r89",
      "r90",
      "r228",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r227",
      "r235",
      "r267",
      "r268",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r465",
      "r510",
      "r512",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r227",
      "r235",
      "r267",
      "r268",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r465",
      "r510",
      "r512",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r147",
      "r254",
      "r255",
      "r468",
      "r509",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r147",
      "r254",
      "r255",
      "r468",
      "r509",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r227",
      "r235",
      "r257",
      "r267",
      "r268",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r465",
      "r510",
      "r512",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r227",
      "r235",
      "r257",
      "r267",
      "r268",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r465",
      "r510",
      "r512",
      "r543",
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r46",
      "r47",
      "r89",
      "r90",
      "r228",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "CALIFORNIA"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update201602 [Member]",
        "terseLabel": "AS 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable Accrued Liabilities And Other Liabilities Disclosure Current [Text Block]",
        "terseLabel": "Other Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureOtherAccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r37",
      "r431"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10110.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r150",
      "r151"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable Gross Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r8",
      "r21",
      "r150",
      "r151"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10230.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable Net Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r39"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10120.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r39"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Professional and consulting services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r24",
      "r50",
      "r51",
      "r52",
      "r502",
      "r520",
      "r524"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r49",
      "r52",
      "r59",
      "r60",
      "r61",
      "r93",
      "r94",
      "r95",
      "r357",
      "r515",
      "r516",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r22",
      "r306",
      "r431"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid In Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r303",
      "r304",
      "r305",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r96",
      "r97",
      "r98",
      "r99",
      "r107",
      "r154",
      "r155",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r215",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r336",
      "r337",
      "r338",
      "r339",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r420",
      "r470",
      "r471",
      "r472",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Adjustments For New Accounting Pronouncements [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r269",
      "r271",
      "r309",
      "r310"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r249",
      "r251"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments To Additional Paid In Capital Stock Issued Issuance Costs",
        "terseLabel": "Issuance costs of issuance of common stock for public offering"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r271",
      "r296",
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Anti dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r86",
      "r136",
      "r139",
      "r145",
      "r170",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r353",
      "r358",
      "r383",
      "r429",
      "r431",
      "r486",
      "r501"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r44",
      "r86",
      "r170",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r353",
      "r358",
      "r383",
      "r429",
      "r431"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10160.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r374"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Fair Value Disclosure",
        "terseLabel": "Assets, fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail": {
       "order": 10020.0,
       "parentTag": "cbio_AmortizedCostAvailableForSaleSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r156",
      "r158",
      "r182",
      "r490"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Securities Debt Securities",
        "terseLabel": "Available-for-sale, debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r157",
      "r182"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Available For Sale Securities Debt Securities Current",
        "terseLabel": "Available-for-sale debt securities current"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFinancialInstrumentsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r272",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r32",
      "r78"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10210.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash And Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash And Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r14",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash Cash Equivalents And Short Term Investments",
        "terseLabel": "Cash, cash equivalents and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r72",
      "r78",
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents at end of the period",
        "periodStartLabel": "Cash and cash equivalents at beginning of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r72",
      "r392"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r84",
      "r86",
      "r108",
      "r109",
      "r110",
      "r112",
      "r114",
      "r120",
      "r121",
      "r122",
      "r170",
      "r216",
      "r220",
      "r221",
      "r222",
      "r225",
      "r226",
      "r233",
      "r234",
      "r238",
      "r242",
      "r383",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1",
        "verboseLabel": "Warrants exercise price per share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r348",
      "r349",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborations"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r41",
      "r214",
      "r491",
      "r506"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 7)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "verboseLabel": "Common Stock, Capital Shares Reserved for Future Issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r93",
      "r94",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued",
        "verboseLabel": "Common stock warrants issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r20",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Common stock, shares outstanding",
        "verboseLabel": "Common stock warrants outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r20",
      "r431"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.001 par value, 100,000,000 shares authorized; 31,409,707 and 22,097,820 shares issued and outstanding at December 31, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r54",
      "r56",
      "r57",
      "r63",
      "r493",
      "r508"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r187",
      "r189",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software Intangible Asset [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Contractual obligation payments"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r233",
      "r234",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r65",
      "r468"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10050.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost Of Goods And Services Sold",
        "terseLabel": "Cost of license and collaboration"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy": {
     "auth_ref": [
      "r204",
      "r205",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation.",
        "label": "Costs Associated With Exit Or Disposal Activities Or Restructurings Policy",
        "terseLabel": "Restructuring Charges"
       }
      }
     },
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10130.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueRevenueRecognized1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue.",
        "label": "Deferred Revenue Revenue Recognized1",
        "terseLabel": "Deferred revenue, recognized"
       }
      }
     },
     "localname": "DeferredRevenueRevenueRecognized1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Net",
        "totalLabel": "Net deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r332",
      "r333"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry forwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r331",
      "r332",
      "r333"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail": {
       "order": 10030.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Research",
        "terseLabel": "Tax credit carry forwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r332",
      "r333"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals",
        "terseLabel": "Accruals and reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail": {
       "order": 10050.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureComponentsOfCompanySDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r76",
      "r135"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation Depletion And Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Stock Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Country [Member]",
        "terseLabel": "Federal Income Tax"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r115",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r318"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Continuing Operations",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r87",
      "r318",
      "r341"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "negatedLabel": "Tax at statutory federal rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r318",
      "r341"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail": {
       "order": 10060.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "auth_ref": [
      "r318",
      "r341"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail": {
       "order": 10070.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r318",
      "r341"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes",
        "negatedLabel": "State Tax (benefit)\u2014net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r318",
      "r341"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail": {
       "order": 10040.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation Tax Credits",
        "negatedLabel": "Tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureReconciliationOfStatutoryFederalIncomeTaxBenefitRateToCompanySEffectiveTaxRateDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Unrecognized employee stock based compensation expense, period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Unrecognized employee stock based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r59",
      "r60",
      "r61",
      "r93",
      "r94",
      "r95",
      "r97",
      "r104",
      "r106",
      "r119",
      "r174",
      "r249",
      "r251",
      "r303",
      "r304",
      "r305",
      "r338",
      "r339",
      "r371",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r515",
      "r516",
      "r517",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r374",
      "r375",
      "r376",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value Assets Measured On Recurring Basis [Text Block]",
        "terseLabel": "Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r374",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Fair Value By Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r229",
      "r231",
      "r232",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r375",
      "r438",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r229",
      "r258",
      "r259",
      "r264",
      "r266",
      "r375",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r229",
      "r231",
      "r232",
      "r258",
      "r259",
      "r264",
      "r266",
      "r375",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r229",
      "r231",
      "r232",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r375",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r229",
      "r231",
      "r232",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r438",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value Of Financial Instruments Policy",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r161",
      "r162",
      "r167",
      "r168",
      "r169",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r183",
      "r184",
      "r185",
      "r186",
      "r230",
      "r247",
      "r362",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r187",
      "r188",
      "r190",
      "r191",
      "r469",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite Lived Intangible Assets By Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r187",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      },
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10080.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r194",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r87",
      "r319",
      "r325",
      "r330",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.",
        "label": "Income Tax Examination Penalties And Interest Accrued",
        "terseLabel": "Tax-related penalties or interest recognized"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r58",
      "r316",
      "r317",
      "r325",
      "r326",
      "r329",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase Decrease In Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase Decrease In Accrued Liabilities",
        "terseLabel": "Accrued compensation and other accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r75",
      "r466"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10170.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Contract With Customer Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndOtherIncomeTextBlock": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for interest and other income.",
        "label": "Interest And Other Income [Text Block]",
        "terseLabel": "Interest and Other Income (Expense), Net"
       }
      }
     },
     "localname": "InterestAndOtherIncomeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureInterestAndOtherIncomeExpenseNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeExpenseNetDetail": {
       "order": 10010.0,
       "parentTag": "cbio_InterestAndOtherIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income Expense Nonoperating Net",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeExpenseNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investment Type Categorization [Member]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments Debt And Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date1",
        "terseLabel": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeasePracticalExpedientsPackage": {
     "auth_ref": [
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether practical expedients are elected for not reassessing whether any expired or existing contract is or contains lease, lease classification for expired or existing lease, and initial direct cost for any existing lease.",
        "label": "Lease Practical Expedients Package",
        "terseLabel": "Lease practical expedients"
       }
      }
     },
     "localname": "LeasePracticalExpedientsPackage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "localname": "LesseeDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee Lease Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee Lease Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee Leases Policy [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease.",
        "label": "Lessee Operating Lease Description",
        "terseLabel": "Operating lease commenced description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease that has not yet commenced. Including, but not limited to, nature of involvement with construction or design of underlying asset for lease.",
        "label": "Lessee Operating Lease Lease Not Yet Commenced Description",
        "terseLabel": "Operating lease not yet commenced description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee Operating Lease Liability Maturity Table [Text Block]",
        "terseLabel": "Schedule of Maturity of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "terseLabel": "Undiscounted future payment",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r416"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee Operating Lease Option To Extend",
        "terseLabel": "Operating lease, option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Term Of Contract",
        "terseLabel": "Operating lease term of contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r419"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor Operating Lease Payments To Be Received",
        "verboseLabel": "Lease Payments Receivable"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r38",
      "r86",
      "r140",
      "r170",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r354",
      "r358",
      "r359",
      "r383",
      "r429",
      "r430"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r27",
      "r86",
      "r170",
      "r383",
      "r431",
      "r487",
      "r504"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r40",
      "r86",
      "r170",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r354",
      "r358",
      "r359",
      "r383",
      "r429",
      "r430",
      "r431"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10090.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUncertainTaxPositionsCurrent": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for uncertainty in income taxes classified as current.",
        "label": "Liability For Uncertain Tax Positions Current",
        "verboseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "LiabilityForUncertainTaxPositionsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiquidationBasisOfAccountingTextBlock": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the liquidation basis of accounting.",
        "label": "Liquidation Basis Of Accounting [Text Block]",
        "terseLabel": "Liquidity"
       }
      }
     },
     "localname": "LiquidationBasisOfAccountingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLiquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10170.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long Term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities Policy",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r123",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature Of Operations",
        "terseLabel": "Nature of Operations"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureNatureOfOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash flows provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash flows provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r72",
      "r74",
      "r77"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash flows used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r53",
      "r55",
      "r61",
      "r62",
      "r77",
      "r86",
      "r96",
      "r100",
      "r101",
      "r102",
      "r103",
      "r105",
      "r106",
      "r111",
      "r136",
      "r138",
      "r141",
      "r144",
      "r146",
      "r170",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r373",
      "r383",
      "r492",
      "r507"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 10010.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "negatedLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Accounting Pronouncements Recently Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing And Financing Items [Abstract]",
        "terseLabel": "Supplemental Disclosure of Non-Cash Investing and Financing Activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureNatureOfOperationsAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10040.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r136",
      "r138",
      "r141",
      "r144",
      "r146"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10010.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r405"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities Payments Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail2": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "terseLabel": "Total operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfMaturityOfOperatingLeaseLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10150.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10100.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Operating lease liability, noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r406",
      "r412"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease Payments",
        "totalLabel": "Cash paid for operating leases that were included in operating cash outflows"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r403"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10190.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r415",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r414",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfPresentValueAssumptionsUsedInCalculatingPresentValueOfLeasePaymentsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r39"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10140.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other accrued liabilities",
        "totalLabel": "Total other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureScheduleOfOtherAccruedLiabilitiesDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10180.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets, noncurrent"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Net Of Tax Period Change [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r48",
      "r50"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 10020.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax",
        "terseLabel": "Unrealized loss on available-for-sale debt securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income And Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLongTermInvestmentsMember": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term investments classified as other.",
        "label": "Other Long Term Investments [Member]",
        "terseLabel": "Other Long-term Investments"
       }
      }
     },
     "localname": "OtherLongTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeExpenseNetDetail": {
       "order": 10030.0,
       "parentTag": "cbio_InterestAndOtherIncomeExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureDetailOfInterestAndOtherIncomeExpenseNetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables And Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments To Acquire Investments",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r272",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r19",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r19",
      "r431"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10040.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "terseLabel": "Preferred stock, $0.001 par value, 5,000,000 shares authorized; zero shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r9",
      "r30",
      "r31"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10240.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Net proceeds from sale of common stock after deducting underwriting commissions and offering expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds From Issuance Or Sale Of Equity",
        "terseLabel": "Proceeds from Issuance"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "auth_ref": [
      "r73"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from licensees for license fees during the current period.",
        "label": "Proceeds From License Fees Received",
        "terseLabel": "Up-front payments received"
       }
      }
     },
     "localname": "ProceedsFromLicenseFeesReceived",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds From Sale Maturity And Collection Of Shortterm Investments",
        "terseLabel": "Proceeds from maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r53",
      "r55",
      "r61",
      "r71",
      "r86",
      "r96",
      "r105",
      "r106",
      "r136",
      "r138",
      "r141",
      "r144",
      "r146",
      "r170",
      "r216",
      "r217",
      "r218",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r352",
      "r355",
      "r356",
      "r360",
      "r361",
      "r373",
      "r383",
      "r494"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r35",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r15",
      "r16",
      "r193",
      "r431",
      "r499",
      "r505"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10200.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r34",
      "r193",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r15",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Useful Life",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r28",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Receivables Trade And Other Accounts Receivable Allowance For Doubtful Accounts Policy",
        "terseLabel": "Accounts Receivable, net and Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r265",
      "r423",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r265",
      "r423",
      "r424",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r423"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction Expenses From Transactions With Related Party",
        "terseLabel": "One Time Expense related to collaboration"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r265",
      "r423",
      "r426",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party Transactions By Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r421",
      "r422",
      "r424",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r313",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research And Development Arrangement Contract To Perform For Others By Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r313",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research And Development Arrangement Contract To Perform For Others Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r312",
      "r467",
      "r545"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail": {
       "order": 10010.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      },
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10070.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development Expense",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Cash And Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring And Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r196",
      "r198",
      "r201",
      "r210",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring And Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuring"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).",
        "label": "Restructuring And Related Cost Number Of Positions Eliminated Period Percent",
        "terseLabel": "Percent of employees terminated"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r76",
      "r195",
      "r205",
      "r207"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Total expenses",
        "totalLabel": "Total restructuring charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost And Reserve [Line Items]",
        "terseLabel": "Restructuring Cost And Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r23",
      "r251",
      "r306",
      "r431",
      "r503",
      "r519",
      "r524"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10080.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLiquidityAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r93",
      "r94",
      "r95",
      "r97",
      "r104",
      "r106",
      "r174",
      "r303",
      "r304",
      "r305",
      "r338",
      "r339",
      "r371",
      "r515",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r133",
      "r134",
      "r137",
      "r142",
      "r143",
      "r147",
      "r148",
      "r149",
      "r253",
      "r254",
      "r468"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": {
       "order": 10030.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue From Contract With Customer Excluding Assessed Tax",
        "terseLabel": "License and collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue Recognition Multiple Deliverable Arrangements [Line Items]",
        "terseLabel": "Revenue Recognition Multiple Deliverable Arrangements [Line Items]"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement, including certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy.",
        "label": "Revenue Recognition Multiple Deliverable Arrangements [Table]",
        "terseLabel": "Revenue Recognition Multiple Deliverable Arrangements [Table]"
       }
      }
     },
     "localname": "RevenueRecognitionMultipleDeliverableArrangementsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r82",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition Policy [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r413",
      "r417"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability",
        "terseLabel": "Right-of-use asset and lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Other Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureOtherAccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAntiDilutiveSecurityNotIncludedInDilutedPerShareCalculationsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Anti-dilutive Security not Included in Diluted per Share Calculations"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule Of Available For Sale Securities [Line Items]",
        "terseLabel": "Schedule Of Available For Sale Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r159",
      "r160",
      "r163",
      "r164",
      "r165",
      "r166",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule Of Available For Sale Securities [Table]",
        "terseLabel": "Schedule Of Available For Sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.",
        "label": "Schedule Of Cash Flow Supplemental Disclosures Table [Text Block]",
        "terseLabel": "Schedule of Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Components of the Company's Deferred Tax Assets (Liabilities)"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Reconciliation of Federal Income Tax Rate to Company's Effective Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r271",
      "r295",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r271",
      "r295",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Recognized"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule Of Other Nonoperating Income Expense Table [Text Block]",
        "terseLabel": "Detail of Interest and Other Income (Expense), Net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureInterestAndOtherIncomeExpenseNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r425",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule Of Related Party Transactions By Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r197",
      "r198",
      "r199",
      "r200",
      "r207",
      "r208",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule Of Restructuring And Related Costs [Table]",
        "terseLabel": "Schedule Of Restructuring And Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringSummaryOfRestructuringChargesRecordedInComponentOfOperatingExpensesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r202",
      "r203",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Schedule Of Restructuring And Related Costs [Text Block]",
        "terseLabel": "Summary of Restructuring Charges Recorded in Component of Operating Expenses"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r272",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r277",
      "r284",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Option Activity Under Company's Equity Incentive Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Summary of Weighted Average Valuation Assumptions Used to Estimate Fair Value of Employee Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r324",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]",
        "terseLabel": "Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ServiceAgreementsMember": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Limited duration contract between, for example, an electricity transmission customer and an electricity transmission provider for service.",
        "label": "Service Agreements [Member]",
        "terseLabel": "Service Agreements"
       }
      }
     },
     "localname": "ServiceAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs1",
        "terseLabel": "Severance costs and expenses"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRestructuringAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Additional General Disclosures [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate",
        "terseLabel": "Maximum employee subscription rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized",
        "terseLabel": "Number of common stock authorized for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Shares available to be granted - December 31, 2020",
        "verboseLabel": "Number of common stock available for future grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Number of Shares Underlying Outstanding Options, Exercisable- December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Exercisable - December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period",
        "negatedLabel": "Number of Shares Underlying Outstanding Options, Options expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Number of Shares Underlying Outstanding Options, Options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Number of Shares Underlying Outstanding Options, Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value of stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r279",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of Shares Underlying Outstanding Options, Ending Balance",
        "periodStartLabel": "Number of Shares Underlying Outstanding Options, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease",
        "verboseLabel": "Increase in number of shares of common stock reserved for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward",
        "terseLabel": "Number of Shares Underlying Outstanding Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted- Average Exercise Price, Ending Balance",
        "periodStartLabel": "Weighted- Average Exercise Price, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period",
        "terseLabel": "Number of common stock stock issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r270",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Options expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r272",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share Based Compensation Option And Incentive Plans Policy",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Common stock price, per share"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r290",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "verboseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureFairValuesOfStockOptionsEstimatedUsingBlackScholesValuationModelDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted Average Remaining Contractual Term, Exercisable - December 31, 2020"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years), Outstanding Balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1",
        "terseLabel": "Fair value of options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent",
        "terseLabel": "Percentage of fair market value of common stock"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r17",
      "r488",
      "r489",
      "r500"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10220.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short Term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r537",
      "r538",
      "r539",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short Term Investments [Member]",
        "terseLabel": "Short-Term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r81",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State And Local Jurisdiction [Member]",
        "terseLabel": "State Income Tax"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r84",
      "r86",
      "r108",
      "r109",
      "r110",
      "r112",
      "r114",
      "r120",
      "r121",
      "r122",
      "r170",
      "r216",
      "r220",
      "r221",
      "r222",
      "r225",
      "r226",
      "r233",
      "r234",
      "r238",
      "r242",
      "r249",
      "r383",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r43",
      "r59",
      "r60",
      "r61",
      "r93",
      "r94",
      "r95",
      "r97",
      "r104",
      "r106",
      "r119",
      "r174",
      "r249",
      "r251",
      "r303",
      "r304",
      "r305",
      "r338",
      "r339",
      "r371",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r515",
      "r516",
      "r517",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Income And Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r119",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period Shares Issued For Services",
        "terseLabel": "Number of shares of common stock issued to certain board members in lieu of cash compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfStockBasedCompensationRecognizedParentheticalDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r19",
      "r20",
      "r249",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of common stock for public offering, net of issuance costs, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r19",
      "r20",
      "r249",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Stock Issued During Period Shares Share Based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r19",
      "r20",
      "r249",
      "r251",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Number of Shares Underlying Outstanding Options, Options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfOptionActivityUnderCompanySEquityIncentivePlansDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r19",
      "r20",
      "r249",
      "r251"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of common stock for public offering, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r20",
      "r25",
      "r26",
      "r86",
      "r153",
      "r170",
      "r383",
      "r431"
     ],
     "calculation": {
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r85",
      "r234",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r248",
      "r251",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r399",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r399",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r399",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r399",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r432",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward Amount",
        "terseLabel": "Tax credit carryforwards available to offset future federal tax liabilities"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardExpirationDate": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of the tax credit carryforward, in YYYY-MM-DD format.",
        "label": "Tax Credit Carryforward Expiration Date",
        "terseLabel": "Credit carryforward, expire period"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_TransactionDomain": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction [Domain]",
        "terseLabel": "Transaction"
       }
      }
     },
     "localname": "TransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransactionTypeAxis": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.",
        "label": "Transaction Type [Axis]",
        "terseLabel": "Transaction Type"
       }
      }
     },
     "localname": "TransactionTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCollaborationsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r161",
      "r162",
      "r167",
      "r168",
      "r169",
      "r230",
      "r247",
      "r362",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Transfers And Servicing Of Financial Instruments Types Of Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r96",
      "r97",
      "r98",
      "r99",
      "r107",
      "r154",
      "r155",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r215",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r336",
      "r337",
      "r338",
      "r339",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r420",
      "r470",
      "r471",
      "r472",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type Of Adoption [Member]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureLeasesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureRelatedPartiesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r88",
      "r258",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "U S Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. Government Agency Securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureCashEquivalentsRestrictedCashAndShortTermInvestmentsClassifiedAsAvailableForSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r258",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "U S Government Sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "Federal Agency Securities"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r315",
      "r322"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Unrecognized tax benefit"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail",
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureUnrecognizedTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions",
        "terseLabel": "Increase/(Decrease) of unrecognized tax benefits related to current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureUnrecognizedTaxBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves.",
        "label": "Valuation Allowances And Reserves Period Increase Decrease",
        "terseLabel": "Increase (decrease) in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.",
        "label": "Warrants And Rights Outstanding Maturity Date",
        "terseLabel": "Warrant expiration date"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Shares used to compute net loss per share attributable to common stockholders, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.catalystbiosciences.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3,4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "http://asc.fasb.org/topic&trid=49130413"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r546": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r547": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r548": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r549": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r550": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r551": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r552": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r553": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r554": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r555": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r556": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r557": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r558": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r559": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r560": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r561": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r562": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=35686142"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>89
<FILENAME>0001564590-22-012877-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-22-012877-xbrl.zip
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M'7!'3.J^M$V,$8E+0^Z"DO)<K=S4@KZ>-SMCT565T@67_>?'LH&%:#95\=K
M,U<YJ51%#M9)?N;R,_?B,U<YP1.T5#;<R::=N9R3[?"IROG,BFD^YR3O@>:W
M$N=%(>C%*%XMM&NE"D=GT/MII5HYB3_L$+WKR_46U+[8DJ^!UBE?O[)$0<O)
M.S:<UAM/IA,%]HC+'<AR\I0K.X7E;TW;V4N\)<XDN&-S</NG-.*<TM>K<>9G
M::/.TBYKJ$O0_3O3"6<VY9#GZ8Z/N!M-).." L*9;_:QT13\[GA#7"JM_&G=
MPT8/9MA6=<DN/)_ZK0=GXQ0&T\'N<O^F.WF02<^A@J__<+W'[][C+D2;/-,>
M(VO-7P]$7V775&3XLONV)8B\[E.WB$RR8T2_U1Q\W?224HY7C-5WW!YT(C]@
M'8??1.%-]]8S?_ 0'@PW!I[K<J?N!2'63(Q\GRL8:'MJ"'+PP:X(''.(>O:^
M;":>O_+>YC+6>SB].\N2\M.;\]Y4H-MKU.DJ[V_7&5EQ]:%-X0'E_4VG(G5W
MU ELRV;^N,7@F'?IDAC>[UV+^X^^'<*!OQEA'2;'"_%=LPOZY@3Y4NR>N142
MCQ?:C/Q\O";*YK2\ZER#%"&LL&?ZFO$I/V&_,Q1"]<"U;1/OESQ=J0FOX62]
M81;/RPA@Z_2[K2* \IL2P%PI4BOXTGZ$N8QO7%YK7X&JW//90$>$<N5P*PGB
M&<EMD058!T( C1QN'8'DE+(.$3]%*XN90?4[5ESL%B9EV4Z$=8%;W(Q 1[)Y
M0"X@BUL7OC= C(Y"LKS==!O,=VVW%]QRO]5G/C\;9S\@ID^A8 5M3Y6FVM'B
MZ2M<1TG?SZ_DEBBP;UG*>2.H>WO-\N^<NC?<"+YJZM:V0 KD.^$I?CNBGKF
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M=>S 8,8CJ"_%'R!& 3/B+(#G6O!#$*&&R@+#XEW;%;$\=Q&(U0?E0[7_&NT
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M)0>7C2+((.H,;)!2L*)22J8!1'%D>*+ G0RTR3%E$[8PQY0<4S:*(%'UL0=
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MY;F+9R.H((>E')8VBB"I?+$(8IOLX>!U8#Y,2]HV6,_GJGT.-_ILQ$62 LE
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M>R1-6=7BT8TPAB'SA9PRX;I,WJXV$>_N<1>X#4!5U(E+B13TW'UZK/X>Z7K
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M<&&4A2G[(!*.B_*CUNB.K N8HH"2N'H6;E5:DL$X1%KR(;,M-3@&"U<JQV4
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M.-KRM:!@YW,BG0CM.&V YN&&??[LH/!OBS?Q&7I'/M;9JKEAC40W]WR_1_[
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M.CK$=_U2.L5L#Z9T80)$X/SS[++>I?*!/H8-*I/M)HMH/>=E.^_7UVS.L$U
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M53)+YKZ') [HQ?=_&?MJ!]_5Y<,!AV%J5HX#L&X!DF12%<TBYRR.FM5-MW9
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M?=7 +!5?3I.9\')*F40OH<4DMFCX=P_^@Z.FL,X+<GXY16<TH CXT8!6G5C
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MA1AY0\^?HP&)Y\6S9 980I"3L.EKD#AB.[GFP-)?R1-A>^V63U:B%+&U!5+
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M_!D_?@Q,W/9U%U0]K"#DGL3DC-_O-Y%OTV=@G%G1A6@>V:;D'!6MIZSW&?L
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MD3+-O3QP? ^,/M0[_/B!9T;11!:<(>..=MF<"4(XL9&4,4@!V4JZ$B\\);U
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M1C11KB%J'+;C[S7X)@J[@+&*38FM[SA=>/:AN<Z&HE"C29!P_Y +/"K)CZ(
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MJS7!7(\O;Z+9\VS2QKLE8%N_>$KO&I(A:1W_,,"KLI!.EK]\3*,F=LS>\1$
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MYPZH1YXPK15R[;B(5@04Y*R<8IE>^5SQXL),YTPW)>I(2L]W_!(I;Q=9++3
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M7.#8CX N/$T%J8\6]',"5F&>:^8Q6I15;XQEG(-:-97TEC*(ZQ!KR_2XTB]
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M52!>3"XL>1;S W +'R:7V/,DEX]W=TUR>9++DUR^IW)9+/<;[?0P[%V"0)*
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M:>JDJ9.FOD!-39ED:7?KW,9UV+!^Z(IRJ$H> #KLCGU5PCLE!7S%8I04<%+
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MRR?^,<*T)#L>Q/58.<P*-Y;M8 [4F%%X!=>X*.&QN$?(8:&01E)W;G9E*9,
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MQ=-(V$ODMNU0\2@"B'!;CIP$G789=\[D/HM(_P:U@:$U_$+!2VW:NA<]2;W
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M/F*(!C%N!N*'OI7(Z-VR\%&%82J!<XPQI&ML?,$V7$1UG.;VX[!F(*;.F4R
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M+#JG/.V.F39PB=])K5$(?P%2\,/;L/$XOA*F+POL?"DH(O'PQ*:O\,P5[".
M!U,/NY)&AVC]*/6\POI'73RH@(5'%$/Q0T-MUF^'  6ZZMIBG;,^H7;(4,6W
M3PC[<^/5S-]=9S5S7A5<S-F_S.KE&FRN/XG,J P' ''CJ.XU-M).]D^L1X9D
M*'QF!&URT=.*$%R39BOA['<Y-Y%=] /G%AH:-)*/\:V;Y?,W0>])6N:X/+^P
MH D%A(]T,E>#287FQO3DV?NJ?+\J2H3)[5V]>;9V/$(9D I1VU84%D@I0,<0
M9F\K6!E#5[$_ >9@5ZTJ+-T^H%F@5^6J4552\8=0#,>&*T'Q$L&7,9E'!0)J
M$D1OABOI8 IA5=H]#65*#!/-;6F<.[?*=]E;K#<8$RR(Z=BQHZTS,@S!?M#(
M#:F1I5A)C6,M W_3.@ YR:=@D3.=<!R.X3UZQU@.Y,@*&#S8JW&0\937%$ 3
MV@'I:$/&;J#8.7083#8JVG.MY&!!HY#J'P1_A,^!ZH$&%*(V@@'S"J(@POP3
MA% ,L85K3TU9%&Z1_(P-,@V0/1T;#G+6C,>,O\(TEE.42JP;"7Z+MBOP5 M-
M,5@72)MM13!+_PL4Q1&G#; ;?>\A%!;[?H<@P&&,W(-P^K9BO0,?0\YZH*;<
M%O@3/JWI<XAK,IS0VDB[(FPCG*Y[?N4"WKT;M NC0P5#D[^M5 _QCAK.W$_;
MX$ B,3Z5U&CH20S.N<AMV_M)!/O]#=72 R2%RN -=CQ0.&MG]+A7QJZ&3H5&
M&'*2?E-PN<.XJB$<YX#_&-*F)G*GI)NT]= !N@>)CGKO%/_41$V@+8;*P]G<
M2 CT?&[%-+%$A^7Q3:G=%NL&6$-ELV#4N4<G(N6*$]35FDX>7X8WK./RC[]_
M.!OS4\#Q\TI\X&%SV@X;TN%ZK)1H[^)F)TQP=A31SL1/8^UFC+,TI\O,U-NB
M6Q5P+I]]]Z%VQ^QY.7@=_;)=KY]AJO=]]B..-;T=.BSB?N^HCP8_]8):^>'N
M;T2/PJ'_#7Y5JA[F"G#AT 12H-*'*\)_^2%]N[]YL*]>T#W^5O3KXA]@-C'A
MMH-3[5,#_5Y!"Q0@T37W5=<V9F[ >8H/3.+"_MX[FA )6I[[@.\Y(K6KQ15S
M>E?*%,N4GSU:6'R(QHR8=\5/#,#>;A6'2G)8YDJF+]><3=,JR_I6<#,;<C?"
M3#"KBDG-!C^ IMEG).,1?T-QPMFX20J0!3UDMK1@)%HE:H$30E"+L,RF;4'/
MG+1+]$L2ND=GH!H"Q(8!!T-S+V,CZ*)P3\ :S@/V<_$[<.4I@T=8:>%"BFV^
M-U#2OU9QBBXXZ5FV0P>M88PA2>I]&QB!8<-24@V0VQR\GB"] QLX*K7(1.D$
MQ3*7 S$9+#VZ/%4R8R%N)N7XHQ]$BOM/J"BLS35<K=7-7$"&A2_N_C&"1!G/
MXP1Z];3O0<P$BH\<:OHDC2[#?1@M(S07%FO8)XYSQ:7T_F3A'6N]R.V8W.\(
MNFQ3*<0. M8.H?5JOE2HJK B2)R&RS=AF^ZRKYZV9\+;@PUL+L#9<SG<5S%S
M@YT2,#X4RM$)VLS4HYV=IED>OH'7X)9$=N%/GE61?=N1YO#].W& 0W-ZI(50
M7_@V)"] ^%1;GBON)AZY("%I*<367'.^W+K84_A3=I5V6D D#C'R2",;H?OM
M+#KSF7G(*3PR'5LL'2M"G&Z,6T=K6?D1P:#FL8L+8SGI\RR+GG+_>Q]H!LWO
MW;CHU/(XEE7B,0T %PU/#W.4$S%'GP^Y^I 8+U(5R!C4+@!K4*J7:EIAP$5F
MQT0[Z+F0?=_,Z ::[(<+UH6(AT?8/#50WF[, %'K0Y$H^H'6CWUSW,G<Y+K0
M,NU<0^$Z9M2WC$#(A;018^&2Z@WA.%OC&P663SR+M]N,Q^TL8#)JQ[V2 N]P
MO)%&.Q[PC*<PV%_+O8U$;#+&<)A?"LE03)=M;C!%O#K)#>D-M37-YXIJ/V+&
MZ;X;BG^U89]\) 2$V*\$6(YRGL7 $:/EY?3Y+S%D2/#(F3R&6##PK*S,!B<!
MR<)V/;9/K(#!_+AFBSK#/Y>JQD<[!3=(;Z.)4L_+QH'[M(WA'R,F[T*6LT'1
M&!NQ+]2R-!D4*7=@9QVFB0?N+JG S$,8+U+J$5= $9?PSGY011<W!'DA[<K9
M-7U/!IMHBJX#EV#-:4BZ#P=EN#S\4=MS'G(.F-?$R^LL5+A-U?<CSRT$.-VR
M+JJ]SP;?NR6 HOG:):=(A6"@[4!2&^Y3Z2K=28V&GL(,BH]]&MHQ*J'))-L$
M#3I6V%$XOR;4*R^A621&+46A\J F::MQ <[]XN &O48T<X8F%P?/X#='T5U>
M)-:YW6N637ZJ&Z_:_CY5;?]EJK;1 3L3W2YZ+[GOPG ?RAK+=Z@PI]AH%UTM
M#7KQHA_3#*UX8F*,%WF$AV)&XD"0,1^T!'?9"XFM8L/%U4>V$![;+*==8XLF
M]D^029LH;&,H%-^Q#D$N&.70]+,_%%4W[;#5YRYM!R\CCT<CHHK[(CE\'RS,
MEZ)N#RGVM: _R3:UW:PAQ  5''W\LP2JS^"/&!NN[<GC^O0\M0*7&;TC0G"M
MXF*08Y&+582M1+V_YL[)R)$+KF2%.P>?@B>5F6<UJ7I-U1'8T@F2BD7+<^K"
M.OJ5%K;U%N?9LJ<<S&KOZ84>D,Y 6F_-#,#<C%D^ 5^EG+>4WWU.7A%\J-N\
M.'U\Z7>5/30KYH%'A-!QDBW7_9?868/[NMHX%'CZ](G_QD^LN2CWX5 %L+5"
MGP&V:@N[U%%J^K-/LB.$[LAJ@@M2T9\W58W/\Y_"]""M'P9=IKB'3<6 B]FG
M9*94LA ;9V]GZ_]!6@;TS-H.22L)'81>[B[[KBF=D7Z^V*[H^564\C'@ZX2\
M/EBB)D1_1KO0JT)@P(- 6GR^&641]]M/EIG7F+/B(5XQ0]X_.RY$%P!\Z@&[
M_+$#XQF( JMPZ1OAVS*\0N=#&H<N!/T=KR7J+51=:YU770"E\%2DVGL2VM8#
M3"<_A737S#UG/NW$-%&H?04E/0V+>)?]5:>H[1+V)W;2+!4E]8APQBR?O)U_
MM&D<'.QRQ?UG.14X4'>A$B(^EC,;Y9-TIM?7M/3&PW+K^ZIO.S_\'I#OL,\8
M?87P\ YGP9Q/"FP[K9E,GT5SD-07B&H@6BV<N3"(V(?=L>>.)@3NB%!.W;[R
M\++Z*2H0HAQU;0///_U2U <<EE40).&M=J#D?)Y7'[S4A&T\AY=/< XHZ<!7
MRNV"$Z>0/(>'AA,-A3841[ZCBF0 C-1\,4/+"5@ ]@?P]R;6@5+ST6+BU4("
M?N70(<M\4Q2-G_A11RZ=&+E6K8G[?3O*\7F-0QY;,M-2GZ62RG2(1"37=[IC
MG;Y'AUJ\'R:UXIP,MJKR#LY=:G*\HC-%0R@Q)."NC2#^0PKMXW15RQKA,75
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M"5-6T?YQ\HHW=C%*_FI$)])\05[2R/0K*HUD__GZM<7_TY6A;\K6K%ON1J-
M5F6$@EEZ!;TVT:;!>FI]Z>84\12;D!:V<Z6KD*8CRA"?2>3-](OX:@HK5ENT
MH?PZB2"&A5C)KCT@X3K3>85)<( *= &HSK?ESUI<KR#FBP&3%+2ML&E.U9,
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M.^Z5U@*U!5^"'1>H5<9W(_(0644U\3X;N&DGK5F&'8\G'Y2S"[%X\\N>'_9
MPA?]E%)$@ !M-7*+N6&/_'$RD6):O$.OHI?XL*.&K;,_+T9AIAPD+@H\XMR?
MB5W[L2>M0:B.!,ZGZ'O+MR'58M/LU#S,LP^3D O\C2U-E';F'?VKW4$4*L A
M0L6)1]'#_7)W(J,=AJ$Y!+*8(+#,>FRGYRM$5S/CK99MC86-<*EN$$>7A%!
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MJK$<SZ;L_',&R:]I/.8[&H*1?=A5!S&BY=C#<Z--)1(&8W$/Q;'MPJB7(7W
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MH6:CA#85C()0S< MP&DP45%:T$P;B<%G3#3X+QUL"2)L)#(BNN20BCB:[G/
M37)TD6/W:G[?\A$"!^TO<5^?]UO#[-<D9^YQ54WQUH9PI<"S(L\KL2OUY)UJ
M,TFUO<29B4-@2S;X70%@7 . ?<-L\D%<3'%BE:"'<Y;$B=\;K"@'G0OMRA#$
M[N#M2]]D28S,HV<X>G2T&*$PFZMY 3X."+AY$<PP>8):>IB&9'UBZ%BN8R&3
MO/#/.XS[2@9D<^#(>)H2I\/($5A#$9G&&&+$V"!>_E7JO9]BH^B^_JB.F>%Z
M"P8WM6 L>3!67/C!,&01[C_V!N_?[.R9A1)]Y=-@AO.+E$3ET"?6(YI &H7>
MX:Y.PJ%5'(<Z6_EZ@)"/L$148; 6.$X>Q7:*ULC(^RU*O2=X@03\?#:?PDVA
MDOF9K7YSP+@UAY)3OJJEQYL;B^SC-:QN2%DH/I^]H3U4V/[_B69E%H!,>_;T
MA?<$^ (T]PCO$!&4)VG\,V^&[79P*^!F@LH9T)_EY;R_UPI;<S$:JO-2>6U+
MDA1Z??*VO[NOLS !P9T2;CX"QQ$TJT,?#%#F_>X]D6^_^EV^^3.'=2L+0H(K
M&+Z=L.1V$'\78:%EI719[C*>^K=;QREF% BE#C,+#LAK&JM1&3/UNL$3-WH\
M-@%Z=YUZB6#CVG8YRC8V'K;OO5YD*1BW<[7.65_L[A[8+3H,*9E#% 0!SAJ@
MR8,(HUZ+A1^_.M724M:#C^L_>P'^]4()4#VL/4-WC#8<(RF*NWAM2<"[UV^1
M7JN&5ZX]=^'P=$YS](@ #;*IT'1 3+_PGAP/+@9O3M\-?J9],)"TGI!('$]^
MH)8$=?:'=1SN]8U.2#$/[/U9@B.(V"!C1.3?ZYE/84;I>'^'.QW)L$R3=!2S
M4ZF%WU#QF#8="C/\ZX24 S!_0=S4I84HHQK&K17D5HJ#2#>"'$W-PB#X,F79
M)>:+O"![U9"Q TQMR"R"!^=S22!+U(H=*V0)/2-O#MYO2F.]>)/![Q_/?3B1
MU[YW>KSS]OWK=VAU7P8Y3V@9:PDJ80MF /F'U4-&TB&3P,/HQN1Y/>]W/<;2
M'@/A7NKM.I,.TGDE/Z5S%%E%K;A<:5/?0Z5'0^AL,!H->M\@$*(Q!B(,?YI3
M11YQ1X&,Z74RL W/AW8#N])SV9:7*VGWOWDH1J*_0/P,&?<YN#3_YKVPVS6(
MP0*"/;ZO,<^3 /&"(PT7/,"XY/\!KA\%/^N$'.6L<5%-]ZV)09B<MH9[+F6@
M**O*)Z D1N"E@12*@^1GFK^F)@N&X16;0!3^\3Y"@4=#G*I V-"GDP$80O,I
M$']03!=&L,/OWVG1[GMO@(K>JMD0S!U""FWXPEOGXT1^>%XOR=E\R1$G[Z7<
M'=]QE*\D CQ1MC!XFQ>#?YR\.SMGU0COY3T65PA('081!=?0/ %SRPI_NU%]
MFHX".2 % T<#?]4[.#X(/AAM!DM#NK?L[5[W,2*J'L/OL\67ZX6J<\GN.!JG
MD@KI$N0-=5Z/>*@#5QY,XG*4CA#5?91&H6-T!"&-.V+#2 9I2ID)FG,)4%]&
M>*]@%J+ #G+D"JP8,P+QR>#=\>#GG2#/TU%$9 (2 DF]B,0]9FD"=S3F.IPE
M&<I<983#[U&8@1>>X!.\\W(^1PAT<*O-Z?Y^[IZMSA//675H<U&D+=]Z-"_X
MMLTSWKQ[O[NW;^DLD"O7-+YL(?SF4($A.WNIA&I?H;MWZ26&'%GRO7_WNV]V
MJ(UP2>KS+!'2L7H:JHUN(/?X(HLIM&IY)[&\P]L\ ]LSQ2F\^  X/KH.PQ9T
MLR:M&M%SB1OA___[O^T?O3#K"^0P]Y<&-1L10R1S]O;\&6A.?:8)6,VHU4&D
MN0?+)E>3,G54;9" >;8SQ*H#^&=,1H)+5#BY-U$\M1F6AJ)*2XO!^?N=/?O"
MP@P^H-&C?RUF1@;R8U$43K' ;IF76?#S8=YHY0Q@\<F7FGDV^/#Z?W;Z_6=F
MXQ1.:]BQ\U;R?Q/\R>[J>,^A\8*G8M'@52)!\7$34TAQO">XR5<)=HW"13G/
MIXLG:=$SZULBWD!LK[Z87DBT;T$Z1.,4[_]MBL?Y3I5+PMI*:VW@;(^[?589
M'UL98(O\;J*24BQ#"M\,4J !3YSI43%5@Y#G-C8Q3BP(=$,C9CJ"A*UY+IH;
M\D!)02%L@ZE$HSFH&(=^;^H$?;:C3*;,-VYR)M_@R+=;GFLJ)?%1?GVE!$%.
MY3"Z; .3QY%.=5 (O7D<>24MRZ%ALU4PF@@!.S,HY_(GFJ/'-3A8*ND"]@FV
MM123Z8(XIYH3!?D:@-H-N1MX4)09A\(7+\-W,:Q\!@ST1:((@C@5TX%N7(J&
M-S405MH#V?FQX66GW&BY@'2+>.NM(.5K$2S1*!G$;K*M,NQI;HHBEC[!(/$<
M0JR.FZ3$:;5T<4*3NZOS;O1\#?(E@6%0:2LNTVPN%\,T95(B&9:95+S9P(",
M./+=<%:MM$P7GN*?&N<G5W.HQIER$X0Z:07&-*@4"5<%HS_+*(],9(L,_UIB
M9#DQ%$;!)$GS@M(>)BE4S;X1F#^)&'M>;,=1^65"51(A#@OGA#T:4W#,24FC
M[^RH%RU.>MZY?$17H>S0U':'%&C*#-;9T>Z%0=VR1>=Q/J=WP>ZD@I8"["*,
MDE*+U9":&M"F7<H,QZB.JZE[%=HE:*_.%8.THDK$NI22WDKQ B?)\5]_ED',
MLW=RJF<EM[8VX\5DR:MK628=V+\N4;&EYDA#%CJ/I@34Z<T);J&N1S+)ZBD]
MQV3@H 4-J:D,[_"U6$5;<.M'7A]N9KYJHPH!VCCX6)=?7U4K:2I%&DLUUD8V
M.VDI9WI:F8R#2Q!$-.,5# 5'].NR5*OKJ_;!'//R6*""[#A505Q,1^PR4A&+
M>'HT5883R5(T!'^KS8:Z*1FV>54.;B,%;9[MJ(9JP=S7Y^Y701MJQAB)O"LO
MS$JG@.02Y=]5%-)(0C37N/1YP3DI^K'G'<N,'!KYQ09(C()9</*0+JJV"#>$
M5"OT*^7M.!@6Q(N>2HK7*D5X;B ?J[A8)8P"M.NIPHQ+IXV584X!]&XZ<TJW
MS1A/LP(QR0@IVPQJ"_A I) F(O+G1@\.95%0FTHUS),U6VA:IUF;/) .O@DT
MEDN.H;'D-887)[F[=/189<XNO8UBN+K&FY]!=TP8@Q1\K5=^V+7@J-_*<$/I
M*\&_5@H]](Q$,G]XN<QO<?.Z!CS.&:TFXPNM+&#EBC^S97+"K1FC"0LL-AZ'
MF'!=M5DS7\X2!W#58UKU7&UYHR.K?)F?&+.W'Q/8U*(R.="7Y/N$!$R\T.-O
M93XS%\>)E:[=/=-79+(Z1$O5=[-URF3-[#/@)B%S2\X(23K&:42]:0TC%<MY
MO7J1PH*VX*M)9BL1\BM*T5=>VA9Y8&?5HUQ'UU5KY\@6=CLD*;B6%3I' TN1
M" 4[:VN Y>AI\+FC45E*RRA 6]>@^U:<-M":)\W*LHXM79GYJ NVY*,1=:94
M&C7=HG$0GZ\=1]UI5&%7O^ZNV^:_Z]XCOZ/YXRKAB6#N2WUJ% UUML-IF.9V
M"1X3&RRD@MBM0ZZ>+44KL.8"ES,C(S^3:Z-"=AQA[1@8X@Q*DC7.U94>64\S
M7E$VPI*Y6>!6Q\*.>5 4:C9W1CBCH&5E-EPP^[-_Z1 -Z<H9BHR&. HZ/C(I
MWFTJ!V4QPIIJ>!@6.S=UY9(U97PBDJ*H[JPOBKR/-P#OGTD%1:9"T'S9C,L0
ML"JUI&H;I$$<%2IS)9C6N< R1A&KXU7R9ZR[G$@21$_#LP&YX]66BMLY66F$
M=CE75Q9*:X;UAW';=88/K51D#B2IKI]="WBM7$P.QYYSB&Z!;6GUC\FX6!Y"
M.2-CB1S+S)X*/-]O%D"\H6NF*/:\,VOTD),=)>;?JR5.!:5  I@8WD55S*TP
M\DLSL9IIEE9GVQ'$X$AW,/6?8J[,*5[Z%S 3CA"^QOJ40UAQR"0#I>];!P@E
M/$S5]>N(5]U7;TF&ZOC=CT1N,WF:<&Q4>M]$A*R:^UW1#FOHDS4[?;9(YW)3
MC1"3&\QJLMH;71.WR@^EE-AHYO+EV63XZ%NC>"&Q5YEAOVKN'#PQ(DH[O'?]
M8!F;+,W'.3P&+=(539JZ'VJY&<I["ZM(J<!#Q=%$C^H>+]&<:86)J"F6DQV\
M+*WFYT%D4L48X!]1HE3FPGN9$0YT$+F(N[S:1*L#NOZJ:*[R9410K?D$E0C6
MQL\:-6K%:S0Y!JDW\6T@T_1&NO/E:;UVN:8-6CX\ T9&:QS6B(IV>SBAJADR
MLBYQW^1K!R.<E,YU8BZ:C"%6;0S8@E)5\-#Z1&?G29+AQ'E?\P07KJ1)\R4&
M,5@)(=9M,:]Q'P^9.G2OYF:&:!K!^N8I![VI \G4+8--8>MNI3!#.HQZ<+K&
M+N"R7'RN42V<+QP2X$3(?&8-"^*9H4P1%B4$'UTR=\ETTR%:=JG9]'0@2(;<
M%B=1"M0K7\Q0[3BX$D^2LW,8J=   =3NGA649..U.]$0ZB4G\496J99Q:1PB
MB_)IRMZY.:JA^9+ZT^KF60I^=\*S?PF"Y2V92907$IDW3X'9I,N%C[_B/N+L
M9"$/3O ATD8MR(9/($5Z1JZDXQ<AG,$<3T'TTSIJELF9#@=8<>K<TLZXI&2^
MVRTB^]3&6V.^I](0-K)]@8$!V] P&Y($]J0K3X;%L_3#<A^_XC\'F.L:@1&!
MX0X+ 5!5WA57C+8/ KAAK/W6]*==$ (&^&CDC5UCL7$)'?)#336;(T,AE(A?
MTO->60 ((2>T^\5(M=2T1H02O1V).%H@'Z(+(OUZH$32ZHS<4+E/<"XSGLET
M/3[,=O7'57+RG/FE8,62U5V1L=(_5F-<+&S.<^E@(T<.E88IO^7,I;:1P?\!
MU>8X#>X8\W-N,%\9EG*#+4[O)/JU)&?"=(;IYY&%WAEF:0 :<$5$AI/O>7'C
M.[4!!J>Q'*[P)9<94MFAO^U];,\V,R_8];'=857BT:,IDZAQQ-D=[0\Y!I>3
MS*_%[EQ?I]EBNTV TBB&ADAE0[D0A@66O/N*_T\+_#XN_RHP$)U?M7LQ ;;0
M!:Q2==4GD3]G%5.X:$\EW!*7HE^87F%!1J7JS-6P.KM0]<&P6X2"%%7<,;".
M$VU&V>S"]G457NBXKAN0,$8+):0E^IX*-M@:EM%JD\@-"T0F-HMF*_D630JW
M*;2^$KQ%ZSPT8X,Y,R"Z5BZ_LM*CTC%*FE*<OL*YA@58LU9VNB) ITTS:UZ9
M+AX,K@9N<M#X2$C)$@/(3)S9&(+:G;D.7.</)7U5TNP%W@ 556I:I^XO$!;<
M)8%U1B/;.N#FYZ0B;U7II( >$K@DY0V*] K;#;3RM\?K"YF8NXV2<5QRI>?X
MQGR'.%8FP6VRZ)=*@RAR82B6.],*] Z169<N&3;-IFQ,E?%2FX&M;!K#H):W
MC9Q\ 4N889#!F4JF@,O>@&-&#DM0!X?0O"7T;7&'!"]']UR9,FC=U[7"<J0>
M%"GS(Y=?H[ER'9E)(.L>K268R&6$2:JB*+'N>GO<$43!2$=E+H?BU)P: #"G
MLX1('!T,@M;@2L!Q',QF,HY1>Q,<R8 GF%9GH$X297B5MC!SKM)YC+G%5 Y6
M P^SR+>XCY4J0JZX'F*LS'F&"!0JF31PD?AD"E50 -H@?9!7Q#85%PJ8UCEN
M:5HAA(@#=1P/?9V9CAOA:\TOB%#<PE&*V"'/&C@!G9HA)6!+<?0C\%PQZRKE
MZ<ZL@53GQW2[#DLCYTA-XV6#BO*]$VRB4+6L*JZ"[8VR6 82,C#(9,L8\X?L
MOBN,X 1P<MHD6WV2N91T7MDE.N5J%;EGLE_4=A)2X2KW_E.@@FOML4:4BNW'
M.HM# 8@Z(VO"IF8S5# <DM*BOE:E]JU%IL.;&.2*1G?G_-N$MPDSS3&<=$4.
M3FPKTM'GKQ5?+5$-%U8OF&JQ^E9)[T[!P0&OAD,30P4N *I6^/DR1=T>;UE\
M"3X9LO'U58>B$QVZFX$^XYKI4JA%0BDB)G9".WH1\+1RMGH5]%"0-AHQ<D00
M"8G&)@/BE>5(XQ/M"2NVM(G&=15*'BGD4+.[K&%*L3:L<93#P2W*"L%*'!6E
M+MRHTQ8W9ZM1J1./XZ;NAO7QGG2]DA3<V0.6]=7O@3[@[L-=+@?IZ2.<L* G
ME8D6 9CNB7+$P<)&W#0)^&1M>%Y0Z= >QC@Q]SA-HDL*W:.,)U,3=+YS&0ZP
M^]^Z*;WMG+_13:[I)M=TDVM:.+D&<^MQRG&#<;W12LQ5Z@7O1H9M)/ET@K<3
MO)W@;:'@=>H(:8 '@L74@'O(-C?1JE4Q_FZT[@8362>>._'<B><6BN>*&);I
M6H*G;C"\,SR62FWU/"@81!7SHR#0)[KM%?>:=Y)Z@^FMD]2=I.XD=1LE=26"
M@7D]!_%&L%DU-B2-,2)$5=AVP"GA3BIO,&UU4KF3RIU4;J%4EGDP8CE[((X9
MP,-,*<@JD.5-Z!.91>;BU&K$Z&DI-@'JHF(I+;")3:GMJ(!Z20HV7G2R?H,I
MMI/UG:SO9'U[93U.1L2">8Z9#"U>+?6O9GIX7:8F ;<U5\K$JV7CCB)@F8TA
ME4YN;R3U=7*[D]N=W&ZAW-:5B5)>Z)2KFR%U(LF=>L,@">*%QNC@AC#&Y%Y'
M-F]\$\@KM]@1&]?KP +2?KY4_>WB.BT5H'[CJM\:V>WL]OJWH[SU1=#Z('O+
M)U4%GM=EI'6P<NJ+T/.JX'/Z1R0_G%&'O\/_ZNZ'2CDJ7P9WM]%T9JK-Y7O
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M0$VX.$YW*:3K22Q4 D-8DH=9"*>&+UDTO%WJM:4E)TJ<W)&;J(O&MFK8S;S
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MF_ 136 EFN'KL;D/B5WD_$#B'#WBA0!0<.*ZS6#JF9?"-6$&#IS)P<#+7YH
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MXAX9'WA[I+!T"S$(6[8VK)VJR![6X$2$HG]]:DS'>ABW&@;%D@\& Y7D$)B
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M$P? &;Z(H[VAB/\K4Z,L=7>@CW=]IS;(!'I>X?+B()\%II901Z]HQG 64)\
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M8Z$4NV#&368K$JA'DM.R__W?#IZ_\.HW#?^3X?^@V(;_@F3O!'P+R;03\)V
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MQ81L.RY1TYE%:(?(%T[%WV77QEN PLI,\3XG-WA:\MD>4*,^@M5+\$ >1*!
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ML;O\0GS*+<2E!N*PCWF5UYZFQB6[2ZG!-+*/"$=)>N7<K9$[JL/K?Q/IHP[
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MA)" @1F#"! L#R1@8,8@"\W)2\C1'>E5Z^=MVB#(7C]I/6A,089%%TOW->;
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M2MX))<\ISKJK*P_=AMEI;*\J*U/R(00P#BZ3GTBLXHMK#5S/C5UX UYZB.+
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ML]%JD\E&8E$G+NI,?42 8'D@ 0-3WQK45^KLM0GU;=(]N]&FDXC+HLYGWG1
M^"2& H3/,4+Q)/P)GWGO'Q(^!6 8V!+9JB72*O7_2O3>G5)[ZSO?.3.C3J?X
M-TLQ<2EF5B,"!,L#"1B8U=9@M5)OKW58;9.F7MT.G0K=+.)\P$T'!-G#WK#T
M,7<ND9A>V(E-$2) G+R>H@$#FR)KF"*E'EM2 >IX?ZZZWXY/N1MFI4VG##:+
M.G%19^HC @3+ PD8F/K6H+Y20ZQ-J&]];[QEMAO;\\99U(EYXX?68OL 7/2Q
M"*T8ELGPA!6)U$G?6XEI[@IZF+%K[@IZ,%!Q5] =&4&E?E>I=OV"RC4Q@YYW
M?LN]V][>+7=N&GJ\.H+)EC(Z3+9' !63[8[(MM3):A.R?:$)=ZM%YXB?^?3$
MS_UK[?-ZDS8*JNNV7:X@3B\2QZ<?1(!8HB'DB6LR&C@MU[N3K9G5K)E24;K7
MNRY0;9C55I,/3:AM(JH*@!F3"!#,F(>!$S/F+ABS5-CN]6X95-MFN\O)].0V
MT:E>,R .R]P[!B9\QM=1 CX"H0D>U;@Z'X$<#%1\!+(C$ZA456_.$<AUJF4W
MRNUO5#I\"G(06XEO%3 Z3*E'#!53ZHXHM52M;T-*?>%B0;=#IS@^4^HA7"S@
MV,*,FP8$;ABPT7.8P?DE(O-L%1T(ELL=M+#9M'6SJ5TJ+9@[C-GAO85FFTZR
M)YM/=%4&DS-E=)B<3P%+)N=]D7.I0N+2Y+S!%8F.V=YB$B*3\R'$-@@W(2".
MP$4P&KGQ" 86&9;O&!?P,5@)X=L@H\;;ZR 61OL=O3@TWP4E @3?!3T,G/@N
MZ!(6#DS<3V9Z%@G[S/UU]N@Z,-3WVJ2I90CCA[G>\KXQHRIO3%!$@&"".@R<
MF*"V0E!U)BA:F%$YOS]='[<?!_:/Q\ #Q1+]UU\ZM6K[@R'^;^+&S^_I12O9
M;B "Q,FK*1HP<%%DLM"PA)" @1F#"! L#R1@8,8@"\W)2\C1'6_2+S1_&R9-
MUB/T TWCMZ4N,GS_-0@]-WJT0KRKD%UJZ)3*/Z0OD'[FK17>A/W8BH7S3\N;
MB%L1]O$A*UY&O+K^O.2-B[D#+25I;F.@I8L9<J"5<_C0C#L74[\PQE:(6WXB
M3&/!W.9-J)0B4YR0''W4F\2/00B[R5ECQ1=<,5D$QIP!=TN74S<9\,R57S3@
MI@D/P/^_!#!J\(:5CN6__M+L?E@#I&[ISL^L.5]%T61C@##^B7/^&81.)/RU
M$"HU3EMWM"^BLXW1EGK=S!KMS22.8LM'A4]@@4N5Z3<:\NJK_!\1!B_O_V5^
M,3YFDE26BOK?1!FX<MO+6T%!!A"]\P3V?XD <?+6/0T8V/]=YIRT@0!V:M4:
M'Y02 8VJ/#&_$ &"Y8$$#,POR_!+D_F%&&@G<!&'OJ.)^2:!OYU0;+?4B4<]
MG58<MENJL+_Q*/<8A.V6PM^YV="+P)9BX&N/=N7P:U4%7S<*P)Y2U&D-=$L'
M B5TMQ)HWG@?5BNEJ'AII-L+VTX/MUXU&Y6NV:[,RHJ=WH<8[5MC?J63CK60
M6%G&UAAI*>*_/A(K#[=6,T&!FIW:"AIA=A36L.)3T@V?A"U& Q$:L)<-E &Y
M'@B!:< BC06LV9/PUNX=SI>SB'BM?/7DR&'@X,$:=306>1#2;=BHNG9]>Y5
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M?%Y[&U7;.')-A#PY+G?D,+ -LX8-TWTE&Z90@V7;Y=,Z7(R6W%:DJB68-8D
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MM%50J>BRE*53E5<Z^=HHKW8G?NSANCM'6FBDI#CG&8^=98S'K4(#(X&% &S
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M68,($"P0-'!@UF#6H 0$22%AUB "! L$#1R8-9@U* %!4DCX0A\-'%@>:.#
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M;01*(L);3\8P#$;&9?_VUAA/0OL1A#LR+-_1?PW&.OU-A+8+?R*7*,IGH42
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MZ9Z4ZJ**TW+VT6G;/E2Q._DKH31@X)0((D PYQP&3LPYAXO=R7/.T=4-(([
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M8)Y<@R<[K\R36SB:;G;-;J/*/$EM\U$YAN8+_4L&";!@_F7_]M88)_7TL(*
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M)*(84RGPND!: <;(2L"\IQ>_9$^5"A(GK]%HP,#=T\A"PQ)" @;V,XD P?)
M @9F#++0G+R$\('DZR(@5^8L&)Y-L(MD%(DX,H)!;+F^<+#(H-#5,O V@!&H
MZP3@(GJR"*'G6@/7VVN/!I*L?Y".(H>^]GWIBSMLD[JO56P">1WX&#2["6^M
M,-8_2$!NAM\BT9.:\T8KSBL_*3+T.0AO$J7Y!77FETQE[KX:H-EITDF$9_U
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M/VKW"W<AJG^8,/+S(SH!ZJPLG;>IO;:\)2 _,9&&"S[(LVQ]B.++,T='W5I
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MZ%O*DTC+Z(.6D'XJO/JG/*V2)UVV &O"44O@ZVI[ZM_BEQO/_!*XM3*@K6#
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MHN6-AHIR 2[O]J@]R[R )#ADAME9A_F&QHR+?)TH :90*%5::'&PV8F%5KT
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M( 4GC.T,X 8RA39KHR*W#-E.=GIF6(HN/$:FZB?5XQ?UQ,%GIGTU<B\@L.M
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M:YB6Y8]@BB:PH%'I2S(V(_AFWX0[6D(+AT)$-:FST^=/YU/JA))&.#L!:[.
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M\='W/<I]0]+3\7WA_89!^H)C\U%4^X$P?U3- ;S?M>D^FY/P2OMULW6Y)R@
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M8I%93!-0PYJB]MD 27V+ ,GI*,DD=;N;BL%"+E0Q!/%W+&=T,S:4@H$! ,6
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M&FZ=>^OBO8IV.:83"5=8"?G$D<P_5&DDF#^!7P&2!!T2**>7/(11>!T_ /L
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M=IN44POND@&@M$E)3VS(HZOT_)1,A42 N'A%10.&AK1"5D)Q"7;'O+2XG_W
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M&%/) $?L3/B/[-8SV&*NNZ7F[+<2::GM;\TQZE4YM>'W!/0[/[B+(["[/B7
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MA04J1!.#@>)U+%<,]Y$SHAL5^88U[4\/OQHE(ZYDG!,"UPN@XL?, D#[P!F
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M!S%3CG$[@UA[V6<&L8H"6%"$-%05Y=-*Q;CD)ZL\K56*8B ;>"#D/&4XA-I
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MJN#C DP"9WXK4[H9A6L%()GE!7HB'9"(Y/-Q_ [J:!^B>/BU'YJ.M?W"X-J
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ME(>.#8;LDYJ5UKN?NO%3#($8-B?>=7/A!<&VZD&SAEU=KUJJP;H/UPS<D:?
M?&9+!E>\6/K68[=6Y*-J,9KS>LZ)73?05HX'SC%(@Y1*=@'!8>#T8[&0)BVK
MW^.M&&W4JI]QSM)?Q'?&YP]2/]TYZ(7W0(>Y\.]__:G>_@POK+#WZM;<[\FM
M)=&2&[PV4(I/\,A2+@22#=JSE#^;8^FLROB?NVY)=96#*1:N/OR+@PW\^&F*
MIE(FZ,T\4\51^2"XA W#$4>*MZ%69^*GC/F[,X/;0.@'^Y_X.HB.A45<0:DL
M#6D?7OP'U;GIX05F=GSK<>">$OBL4JUBJ]2)DJEC@UMXV?PH:QZDO-+F[K2>
M6*(W]%E)1K6J-,,P2$8X D$M]P-N_EX6H>0GTWTQQ\#PCX=HBO77J;Z(.0!_
M3=C\+=KOD#MY,V#T8>@0"S]QUE)$\BGPPT3%I9@$J)1XA.KJ_R8 MB9C6#_"
MGRG+-C?"#Z2*DH9FKZIMKHZ;ZHA;G=/-5#/&I,A.8MJ *F58S4B8,UB3O_/$
M)C,N37H*[(R4HS-MS-6D)?98NHV)M7V!=X(A'$_9=C,#( G$7:^I>BT^!0^#
M9T6XD2_N P88+1=H>8E+R7%^]:59#GO@IQ[0-B=B6\980'^Q_7/B;$DUF%6
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MW:@UC6:UU6FU6Q_M=KM5ZW1L_J-F5(;1\U1VAB#*YI8O^VE+JM[]U'T*^.0
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M[YC%790RR_&>TL\CT[:3SSE"/YEQY'^6=Y=!/%US%/)/R1^?66+/JY,E58@
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M8Q+=8V>4)7AX\O4(#0C2(TA/,ZH(TB-(;S=SI:&P$Z2GH5$G2&\)I+=.D$:
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MAC(:?=\>B]D<1L\N_/'_ U!+ P04    "  I:']4*S=P7+86  #N 0$ $0
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M/G\),9IP;)M9\FDGB.GPFH>IU @%VZ*H8#X]0*V3[>SPI=F-IS&68FSO( N
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MQ\!*LZTJ@\)I=;ATZN4/\G_/2."?_@=02P,$%     @ *6A_5$^'Q(WE*0
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MGX $<>-'M+_4DAR_A03R7(NR[#[Z&/@Z/CHZ3A?G'QX0_ H,^3 Q)NL<,=G
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M%(WC8.B/I8IQ0N2T"#9$$/#=LLD,JSI@IV@\G^VVL@[+,D+5DC+?%4T%G2)
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M6?EC'WD#6@4O5<!?ZF+',LAFYV(K70BQ0F@YA$B9HOIY/3>(E*IDX+KQ- [
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MOT,4S#5B/NPRCF*"%@+(O'0%XKU8)Z,XHI$3>GXX2>?C5>B2-.F6_K_.E2'
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M?*@@\SHV3T/?>4R0;[ BOX$$!$8.@;-;3!.^Z%E,")*[FEF<IL8L 8Q_\>I
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MMUC99T[@LH,C+%94@EZV-Z!E>,P6!--156)L>JML^HBF.&KDI3CKZ2R.$L;
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M,R=?9C(>42#3U+L?("IR^AM*+C^AOSIY^TZ$WG_I(-PO.9.%3O?BDY3BP*S
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MDQ(-=9H6.S%%'AXVQC5G%N%SB??O_N6G]^_^^&<6]>=NQFN,,#;5\E+01,=
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MK0*:M#P\]\XY!-)=LE?O>$PGH>D8-=2;S]@T4HAP011-6[Q2&?Z:%(^GA[S
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M/."M4U +"X2T@(M;AL#YGN_LT+I)^!HD8]63L8^LK\/GXQ5*&'%"!2BLH;F
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M;WY;///M+'']7X>\H&O*_ [WI"&9E/=1#MD-,ICFXBTCXO%Y4D#1A9&7T-S
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M*H[Q@2R#R1(8)D_TZ5$['^VBYQ+'8_J6"/[,$4SA ^VA6NY&!1>Z#Q5L0G7
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M5(![^)"D*357LG\J'B'@WW\%4=G4>EW%9"/TOR9+=1J/Z[!;#@&P,; ORJ,
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M=@RE/^\-43$'K)^JCT+WJA%_&!ZE  Q65U6X( @_J=F FL],4],-?(+I =[
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M%5+.GORKG:\GOR*J.+!'Y:*L>/D4[:!J\^'^[^I;8!\M'Z96<P&4S;S!810
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MA32="C>K)_+;!W@#:>,X.3)HG<;JTW8%V#@O]]Y4\CR).%.0E5REN2E$W](
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M=91L+G#&?8P^/((.&UI3?_<(/Q)NAXQ=>5UOVQM]%3]PP,3P=K,-4R_7T*E
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M63;TK0>8YFRI(K_P].&E_HR0=_4ERC863\Q;,W7QV+BE$'Z?HF>, >,,9/%
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M#99_')+B12?>J% S-X=QZA[R=X(GH'X(+H-:MVA@A_6U&#Y.J 71A0P16&>
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MYQQIB-X4[O<890_0PMW*[[O"AM/[_ZN[EMV$82#X*S[U)RI5"E)[J"(5H?Y
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M-F1';WW2,.PM34(P&TE!][FO:%ZN3_R_;]?I>B<$=__Q80@1?+95%Q+H?*L
MUYX/S(0%@F%=.*C$'*G#9DU%$EKV9;1$=/RQ%Z-AMP#V!H183"!GH P.P#^5
M0C6+]IID09DH/=H BZL%-?KB:NU)1_$#OA__X1\.'_$_:[Y1>/L'4$L#!!0
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MVTAYCIWI?AMUV!5W%#$\.BD+H) -R$$TW7G3&,0*\6=XN%(9>'NRS_"'6,J
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M/CHP#\Q0BCR*;; *']U0RA76^SJQF&=V**7W0(#5..6'4F\.A%EM7&8H1>A
MJ!4$Y-JL0=>G%V= 69\/M+99?NYP(!(,I[=9F:Y/YTYL/^WD0K19;.YP=I)P
MG@N'RVP9+@:7;/J3U@I]_4H&W'K3GT^Z:9836$KV4%(#]R>@Z07C;H4%F0[
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M@]L_R/TFO2DEY3\OW&"% \O[2G"TBHL'!3;VZ?RH,"_K@%>3KZF1+ZV/+D?
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M#]9A5_.DQ#FUVZ[I6?19N.[>LWP)&*3(ZTTZ:;"GRVEHNJ)L&B\&3\1R>+/
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M&1;-9Z:Q[TOB6/3CL\"J;IU'04AW/DD<C^SV'@3LM0L+3,-4G@1YG?>B7,7
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MN;;UB4NU7MDBE TA$E"K_EY/2Y522')]X^.:/M^HP+ \]R]Z>.F?SM",&A3
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M]JMHWB>^>RJ(]$,P->ETV.K;^JKQM4#'&0#VF]_YL*^'7+B_O&:&Q@<XIC[
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MAHMKJM)G5(2$Z,:=B4L?&%'%?//U!8DE<8):-HP:_W+G[N3]JP_3]!LO4?+
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MB\U&D[-_Z3M],)?/L4=E.TZKQJA[]@.FVSM#6GP&.DL#/* 7Y$<H^]=F"Y^
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MZ.2HV2F@^V)+N636J]RYJ"4GQ>N9B^<(\%:PX*/6-GN:=2'.7,%'[3&7Y-
MF=O^J#7F'IBLA[&V]4F[C$&$5NX#J?T]6<:.LR0%/8QK-J7'2?(TBA/44_2
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MI)BY_21\A!CNN>0HFOFVI2&*.1<V1\K,!P!R2,G&+3(T/YF9\]]LWPF$KCB
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M:_JFU>FWW[?8U46S4UB$_)1/'ILYEJW+1B[""_P^MZ6N<,*((S.?)C#(R/>
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M;SR)P])%6!7>MKA$OHAA6_=UR.M4,41NU5Z!;7<3@5GA[MN#*2XF=;'S\OC
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MH&HB;27B;1_W7643QR=ZY<PH=,+#0*@J<B_ RQ?=$NGJQ:8(5,?X' 7=/7<
MR$!(YH2G;57KU4%?)2(LZ67.U:@3-IPB%00=M36=&B521BUAUY2P&X+#<Q9F
M58QKR56':Y#K1,X#T2^T[KQ @BY7P 1HY %_>NKVIU2-Z[.@BV\A7 (2><$I
MKU].)Z$2(>Q+O7)#UDG44XP/9([0[)XI;4)BG@^LH9+LJ 02'\4H#4KA0NJT
M!3]!_!MCM>B/\\^9)O)7(&2U7I2_I[/\PLAD]^EXOVV5DZ-4:XX&"(FT@EN/
MF#D^^F53I ;+W5OSYRK\N2&UD,W\971(:.T<=:_,M$U0.^8*/.,E1>\2%@='
M:7BW< G>'%.M?IJP :'S<%)I.#^:*_@+[PC"H@2BR_62G-51-K]2+-9T4(BN
MHOC8!/=PM=$%IDZX-?.LPCP;4A&HB'/U6 2RB(833L$L5;!=$RYZ\%2P.26@
M&Q#(E(I@'(ZY[&:MP>SXN7J!0LB*QH#^#(1/0WWO"HI?D(Y+T7TH8&Z<![@
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M5%Q+7O7\24UXGLFY[LG:'?Y,DPW _!"H-B=D\+"!FO'\+N#01(#_1T%4,4[
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MJ8L-Y U\./ 77.(_"E(<2R2S@<V3>#XV,*Y:S@8&,PI0LJS/N+5 E !V)60
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MPJVTC3.6Y8EVF]9.'[*#8ZXOF,6M7GED)W?KRS'5;UA(7GS%ANI#.^LOZAV
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M2%>Y<]#XA>:3ZZEF-U(=Y1M3>==][5D7*L^S@?(3EDS9WS^T%B;PC!<>S]C
M]3NXK9/+&H8#-_[),V7^>[(>KLZZ4&CS']A[[ZBFNFY=/(J*@D@'J5$!D:Z
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M1*-5O,T3:BS*^H]5644VD9]_\?51_;CVY;=CCS7;#=L\!5[W'MRZ>; @C3>
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M!U$S!1GE72+%DG%:F)YPA8V$F(>[):W&@"*Z.=J!L,X#]J#VU07EX*H]^C@
MP1;KV+@<'RCY^.?ZQVRO5!K-'6FR[6'CS_M4"@]"G<);[^2($84Z9>F^AA(1
M0J_F@\*]/:.:!O.T2V1]$LK&[3[W>=!387>5QJ4IU\FZ_Y(U[H)]SH"0T"O6
M:1%C)<4P3,DOVG?U@K6)QUI1.DZW7^V;*Y8+H$30XV$N2KC:/ZI^H%PYPX6]
M(S^5.:NI\ZZ_6!SU5S]<?/)^TOD'B@OF^ZJ*+S>T<:YI4]T1%^A?078&I&F$
MI/8ZUQ6#0V8K)A)*V%>YW]3V^YUYHFRCWS!]MK-SYFB!P[,+@8/CRG(RB^^R
M;]YK[:R;,JN8S.Z9('RC;*J]N)TXV*@E>N:R24CC%=ECNS2UJMTU1/,L)R#A
M3>.-: RF8U^JKH_7C_PBC%R6/.<AO$ G?KV+BCNRY)JU=]"HW1JJD+6L8?\T
M>\(U6/R]MXN3B]<KJW%<4VGK@>L?S;CO0/(_0/@@D./\CJHL*99K@\K=*8$U
MFWF>7[,6O TP=QL6K.S-4QI_A&NN=QQO ZMNS.H&,2!$*S(#THPJ:U^;FX/A
M.%M-KU+@;#]5IILY6FH%5I9$/(EA_FXYKI_@E"Q^PEXQEXDY IQ8,L/)[P:K
MD'["Y$=':-=(7D4/4D8C?D_81-YRVT[J\'%ZO-#[J_^=8(]I]ACZS+F)NC.S
MVBPKG7($)4#>F,870(FE/_5&BB[CRT>;F:QA=3.PIJ]%W;H0*57Q]4WSL?<<
M60MS&UXG&[B[5-0">+A]PEXAOP(P\M5FN B2%W"9@X;=Q([KR/[P/.^I:GN&
M1UZ=JS"W>-^)"\=8($:')53W#9C #P..(-M',A/=DLR[X&,Y3>E'214,"/LB
M6:#T ZKIEN>O8]F*V=D_\0_JPVWZN$L2'W5P=TOR]QY/M]!KA55FT/@&"6CB
M1W(8Q8?^BB9$,C44G+V#$[:U#P3<2Z>,SHMP5B@*X^ZA(_2?[O"RN$Q?5-U'
M(?*3EB*Q,YGPJH U.(%###63C2H7?%&DQ5WD_F-,O=4[/+AE5,,_6?XK#B-@
M(5*\/Z[HM,63:>M.O%1H\]%^VRL8@8W"U]\_9KX6.?GF]XEM/LC*_XTX'-I>
M-N8S@ 'I.$>"T]M@OV_R[^Z#9S!W#QRZ<UJ'J>O5[>#+9[5,KKN]"R>@%^.T
MFNE-)8#3C@HYCLFJ?K$ ?_QO';[U:O3#O5"-@DQTE XE#6,%)N8B6L7$+]9#
M 5DZ.\[N:HVVARE$R[]:PD/WN)SDAWFN_L\C/.?@2A=[O@2)V]P6>>D?(]A3
M_S((\XGFJVV;(-WF,IZF=8S?_C9*L@8SGU1"&FD?A9&N8@%I:P0G$ HE.I!#
M+NF2(Z(*+Y-ZLCM_A4(-7MW7#]N6KC[N.)RD4)"H?"-QE_,2Y.@^7134Y=V(
M2J3*C;>3!MM9O^U.U>@&26W78@I<*%Y7X^\" 7(Y3YN5_.4L1HP+,]ZC'I59
M2_*9Z :Q?OGO%,S-2EC_^Z7O'%#_4!4]NF<3:N/R+ .R.DA[1T.U03?@]V"K
M*PS(A/%R/%-;YA.H$$ )/*8PY&?C/29B..#P+85#Z0[P+LL:B)V[E[EFH^BT
M\^UY?],D^55]XG9H6E%18I:_^2W)A\W"6>?:/LB>.0[9]V.?O2?U/M@%<M/+
M8<XE_,A>\?/?0C3AW&,',$/WT"&64VVKY[\UV!83$Z[%W'ZT?NO[]:,>B]!P
M:,4ZC=^1<I^DED&Z.L?D6JNF0%Z!JW^!0P[B"@D>IY""MXN#Q5_\)>"GW+*V
M?SWI5N&2O*/]&F=%)LFX.8M,F]:);K(^0S98?NFF5E'%Q8"XBF@O) F\%W=)
MJ#O'9C35\$HE96,=5]N,KVI-?EJ(V+O <S=BUBC63\4^S7FNW63ZU$10V"-]
M%[$L0Y&;3D%V,0V?UYS@CQT[8'N7.^I1$LA]1$."-W FASCX:7D:2DXJ^J@>
MH<5)6M<?XOD%8_NY*B/=_37F2_SB%7:OER2MG9=L][D:6VEBP&L&Y* !_;DO
MW9$2"(11SP:64Z(&/?TFWFFQDC7P[0($PFZO78FH(-X5KWHS[I>POCY[YVD@
M4^^$&">-B]H*Y:Q8?UJO!NS74BEQQ?)I\<YUM0$]C@2%RTJGOX[\LGN#EVJY
M46IPM."!B=H3B[6ETY?,@[ZQ@FP[U.N!JQ0K^I,Z3[+<K'_6B+W45QL[:=UZ
M,\^1,KM)227E1">94U<&*CQ3Y9\>.;#_&(K&JT*Y 8R2C.8(+D0IZBU;7#-9
M;D[OY:EAVM4/;@$&Y],C/ \GKU6=64U;/UZ=:-5<D\C]Q+) <U>0QL=.N15-
M&:>_KG.@7OA<+OX^M&B\71&=VXV5^K95U^&S#Y48&9L5:]+Y;-JF?MI'[Y;.
M57HN:B8:6Z[>4#(&)["V<D: )\B&&:U*G#3-X2V%$((>31)3])APVN9B-O;9
MXJ'4YOFIG/<B9^P:+DBEOL!'4&V0@^DG@)/,=<RBOP'Y?]IKC-8I,:?:#/(/
MT$P(2NQ-?7G6KJ^7DWH"%=003?X<QVT?603/+18W$TI:\8 <ELA*E07>4Z[N
MA8^$*B;.>=HT8JQA+[5"<@,GC,'OM2^)5J?CQP5?I"\'_/$Z8OQH0H&FK(3G
MJHXFV(BM@+9P M(Y#6(2LXGU[[)HK@!'3J"'5;_O-VO7>4SUT /Y>W%SAD&O
MN^]J?FA^<:[\2KZ=27<^_0^$ ;F@%4LR1#_%<\P"F<S!-Y)<6O'[:<ZDJ86T
MMK!"Q>0B+8U"#]5[A)$MQ?3KUD(2TVM/^:TRS20<[L.LD3_4=Y=H?%A*#:!.
M/0%T4N^0F("'J#=3A&E%18J+E \Y56:TL&LW-7IG]WYG*?2Y*>&\[^G=#>ZJ
MZX37P4JBR"$XR<(;':R+;8(^@WWQ94!8Z_1U/GJE++48"P06& _YTL7Y$V_&
M>@LFZ2YN'7R4OV 6-]S!<WJ)F$R2GJMZ2;U%@]%+8(Y% 9?) :TE+( >%=J&
M/U99%*R@,]<*"J?[XU8W"\V[DT\3S/S-(JM[+1N^7-^WB2?N?;O<!ARH L@?
M^/)C&*J2?GY@0(,&GL@_FXNX.A-4=]DOQ-G/K^;0Q*V77O9Z^C>A;E%7L6YF
M$6R')5<"NRBV@ _5@0%I] 7E$:+ [+'LW,!3T!<:1B4%@?[MEBF=8N8KQPL_
M5AF\>!IO'J?R6+[1;"CH=9O1%:+6*!%#%J3, ]^H=Y&=&ABB$DGZ!F"1V4SN
MNF''VJ"&5(ZV&SHOE%E7'K]T.\7FUDDN71%)UP^L5R5;08NK<'.:##U%1PWP
M -F/D*]2/H_4\<\#G"WPHP]\TT3LP($J[PK[:P\PK?.%+^ZW)TAW?^<CSJ3&
MA&E%4];HJ=B9--2!+72$.!N]%.5^C81OA!X&G JUE$@\/97[_=@)@ZB6 8*-
M3/K&[!V>CS'N KK0;_3YUUUS\%+,7@FI/A;FC"U 'B $//+.90[&2=,@+T5L
MU7**6*V8K.AGK2:,+V];/#3<-R26'6\YX3S7H"M3P:EF.+U.O4$3I>=@7;"
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M^NKPM%2\\0-Z+'@^,+,5]05&#"?M'VVIER5S,J%V1#W+,'P6%:GEX:BJ\7I
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M8\.@>Z?/:((=N^'7:+-!Y#A'^RMBD%:4UG>QN0>9>3N66^VV4<7/=)#,\;J
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M>T?QP/]T7-!P:#C?K7V 11\#4H5:8_^ ')Z6).6TX@_3K$;K16DW2"*VT,/
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M_-E<-N=G;'<%+E%EXIN791*_%Z?O=RH<'=UN.P]BJJ832G>^E/BQ_)O@^VS
M.83!V6J8$)5=5XR#L)K6@R ]@C?ZV%R70-5 ='P9&/J@BV:;4!U)6=N27YF7
MB:N)&ML* _'VQ$AHL#?6OH=/&&M N@K$6 780=Y2C4P)^4.(+T1%8\2JGR_=
MD<M(ID+L6*(@0ON#UO4I)P[)/N\KO"6O^@,Q!='Y>@WQDKM3,A4)>H%0G\G=
M$Z]GE8^6)3$Z7!'.O0H,DE91QD;10>KF ZM3#\5G"H+$(2?G_E2:<4$M92J;
MQZQB0WIVS@JXN#,PN[&W %O2AP,4%3_<$-M"'KO4WU-BT)3;75 C'&$CT05M
M_0FS]%TMBM4&%ZQ=?RRBWDJ8[ET/LM2YN):PO;DCIO ^C)7AXI.7WN D$,VA
M1Q3W.HEE%CBSW([$:O[4[6)OP+]^,;G(O+/+]KFA^?WW9^-3[#0Q#X8:.085
MM3J#:E;,/P>K8$$[9[ =E(L*.'MTV0[=4HGU7TTCOJXY/WQ^N@WFI,@>"W_+
MO,IHJL!BLW2RXE?*T!^Z_U).M#MYE6,'K5U@E+RJJ&/3A'L\>5EM66#'=R;W
M1[_BLG*91M[F6&S:MRQ3D='BB^U>"0H"F;_3(:YWBV>.]$*<%4AL1 K=MK2J
M M7"K>^,!A13[D+LT3_O:0 W&-W/%UY?I.>R?\(V?IL'S,-E60UR 1'$-*E[
M]S9ATR,"S :[+0&[7FVJ,&N7EF^ST%R*?B?H8N^@T7VE?:[U^KLS%UI,J"SB
M]I^ 8"<X$#:0S4;^ A,B,%5[<"K$"D[X7#.LUBV$M4JXM]\+%5FUR#L+\?=N
MOK)WQ_7[V::C9= VCFJ%SI##3P'/$Z) 50GMP!GGCE, :Q7P6D#T"65H?[U]
M<4[/X]K@0)J*ZOMK[B59JNWQK1>1YU2^Y6AAAR^,#XNO_BXV6?N45Z(T5K C
ME)<FX=@W6M&\Q]-;G)?2;F/8G5S!S17G)GL,46P<"]?)'KJBL);,FA0\-%E5
MPGH(K8(A8(/ &N#V*A$< #OJA%>N=Q9#7ZK).,:85!-5:X[DG[<F']SX8/30
MK ,:TLB9&RY0?&8CY3CCC[^!G',*>'8*8(=-+@B,5#'.O'E,,,2!P97-\9BN
MX+NJL]#)'NW=G6<U3SFK$NV$$I_LO]=(5(ZT>0[Z;(J;-TSJX1_,CP@3YIR1
M_?*BWK(4ZRYCWIQ7,MN;NZ-HKIP:E-3#HM1NU!CC<YSLCMP?%'TX.Q6#\IE]
M^I#5? BI]=\=8O1_K#"A^6?8=WC%8B=PCF-Y* :K@MZ6YDT;#6RH*5CAXA_=
M?IR@O*FO>>DB@%FA\>99^NB#9F'MB6JRV=3='SZ-,5M;6V&U%165X7GI&.<G
M1=PW0P<&.@$?F;4!YGN1).9B/& ,]'3QM0A%N"*.%()YCVG ^4Z_4ZQM%1+G
M_'[L]X!S]XG^,=><E^UKF'2\8FD:_:J4I^MDUH3<^J1!'RBF8LOWB)>V72Z@
M3.%QNENXBG)"?Y[QGF13RJ*N>D<;G":8AJA,J$0SMH$BK+RM?F5?&_7E@<B]
M*T+<7[FC.LH&D$6HJ,:W H:V/>]$'^G\@V]K*,2669'=UR_C_W?-'"AR:MQE
MK&,D3LQ5I$L ,2/X2;?W^J=H\3M__5/?#?]U/C=R^@(XCL2&!D?Q,4ZHGEF.
M8[ZFJSGY5;!B0D+J3@6&[FIN3MMY1^V5JYJ/[Y8-EG'!V^CAKN W5KLY1; V
M4$U+/KH99%%G&)CO]K)Y-^6F]9>L8L'!"+3/_3OV/K=?<>[K>Y]X/PRJEV9V
MFF%4]:RTJ:R5=4C^M%,]9F#ZTS+[BF^'$NCJ"UT.VF'Z_3X9KV2/YG2(YLS/
M0. ->)LJ: F!I/;]F0>K7?!3'#+> =>34);CLCQ9*A'\WF?BG=/3LW<:94MU
MQ?4'N))6+[W.8^RE3".Q5.X61Q$D%]TD5\.?&L0KPT-5?7UEG2VJ)]_TN/)?
M#*[-XE9TNMQL)A<@$)78ZR_!V ?;^-3 WS6S/RB<D&47.*2*,(KV2@:E=,\W
MM6A+^NYZZ[XAA*P^[D?K(C(%ASFXM'7N@*'ZI/D%:+/L=K *D07>)JXN1@*1
M\_;@4.FYH&7!A/B6F\>C64)JDOE!NDXN86!79X1BK4RWG2+:(E7Q%4.]BFJ+
M/S[JSQD6E!]('OC2)[OKY+(F8=R8)A:6Y2GAWJ10Y%JA)U_T- 12,'>71ZWQ
MWHV @6\UJP?U<?5#.N:_!-F^!@RKQS]5?989F&\P8YVJ6AX^MAH+[4O-L"S9
M"WK?'QH "PR^I<^\$F?@MBA;GV\TZ*UCO@8M:!Z;G2P_GLJ%MXG H0:S!OA0
M;$\7D"#JOR.*1G'^4F>ZA.<&1BRI>'B)O)OK!4[OY$0K<4IG7#='/'B8(!X6
M0#Y8,MAVQ2FT@[&/D='(FN&N:Y"[""";J_P)*,QGD&\_,*^V//:OKT=\S[7*
MO_>[GH/&-NRF&F8"K#>BQ26<V9VF^UX42%FTM8T9QIK8<]:+:C\4%QS U&?O
MV=L +ZX0Q!*+^%SU]$Q>9&;FBQ;6/>S3W]DO4C>M>+D;8+ZS3#Q+$B WM_!8
M$U1ZCEA<7W8C]G71*!:+SC)Y)'_AE?PKY\O5QQ?YS/VZ;B2_ZL!$4@>8$S:7
M+0@G&"THDE$"&6C;3+=TVPP[-W,+"]Q*&=X$4=+T%U/WS)S3#XV7C.-]8A79
MMX8K;*0GL!,<-Z%=.K?3Q$/L![*0:+^?I?H>;9F@[&<ME5%YQ[,Z^C+)@:,;
M4F:E*!Z!,GOJSG,>GJY<8MS>(:I9PP;M>+%ZV27H'Q18"5^S,]O(1&D,O]Q@
M7\5VXI$FG[J-2/RMC^=M/$\!-1XDEC$TN)NZU3.ZP/3JM"0>@C]ZD<UM\H=0
M0HDN>EJ2?2)U393S0\F2*XM(/$HL<[=M*?WD7O2!R+IE/N^+;K$*[W5C:*VS
MP%BCK0<TN$I-9X;/U%HZ0$%'#,D?JBU>6#61]--23?50W8R<!EI"GJ!:/0C"
M+?E$N4TKYS=I&/82]#5_K?$F@[S6=O':QM2=$M+<F[,& BY)G04OF!LO/OZ+
MZ[@?3^UIJ,X?601W,(@\B2@@*E*F6IBPZ[%R6?9]DU4UX66R,<UR-XT9VG:?
M"S@T:#_J,[EW7_-Z9TQURBE K[#,*H%S7=;Q+4H@)?!@4/^2H?O.[&A#38-4
MJMGT/L333M=*T:=^Z==]Q!463X29SE$<\HZN^>3N4?T^D,2B0J'+*87U*"]&
MP11)7H1(QAAUD8#>SWKV)I4(2\F=G* $Y8?:@J:(0*%$(TL!'SM34_-5YZ2M
MV@>)#"]$')]&&"^D1N.\'XWQ9-H[1G?I'/AM."!&!%*C!#^!BW8<E?1I!5M[
MZ,+B<G@.H36'T-IBZ.;BA@/L!9(@<+331A0G>>(48E%+Z>"JJ0@2/QK,)M8\
M&8,)#^0;9FZ4_&8I*;6<=?,RL7[N>8Z#@])QME["#)A"QX.;P[^@CEFX-66"
M>[T[A*,K_6+\;HC!XW&A;#7[QRV-WQSJLSY>?6]HM6MI:3[TC'\.,9A)>6UH
M1]97'"Y^NFF<\0;_SF==2NM@2%*@/M_=:71$_J1YYN W@3'R%T9T(C3=9.W+
M/=7]E; DZ'Y;BTG&1%Z#9"(6N4.U^^?KR;FR\-F:4P">NBI# X)#1ILN8Q*8
M)&(P>G<ZKR(K5'1RAQ,OS0U52)26?__1SW)&1*;X3;EQ'CD"M92-K(ILWYL]
M9TTN 3U'S2H&-':G(WI9N9TC2@LB'QU_C 96#>1(CIHS":=^.SXK>ZF47O$^
M<(;57$Y?:DB<RG5,DF*:V!34M8B:-%6\.X/]J]Y?D+0K5=[ TKO:5NZ?(E6;
MTPN/TL./ YNV8>8D*X("MJ<;B#4D>W?!L7H)<\5Z6%"WRJ ;?JZ3<GFJBN<7
M-'U7'KYSCG?/#3OO'D#J<-^XJ1*9"#[#%MR#H=W&%0<K4%^Q/_@&5G*JI_\4
M$&UWNVY*-@32 [O18&+)WQ)]XFK%=.D..>MF>6WM39D>MWWY(A/P#^!L&86.
M@\A-F5*7;B(D+"=<WCP!1OE>B-WD/@JOON$A-]0*D.8M$A",?D5_'/1V\\49
M*I]SD"8(PK?CB!P!B<'^V/X.Y=0BC$.$UA.<<-1>ZN;F@M(%W@=,_-$W-4P:
M-'B+979G!QCGGA*FQ-M722/%1J9J,?F]8C['F>D5S8ZNRE[$VVYDVY\E6$(\
M[6!Y8)I$X5@XR/W+07>^OIW)[HZ&>721=+7 \4MQ\<6A4X ;F""LT+T8#\0:
M@2-!-=+AP:9H:S@#X3X12-3I>=Q<;[T!ZPV4V ]T2=WAZOM^=C?QQ=TA6KE?
M8*PQ:EH9/K>\I%;VBJ2&*89R=%JQ%Y'S/RXLBE=7E:VJ0CWD!U(T&0H&3)V,
M8E[==01I&8)I^(0&<ZSIS9AU+!S[+R!& H^:9V&:OYC1P=GY#+9<;748L-R#
MN8D9Z.RD7B RO85*>D,M_F>^@TO9JRG@19 K?,Z@_22E+')G>Z[UY%IX(X_K
M[LU.Q[W=\%CC;UH*X8+.S@B][;O&J$7J<@WU=@-R46ES1C8W.1KE"F)R]21$
M=C0$>[FV\&-[/GC1A ]6?D]-8_K:SZ)+B6]7,@QU9]9A2][Q.O1EFXA:9MAB
MXO:*"0<Y@USYM#1X*ZJK*BH-_(-^[GV.Y.,(W7\DNZFCXWM-!S84?)!\G!N4
MM[N;/B,'D:P>)TV-@);2D%B316;2N69R2HLD;':! QR9"N-)G[O[XW=R8'Y=
M7<Q:157VFB[G>O2( WTCLXZ98B>$ZSSK(6IZD4+G6QRL2'X=[$QDH5!!-;'H
M/F;OJLVBVGJXM)-OK4;TV/=$*Q=[]>?>5E$ D<<[-KOG2T(R'MI)Q]UILJ75
MG0_U-E7[KL&8+;5I'FUW> C]V7C3,Y@E<6GKRP)I-JR(>) \)9"2"14BCU=I
M6XI7'O"-4>BH&XS& 0MJUS/&ZQ&\B6X!"A0VO2T;*W+TKE). Z+;>:#HM:/$
M.UJ:F+_2!*\<&76J.&^ V>%MZDT/J?RS3=ZW;#H&O=Y9+U<29#(6JHV!<]@]
M*O+VFS(<%HAE??2C9S]%:US]!X?@^TIDX:^B;J\(K]@4)5V$:I*IVK2&Z@3[
M:!9B+81(GOP*I%FIXS2)55H=UAL]^J)C4[6 "Y];M6T,.<(!"<+.VU/+R!D>
M_ /L<"LPBKLF*>2K2R6X>6(H2K;"^E8VWG4,HLO[W+-"1,GPN^+W%5(7)H$@
M*+T30U0AP7'2W8P$(3B5C2Q>V,B^[6IMBCV*DO@KNO=1J&D$&U%PP.AF?5*_
M/:\',U""@V$;?N]7Z7,%EK7W-G[\K/6..W.^_")%]\R#9[L^5[EOU>8/?36G
M=U3\>@%X:3SWT"=%24/_3APB'J&G9E2YMV6/&9Y^0Z'[@'N#+MNY4PR;0]4@
MNZ])=R-9I&\&2%C?KQ6'0!I^0@?;O%F5DKY?8(M[]N"!9'\JC_K8I^BE0>_G
M[M[1ICA)6T%6A&&L_;5<SF*!M ?QVP7"K2MUYO<O965FYLV]2,Z77!55J5DT
M:X\6*9,]_&>EQ'_Z^GOI"7MEWK:(M4E@V,J6PZ(ZD!<(SUI_NEE54_(="V:C
MV((W5G5]XF0Z1?IO<0F<R=8J_<J0RPL5U9X1U3S0E%*62;WT]5GI_)^36XRB
M3[PIO#/4M2=*U2[V#:> ]B1=JL#Y D(/(K%&R!-YE3*2J"R*HE.V[7&8$7$*
M^"6?0&&@DB\!./LIX,N\WBG@+SD4UN1/]L6:LOC&,,';F<1:0(F+WSH%7-*C
MZAA$X2D@4AY.Y1>_IG=1V#RJ?CH62_BW;0$W42SP'Y<]2&P@RH/C^/]TIW+)
M3FC4R>7<4\";&W_B]$_*.A=_G[.F_M+@%)"H;O^I)?,?/?P?]M&RSH/RQH4Z
MTM_A^W<IQ3@%,F"2NK&,_^1TO/]55O#W#__'?9QTYSD%?)P%$62 I'?P+Z1_
MC=#_'T>HF0=O1 4X7MADBR)AX],&LJJL0SM8>"DFL&4,0X^?E!1&K'%^!SE&
M0=>=F'6/%#(OCE>2NN[)*\9+H3/E^4P=8S^/&_O%+@OMC CL+CK4RG=XPEF?
ME5_-Y64S61EM*AH2!1=#+:5VMH,X2%?A%+K9AKA.<"UC-YBQ&X^M[,&N&S3T
M_KR)0&P^RKJ5)^NY.SRXIEW%%CZ\V?H%!L12PM%J%_K;*9PC)3X["GI5\5,&
M8]O021'HD[A[FJPN'\5N%EYB!0  E^K!?9EZG9RE@H,%L26?7FJH\;-5D*TW
MYYP/R^BQNRSA^P%/"MTF*](LM7<75](>(/YSU=2V6M7#_NGHV']S^-%4WE2&
M&VK?-]V9'#4*_W7TD5'[OQ+=_;=G'YEG;,#W?961Y"@<=>7\+M/Z]_T\78O_
M\3FZ(:< ZG8@"'ML1Q*M ]:F,*">4T X I+>E9K$EP'Q:S@\+.TW2;4TE;<>
MB/8\T/*_:C 8NP107&2 M_&@EK)@EW%26<N,ETDTZ8N/1SURFK[5G0+"*DWA
M4BZ9RO*3]6*>?5<N7C^Z@'KQG?3H^XL%KOPTTP+#H5M>4 WYEF:;L9KFA+;*
M/7K"&UE,='V<6'*RH)Q 9OX@5$'G,EA_?>RWX4,8-VS_?Y6?]+_-WTJ="Q(;
M+46GIQ5(%#EW"M"<,9_^!_]\3#O]7VD^L*>3\5@12341AQU44S7J;9=@Y_5W
M89<__ND*TG_K3VP6^MM$*<!+/=;_1X[-?_+B^SM_8M/?9TK]'Y^T?TWZ_X<F
M'?!F--1K$L6'6EI*B#H%,)-8B(X$9QVL<Z>:OW9U$CHNN<+:-;UI$E<5:3A^
M]T5A*_L-$^=2P.\R!,KI%!"/XBG[4W_EC,5BL#W.Y,?@LIZ44DY:IX)$A6CC
M6[;K+1?Y0QFMR,;B6!13NH//@6"TH5%,FK2XWZ+N0: ?2'"PR:S#T7+G437:
M)E,@=W H90\*[5^?I\07?HHF?26[_._*K_AOS<M8!A/$%BKS"/X8VE;45<A)
MLKR?O+I\4,Q<?]%9S?.BDAFJ\3WAIH^UA5_1R&9FO<LP-'>>,3%/2""(2&]+
M:6CNA& 73P'T/""*DB9)E07/29W4%L*?_.,XY"F MXRJ[N6I'"B02J:83P'\
M0Y297BH@W412:($':J'1U'U "!#>ODV=]__WAG+_33O7_]7,OYKY5S/_H!EY
MV-^F^1W'] !K#;;!_KBI-NZ)LAU3+$571='WC+\O,$;RD>?NJ_#Y.:Q, -<6
M^&ZP&B%IB3%&G?U-#Y AV/$SX<W#!F=K6W.M)MV8P.C;&G,WF4LB:/09SS.-
M<W>WG+L6'JGF9A0]NRLI3AJI =YJ?5;0J_'5X:C*(:,V2 @Z\I#MN]\_A0]_
MDV[]._W?IE[\/K,A^U^!R+]+MO[;W(M__Y!10N,I@):#BE@[ 6!*KVT");-:
MC'"$=Z B%H(0= JP[Z9B87ZB^308ZP4G94^%4U$L99JJ%_J-RA+@3@;'2M*1
M*+RJ*^C$D@UN[8DDO0N G_S^D^X#Q$62TJ833DY0^+$3AS\Y?P*4UK-M&MIE
M"11EJMCT0CT9#E7G3VM/S1:=;(($0CU_+,#;63[W>#$P*%,H@4\C#/=8ZH:7
M8Y!8*RJTM0@2N(@TD$'TY7NZ:O>[&E)0D4;[O.[17!W-K5RT>VT,(RLO5 ="
M+Y[W1&&U$PC"H&V4(Y$GP!GCWP4.M>/&^4>I0ISD=(G#K+^^N=&?E]C#!WS4
M'DEE8V*3K'+W?V;QCLE\IR(6*=BQ8J X6+]*"W*^>#>/JM_RA?9<2E*J&[:#
MU;TRG=_''CO,: HX<\-&O=.A#Q5<ND6M]H,:-SSN_-J;,<;ODM^? I[OJ&_"
M7X.N+K=0!:2EG"3SR<^=LA*3)7>7S,N]"-KWX>^8+VSC'I$+X1[(&0.\<F/Y
MJ+I:L'&D[GBUN+>7?9[5S*"_K\"-Z.//BH:Q+A:WKA!-HQ6-=+[Q:6,K*72,
MV.4EYYV14\!E.!:,L5T/_VT:_TR=;T/9PAIZ\)=]BNIZ"FID)BKI.Q,@KK;?
MX>)K6Z(AK!->#NH 1<-N_SDS!C;&KKP8<P69'U7->!E"[QB8CX9BJJ*>52%8
MF;5??8F1^-IBOTN<L_2VD&(JRM20=9O(XKHK=SZM"A\W8]1HTTC.2_]5>BBY
M7->7JBMJEJ_#AI;/5Q#>)B/,?9\CY1>?5ITT/@]2V.XANL,&D#5L<3N+K<"H
MR9/.6?>Q(M=*:UV([W.>7-D[8N7W A8^?@[XF1E]Z$:BKN!0$X(_5:,!_Z35
M9-\F%X&<FM6'T4<=65*3O\I"G[74QJ_M<WW4>J#GS/HA^IP2A^:E'ST"7IUA
M[RZ1!8EVU!5UESKV:N?PQ0;31_AKY/?/2888<4F%G=G/)9CJ@.U=_OW<Q*[&
M0#PN+%;O4E69% ,B\.XYJ.1(IF=DQ7 V[1E)-CDCNU'#A(J&IEPE5Y[N+=//
MQ97.ZKK==E.1%-1[37/#L3?Y7-JFE56.%[?$=:V%2Q,:-&<GUH'7X&Z+H:A*
M9%03S])BM#I_^I0)#E\EBZ*WF+/H54WSY\$\>GIF-J?@+?MS@(UY/["\EL1Z
MA,_">>SD>Q'I87/ L[+2#(0&S,RB7EK[&,NUJB@GC^#Z#AL;@1C!.HD*3>&^
M5E&->2ME%-\(RM6#(+G>OA<6<W/Q%YR6)"@=)1=C<,>ULB5)1N!-O?K346N/
M@JW^2+35M,V0B3<0W1U;['U/N^CNPWW%7ELYT5GU$.4[Q4Q=R5Z6-I#5Q<X4
MEQ^KF59>&8AUHYA*_5M-30W;(X>:.TI$1]@0LGPOHJ1)#T?$R+7$R]%QR3:K
M*]IA]@^3'9L*;S*L:I[)NWXS]?$ O50P(QI(XO#'7R(4+<MAG7)*" GM0I#P
MB#$3G%\2K[QQI?R/X&FAY'O-=(%A+A]7W[;U],$9U'E_G0*P1B""9&2GF@(^
MU%7.X KABI[Q=@NPKCZY3>YSAO^U\.:*N,7&N/QDFP8IMOG>=\'=PS.+U7LD
M9GZ\ 3D?Q@Z\0 (1O-#PB 9R\X"W:XL(%A6V%-9U4/8^Z>Z95S:YUQW/O'_^
MC--';*'K4=J;?<W[M!DZQ<5&3,D%]"_&UB8$>13$I6-"U-E"&+FS_;L#,65Q
M??S:AOE*]ZZF!T\$RD+[-C3VT'/@J#GC36U?'A$?_(3=+JCRJSK$H.[Y3.SN
M\&>EP>#F4P#CUS_U;I<I^M:G (F?D%/ N\WA+O"E4T '/755BJJ:+EWSQW2M
M52N$P;@WN>TR,-![9U@K#&2T+R<_/2??92D4RCGE??7+*T1@63]H>@L#(C$+
MMX/IMF6!<QQ+H'A5XV7Q9GU7Z>H2*4S UVUH?UCT]1OCUYTO%:_=9KKCI''.
M#Y ;$: I/N@9D&GJ:%5UP_ >7]=#)7'YE?')R56_!C>\:\V;:,4.N3ZO.AM!
MCGNQF\;>R-H7;E(;(@5Z>S#'(-D=G]%'Y!;"#5P'&K[#@QTS('1@(9V+<WR\
M$U:.8X? <@./M??Y 0[D^5\(*8&XJ12N;HV[YP]3#D D:=!,!EZ2^OXPRV!K
M,D+ULB^F[.QL!ZIMEB-BMW0W;F7*7'\@3K;=]0G]G3X'F=A.P]RY)@GG5205
MU]L>PY?*%AE@EUR!U<*=IX 91O0\Z,HA37D#9:+VP$R[Q%WG_=N'XRNIC+=D
MPOW#PJ7JC=\Q1D6@59T@=GG?S,)!+F@:*Z^PE;T\J&]@OKM#2MFGF;GY+B\_
M6M&.T7CE@Z+M">V&6YD;7=:6/X5=%&!F/W>*?X)_GT13E:/3<+P='SF_Y7R
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M!>XI(XA)9,M.JD)<"_Z<\TOW^P-"1>/#:MR*>01=9V#M7W-4V'RG*;,]A%&
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MT &H]0GD5U2.MUEE[72JT8]"WQF1F1K1Z74S1[6I7YY#KDR> 49M FO_KJ^
M:5M[K"AF<0 Z041,0W\YT8\<@*)<#D"4)$9*.>[& 2BA;@C\<Q<"'#7_B"2>
M>N1)_Y/'9)>DC#//LSK!?>L"V)E_WAR 5@60 U?*.H09PA!6=,#;XN@/<*X7
M*I@2-:>1XR.LV,#/!SS[S)J27M4!Z.D(/9C5<R#$1_G/101KP%@4$A@$4WAE
M2?H'(/WQMY"]F9T#T&G4_+L+_Z<1W&2>UV1#CM<A5X+^U@8CGC%?3&8FESU!
M[C3@F9<-Z3<3:1;(B6 R'^-WY %H2(&JD@0AR@?&T^GIS$,G6!V9]I;]W(("
M9]*'(4#\*6KY :A\X[^S!.E 4O'] Q!$\@#TY!;DOQ;@/_,"F*4S>?H9-2E)
M,@!I1=T4KZJ\9/?T\],U[K(!VVUKUO!8T7R?!J8?AJR!*1RO59E1)@>@(WG[
MQ;+;<S0=NA8C!\OM57943VB3Q)M7X;#M77V^&E/\4^E]H]ZO3"W%1X=32'?J
MZRMZRI/H?]X\GJ^?;+(QL\SR0_<$V.#K_LB<C3VC='JB0O#T?[M+Y]._<@D/
MYO]YK*LQ-?I_-#3\IRP4]+]*^]=/(?S??_:"[]6_I_-_F\G_Q\'@ORS^/V5Q
M'"!_IA=QB3G>"6@%G!6B-RL:_D:U**PB 7EE>BYN88<YG CY56/^@J_UOZS^
MOXO5AP] WO@%E25J)J6&98?33K MTS, GZ.?OM*4^:FH]@(E_'WIN;$#D$4*
M ;MGID7EO  2&?[W9/@'=[/ 47).[]PWO:M^%A5^O#HYCE!9B0#MJ\6="*?0
M;\'.@O^.5 VG];G^;S\0<HYP4^:TNV^4>..QLJS^P^M[/\:QE].'NK7_776>
MCI1T HA<O,!%K R/1<$/M=@6&CBK[PD!_6.\\W+2M]K_=[>!R(9  2W<D)[<
MF^X6<CS]5)'53.%$RY4IQ#ECK>N9A^X56BP5G_%X$T-E:<&8:#TVYB?\Z7;<
M$X@(@LOW ,0-MVCRX=_\\P#OHO2[R,6(YHK.-+\H\B!<1MVI'QV\TOJ$ X R
MCUO30ICORUKX!J!)HCB2W.I"NQB2WW[^9B5&^^K,1C'%]-''RP%B.6]#:?,?
M83LVN(#QM&5N%E/N0?8:(T2  *HDN1JE/ICZICD/DBPUY<+A<1?CO;A=;2+=
MT>[OI%.O]\^3YL,>C<:TMQ=0:<B5<M%XNJ#M,$04 R;+4@5?=9"1ST)UD)J#
M$$'E8RQEY9%?T.:W;B25*66T:K/<XI]I7''MVQ&A_?@;C!86IWF)>V5+%Z"Q
MU-VV+\V8.;5H/CC."^RNFG06^>=PGUS@N;'9)/$\.]4M#K9N^E5EUX#<7<SV
MR-7F L.M&4G$#0;$(X]@SWP'"S$5@<ZI&^0?,1YS#IUU\.&QN,O#U[ATVD[4
M)W'UM-;'>8"8?BR&[\!Z9B48#=Y&L705+QGYMFRA:. !S93"'KV].-[K5V[_
M@5'1\.4SWN$M?"Z6%8OL.C?&C$]HYJ$5,!VP<5(P>8S)E??W+0P-R""F+YFL
MZN4%$'1\:4)SNLIU2'<GYRVAIF"VV6@3,6^-0T%D\3BO5Q+PPV+<=GRSXPLQ
MU P@F.8$/SF)] (_*PL(X/V>)SRQ&>1C4R[BX>BX0!)U+DJT#G]:<O-^I\H/
MZX>U.PV[-<SC.WRD=7(_DV.,R)?FD#XTSH?N*X+$8B]T ^Z$!L?3CA:3ZC!E
M_Y)F&24/W8&?Y=WW4+KUMQ(X#_7]+".;IR^:,[E4_V:O 3I$/\E>2(=L/%RQ
M5&16!*4;6@=SF7:!CJIW[XNZ779<3*A(4A4;DZ+!5_Q=0=W1+UZ!46JV&V Z
MOS"5);\;$#IT&Z" )L6<U]YVV$C497-P=';=?C08R!^WL9UGT]I^R#7'QEPI
M@[KSU?3]R@NS(P0\*8KU9'&6>W4AIIB03\@'RHM<)H U&?U6,<-QR[1J,# 0
M(14Q.^NM.[)HD[DZDD.5,R*DWGC^X\AM.UN(S3?4WPH5.4AT'DESM6Q1DBA+
M/[5$Q>>93S,EX%I)O@T!@MYAH]P.396V_ /K,Y;J6L)"N[>^BPHG?OQM:^FX
MY@@%+B#I0E;4=$:-GB)B!-<ZEPI!JYM"!AV2O54O%E4LC+[<%+*=NK;5.BK@
ML_0^M^ZKT?M5+ZZQW&/1&]\\Z0)()J?TJOF\I@59,/X9TIUD1=0&)B.!'Y53
M'1%*R%;LQ]DG0@O>@3CDHJ/(0OJ%W^-COT^@1EEDZ$( J80U=75&+,0S?2'O
M&D5Y&+K-8N(N\NC9\8'D]&T>F6^?C<4'DQW?&D<;Q5P7G+KA<H;CN*+)&=%?
M4$ )11> 4"L8<5AMNG@'P$^L=A:SH^GC$W55NITK:QR-_)OB%S +]W+MPBMT
M(\O/Q]%3GE]XY<00*\=)_'UU#3G-^MJ!)YN_.=*'[T .H!;G^AY7I2?HWNK4
MCH]6@_+VA9 T")..SUH/&]W*NO8@[JYJ1/*EI;U1B=M[Z8 <DB[8/PAI2]\&
MDX=797M1?/TUP-*J38QO+2PT])@P_[?<2?OKP8%ZG*12.^S44:]&#:&L2+;C
MKD']77OK@OLFE+)!"-EI?%Z3:HAE-& 5F5.(LY1_A OMD@>6Q;HF_?3F" K)
MPT9-%PG/EQ(V,N76$Z6?L24(WVN08/Z!M$%6,G%G]1284U"R.2K^ "3&U 10
MM.!!43P51:VNHYY6PNS(VF#0Z7MAWS*:)9+4]^]Z^IL92^4>^;:E,(0+P"VQ
M]R-?X;8[B)!%L,N4Z[2_VGK:TLV)Q<T'VJGTCR=/7Y?]D5( ]K?3%T@YI) $
MZ!#86.!][#>C$>(YQVBG"]/LOB%$BVS1>7?)GOVQ9$:C;Z2'R+OR_<Z/=6^N
M[>I^S7IO<U,J@??/-42#!;04V1).%RPCRI)8@NSH C!#D:$[>"&%$"<!OKO=
M7;@IDF#31D;(]X+&T&-QUFXV*HXC9T^*:][L.23%CTID]D+/_#45DFR%BUZ<
MV8O&^8SS 1!3,K9.[23P[F>_37)DDP^?0)#T$Y/(J.>]G \]GDN,%F4P,? ,
MG4-_*/J(Q\C>LZP>6%*TO6P(G 8] ;EW %JZ,U@+OT[F6_P:/V S^^K&1=>.
M'A/'?&G^HX:A$0^\UM(N?S7$M+R+9IZGZ3(_X\@VZ4M'J%B@A29.%P-6R^<-
MJX&D?1+]?A/,?Y@IYRPQ?B>7W4XR:3ZJ.@(^!IO[N'S-0-);YJZB0AGJKNWZ
M#DO^!2,^XUORZ *9K#CUD[6:7$!--8#7IQ2@S3F 7L59.<G,55A;IJK [8]9
M9CR-&?_4C&4K2$6KR3A#%U%4@-&)]$$"%X[MT$]E,3F&B27*?0V$V.? U#!:
M(S'(];($HT::^/RF@*51[@%(/B(U\.D;@:_)W RE<IP\W)CV\%^*^ZQDE74$
MQ##%$'C(Z1!4(IZ3'BJIA$JJF')%OVY)=3/:R(\(5(PVXGXU*F7^M<)@2_+1
MP/8B*S8ML* /\M!\OHC:!@00E!?PP_PWR[?.@F,L9G0O![Y8=#9L>*>\?I/+
MB-S^K57B^'CVM[=GZFSV:UD;3IZ2G@)7(._U%::G88*)8J:RAI.*:SW3OQ7V
MGSU:NI9DOQ:F*_^$X\,C2"N4%$&.I,X P4B*[XKS\LM0 @URPFGS$GY+2 9/
M2N<<^F>B0IRH\9/MRU9Z[[LFA#O=^>\)Q6/K+)[YH"Q5=(-D34&,WYPDM;\.
M"%4"VZ8;O#:UU?=U/ "1Q"+#6J(]HMW=VSD+$N[/QY_>>,EB$*&Z6K3[WKBC
MOU$)@?2[G^)[\^?LXL;['LSP5IS%",U@9YT6UP;7XYRK5U+*?D=MSO/-:BO\
MQ#&/<]&"F3/@3FP\Q> GM1BH.@!QJ)6*]TQ,&01LFX@IMS5^A[F#OST?Q 4F
M0=X4^ZV*:(W_+2R&6"[K2!_F Q3P0^,+D<3X023)_#!@8'X*%=\.V58XCAA1
M4J]5:CH 10EPJ6['+B#"_1;&W%:FG_ZYKH_0AU]B=.%6&I'M<W0!\U7A;5NR
MY&IIK*=[%:S"*;K?;@ZC?L^JKU _M_'^3R*_8WQWD7?<%R'7<P%JN;V,7U'"
MVQDT3V3O#:1G.J @!2&;L;; D57WO(&K8!N50=[:[H>7VR.W1:F+7X6,*IX+
M+;88G\J[I4@S\;/UO-?U&S\X#ES@2]%C!<W>:[IBM%-VB ^BN:@J &4>_765
M>%2[/3&@1BUN]<*G9!L;A37>?\:8KQY='@^EJ%+7&"58(>:$RPE&UF^<\)NY
M=(QG8)OY)[5Y^$9[\KM,\W:GSAO](OS/#TG//[?F_'%_EV4M3=I#YA2.#[G2
M@>/$N2&/P_^A@?OQ)[W"PD7G6.&NY6$E[9^T +1F*;E@2N\?N&(2&SZX+.$
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MRFV).79D1WI6WT+\L>?V=0(N@<76S)' 14\Z:X,0T$/F_#YXGM!\__4BD[D
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M.I<[17F0*0R$$]\HFJXV!?>INMZ9YJQJ'>/=I>2Y1]L[W_>VU"HT+]-S:(T
M;\^1IU9PL4Q-0-/V+PS\);E*OV@[:$-( O,,/6 6%9+?43 VE.R3R)-T$^%N
MZ7I9OCTQ%K:F>,@<!5FI9EYE=#)/P24 UV#R%-66O#$8$&M2M8DGM\(EZP =
MFN6^%-K+W2U3B_OI^4QIMY/)GI>T=70.3QS:'Z?= A2H+)80_036T+_,S_K&
MG/D6>B($+&1<KPKT;87?K[G^]5%+#NT6>7$(E2FMY)_$]B5>\MX39FQM8QG(
MJWLG#L-1#@L>/'L^"FHU]:O(U\_0)B.L8WOS9&-6QGS/87RJ[]WL_^CB'?\K
M-OC?2P\E_YXNJT+.U[ SL[_8IL+_EI8J(.!IO L'H&]KJ+^7E;*$V&C0)&[;
M*N8 =-N_80C[]YKS?\@[C/B'!Z!?03;/&!6_F$D7&M_]F]+:(9S_\?3]?]7V
M_ZGLT(^RM9Y2NZH1Y>HP?:ZMO2.QJJN[N\ U3<HB\_W[:W?8I;*>.IEET>XB
M/A3^:#@;7PF/(*<.?IX\3HB&G'#,S4E\:[V/?6!^3<44SOA[<PDT86.E)GZI
M?]F3+NG;I$F7BN99PGRHV*ZB'( 4T1%=7X;S'^QT8HJL ?=_(:YX<@63'_>D
M5+F-')XFNBRBV*SKV[#L*!<J?U8G_OF;+L4JW/3:SA ^6Q!2YNGDG'_O9]+K
M,XIR+L6N"M9%S^J#94@F)AI-?BY_0B!W"<M'WOWD!;\L<)6W\6E?%YNHKC=(
M5S I;'M#+-EOA_*^,9]X OL0R-1@O,"RPS5FS&)7=Y)+STSLY%@7#M^9O9_F
M;JG"D=*Y<OR;42]*DN*9B+W,'"DCF_LVX$6 S&$;2GA\2(:K;[W]9Q%)!NE3
M]**^RJVJ]Q8F(OVR[Q^L%6>Y6-.XF6_+V)F7Z&+QJS6D8^Y(8BIT,,_JBV+X
MXZH!B*>%;H)SJ9S@>J:!E:1."R';[ZBJ)D(U0?5V_I8( AKOLAPR8R^?Z:-&
M_-*X;^7OM&COYTNJW]UE"HYZK;\NGE(;--F:_JY](N1!E7R;22'E:Z!%NE)5
M1$"DUTS9PEE.('$%DBCJZ(ODPWA7^>9ZR^9)SV;5&@:*8E7;LZ78AET_/)S;
M0 ZA#O7^Q65&LZXL19B :(OP7<&='.F_,^7VVCO)L;$6;;-VJH#?-5<SM3B7
M;SJSI^C7C9[72-T!CZR!^X$A,]J_I"K42J8L;5/*MTLJ.[N[OE+,>>\'^<"<
M/-C:&N(&!M\55W:Y%4,5"5)%3A-AIC5^9B8#!R"P'AL@ZU34?U8%^$"X*FN)
M7O178U@-A,W^'.ZZ>?';EW[NNJ-N0<>O?G\Y1[_Y$F9K5#9P5F:V\1=);T;S
M"Q3JU'BI#[<<'B1HV*6^_S=+D8M<6K.JO%0Q+.J1652%GB#@6.C[3U,[K.8Y
MDW]HF(QZR&C0@WR!&[ B5P",=\F@8"?4_*QIS69XX.A9F5)?EKXV<A,9IT<Y
MEL=\O)GNL%^H&VFUY!&R-6FR]9F>&X!?RY,N\W,2*OOP+2H'R;49!95IN-&#
M=*(B)C<1)#/.<.?)%!_UJ/TH\U?T4Q1;0OI =9=Y/(2_'7Q"[&K<3]HIN^B=
M$7R/_P%(KL@_K%,UA73EFR\"*\$:SC] D/)A^"U@C, /<TLWG&YL9$[(L/U.
M\OWU.4H5K3Z%I@NHKJ(&%-Z$NS!*(6ZTG1. 8S^:3WRV)3R,8APD>%,\8_NH
M7I_8&/1R7_=)MA6%V3'8,(^5],N4X>;;.4Z3SR3E<%]&ATPO5&]G]D0JE)X-
M)#!5\O@?/!)QR[E]UUICZVZV'&JY3R7)WTR>U%F.#IO_LYA$WHF!=C9G4+*H
MSA1EDD@U3,+7,9US88NO]IL*_O!97U]D^T/CZ*AA _/\%_(F/#7^YGGTOQJP
M%+:WJIRLJUK.(GT% 95MV!FE;;AQK3%2;?;/P[;/:H'IVCI1+V_==U-<.95[
M!R=#_25/">>;2&7[#EVZZ.6@ZG^;BLV8' _9GNWV&K\8?XAB(V'WK-9Q:S>P
M]O-*MEM66$_FF\F)ANI%XZWT5UZH=+KSOQPM6%^Y>O'[P%EEQE.X;;5W;N:Q
M(JOI#JXBV*F+_"8ZFP3;X!-LYE)/E]^(K4!(XQ5T2^ (47E1@<C^Q)V<%D^@
MU20'^X!]:??NFO]^^"!9T7G@OL'UX)2-<V;"*5?"19)@CT/+M).S+&.-%B_/
MC';I2^6@7U.*CPS"N$\.SKPHT;S0>V6Z2N>CZ87!"V:FZ-!RPS<64#%]UL"N
M $.ZEW!B_C@WO^L(L<Z75*MFP_I3\JD$;MQ67\[GL.AK*:,TG&KHXW'2(9H?
MS)/ M_W]!7,"RT,>H1@4$+F^PQ1)!Z!V[(BU>Y*]IFI$T/WL 8LL$9[G1I)'
M7PZ=@23TSS2)-AD4W_U"4-L_F^1]I>8"EO*/7?,A8N-%^;2S=T_EV'<'KI=H
M*7OE?):6ECW]06FZ\&I?RMPP4X5EJQRZXP1=G6\(PHL8[<X9[I]2Z8-?CZQM
M-PB[8OD](3U/.#],,:52Z^V^W;8]2^/L+ X[SAR W**4!Z%'X#K-SE[+5UJ4
M XDD#:*1>?RL0M&]!\4#C?63;2;^=T=B@EX?^V,C^'I.(HZ/WZ7X<\F%X-W=
M#UKZF\)BPW9H]_<HP<C.W!H;<#]6NB[__J.9^Z?E?U\MS-.5JI!NK-"SU[,?
MTH2G38:M)P5]^K.L]: @O%^B]8>D_,+:&?[]J88UY (7M64:PT$3_P)+)T)Z
M4P,,)^A<+^?U*[:X6R]11')*!);B$@5X"(?D/X*RI)YH?9AA822X/3T6(^Q)
M:1@L:QF8Q7),%_"4[%&GV.</0%M?BMZ-&#"%O6:@023()6G#U-8K*W4/%&Z;
ME)XA7;B;IQC@L>ZU*2@UF66LX^PLJ,P+R[1/A2L=-W#Y6--F.EUS-L+^]N74
M#6_CP;HKU9\#O.T;P.X6+L:L_3, ^)&1U/ II%?DDLG8V-7''Y?-^3:37LI@
M"F'P^7+7=P.'HYV[%@5?B7<VP-;*R)9\*0<@WH_)Q)U%+JH%CKSS3/?Z(\FV
MV?-O/#./:6F%N(D5>2GR8SK=;=R/<MMZZ"2U*G:WUCB@]&6FW:5/CQF],Y.K
MK9GH[-F.V \X2KGH%Q_ZZ%?(UVS+[)<BMRULL^^+&&N];IJV(F'CYZ9MTYDS
MD$[($YP''V@3H=@]M3:'ZJ .Q__J$7M2]O!._8?S6=Q"E\3U[C4:9URSY)!\
M]X#E-JGTNX [D4<$Z1.P$&E)1CPE<AQJFR5V1?#4GSD -294FR@?FY*3J)4R
M&.;\)US0S3Y,CO!]ICU/6=4B*T4+>S9":E7LUU=?T[!I>]8 -?R>VF'4N8:<
MWLF]X\_^K"=]_/9MJ_7O[TJ[%=[P-=6B!!G-D(=X;N884VQBHXV\72HUIVM\
MWIG=N.WU8EOM0K?-<P4X#G/MY=T\J4-#7Z'2E'&ZP!)QKE?\\ >$%G-4-"ZK
MT>>?+.]'G2UK2\Z.@JZ2 9>UC%UE3CPX]^IGT-(EP9I+Q.T8A0&S-)D&,PXM
M=9%1@S^#MRV2C4<?%O7L-VSFD&4%/.T<8"G21V<,ID\52\KM]A@/J63ZZ=--
M%93\?X713B:Y8ZHC81L*Z,=QP]7ZL'22)^W!9^;XXQ\Q9/S;,AYE76?BSDF-
MAR$CXA5I%\8$;#R/+Q44G^ WO.7A<4<XO"G?PTX7=9QRI2"HU['"KW,[TUAC
M*>!6!L'=WNQ^B6M%3&]_H?].2*:Q,UIFTE@Z;,EH3[07F03FJ:"TTM6RB&QQ
M6,F,H%*PGP.X\]6\VTA,>+[!6VC-%Y'-#S"^/N@2CN@\3CI2P_P(:0]_:TM&
MM#3VXTRZX^^<'!JH4#E\O%]2(/2D9.>9API[2?L?&UCP5#^%_-Z+^S6H!%]6
M2"9CAV+_$?VZ,7#C679VQ06M %A[R63GUF*9\],51<_9RW>#V4>WR1V7+SW*
M]A2I=9C-=C13^J)1,I/>S#P']P:,R?6.,#TI^NU/O^0N9G>T:U?7"?#)QT2_
M:[Q^C^_HTR>^GOVE,N0#4(J:(Y(?L'5LGVZGO=Y;Q-M]5OSTOFO(>OJYP?4S
M9SOVBR@T8GPB0I;YI?// 6B ;\'584[,#.VK@XQO&PW<\+DT>&9=QOE5P,+K
MHI3C"T:6'/+&J&J,/<WC[[G% #J8IH,8Q[=)?]E+O*BKZAT<2%B0B82%7",K
M1G_*31%VL_K9%N&#NVC\X!U&"RE^/_!*HQ7*:[)&SVA1_<R&K%O[>L=R9])>
M3O.D \Y*G3PN$M-[;S4.\WVVAB0;,7F7(% 4#M^[K>T2\#F\W3$W><M'82-@
M(9V*IT &TU.ZT=L42A:!NY2/XI'G,Y6@OU%PIC<L]Y\3G"5I:8U<#<UV)S1^
M_)'!]BM^N*0U)+9$<(=5$W\4.V1.5!>:JB]4K 2GY*F,!);9# T:F,HIJ$M?
M&'5122E?]&XJ]'!I684>AR$=IC!:S4"#:>NT>GC(Y$/_G8HTW]EK7 D9"=Z<
M<2*<O"JJLRVZ^K1K='8RH@T2K^M(:>O3=JGPZ?4/89@,Y+XRY3AWB3N-D'<N
M9N3;=50QQ$/)&>*-!"[P#2BG.22F14'>:E3<)/=%%&%>[)J>*#D^=+,QW#2:
M5V\J[>U<*MP1S2AI1JY48=63J2^]YOJPE@6ZHQ>?1U5LAS&A&I7&WTG?H6+I
MJXK6BMC3&-US+RU[JCC,S"ZO.XU^-%4ZE0TUE?3=BF+:$YB\G;Y6AY+J+#ZF
MB=C6B3ZR+-,M=J@YC=Y1YQBNQZ#\^# ARHO@%>$D]60D'\QS-3[FM]*-+=/<
M3FUD8I-'H0=SJWS$/OV58-4*/HEE=3T)YR]V+)C7BVDV=3N$B3></=?MI6(D
M-O#P]EJTUO!-J"[S0]G?G+C\95F@SCN2IFW7'TI,%9695OKG<1PJW^+VRRQA
MOO5.[J1+UVE?%-[3(:+,$1S9VC?U_&C\=2#Q];7)BX'4C>6G-U8N"$_DQSNW
M,$,_ 467^R;ZYP9H(E-UUE;9=:8?+W]U^=YC0G(V*;>9_NHDEKW:<AISD9\H
M-UMU?29%82I%6E9X1U_?^(VKY]DFO$$&=2=%-W@%%]]M-(>)(#*4;[6H*M[X
M:3LMV9DP$OP,+WGL\Z-'JEDQ]G-@4;T3]I\W-<*1@KJ: HOT0&RL0"&IN[.\
M]=)=KT/P]R()H.H@,S;?-1P@;]""HCL />0YJA&Y<5>QNV,+NJR<U77$]'QG
MM,U;Q:,^Z'_F5Q3<?C7BER+["PU9>OXAZHG>*3*C<&G>.\A;*%?C^^0%UVD+
M?N2Q.PJZ8RF7[?XQD+.HK.(\565&>N-NT>S61*]#%52;O[VB&R9\E")8)9J?
M;]OP+G/OOK&>S0Z=I!,14>;I4R:@)_8-H=!!ED&O,GC'G;#6ON)"WVWB='J>
M#,3*<5T*/]IPZ$G0]5]-6T \M>( E-U 5V+)4T3) :A*,_0[M!U*:B+^K>?1
M> #R1#W%L5W$>!)[DBVN3G;T1B_/J^Q8?YS";.\7)$N<<]_/S^7Z9D'$Z$HG
MPP;'1-6CLA]6R1FW%]Z6TUC"CH9TK1.O@(4M3PL^@>^BKL_FJ::X'BTR[3*N
M+,]TZ.P(VX[BL$<(4= QF$"_P(@5G)!W(48CW,\W7"8/*=[7J_W$0?:"V=RA
MN+LK?]\?<3 *_OZ7\A3=%AAM0'P\ (D@3HRQ=+C09FZ3=M]%^LA7KO;6>T_N
M;H>$WG-V5GG[%!TN1E R^$Y]Q +3LBT\;]-%?ET(!7I;M'ZA@N?5LE\.9G;D
MX]="KI<=1D>=+@;==34.-..MTM63Y-NQK+-=,&Y?O6#Z16'(6'W'0<7<M[K]
M<DVOW9_00)B3;9=+#CC@:+&[Z'.;(!\+/YW>+OWJG7=3TW]VN_+U5.GGNV?4
MG7F7B#5Q:]A/35]?SVY/.:-5-LE]@8I9U?2!6B/N]R#+B,&0!53&+_ \DIA6
M0KL%?T@I;O)0@X!A$+NI7X[C'7+//T/;+4^,SEB?UE[[_78HV'E_2$>U]UU2
MWQUJ\:2/(ZTAI_W7M\6.Y<**,0(=+?M>,@%&-VQ92\H.VRM3LW+X;8QV;TXO
M]YRT 8LP^7U*3W93F 44\_YP49Z495-J!UN7/S5W%XZ3? ]^H/FQ^"3?1VQY
M#=EVT#P.>C)UG*Y0EM#-EZ WW$8JFW\\H(GTQ/=X_(NH(C6EK.J8:8L"-$M&
M"=V=IH[L58)'K(PG<)QYW/FROKHB-(#[N\3-[JV/TG?&>M_=:-JV2_J) Z3C
MT+5T%<9+M3*^+?3)J'2B8<R/FBG"M; "I>8:S@^_A,*O@:F49:P5(^3]H_U9
M]B/)_;61, .KF67>H&P)EBN^>5?RNZ=E#T+A4RFVY?.P+V47VHIRJ"28ZX]9
M7GKF*>>,#"]I\/;"N^Z@A.F!@#(+[FR9;RGX03S7-_2RY2A5R7% :';JX54Q
MMS0Q=G;VTU>:RT7*7\=Z1NN'9-R4;'"[=/7XU4&$,6)!4X5N Z IDJO%5LB7
M"\#6W/4VKU<3GR4</QN(VX7N*U;X:^]WH3XI+ZI2F]L9^0@QX.XF\QB6HO&&
M*)TT=W/B(5JYF.#*;3]S)LU-_RZG_<*3(W5B:_1 <S%'<=V[UMH"HNNY3>\N
M!D>'W=[SUY8J\ENRRH.0B9W.\6/>*Y[RKU-NPS^%W3YYIT8CRT]!6C-LT5BA
MQR?23W#W;_G@E1=@$8PX);(?PHGS3E\HAW*ADI4ET%.A"J;_&-5.7DDU/BIX
M3SP+QBLBV-9.%D-242SOC[9'C$&$MA&GMZ!<'K.2.#*>6AP^^P>=O>Q[=2"P
M=SU"Z?GDC2?8G6PCLRDTS_8!J&G_Z*/@@>EZPFGC&TZ?BMU%3.X6.T7DS#DZ
MOM_?^<V5))U>$U.E;Q9Z7JX_LTK+P"*YO=BMZMWVKXZ=M2@Q?7A-%6*YK+T!
M8%,6=$+TZYV?5BYR[IKZH?9&SV2P<,8UCL/&6)(FULIV*O;H:J#!\#\V9UDS
M.V9-F:V@.)H".HV($8?2O":HCPTUTWNO]'S&Q7L_;Q,*A5MM:"G@8O>(D3.S
M)U?31&M&ZJVS(QIS-JUGWN3L*R$52N[2-5<YW_GGG#:^KD%R2&Y-^[$\277>
MCGINQA;HQ%H'/07X)2#7/[X?E;#(BZ,JE3UD#K+P:E=SP___XML_S8$+LD,O
MR894*(6MR?/Q_1GUV@-0RZ^@GIB(J0:V>V-[]N=/CG"\_?S$4\IVZ #4ZIZ7
MA'R 6O0D++]<7<IQ5B!ZQJZ<T@TLOBZ^REP_TW7(02N3[?D!B%/G4>1/3[@S
M(Z/TT]MZ^"<X=C:<"=;MNK_WQOF/W3;AXY&(/6YBL*QM;OE7ZB4TQ?G*SVFT
MLV0Y>K%[T_77QR[\*;@C8+_R!C'75ZH,Y! 8"G>Q=WV5-"UG[T435W2R+3-Z
MV.[9"9YFESJA)3AQ5@BGP%)# 2+,!<@I/47$I](391\_P8_Q8,)\N42X<WTU
M,U/!-^I'\H1->[E^\J[,V0H'2ON+]TW!'KO,-BZU!P2$\0<5XTC3N%/I3Z\8
MQ NY^@P+.LY/5%=$+.B8!=^I$4<6FI,?5_PV(3>'+1'W^HI&?R?[0A*Q9PO-
M>1M3B<=79U]X3!T6XO4'(3_'RK_=64JMN<H3A&\%#[VD[%%A9/R ;\-TD47F
M@*.OH[VFTC:D)[NUA@.#RA<^LI9A=DD?-MR/6_@=LG.*.:&G.XMA7S4)X $Z
M=<;L&N'YCM;3\T5Y;S(_GKO<4D()Z G/KS(S"W2V*]["U!)\[[VHX1Q]]^./
MX4)7-2G2N;+D3X^2V1DPW_V7"4.$GZ)I);=Y+QL[+F?5OY1">2R:CCJ6^RV
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MN/V-:TW-EAM@1=T0[5\ZRQE>(Q;F@D"'_]ED*T%Z\&K@+U3&82A1FS )9#9
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M3$B!J=)E!?.DNS]T^GV>/U(92CH'])V> YQ ?T7 3$"LT86_&9FC(K$;SRR
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M)C$?# )YI,X!:)H9:$!X4[/YZ_\\E1S:)\(L7IB-%XJP$=_R.4_?#O_SEIR
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M9TF/@TH[_O(V1P<)\,S8O2)_!SGD/8EJBAG7,653H<HA^@RN7L/"^I/I?T"
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MD2[-;%R9B5(E?]H#4SG5'M9])[*^!'+AUI8DGN"F$I$>##%K#5D)6\NNV'/
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M6^4AKV0ZKOBL\][W>K+(R:88*5.0-H*HI_C0#:M-_BDA&D,T'F.52$R;Z'-
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M$# YH[>;YYI#-HFM)XW='R5'7R\3/&8[%M/4$[O0GS&=+/-9UK_WP^_T6M6
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MB,&:'>Z6MWG9,_N5L16?I24+EH^HVE5+5I=KH)4.TX@/H70XR0)9@AEVE5[
M.&>BVJDMZ>_&DV\-$JS]J;);A079&QW<%)H#;"_E%WHH)OPAP5DPQA@;755G
M:[<L7CGD(R<]8H5KW\H7H)'[S]5QM:N["L9'8.@%,I/XOT"HAG($7R>E5&AL
M@ZU&QPLUAP4R[J2_NT17_.^_Q*7:KY/*(51)PQ+.+6Y:.:G>:N6:8I7*[9JP
M^Q;UG<EOAY4;9,<@10RY&_N&#1%ZMC/^:1&&]Q.W_IS:Z"IYPIDIW?X'_(@0
M3,;&,>I@ /5,L;)X:8 UH\J[7R- \N[JP^($61M(*?VP:K%)DH'[A0T^AFT1
MNVZ< Q:U+V3O;.'"W#G@>M=5J!@9#E7Q0P,C[5FX#.$AT(606^3ZL'>_6)Y*
MM;D&$[\4<78//AI1J<317C@4.9S)4 Y__QH?016#VHT13#)@(Q*?;,@T-/J_
M?WZ8I*G=]U^XL\I/R$97L-J=C["*@ROB*9EW@\RL4[U.1FWWC4.V.P]3K:7:
M^*VD'X["%K2SGZ1O1D6Q/TEG,C2*:?"-<Q^=W_%"ABZI5YVY_A^YLX'(1B#F
M"@ZVP8]Y7T499P,W!F7UPFGW@G4$YP437^:@)SI,8#4N6A:.PBS4+^WB"VPN
M=97@0(=K6,=!)&LC,G%5&!N"@AH5#O&\=BF_X(@"O<')837$!ZW%^RIGZ;MJ
MNY?K*3+A0_"&D*'D6T,;4W%P.JD_4GK*T-JFH3 _3X%//WEZ[H9^_*GD]+:[
MNR0!_>K$:."-?94%HJ;"IL#/N&S,E5J/-D?I-;%YV?\KCU>?7_F[ORO48XL.
M^7S>>@&^E5/C%4^8TR)3K</F/4[K<+6'H0Z??\*QQ@>)$MH$I%)288Q^"XB@
M+UU#EU@^*9DV\6([U]?B%ZOA#O=SAX_^;YCQ/;,^4.W_*12C5.1VM03369VX
MW2?#V1R'W["B(A/CP)-=[R_X(XJH3%#ZW_PA@Y@-NN /<IIN6UU;@5#TW=0[
MXQX;*IR1]=XAYBY2J;H]M3*$>]CF(7[F<X WC"M\%LRH=J]B+P<4_>VG.E73
MO.0JVT?Q4'_;@7;W>[=<G(7TFE&3W/=2[ ,AGKQ9VXTG(\4KKXS+CU04N#QF
M,WYDS+6&FBU[M>PO!_]Q'N3T=L\SFW1OU9*7-<PZ9F'.MWCMIR<;[&&[;R"8
MJF<MF$')!K=KLECL#VU0O8?U:"&WQDA^YP#[>=A?&Q\P,R23-PP-.RPGJE-F
M5VF:DAYJ/)D+"E.-+W7,9L!G]&.?=O,]CVJC^J[">_"[<D.[+_DZU!9K=MJ'
MC'T Q$<GEXM+8> HP?AQFOV#7X.C?705$(&R4L_4[^< )_#2KA4!6 :]^IW"
M3PT5*5Y5F(<7YQO_#)5CSQ@[*P3+DV9UYX;/ZKX!@, -;^9QN:J94O'(3>YO
MS^.]2BNTJCRTK#67W#W+8!+\%;X^O,Y0U33CGI?ND\'];0VZFH.F)4],G7F=
M:B5&\>[:^K_ &K^(@T@&J@CD>F8!*TYRG,N'&6KJI;T3XZG)@>AH,ITROVIS
M%D%I"U?X'8*9(CZ#6A*,_+#+:)$^,-MCM#+4Q(<?7Q8OXV54U)30:.1[G*'Y
M"",8P_W?"79L\LVO06#]0G<R/TEJFD(+:>B.#T+G7]<!Z\ZR&[7&#[L50CZ<
MI0S7WZ,62,Y.TG?:^F7>)4F9A%WK4B&\'NI=8X52^U1:[56W@YA DL8VV$NT
MDL_J 8]L$Q>]*C_XWAO2CI!+N'D=P</JUFM<\H2Z7-?3H-D8(S%@>#2I]+J3
M<0W<+QES?_SK8D(?@_B'J%<&%[UGLD68FDEHCF4:\E3LFUOHFX>'D1RQDQ%H
M&90JVBN;7.U-D=A/WM!W#Y(R]#P'J-.K7PFARF#B?_"B2B<[.^3WTDG-8Q\W
M<I4\T<"$0O,9&X?"LZ:P:\]NFSE,;W9V!0(C1(%182G_;LND#*TMFJOSQ:]W
M5CUW/_4)\%3H*@GA[1U='%&BE<WH1LE6;4DK7VX[!S!3)L\!5!VN.!M=PLH&
M^ :Y;("+M>UQB0<<Q4Z]I54M('HR_YC;H>3#=CH\=]&1!WAUYT.).1/>W1!!
MDVE<+I@!?*^DW*KX5_&/UUJ68QGKAJ*^,8)ZP"RM3(-1MYG&R-LLG%JT5^^>
M?H6N?W'U^-&D''[EH@?P)1 :C.]LI [:,' =;\:N),!]AS_Y%(#^NMYR%KQI
ME<W^WT!6#W(=;JW4+0,0FL*PXV;Q;[%V"\D=S^PA"\]Q0;F@,DVQ'P-OT[9;
MTH! W%T27.R^V-^L3=?#,:PV/OZ! V%DO1:3? A3)2I1A"T4*1:Y#>/G *.[
MWE.9\##EY<'[ ;UE)&8@7B@QHJSGU?V\B', M7#).6!$87]G28;I)2%5^:]'
MPIXQN"UR6V%,.$L>E<#EW_G=[C C/TU-,CD6 KS2*S<FWO;[8![6E:]LDB5O
M FV<S=!!T%J-6!]9&+3\A*Y=<)+(?,<;H@[E>P[#82L6KD7YWHXEQX^C8 5?
MSQ92^_#OKZBE2H:9K]R]G5HL-WQ?]_*_XW*[Z"D2B_X&PUL,R8?X%'J_R4ZF
M5T)P>G6O8=$'D63"U;KD)2<G,\(IXHYB]NNF\SQ&7@N?X+^FS@=]/D>1(VCT
M5'MN>(5,<966HC+&!QWD*R4CG%+EW;,T@>()E]Z^'0A:%<#B$S>.&< 0D_Y@
MVJ"R_6!_%-BZ]8Y+]%/1G[Z/>XRUJ=06\N.PYP#&7'UN,/?[= ^+- _9K*,S
M1Y*0/#I4&74T?[)@,M=-*(D:WLQRJ"?Q".G3L^15:)QV_*+(E6Z:9(J'U'>N
M_;)SZ[+"'6,J?)#KN9ZX.'K/,9PTHBR906[@CBZSZ8MI@]OW'$=A4D*MAA^Y
M'VI!!=:I>D$$T=.(<!H#=&WD&HW\4H?8IBJXV0 _5GTO!T^;&V@/'>FK:+0\
MT[GJA*56P+/ L2#P$A.85F,]6YW-,/"C K5,X>PY "W\O0/1$JB#LGU3=,R2
MR*X>?Q1PF!D<W/:FV)Q-<8].=K"NC\6#U>A1]W.J1]<"]2/E$I8Y#;O<W_L&
M[FDQ!KK,^L/ZT_,^XQNGO9N;[=UP1QHISG]\EZ3I3<TJ]8HS[U(/WC/'&\5%
M&=@JA(0IE1R7]0*Q^B .0O-Z\R"(+7P8R7+H-!M$G;Q<+2DMS=C1/IP"_6X7
M69E]6^SVBX'@Y2W7NUTGW;]KJ,S(']6O'X Y,!3@&D2 3Q;AAGKHL6;<&O7^
MZ<F"O_;=P7- ^]G-;=6L;14>BS=@S=Y6=;D[8_;7&[^CJ?67VIO(N2%QF?&K
M%B&(^7EU4&+#(?)]0U2VPUZ+8?$=C(FN-JK$7=G:&%HMY+FTBMD_8C'2?'/G
MY)(FRW.J7F#3Z1 8=8J7(]==!*S)I_2UD+3UE;EBOXG"I6&FR>D<H7>63G=
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M F>CZ^RZ^9U$&C^#-$K1Y.$' =1'+,M?J%8\=91$).CV_'.\:4ZIE0_UGR#
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M^+3L=_G:9V-6+=-UK2DK;61[47L'E&W/(_X-$3S9ICFS#&&+N7(5EG9 AUD
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MCGD45K?A?S%,HF]K^R=O>$+ ]?^<:J*->W-LIU%=BA#?3#D*?Q<J$4J_#LG
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M,?Z<Q<L/I5T.N2FE$U !F#DX;\CP^0#F0TZ9B55UX$8@2A+:P]_3UF8HUKJ
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MGO.<SQ_7S)D_YCWW><]U7:_7ZWU?UW6__9G1??N)YI6YIQFK8U7?/TJO":[
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M]3RHBEI$](NG@^DNV#EGM C;%HBA.HIR1^%"OX00O\)K V_-U@\X!!WX?8/
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MZ\8@79'JC:TA&$K!4;_0O31!.8#'7GJ/=BNPK>E:-$76^1]%QP!,7>#TY8/
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M(&!OASY'AZ__>/3M)-AQ'*Z'_@2G.V'2,2!,,$P(/8SGVP9=@P">4 U&<E+
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M/ +BW\L.?_5#P4##_-6"!(^$] $.[>]5 "S&!TPX<C8L$15L"F-0/#P.+GM
M7MWTQ2=*455UC:3>N4TJCH3$Y)E9A'\H,'7)G[_DUG1R=BVL;VC<HA8+;-K&
MHY'0,C-W2UVD%0]*:5[8_0)T+QAX7P%\A/GK$08,!D (\/RPE?3?'<FAM9T'
M%PE*M5O+GG57Q;_M=61_5=()SE40-X!?LYRDV 5,RDQ#@,_.I5)KV.='=>\
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MQ38/Y+^1>OF?2"V(VHG_PX?_'4RFSQM8OX?GJK#I*9K6YU2#"MKHW])R> ?
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M&JO(CLCAUPV*_/^XZ_WG4;&AZ8U0I39+\[2D A$@9-&:_V)J1 7O*19''']
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M^\7@Q?=GJ.?O[O;08O^H63NU?N_?,N\ \ZU7C<-Z[Z9CVH<J0GFEQQ'FHG=
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M06&R-CA*.&>251B&-C04_6XE\]S8(1_9*"93"Y=3N5=6$D!K\>.YI,U*P_2
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M>5S,0_HO2LK]8C?^PE^4V8S%;YOGI7T4:?DZ.]HUST*X_X44_R]LV[=5^:7
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MB$H*W5O0A>*6ZDY.N\Y2Z[.% 0T^8A\S.3\GMM%TF"%.02B ";5AS]AOM49
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M=OQFY]XW9__:[UGO^*G^=G=W-VKOV[6'KXA&07MYK=+*=_K)I#8%['EA(=A
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M-QC,O+T]Y4FS#5_(!H1:1N<^V"#993V-U5KNE=L9'22NQ&(HXYU9$W*:U%=
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MDIIS75RY6QDER4Z%&"5FU A("<<LL=X4#JF9&UKJF2>QTXC,W,6QV,XSK+N
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MF\E?% ;.!$^'L]Z<=HU89X-Z,-_5#4YC72U%[.5;BQ?,- "Z6/IFCZ2H;CU
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MFLCK8\48>K;$P#L&.?+FISMSN?9]0S95I)#]T9Y$R\ ;!6?J:KDZ$Q5A@V=
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MG*_#^BIQL8XS+_JHSF/[2F :@,>1O.U*6>_B"Y=MKH1P-FNRPN9)^II?:B%
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MD&\".2Q(0T8IH!;^[_N (Y)"WQ[X/::-JM5JOX@(;[VAVFD4$+5R5Y&/];,
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M*,(JN5B=*-%@K,EIS15*@/BS\#.!,^YL\H)[N,K<R'S); 1G= ;3^9\>2G^
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M,WK^\7;7O7EKLGGO+S54WY!YHY:S8E)>X=AQB.$#%3,JWKR1H.)'L;4YO;V
M1\W,Q51>MW!75^RONKC,617 4.)=4^SW'#,(JB5);?@;2^UCV:Y&O(6V-8&N
MS 6H?0J)\6B:RT"%(QG!,'_;G4PV6TM=KBNE_6 '<=;8^8#]<7@JKU9LT5PU
MO[/$K[0561?_PZ31..)&<!>ME5)3L$W/>N3QJ=EB;.TT(9E2.#F^#^B*$5D3
MI:=PGWN<\D "YG][<"*,T>1YA>LX/'OYYP;;\#IJJFG%I$75F<N 0#@[M(JC
M\]\]H=!\"UYD6?HLWN5ATIKHA!H2R@YOP=?(8T!Q)K7+&=@ELO6CMRU=>_B3
M$WI]-13T4=W_9FX70GHA?#">R;:313O<,<.RX.R6=?MQ[O!QM)8$];2N[L![
M5^Z$@1VD8C6O-R]. E:>RVX9'Y4597IIG"/:&_A&+18/.;#$OR**WMV5 K_X
MQ34]-*N1PFDBIF8VP1 0B6.]&R)<MR%O]Q9ZL>/:!&E=V598C>E-JLP'OQR\
M\,\&?P^>.?W0HC,7E8R3W]?]*V/!;W\L6$J^VFGCH%.CV..17(B=$YJG56.^
M9)+*WY3AZ=M5?:QHGSJ6^P_.GQS].C]6=_^G2O\")-LB?_-&_04("AZN))[Z
MM/T%[(F?;?T[E.J_@.?DGXE_ 5%'V7^2/B5KE-Y&*SRM5,V^-#-1+DV:DKO5
M]YVO$ICP($Z#;2*[%1;(48?=4\,]GZ*<W72'?>7XZVBOU#+WXQ!X.N+1@*5?
M8N^'R$CP>NVM@B7.&?0[NM)M8!^*$>G+]*W)I%H,]L(R4MH&6$@UK.MOUS/7
M%==9P_DWT+<_,L3]!<@MNNICCAO>^T7"Z5+KLUG+,<S [>SINZJ9>'([#6U0
MB8TILVG1HJ  [],.Y;F%*P$*J5D:#4&9-4(!(/B.VL4'TVS3Q.1FB$JXX8V6
M9\/U:,5U%CWPBHTTNH@*%Y-TOF3WXY?-5<.+TDC'.C44A"#)(T,1M??;8381
MMRJ;BDD'&E:D]@^GV6LIR@5)$I0 [ =*X-P];DQM05=+'K;"S+CQ;!%W?63Z
M#3O+DQKB6YA,<1.+6\J1@"963(<L+8&!,'<'8[7(IM4\A[RJ,;O?Z9>*\[VU
MDN)++:%WAC.^U?RM_7A7SM1E*B16B@'O)9(B4-D(HG74'V55;%@H45=F=6<Y
MV5(P1<4%00O>N_51U+$=^M^F:Z$CNI'RBK/T&QV@Y+-7;F81 NVND.UCU3GX
MN;%S59>B[O0-25>V]GF+<OW\280ZD!AR6"%?WP*(==.M6,.X^;:+=[WNT[S4
M<FX$'Z#(9C=O1B^YJ?^H\MG=6BG6 V>K9;+VOBY?(Z&R^;51*)F4;1)=0JR.
MIW1W0\$4^-VKOP#?A?).Q=+#;-^8[OOUW[YE=@.S)JO!ERK)-GM<&R:]3;E7
MW;G! 3\4D, ,+5":NFR:CQ<ON\\$'XF;VML60NO$3(@FL_VEN!_H!/&ESX,R
M,7I\K<ZJ=U*T!^4\3#G!]3M)G/YKA[>AD$V>9^EE6E:2-SB+9+YE2G)07KN1
M.3O^]'%/D[A\6*K_X%;)A&2#E8EKE*'5;^6JO<7<0,ZFI4VBY6/\]4.!?HW6
M36>Q3!(91]L)KT$?[&+E2$4NFTL_G.H#9@BT<JRON[AU5E7PBKPU)(\^BFI*
M_FHK!9T!TML8]JY9NQCR7A99]I56<&"A$Y&U?K@7 4L8QT#Y#4GC7=IM/W$Z
M%67A(/:GAC/T 3WE/)EZYLBA\ 8:FQBA(C1@FGY=<<RL!LY2V^71);"& $1O
M8C_[L_EDPVMI<'=ZI4I5=PLYG]&/]I7;I0H%@6?1;+(Q066474<&Y!AX2D?0
MN:N -DX@:F=>)NJ/8VF@T/2#DV"O<#.-&:#>04J*T5S&/.KY@UD0!R0(W5GA
M3B&@1_!<G?HDXUUZ1JTKZ#7>,3=E[)O3;J? $<8#[1]SBWDK+%CJIO7//Q90
M23%LG-V^'+(O_060$C6,==O&J7^#U=#&>N?B<3GGBG.<G?<ER0D:Q[8L.PZW
MFP0Z&QKKO2, 9:&S1:"/Y_6;!_]_Z!!@'F3%%[8(;U24Q+6.AN;&,0*O=O;^
MR9X@+]0!W3B:N<7D"G]3V'6"$4>@-ELF!6XC-MS>V-P=>5KK^K6CY5,B]@"(
M3PT641PWGIS/7Y\NUHL*_^[^>L(5>X!;XVV0XYY\,F[H2@\4M@.%?8TK79<^
M'#/OFO<U"281<"HN!OO81UF3'3A9TS-EM/3( G/D.CA^LS-2CQ!$)8G^H^Q9
MLC$*A%"O+_=O"]P&6^=<=&]@X_ISEO&9'M%C5'2O6FF8*'OT"UH#U=X-Q'=8
M)>^O6I@-Y$P)*ZX2FBL"6,HI^TK\*=F+RKEF!>-=0%Y:S<!84;:FZAGC27^Y
M(%,\SM$1LA@PP9YBL#4:[_>2K]OFW/.T:%8M9F/XG^\9^_69Z4_7X9F%"\(<
M=)DZ[9US?73*MOXH)#S?\>WTV 2D3),C47[JCRO\'.$/-E"=<6&ST)GG-Y/Y
MKC;[M:L#+'>WN(B_LB+;_NC3&-W4FL%',&$3)W:>(B?/QA 7&86\K@,W8;&E
M'FO.Z\*TKB9>BE!$Z**L.<YH[GY]]0:O+NF/)ZU(,@:AM4)?W?A.PQ'A2H S
MV"IO92/0&KOSASP;"K.450K_AQ@%/=O7&$GP2ET("]J@.W\PS5] ](VKAO0\
M^V!I6:&38+M"D2-=E)7SI]*U<0<_-P9$BHF_G"#>*# %W3:R[RQ.40;N2V51
M[2-4\HG5F%PFQQ,D@Y?.[FQ<E_8>?4BWA%EYBBNM##BE"S\ #G'G'(C7#YNG
M 5)#>#2HWV@'L2 ,[Z9?2]P;[U.#M)8]76J61;:PI-J/G<8H;J20[^D8EI5_
M%_^<D*3 C)/IH@@SF:*86F 7EL+V/HF WG*'V/4>=GUA)I6,DZT[US+C;\&-
MU$O5SMJR1XHLQJCV0#I<&7F H8K[$J7W2$ JQN:<S%KL017*DE:@N$B';M2:
M@=Y^G,U/D4P^/VUW=?/CJ:R.#5S\ACQS#K)DR.7N$>7KJR7^%/GJ1,E(-QP2
MRBOT&9EX P%!;@'N;1G@SX_*T3"N8"W81RC&]5MZ+YE.UY/ &8/-;IX*S4V-
MC\]_ 27X9,?"PTOCP1V!HA#?WDUG]S]1[QADPQ^?^;WJZ\5@7ZP5HVV/7QK&
MJB\/)+*_*YZX5F,55Q ;CLNBG4(C[2.!!OI0AZOR]%H&X:&<TY/^VA WT8,!
MQ/PJPK6Y.2=K0@/]CZ,MW:M#D-]NP"M.]2ZO1(ZLX@DNUY)FEZ! HZRA(%4#
M!BGIO:0&1G4Y^S)EG+78-I(C9KQW<..9OI$![EJ$TB4;/^P\]373C(F]6JE.
M#ONM[H\R6,Z>.TI&4IE_;5OCAS>.4/IHH5-"/,V\,#EA)@W/406Q\+=C32)1
MB?PIOA<C+?J18;<C)<8,DD1N-'2?X[W_"?-P2AL=1J9PM'' ?X*Y9F^Q;RNJ
M'&_7DP/2)M@%$BS2FHSI?V-%9-A8%LAY'])ZOB-X/V._:V7DN:D X(D/[/]I
M%6TZII43V-$12&X2OUHARNIL:)OG+]!Q$D?/<=[ [^=:B;X2-Q$ 4'.[=X[F
MS^/<QB:); WXOHGM%^,C*OY.J5Z0&!%VKO4ME[V:?7+R9&'!]QD^0^/;(HC7
M2^4'HF%B>[\!5[8\2Q4)Y]-[""<MO.66;=LR%AM"*U46&_N#0\^JF-!<8DY4
MPJKQ<4R="+I#BM8;QI-3Y6KIH2#=^^8-"D0<[<U0TU4_?6>J-,M)!DD*J0[+
MJFU"%J4?LYTKO-@.I ,-4\ VXF")^\_^>XU8B8XC0%SZ,1Z,-!B_]W[:&LJ>
M?IC>' _^=Q\\($93D%(,2E<"D2>A\>I:H#ZWNXO+#;E?4S<B[FA#U2W.%J?M
M'5&FV/1BI5*D&2Z_I?]\?+QS8&LVYF>;/(:C%":KY.GH@(8; VU2#7[J^8])
MAR-?">'3 G)_\+YA:B*2HCOE<2->/$-!7#'CM*]*Q)/2NB0<0B7F=L13<B"\
M'M[U!-ZY;I<+DKW-WV+Y3;R'Y1/V/KAK 79?F8U"<;;BIKO#Z1SN<4H\D;T&
M!)5:ICE#%'QA/YD.HUJ#_"![6@*]\-,N+W),!I>\]FPJMROI0MSD(GA]+>)C
M3ZNLCHUZ<+0MKC,RBLOLZYR,49-ETLPNRA;*,?(IYJTS)I3(CA]T%+^'*!60
M/3<T53R0:/M4':;UU;]4U[Z7R&3D$@2>[3 R4LR)A2]M)*HIO?KUW "IRU(+
M50YUV-*NND$'>7E=:T?O'PSC=SZSQL,"@=_[9NI/]D#]8O+,R,$6*DWF5PZE
M:Z9CP4AGM03\UV]?[712_-3ERS67O1M_8O7Y!Z5O(6-_ ;0:'N6XQ4.*7^^4
MFM605$*2"7P]LN)/H20$4MH9EX9LAGWUI]<Q ?>RKRT2_%F&"$?9AX4"294A
MX8$[+%,;_1'>JZ"BCHZ4 X.NV/!!SPH1$ 4!3N I?%L)_M/2OSC^E6I./;N#
MB:-OTDCJU*S%6@%6RGI#^\!F G8[B\F ]'X-+0\'*MUW7F&OBNI)H1++D^9R
MT0C"7*=1,K$FNM8QPM_H?9TMV5/:3<RL,DG'N'5'Y$'6AB:V&+)J>*+5G3/$
M62CAR2-Q84B[SCE?6LJ$S105NUP"]GJSVJL96@2=:%!'J8[@:(F1KQ_>A.)X
MO%DA!NTUC7VA=!B.^D82CD*X'Z0!^>FA-$+;N@.4?']XN.^5XKFN2R@^$-3E
MI%MR[0.E$%Z5F>&[IVV-#A[5[V40H-A#P)F9LM*YHNEV9?0_E8;PXKN*IY6A
MB#RQF&"02A+B!:GCUOD%JB%_R$\*]O%;MDO.<O1< 8<N@1&&5ADSLVP-,QY1
MV>!B*R;7TA]I!8@?:27HZ@0Y-L A8:<:@]3_A/QZK5$*&PCX/S0J@+YI= 2(
MRHH+ !.H4$9VRGIXB8%^E*1ORFT_6C/WIQ'&8]T;C7+BS+()&K>9RR'SYE"9
M]XD$[4SK-H3_DG1KUK41\6@<-SUP5#M5 \<>#;A@34+1?CC0.6P5G.*J-"+[
M:];B >'V:IK:E429=@;Y:-TVK2J<T)WY<P!6E'A@SRCP^EWF?J7 ._PCRDVW
M\W=D'<:9*GH^0/IM>KOQ)?JZQ5I7@@WMXEV/*=W22#N$9NB.=;3Q0D&1K(R)
MNEXTFD<A]\'^*K>[%"7@R4LB&\YD89&@2E%:6498UO_[0KE4%+-8BFX/*V<!
M@<J"D_=4\L4@-=$TP<BNNT3H:OICG%19C]6!?DLN,.C+N\@J(2"^UI58*]U>
M&.]/18O,UNOGH$E-';'>X:+3F:]=\K/-F>"!=$EN2$*-5*C?,F$X:DA\4-L.
MYH()\6QUJ3G>(>-O%,<9;1]9C01ZRQ&\$"42SKA1"6<UW:FNGFM*#?67\Z3
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MDCIU#+Y!/M$)'F_.*#Z(NGYZ'O32V/UC\S ;_:W@!O=V,,#AF^3:^%_ _%]
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M-0,X_42?801&=RW-=LIEB5IQ_4<,_C$$[;3W0GW:__%+<,/,I%!_  "6 &$
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MWA0-@RH38Y/VGQ&.@; N$TB.]T'>!U+:D@Q+VX/2<J* M90=#AX2)2,FL-4
MQ;;EFW _1C4C")*A9C$V.3"%S,-+L@#;>\@F[^(KO$QL?H37280(3NI<M@!W
M*](;=3R%E[S=F%JZKV<O',<DIN95KX=F5JL-V;;/_$S,[7<BGF78L*-I\:2?
MB.Y%>;]#]Y,[B5%_T%#L&/LTQ_>[CK;1<) #PH>J=4JT3$C;ZY1DJZ\>NB.)
MPPO]3_6_!<BW^)?ZFN_8]YM'<<]W]1M_ :N"C'?%BY*C'\9>.!^'/KL/_07H
MZL<W7.?K^ ;(G1 I5C$+89*>AL6,Y@<:!QE4Y=JKTIC3SE(ON6E0X6=]HH+V
M)S1]BO^!Y8E$(%/W[Q-3'S?UN#83KG!;%G]5X!RJ=@;5^#JYG-8E) <X1=.P
M)91Q:347LL]80[?4*XCN-6X%N"&.SN_Y\)Q,/HS'*N<8IY4<Y&]_ =<*^1DA
M6K2O5,K6;CUK5)1'(I_PA%/L,&Q>=2)8S>#]]$.IY;)X[+0KX_52HQ"\%GL
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MI[HGVN0[Z<3=\L.A^7%)(5TGYTVUNPY$$"W[V,2$QL%AXP^-<=KY!$=,_LC
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M"+.G\-GU.(47U>AQ>#ZX(@%EL7#J@1?JRAB<4ED'4QBV_!%F*F'$U)JP9-:
MB0+7".ZLCEJJ.>PF3+Q!P99%F*6O(WN.]PC)=R#\ ;<2Y=Q9G5FQ2F<I4T@]
M,YII^<3/.TL>-U829:.:A,V:V4 2TJI0JBYI:Z-.]/&-%35%P!Z@_[W/-V$\
MW;RN.U_GCXKQ7ZR-F+OW;TQ5L7:E%J!0 #<F=12Y$W+]T!%N:>RN4T<ZW8'K
MCD]4][<%<BPCU9Z%O?CK[M98AW.Q,30<PHT2YSFT?FKVKZ&R:)@]*K:D)SO3
MP=^:.EH\)48'R=;7N'Y9%J!8!-]06RNL8\M8?XGR3)*/')63K(JI4[.@L=#M
MIR3CNU;-<.[G?Z.A></."BG(Y;=79!<69BR>= W;3$!FW!=)03$/UQ2LZH.6
M59"L(*^23@+#F8",$;0VQ,#D(C1N56[[PB!83%_W^NCT2JB>&](812ZU>Z@;
MP+0D15>W3K_+$"FQ]G0BY'9MS!R#2*QS@T &Z"BJ$$^ET6 *&S./&1\@P2WY
M*H:,_H$@HPB:[I9WQ=]5/PP[9;#.LX)889;<Y[96OD;(DPH8L#F6H7M[<Y%P
MH<5B!"*44S,$!=[9DX:L6CFQ=3NZ/CS,\3+'^C43S:,4^'*EYLT+MH']4\96
MX<"6Q.#2P7[EU=TOM$A69XVW<V/&B\=#XMMN;N*Q<** YOB0V5[SH%#:U<$Z
M)K9F!*-3\S-]6FE_J3[B^#YD39"P\9IB?IHU<5X%PO,#-=/79#^E'O6 6JKB
MK;"_B+XCV]>6\/R44"6A#6#BF2G(4B+\6F'J[.-K8#  \*9,#99OP;P8[<,6
M8B4?L-U8?!HOAWK ]9.-I0G4C_]#[U[H5KE:0NGGC<UJ6^R#]^/OCD=_%EJ?
MV]^]AD-\\ 2UT23%91&2S%X!8N<2PZNDXKV=>;C[O6N&U2=IDEG:)G':P]$Y
ME=V^7ULF"H0S51Y#+V>1.N&=*765C+;^)1K)F)6*LXY@[DOJ%8+#82BXL;0!
M>BCQ+[7%#%6QW]4R^1_GWH(,ZI!;OS\KU9B#9P23,O$W,M@OMKY1*Q#LQAM5
M!@PG>+X+LW1"C=! <C,+DZ9[?+G0"*1 2T?'\*3)4EFKZKN.X6K=\,RG^&2L
M<<C[S(2XVB'LP9L2^>["7,J/&604Q%R@T6QFU8!,@E76^AT6R530 9IWHF]
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MMV:2_-YIOCW3CO1C;.;/"!WVBUW<$0&>L4> ^W1<5_N7X$GJP(8+(>LMVDP
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M.B4.3:6S[L ^+95>C$J6S_1U2*9.R<^JAPJ810N]?DML81DB9;>(M_UVZRA
MS)-PY^1YLF\Y1>YJ9=6(!^14#AQTG"?YYQ-TH5.6N7FSF\CX,(I7[^7^+RO?
M^1^?3K!PVV4]6MK"FZ1M&S$5#N3>6K>G?)1SC8[.2T'"U)\KR/92T[IK-]G
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M<KXMPKLY33]V2U@VZ[-_.$2HVQV9"FR\UBVTU(NT-_^V#3Q"7=K4.;O%R50
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M&)F7N/9:G+C.CY1B_'J<JL^QX(I.'NYQ+D[4L1F9O=DQ=+]'GN>%\_.+3C%
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M@QY4"Y^5Z*^-=21"@^*/X9KMU*3(U#L&@V[75&0+58? .!IWY IP[;0\JU!
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M%8]PX:W(C&CRI:OG 7[-M([6S&T(5VI FB&GU$'Y/([*UEEY6B3P1*[L>_9
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M,P]U,FQK[><Z1WUVP.8Q$*^=(LZT4[8_4M3WH<JBZCH4U74>>9,8+M7*#3/
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M#,KULF-K^)5T-N-V)$X'7G;(OZ=&J--D(['2O(S6Z6GK@'*L,%,TW<G<%BR
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ML5.-OJ)5KK"8>J,ZI +5+:H*FP^/FB--8(RKI#)_N,T\2D@HF:SSLW6L$_;
M"/E<??R%]@IEA("*@/&:5!^GL (E-9$%HDN'ZBA,#);<=WY:DH;L"@$+%UF'
M1&%_?Y5U#Q88_"5$\LN5?U46%!RB1MVCIS_=?S7RJ=X;Y[CD$8.:^'8,U@L4
M+?3/IMN^>#5D\GUR*GX)F?_5A[,3:ME/TQ"D9ZTZ1;"51J8P%/M$HB"+A'"K
ME2)!(S@S8@5'/3,.\XFZ5N3!Z8R!(ER]FT+#6#49==&HHD_:PB^MN#.B4WH^
MJTYM;'*.CQ?1^,^]MLT<0M%0Q).7GF6ZG9G>!0'CY!IVOP'O+JZJR .HCK>E
MGN\/;LM!F]1+D#YU(ARS91=I11^"AC87\*L(VLK::/J(&M$>T U@97Z86U;0
M1PA@YW7O=D^N@SJ65+(_VA&QAONT"\+-TYR'H %L->;KDU>>E+,W;@@(.[4,
M[W\EY$0 3GX-2?$Z1XQS@'&7W13DXU6K;)-4<1#B<#U7=>CD$-0+_WP6'M/Y
MTG'FP*^63RPAKPU@2N8 >IN%F^6C9=_0X&:3@\HD-<J-)2Y#>-'7S2=I?$IT
M_L4@QN!Z)'Z2(ZT_V?-HT7F+PF(+/?%N<3D\N!?^8@A[S"J;L#Q_-L0425;
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MBH$SZDR<)=F?U1N;IX616D3;P"X+P2ZTM%[,"CMB#T/D8TQ8>)PLA767W1\
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M>H*"71</PJ9C'8MZLDO%=9)X=OK3K7PF]6O"-OO=5&N-G%UD_RS7H(8T"31
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M7H@7W;8:%/[K'.M,X*0KOL\MT[;XF[6D!#"@.C4810<6-4>--53I^CUQ<38
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MYS]_NM=8*#"2,"1O;5]ED!.FE#RO+3@V0CZ,Q5'DCV([QO[(@L](A3JK;/F
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M^H9E*V[0<S; !T><&]-IATD0/)"QU+)-%3S)5<JWUIF,5'7&$.6'TBJA:$C
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MW+-V,@XJPX.W2\)#?RR+NC[-59VU7P_E2NS9GPGNX6??2[ 9V2S4AI\!GT!
MTCZ'Q*IZ9P]IPDFFE4%Y5.U(SR&'(F?Q#24XRE(+"%I?(B=_NT:1!6+6-3_P
M/HV*G (W:KC'FRIV>O2<8MPC,MB7B$OX3%H*T2BD]$;X<]15\<%57!G:3.*,
MZG(^7V;J>X,^ IYW<PRPLI X%Q+EL7PIP"6XI@S5#22:Z%J=.*-6G+9I+V>R
M$RT-B:MVS. ]UIZ[JN/>$)D%%5%%(PJB$8UL\8KMTA6^97I#DXB2I)W251ZJ
MW%DZPR6Z4G%Q(?=PG):\R(I6WKP1). 77VR/$AA/QG/I1P'-6O'#Z"W=5&,+
MW=VQI-1]-!92Z3H2<=VEN@11]W.C\TA-21<_%*VD-]'KWL)T85XM9J^ ]P\#
M#3PA5/LNOLLS&0KW(OOR=_4N4"LS',-$VJ;X9!H4"Y)<5UL>:R9AO1&7;TI#
M=(&3V@W4&=83OCVFU\;C+VTOH%T3DZH-4?66%CW??/,Y;3FPJ_%ZWQI/QCAT
M2=%.8(4T#4W3FCSSW9_<GVM5)APRFAT==K(QTHMF3(DU<^Z2%DAFRLM:$ZAM
M8W1BPX>UBTS=W5D>$3U'*N)9**2T B%_0Z48C#=JN@/T7,2-'4+PUT,38RA'
M[V=L89?U1='HD[TK@>A\[]R]'/4%R7PZ'1U7BWVN+O?'P"Y+1UZO -9@,\%)
MJP.C%65K.R&(0>K;^Y3<J("\LYZ"PD\;/LF,@[DRP-66-1.!;T =98B8XM*5
M5"GW<1'/(/@<K8WXX/.74=)*;VS'8^+*YE_!#6\JJK:=@((7B2S6BT[P!MY[
M>Z )]@>'V^&=!QE9F[9+/QA^1*/[A&G G(2<-(5*Q>.7YTK+[,!S2C4N3=C\
MW=MH';<;0_27R[Q'&>IT8Y(5N]6$"Y?2OM8":J<O[@<U_2+R8753YV%]V3.D
M1WS'>$S)CB57"6Y>4%\$47K^L4XQT4%G?]<]4UF.H>Z>L6<C42L9^F Z((?.
MTAK9A-5WQB6BRI0DNSA7KTN2(W(:"3>UY3TB39?\ZS[B7^J080K;QA><?'GC
MN8>B[I_7BU>++S'X">1S?^0L?G%PJGS;/HM*D]Y/D^PY:ZX?Q6R!I>926/5<
M;E/Q/@!2XW];B9J[G?/ .D)H9[7A!QH^#9Z4W0-.^A,8%Y\?/L2T*A:ST<NL
MR<$KT\[H-]KD/TF\ DQJOTK,F:5+SJ)QNB^9;QE_?@6$B;&] NS^=C%OO )>
M >=L&W6O@&MLTE? \]%@BV5[1QUWY50;+8=6YQ<UX$HEP^9TG9;3FD<9FU[U
M=\.A>#Q?2\F:A#H7Q92:F[OR(CTT4L46':Q1[<QZ$/(@K?L.F&COR3T=G27:
M036<R2=N '96W7"!24Z@;PDYWJ5WU;0)?VNJ+2"2VMP@C;;^$;V3U2?<'XKY
M U0^XVW ,5/\ !M:)FNO5&];NA6*+^F@NL_#T]TT4>5H(N^@FB>T3DNK;HW/
M#;NK=&*T+66[&B8U3X3-K$S^6^^IX453#6",2P7VSCV(]/%L3N)W4E&\$EV>
M=40)A(8W\:S1[TB7JA3DN-KS&JM+>J<-+)$ _C<N;YE1 #;OV=E<?$W/4CHR
M6M=HV-;HV ,E=I9\^$UE5RRQRU27-+.=R@R^CVB<%'_2O*U).U*,^%F0"/Y&
MSCZ9?:)]Y?%-MG\\<TJ\F&F5,)L>1JICF<R'9FSO-S[6! G]:,& 2!ZFK5B^
MWIV)5-'/O=9\L6Z:(@/<0Z%S6Q^6%U[X+%A];S=6=,<]__1NJ_HP^4=.JI8#
MW-2] \K;O.'SPYUYG^I7@0!&._,I,,?"BNJ'I><5#O\[%<12$MYX\!1DQJV-
M,4D0]A<'4OZ5U-Z#D:,=68)-'I#$N/Z-C=C#0XI<CQ6C<O;EDON,WM>* J;[
MYD>YJ*:M/!K',B*DNAO1?.5*#SWA\"2XB>==3<<@M#*A:>-]#GJ D_':4REG
M-TM(S83+,^=0[?@$6L,GV'=L%/'/:1_>U4!UZ^NE4),*VAVSF;P&P6P^C+9L
MY"-(4W (O6V<M46I>+M%*+$6.+?M6SJ#_]@5]XJ^KA5%+DY\S94 1!K4F/0*
M$*EZ).,+,CB&IXG<<5G+;SH%LQ<9:#/]>N:D:T>17=6Z3\DO)&SM1[>4:_"*
MBX[%DS!^H,#Q/9:-V#$JHMLN?;$VIWQ^Z>[\,/25C_R33VT=J1V$-Z;Y5 ET
MRCX8*9S8RZID*L#Y6=J<O?C#VAJKDJTDN7W.06IJ:W;]*#.)T D9)+U$T5B[
MF458&5)MJ:2MES2NG/KU][@GZ/_:J4)ZEF_/3Y/B@85Z@'J,G6BMY_UU;NXC
MWA6!$<E!T9:[^G-.WBUT\*VSOOZ.E2VB0]DPJ?*TQPI2M(JJO?  5_.2-ES$
M68(&7ID!;DHGP5=(G 3T;H*DF(?2P@,7OGKG$1YI$LEQ)(':UK_L(X+RU>4#
MASW4#8R\'NKO@Q2A*';.A&2S"A,C;3I8U)*6$RF>*-+4O\#G$:0D,Z#1'6V>
MMU2O@*AJV'6X9X_QP:[:(M#;A+^[&>^>BV.2E5$SL6?IP,3( U& N"7J'L=C
MHCG7)GZRJ2WIZ8T[UC:YV&SBKC-RN'W8(X*\X/":_XTIE>SU+UC7<GJ-M1%1
MC0'I4KCML@I[_WH?GL>US6\/F^8*/QG_]]>-D9;._>2.I3DV6ED6^B2678U*
MPLP/V&]^5?\ D#S;M2;]9Q/R_VR:SL2O &_7LHC.EA>4 I'6!CE]KC-F*E.S
MSF-S.CYBQ2X6U#^#)(F+>#@+)CP2RF13UW0Y-):. ;U6RV-JKX!O_$,=5*ZI
M@WP*;U>.*+^V-BLX>TGM@8_=*^'J*XCCNS!?E\G!%^J25\#C]@-C?LS6Q=]?
MFSMPVX.Z =>@DVGFA_=G7V_,MR^G#M?-+@G/!KODBH?@?$D4/<M B]#2+(2$
MFVE8CUL90>7)8LQ=>/>7"9U7P'SE#*L&2,+\VP)5/NL+7;4!2T6-O$^46F/G
M$;[W:)/*B^1>P <HSUJKBQ(:>'J8)]F.)YP'%/2I\R9CR8\M2BA<?<O@A]=)
M9]V$K(1&",^HU=^%O@# .8(;BK=K\SG]LE?:Z>V+]ODF]5BG^M)RK3]\FJ%5
M6&S:ZG#+&'+;(OK=,JXE?%,\SL;$ZZ^QND2XFU(Q&\E(7W+VQ;W_Y/=VKG>W
MK6T[SN^?"UMV\CR;J$(YN9@M).^;CFKFK@[:DWN&BDQY3AC@3#E=3Y/Z5]AW
M@2?CTQD%S$)C!1.3]M0(=NRIAWSYGT/&23U8""?M?XZ;VCJ>707Z>TAZF*$C
MD4]\TM&CO_3^],6D*_9W=&O@76L*U1V$V5Q.\X_OH#W=9B ;Q9V B%F.ZRN
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MA3#E4V 1G$+]1W(-KX3O/!!/#G=O]-(I?) LP7*6X"C2TA$*RS49=JR!]P-
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M;I.T,2"9>MZ5=;0T2TLO(3S4$KPD"-;[G.'\-LP"AME4OLT3^U@S/A['H[(
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MH-90M2SRB<'8YS<U$9HF=1EO)CBG26Y#[M$KJ5W'Z9;(JI% .?3R(9^XRQV
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M=2)P3'MLJH)K"W!/\3UG=G_=75!S#(UNLV.WADMV='?;<H2'CEHB1(EG^Z@
MJ]>8%+TK\<F5[<#:%S2ME91\MP 9?@>8SGFAE[6YUIT^YH2DIK5!3TDB'D$&
M.;:(AH[5 LY+3.+]WC:(J-=I%-ON8Q[VI:9KYLTGS1-H 9IY<YL7;!9A>V/7
M8_1ANW3LT;DN%[(Z R2P4X(_B)M<)YU,"MFZN#[/W!/">2R_,*(ZC7R%2MJ
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M3!(.,$[PRP3V13;=3GZ7B\%<B.GX%/_GW/G6?ZDEW/^'*D%W)9:6I?W4O'J
M4IIX5S8"^) :$FPVVU;W55A(-)%?]S'1M/H>7MXQT4, /WRBV<Y3G(Y/W@F7
M\H3@_O4L+C[2EF;:D0/7#7;8H?[3>BR=;3\4_$6>@J<D$.\X_<HE+ZDF4.]!
M!X%P3M2TGL?$QM^N;N3R(K 6L=OT%LYE2<C[TL^54,_=R)X\T'XNV4T2497Y
M%S%E%OMXEK<4/+P$VA?&(4SQ7Q+.Z4+3*+VG0DF^HK2%;57%313TY7:)2?<
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M3U8BM;;(/NJU0DZE2AP_U534-\=N4G"'2N+B=/8[&^P(QZ\-]Q2?NS6/D8Q
M4&P2PDVGC,T=G4X3O/SYO\IG%%0/J-39=,,/>5'JD6'7ZXM]^,A]MH2Z-Y3N
ME)&.P:AO.]0^OD^K*-*W276I9C!;ZW+H:X73YV8O)!)YAQ-SCX:2TB;E81^
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M6(C&\PZ8> ><MIHV:6WU)SW'O@-\Q]\![/N7?GWO@!RUD^?"B[0G_?HWTW>
M3N-K3ALE@( 5N-_G.(H%^CV/X;OA,>%*//VYD+3:,.XB[WBMI5K,-M\X/;TU
MWQ$A/2\PH:41>3?I"\1)7 'N2\T-'Z=?$_!N"7*TY]AQT-$>-&>?^R6I!=?#
M#/U"1ILLY* *Z5O/M+5.W/]#IJN.8\!5L%_H\3DN)T:X02@J</E+11@][02O
M=JAE,;5%<:A=+(I]=D=J:'1$#,!G.C6=G__WJF<8J61W=%Q[4\S=&UW@1X4
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M_KXC%3J7"6NMGB1],6<YN9LI]]F,0'KW2]5EFXG;"&%>I=^,B*'LG),G&^^
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M!D;$J696XS;L%/#)FWXB-2!0>$ZYJ6C:+&^%&J+^P+5VG[)NF/DAC@XW@3F
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MK^4J1[_&*/\X+$FF[;@^".7_!<P(TC[8G0T)?/TQ6/HGQ_,O(&"AP3/8L.-
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M>YC+Q-NW$=(GX3OK_EZ]E1Q%?GM#%_<"IC4DJU]FRT<67L'=I49LQ$O4/TG
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M*IY(/[WTV>YG9<GIJDW^J F'-XY8J]9X@]&Z(CO+R40J)M40W[R>X#TL'2=
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MZ/,&'LY3/XTI*@W[Z?_^=5DVE)KSTW AZ_& .&&,USE%/K[#Y!NE%^X==6
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M;H7Q^"'0GT2Q2L\S'OIZ'L;?PS-&[E$O;UTWM=XX4S[BT&W:/19SDZV8;[P
MZ+G V<9&7";[G60G9_X8>8<M&6Y,J" G3R-P9"YF:Q4=A&\JW1_RX2%["S9X
MKO,X[C3EJ+C)(;B_%B*M+6TZ<4X3-YN'EF7_-3WHJN?[+/22MC6(?: U<A#4
M$6'> C:0I;QY\-0CNF3?LP!][3A0*(BKM.L'\\G.;AJMCA#7H(4I1^ UI-._
M=KDD?Q<&0E&,OFX(_<K09KW\ BADP/:CVXQ-?@TC(SI=_/G/V"=-AN^GFB"E
MY9@&1WV6$06A5'+M\0%$X5OZU==Q4$7NF7';66LK&;*@"%L<3BZ#V?4"KVEE
M)T_W&U7:&,:P63U%2LIW/3H@.K69U0D9&[82>N7E'? K/8M$Z1>%GPU0BC,&
M[])?)^CCK0:Q",,U@-'0OH7!FNHYF?96,K_DV FI/[ZY42%E!+[W7!4516Z?
MND=0NWZL66'EZ]%O),4P?&9=M6PBZ&4(7.,UP?5TG\(E.S.VJX)1!3]EJRK5
M0=OTK3D/$HL+M'Z%S4[XC+C;A"3QUG9["7P.6I_AU_U,[+SXHX@]W:^I8>PV
M*Z)*K<"SO5$2K?%^GBB1"NY&_8==LF>Q6<A@,\![]#@RB/;N-&R[ZN-*Q7DA
M=IKK2KHF+3!W@KAOE)KSP+6#KI]=PJA"W=IR=;-;HGRKB3FT4>K5/T#>>Z_?
MGC6$.^^O-HK^QGTY8_3Y]'Y(?O.3=^Q3Q.7P[Q,!P?!)B;;9):(N%5L-$0>X
M;W7.O>>13TEKKM^FZ7-5*X9W\Y+$ W7%[1\^.M%GVW(KWQKV\?.C:J_?5#,[
M56ADPU=_/# "YY>\O3_\G'TV^67BGKHSVS#F])_.X++_91!%,EQ6^LI,XVSN
M00MD^<+^FA(H-[TS3I*U[\0;\I[ZE8G4]8K^^2;K>6XXU?44R2X4;P?/]E/.
M/X!Z0XR#;= *">H$16\H%-2RPE&ZB\N3T"(N)^LMB _#3RXYUC1<7^-S S7P
M:&),<M^0:K<R6!^\4=GSG'_G>PP[C[^ P=,4*5,UT^F]FUE-N]2TF?)!XR')
MU91'B4FGQ+AM!B(X4"V^GOG/(70)OP?J$N1)'H3'3#%WC226)<V=D#O\D78'
MN<JMD3(&6E9X)'UCU!#]F07D!28LN[+G_& '2IG;<,Y5/*YF%9W ?I2M7S"H
MX)5,@4F5%*04AX@*D(O[(-4$""]X12/'Q4?E:52B75%WG4FZ1$/]1]UTF-XP
MUK@)@[$NOL;EWH"OQ9%6#W[&B7&<$.%,K3+>+F^50[A[(*CR@+Q8<C,V5KD4
MB+M@;C=)Y?UX-E!EE2VV0K[<K\]FFP5+KN?_^TX3I_*F_ <ECUP%U7-9Y,MU
M7%< (-T":L=$9,DE(AJ&HA>1?XFC@?B*2HRF)/F[V;![\V?2>-N2J_EH1"@S
MI- *L?C"<C<TBQIJE_ ]F"3CE^LMD5O^0"P?[%6KC1KV;KK&X(,+B8.R#_/
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M,!;6E;]Z.,Q&(/S\X,:$).5*1!@QW()P^(^MQB 0[K<F4G[,>%W7CU74TA7
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M7;&=2]OIA85M@%Q1L&H$YGWE&B?,@V1-2R!<?'UB(::,B"]NA7-M"L88DT_
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M1JZ#Z_<.X*-%D:_-:%P)^NA:ZOI65G#V^> =9D:R3!TKMX?=@JT"R$(#C'R
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MF@0DQK\;S#PL5NJ]7G*AKE\OA.]35_Q4^C=[VMJNM_#YI8Z+J1G1):38:/Y
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M[D7)1$^ 8\B"./N[:C$=?NU]HLBY/^:S,587-XF?_;E=[-C0H:=#KP]":IP
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MOOJZ@*,GSL7U9^E></1D_BKD]WD&C],VS[*T9R0GEANW-(F!6! 14C .[NA
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ML:R?2RA ]XT)'&0G)84DH"=ME*5];.GMC^*S%_R!RAV6;M;<]GL^I%RS'.W
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M>E?L+G A->60"$H.LW_QD$J^C7V:/^/4>DB;O],,O-W KPT"7>_AVQX>U_O
MN,E9W(_!4'5CI(^L>LTB*[L\L(6\"X;3*#AW'I/J.2TWS>7(MGCKAUJ0$;V;
M^1"TB(!"4'1!="7[F6YXX6%-NY]33C[EFS2/PZF<>^%Y&:L%S<AT/$_1["*V
M8755C.!J6 'F%(VX0-N XU3T\87<#.FU..'YV@SI^AP']FOG*_2&#+[*"9MN
MTL[08#&G08^&LP(JPH$A,ZHI5FKD8_HA8U#UE):-AM?P^N>D W+7K)6B).<8
M=H)]"N5*WY6*VT64!'FMZ_A  DRK#I;]+_M:N<5JQ01.WF8PN7"/48W<2#0U
M/!<T [#^+OZN/HS]QF)8$O*]+PV-H8T'R+O/U%*R7'0\5^ 1N@_&MLRATHC<
MI\3G%$9@Q>I3#H$L=E0-$&?1C0;T!7OU!2*A"O0^3GL?\]\O=UMT!/P%[/74
M$)G&YYSBE 5Q8!G^UJ>-%6BQ&K[$3_;Y5DOW@&"W++BDW2DB!)=%"2&RZK<A
MV.^2Q,8T>F+K^GZ,^!?@BHIAZ9Z@>88]:WW3'T@.5F<9+2L$,"LB$N\U:.XK
M C3#^5^>,7TB'?W1M\;\US9//1+KO8X63"5%KP;!=V(,*ANIYI0Y/P 9XA1C
M](0F+[/?/[B6;JJ<[G_IN6'^6:\,DJ%(*'VD9+_44ZOW0NQO)''J'%VW3=7R
M?HV\Y705<&(OR!7G;Z72,QK!G8CZW@$;V3PA9>MZKLD>82X.TC(QH:@",0LA
M=UH-B^-K 0TE/>,8N$TV)8+;K*_H_TR?JW8%#J;<6RM3%, J(W0YB6%B[RT%
MF,;WFD<&6!ZJ@'T:%T.M?\F=\AFJ6BLFJ&4TFQA &]1H& ;@,V$CH) YY8F)
MB@Z';)!#$!%B(,%]-6'?^(*R8,<>D@\_S(]U +;2UM(K2M%" DM>:&UM1?-U
M$J:8&\N@2U& ;5:9L3C+(-0< ;@ B # %< 9LOH;XY+J/WMF?=,->@_MF%K:
M=%+73ZH?1AOBZ55B>/K;1Q,:SDU"$FBL>W3T>DL+5&,J#5_Z:73L4F=-\DNU
M8.H%!X</.4_5SSF5'NF+MFSG="433Q$)=_&*T* W?!Q-S$*1-JKS=BCJ4ML"
MA@C''E"Z<PR$7M_40L;1DLRZ\GD<:&_,NDKQQ)6R/)UC2EO#:<?]<HBW.GWX
MW(]RJ7G&IEUR/EZ.ATLJ[,RD3VNN"6IBIW5F._%MR,^\J-FR$"N^.==ROSU"
M7!T?015KC^L,6UMLCD.'IFEUS"$0&G-\N'S^JUR_N<]=JUIHUD=P%@1G6G,F
M!!2J_%BJJ5Z!+RN#+HZ@?-WL?UP&C#!=74M$/'KZ\-.MNV3]'TFG:G/^ A)[
MWK#^ @Q0-X-3@=>OW_7HZ[9(/D[]F#YK.F1NK;0.D?^Q9U#\!5OFAV7<CO5_
M0E[\/Z@,#=Y>R^;3$6(+A%&R3=HAN:?KW4%M<RT;1'_<%TUKJ9-CW5O?<<<8
M1OW!N[8_7*6PQ#PC'L#@E=QIWB74+-^N/UL?M[I<F[=8'D^#JBF_"R8O&%6R
M;16Q/.<XME*M^D5LV5>)?_J6\U:;(XR^)-ZKC9"*EFG*1BH4&+..8.'1P#?2
MH:L?^[/L@?0^[L^N*KT.)VJ\[J^N'A^_U\Y!+U5R-EV/(T=6V#UU;[I>=:!P
M0JYI-ZY> 6V:7#\>9//9?,ZI9-4#JONUCJ;0EZI,#\S,+%H$-+!#-?4XE[#Y
MIF\?7;X0P<_$@;Q>'C%R9'E,<N731X=Y@@-!%V]B'M&%5-%JI3:8TS@13</S
M7RCU=VC74E9,R;C%_7E+PV/)<K^W3I$UB-^^8X)4J,5.9[AOKUZ[:^VD=N[\
MNG?4Y-UV<A8</VL^N7^R>I<>=N^=?Q=>\CM>%$PI;QG2K-DHV YM^C&T2FXP
MC7GAVR:2Q:DKSQ;"'S8J?+-PZ=F8$F'3>T\W$UGZM=8!$.\,#SLG#'&NN/O)
M<*(4+66UTM]55(LH63*U5@1DKK+HL1TD89?5SKR..Y5&971_\N3SX5%__K#W
M8YL0W+0X/-_ZMTLYLH7B(&E8"@OZT7GY.<&]A@%LY##T<".FK,P#^2V:5KA/
ME"WQ2=2_AWDD])O5?'S_-\139>U_[,V.Z1<N"V:$G?A)_#?-7QG*J3&?T3J%
MZR&^*C8:P@,=5TC'KP4D5V3>.50&'37MI$T4DW188TU1<QY[P6A"UR7R>@$2
M)TQA&<$ODYO:O2GJI^5;PP?CE+RR)F-K5!VM*91<."RR%-],$/$ ^OV2-5=D
MX*5T-:I!EZM7?X^-U%!9M?$#+&%(_$J-2!B$=KT8%'QT?(X0)"A371\X7.80
M(]Q^';,P A'+D6:MR]_*256'6LL*_"ML,DY.P"G^._:&"3*&.\F#1CZ,1;#4
M=RZZG.2,PPKU>I>2Y2=D=>]DAVAS\V93T$]6;9Y'[FUBH@L36K<@7!W3$,<X
MRD)@D8A7<*$"H4D?J0N,V8&I]I:"F1/R4E,LY@TWF$O7V6CQJW-5#+P66J 4
M6CJ1EF;0N6)W0=L:O3OY _%2DK?ZM4&,NW&@)Q]R4_50M8A?P$:NEUQ^_N?.
MHAX-KD F/B^!3#@&FA.4D3%C02!!TV*U80[6,OO)H'NB)+"K23;7YUL:-G/@
M9#1??"UC2(Q"6L-Z(WO+Y#7@ON\5->)MQ+^ERI_=[3__YO]KZ,IZE?@$=4TK
MZ8]=V=&!R2!9VWB%?1[+^ DKV:YMYZQB2W7%JD.4EB+>A329:D84LO\F58&;
M >KNMC]T-E90\6=83MGR#F-7C1RC*\VIC][69QU"CJ'2G+" *XSP1"3Y,=))
MNX!, H0349>9^7U'7B0:P$?/C[:K2C%4#Y:G<^U/_]+L#7/&>MV*>BEHFW[)
MK&9I,;23J>>/)6/A/A(JJ\%BHKL!41YB>I"G\IZE1*1F]@DOV&D3UB#U\J0,
M;J23N*?%I@"_1[O/NB)MR9.#7][WN8CR<**?V?=@SE,<.8EK8OAK<F=8AJ$[
MP<>DT"JN^%U18VC% HM)XMF77D^U668610%Q:H_FY9*]G(S:98GY>5X)Y?X5
M1I%&VLAT+=[/5-,Q1,2L3HHZ%FI"O^Z#S]CA,!V[@9*(%G&L5Q<B5>=U?F=_
MC:O7TQG!&-25B=.9L8GNZN/__%54:.@^>T]]*?Y5S64K\#):0"X<)E4M-C'.
MN1G25$<NP:EL#!#H3:,HYJ239T$"!!D0>DB)#-:%4TJPG,/D=Y HO='-]DU)
MK.Z17; P"3ZH/NCZ3IH40_H:,8V,PXWU<8O:YO5)C737Y]K)!Y/CAL,=J?:9
M,(O8LZ>5EYT;Z9L!$L/RYF#CLE;=<0HGF'A<YM!,53C>P3PP PU%X3SED+DP
MW^#<6;M)9\%KF:W)6/A"U0/DWLK4)F:6<82MJ69[#2&\54%XICJ5LYE[=;'Q
M!>&)Y%+IQ7$-+5H42&;,(PPD*'\!>9Z?G>?6^2H_5AYIK-/051(EHXD\Z=RG
M:$270#\E2[-8E9V=%;->)A*3XWT3I>[B>T7*+^#Q25D&(@APGU,5?%P8)XI8
M\. VD+MLD+X.YS$XB>#?:>Z+J>D>9A(4622DKTM\V]'Q9RG_9^NK)+^]='%Q
M=A+SA>Y2_58MT7JANO8'*,B4-I54TR_@ ,R;,F^:7P1-T<:GY_>L@S*AD9@2
M0FM'.A@_/2*WB!QR,8/;UM06L[&CU8DE4ZE!VF06SIZ,IVYC%< (/>@DG7>Q
M;ACSQH\:6.6>OR'9(T$ ;X7$"UHMDZQHKJ>1YD)IQS,D%,6/I+L;':"4F[^8
MB[(>4<BQBS%\(8^?FPKE(&'#(]$O+O4BC&3L%)C.=L[^E7PT"4_&H%BTX5RO
MIS.*A*.8<D^E6VZ90^W(\PB26'GT5/U'>_*_.W[V3_R_+?VN%G_;CU6ESK*R
ML1N$C2FV*Y?4=CGF )TJNX2:"/S*OLUR2=V7\'S1T?+<*G1K5JZ)44MZFD,*
M4X;C/AQ=/@]/-M!>6%K2DCW ,L23O-A)@"6-TU/]KC7VLRS[68MDV.7HV[?N
MCY;KA_2>6OVI@Y3<1)V_ #:21VO^$GM)OIJFE7=='8AX-X%DW7PM>ONU ZUP
M>D;;^CW=TL&,Y%%^H,K\L":Y46@,[ORR[E[AL$2;$6I<N/.5CGI+5V>]36<[
M=6/&&5X(%PXZD^UDT&^Q/B3C6&.PN',%-B73GA!W/8*FG /T;&NK9 TP2'(R
MOC\<!P))>C,"95A4*"^K':$(S':0MN7]I^O!<.'=.A=.=''ML<R=\MJQOE9Z
M]3<(GTD9DJ>04DNK4:G!/)S05W/,<7:&07'4J$'2K'G00C>))^*L(6)?JH@E
M<P1M@+RQJ$:#S,15W=6]OZ&2F0+26LMUD([(5K&SR1)7I]P**ZB!26CS;)">
M9@*&% T,[0W>&$_5QAX NJPR)UEF;%5C#E Q/D<M,N@LU&@45EV&S=FOJ@=,
MZ*K&%5'16:"YM!,*%_FIG;F%4IA)72].(>A,E.N.L</LF;1R-7!'R-Y@T^$P
M%(B.6!&_-(S_*K5JQR9R/1EHJE_KKQ];PTFV2_!(6Y8US9&PL;"Y](7<<,<R
M(:]G-Y)EE9P?C&=!YGPY8/:I97Y'!:*PWS.UG&6ZE>HHJV]$*,<WT2/(.V?M
M\P]RK0>!J[T\<='AN# @X;A)@UZAB$6)#9=N;2R%R-=7@UCAPLCA!.#XO(*U
M*SO5RX8&[3S_C-0V^K,SC$9*N.\0;G65?3 K\7![KQ^PL+ZDX0(E'\+Z502%
MS'[MWXUX2793+"-WZD5RL%E7U]<$;Q&X^8:N+GQ9"]L<YTR9UD0RC5EG.>U7
M@@"-RHKOP6OR*;=1.\81C/8GQK.$"L(TW;_%K,1H4%?=9**S7I-HU*F?8V.7
MI:1E2L4WJF<RN"DSTXJ;'&%&/"?24FQ+F8YH^M6'<0RO><W=C==6>>]ET% D
M*K5X_<ZP[*J0:<.6W L]=A=^V48@6U?%HBBC^)+1,B(+=\?@[ESE+$&8'?6#
M3")%+%($>GJAO3TX., 1'K>Z.[LAO;/5Q!UW;7A!HTW3"ET_ZVQU_(B><I<'
M!WI K"?\AT[%L)B?E]6*TJ4.LL61E_%O._G5?HI?[>^?71JT+6<NS^VISO83
M2)RP63P!WA@:Y%'C1F0RFH+/#/$MAA%>MRW+(QG.;+//H#UU1"5\(^S4^%?3
M[AB1E"JRXRTW;G4X1%QU].9*8@83GF&VC6Z6K/W]&;X=%\3*]#:0:<9O+Y7M
MSI0-AGG)SI"G **J05-((>X9MGW=$;P^*&]A=L<A B]3H+-XQ"K+5$*RHJ,C
MCUK:\2S6H9L^;V['!HUWSPI[>[*0/(9=67^!$D!<BILY$8,!QEP;79>M5R?:
MR%I:]:;&C.B]L+]F?$2IG]<OI;@R[=ON7:9K?7<;<[IY"%_?%REB?7A@$J 7
M'6O8YXZ'V"2Z]MKUDG!34]ZN!O]N&H(91"M=M% AB&X*9I7.<E$!71"[B?]Z
M\PYZNY?Y.?_8>B^1$WB-BO3',/Q-0OVSH^MX#Q7CCU_J S+;D[3/PR/TXU'*
M9_&YPU$<\<W-S!&<?Y&;PT;Y37CD7X#@Q!M,^CNEP'\<*\[3T^(>ZOL\;^OE
MXHO(X%] KMGG%]E/<,ZGP \_K^(>*^^-U\*1+GZVUR"24R*=IS-?LM_^,PU_
M DM^CADL$&S\A* V<,VN\TVK7;=.& ;(B1C4C1E)KY'O(QF-!%>BJ&@Z&F\-
M$Q(]Y8C[T+9^K3+2)";:*S=I5YTS"1W*OHBDVSF+F1M#+EH 0H-O$R)<5<+5
M5;;A#I6SI ;KIVP-M,"J-A/<.9SU"\EZ5!UAU,ICUC40$D;)9H9>0<ANE3G?
M]-?^*7X*P7N_DZ$V.A(7FNYR8NF6-S?;SI2)(LK#]-*&L\5]&,%Z4981-SGB
M3FNV.8XUU *W2?O<,]:#]E[[7P;OSL_?K,%G?/=G[\8%#;QS99[W$9]>]=$.
M>-/,IPQJ)HY=)N\4+8_9(W59']P#$79^G9[Q6>\L NE$^P<\G_KKI4U$O9\D
M>CZ&;IE";E;VZIGU^?59'W-X$6$I6+@O=[4J"AGV/KX"F=!>TRP7U[D61.D\
M1UU=\FQ/CXO7Q#"EVH)[RYU$TN:Y]C&) G 3H('.U'UJ+6&G+1MW%+7X8N4%
MO\;0GD#68;8XD_9AIZQYM7"ENT?BN00U&-C\<OJDQ7^Z!O\>J@0.9]\5%A"]
MV<]-6.^_E,O]0E;_.L%RT9%UC&A:-<@J*<0?L]^P'L\@5BHXN4^\K8X6,<W,
M>W!'TB.P>JZ:HK23J_%]2U%@H4)/PS,@I6SFC+ZZNYJ34S@E,C>NO)Z @I-0
M9$RD ,?<:8CR&_O")>UPNE=IIMVB$4I+,I4[\W'"Y>V#R<8CFE*7)TGKA%80
M[TII+*')V0H!/34S&P@.@TQ=VK1U/G<R_"&A:F("5[O32)[!'Q(MYIB8TEW<
M&D0Z'22%3<'P952$66R&DZY"<[\74B&,9\'SYCO7BDZ/0HJ?%QV>*5M]Y?-G
MH]%(L3X#0DVD9,.D-T]#Z? @BS9EX+%.^8)V*BM^&46@RN"P*"4\I[/DRCA_
M5;7P^3B1,JYI<WUP<G6A',4$'"V^%)#-2&YH+-:LW7,_DE@E*8H=+EJ1](%'
M<*;N6-TAX^W_5N758/_,XAC[%%9YJZ S'H&MLUR*U(YD\LG7MV93@X<[31!0
M8T&E#8("6?.?IE(-T2&?F/%0C1,G#@:I-QU;;\I1Y0ZLO,DMIC"?HDNG-FSJ
M1EQ.%=7SRZ_ G#198X'),#*#SNK!7TN@-3#19^C$H)3EV$,HG$1K*< LTUA
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MMZ!2<N]2LSSN=H2Q4F$]<%^T_) [<B\20!X=XIV%-D_;6@5G[MK9+4)6#%?
MS$:3F<9TM.@^:F!:B6J\1UF-CN("!S*= _6B;8UM21]=*AJ_SR*A0VR:73+;
M*+_MJ$]&(__Z,C)WL?I6-1L3=#[#%WH* N)*M)^2X9A\^AR\\I@]C*F*<>AU
M629TESO<PWS':R!/Z@[Y\O*U6W01J[*=]:%KM\8G]16/KQ*_BMN0-L@3-)P
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MG#>"M2OE5[D.<34TW:_E2^^ K"Q?GID 'MO<DA7_497_&X,JQUAE!,E'\:U
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MELZ:HUMI-XEZ='^?I:!0S:59NXP[S9"D5^?<^.1X9+QX#_G=2?E!$"T!ZAR
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MA 2?-'>[#/;/CD^J?Z]UU@)=E*G<W?@^AJ"M*$X0NH;B40P?B\-A 66Q?NZ
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M/I[)*_JHKI>3HDAF8L7Z^5Q? _\Q]*_2PH;7XZ?KMLOS 17X/6?1[X!=_I&
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M5%Q+7O7\24UXGLFY[LG:'?Y,DPW _!"H-B=D\+"!FO'\+N#01(#_1T%4,4[
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MJ8L-Y U\./ 77.(_"E(<2R2S@<V3>#XV,*Y:S@8&,PI0LJS/N+5 E !V)60
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MPJVTC3.6Y8EVF]9.'[*#8ZXOF,6M7GED)W?KRS'5;UA(7GS%ANI#.^LOZAV
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M2%>Y<]#XA>:3ZZEF-U(=Y1M3>==][5D7*L^S@?(3EDS9WS^T%B;PC!<>S]C
M]3NXK9/+&H8#-_[),V7^>[(>KLZZ4&CS']A[[ZBFNFY=/(J*@D@'J5$!D:Z
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M1*-5O,T3:BS*^H]5644VD9]_\?51_;CVY;=CCS7;#=L\!5[W'MRZ>; @C3>
M$K97@-D5S1E8T(;:*U6^ROG$8;"8N+8U&:AG-#!?YQE#7EHSO?#ZCF#;QEG+
MF4<>LQF 5$ZC,3NJT1#U8/TEOM*%J/NYG< >*KR"H\".K?"H)JW[!$CBG5XV
M0Z=M)IK=^R/?R^HE'9;--E[&-*"CH*5+,4I*-!FJ,K ^.T5O:E+TTX8U"E*,
MFK2>\WQ/:K_0=7!2#V&QL+ZF0"XPWBL7CYR$<6-=O'&A2KYXMM5/%S)'1XU5
M?AD$286PKUW]FB+DD'*KZ6QW\4KAA[991&&<V>JM7@&[(\V\9VY3?!*\2DXE
MK_-XRJ@-%SF%QFL_V+@0S+_A\K8W[::JRVW<#1E9VU^P6L_3A/B ;U/UI_OR
ML5Y]8ZO@$0.R=%- QB%%4((F!*C,>:H1CMP=\MVI*-+8: ](/FD3_4?*9'?9
M%:3)21%$J]]O[X^PN]C#" W FZH8Z#$;T83''>HC>"7,5F=]0;>::[P1-/G>
M= TEJ7IL)?KX:Q/'Z5:N4_-/Y&:8UE=V- XU\TK\(LDEJEXI,,!J$&%%CFY-
M,:MUK4E^4;E*_2CZ4O26GN2R*&& X_4?']I61.<TC\=[3#%MPA-SP1'4%]''
M4^.&1P/LE8>R*X,D9$^CN3YO2:\K_O;[/B?;G'N^(_6N3\:*O-Q(@75_'O11
MH>GV)%SE^?O'#Z?D*C (S-?Q!$<2:I5X4UM854GV$7(@9AY_*GXAAA#_[+VY
M5T?EI\5*=-7/3U&T%OKUO_I1[*_^Y C&@+Q%[!I2: 7%"DJL)#VVM090+:/6
MB:W?ZK4Z))X6.3G9OE+GRCKZ2@7N.?HW,H]CI"Z,M-[.44B-1\:F IWQF>%Y
MIIJY5=],56 $"?QX,A@)8P+=]0(E4%N/]D<(E6FB^UG)>/J6$P/27D#&18'I
M#$BD12,#LKD"!T2QW: %\^_2MHQ-"@PX@/I.?\G\$XURAN^> #49D/I"++ %
M)7.OKW4Q('] VU';P\D,B'A)N_N9?]\,C"#ODT.CH\%]T W8/=0_-A88@9^$
MHNTF@ZQ*FYQ M*@; P)CLL4G>C3T6 80N4UA_L=/G'-8Z@JS=_1>-(8XV(W]
M?9D6P("$6J'(*S3_3V@@' %E0'28$/]I%ZT9/-4NC.H;8^H.-P,B09$&3VG3
MWZ%^A@'KX&X9 S(WA&K1PY8KT;E08@P(WAQ."\:*Y6:")^%,HMJ7AYIYQ("<
M_:= _BF0OR(0>[(Z392%JNF!XD.HS!6@GB'/VX0>TZRL#H_]O*,U5L6!_=;.
M6FSHYP@>^_==#0-$72B9#8"!H08,"$OR3@1--TZ5 <E@^JD&"5!OS?A/0LG]
ML_"1FB9ZM"OUG,SW]D(D%D 'IA@<8V%+:RC280;D-97WSV+YD[& QPTQI<=5
M$L: + UA21=1;U$MEG/&.U0H;3]L?H\@_$>IH/\D?HNY2CY4RY[-W]E2HAV#
M+T+) A<&0223KD'0.]!2V)^UQ/U?+FW)%V>CUR%/N8L? BQ(2JTC:C7::%QE
M;(@Y]4)%^='K46KGOK=T2!S"I5W7%_DD3),!'$F#[3 AY$E7!H0-% X,]K2P
M'RW)+!]8N]N@?+T]3S+\#Q;YWA99V?)S$![81^R8,4639+&F2]5Q0['6*9V:
M6N$ WQ$\':%JF;D:N4E&80\\GHIZQ$3V/_Z*44%P0A\N'2)5V7^\\CXP*H/M
M<<*"W?UARL_:^F65WTJ<@<FQ@27G'K?<,> T)KASV_9E\5;1;6P4>S+'60>B
MSI2T]DW\IX47_ZM5NO_>0?3_WF5"=@Q(6#0#,D^I8_+>^\7,%3.R3D0P=0_5
MT8'09D!*Y_09D('O!6M*P 4L:.RQ=\AV8PWU>R'/HAU;+DU+36[&4\55,^CR
M4=BB:F/PNA:,'HQ*@*&!9M!@38\>"J>ZT95-=/EI\:B[HNAVZ%,4.\P-^@*#
M/ZRC L"I+LTU"4W;-:B)',RFL(RY9=\[EJRP8U&!#JEWY^_?P1_2.8I0HZ>#
M0LLHUGHN)@:1;D[1Z*SQ2J-T%&N]EBQ1 3=<@D24KQ,WS[4]/ O9IZ.&< ;\
MJ%JT,Z/UYVE69#YK>$3=Q9QOB]E!<L?X[LJ['A&9#Y 3/K$P-7S-8!]<"J%!
MS]G+J(968EZ< .:HRF ?GE6+=4;,'J;95(4_?E[!*-3&O%RK/11CU'15-/=.
MH9>R#LF-._[:S]T1F5ED$5%J;;VG*Z"KQ^/Q(V*(6X@]3I0!,6NB>ZSJ].H,
M3-:-V$YBL$IJ-,S(:.66]B !2^,MIZ@"L^1X*'.U^.J/3+C7*[PPL!#.=!\M
ME8_U1DMV'+TMKTQD*]C,]#)C&X>P4?)W(BC"]'J:'7F)X!T-N\^ X%QF59'[
M@*X9S0M>E3T\O23;,?<JKU(T9KPCWEQ[0._MV%>S%'G]DXJ\W;\Y@3,9Q"FJ
ME4?Z*7(?C;>=8DZ*PY*ZFC2&>U.U=.>\><X7]<5DA75-I[C+G<(M/7Z0%$K^
MXB1O,DRP+HEINY?7E.8>_^9N$=\\+HK(-QWMR7T!(<#.;NIWQC3&23WH0JNT
M]+2A'*9X_?8*%J="L0<$J=:!IT9G^X@L,RC@NJJ-@KGV#5P?U6AEU&E 3][@
M--7-\?'SE,L5\5@UGU>'5Q"L,RAVFC))!TV::Q1V&:NP8S' #%:\AUV<WU"X
M&^L8I;VAHNFIR_*8IUU(,MVC&^N GH V96 X&W)!)0#5A)D6&Y+?,HB%MMH+
M#KWWW54K\,;T5KK@:DEBQ]6&I>P"9-7FX8YY27+\\EH/-U)33TV8U"X8_AH8
M5Q].%%44N/#RGH21;%:\D;EMCP*3%-><;OJ*BLXX6,]+"R:% >QSZLU3TBTU
MFAV+T6+V/<Z6"[CO4C&OW\ZS_3H0>172?N#^"),CD*_: 5)4%=H?0-^LAYQ!
MVNTFG8/#6T4:^%O77*721SJMYJSV*Y=>Z7_2:*5_8":L1WJMG&Q@#\Q2E6F:
MP""A0%/3T[AUFG7 K^@:WC@V:5KF5R$A73=&4^7 T?DSSO<@0I*;5H-YIK&Z
MIJFI]ZO<QG/F^[.M[Q3<]EW1O:%T+:7&HT=;: G+QM3C)/P7I4:4B US**%4
MM64N#X%D=A\7OUQ[.WQ116=CTO7,FI0_8H>?R'9^R(/D'6#;,HY%'0"%D/VP
MHY5*81G'Z\[32V>_.7:  X/(\?/8M 5#43*XP:HOR',M=N-+[]E'1UCS)[5=
M>P]Y%%>YI=SSX6XQ+[EX)S;U_H*TY&!-N==*GYE+YH6?3A?M!3FTM(6Y8B].
MW9#E-HEW[UV6TRP2&\G=<01%F1ON0"<#DLETZ5U=UDS;T[D%'9^CG* GPIQ$
M:HN,9U@;0Y6:MT>30-W>K#*#Q_ZD7^;G@K8Y)3\I?X^Y==;41/] KL0PAHV=
M#<^;X5+=J9@DP6_J$Y)W)\%X6*V_+WR6%L9B9=X\*W/%PT7X8;1]K&1#3(Q%
M#ZC#9%QZJ$9M\$S@G"7P>J[OB4*NAS4E6^UC 5P]NC*P>YOG:Q#4W2X_5[Y]
MX1;?,0AD'_RZEWB%\]>'5DD.21U=1ZQ])_JK]5LKQ\<+TBS7, K=,Q]C,MGR
MW-_,"4E2B^^O(59)[> 1&!5"$P&>9M%, 6\2)U7=_L>ZP*I!/0/RO,#L_?=W
MP6H=7N]$?G;J509 *Y+7K*BJR-''/RV@%;!F;^"Z3;/A0]Q)<*RN@GHNHW,3
M-8=SW?ZU<8I*+<7$W%\:>MF*:"?U48: M#EC0!;= A_SODVBA$'#$2=)X*C=
MH-\9A47AYQB>T+!'UQ=O"QG_SCLK<!XFN]G8IWMS5:,@*NYT8$I<UFV3A-34
M^ !#&?MES=KQ+6?5#:WX. %+2P>W?%.W3C9NDP3S<I_*]^;FGKYVZ)QS;7)M
M*+=_N>HGG&J]6E4O"ZR3O ;-AXM.;MP;]EPOEO]EK?-]PT9?*%&/%#$I*.VE
M[#%>WGNFYY&#S]MN#B<;#M-;*:L"!'#+V<_QK*564W1F5([P*Y2SOK[;_*#>
M6[ GHQ2S-DX]Y2:(4U_;)M6/7K(SU0V],6]KZ./CA]&\VJ-9%VXA?:365;X%
MHM^7O HC7<,"IYEXJ#(:R^6145Z7;($9-;6UM^V:TW;Q+:L5"( MIQGPH(1W
M0\[KM:1LH</KM%$$3V/4>,7J1:]BK<K):5M7NR^:J2QVOIO=O^).^2T3\J\]
MQJB^F4\MPJ@8_9I2*FV_??+[JL/LE<\"J1_9-UJ;%,_5T_(*Y+:JEB)H?$Q%
ML@>9GK <TS*E,@=M['O*=+6@9#]M?6W* .3Q-)KKV'0(E*1/;BN).%\40SI=
MZ+UV^$#(%H+I:0\,TIF.V0L[87.IE/Y91PJPF+T61D*WO'9W:4XQ?WDZ6RGR
M8SS[4E6LHOA5BO/E^9ZOPW=*V:Z<N">XFM;TE?R6YN]@=J=U.%%?RJ/7R A7
M:U=%]/^]Z6+.JM2U@5-,.A;CUEI;>3CW\V^+,GW[#KD=B4XM/^HQL O+ VHO
MPRJV8^N/TS'M&J))96[!2Y3A->15FZJ?Q@FB7>R>7LC[%]=3MJ*4SZ6H6(VT
MWBOE?NX^].8-_Z?WGKK^%N-!"AQG[I*JK8SNN+4I>FVX2<Y3.[LL%K<N0)F&
M_RX@0K4"Q"=FVXG[9E!$ND#?';0)IAP<^%HY_NAUAW!'/<YR<O;T*T_)DI[4
M^_NU;/Z6'>AG"C85.0(7PS*=7 26LP3F@N(,M# E2Z-U9-SJN3'HMK.3E:FH
M!U$S!1GE72+%DG%:F)YPA8V$F(>[):W&@"*Z.=J!L,X#]J#VU07EX*H]^C@
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MU7**6*V8K.AGK2:,+V];/#3<-R26'6\YX3S7H"M3P:EF.+U.O4$3I>=@7;"
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M^NKPM%2\\0-Z+'@^,+,5]05&#"?M'VVIER5S,J%V1#W+,'P6%:GEX:BJ\7I
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M8\.@>Z?/:((=N^'7:+-!Y#A'^RMBD%:4UG>QN0>9>3N66^VV4<7/=)#,\;J
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M>T?QP/]T7-!P:#C?K7V 11\#4H5:8_^ ')Z6).6TX@_3K$;K16DW2"*VT,/
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M_-E<-N=G;'<%+E%EXIN791*_%Z?O=RH<'=UN.P]BJJ832G>^E/BQ_)O@^VS
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M6M&.T7CE@Z+M">V&6YD;7=:6/X5=%&!F/W>*?X)_GT13E:/3<+P='SF_Y7R
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M!>XI(XA)9,M.JD)<"_Z<\TOW^P-"1>/#:MR*>01=9V#M7W-4V'RG*;,]A%&
M-07KD3-@-*2GA+NG@$N,&(X.2:FCMBTH _L)ZV-R-H\6&O#@^K[.>WG V?=]
M*;P,5\2[27^*&_V):_<A*.A/^,R!9S +Q[XQ=R"^0L5?%^:U>1^FE--7S7U\
M7DA><71H$V]TO4YFIXVOX XHLG=[G*(\5%DX_U3?_;%?E=+:6'A)F9AYD.P"
M4BY^2>IZ47C\A:R \4^%7UQU?*_GR@4-(^B*%DZ\%1QS]22IYCY43;(!WJ:@
MSA'CJB"-]]T0'D%52=4RMJZ8Q\/;.F%<N N51(Y?W+LI3[W4/B?@SDZ&&.;$
M5K2QS-H^J*BG,*TI:S#JC1;NBF\OAH+.JW-2AN"7?:AF!TBKJGBB&>E3\W[C
M!.+&P6%GD"&NLZ36&4^0VIZ6^.MG-PTTH*=M@8WP!DW%K/,!RQWXAM+$+U;-
M-;F?%^\)1&"$.!T<5:\^#'8'@O+?8(XRQF(\\17I^KUU?7HS,U592+_2D!K^
MR&)[13F'":%<D#TWM+@JGS/?UR?#W#:I' ?OW)N[CP?745]0U<XM%<RL"N+9
M/ 70#D<^#U:!%-Z;>KR)V&C_8?E6!NACI"@9?FQ_7W@>,-4#NM $Q" YX6UG
M8()(>L%.U R8G>/Q.!2:X\IM;3&FQ\S,"DQ1H'N?26/Q(0I@_@L<AEJ*!V+U
M$RYL6D44?(8-WQJ:#0_O2NHJA$P=B3+<Z1[YSL^L[Z<^J>( ;+H?H6'&569%
M8"2*!@/('RB\X.";!$GL[C7QCI<IVU/^)WI=AUV_O?LEM%G#X\81M\VT1G36
MW6GU]6&(!#8LQ3@\688PD9D58'8T;E1E>^R3G'7B;?ESRQ$*<RJC\V+WBHX]
MX#(*,^/S@?NM_%PI&?SZK"0DT/UK2NE>P:ISZV*$N;H(^94Q1JB1RH-BQE5%
MT1>#05[V9<$*>C?<^;JT$<)C777CAOD'&G[2J2W/OE\!"$Q]<J7*XC!5!>H<
M"1)*/E&GE^T0]'96OPCCB&-X^36;$:GA(3:[I<>A<R-;4T:3U<](Q\%,3*=B
M^<6MLB_52,)-%(DER!KWH$6DCHP<D%1K2[?F 3&!.]PL$%H6"$]^&V1=ALD5
MP+GHP^$X,XH2@8-XVVT$UHNDE]4=M.Y0UE&((%V??)Y:V<&2DSJKB!;SK[II
MR&E7P?K=_>YFC]=G'K:HO&]&&>Y-8B^&6%WOONB5X])A>I%D$%@O+FGU?*45
MJ\Y/%_X5]R-4EU$Y^$>66V7PB&O?[<SD9^FSEZ3V'HRJ4ZU<J-LIH.T>W($Q
MC(IT'HQWJ10XIH5WY-#C@NL1UFV!->-QM)H&QK0NW71?,@,RSX5X\&2D6&J#
M2]<1R$=EJN>Y5%HNP,8>T9+ZE?WU%W_-5K] 70)!]PA"C!U@UL5@3<((]:;Q
M)BR5/-H"S>IONYR(5:4_XA!1M\6G^6NEOI"8&_\T!THJMWS1X4;FHM[+1$Y6
M#5HRF#GHH<@1>M%4R:A/2)/,;T'F;][J]5";1#+<65OGE>F2GIWF]]2*K3NV
MY"363W+0)ZU\R \<+=+#B!DA\/&,'[Z4OHA3-SM.-EV\\_)SE1F4P,4GSI;E
M_,'THFF!X=.-R1B\&R1%68<I1=^EU%S8L2\U3LUVU!2^-#?,Z"J_2"5-G0;L
M]]U"3XZZ;\W:Z+.Z!SRMTHS3WGHUUJ=)7!^? ,YNX6?)A2UBU.'3E (],0B'
M5ZFG89T[Y-U2TUI$FBK#2Z56$'WBGS#:GH:]'E*LT5HQZX*]CO1'FMMHHDCP
M&7(B23ID"36SUPK&)FPTI.;@Y^8\=G2+43(A,7SD*9GO':L/.<]?47:JVYO5
MI=!5$GE@DW8R"1A@=UF8:U!I?D.;4/'3HOF9?E7(D1GXYD/F=XH,K=\>L_("
MQ%= D\$)+%W37X?9=(P*C"3OX<)6Z:S$9#R35M(DLY*@ST/23DJ03P- ="EH
MMVXY46VE6>\P9Y[>/C$O&]Q:0Z.VVLAQ.!I,[[I 1UT@WTG2V,S%ZN:C;NO&
M:VYM<A[<8#LNU&AO2DLO#]=G'GL:#I?$T$9E[%W#+22SJB,:.3-%N7(=Q Q3
ML+N?0X#;5-92!J>J/7[.?=++D<ST]NAF!U7U"-:_0YLS6'R)D,.71:*64L'?
M-,-(NF@P)P&,?UDQY@NFT6-8X!N7\(WYY1AM47 G#Y&<&5+4&:E2<$!G<Z/O
M56X9^3/J3\7",GS;R+8/?)86G=522T[C5T\+2#.:L[5*Y7R2=&^3R'@^1Y#.
M5%#[L6;^V^58)%-\I*J;\HN.84:%_HO]"_[KL<^.7TK[/Z@QKVEQ KZ^DZE^
MP8WY\Q=-%H:'<H-*FC_-5I+SZD]0069'?BW(#!#6"]@#"D,RD:#88?34JR;G
MSQ#EVDCHH6X)A"BUX6PMVR ?ROGS1\J51>?$:.<7I=W7:8T<J$,X$F#>J0PF
ML1Z@X3&''F^GLFE'?:$<NF_T</M6=WIRM=E(&,ODW;\&:3-XA\Z%%HLA-!Z&
M-*&PFGL$86VL&K*#F##3-ZO+HS+5: FOK;ZXZ_@A6=35.1[MD Q0-W$2R7C_
MI71MN!3V UAIT+HWF]2ZB"V%J9)4*W%7DBOI/L:CLY6@J]<$HBUF'*+*W^G<
M^BZH?_?Z$&.<C$W1$Y&G.48FOS2J!%9R!B;,.0;9 C4V/A\[YG\M/71<#@"J
M#F8_!;,I>Q79F0C3<*B;;(A*6:I;] W*UN>6'%:, %-0U8O;]=AE*YS_&]@U
MV.@BUO*:<??424Z@ZFT/9RP%ZELR,,Q@3P\IU/GE)"C_U.##*J]#X?!'>-MS
MU=L%A"3\(CF+Q(5Y8#UGC:^N&&<WX<Q6&,_1/,]+7M+75(-L>[Q:Q.KL3=OC
M/7 3J,[A"#B-O>W+[^L&X[Y0H[7#$AXB3F!4AC]^B"-@_;S#E <N R]'SD"Y
M@-["> @EN"#T,+X%A::S3^JH/07,<:2> AP<WC\J<&"YJ1W%JC!4,G9-L2B!
M]XG+VGNWI@EA_5BQXGVC-VN%);OM2#%=R()>\ZBM31T+T%JTRVBE0#_?==0/
MG_)%RNJ%_FB6OM//,H=/B)G:L4SJ#,=N(0&_0=,'71UX)':WOI# O:\"L74-
M5KD(*7YQQ/16^%%%N*C7RC>!E'E6MB<ZR/YB\(RQ <&1J+H)K%'8IJ5BDB2E
M8R1U,FCG?GLZOIX<^?6OZQJ.Y6G;:<R"@\NWIA-EO?*RG[$)VK 0S<L(\'LX
MN_! -)S5I:8A-:/(JA=:Z'HTN27+\5@KWTZ4Z;6YAI%)T?FK6G+[JXLD)GX*
M7;G_5_FOL+,V&B5"^,K(KI>(=H,?-HZ:WZY?F69;PZ:Q+KUXQ( ]7#=22$\R
MC!6[YU6A+\4"2;62?BEMRV(%V<!%7K(_&/"YS1E@G/(1DYFO['M#O":OX/QQ
M;O&10&VC@:T$U0P"X:[_L_)U=<+V*^35%N7OM5:32(QNLY3:$\L\6N-0172B
ML]AKXQOY 5&/S]Q:B9N+.DDO;P$&JV)![0D7J+^]0N$),.MY\.-WH6H62'>L
MI-.SM5Y@Z<IJE),]8J K2B#)6@YW7"-.'S^P9=YA;++1I]<MOOWYMY5+,WN,
M8P[>4IV#[77?+S1.[IK.NVBC)**>I%T#RKSXYR:KX</ ];S_90&E_[M/;7"^
M!CE<IES4IJ(ESB/2CB,&/T9HS(5.56_)&YQS/3*;AEQ6OQO1?%S/K)_WY>J%
MZP*K82O2O4"LE@%!.*1G)P.71F'9>WLB>PK EJK>\$% KHQ@U.RP3W/')A(,
M0_F>.WQU-%^]P\_X\_W3Z(N3G/:FIH_93#T!UUZ5=0:;+#/:ZZW4:0>-@ILA
MGX+N3^Q)BTN5+C8$&+1E+WP:OIUX9$\2.&FI_&VM.;2G*WX\]2<:-N$_B(:=
M6A+^?>N?+#<,,/\W8?IEVG_C'OR++^F_X ZF_=LP_;*_\P[^NXY=8 SJ/XXY
M"OF3&((G<.%J,?"=*'1S$+JL;9$M(*(;&)'J=V#W"\97WQ@NQ!WQJ5L&QR_R
MY&N!NW<$;5U9,LC98,8:_W$4Y (ZL]E0MKVXO&5M[<'E^F+>QB9 _?!_L/>>
M44UVT;IH;"!=E"(@1JG21*E2)#::?(" ]!*5#@+2@X1$07J3WD'I/5(C$!/I
M("K2FQ(20 2))*CAQ11NW./\N&7?<?;9Y]ZQ]SEC_U@,!I#UKK7F7/-Y'MZY
MUI1,4N]):6L[_:H>))7U]C"N 68K$A-_Y-.S>GV(VZ]NG$L>)/,*^EAJW7!^
MXE!Q(;7A;DEW!'CB*LO[WAG^?OUO7?-[CRV>:'/^_W38[+_7L")_K\R#R=X!
M\KS):,)05CC/F[D$]0:2QF)DRG[@Z)7.1/M7'(M<AQ]Q#$9]@(+_Y87]6B/\
MT &H]0GD5U2.MUEE[72JT8]"WQF1F1K1Z74S1[6I7YY#KDR> 49M FO_KJ^
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M@>/$N2&/P_^A@?OQ)[W"PD7G6.&NY6$E[9^T +1F*;E@2N\?N&(2&SZX+.$
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MRFV).79D1WI6WT+\L>?V=0(N@<76S)' 14\Z:X,0T$/F_#YXGM!\__4BD[D
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M.I<[17F0*0R$$]\HFJXV!?>INMZ9YJQJ'>/=I>2Y1]L[W_>VU"HT+]-S:(T
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MX4)7-2G2N;+D3X^2V1DPW_V7"4.$GZ)I);=Y+QL[+F?5OY1">2R:CCJ6^RV
M[\#,AUSX*5]3L!)DPZ20+Z[F&0N2V$E4Q>O8 K/3["DY4F<Q% ?K5198YO5!
M^>&G&87M+%Z(NEW8QS3^@9*9^B%C+]5A7Q.>)NL.4DV@^J_ !^/8%.85IL<N
MGTYQ<39X PLRLT@.G#.869QSUOW] ]8U),SU]$,#X=7,U:HK9A8I[7N9?K+5
MA3O5)=%)%YI7/^C>I+YAX)B'$4.2YE-8:2<?T;B.>@./-C(SGM,D=,T-52:S
MIY]V]=W=DPL/Q+S\TM%C3$YDKS?2'97LHM5"YD6_A"7WH45+)AT7MD0',4J>
M7[LXDZ4RC#Z<_7K.7^%5J,<=CN8C3$XYLB8U$PBDN<%<J5N ++D#'N%>N7!=
M<"CIX?+O[1\2)ZM7_6.0>:W7)6X7I015Z!SK$_J)3,1WXK8M:$B?Q^!HY$-4
M'/8B$-#@+4P23$\($;\AED!(N[6_VA7AMS<L\NC9(2Z2I,YTP/BW@G"^=;O&
MSARCR1P7+[16GV]A<<?4@L./Q<<_$ 6YCY;-D]YM6J>*S%HFA\IRU,@'S9F[
M^_9X+].H$&,].;@M$$&V>HO&G\3* =5+!A,AW_:<H4X_SKFMR-='?QP@\U_W
MD 6=@H*7#T"]$4B/TZ$!;?9T!<HTU6?>%]6ZT%#V*&ZUIMH.?$?;5I@5<%IQ
MLQA[XDX,LHV1GGA1<NJW[ZC[Z](;HEK5$><ZX\*Y8CWT(])!@0JN(B@,YCPY
MGI#W!"OF2#]'KGGZ:PG*O;1)\NA67K!N6A8ZJCW2R)</573"FN0^&,@TIFRN
M[,+;Y%XF#4WEV,\&M5JN6:0XHR(UEJ(TT/Y8<5TADQPW .ZBG=U@UI-E\?>W
M4*4=CZ6 NYUH_]?(MAJ2%CF<6DN6H%\#=(CWHQXV2F+;"B$7M_H>J*Z;BJP[
M?C[9%&V='^SR%%H$;A'* V^/LZ831-G;_KWBF0GAV9K=RQBN4=Q9=WSQ?S#W
MWE]-?=&W:*Q($^D=5'I'Z8)$1;H0Z9V(=)#>@D3R4:I4Z5*C5.E20H?0>Q&0
M%J2$*B60H(9@"A>_[[[QWACW'[B_GGG&.+NL/==<9^^U]M/.YC/=LQPA&9H&
MIZB4LS$NLD@M,/8^BM->12O".V^3<Y!X,F(GLH-06[T[BCTS5+_7-](6=(?K
M0Q>IWD)WN6*.G_/@'("UA2VI]N7\.8VII?"1GKI7R0@V9Q?.O*)I$& 5=/G-
MX^3W06(&Z7Q,$,LZ1!(M(5\(5-VHFO)B3PRWKFL1)'5":KO#C#. 5ELPI?W2
MB $17REK7-$/H2(Q*CPFP'%$2A_*E9(\)Y%^0=(3!/[><T##Z2!_U#F@T;4'
M<WGH,4X>%?7CU.+UFPJM9G:VU&6#JU,<W'9].NB/[^R"*YE8+OTQNZ\6W10D
M69"O\J1,W _^<$'I;GZ>;:"=O-=??CN+.^C]L\-Z:],RFB2QP;(+L,'DM'"S
M<*_(9[9LS^71OMOPG]I<H(_$U'* $?)".40!7=Z$:&%A4=OC!?<);\OWS5,0
M<4P6+W0GMS2?.\EP2(\_O_P6#)N$7T)Z_+NPG@KIPT\?/OD:CH$5D]RP/G%L
MRMMSKZ#9D<QZ2<Q, DI9XKH<HY+U6HYI@E1 D8EU0G"7ZA5)3?&O7EK&6^W>
MTZL8$98UG:9<=<<K?<H)?3*9PAEN*J*CT"QOO7L7&$=S6[Q[XQN_(*(?2;21
M7(N!O<R&JF[($/1J/M\?^B)5S+^$UDQ;]:>$9,.E;EP(G].O#Z!SATL7(?UF
M#3]A[2CY'/!BYQSPW?_UGKIB^#02H8T!$7WWP759AT4X]86>!S*1ARLDHPV=
MZDSW7=$7S"T_VM_&Z9JS)-V/R@U3S9#8QF^T!+.*/S?EBK2[,5<NIN0<//M:
M^,^T8%J(*LY6CB9#]H!!Z$:'FH1I>FZC-\KGZ6J;$$LN<ISXI4!B&.:*7 :A
M0S B.*7!-1HH_2=/?$[,?\<Y"Q:YYHAWRBY^\E]WF'DFQY6>#NV8*0LD?0J=
M.HQWO3!H1H(CKL^28$#4>]:EC.7J[GN"(_E;#0CZB][,W5QM^!KT,HE3T#F=
MOL:1;I>?0OV+""(%$#:)SZ >A#<X[2%^5 XP$C$B10*ZDK,]&98$V)N-KJW0
MZ4V=:$5(6^(*BM,&R(E<EM!G9Y^-3!($2SC;A<2$FJ5KBQ):;4,6:AGP/&YH
M/Q/C*#-#V=1TE\/TXLP?;5U)][?]UNQD_NQH5W/63@ 7D9NU))9<_"FV]GV'
M4&'X]%^?&/2WTB2;<P"+ ?K (?1.CMA51=^J6X5WV=[G;Y\#+%L-BA.*7B^0
MF&KQ)>1/Z@*$Y VE;AC*HA^WCZK]KY;Q[IQP(IL;?D22N4_@B]%=B?ZJFC'D
M[IOQ/C>[.I)$_-B>17I%KW'1V 1'JV)Z5=J\6!#J5#_@55^D7[87UTF^AW\&
MGSUD8*2QQ*F@3K]BY@+#2$[GD/X07'%A^)\7ZRN;]!AG$4NY!O5,1H?TU=Y<
M(6<]<Y/'GBJE?L!P^JN[?*CIN_V+58">[WM "UR7_!;HZ9.<4SL$8P_OAR.J
M)Q+/ 0D=(E>SV-3O-%ANVCUA"1S]^OSMB&YAJB)C)<<I)^!%0(%$M)^EM0)W
M.95QCG$>,W3:$-4IB0F:<#ETCD?;NC!%Z3[XD*&GJQ<X"_UV ;'8U;2F>B]H
M+ZKP-5YFT #G@Z_!W/@)HB ,F*A! I'S.^AQJ+[',X' 6W;>.(6I&"_[39VZ
MN/V-:TW-EAM@1=T0[5\ZRQE>(Q;F@D"'_]ED*T%Z\&K@+U3&82A1FS )9#9
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M3$B!J=)E!?.DNS]T^GV>/U(92CH'])V> YQ ?T7 3$"LT86_&9FC(K$;SRR
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M)C$?# )YI,X!:)H9:$!X4[/YZ_\\E1S:)\(L7IB-%XJP$=_R.4_?#O_SEIR
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M9TF/@TH[_O(V1P<)\,S8O2)_!SGD/8EJBAG7,653H<HA^@RN7L/"^I/I?T"
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MD2[-;%R9B5(E?]H#4SG5'M9])[*^!'+AUI8DGN"F$I$>##%K#5D)6\NNV'/
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M6^4AKV0ZKOBL\][W>K+(R:88*5.0-H*HI_C0#:M-_BDA&D,T'F.52$R;Z'-
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M$# YH[>;YYI#-HFM)XW='R5'7R\3/&8[%M/4$[O0GS&=+/-9UK_WP^_T6M6
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MB,&:'>Z6MWG9,_N5L16?I24+EH^HVE5+5I=KH)4.TX@/H70XR0)9@AEVE5[
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MY)(FRW.J7F#3Z1 8=8J7(]==!*S)I_2UD+3UE;EBOXG"I6&FR>D<H7>63G=
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M F>CZ^RZ^9U$&C^#-$K1Y.$' =1'+,M?J%8\=91$).CV_'.\:4ZIE0_UGR#
M=:GY@L,2='Y"1_?5G.-QU>].G9/YN&*F@_I\@N'*28\B_KNV^7#;E9S/EBK]
M")71TS+N(QZ"W(834+>^_G7+N&]V?!PI91'I<WKNZK7NZ'H9&8>IJ135($O^
M)Q:Q6UUPPB!Y9@":010W.P!879ZF_84GNI<7H5-"]34";RQ2;)^7Y>B&?M9H
MKA1MH_U.$#LCXD!!T2\2MRU4N_&L+-3*UO5Z/D">OL0#P.K=$O^<FDY#UAGD
M^'MH=Y$9L:] :^0#Q:A3^D![;*3AG+]'[,U7[9&))PD!,4I&_WT6K#^TV8M\
MZ0 ]A!Q%8:&T/721;DC+S"-("%[T)C /Y;SD#E9Z *7V+?%7=T )68/76PJ6
MNP\D2:S3EKV/W;U2O=]0L"(FHP-83F6Y<V>09X&S<):UR*[-Y*7[9)-RWE,A
M^WS'V69Y+M2>$;N3MG-UN#DYB5[X.VD;(>WG]Y;'O#%OG5Q_1@U  #41FB0C
MF02A8AGV3&O&?FQ"*SB3JYY_85HKTDY=Z)-6Z+55(X^MRJ$QCP4!Y1OELA:I
MYH?.NF]B4A5V]W/7(K2 R-=L#?H6S>T54++AQ7 >GDG'F4;'=[M;/A-YU'*J
MEO:EM^!Z7'[XH':QRR5/2P-\WC%;F=MFGTKP1D@P=P;38O@1/Q]/AG1!)'B\
MO%.(91&-HJB4QY4!\39C)EIE05M(A1?>(B%F$2N^1D&'#SY=NOM.T.9P$;)C
M"0*<^DD[P4*Q_^,4X/9R)PG0'OA^A'%N3_Z9U1D%OJ9I;:W%#>LT;[]]COM<
MLVR$>\<_:W2\MG8QK1HZV@".'(,>8!L#VZS8NU+X%GZJ*(68X2)-/&8F'QUJ
M&DO&]&JI]ACDT2BQ1JXC*:9/QPIOSJ.>P11!SG:?^Y>3AY&8/B+]1NH;WBR8
MFK/^ ]RW4>0STYV*AXO*/>8) \NH;D=-S&W?I$6[;@=Y4HZ#PM&6Z[DM66I[
MF)Z2@VS1<3.50 @_0KN4'<BX 2L^@_T:XM@GVW+=0B+*/?DI/C#".EOT^N>.
MP(/XT^>&(R5 #A;_._8PM-D2:*YM'@^D[KP$_W.,]-*GX[E7 I)15&.>.B_-
M^9#/%;3: 2D/\C"H\9H(1^U]O2P Y7V@VX-GRO-$P=AG=W$F>N+?J9+F4W3P
M_.H 7AXA0*))_21M?\ V%ZP[U/Z6C<-MOU8,>/+B>XF1=F[6E:KOH3T/X-0=
M4 W":H9[./#\0%^M42W"W/3%^00=CQ2,\:SB^4/!]R]D##Y*NG/FW4?JO>*2
MM&VJ@55*#T,9,4:I..64<.>MX1^+ZMC/4?>IK4];HURVSLKT"<X)'VOW?BWC
M^+3L=_G:9V-6+=-UK2DK;61[47L'E&W/(_X-$3S9ICFS#&&+N7(5EG9 AUD
M:@=TJ(]W_-@!'31DVZ$:=M,$=Y$[O0-ZTOJSZ"<G=PNRREXHA/PH'F+/U4_0
M'O2'V)MW3H1\23VMY9MF '\O\_01)A36!R$50)JET7@?^&Q^%[0YJI?C88V;
M,3'DE#-7:P]0W$+ --EG4^/!03Z9(V(1_*?.=#W\U 6Y%!WP"2.((M?AR6P%
M(9XV&>'QG]U*LU;L4X7UO%D"7,!P%C\3-:]]/P83ROF)6=[>'OC</#A@7-U#
MX51"[D#FM2GV:#-U7HJVZ+S'\'$+1'A6SK+UZ0%)(?K*XPC=BEX78]@LKG]O
MD7F2)G6H;"G,< _*O-.3I8"PF\&3JI#2G'<U?VN%$:HE")7<[BUW1+ZCL,6:
M[.\_MU>.IO3?F3\OW']A3GB=+K"NQ4>R8DO8<@46ED9E5Z"-^5V\66.[ ]Y+
M]9)>JP3[I'KVY0*S<K+GI5]JB,]G1>U\RR^E?'TAQZ?@]LTK 3$:Q?)G^TSN
M+II%M6PEF,@SFBE2%3#Z:"]7 9ZT Q)#7-0?SOI@@*Z$29&UE@N#PSH;#[[)
M+!OQ]"?L?>5<-[^[?4$)P##5.2\[-5BQ[#,\&@(W'*B&B@9E1Y<.%%2D^+V(
M[.L,_ARD7/\OA;J4#\\/S::*:N=1KAV-1?5ISVHS:9S7$%+Q#DB2*X"(!CCD
M!3C%M7=-U.VWBP$TL#V]I_AH:_*-UG8I@SKOV,S'YZ!Y+M_[.VDQ97_M 34(
M-9&AR^SEY+P&A.D#[E^ID2E_:>I_Z_3GWY:TK=/*A(\O2-PPH/ /KI.*RZ[S
M#V-:[:DH\N@L/Z5BM^@I"=,ODN((K/;AY3LA9'#*XO$9$T_]^>CN[LVA\?1?
MWX=\JSXJ9OHX7789&?^=]<$UW4SR&\^J5U&D$I0T<B\[CL'\ .Z&/+XO*UP&
M.;PI[PZ3@XMY_388CIB1C>_^LE[C;^!LH9%AZ52_AB B.#B('SX%VJJ5W&T+
M32:TH?T7^0#R*V#P)G?V7=Y9_<PG[\0&1/*/%;XQNTMS(53PG^X,&$8:<$?P
M;5#J3YX8*V7.<))-#,D[(/F;[,OC-5HX);8V0ZI!;S5]L%II/:2.>GHVQN%,
MRC._IS29)Q3SD]O'%6"D=(CL+KO> <&(,LCN17Z@EJ(%(U>DX?A_>VG1]9-3
M](U"0]F*L<'^*03W;U+?VCI$7US\+@HVSK/*QW#2(:07.R Z =P(38 $$@D^
MS!S@127B^K2>4CM=._TU(_$+_O&2C<SMV,NN>Q:=K GW<\/;E30L>X;,2DDB
M<S#F:P8XRTP%221B]P\D;Q*EO!"J.#KQ,9N/[)%[#T:NU2J-^>Z1.H="W??]
MY)_YPBSFH+*;F+84#WC#@62NX%09;_"F;"'Z%A-.%^E9B#5G6.9&X$2 Q#K8
M,$SU\1+K:K<#*O#+<&PRD1D.^N\=5%_&\@OH.]( \1\PQ?)&[3[<]#>U[5,X
MQQT%4J5I%\NB_5?[7)BOAQXDMD]JD?"$[ZE*0M^_;'=W/J)+'.%_@YQ!-;D^
M1I$*H:(X?NXDN+F^=S3% 2CMQ<A&@ 41%I/Z]3+VE9",FM-Y]XO^[C'[D7.G
M(>3&(]&H/*?#E8._'V#98CV]7-%=HAF GL.3M3/UYC^;B2/\QM@PRK!/KUBG
M5E6,SH+] V_12]O9Y>TGE7*/9CI[W7 -?X!B2T"9M@":Y1EM3LZ*I\_?' OV
MYZDU.^F^@E)8OJYETYR[55B3E?0SB<0W*GZ$&LEKAV_>>W*8CTQ$=T95HKJ@
M.$.$T:0)K-J>S(&0#^1&5OS2O7NCM:AE[0<\[YQML%7PRP;0RW78#_@C!1/&
MZ$->X#_!- ;C#C"*:TO::EG7;JZ\+PTZG]'6OS[B";NUH56^/AN3;3:U(.?G
M$?CIG.26:CS*%Y5J)K_[@I9]E5,+CRP2[31<TDYNDY7*#Y <ZO]G_-P 'G2]
M5_'FR,3CIK.FDZ[I@#E7((IU 4 Q13@O\?Y"HU+1IIT7Z<E+D9@,A&V4U.N(
MX#_!=R;U-?*RYH8;H@K]OE_0*(.UWX*#]EX?XBG>?;Q4Q^).V^VJ%"5.L__N
M(V8>RG'>T3$?B8?LJS2^?2-M8]U?/O@OX,[(QX\_2A8R7U$,B>@=T+XPH)W<
M 9DWIZ!X 00!,!3YT:YW;+F NFBP%9"A*A84_4Y49[9F(&RN\<7C'+XSJ5&A
M?J<7$Y? <QO,54[>#@A>GX)IC:(.TU6[4%(1]NF-*PU>7371V7JU'CTZ[O.:
MQIW;3ZO=,)UCO0I6 D<)N.L!*WA?[=D!YB<@CG4?P#)'.)5<14#<O; ?+T(9
MKX]8.ZC\_>R*Z[U;W3Y8K,W7[;SNHU$R1=.6.98'3!!]*4SH_ #S>1/G"<07
M+H_\&MZ)@GUML3F0+I&]YM:JEO)X3"9,P-PD>ZWKD]U *](B.I?YAA///8;J
MTL.)KZ#V00(KX6:F/% (24:?3%KM^E=@4%IK_Y_2I&9 >Z"40:;+A0QNJ(K'
MP7YD*.0Z/G1MCH\20$,S^$B\.<5X?+T->),AQ[13D2>"HD85O>ZN>ZC^DZ]Q
M2"DP3$R_VI0<^>53V=Y/>_[)N8]%H$5_89'RC /Y\+@*XKQ-2)Q?S,$<N13/
M*YVA&0?]_)0DCS\6./!D2.0Q1!JAQM@@;269&40K6(6H]KE+UKV]T[2$N#<L
MB\\#E/AOT;R+9:QI4,E5C" OG\3SK+P/^$ /9SYB+'?B#W(%3Z/?S+&-OOX-
MHFHAS.-B^+[9A%>:7%-PD.O_DE9^9I_?%0K4>!Y%>KX#:H+WPV?1I#>MK/-L
M*T92=EUT^!5&(F>@I[!#Z*T"15XAYE#Z_G$]T:JK2CK6\[(6"\:@6>=1(48A
M,X+3C/>'$S;Z,&U15%TR2@1@7070%;,6#$4R/$4_82+TM+;FQ&=LQ\2?A<L.
M8,VB535%K1.]B1.?0>N%^Q@[(*HPZQ+;C9-H(L!([B6,]BQ F>%3G?=(&G&Q
MCGD45K?A?S%,HF]K^R=O>$+ ]?^<:J*->W-LIU%=BA#?3#D*?Q<J$4J_#LG
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M,?Z<Q<L/I5T.N2FE$U !F#DX;\CP^0#F0TZ9B55UX$8@2A+:P]_3UF8HUKJ
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MGO.<SQ_7S)D_YCWW><]U7:_7ZWU?UW6__9G1??N)YI6YIQFK8U7?/TJO":[
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M]3RHBEI$](NG@^DNV#EGM C;%HBA.HIR1^%"OX00O\)K V_-U@\X!!WX?8/
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MZ\8@79'JC:TA&$K!4;_0O31!.8#'7GJ/=BNPK>E:-$76^1]%QP!,7>#TY8/
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M(&!OASY'AZ__>/3M)-AQ'*Z'_@2G.V'2,2!,,$P(/8SGVP9=@P">4 U&<E+
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MZ?MB;63*_O\'-?]C_]C_),-LS_X'4$L! A0#%     @ *6A_5*R@\'">#@,
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M,#(Q,3(S,5]D968N>&UL4$L! A0#%     @ *6A_5%A;@N/7=P  (3$' !4
M             ( !85X# &-B:6\M,C R,3$R,S%?;&%B+GAM;%!+ 0(4 Q0
M   ( "EH?U1@:*T2/4@  $9Y!0 5              "  6O6 P!C8FEO+3(P
M,C$Q,C,Q7W!R92YX;6Q02P$"% ,4    "  I:']4*TPJ8M$C  "<&0$ $
M            @ ';'@0 8V)I;RUE>#$P.%\Y+FAT;5!+ 0(4 Q0    ( "EH
M?U28'!V)-@,  +8.   0              "  =I"! !C8FEO+65X,C,Q7S@N
M:'1M4$L! A0#%     @ *6A_5/H]V)V<"   )$4  !$              ( !
M/D8$ &-B:6\M97@S,3%?,3$N:'1M4$L! A0#%     @ *6A_5%-8]<:="
MM40  !               ( !"4\$ &-B:6\M97@S,3)?-BYH=&U02P$"% ,4
M    "  I:']4"LR.T;T$  !U%   $               @ '45P0 8V)I;RUE
M>#,R,5\W+FAT;5!+ 0(4 Q0    ( "EH?U1_/0A\PP0  #D4   1
M      "  ;]<! !C8FEO+65X,S(R7S$P+FAT;5!+ 0(4 Q0    ( "EH?U3^
MC".T/:D! /;] 0 6              "  ;%A! !G=7EC>7HP:6(Q:6<P,# P
M,#$N:G!G4$L! A0#%     @ *6A_5(L]/H.'?P, &Z0# !8
M ( !(@L& &=U>6-Y>C!I8C%I9S P,# P,BYJ<&=02P$"% ,4    "  I:']4
M_HPCM#VI 0#V_0$ %@              @ '=B@D 9W5Y8WEZ,&EB,6EG,# P
=,# S+FIP9U!+!08     #P / - #  !.- L    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
